NZ548918A - Gene differentially expressed in breast and bladder cancer and encoded polypeptides - Google Patents

Abstract

Disclosed is a human gene that is differentially expressed in human breast and bladder carcinoma. More specifically, an isolated polynucleotide comprising a sequence encoding at least one complementarity determining region (CDR) or a functional variant thereof of the murine 1F2 monoclonal antibody, wherein said polynucleotide encodes a polypeptide that specifically binds to C35.

Description

548918 *10052292860* NEW ZEALAND PATENTS ACT, 1953 Divided out of New Zealand Specification No. 537579 dated 10 June 2003 COMPLETE SPECIFICATION GENE DIFFERENTIALLY EXPRESSED IN BREAST AND BLADDER CANCER AND ENCODED POLYPEPTIDES We, VACCINEX INC., and UNIVERSITY OF ROCHESTER, 1895 Mt. Hope Avenue, Rochester, New York 14620, United States of America, and 518 Hylan Building, Rochester, New York 14627-0140, United States of America, do hereby declare the invention for which we pray that a patent may be granted to us, and the method by which it is to be performed, to be particularly described in and by the following statement: ('followed, by page 1a) I MltLLECTUAL PROPERTY OFFICE I OF NZ 3- AUG 2006 RECEIVED - la - This is a divisional of New Zealand Specification No. 537579.

GENE DIFFERENTIALLY EXPRESSED IN BREAST AND BLADDER CANCER AND ENCODED POLYPEPTIDES BACKGROUND OF THE INVENTION Field of the Invention

[0001] The present invention relates to a novel human gene that is differentially expressed in human breast and bladder carcinoma. More specifically, the present invention relates to a polynucleotide encoding a novel human polypeptide named C35. This invention also relates to C35 polypeptides, as well as vectors, host cells, antibodies directed to C35 polypeptides, and the recombinant methods for producing the same. The present invention further relates to diagnostic methods for detecting carcinomas, including human breast and bladder carcinomas.. The present invention further relates to the formulation and use of the C35 gene and polypeptides in immunogenic compositions or vaccines, to induce antibody and cell-mediated immunity against target cells, such as tumor cells, that express the C35 gene. The invention further relates to screening methods for identifying agonists and antagonists of C35 activity.

Background Art

[0002] Cancer afflicts approximately 1.2 millionpeople in the United States each year. About 50% of these cancers are curable with surgery, radiation therapy, and chemotherapy. Despite significant technical advances in these three types of treatments, each year more than 500,000 people will die of cancer in the United States alone. (Jaffee, E. M., Ann. N. Y. Acad. Sci. 886:61-72 (1999)). Because most recurrences are at distant sites such as the liver, brain, bone, and lung, there is an urgent need for improved systemic therapies.

[0003] The goal of cancer treatment is to develop modalities that specifically target tumor cells, thereby avoiding unnecessary side effects to normal tissue. ImmunothfrapyJi^ feapoteatiaLto'pro an alternative systemic treatmentfor most types of cancer. The advantage of immunotherapy over radiation and chemotherapy is that it can act specifically against the tumor without causing normal tissue damage. One form of immunotherapy, vaccines, is particularly attractive because they can also provide for active immunization, which allows for amplification of the immune response. In addition, vaccines can generate a memory immune response.

[0004] The possibility that altered features of a tumor cell are recognized by the immune system as non-self and may induce protective immunity is the basis for attempts to develop cancer vaccines. Whether or not this is a viable strategy depends on how the features of a transformed cell are altered. Appreciation of the central role of mutation in tumor transformation gave rise to the hypothesis that tumor antigens arise as a result of random mutation in genetically unstable cells. Although random mutations might prove immunogenic, it would be predicted that these would induce specific immunity unique for each tumor. This would be unfavorable for development of broadly effective tumor vaccines. An alternate hypothesis, however, is that a tumor antigen may arise as a result of systematic and reproducible tissue specific gene deregulation that is associated with the transformation process. This could give rise to qualitatively or quantitatively different expression of shared antigens in certain types of tumors that might be suitable targets for immunotherapy. Early results, demonstrating that the immunogenicity of some experimental tumors could be traced to random mutations (De Plaen, et al, Proc. Natl Acad. Sci. USA 85: 2274-2278 (1988); Srivastava, & Old, Immunol. Today 9:78 (1989)), clearly supported the first hypothesis. There is, however, no a priori reason why random mutation and systematic gene deregulation could not both give rise to new immunogenic expression in tumors. Indeed, more recent studies in both experimental tumors (Sahasrabudhe et al., J. Immunol. iJ/:6202-6310 (1993); Torigoe et al., J. Immunol. 147:3251 (1991)) and human melanoma (van Der Bruggen et al, Science254:1643-1647 (1991); Brichaide/a£, J. Exp. Med. 178:489-495 (1993); m- V8A M-m5-3&19.(l@94);.Bbel et al.

Immunity 2:167-175 (1995); Van den Eynde et al, J. Exp. Med. 182: 689-698 (1995)) have clearly demonstrated expression of shared tumor antigens encoded by deregulated normal genes. The identification of MAGE-1 and other antigens common to different human melanoma holds great promise for the future development of multiple tumor vaccines. (0005] In spite of the progress in melanoma, very few shared antigens recognized by cytotoxic T cells have not been described for other human tumors. The major challenge is technological. Hie most widespread and to date most successful •approach to identify immunogenic molecules uniquely expressed in tumor cells is to screen a cDNA library with tumor-specific CTLs (cytotoxic T lymphocytes). Application of this strategy has led to identification of several gene families expressed predominantly in human melanoma Two major limitations of this approach, however, are that (1) screening requires labor intensive transfection of numerous small pools of recombinant DNA into separate target populations, which themselves often need to be modified to express one or more MHC . molecules required for antigen presentation, in order to assay T cell stimulation by a minor component of some pool; and (2) with the possible exception of renal cell carcinoma, tumor-specific CTLs have been very difficult to isolate from either tumor infiltrating lymphocytes (TIL) or PBL of patients with other types ?of tumors, especially the epithelial cell carcinomas that comprise greater than 80% of human tumors. It appears that there may be tissue specific properties that result in tumor-specific CTLs being sequestered in melanoma.

[0006] Direct immunization with tumor-specific gene products maybe essential to elicit an immune response against some shared tumor antigens. It has been argued that, if a tumor expressed strong antigens, it should have been eradicated prior to clinical manifestation. Perhaps then, tumors express only weak antigens. Immunologists have long been interested in the issue of what makes an antigen weak or strong. There have been two major hypotheses. Weak antigens may be poorly processed and fail to be presented effectively to T cells. Alternatively, the inadequate for a vigorous response (a so-called "hole in the repertoire"). Elucidation of the complex cellular process whereby antigenic peptides associate with MHC molecules for transport to the cell surface and presentation to T cells has been one of the triumphs of modern immunology. These experiments have clearly established that failure of presentation due to processing defects or competition from other peptides could render a particular peptide less immunogenic. In contrast, it has, for technical reasons, been more difficult to establish that the frequency of clonal representation in the T cell repertoire is an important mechanism of low responsiveness. Recent studies demonstrating that the relationship between immunodominant and cryptic peptides of a protein antigen change in T cell receptor transgenic mice suggest, however, that the relative frequency of peptide-specific T cells can, indeed, be a determining factor in whether a particular peptide is cryptic or dominant in a T cell response. This has encouraging implications for development of vaccines. With present day methods, it would be a complex and difficult undertaking to modify the way in which antigenic peptides of a tumor are processed and presented to T cells. The relative frequency of a specific T cell population can, however, be directly and effectively increased by prior vaccination. This could, therefore, be the key manipulationrequiredto render an otherwise cryptic response immunoprotective. These considerations of cryptic or sub-dominant antigens have special relevance in relation to possible immune evasion by tumors through tolerance induction. Evidence has been presented to suggest that tumor-specific T cells in the tumor-bearing host are anergic, possibly as a result of antigen presentation on nonprofessional APC (Morgan, D.J. et al., J. Immunol. 163:723-27 (1999); Sotomayor, E.M. et al., Proc. Natl. Acad. Sci. U.S.A. 96:11476-81 (1999); Lee, P.P. et al., Nature Medicine J:677-85 (1999)). Prior tolerization of T cells specific for immunodominant antigens of a tumor may, therefore, account for the difficulty in developing successful strategies for immunotherapy of cancer. These observations suggest that T cells specific for immunodominant tumor antigens are are most likely to have been tolerized. It may, therefore, be that T cells specific for sub-dominant antigens or T cells that are initially present at a lower frequency would prove more effective because they have escaped the tolerizing influence of a growing tumor. {0007] Another maj or concern for the development of broadly effective human vaccines is the extreme polymorphism of HLA class I molecules. Class I MHC:cellular peptide complexes are the target antigens for specific CD8+ CTLs. The cellular peptides, derived by degradation of endogenously synthesized proteins, are translocated into apre-Golgi compartment where they bind to class IMHC molecules for transport to the cell surface. The CDS molecule contributes to the avidity of the interaction between T cell and target by binding to the <x3 domain of the class I heavy chain. Since all endogenous proteins turn over, peptides derived from any cytoplasmic or nuclear protein may bind to an MHC molecule and be transported for presentation at the cell surface. This allows T cells to survey a much larger representation of cellular proteins than antibodies which are restricted to recognize conformational determinants of only those proteins that are either secreted or integrated at the cell membrane. {0008] The T cell receptor antigen binding site interacts with determinants of both the peptide and the surrounding MHC. T cell specificity must, therefore, be defined in terms of an MHCrpeptide complex. The specificity of peptide binding to MHC molecules is very broad and of relatively low affinity in comparison to the antigen binding sites of specific antibodies. Class I-bound peptides are generally 8-10 residues in length and accommodate amino acid side chains of restricted diversity at certain key positions that match pockets in the MHC peptide binding site. These key features ofpeptides that bind to aparticular MHC molecule constitute a peptide binding motif.

[0009] Hence, there exists a need for methods to facilitate the induction and isolation of T cells specific for human tumors, cancers and infected cells and for methods to efficiently select the genes that encode the major target antigens It is an object of the present invention to go someway towards fulfilling this need and/or to provide the public with a useful choice. i BRIEF SUMMARY OF THE INVENTION |

[0010] The present invention relates to a novel polynucleotide, C35, that is differentially expressed in human breast and bladder carcinoma, and to the encoded polypeptide of C35. Moreover, the present invention relates to vectors, host cells, antibodies, and recombinant methods for producing C35 polypeptides and polynucleotides. The present invention further relates to the formulation and use of C35 polypeptides, in particular C35 peptide epitopes and C35 peptide epitope analogs, and polynucleotides in immunogenic compositions to induce antibodies and cell-mediated immunity against target cells, such as tumor cells, that express the C35 gene products. Also provided are diagnostic methods for detecting disorders relating to the C35 genes and polypeptides, including use as a prognostic marker for carcinomas, such as human breast carcinoma, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying binding partners of C35. 1001 OA] Specifically, the present invention provides an isolated polynucleotide comprising a sequence encoding at least one complementarity determining region (CDR) or a variant thereof of the murine 1F2 monoclonal antibody, wherein said polynucleotide encodes a polypeptide that specifically binds to C35. [0010A-1] The present invention also provides an isolated polynucleotide comprising a sequence encoding at least one complementarity determining region (CDR) or a variant thereof of the murine 1B3 monoclonal antibody, wherein said polynucleotide encodes a polypeptide that specifically binds to C35- [OO10B] The invention also provides an isolated polynucleotide comprising— (a) SEQ ID No: 148; and (b) SEQ ID NO: 149. [001OC] The invention also provides an isolated polynucleotide comprising I OF Nx. (a) SEQ ID No: 150; and \ 2 ^ 0C7 2006 (b) SEQ ID NO: 151. i received -6a- [0010D] The invention also provides an isolated polynucleotide comprising a sequence having at least 80% identity to SEQ ID No: 148. [0010E] The invention also provides an isolated polynucleotide comprising a sequence having at least 80% identity to SEQ ID No: 149. [001 OF] The invention also provides an isolated polynucleotide comprising a sequence having at least 80% identity to SEQ ID No: 150. [0010G] The invention also provides an isolated polynucleotide comprising a sequence haying at least 80%) identity to SEQ ID No:151. [0010H] The invention also provides a vector comprising the polynucleotide of the invention.

[00101] The invention also provides a host cell comprising the expression vector of the invention, with the proviso that said host cell is not present in a human. [0010J] The invention also provides a method of producing an isolated antibody or antigen binding fragment thereof that specifically binds C35 comprising culturing the host cell of the invention, and recovering said antibody or antigen binding fragment thereof. [0010K] The invention also provides an antibody or antigen binding fragment thereof that specifically binds C35 produced by the method of the invention. [0010L] The invention also provides an isolated polypeptide encoded by the polynucleotide according to the invention. [0010M] The invention also provides an isolated antibody or antigen binding fragment thereof comprising at least one complementarity determining region i intellectual property 0ffsc, , OF N.z.

I 2 5 OCT 2006 RECEIVE -6b- (CDR) or a variant thereof of the murine 1B3 monoclonal antibody, wherein said antibody or antigen binding fragment thereof specifically binds C35. [0010N] The invention also provides an isolated antibody or antigen binding fragment thereof comprising at least one complementarity determining region (CDR) or a variant thereof of the murine 1F2 monoclonal antibody, wherein said antibody or antigen binding fragment thereof specifically binds C35.

[00100] The invention also provides an isolated antibody or antigen binding fragment thereof that specifically binds C35, wherein said antibody or antigen binding fragment comprises the VH region of 1B3. [0010P] The invention also provides an isolated antibody or antigen binding fragment thereof that specifically binds C35, wherein said antibody or antigen binding fragment comprises the VL region of 1B3. [0010Q] The invention also provides an isolated antibody or antigen binding fragment thereof that specifically binds C35, wherein said antibody or antigen binding fragment comprises the VH region of 1F2. [0010R] The invention also provides an isolated antibody or antigen binding fragment thereof that specifically binds C35, wherein said antibody or antigen binding fragment comprises the VL region of 1F2. [0010S] The invention also provides an isolated antibody or antigen binding fragment thereof that specifically binds to C35, wherein said antibody or antigen binding fragment thereof competitively inhibits the 1B3 murine monoclonal antibody from specifically binding to C35. [0010T] The invention also provides an isolated antibody or antigen binding fragment thereof that specifically binds to C35, wherein said antibody or [i Or NX 1 OCT 2006 1 received -6c- antigen binding fragment thereof competitively inhibits the 1F2 murine monoclonal antibody from specifically binding to C35. [0010U] The invention also provides an isolated antibody or antigen binding fragment thereof that specifically binds to an epitope of C35 located within positions 153 to K104 of SEQ ID NO:2. [0010V] The invention also provides an isolated polynucleotide encoding the antibody or antigen binding fragment thereof according to the invention. [0010W] The invention also provides a vector comprising the polynucleotide encoding the antibody or antibody binding fragment of the invention. [0010X] The invention also provides a host cell comprising the vector described in paragraph [0010W] with the proviso that said host cell is not present in a human. [0010Y] The invention also provides a composition comprising the antibody or antigen binding fragment thereof, of the invention. [0010Z] The invention also provides a use of the antibody or antigen binding fragment according to the invention, or the composition according to the invention for use in the manufacture of a medicament for killing cancer cells that express C35, or for treating C35-associated cancer. [0010AA] The invention also provides a method of detecting the presence of C35 in a sample, said method comprising (a) contacting said sample with the antibody or antigen binding fragment thereof according to the invention; and -6d- (b) assaying for binding of said antibody or antigen binding fragment thereof to C35. [0010BB] The invention also provides a diagnostic kit for detecting the presence of C35 in a sample, said kit comprising (a) the antibody or antigen binding fragment thereof according to the invention; and (b) a conjugate comprising a specific binding partner for the C35 antibody and a label capable of producing a detectable signal.

[0011] The invention of NZ 537579 relates to an isolated polypeptide comprising apeptide comprising two or more C35 peptide epitopes, wherein said peptide is selected from the group consisting of: amino acids T101 to VI13 of SEQ ID NO:2, E100 to V113 of SEQH>NO:2, 193 to VI13 of SEQ ID NO:2, D88 to VI13 of SEQ ID NO:2, P84 to VI13 of SEQ ID NO:2, K77 to VI13 of SEQ ID NO:2, Q72 to V113 of SEQ ID NO:2, F65 to V113 of SEQ ID NO:2, and L59 to VI13 of SEQ ID NO:2, and wherein said isolated polypeptide is not SEQ ID NO: 2, SEQ ID NO: 153, SEQ ID NO: 155, or amino acids E100 to R109 of SEQ ID NO:2. The peptide G99 to V113 of SEQ ID NO:2 is not included in the scope of the invention of NZ 537579-.

The invention fof NZ 537579 also relates to an isolated polypeptide comprising at least one C35 peptide epitope analog, wherein said C35 peptide epitope analog is selected from the group consisting of: for the peptide epitope G22 to C30 of SEQ ID NO:2 and FIG. IB, the analogs with either alanine or glycine substituted for cysteine at the mnth amino acid residue; for the peptide epitope 125 to C33 of SEQ ID NO:2 and FIG: IB, the analogs with either alanine 1 25 OCT 2006 1 1 RECEIVED or glycine substituted for the cysteine at the sixth amino acid residue and/or the ninth amino acid residue; for the peptide epitope K77 to Y85 of SEQ ID NO: 2 and FIG. IB, the analog with valine substituted for tyrosine at the ninth amino acidresidue;forthepeptideepitopeK104toC112ofSEQIDNO:2andFIG. IB, the analogs with alanine, glycine or leucine substituted for cysteine at the ninth amino acid residue; for the peptide epitope K104 to VI13 of SEQ ID NO:2 and FIG. IB, the analogs with alanine, serine, glycine or leucine substituted for cysteine at the ninth amino acid residue; for the peptide epitope 1105 to VI13 of SEQ ID NO:2 and FIG. IB, the analogs with either leucine or methionine substituted for threonine at the second amino acid residue and/or alanine, serine or glycine substituted for cysteine at the eighth amino acid residue; and for the peptide epitope N107 to LI 15 of SEQ ID NO:2 and FIG. IB, the analog with either alanine or glycine substituted for cysteine at the sixth amino acid residue.

[0013] Preferably the isolated polypeptide of the invention of NZ 537579 is not more than 100 amino acids in length, alternatively not more that 95 amino acids in length, alternatively not more than 90 amino acids in length, alternatively not more than 85 amino acids in length, alternatively not more than 80 amino acids in length, alternatively not more than 75 amino acids in length, alternatively not more than 70 amino acids in length, alternatively not more than 65 amino acids in length, alternatively not more than 60 amino acids in length, alternatively not more than 55 amino acids in length, alternatively not more than 50 amino acids in length, alternatively not more than 45 amino acids in length, alternatively not more than 40 amino acids in length, or alternatively not more than 35 amino acids in length.

[0014] In another embodiment, the invention of NZ 537579 relates to a fusion protein comprising an isolated peptide comprising two or more C35 peptide epitopes, wherein said isolated peptide is selected from the group consisting of: amino acids T101 to VI13 of SEQ ID NO:2, E100 to VI13 of SEQ ID NO:2, m to VI13 of SEQIDNO:2, D88 to VI13 of SEQ ID NO:2, P84 to VI13 of SEQ ID NO:2, K77 to VI13 of SEQ ID NO:2, Q72 to OF n.I \ \ 25 OCT®6 ' \ RECEIVED ID N0:2. In a preferred embodiment, the fusion protein is a homopolymer of said isolated peptide. In another preferred embodiment, the fusion protein is a heteropolymer of said isolated polypeptides. In yet another embodiment, the fusion protein is fused to a T helper peptide. In still another embodiment, the fusion protein is fused to a carrier. In another embodiment, the fusion protein is linked to a lipid. (0015] In another embodiment, the invention of NZ 537579 relates to an isolated polypeptide consisting of two ormore C35 peptide epitopes, wherein said isolated polypeptide is selected from the group consisting of: amino acids T101 to V113 of SEQ ID NO:2, El 00 to VI13 of SEQ ID NO:2, 193 to " VI13 of SEQ ID NO:2, D88 to VI13 of SEQ ID NO:2, P84 to VI13 of SEQ ID NO:2, K77 to VI13 of SEQ ID NO:2, Q72 to VI13 of SEQ ID NO:2, F65 to VI13 of SEQ ID NO:2, and L59 to VI13 of SEQ ID NO:2, and wherein said isolated polypeptides is not SEQ ID NO: 2, SEQ ID NO: 153, SEQ ID NO: 155, or amino acids E100 to R109 of SEQ ID NO:2.

[0016] In another embodiment, the invention of NZ 537579 relates to an isolated polypeptide comprising apeptide comprising at least one C35 peptide epitope analog, wherein said peptide is selected from the group consisting of the analog of peptide T101 to VI13 of SEQ ID NO:2 having either alanine or glycine substituted for the cysteine at the twelfth residue, the analog of peptide E100 to V113 of SEQ ID NO:2 having either alanine or glycine substituted for the cysteine at the thirteenth residue, - the analog of peptide 193 to Vli3 ofSEQ ID NO:2 having either alanine or glycine substituted for the cysteine at the twentieth residue, (he analog ofpeptideD88 to V113 ofSEQ ID NO:2 having either alanine or glycine substituted for the cysteine at the twenty-fifth residue, the analog of peptide P84 to VI13 of SEQ ID NO:2 having either alanine or glycine substituted for the cysteine at the twenty-ninth residue, the analog of peptide K77toV113of SEQ ED NO:2 having either alanine or glycine —- r, substituted for the cysteine at the thirty-sixth residue, the analog q^pepftae Qj^kz. x 5 OCT 2006 I fi— iC to V113 of SEQ ID NO:2 having either alanine or glycine substituted for the cysteine at the forty-first residue, the analog of peptide F65 to VI13 ofSEQ ID NO:2 having either alanine or glycine substituted for the cysteine at the forty-eighth residue, and the analog of peptide L59 to VI13 ofSEQ ID NO:2 having either alanine or glycine substituted for the cysteine at the fifty-fourth residue.

[0017] In another embodiment, the invention of NZ 537579 relates to a fusion protein comprising a peptide comprising at least one C3 5 peptide epitope analog, wherein said peptide is selected from the group consisting of: for the peptide epitope G22 to C30 of SEQ ID NO:2 and FIG. IB, the analogs with either alanine or glycine substituted for cysteine at the ninth amino acid residue; for the peptide epitope 125 to C33 of SEQ ID NO:2 and FIG. IB, the analogs with either alanine or glycine substituted for the cysteine at the sixth amino acid residue and/or the ninth amino acid residue; for the peptide epitope K77 to Y85 of SEQ ID NO: 2 and FIG. IB, the analog with valine substituted for tyrosine at the ninth amino acid residue; for the peptide epitope K104 to CI 12 of SEQ ID NO:2 and FIG. IB, the analogs with alanine, glycine or leucine substituted for cysteine at the ninth amino acid residue; for the peptide epitope K104 to VI13 of SEQ ID NO:2 and FIG. IB, the analogs with alanine, glycine, serine or leucine substituted for cysteine at the ninth amino acid residue; for the peptide epitope 1105 to VI13 of SEQ ID NO:2 and FIG. IB, the analogs with either leucine, serine or methionine substituted for threonine at the second amino acid residue and/or alanine or glycine substituted for cysteine at the eighth amino acid residue; and for the peptide epitope N107 to VI13 of SEQ ID NO:2 and FIG. IB, the analog with either alanine or glycine substituted for cysteine at the sixth amino acid residue, the analog of peptide T101 to VI13 of SEQ ID NO:2 having either alanine or glycine substituted for the cysteine at the twelfth residue, the analog of peptide E100 to VI13 of SEQ ID NO:2 having either alanine or glycine substituted for cysteine at the thirteenth residue, the analog of peptide 193 to VI13 of SEQ ID NO:2 having either or glycine substituted for the cysteine at the twentieth residue, the analog of peptide D88 to VI13 of SEQ ID NO:2 having either alanine or glycine substituted for the cysteine at the twenty-fifth residue, the analog of peptide P84 to VI13 of SEQ ID NO:2 having either alanine or glycine substituted for the cysteine at the twenty-ninth residue, the analog of peptide K77 to VI13 ofSEQ ID NO:2 having either alanine or glycine substituted for the cysteine at the thirty-sixth residue, the analog of peptide Q72 to VI13 of SEQ ID NO:2 having either alanine or glycine substituted for the cysteine at the forty-first residue, the analog of peptide F65 to VI13 of SEQ ID NO:2 having either alanine or glycine substituted for the cysteine at the forty-eighth residue, and the analog of peptide L59 to VI13 of SEQ ID NO:2 having either alanine or glycine substituted for the cysteine at the fifty-fourth residue. In a preferred embodiment, the fusion protein comprises a homopolymer of said peptide comprising at least one C35 peptide epitope analog.

In another preferred embodiment, the fusion protein comprises a heteropolymer of said peptide comprising at lesat one C35 peptide epitope analog.

[0018] In another embodiment, the invention of NZ 537579 relates to a composition comprising an isolated polypeptide or fusion protein of the invention and a pharmaceutically acceptable carrier.

BRIEF DESCRIPTION OF THE FIGURES

[0019] FIGS. 1A and IB. FIG. 1A shows the DNA coding sequence (SEQ ID NO:l) of C35. The sequence immediately upstream of the predicted ATG start codon is shown in lower case and conforms to the expected features described by Kozak, M., J. Biol. Chem. 266(30):19S67-I9m (1991). FIG. IB shows the deduced amino acid sequence (SEQ ID NO:2) of C35.

[0020] FIGS.2A-2C. FIG.2A: C35 is overexpressed in Breast tumor cell lines.

Upper Panel: 300ng of poly-A RNA from 3 week old human thymus, normal breast epithelial cell line H16N2 from patient 21, and 4 breast tumor cell lines derived one year apart from primary or metastatic nodules of the same patient^i^-^r^^^iCt OCT # 21NT, 21PT 21MT1, and 21MT2, was resolved on a 1% agarose/formaldehyde gel and transferred to a GeneScreen membrane. This blot was hybridized with a 32P labeled C35 probe. Hybridization was detected by exposing the blot to film for 15 hours. Lower Panel: To quantitate RNA loading, the same blot was stripped and re-hybridized with a 32P labeled probe for Glyceraldehyde-3 Phosphate Dehydrogenase (GAPDH). For each sample the C35 signal was normalized to the GAPDH signal. The numbers represent the fold expression of C35 in each sample relative to H16N2. FIG. 2B: C35 is expressed at low levels in normal tissues. A Blot containing 1 miarogram of poly-A RNA from each of the indicated adult normal tissues (Clontech) was hybridized with a 32P labeled C35 probe. Hybridization was detected by exposing the blot to film for 15 hours (upper panel), or 96 hours (lower panel). FIG. 2C. C35 is overexpressed in primary Breast tumors. A blot containing 2 micrograms of poly-A RNA from 3 primary infiltrating ductal mammary carcinoma, Tl, T2, T3 and 1 normal breast epithelium, N (Jhvitrogen) was hybridized with a 32P labeled C35 probe. To normalize loading a 32P labeled beta-Actin probe was included in the hybridization mix. Hybridization was detected by exposing the blot to film for 6 hours. The numbers represent the fold expression of C35 in each sample relative to normal breast epithelium.

[0021] FIG. 3. Expression of C35 in Breast Tumor Cell lines. C35 is overexpressed in different breast tumor cell lines. UpperPanel: 300ngofpoly-A RNA from BT474 (ATCC HYB-20, mammary ductal carcinoma), SKBR3 (ATCC HTB-30, mammary adenocarcinoma), T47D (ATCC HTB-133, mammary ductal carcinoma), normal breast epithelial cell line H16N2 from patient 21, and 21-NT breast tumor cell line derived from primary tumor nodule of the same patient 21 was resolved on a 1% agarose/formaldehyde gel and transferred to a GeneScreen membrane. This blot was hybridized with a 32P labeled C35 probe. Hybridization was detected by exposing the blot to film for 15 hours. Lower Panel: To quantitate RNA loading, the same blot was stripped antehylipfc^ For each sample the - C35 signal was normalized to the actin signal. The numbers represent the fold expression of C35 in each sample relative to HI 6N2.

[0022] FIGS. 4A-4C. Surface Expression of C35 Protein Detected by Flow Cytometry. 1 x 105 breast tumor cells were stained with 3.5 microliters of antiserum raised in BALB/c mice against Line 1 mouse tumor cells transduced with retrovirus encoding human C35 or control, pre-bleed BALB/c serum. After a 30 minute incubation, cells were washed twice with staining buffer (PAB) and incubated with FITC-goat anti-mouse IgG(l ug/sample) for 30 minutes. Samples were washed and analyzed on an EPICS Elite flow cytometer. FIG. 4A: 2 INT. FIG. 4B: SKBR3. FIG. 4C: MDA-MB-231. These three breast tumor lines were selected to represent tumor cells that express high, intermediate and low levels of C35 RNA on Northern blots (see FIG. 3). Abbreviations: nms, ns; normal mouse serum; C35; C35 immune serum.

[0023] FIGS. 5A and 5B. CML Selected Recombinant Vaccinia cDNA Clones Stimulate Tumor Specific CTL. FIG. 5A: CML Selected vaccinia clones were assayed for the ability, following infection of B/C.N, to stimulate tumor specific CTL to secrete interferon gamma. The amount of cytokine was measured by ELIS A, and is represented as OD49Q (14). An OD490 of 1.4 is approximately equal to 4 ng/ml of IFNg, and an OD490 of 0.65 is approximately equal to 1 ng/ml of IFNg. FIG. 5B: CML selected clones sensitize host cells to lysis by tumor specific CTL. Monolayers of B/C.N in wells of a 6 well plate were infected with moi=l of the indicated vaccinia virus clones. After 14 hours of infection the infected cells were harvested and along with the indicated control targets labeled with 5lCr. Target cells were incubated with the indicated ratios of tumor specific Cytotoxic T Lymphocytes for 4 hours at 37 °C and percentage specific lysis was determined (15). This experiment was repeated at least three limes with similar results.

[0024] FIGS. 6A and 6B. The Tumor Antigen Is Encoded by a Ribosomal Protein L3 Gene. Sequence of H2.16 and rpL3 from amino acid position 45 to lenceof cDNA clone rpL3 (GenBank Accession no. Y00225). FIG. 6B: A single nucleotide substitution at C170T of the H2.16 tumor cDNA is the only sequence change relative to the published L3 ribosomal allele. This substitution results in a T54I amino acid substitution in the protein. (0025] FIGS. 7A and 7B. Identification of the Peptide Epitope Recognized by the Tumor Specific CTL. FIG. 7A: CML assay to identify the peptide recognized by tumor specific CTL. Target cells were labeled with 51Cr (IS). During the 51Cr incubation samples ofB/C.N cells wore incubated with 1 pM peptide L34a.56(I54), 100 fiM L34g_56(T54) or lOOpM peptide L345.54(I54). Target cells were incubated with the indicated ratios of tumor specific Cytotoxic T Lymphocytes for 4 hours at 37 °C and percentage specific lysis was determined. This experiment was repeated at least three times with similar results. FIG. 7B: Titration of peptide L348_56 (154). Target cells were labeled with 5ICr. During the slCr incubation samples ofB/C.N cells were incubated either withno peptide addition (D) or with the indicated concentrations (1 |iM, 1 OnM, InM) of L348„56(I54) (■), BCA 39 cells were included as a positive control (A). Target cells were incubated with the indicated ratios of Tumor Specific Cytotoxic T Lymphocytes for 4 hours at 37 ° C and percentage specific lysis was determined. Theexperimentwas repeated twice with similar results. (0026] FIGS. 8A to 8C. Analysis of L3 Expressed by Each Cell Line. FIG. 8A: Sau3AI map of published ipL3 and H2.16. Shown above is the Sau3AI restriction map for the published ribosomal protein L3 gene (Top), andforH2.16 (Bottom). DigestionofcDNAforthepublishedL3 sequence generates fragments of200,355,348,289, and 84bp. The pattern for H2.16 is identical except for an extra Sau3AI site at position 168 caused by the C170T. This results in a 168bp digestion product in place of the 200bp fragment; FIG. 8B: The BCA tumors express both L3 alleles. RT-PCR products generated from each cell line or from vH2.16 were generated using L3 specific primers and then digested with Sau3Al, and resolved on a 3% agarose gel for 2 hours at 80 volts. FIG. 8C: The and Thymus. 13 specific RT-PCR products from each indicated sample were generated using a 32P end labeled 5 prime PCR primer. No PCR product was observed when RNA for each sample was used as template for PCR without cDNA synthesis, indicating that no sample was contaminated with genomic DNA. The PCR products were gel purified to ensure purity, digested with Sau3AI} and resolved on a 3% agarose gel for 15 hours at 60 volts. No PCR product was observed in a control PCR sample that had no template added to it. This result has been reproduced a total of 3 times.

[0027] FIGS. 9A to 9C. Immunization with iL3 is Immunoprotective. FIG. 9A: Immunization with H2.16 induces tumor specific CTL. Balb/c mice (2/group) were immunized by subcutaneous injection with 5X106pfuofvH2.16, or control vector v7.5/tk. Seven days later splenocytes were harvested and restimulated with peptide L348_56(I54) (26). Five days following the second restimulation the lymphocytes were tested in a chromium release assay as described in Figure 11. The L348.S6(I54) peptide was used at a 1 micromolar concentration, and the L348_ 56(T54) peptide was used at a 100 micromolar concentration. Similar results were obtained when the immunization experiment was repeated. FIGS. 9B and 9C: Female Balb/cByJ mice were immunized as indicated (27). The mice were challenged by SC injection with 200,000 viable BCA 34 tumor cells into the abdominal wall. Data is from day 35 post challenge. These data are representative of 4 independent experiments.

[0028] FIGS. 10A and 10B. FIG. 10A: C35 coding sequence with translation; 5' and 3' untranslated regions are shown in lowercase letters. The predicted prenylation site, CVIL, at the 3' terminus is boxed. FIG. 10B: Genomic alignment of C35 gene on chromosome 17.

[0029] FIGS. 11A and 11B. C35 Expression in Breast Carcinoma. C35 was labeled with 32P in a random priming reaction and hybridized to Northern blots at 10s cpm/rnl. Each blot was stripped and re-probed with GAPDH or Beta-actin to normalize mRNA loads. The numbers indicate densitometry ratios normalized H16N2, and all values are relative to the level of expression in the normal cell line. FIG. 11 A: C35 expression in breast epithelial cell lines. FIG. 1 IB: C35 expression in primary breast tissue/tumors. 300 ng mRNA was electrophoresed on 0.8% alkaline agarose gels, then blotted to Genescreen Plus, except leftmost panel of B loaded with 1 fxg mRNA from 3 primary tumors and 1 normal tissue control (Real Tumor Blots, Invitrogen). Similar exposures are shown for all blots.

[0030] FIG. 12. C35 Expression in Bladder Carcinoma. C35 was labeled with 32P in a random priming reaction and hybridized to a Northern blot of tumor and normalRNAat 106cpm/ml. The blot was stripped and re-probed with Beta-actin to normalize mRNA loads. The numbers indicate densitometry ratios normalized against Beta-actin. Values are relative to the level of expression in the normal bladder samples. 300 ng mRNA was electrophoresed on 0.8% alkaline agarose gels, then blotted to Genescreen Plus.

[0031] FIGS. 13A and 13B. FACS Analysis with Anti-C35 Antibodies. FIG. 13 A: Breast cell lines were stained with (top panel) sera from mice immunized with Line 1 cells infected with C35 recombinant retrovirus, and (bottom panel) 2C3 purified monoclonal antibody or isotype control. FIG. 13B: Bladder cell lines stained with 2C3 purified monoclonal antibody or isotype control.

[0032] FIGS. 14A and 14B. Inhibition of Tumor Growth in Presence of 2C3 Antibody. 21NT breast tumor cells (FIG. 14A) or H16N2 normal breast epithelial cells (FIG. 14B) were incubated with the indicated concentrations of 2C3 anti-C35 monoclonal antibody or a non-specific isotype control antibody. Cell growth was measured by XTT assay following 72 hour incubation in the presence or absence of antibodies.

[0033] FIGS. 15 A and 15B. CTL stimulated with C35 expressing dendritic cells specifically lyse C35+ Breast (21NT) and Bladder (ppTl 1 A3) tumor cell lines, with minimal activity against normal breast (MEC), immortalized non-tumorigenic breast (H16N2) and bladder (S V-HUC) cell lines, or an NK sensitive PBL. FIG. 15B: T cell clone 10G3 was selected from line 4 for C35-specific activity. Target cell lines MEC, ppTl 1 A3 and SV-HUC are naturally HLA-A2 positive. Target cell lines 21NT and H16N2 were transected with HLA-A2 to provide a required MHC restriction element.

[0034] FIGS. 16A and 16B. Cytokine Release from T Cell Clone 10G3 upon Stimulation with Targets. FIG. 16A: IFN-gamma secretion. FIG. 16B: TNF-alpha secretion. Breast and bladder target cell lines were distinguished by the presence or absence of expression of HLA-A2 and C3 5 tumor antigen, an amino terminal 50 amino acid fragment of C35 (C35-50aa), or the irrelevant mouse L3 ribosomalprotein. Eachmarker was either endogenously expressed orintroduced by transfection of an HLA-A2.1 construct (pSV2.A2), or by infection with a vaccinia recombinant of C35 (w.C35, w.C35-50aa), L3 (w.L3), or HLA-A2 <wA2)

[0035] FIGS. 17A and 17B. Effect of anti-CD40 ligand antibody (anti-CD154) in blocking the reactivity of murine T cells to specific transplantation antigens. DBA/2 (H-2d) mice were immunized with 107 C57B1/6 (H-2b) spleen cells intraperitoneally and, in addition, were injected with either saline or 0.5 mg monoclonal anti-CD40 ligand antibody (MR1, anti-CD 154, Pharmingen0902ID) administered both at the time of immunization and two days later. On day 10 following immunization, spleen cells from these mice were removed and stimulated in vitro with either C57B1/6 or control allogeneic C3H (H-2k) spleen cells that had been irradiated (20 Gy). After 5 days of in vitro stimulation, C57B1/6 and C3H specific cytolytic responses were assayed at various effectontarget ratios by 5lCr release assay from specific labeled targets, in this case, either C3H or C57B1/6 dendritic cells pulsed with syngeneic spleen cell lysates. Significant cytotoxicity was induced against the control C3H ailoantigens in both saline and anti-CD154 treated mice (FIG. 17A) whereas a cytotoxic response to C57B1/6 was induced in the saline treated mice but not the anti-CD 154 treatedmice (FIG. 17B). (0036] FIG. 18. GM-CSF Production by Line 4 After Stimulation with Native 21NT-A2 Tumor, H16N2-A2 Pulsed with Different C35 Peptides, or H16N2-A2 Infected with C35 Recombinant Vaccinia Virus. T cell line 4 was generated by Stimulating normal donor T cells for 12 days each with autologous dendritic cells (DC) and then autologous monocytes infected with C35 recombinant vaccinia.virus. Weekly stimulation was continued with alio PBL and the 2 INT tumor transfected with HLA-A2/Kb (21NT-A2). For the experiment depicted hare, the T cells were restimulated in vitro at 106 T cells per well with 5 x 104 irradiated (2500 rads) HI 6N2-A2/Kb pulsed with lug/ml of C35 peptides 9-17, 77-85, 104-112, or 105-113 and 10s irradiated alio PBL per well with IL2 (20U/ml) and IL-7 (lOng/ml) in AIM-V/5% human AB serum. After two (2) rounds of stimulation for 7 days, T cells were tested for induction of GM-CSF secretion following incubation with different stimulators pulsed or not pulsed with lug/ml of peptide or infected with wC35 or wWT at MOI = 1. T cells (5000) were incubated with 25000 of the various stimulator cells overnight in AIM-V/5% human AB serum in triplicate. (0037] FIG. 19. C35-Specific ELISA of Hybridoma Supernatants. Results of a representative ELESA experiment involving hybridoma clones with demonstrated specificity for C35. (0038] FIG. 20. Western Blot with C35-Specific Antibodies. Western Blot Immunodetection was performed with supernatant from selected hybridoma clones. Antibodies from 4 hybridomas (1B3, 1F2, 3E10, 11B10) reacted specifically with hC35 protein in this assay. Results for antibodies 1B3,1F2, and 3E10 are shown. (0039] FIG. 21. frnmunohistochemistry with 1F2 Antibody. Monoclonal antibody 1F2 was shown to have utility for immunohistochemical staining of primary breast tumor sections. This Figure demonstrates that monoclonal antibody 1F2 can detect high levels of endogenous C35 expression in human breast tumors, with little or no staining of normal breast tissue. Specifically, this Figure shows strong staining of a section of invasive breast adenocarcinoma from patient 01A6, while normal breast tissue from the same patient is negative.

DETAILED DESCRIPTION OF THE INVENTION Definitions

[0040] The following definitions are provided to facilitate understanding of certain terms used throughout (his specification. {0041] In the present invention, "isolated" refers to material removed from its native environment (e.g., the natural environment if it is naturally occurring), and thus is altered "by the hand of man" from its natural state. For example, an isolated polynucleotide could be part of a vector or a composition of matter, or could be contained within a cell, and still be "isolated" because that vector, Composition of matter, or particular cell is not the original environment of the polynucleotide. {0042] In the present invention, a "membrane" C35 protein is one expressed on the cell surface through either direct or indirect association with the lipid bilayer, including, in particular, through prenylation of a carboxyl-terminal amino acid motif. Prenylation involves the covalent modification of aproteinby the addition of either a farnesyl or geranylgeranyl isoprenoid. Prenylation occurs on a cysteine residue located near the carboxyl-terminus of a protein. The C35 polypeptide contains the amino acids Cys-Val-Ile-Leu at positions 112-115, with the Leu being the C terminal residue of the polypeptide. The motif Cys-X-X-Leu, where 1,X" represents any aliphatic amino acid, results in the addition of a 20 carbon geranylgeranyl group onto the Cys residue. Generally, following addition of this lipid the three terminal amino acid residues are cleaved off the polypeptide, and the lipid group is methylated. Prenylation promotes the membrane localization of most proteins, with sequence motifs in the polypeptide being involved in Pto the |las^4 ftuclbar, of golgi iftembranes.

Prenylation plays a role in protein-protein interactions, and many prenylated proteins are involved in signal transduction. Examples of prenylated proteins include Ras and the nuclear lamin B. (Zhang, FX. and Casey, P.J., Ann. Rev. Biochem. 65:241-269 (1996)). TheC35 protein has been detected on the surface of two breast tumor cell lines by fluorescence analysis employing as a primary reagent a mouse anti-human C35 antiserum (FIGS. 4A-4C).

[0043] In the present invention, a "secreted" C35 protein refers to a protein capable of being directed to the ER, secretory vesicles, or the extracellular space as a result of a signal sequence, as well as a C35 protein released into the extracellular space without necessarily containing a signal sequence. If the C35 secreted protein is released into the extracellular space, the C35 secreted protein can undergo extracellular processing to produce a "mature" C35 protein. Release into the extracellular space can occur by many mechanisms, including exocytosis and proteolytic cleavage.

[0044] As used herein, a C35 "polynucleotide" refers to a molecule having a nucleic acid sequence contained in SEQ ID NO:l. For example, the C35 polynucleotide can contain the nucleotide sequence of the full length cDNA sequence, including the 5' and 3' untranslated sequences, the coding region, with or without the signal sequence, the secreted protein coding region, as well as fragments, epitopes, domains, and variants of the nucleic acid sequence. Moreover, as used herein, a C35 "polypeptide" refers to a molecule having the translated amino acid sequence generated from the polynucleotide as broadly defined. ,[0045] In specific embodiments, the polynucleotides of the invention are less than 300 nt, 200 nt, 100 nt, 50 nt, 15 nt, 10 nt, or 7 nt in length. In a further embodiment, polynucleotides of the invention comprise at least 15 contiguous nucleotides of C35 coding sequence, but do not comprise all or a portion of any C35 intron. In another embodiment, the nucleic acid comprising C35 coding sequence does not contain coding sequences of a genomic flanking gene (i.e., 5'

[0046] in the present invention, the full length C35 coding sequence is identified as SEQ ID NO: 1.

[0047] A C3 5 "polynucleotide" also refers to isolated polynucleotides which encode the C35 polypeptides, and polynucleotides closely related thereto.

[0048] A C35 "polynucleotide" also refers to isolated polynucleotides which encode the amino acid sequence shown in SEQ ID NO: 2, or a biologically active fragment thereof.

[0049] A C35 "polynucleotide" also includes those polynucleotides capable of hybridizing, under stringent hybridization conditions, to sequences contained in SEQ ID NO: 1, die complement thereof, or the cDNA wittiin the deposited clone. "Stringent hybridization conditions" refers to an overnight incubation at 42° C in a solution comprising 50% formaxnide, 5x SSC (750 mMNaCl, 75 mM sodium citrate), 50 mM sodium phosphate (pH 7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 ng/ml denatured, sheared salmon sperm DNA, followed by washing the filters in O.lx SSC at about 65°C.

[0050] Of course, a polynucleotide which hybridizes only to polyA+ sequences (such as any 3' terminal polyA+ tract of a cDNA), or to a complementary stretch of T (or U) residues, would not be included in the definition of "polynucleotide," since such a polynucleotide would hybridize to any nucleic acid molecule containing a poly (A) stretch or the complement thereof (e.g., practically any double-stranded cDNA clone).

[0051] The C35 polynucleotide can be composed of any polyribonucleotide or polydeoxyribonucleoti.de, which may be unmodified RNA or DNA or modified RNA or DNA. For example, C35 polynucleotides can be composed of single-and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single-and double-stranded regions, hybrid molecules comprising DNA and RNA that maybe single-stranded or, more typically, double-stranded or amixture ofsingle-and double-stranded regions. In addition, the C35 polynucleotides can be DNA. C35 polynucleotides may also contain one or more modified bases or DNA or RNA backbones modified for stability or for other reasons. "Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications can be made to DNA and RNA; thus, "polynucleotide" embraces chemically, enzymatically, or metabolically modified forms.

C35 polypeptides can be composed of amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres, and may contain amino acids other than the 20 gene-encoded amino acids. The C35 polypeptides may be modified by either natural processes, such as posttranslational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modifications can occur anywhere in the C35 polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given C35 polypeptide. Also, a given C35 polypeptide may contain many types of modifications. C35 polypeptides may be branched, for example, as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched, and branched cyclic C35 polypeptides may result from posttranslation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment • of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphotidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation ofpyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, pegylation, proteolytic processing, phosphorylation, prenylation, racennzjati^^i^l|p^|)g^|^^^|Esg^-EU||^®iediat^ad4ition ofamino acids to proteins such as arginylation, and ubiquitination. (See, for instance, Proteins-Structure And Molecular Properties, 2nd Ed., T. E. Creighton,W. H. Freeman and Company, New York (1993); Posttranslational Covalent Modification of Proteins, B. C. Johnson, Ed., Academic Press, New York, pgs. 1-12 (1983); Seifter et al., Meth Enzymol 182:626-646 (1990); Rattan et al.,Ann NY Acad Sci 663:48-62 (1992).)

[0053] "SEQ ID NO: 1" refers to a C35 polynucleotide sequence while "SEQ ID NO: 2" refers to a C35 polypeptide sequence.

[0054] A C35 polypeptide "having biological activity" refers to polypeptides exhibiting activity similar to, but not necessarily identical to, an activity of a C35 polypeptide, including mature forms, as measured in aparticularbiological assay, with or without dose dependency. In the case where dose dependency does exist, it need not be identical to that of the C35 polypeptide, but rather substantially similar to the dose-dependence in a given activity as compared to the C35 polypeptide (i.e., the candidate polypeptide will exhibit greater activity or not more than about 25-fold less and, preferably, not more than about tenfold less activity, and most preferably, notmore than about three-fold less activityrelative to the C35 polypeptide.) C35 Polynucleotides and Polypeptides

[0055] A 348 base pair fragment of C35 was initially isolated by subtractive hybridization of poly-A RNA from tumor and normal mammary epithelial cell lines derived from the same patient with primary and infiltrating intraductal mammary carcinoma. Band, V. et al., Cancer Res. 50:7351-7357 (1990). Employing primers based on this sequence and that of an overlapping EST sequence (Accession No. W57569), a cDNA that includes the full-length C35 coding sequence was then amplified and cloned from the BT-20 breast tumor cell line (ATCC, HTB-19). 'This C35 cDNA contains the entire coding region identified to the 348 bp coding sequence, 167 bp of 3' untranslated region. The open reading frame begins at an N-terminal methionine located at nucleotide position 1, and ends at a stop codon at nucleotide position 348 (FIG. 1A). A representative clone containing all or most of the sequence for SEQ ID NO: 1 was deposited with the American Type Culture Collection ("ATCC") on August 1,2000, and was given the ATCC Deposit Number PTA-2310. The ATCC is located at 10801 University Boulevard, Manassas, VA 20110-2209, USA. The ATCC deposit was made pursuant to the terms of the Budapest Treaty on the international recognition of the deposit of microorganisms for purposes of patent procedure .

[0056] Therefore, SEQ ID NO: 1 and the translated SEQ ID NO: 2 are sufficiently accurate and otherwise suitable for a variety of uses well known in the art and described further below. For instance, SEQ ID NO: 1 is useful for designing nucleic acid hybridization probes that will detect nucleic acid sequences contained in SEQ ID NO: 1 or the cDNA contained in the deposited clone. These probes will also hybridize to nucleic acid molecules in biological samples, thereby enabling a variety of forensic and diagnostic methods of the invention. Similarly, polypeptides identified from SEQ ID NO:2 maybe used to generate antibodies which bind specifically to C35, or to stimulate T cells which are specific for C35 derived peptide epitopes in association withMHC molecules on the cell surface. {0057] Nevertheless, DNA sequences generated by sequencing reactions can contain sequencing errors. The errors exist as misidentified nucleotides, or as insertions or deletions of nucleotides in the generated DNA sequence. The erroneously inserted or deleted nucleotides cause frame shifts in the reading frames of the predicted amino acid sequence. In these cases, the predicted amino acid sequence diverges from the actual amino acid sequence, even though the generated DNA sequence may be greater than 99.9% identical to the actual DNA sequence (for example, one base insertion or deletion in an open reading frame of over 1000 bases). (0058] Accordingly, for those applications requiring precision in the nucleotide sequence or the amino acid sequence, the present specification discloses not only the generated nucleotide sequence identified as SEQ ID NO:l and the predicted translated amino acid sequence identified as SEQ ID NO:2. The nucleotide sequence ofthe deposited C35 clone can readily be determined by sequencing the deposited clone in accordance with known methods. The predicted C35 amino acid sequence can then be verified from such deposits. Moreover, the amino acid sequence of the protein encoded by the deposited clone can also be directly determined by peptide sequencing or by expressing the protein in a suitable host cell containing the deposited human C35 cDNA, collecting the protein, and determining its sequence. (0059] The present invention also relates to the C35 gene corresponding to SEQ ID NO:l, or the deposited clone. The C35 gene can be isolated in accordance with known methods using the sequence information disclosed herein. Such methods include preparing probes or primers from the disclosed sequence and identifying or amplifying the C35 gene from appropriate sources of genomic material. (0060] Also described are species homologs of C35.

Species homologs may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source for the desired homologue. (0061] By "C35 polypeptide(s)" is meant all forms of C35 proteins and polypeptides described herein. The C35 polypeptides can be prepared in any suitable manner. Such polypeptides include isolated naturally occurring polypeptides, recombinantly produced polypeptides, synthetically produced polypeptides, or polypeptides produced by a combination of these methods.

Means for preparing such polypeptides are well understood in the art. (0062] The C35 polypeptides may be in the form of the membrane protein or a secreted protein, including the mature form, or may be a part of a larger protein, such as a fusion protein (see below). It is often advantageous to inclu^sjn-^-^^Rr7offlcE\ Of OCT 2808 additional amino acid sequence which contains secretory or leader sequences, pro-sequences, sequences which aid in purification, such as multiple histidine residues, or an additional sequence for stability during recombinant production.

[0063] C35 polypeptides are preferably provided in an isolated form, and preferably are substantially purified. A recombinantly produced version of a C35 polypeptide, including the secreted polypeptide, can be substantially purified by the one-step method described in Smith and Johnson, Gene 67:31-40 (1988). C35 polypeptides also can be purified from natural or recombinant sources using Q antibodies of the invention raised against the C35 protein in methods which are well known in the art.

[0064] Described is an isolated polypeptide capable of eliciting a cytotoxic T lymphocyte and/or helper T lymphocyte response in ahuman subject, the isolated polypeptide comprising, or, alternatively, consisting of, one or more C35 peptide epitopes or C35 peptide epitope analogs. In a preferred embodiment, said one or more C35 peptide epitopes are selected from the group consisting of: amino acids E4 to P12 ofSEQ ID NO:2, amino acids S9 to V17 of SEQ ID NO:2, amino acids S21 to Y29 of SEQ ID NO:2, G22 to €30 ofSEQ ID NO:2, amino acids 125 to C33 ofSEQ ID NO:2, amino acids T38 to V46 ofSEQ ID NO:2, amino acids G61 to 169 ofSEQ £ ID NO:2, amino acids T62 to N70 of SEQ ID NO:2, amino acids G63 to G71 of SEQ ID NO:2, amino acids F65 to L73 ofSEQ ID NO:2, amino acids 167 to F75 of SEQ ID NO:2, amino acids K77 to Y85 of SEQ ID NO:2, amino acids Q72 to E86 of SEQ ID NO:2, amino acids G81 to L89 of SEQ ID NO:2, amino acids K104 to C112 ofSEQ ID NO:2, amino acids K104 to VI13 ofSEQ ID NO:2, amino acids 1105 to VI13 ofSEQ ID NO:2, and amino acids N107 to LI 15 of SEQ ID NO:2. In apreferred embodiment, the isolated polypeptides comprising one or more C35 peptide epitopes (e.g., one or more octamers, nonamers, decamers, 15mers, or 20mers in Tables 1-3 or 5-6) or C35 peptide epitope analogs (e.g., an analog listed in Table 4) are not more than 114 amino acids in length, more preferably not more than 110 amino acids in length, more not more than 105 amino acids in length, more preferably not more than 100 amino acids in length, more preferably not more than 95 amino acids in length, more preferably not more than 90 amino acids in length, more preferably not more than 85 amino acids in length, more preferably not more than 80 amino acids in length, more preferably not more than 75 amino acids in length, more preferably not more than 70 amino acids in length, more preferably not more than 65 amino acids in length, more preferably not more than 60 amino acids in length, more preferably not more than 55 amino acids in length, more preferably not more than 50 amino acids in length, more preferably not more than 45 amino acids in length, more preferably not more than 40 amino acids in length, more preferablynot more than 35 amino acids in length, more preferablynot more than 30 amino acids in length, more preferablynot more than 25 amino acids in length, more preferably 20 amino acids in length, more preferably 15 amino acids in length, more preferably 14, 13, 12, 11, 10, 9 or 8 amino acids in length. Of course, although not explicitly listed here, isolated polypeptides of any length between, for example, 8 and 100 amino acids, comprising C35 peptide epitopes or C35 peptide epitope analogs are likewise contemplated by the present invention. In a preferred embodiment, the isolated polypeptide is a fragment of the C35 polypeptide shown in SEQ E> NO:2 and FIG. IB. In another embodiment, the present invention is directed to an isolated polypeptide capable of eliciting a cytotoxic T lymphocyte and/or helper T lymphocyte response in a human subject, the isolated polypeptide comprising, or, alternatively, consisting of multiple C35 peptide epitopes. In a particularly preferred embodiment, said multi-epitopepolypeptide is selected from the group consisting of: amino acids T101 to VI13 ofSEQ ID NO:2, amino acids E100 to VI13 ofSEQ ID NO:2, amino acids 193 to V113 of SEQ ID NO:2, amino acids D88 to VI13 of SEQ ID NO:2, amino acids P84 to VI13 of SEQ ID NO:2, amino acids K77 to V113 ofSEQ ID NO:2, amino acids Q72 to VI13 of SEQ ID NO:2, amino acids F65 to VI13 of SEQ ID NO:2, and amino present invention is directed to a fusion protein comprising at least one C35 peptide epitope listed in Tables 1-3 or 5-6, or a C35 peptide epitope analog listed in Table 4. In one embodiment, the at least one C35 peptide epitope or C35 peptide epitope analog is fused to a heterologous (i.e., non-C35) polypeptide. In another preferred embodiment, said fusion protein comprises two or more C35 peptide qutopes or two or more C35 peptide epitope analogs, either as a homopolymer or a heteropolymer. In another preferred embodiment, the fusion proteins of the present invention comprise at least oneC35 peptide epitope analog joined to at least one C35 peptide epitope. In a further embodiment, the epitopes/analogs are joined by an amino acid spacer or linker.

[0065] _ Also described is a pharmaceutical composition for use as a vaccine comprising such isolated polypeptides and fusion proteins. {0066] Also described is a method for stimulating a cytotoxic T lymphocyte and/or a helper T lymphocyte response in a human patient comprising administering to said patient an immunogenically effective amount of the pharmaceutical composition of the invention Polynucleotide and Polypeptide Variants (0067] "Variant" refers to a polynucleotide orpolypeptide differing from the C35 polynucleotide or polypeptide, but retaining essential properties thereof.

Generally, variants are overall closely similar, and, in many regions, identical to the C35 polynucleotide or polypeptide. {0068] By a polynucleotide having a nucleotide sequence at least, for example, 95% "identical" to a reference nucleotide sequence of the present invention, it is intended that the nucleotide sequence of the polynucleotide is identical to the reference sequence except that the polynucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence encoding the C35 polypeptide. In other words, to obtain a ^ polynucleotide having a nucleotide sequence at least 95% identical OCT 2006 RECEIVED. nucleotide sequence, up to 5% of the micleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence. The query sequence may be an entire sequence shown of SEQ ID NO:l, the ORF (open reading frame), or any fragment specified as described herein.

[0069] As a practical matter, whether any particular nucleic acid molecule or polypeptide is at least 90%, 95%, 96%, 97%, 98% or 99% identical to a nucleotide sequence or polypeptide sequence of the present invention can be determined conventionally using known computer programs. A preferredmethod for determining the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global Sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al.,Comp. App. Biosci. 6:231-245 (1990). In a sequence alignment the query and subject sequences are both DNA sequences. An RNA sequence can be compared by converting Us to T's. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB alignment of DNA sequences to calculate percent identity are: Matrix=Unitary, k-tuple=4, Mismatch Penalty=l, Joining Penalty=30, Randomization Group Length=0, Cutoff Score=l, Gap Penalty=5, Gap Size Penalty 0.05, Window Size=500 or the length of the subject nucleotide sequence, whichever is shorter. (0070] If the subject sequence is shorter than the query sequence because of 5' or 3' deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for 5' and 3' truncations of the subject sequence when calculating percent identity. For subject sequences truncated at the 5' or 3' ends, relative to the query sequence, the percent identity is corrected by calculating the number of bases of the query sequence that are 5' and 3' of the subject sequence, which are not matched/aligned as a percent of the total bases, of the query sequence. Whether INTELLECTUAL ~?R0Ptw' OP N. -1 AUG 2007 INTELLECTUAL PROPERTY OFFICE OF N.Z. - i AUG 2007 a nucleotide is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This corrected score is what is used for the purposes of the present invention. Only bases outside the 5' and 3' bases of the subject sequence, as displayed by the FASTDB alignment, which are not matched/aligned with the query sequence, are calculated for the purposes of manually adjusting the percent identity score.

[0071] For example, a 90 base subject sequence is aligned to a 100 base query sequence to determine percent identity. The deletions occur at the 5' end of the subject sequence and therefore, this FASTDB alignment does not show a matched/alignment of the first 10 bases at 5' end. The 10 unpaired bases represent 10% of the sequence (number of bases at the 5' and 3' ends not matched/total number of bases in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 bases were perfectly matched the final percent identity would be 90%. In another example, a 90 base subject sequence is compared with a 100 base query sequence. This time the deletions are internal deletions so that there are no bases on the 51 or 3' of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only bases 5' and 3' of the subject sequence which are not matched/aligned with the query sequence are manually corrected for. No other manual corrections are to made for the purposes of the present invention.

[0072] By a polypeptide having an amino acid sequence at least, for example, 95% "identical" to a query amino acid sequence of the present invention, it is intended that the amino acid sequence of the subject polypeptide is identical to the query sequence except that the subject polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the query amino acid sequence. In other words, to obtain apolypeptide having an amino acid sequence : amino acid residues in the subject sequence may be inserted, deleted, or substituted with another amino acid. These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence.

[0073] As apractical matter, whether any particular polypeptide is at least 90%, 95%, 96%, 97%, 98% or 99% identical to, for instance, the amino acid sequence shown in SEQ ID NO:2 or to the amino acid sequence encoded by deposited DNA clone, can be determined conventionally using known computer programs. A preferred method for determining the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al., Comp. App. Biosci. 6:237-245 (1990). In a sequence alignment the query and subject sequences are eitherbothnucleotidesequencesorbothamino acid sequences. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB amino acid alignment are: Matrix=PAM 0, k-tuple=2, Mismatch Penalty=l, Joining Penalty=20, Randomization Group Length=0, Cutoff Score=l, Window Size=sequence length, Gap Penalty=5, Gap Size Penalty==0.05, Window Size=500 or the length of the subj ect amino acid sequence, whichever is shorter. (0074] If the subject sequence is shorter than the query sequence due to - or C-terminal deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for - and C-terminal truncations of the subj ect sequence when calculating global percent identity. For subject sequences truncated at the - and C-termini, relative to the query sequence, the percent identity is corrected by calculating the number of residues of the query sequence that are — and C-terminal of the subject sequence, which are not matched/aligned with a corresponding subject residue, matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This final percent identity score is what is used for the purposes of the present invention. Only residues to the - and C-termini of the subject sequence, which are not matched/aligned with the query sequence, are considered for the purposes of manually adjusting the percent identity score. That is, only query residue positions outside the farthest - and C-terminal residues of the subject sequence.

[0075] For example, a 90 amino acid residue subject sequence is aligned with a 100 residue query sequence to determine percent identity. The deletion occurs at the N-terminus of the subject sequence and therefore, fee FASTDB alignment does not show a matching/alignment of the first 10 residues at the N-terminus. The 10 unpaired residues represent 10% of the sequence (number of residues at the—and C- termini not matched/total number of residues in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 residues were perfectly matched the final percent identity would be 90%. In another example, a 90 residue subject sequence is compared with a 100 residue query sequence. This time the deletions are internal deletions so there are no residues at the - or C-termini of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only residue positions outside the—and C-terminal ends of the subject sequence, as displayed in the FASTDB alignment, which are not matched/aligned with the query sequence are manually corrected for. No other manual corrections are to be made for the purposes of the present invention.

[0076] The C35 variants may contain alterations in the coding regions, non-coding regions, or both. Especially preferred are polynucleotide variants containing alterations which produce silent substitutions, additions, or deletions, but do not Nucleotide variants produced by silent substitutions due to the degeneracy of the genetic code are preferred. Moreover, variants in which 5-10,1-5, or 1-2 amino acids are substituted, deleted, or added in any combination are also preferred. C35 polynucleotide variants can be produced for a variety of reasons, e.g., to optimize codon expression for a particular host (change codons in the human mRNA to those preferred by a bacterial host such as E. coli).

[0077] Naturally occurring C35 variants are called "allelic variants," and refer to one of several alternate forms of a gene occupying a given locus on a chromosome of an organism. (Genes II, Lewin, B., ed., John Wiley & Sons, New York (1985).) Also, allelic variants can occur as "tandem alleles" which are highly homologous sequences that occur at different loci on chromosomes of an organism. These allelic variants can vary at either the polynucleotide and/or polypeptide level. Alternatively, non-naturally occurring variants may be produced by mutagenesis techniques or by direct synthesis. {0078] Using known methods of protein engineering and recombinant DNA technology, variants may be generated to improve or alter the characteristics of the C35 polypeptides. For instance, one or more amino acids can be deleted from the N-terminus or C-terminus of the secreted protein without substantial loss of biological function. The authors of Ron et al, J. Biol Cheni. 268: 2984-2988 (1993), reported variant KGF proteins having heparin binding activity even after deleting 3, 8, or 27 amino-terminal amino acid residues. Similarly, Interferon gamma exhibited up to ten times higher activity after deleting 8-10 amino acid residues from the carboxy terminus of this protein (Dobeli et al, J. Biotechnology 7:199-216 (1988)). {0079] Moreover, ample evidence demonstrates that variants often retain a biologicaiactivitysimilartothatofthenaturaUyoccurringprotein. Forexample, Gayle and coworkers (J. Biol Chem 268:22105-22111 (1993)) conducted extensive mutational analysis of human cytokine IL-la. They used random mutagenesis to generate over 3,500 individual IL-la mutants that averaged 2.5 mutations were examined at every possible amino acid position. The investigators found that "[m]ost of the molecule could be altered with little effect . on either [binding or biological activity]." (See, Abstract) in feet, only 23 unique amino acid sequences, out of more than 3,500 nucleotide sequences examined, produced a protein that significantly differed in activity from wild-type.

[0080] Furthermore, even if deleting one or more amino acids from the N-terminus or C-terminus of a polypeptide results in modification or loss of one or more biological functions, other biological activities may still be retained. For example, the ability of a deletion variant to induce and/or to bind antibodies which recognize the secreted form will likely be retained when less than the majority of the residues of the secreted form are removed from the N-terminus or C-terminus. Whether a particular polypeptide lacking - or C-terminal residues of a protein retains such immunogenic activities can readily be determined by routine methods described herein and otherwise known in the art.

[0081] Thus, also described are C35polypeptideYariantswhichshow substantial biological activity. Such variants include deletions, insertions, inversions, repeats, and substitutions selected according to general rules known in the art so as to have little effect on activity. For example, guidance concerning how to make phenotypically silent amino acid substitutions is provided in Bowie, J. U. et al., Science 247:1306-1310(1990), wherein the authors indicate that there are two main strategies for studying the tolerance of an amino acid sequence to change.

[0082] The first strategy exploits the tolerance of amino acid substitutions by natural selection during the process of evolution. By comparing amino acid sequences in different species, conserved amino acids can be identified. These conserved amino acids are likely important for protein function. In contrast, the amino acid positions where substitutions have been tolerated by natural selection indicates that these positions are not critical for protein function. Thus, positions intellectual property office of n.z. 2 5 OCT 200G RECEIVE tolerating amino acid substitution could be modified while still maintaining biological activity of the protein.

J0083] The second strategy uses genetic engineering to introduce amino acid changes at specific positions of a cloned gene to identify regions critical for protein function. For example, site directed mutagenesis or aianine-scanning mutagenesis (introduction of single alanine mutations at every residue in the molecule) canbeused. (Cunningham and Wells, Science244:1081-1085 (1989).) The resulting mutant molecules can then be tested for biological activity. .[0084] As the authors state, these two strategies have revealed that proteins are surprisingly tolerant of amino acid substitutions. The authors further indicate which amino acid changes are likely to be permissive at certain amino acid positions in the protein. For example, most buried (within the tertiary structure of the protein) amino acid residues require nonpolar side chains, whereas few features of surface side chains are generally conserved. Moreover, tolerated conservative amino acid substitutions involve replacement of the aliphatic or hydrophobic amino acids Ala, Val, Leu and lie; replacement of the hydroxy! residues Ser and Thr, replacement of the acidic residues Asp and Glu; replacement of the amide residues Asn and Gin, replacement of the basic residues Lys, Arg, and His; replacement of the aromatic residues Phe, Tyr, and Tip, and replacement of the small-sized amino acids Ala, Ser, Thr, Met, and Gly.

[0085] Besides conservative amino acid substitution, variants of C35 include (i) substitutions with one or more of the non-conserved amino acid residues, where the substituted amino acid residues may or may not be one encoded by the genetic code, or (ii) substitution with one or more of amino acid residues having a substituent group, or (iii) fusion of the mature polypeptide with another compound, such as a compound to increase the stability and/or solubility of the polypeptide (for example, polyethylene glycol), or (iv) fusion of the polypeptide with additional amino acids, such as an IgG Fc fusion region peptide, or leader or secretory sequence, or a sequence facilitating purification. Such variant polypeptides are deemed to be within the scope of those skilled in the art from the teachings herein.

[0086] For example, C35 polypeptide variants containing amino acid substitutions of charged amino acids with other charged or neutral amino acids may produce proteins with improved characteristics, such as less aggregation.

Aggregation of pharmaceutical formulations both reduces activity and increases clearance due to the aggregate's immunogenic activity. (Pinckard et al., Clin.

Exp. Immunol. 2:331-340 (1967); Robbins et al, Diabetes 36: 838-845 (1987); Clelmd etal., Crit. Rev. Therapeutic Drug Carrier Systems 10:307-377 (1993).) Polynucleotide and Polypeptide Fragments

[0087] As described herein, a "polynucleotide fragment" refers to a short polynucleotide having a nucleic acid sequence contained in the deposited clone or shown in SEQ ID NO: 1. The short nucleotide fragments are preferably at least about 15 nt, and more preferably at least about 20 nt, still more preferably at least about 30 nt, and even more preferably, at least about 40 nt in length. A fragment "at least 20 nt in length," for example, is intended to include 20 or more contiguous bases from the cDNA sequence contained in the deposited clone or the nucleotide sequence shown in SEQ ID NO: 1. These nucleotide fragments are useful as diagnostic probes and primers as discussed herein. Of course, larger fragments (e.g., at least 50,100,150,200,250,300 nucleotides) are preferred.

[0088] Moreover, representative examples of C35 polynucleotide fragments include, for example, fragments having a sequence from about nucleotide number 1-50,51-100,-101-150,151-200,201-250,251-300, or301 to the end of SEQ ID NO:l or the cDNA contained in the deposited clone. In this context "about" includes the particularly recited ranges, larger or smaller by several (5, 4, 3,2, or 1) nucleotides, at either terminus or at both termini. Preferably, these fragments encode a polypeptide which has biological activity. More preferably, these polynucleptidesscan be us# as prolls^Efflnmers a&disciassedhereku___ ' intellectual property office of HI 2 5 OCT 2006 RECEIVED

[0089] A "polypeptide fragment" refers to a short amino acid sequence contained in SEQ ID NO:2 and FIG. IB or encoded by the cDNA contained in the deposited clone. Protein fragments may be "free-standing," or comprised within a larger polypeptide of which the fragment forms a part or region, most preferably as a single continuous region. Representative examples of polypeptide fragments of the invention, include, for example, fragments from about amino acidnumber 1-20,21-40,41-60,61-80,81-100, or 101 to the end of the coding region. Moreover, polypeptide fragments can comprise about 7,8,9, ,20,30,40, 50,60,70,80,90, or 100 amino acids in length. In this context "about" includes the particularly recited ranges or lengths, larger or smaller by several (5,4,3,2, or 1) amino acids, at either extreme or at both extremes.

[0090] Preferred polypeptide fragments include the secreted C35 protein as well as the mature form. Further preferred polypeptide fragments include 1he secreted C35 protein or the mature form having a continuous series of deleted residues from the amino or the carboxy terminus, or both. Further preferred polypeptide fragments include fragments ofthe C35 polypeptide comprisingoneormoreC35 peptide epitopes.

[0091] As mentioned above, even if deletion of one or more amino acids from the N-terminus of a protein results in modification or loss of one or more biological functions of the protein, other biological activities may still be retained. Thus, the ability of shortened C35 muteins to induce and/or bind to antibodies which recognize the complete or mature forms of the polypeptides generally will be retained when less than the majority of the residues of the complete or mature polypeptide are removed from the N-teiminus. Whether a particular polypeptide lacking N-terminal residues of a complete polypeptide retains such immunologic activities can readily be determined by routine methods described herein and otherwise known in the art. It is not unlikely that a C35 mutein with a large number of deleted N-terminal amino acid residues may retain some biological or immunogenic activities. In fact, in the case of C35 peptide epitopes, peptides intellectual property OFFICE OF N.Z 2 5 OCT 2006 RECEIVED, composed of as few as 9, 8, or even 7 C35 amino acid residues often evoke an immune response. ..(0092] Accordingly, also described are polypeptides having one or more residues deleted from the amino terminus of the C35 amino acid sequence shown in SEQ ID NO:2, up to the Threonine residue at position number 105 and polynucleotides encoding such polypeptides.

[0093] Also as mentioned above, even if deletion of one or more amino acids from the C-terminus of a protein results in modification or loss of one or more biological functions of the protein, other biological activities may still be retained. Thus, the ability of the shortened C35 mutein to induce cytotoxic T lymphocytes (CTLs) and/or helper T lymphocytes (HTLs) and/or to bind to antibodies which recognize the complete or mature forms of the polypeptide generally will be retained when less than the majority of the residues of the complete or mature polypeptide are removed from the C-terminus. "Whether a particular polypeptide lacking C-terminal residues of a complete polypeptide retains such immunologic activities can readily be determined by routine methods described herein and otherwise known in the art. It is not unlikely that a C35 mutein with a large number of deleted C-tetminal amino acid residues may retain some biological or immunogenic activities. .(0094] Accordingly, also described are polypeptides having one or more residues deleted from the carboxy terminus of the amino acid sequence of the C3 5 polypeptide shown in SEQ ID NO:2, up to the valine residue at position number 10, and polynucleotides encoding such polypeptides (0095] Moreover, also described are polypeptides having one or more amino acids deleted from both the amino and the carboxyl termini. In preferred embodiments, the invention is directed to peptides having residues: E4toP12,S9 to V17; V10 to V17; E16 to V23; E16 to B24; E16 to 125; S21 toY29; S21 to F35; G22 to C30; 125 to C33; C30 to T38; E31 to Y39; E36 to A43; A37 to A45; A37 to V46; T38 to V46; Y39 to V46; S44 to 153; A45 to 153; G52 to L59; E54 to T62; S57 to;F75; R5*8 L59""to'^1T3 I69f®62 tfr N70, £ WtISlectuai property office of n.2. 2 5 OCT 2006 RECEIVED NO:24); H12836 (SEQ ID NO:25); R22401 (SEQ ED NO:26); N34596 (SEQ ID NO:27); W32121 (SEQIDNO:28);T84927(SEQIDNO:29);R63575 (SEQ ID N0:30); R23139 (SEQ ID N0:31); AA337071 (SEQ ID NO:32); AA813244 (SEQ ED NO:33); AA313422 (SEQ ID NO:34); N31910 (SEQ ID NO:35); N42693 (SEQ ID NO:36); N32532 (SEQ ID NO:37); AA375119 (SEQ ID NO:38); R32153 (SEQ ID NO:39); R23369 (SEQ ID N0:40); AA393628 (SEQ ID N0:41); H12779 (SEQ ID NO:42); AI083674 (SEQ ID NO:43); AA284919 (SEQ ID NO:44); AA375286 (SEQ ID NO:45); AA830592 (SEQ ID N0:46); H95363 (SEQ ID NO:47); T92052 (SEQ ID NO:48); AI336555 (SEQ ID NO:49); AI285284 (SEQ ID N0:50); AA568537 (SEQ ID N0:51); AI041967 (SEQ ID NO:52); W44577 (SEQ ID NO:53); R22332 (SEQ1DN0:54); N27088 (SEQ ID NO:55); H96418 (SEQ ID NO:56); AI025384 (SEQ ID NO:57); AA707623 (SEQ ID NO:58); AI051009 (SEQ ID NO:59); AA026774 (SEQ ID N0:60); W51792 (SEQ ID NO:61); AI362693 (SEQ ID NO:62); AA911823 (SEQ ID NO:63); H96422 (SEQ ID NO:64); AI800991 (SEQ ID NO:65); AI525314 (SEQ ID NO:66); AI934846 (SEQ ID NO:67); AI937133 (SEQ ID NO:68); AW006797 (SEQ ID NO:69); AI914716 (SEQ ID N0:70); AI672936 (SEQ ID N0:71); W61294 (SEQ ID NO:72); AI199227 (SEQ ID NO:73); AI499727 (SEQ ID NO:74); R32I54 (SEQ ID NO:75); AI439771 (SEQ ID NO:76); AA872671 (SEQ 30D NO:77); AA502178 (SEQ ID NO:78); N26715 (SEQ ID NO:79); AA704668 (SEQ ID N0:80); R68799 (SEQ ID N0:81); H56704 (SEQ ED NO:82); AB60416 (SEQ ID NO:83).

[0099] Thus, further described are polynucleotides comprising the polynucleotide fragments and full-length polynucleotide (e.g. the coding region) described herein exclusive of one ormore of the above-recited ESTs. Also, the nucleotide sequences in SEQ ID NO: 152, SEQ ID NO: 154, and SEQ ID NO: 156 are excluded from the present invention.

[0100] Also preferred are C35 polypeptide and polynucleotide fragments characterized by structural or functional domains. Preferred embodiments of the intellectual property office of n.z. 2 5 OCT 2006 CEIVEC invention include fragments that comprise MHC binding epitopes and prenylation sites.

Other preferred fragments are biologically active C35 fragments. Biologically active fragments are those exhibiting activity similar, but not necessarily identical, to an activity of the C35 polypeptide. The biological activity of the fragments may include an improved desired activity, or a decreased undesirable activity.

Epitopes & Antibodies Cellular peptides derived by degradation of endogenously synthesized proteins are translocated into a pre-Golgi compartment where they bind to Class I or Class II MHC molecules for transport to the cell surface. These class I MHC:peptide complexes are the target antigens for specific CD8+ cytotoxic T cells. Since all endogenous proteins "turn over," peptides derived from any cytoplasmic or nuclear protein may bind to an MHC molecule and be transported for presentation at the cell surface. This allows T cells to survey a much largo: representation of cellular proteins than antibodies which are restricted to recognize conformational determinants of only those proteins that are either secreted or integrated at the cell membrane. The T cell receptor antigen binding site interacts with determinants of both the peptide and the surrounding MHC. T cell specificity must, therefore, be defined in terms of an MHC.peptide complex. The specificity of peptide binding to MHC molecules is very broad and of relatively low affinity in comparison to the antigen binding site of specific antibodies. Class I-bound peptides are generally 8-10 residues in length that accommodate amino acid side chains of restricted diversity at certain key positions that match pockets in the MHC peptide binding site. These key features of peptides that bind to a particular MHC molecule constitute a peptide binding motif. (0103] The term "derived" when used to discuss a peptide epitope is a synonym for "prepared." A derived epitope can be isolated from a natural source, or it can be synthesized in accordance with standard protocols in the art. Synthetic epitopes can comprise artificial amino acids "amino acid mimetics," such as D isomers of natural occurring L amino acids or non-natural amino acids such as cyclohexylalanine. A derived/prepared epitope can be an analog of a native epitope. (0104] An "epitope" is the collective features of a molecule, such as primary, secondary and tertiary peptide structure, and charge, that together form a site recognized by an immunoglobulin, T cell receptor or HLA molecule. Alternatively, an epitope can be defined as a set of amino acid residues which is involved in recognition by a particular immunoglobulin, or in the context of T cells, those residues necessary for recognition by T cell receptor proteins and/or Major Histocompatibility Complex (MHC) receptors. Epitopes arepresent in nature, and can be isolated, purified or otherwise prepared/derived by humans. For example, epitopes can be prepared by isolation from a natural source, or they can be synthesized in accordance with standard protocols in the art. Synthetic epitopes can comprise artificial amino acids "amino acid mimetics," such as D isomers of natural occurring L amino acids or non-natural amino acids such as cyclohexylalanine. Throughout this disclosure, the terms epitope and peptide are often used interchangeably. Also, the term epitope as used herein is generally understood to encompass analogs of said epitopes. (0105] Protein or polypeptide molecules that comprise one or more C35 peptide epitopes described herein as well as additional amino acid(s) are described. In certain embodiments, there is a limitation on the length of a polypeptide of die invention of, for example, not more than 114 amino acids, not more than 110 amino acids, not more than 100 amino acids, not more than 95 amino acids, not more than 90 amino acids, not more than 85 amino acids, not more than 80 amino acids, not more than 75 amino acids, not more than 70 amino a^Ms, not more than 65mmino acids, not more than intellectual property office of n.z. 2 5 OCT 2006 RECEIVED 60 amino acids, not more than 55 amino acids, not more than 50 amino acids, not more than 45 amino acids, not more than 40 amino acids, not more than 35 amino acids, not more than 30 amino acids, not more than 25 amino acids, 20 amino acids, 15 amino acids, or 14,13,12,11,10,9 or 8 amino acids, hi some instances, the embodiment that is length-limited occurs when the protein/polypeptide comprising an epitope of the invention comprises a region (i.e., a contiguous series of amino acids) having 100% identity with a native sequence. In order to avoid the definition of epitope from reading, e.g., on whole natural molecules, there is a limitation on the length of any region that has 100% identity with a native polypeptide sequence. Thus, for a polypeptide comprising an epitope described herein and a region with 100% identity with the native C35 polypeptide sequence, the region with 100% identity to the native sequence generally has a length of: less than or equal to 114 amino acids, more often less than or equal to 100 amino acids, often less than or equal to 85 amino acids, often less than or equal to 75 amino acids, often less than or equal to 65 amino acids, and often less than or equal to 50 amino acids, hi certain embodiments, the C35 polypeptide described herein comprises a peptide having a region with less than 50 amino acids that has 100% identity to a native peptide sequence, in any increment of amino acids (i.e., 49,48,47,46,45,44,43,42,41,40,39,38,37, 36,35,34,33,32,31,30,29,28,27,26,25,24,23,22,21,20,19,18,17,16,15, 14,13,12,11, 10,9, 8, 7, 6, 5) down to 5 amino acids. Preferably, such C35 polypeptide comprises one or more C35 peptide epitopes.

[0106] Accordingly, polypeptide or protein sequences longer than 100 amino acids are described., so long as they do not comprise any contiguous sequence of more than 114 amino acids that have 100% identity with a native polypeptide sequence. For any polypeptide that has five contiguous residues or less that correspond to a native sequence, there is no limitation on the maximal length of that polypeptide. hi one embodiment, the polypeptide described herein comprising one intellectual property office of n.z. 2 5 OCT 2006 RECEIVED or more C35 peptide epitopes is less than 60 residues long in any increment down to eight amino acid residues.

[0107] An "immunogenic peptide" or "peptide epitope" is apeptide that will bind an HLA molecule and induce a cytotoxic T lymphocyte (CTL) response and/or a helper T lymphocyte (HTL) response. Thus, immunogenic peptides of the invention are capable of binding to an appropriate HLA molecule and thereafter inducing a cytotoxic T lymphocyte (CTL) response, or a helper T lymphocyte (HTL) response, to the peptide.

[0108] The term "motif' refers to apattem of residues in an amino acid sequence of defined length, usually a peptide of from about 8 to about 13 amino acids for a class I HLA motif and from about 16 to about 25 amino acids for a class II HLA motif, which is recognized by a particular HLA molecule. Motifs are typically different for each HLA protein encoded by a given human HLA allele. These motifs often differ in their pattern of the primary and secondary anchor residues.

[0109] A "protective immune response" or "therapeutic immune response" refers to a cytotoxic T lymphocyte (CTL) and/or an helper T lymphocyte (HTL) response to an antigen derived from an pathogenic antigen (e.g., an antigen from an infectious agent or a tumor antigen), which in some way prevents or at least partially arrests disease symptoms, side effects or progression. The immune response may also include an antibody response which has been facihtated by the stimulation of helper T cells.

[0110] The term "residue" refers to an amino acid or amino acid mimetic incorporated into a peptide or protein by an amide bond or amide bond mimetic.

[0111] "Synthetic peptide" refers to a peptide that is not naturally occurring, but is man-made using such methods as chemical synthesis or recombinant DNA technology.

[0112] As used herein, a "vaccine" is a composition that contains one or more peptide epitopes described herein, see, e.g., Tables 1-3 and 5-6, exclusive of peptide E-100 to R-109, and a pharmaceutical^ acceptable carrier. There are numerous embodiments of vaccines described herein, such as by intellectual property Officii of n.z. 2 5 OCT 2006 RECEIVER a cocktail of one or more peptides; apolyepitopic peptide comprising one or more peptides described herein; or nucleic acids that encode such peptides or polypeptides, e.g., a minigene that encodes a polyepitopic peptide. The "one or more peptides" or "one or more epitopes" can include, for example, at least 2,3, 4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27, 28,29,30,31,32,33,34,35,36,37,38,39,40,45,50,55,60,65,70,75,80,85, 90, 95, or 100 or more peptides or epitopes described herein. The peptides or polypeptides can optionally be modified, such as by lipidation, addition of targeting or other sequences. HLA class I-binding peptides of the invention can be linked to HLA class II-binding peptides, to facilitate activation of both cytotoxic T lymphocytes and helper T lymphocytes. Vaccines can comprise peptide pulsed antigen presenting cells, e.g., dendritic cells. £0113] In a preferred embodiment, the isolated polypeptides described herein comprise or, alternatively, consist of one or more of the following C35 peptide epitopes: amino acids E4 to P12 of SEQ ID NO:2, amino acids S9 to VI7 ofSEQ ID NO:2, amino acids S21 to Y29 ofSEQ ID NO:2, G22 to C30 ofSEQ ID NO: 2, amino acids 125 to C33 of SEQ ID NO:2, amino acids T38 to V46 of SEQ ID NO:2, amino acids G61 to 169 ofSEQ ID NO:2, amino acids T62 to N70 of SEQ IDNO:2, amino acids G63 to G71 ofSEQ ID NO:2, amino acids F65 to L73 ofSEQ ID NO:2, amino acids 167 to F75 ofSEQ ID NO:2, amino acids K77 to Y85 of SEQ ID NO:2, amino acids Q72 to E86 of SEQ ID NO:2, amino acids G81 to L89 of SEQIDNO:2, amino acids K104 to CI 12 ofSEQ IDNO:2, amino acids K104 to VI13 of SEQ ID NO:2, ammo acids 1105 to VI13 of SEQ ID NO:2, or amino acids N107 to LI 15 of SEQ ID NO:2. In another embodiment, said polypeptides comprising or, alternatively, consisting of one or more C35 peptide epitopes are selected from the group consisting of: T101 to VI13 ofSEQ ID NO:2, E100 to V113 ofSEQ ID NO:2,193 to V113 ofSEQ ID NO:2, D88 to V113 ofSEQ ID NO:2, P84 to V113 ofSEQ ID NO:2, K77 to VI13 of SEQ ID NO:2, Q72 to VI13 of SEQ ID NO:2, F65 to V113 of SEQ ID NO:2, aiidL59 M#llloi; SEQ ID NO:2. It is contemplated intellectual property office of n.z 2 5 OCT 2006 RECEIVED that fragments of C35 peptide epitopes and polypeptides comprising fragments of C35 peptide epitopes described herein will, in some instances, also be Mffiil for stimulating a cytotoxic T lymphocyte response. Thus, also described are fragments of the C35 peptide epitopes in which 1,2,3,4, 5 or more amino acids of the peptide sequence provided have been deleted from either the amino terminus or the carboxy terminus of the peptide. In addition, it is contemplated that larger fragments of the C35 polypeptide that contain one or more of the peptide epitopes of the invention may also be used to stimulate a CTL response in a patient It is further contemplated that polypeptides that comprise one or more peptide epitopes * described herein h* addition to heterologous, i.e., non-C35, flanking sequences may also be used to stimulate a CTL response.

In addition to the specific C35 peptide epitopes specifically listed above, many other peptide epitopes are contemplated herein. j Thus, the isolated polypeptides of the described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 8mers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to T8; S2 to S9; G3 to V10; E4 to Al 1; P5 to P12; G6 to P13; Q7 to P14; T8 to E15; S9 to E16; V10 to V17; All toE18;P12toP19; P13 to G20; P14 to S21;E15 to G22; E16 to V23; V17 to R24; E18 to 125; P19 to V26; G20 to V27; S21 to E28; G22 to Y29; V23 to C30; R24 to E31; 125 to P32; V26 to C33; V27 to G34; E28 to F35; Y29 to E36; C30 to A37; E31 to T38; P32 to Y39; C33 to L40; G34 to E41; F35 to L42; E36 to A43; A37 to S44; T38 to A45; Y39 to V46; L40 to K47; E41 to E48; L42 to Q49; A43 to Y50; S44 to P51; A45 to G52; V46 to 153; K47 to E54; E48 to 155; Q49 to E56; Y50 to S57; P5l'to R58; G52 to L59; 153 to G60; E54 to G61; 155 to T62; E56 to G63; S57 to A64; R58 to F65; L59 to E66; G60 to 167; G61 to E68; T62 to 169; G63 to N70; A64 to G71; F65 to Q72; E66 to L73; 167 to V74; E68 to F75; 169 to S76; N70 to K77; G71 to L78; Q72 to E79; L73 to N80; V74 to G81; F75 to G82; S76 to F83; K77 to P84; L78 to Y85; E79 to E86; N80 to K87; G81 to D88; G82 to L89; F83 to 190; P84 to E91; Y85 to A92; E86 to 193; K87 foB94; D8&toH95;C89 to A96; 190 to S97; E91 to N98; A92 to G99; intellectual property office:] of n.z. 2 5 OCT 2006 | RECEIVED. 193 to El 00; R94 to T101; R95 to LI 02; A96 to El 03; S97 toK104;N98toI105; G99 to T106; E100toN107; T101 to S108; L102 to R109; E103 to P110; K104 to PI 11; 1105 to C112; T106 to VI13; N107to 1114; and S108 to LI 15. (0115] In a further embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 9mers (residues correspond to SEQ ID NO:2andFIG. IB): Ml to S9; S2 to V10; G3 to Al 1; E4 to P12; P5 to P13; G6 to P14; Q7 to E15; T8 to El6; S9 to V17; V10 to E18; All to P19; P12 to G20; P13 to S21; P14 to G22; E15 to V23; E16 to R24; V17 to 125; E18 to V26; P19 to V27; G20 to E28; S21 to Y29; G22 to C30; V23 to E31; R24 to P32; 125 to C33; V26 to G34; V27 to F35; E28 to E36; Y29 to A37; C30 to T38; E31 to Y39; P32 to L40; C33 to E41; G34 to L42; F35 to A43; E36 to S44; A37 to A45; T38 to V46; Y39to K47; IA0 to E48; E41 to Q49; L42 to Y50; A43 to P51; S44 to G52; A45 to 153; V46 to E54; K47 to 155; E48 to E56; Q49 to S57; Y50 to R58; P51 to L59; G52 to G60; 153 to G61; E54 to T62; 155 to G63; E56 to A64; S57 to F65; R58 to E66; L59 to 167; G60 to E68; G61 to 169; T62 to N70; G63 to G71; A64 to Q72; F65 to L73; E66 to V74; 167 to F75; E68 to S76; 169 to K77; N70 to L78; G71 to E79; Q72 to N80; L73 to G81; V74 to G82; F75 to F83; S76 to P84; K77 to Y85; L78 to E86; E79 to K87; N80 to D88; G81 to L89; G82 to 190; F83 to E91; P84 to A92; Y85 to 193; E86 to R94; K87 to R95; D88 to A96; L89 to S97; 190 to N98; E91 to G99; A92 to E100; 193 to T101; R94 to L102; B95 to E103; A96 to K104; S97 to 1105; N98 to T106; G99 to N107; E100 to S108; T101 to R109; L102 to PI 10; E103 to Pill; K104 to CI 12; 1105 to VI13; T106 to 1114; and N107 to LI 15.

[0116] In a further embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following lOmers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to V10; S2 to All; G3 to P12; E4 to P13; P5 to P14; G6 to E15; Q7 to E16; T8 to V17; S9 to E18; V10 to P19; All to G20; P12 to S21; P13 to 022; PI4 to V23; Ef5to R24; E16 to 125; V17 to V26; E18 to V27; P19 to |$tfeLLECTUAL PROPERW OFFIi OF N.Z. 2 5 OCT 2006 ECEIVEC G20 to Y29; S21 to C30; G22 to E31; V23 to P32; R24 to C33; 125 to G34; V26 to F35; V27 to E36; E28 to A37; Y29 to T38; C30 to Y39; E31 to L40; P32 to E41; C33 to L42; G34 to A43; F35 to S44; E36 to A45; A37 to V46; T38 to K47; Y39 to E48; L40 to Q49; E41 to Y50; L42 to P51; A43 to G52; S44 to 153; A45 to E54; V46 to 155; K47 to E56; E48 to S57; Q49 to R58; Y50 to L59; P51 to G60; G52 to G61; 153 to T62; E54 to G63; 155 to A64; E56 to F65; S57 to E66; R58 to 167; L59 to E68; G60 to 169; G61 to N70; T62 to G71; G63 to Q72; A64 < to L73; F65 to V74; E66 to F75; 167 to S76; E68 to K77; 169 to L78; N70 to E79; G71 toN80; Q72 to G81; L73 to G82; Y74 to F83; F75 to P84; S76 to Y85; K77 to E86; L78 to K87; E79 to D88; N80 to L89; G81 to 190; G82 to E91; F83 to A92; P84 to 193; Y85 to R94; E86 to R95; K87 to A96; D88 to S97; L89 to N98; 190 to G99; E91 to E100; A92 to T101; 193 to L102; R94 to E103; R95 to K104; A96 to 1105; S97 to T106; N98 to N107; G99 to S108; E100 to R109; T101 to PI 10; LI02 to PI 11; E103 to CI 12; K104 to VI13; 1105 to II14; T106 to LI 15.

[0117] In a further embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 1 liners (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to All; S2 to P12; G3 to P13; E4 to P14; P5 to E15; G6 to E16; Q7 to VI7; T8 to E18; S9 to P19; V10 to G20; All to S21; P12 to G22; P13 to V23; P14 to R24; E15 to 125; E16 to V26; V17 to V27; E18 to E28; P19 to Y29; G20 to C30; S21 to E31; G22 to P32; V23 to C33; R24 to G34; 125 to F35; V26 to E36; V27 to A37; E28 to T38; Y29 to Y39; C30 to L40; E31 to E41; P32 to L42; C33 to A43; G34 to S44; F35 to A45; E36 to V46; A37 to K47; T38 to E48; Y39 to Q49; L40 to Y50; E41 to P51; L42 to G52; A43 to 153; S44 to E54; A45 to 155; V46 to E56; K47 to S57; E48 to R58; Q49 to L59; Y50 to G60; P51 to G61; G52 to T62; 153 to G63; E54 to A64; 155 to F65; E56 to E66; S57 to 167; R58 to E68; L59 to 169; G60 to N70; G61 to G71; T62 to Q72; G63 to L73; A64 to V74; F65 to F75; E66 to S76; 167 to K77; E68 to L78; 169 to E79; N70 to N80; G71 to G81; Q72 to G82; L73 to F83; V74 to P84; F75 to Y85; S76 to E86; K77 to:K87;-L78 to-D88;J7.9 to L89; N80 to 190; G81 to E91; G82 to A92; Actual property office Of hi. 2 5 OCT 2006 RECEIVED 193; P84 to R94; Y85 to R95; E86 to A96; K87 to S97; D88 to N98; L89 to G99; 190 to El 00; E91 to T101; A92 to L102; 193 to E103; R94 to K104; R95 to 1105; A96 to T106; S97 to N107; N98 to S108; G99 to R109; E100 to P110; T101 to Pill; LI02 to CI 12; E103 to Y113; K104 to 1114; 1105 to L115.

[0118] In another preferred embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting of, C3 5 peptide epitopes include the following 12mers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to P12; S2 to P13; G3 to P14; E4 to E15; P5 to E16; G6 to V17; Q7 to E18; T8 Q toP19; S9 to G20; V10 to S21; All to G22; P12to V23;P13 toR24; P14 to 125; E15 to V26; E16 to V27; V17 to E28; E18 to Y29; PI 9 to C30; G20 to E31; S21 to P32; G22 to C33; V23 to G34; R24 to F35; 125 to E36; V26 to A37; V27 to T38; E28 to Y39; Y29 to L40; C30 to E41; E31 to L42; P32 to A43; C33 to S44; G34 to A45; F35 to V46; E36 to K47; A37 to E48; T38 to Q49; Y39 to Y50; L40 to P51; E41 to G52; L42 to 153; A43 to E54; S44 to 155; A45 to E56; V46 to S57; K47 to R58; E48 to L59; Q49 to G60; Y50 to G61; P51 to T62; G52 to G63; 153 to A64; E54 to F65; 155 to E66; E56 to 167; S57 to E68; R58 to 169; L59 to N70; G60 to G71; G61 to Q72; T62 to L73; G63 to V74; A64 to F75; F65 to S76; E66 to K77; 167 to L78; E68 to E79; 169 to N80; N70 to G81; G71 to G82; Q72 to F83; L73 to P84; V74 to Y85; F75 to E86; S76 to K87; K77 to D88; L78 to L89; ® E79 to 190; N80 to E91; G81 to A92; G82 to 193; F83 to R94; P84 to R95; Y85 to A96; E86 to S97; K87 to N98; D88 to G99; L89to E100; 190 to T101; B91 to L102; A92 to E103; 193 to K104; R94 to 1105; R95 to T106; A96 to N107; S97 to S108; N98 to R109; G99 to P110; E100 to Pill; T101 to C112; L102 to VI13; E103 to II14; K104 to LI 15.

[0119] In another preferred embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 13mers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to P13; S2 to P14; G3 to E15; E4 to E16; P5 to V17; G6 to E18; Q7 to P19; T8 to G20; S9 to S21; V10 to G22; Al 1 to V23; P12 to R24; P13 to 125;PI4teV26yE151$V27; E16toE28; V17to Y29;E18 to C30; P19 toE31; intellectual property office of n.2. 2 5 OCT 2006 RECEIVED G20 to P32; S21 to C33; G22 to G34; V23 to F35; R24 to E36; 125 to A37; V26 to T38; V27 to Y39; E28 to L40; Y29 to E41; C30 to L42; E31 to A43; P32 to S44; C33 to A45; G34 to V46; F35 to K47; E36 to E48; A37 to Q49; T38 to Y50; Y39 to P51; L40 to G52; E41 to 153; 142 to E54; A43 to 155; S44 to E56; A45 to S57; V46 to R58; K47 to L59; E48 to G60; Q49 to G61; Y50 to 762; P51 to G63; G52 to A64; 153 to F65; E54 to E66; 155 to 167; E56 to E68; S57 to 169; R58 to N70; L59 to G71; G60 to Q72; G61 to L73; T62 to V74; G63 to F75; A64 to S76; F65 to K77; E66 to L78; 167 to E79; E68 to N80; 169 to G81; N70 to G82; G71 to F83; Q72 to P84; L73 to Y85; V74 to E86; F75 to K87; S76 to D88; K77 to L89; L78 to 190; E79 to E91; N80 to A92; G81 to 193; G82 to R94; F83 to R95; P84 to A96; Y85 to S97; E86 to N98; K87 to G99; D88 to E100; L89 to T101; 190 to LI02; E91 to E103; A92 to K104; 193 to 1105; R94 to T106; R95 to N107; A96 to S108; S97 to R109; N98 to P110; G99 to Pill; El00 to C112; T101 to V113; L102 to 1114; E103 to L115. {0120] lii another preferred embodiment, the isolated polypeptides > described herein . comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 14mers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to P14; S2 to E15; G3 to E16; E4 to Y17; P5 to E18; G6 to P19; Q7 to G20; T8 to S21; S9 to G22; V10 to V23; All to R24;P12 to 125; P13 to V26; P14 to V27; E15 to E28; E16 to Y29; Y17 to C30; E18 to E31; P19 to P32; G20 to C33; S21 to G34; G22 to F35; V23 to E36; R24 to A37; 125 to T38; V26 to Y39; V27 to L40; E28 to E41; Y29 to L42; C30 to A43; E31 to S44; P32 to A45; C33 to V46; G34 to K47; F35 to E48; E36 to Q49; A37 to Y50; T38 to P51; Y39 to G52; L40 to 153; E41 to E54; L42 to 155; A43 to E56; S44 to S57; A45 to R58; V46 to L59; K47 to G60; E48 to G61; Q49 to T62; Y50 to G63; P51 to A64; G52 to F65; 153 to E66; E54 to 167; 155 to E68; E56 to 169; S57 to N70; R58 to G71; L59 to Q72; G60 to L73; G61 to Y74; T62 to F75; G63 to S76; A64 to K77; F65 to L78; E66 to E79; 167 to N80; E68 to G81; 169 to G82; N70 to F83; G71 to P84; Q72 to Y85; L73 to E86; V74 to K87; F75 to D88; S76 to L89; K77 to I90#L78 to E91;« E79 to A92; N80 to 193; G81 to R94; G82 to R95; F83 intellectual to A96; P84 to S97; Y85 to N98; E86 to G99; K87 to E100; D88 to T101; L89 to LI02; 190 to E103; E91 to K104; A92 to 1105; 193 to T106; R94 to N107; R95 to S108; A96 to R109; S97 to PI 10; N98 to PI 11; G99 to CI 12; E100 to VI13; T101 to II14; LI02 to LI 15.

[0121] In another preferred embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting o£ one or more C35 peptide epitopes include the following 15mers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to E15; S2 to El6; G3 to V17; E4 to E18; P5 to P19; G6 to G20; Q7 to S21; T8 to G22; S9 to V23; V10 to R24; All to 125; P12 to V26; P13 to V27; P14 to E28; E15 to Y29; E16 to C30; V17 to E31; E18 to P32; P19 to C33; G20 to G34; S21 to F35; G22 to E36; V23 to A37; R24 to T38; 125 to Y39; V26 to L40; V27 to E41; E28 to L42; Y29 to A43; C30 to S44; E31 to A45; P32 to V46; C33 to K47; G34 to E48; F35 to Q49; E36 to Y50; A37to P51; T38 to G52; Y39 to 153; L40 to E54; E41 to 155; L42 to E56; A43 to S57; S44 to R58; A45 to L59; V46 to G60; K47 to G61; E48 to T62; Q49 to G63; Y50 to A64; P51 to F65; G52 to E66; 153 to 167; E54 to E68; 155 to 169; E56 to N70; S57 to G71; R58 to Q72; L59 to L73; G60 to V74; G61 to F75; T62 to S76; G63 to K77; A64 to L78; F65 to E79; E66 to N80; 167 to G81; E68 to G82; 169 to F83; N70 to P84; G71 to Y85; Q72 to E86; L73 to K87; V74 to D88; F75 to L89; S76 to 190; K77 to E91; L78 to A92; E79 to 193; N80 to R94; G81 to R95; G82 to A96; F83 to S97; P84 to N98; Y85 to G99; E86 to E100; K87 to T101; D88 to L102; L89 to E103; 190 to K104; E91 to 1105; A92 to T106; 193 to N107; R94 to S108; R95 to R109; A96 to PI 10; S97 to Pill; N98 to CI 12; G99 to VI13; E100 to II14; T101 to LI 15.

[0122] In a farther preferred embodiment,the isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 16mers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to E16; S2 to V17; G3 to E18; E4 to P19; P5 to G20; G6 to S21; Q7 to G22; T8 to V23; S9 to R24; V10 to 125; All to V26; P12 to V27;P13 to E28; P14 to Y2£; E15 to C30; E16 to E31; V17 to P32; E18 to C39; P19toG34: INTELLECTUAL PROPERTY OFFICEj OF N.Z. | 2 5 OCT 2006 I RECEIV H • G20 to F35; S21 to E36; G22 to A37; V23 to T38; R24 to Y39; 125 to L40; V26 to E41; V27 to L42; E28 to A43; Y29 to S44; C30 to A45; E31 to V46; P32 to K47; C33 to E48; G34 to Q49; F35 to Y50; E36 to P51; A37 to G52; T38 to 153; Y39 to E54; L40 to 155; E41 to E56; L42 to S57; A43 to R58; S44 to L59; A45 to G60; V46 to G61; K47 to T62; E48 to G63; Q49 to A64; Y50 to F65; P51 to E66; G52 to 167; 153 to E68; E54 to 169; 155 to N70; E56 to G71; S57 to Q72; R58 to L73; L59 to V74; G60 to F75; G61 to S76; T62 to K77; G63 to L78; A64 to E79; F65 to N80; E66 to G81; 167 to G82; E68 to F83; 169 to P84; N70 to Y85; G71 to E86; Q72 to K87; L73 to D88; V74 to L89; F75 to 190; S76 to E91; K77 to A92; L78 to 193; E79 to R94; N80 to R95; G81 to A96; G82 to S97; F83 to N98; P84 to G99; Y85 to E100; E86 to T101; K87 to L102; D88 to El03; L89 to K104; 190 to 1105; E91 to T106; A92 to N107; 193 to S108; R94 to R109; R95 to PI 10; A96 to Pill; S97 to CI 12; N98 to V113; G99 to 1114; E100 to-LI 15.

In another preferred embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 17mers: Ml to V17; S2 to E18; G3 to P19; E4 to G20; P5 to S21; G6 to G22; Q7 to V23; T8 to R24; S9 to 125; V10 to V26; Al 1 to V27; P12 to E28; P13 to Y29; P14 to C30; E15 to E31; E16 to P32; V17 to C33; El 8 to G34; P19 to F35; G20 to E36; S21 to A37; G22to T38; V23 to Y39; R24 to L40; 125 to E41; V26 to L42; V27 to A43; E28 to S44; Y29 to A45; C30 to V46; E31 to K47; P32 to E48; C33 to Q49; G34 to Y50; F35 to P51; E36 to G52; A37 to 153; T38 to E54; Y39 to 155; L40 to E56; E41 to S57; L42 to R58; A43 to L59; S44 to G60; A45 to G61; V46 to T62; K47 toG63; E48 to A64; Q49 to F65; Y50 to E66; P51 to 167; G52 to E68; 153 to 169; E54 to N70; 155 to G71; E56 to Q72; S57 to L73; R58 to V74; L59 to F75; G60 to S76; G61 to K77; T62 to L78; G63 to E79; A64 to N80; F65 to G81; E66 to G82; 167 to F83; E68 to P84; 169 to Y85; N70 to E86; G71 to K87; Q72 to D88; L73 to L89; V74 to 190; F75 to E91; S76 to A92; K77 to 193; L78 to R94; E79 to R95; N80 to A96; G81 to S97; G82 to N98; F83 to G99; P84 to El 00; Y85 to T101; E86 to L102; K87 to E103; D88toK104; L89 to 1105; 190 to T106; E91 to N107; A92 to S108; 193 INTELLECTUAL property office of n.z. 2 5 OCT 2006 RECEIVEO' to R109; R94 to P110; R95 to Pill; A96 to CI 12; S97 to V113; N98 to 1114; G99toL115.

[0124] In another preferred embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 18mers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to E18; S2 to P19; G3 to G20; E4 to S21; P5 to G22; G6 to V23; Q7 to R24; T8 to 125; S9 to V26; VIOto V27; All toE28; P12 to Y29; P13 to C30; P14 to E31; E15 to P32; E16 to C33; V17 to G34; E18 to F35; P19 to E36; G20 to A37; S21 to T38; G22 to Y39; V23 to L40; R24 to E41; 125 to L42; V26 to A43; V27 to S44; E28 to A45; Y29 to V46; C30 to K47; E31 to E48; P32 to Q49; C33 to Y50; G34 to P51; F35 to G52; E36 to 153; A37 to E54; T38 to 155; Y39 to E56; L40 to S57; E4l to R58; L42 to L59; A43 to G60; S44 to G61; A45 to T62; V46 to G63; K47 to A64; E48 to F65; Q49 to E66; Y50 to 167; P51 to E68; G52 to 169; 153 to N70; E54 to G71; 155 to Q72; E56 to L73; S57 to V74; R58 to F75; L59 to S76; G60 to K77; G61 to L78; T62 to E79; G63 to N80; A64 to G81; F65 to G82; E66 to F83; 167 to P84; E68 to Y85; 169 to E86; N70 to K87; G71 to D88; Q72 to L89; L73 to 190; V74 to E91; F75 to A92; S76 to 193; K77 toR94; L78 to R95; E79 to A96; N80 to S97; G81 toN98; G82 to G99; F83 to El00; P84 to T101; Y85 to L102; E86 to E103; K87 to K104; D88 to 1105; L89 to T106; 190 to N107; E91 to S108; A92 to R109; 193 to P110; R94 to Pll 1; R95 to CI 12; A96 to VI13; S97 to II14; N98 to LI 15.

[0125] In another preferred embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 19mers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to P19; S2 to G20; G3 to S21; E4 to G22; P5 to V23; G6 to R24; Q7 to 125; T8 to V26; S9 to V27; V10 to E28; All to Y29; P12 to C30; P13 to E31; P14 to P32; E15 to C33; E16 to G34; V17 to F35; E18 to E36; P19 to A37; G20 to T38; S21 to Y39; G22 to L40; V23 to E41; R24 to L42; 125 to A43; V26 to S44; V27 to A45; E28 to V46; Y29 to K47; C30 to E48; E31 to Q49; P32 to Y50; C33 to BS1;JC®4 toG32; F35 to 153; L36 to E54; A57 to 155; T38 to E56 INTELLECTUAL property Of of n.z. 2 5 OCT 2006 Y39 to S57; L40 to R58; E41 to L59; 142 to G60; A43 to G61; S44 to T62; A45 to G63; V46 to A64; K47 to F65; E48 to E66; Q49 to 167; Y50 to E68; P51 to 169; G52 to N70; 153 to G71; E54 to Q72; 155 to L73; E56 to V74; S57 to F75; R58 to S76; L59 to K77; G60 to L78; G61 to E79; T62 to N80; G63 to G81; A64 to G82; F65 to F83; E66 to P84; 167 to Y85; E68 to E86; 169 to K87; N70 to D88; G71 to L89; Q72 to 190; L73 to E91; V74 to A92; F75 to 193; S76 to R94; K77 to R95; L78 to A96; E79 to S97; N80 to N98; G81 to G99; G82 to E100; F83 to T101; P84 to L102; Y85 to E103; E86 to K104; K87 to 1105; D88 to T106; L89 to N107; 190 to S108; E91 to R109; A92 to PliO; 193 to PI 11; R94 to C112; R95 to V113; A96 to 1114; S97 to L115.

[0126] In another preferred embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting of one or more G35 peptide epitopes include the following 20mers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to G20; S2 to S21; G3 to G22; E4 to V23; P5 to R24; G6 to 125; Q7 to V26; T8 to V27; S9 to E28; V10 to Y29; Al 1 to C30; P12 to E31; P13 to P32; P14 to C33; E15 to G34; E16 to F35; V17 to E36; E18 to A37; P19 to T38; G20 to Y39; S21 to 140; G22 to E41; V23 to L42; R24 to A43; 125 to S44; V26 to A45; V27 to V46; E28 to K47; Y29 to E48; C30 to Q49; E31 to Y50; P32 to P51; C33 to G52; G34 to 153; F35 to E54; E36 to 155; A37 to E56; T38 to S57; Y39 to R58; L40 to L59; E41 to G60; L42 to G61; A43 to T62; S44 to G63; A45 to A64; V46 to F65; K47 to E66; E48 to 167; Q49 to E68; Y50 to 169; P51 to N70; G52 to G71; 153 to Q72; E54 to L73; 155 to V74; E56 to F75; S57 to S76; R58 to K77; L59 to L78; G60 to E79; G61 to N80; T62 to G81; G63 to G82; A64 to F83; F65 to P84; E66 to Y85; 167 to E86; E68 to K87; 169 to D88; N70 to L89; G71 to 190; Q72 to E91; L73 to A92; V74 to 193; F75 to R94; S76 to R95; K77 to A96; L78 to S97; E79 to N98; N80 to G99; G81 to E100; G82 to T101; F83 to L102; P84 to E103; Y85 to K104; E86 to 1105; K87 to T106; D88 to N107; L89 to S108; 190 to R109; E91 to PI 10; A92 to PI 11; 193 to CI 12; R94 to VI13; R95 to II14; A96toL115. intellectual property office of n.z. 2 5 OCT 2006 receivet (0127] In another preferred embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 21mers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to S21; S2 to G22; G3 to V23; E4 to R24; P5 to 125; G6 to V26; Q7 to V27; T8 to E28; S9 to Y29; V10 to C30; All to E31; P12 to P32; P13 to C33; P14 to G34; E15 to F35; E16 to E36; Y17 to A37; E18 to T38; P19 to Y39; G20 to L40; S21 to E41; G22 to L42; V23 to A43; R24 to S44; 125 to A45; V26 to V46; V27 to.K47; E28 to E48; Y29 to Q49; C30 to Y50; E31 to P51; P32 to G52; C33 to 153; G34 to E54; F35 to 155; E36 to E56; A37 to S57; T38 to R58; Y39 to L59; 140 to G60; E41 to G61; L42 to T62; A43 to G63; S44 to A64; A45 to F65; V46 to E66; K47 to 167; E48 to E68; Q49 to 169; Y50 to N70; P51 to G71; G52 to Q72; 153 to L73; E54 to V74; 155 to F75; E56 to S76; S57 to K77; R58 to L78; L59 to E79; G60toN80;G61 toG81;T62toG82; G63toF83; A64 to P84; F65 to Y85; E66 to E86; 167 to K87; E68 to D88; 169 to L89; N70 to 190; G71 to E91; Q72 to A92; L73 to 193; V74 to R94; F75 to R95; S76 to A96; K77 to S97; L78 to N98; E79 to G99; N80 to E100; G81 to T101; G82 to LI 02; F83 to E103; P84 to K104; Y85 to 1105; E86 to T106; K87 to N107; D88 to S108; L89 to R109; 190 to PI 10; E91 to PI 11; A92 to CI 12; 193 to VI13; R94 to II14; R95 to LI 15. {0128] In another preferred embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 22mers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to G22; S2 to V23; G3 to R24; E4 to 125; P5 to V26; G6 to V27; Q7 to E28; T8 to Y29; S9 to C30; V10 to E31; Al 1 to P32; P12 to C33; P13 to G34; P14 to F35; E15 to E36; E16 to A37; V17 to T38; E18 to Y39; P19 to L40; G20 to E41; S21 to L42; G22 to A43; V23 to S44;-R24 to A45; 125 to V46; V26 to K47; V27 to E48; E28 to Q49; Y29 to Y50; C30 to P51; E31 to G52; P32 to £53; C33 to E54; G34 to 155; F35 to E56; E36 to S57; A37 to R58; T38 to L59; Y39 to G60; L40 to G61; E41 toT62;L42toG63; A43 toA64; S44toF65; A45 to E66; V46 to I67; K47 to E68; E48 to 169; Q49 to N70; Y50 to G71; P51 to intellectual property office of n.z. 2 5 OCT 2006 rfteivep Q72; G52 to L73; 153 to V74; E54 to F75; 155 to S76; E56 to K77; S57 to L78; R58 to E79; L59 to N80; G60 to G81; G61 to G82; T62 to F83; G63 to P84; A64 to Y85; F65 to E86; E66 to K87; 167 to D88; E68 to L89; 169 to 190; N70 to E91; G71 to A92; Q72 to 193; L73 to R94; V74 to R95; F75 to A96; S76 to S97; K77 toN98; L78 to G99; E79 to E100;N80 to T101; G81 to L102; G82to E103; F83 to K104; P84 to 1105; Y85 to T106; E86 to N107; K87 to S108; D88 to R109; L89 to PI 10; 190 to PI 11; E91 to CI 12; A92 to VI13; 193 to 1114; R94 to LI 15.

[0129] In another preferred embodiment, the isolated polypeptides described Q herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 23mers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to V23; S2 to R24; G3 to 125; E4 to V26; P5 to V27; G6 to E28; Q7 to Y29; T8 to C30; S9 to E31; V10 to P32; Al 1 to C33; P12 to G34; P13 to F35; P14 to E36; E15 to A37; E16 to T38; V17 to Y39; E18 to L40; P19 to E41; G20 to L42; S21 to A43; G22 to S44; V23 to A45; R24 to V46; 125 to K47; V26 to E48; V27 to Q49; E28 to Y50; Y29 to P51; C30 to G52; E31 to 153; P32 to E54; C33 to 155; G34 to E56; F35 to S57; E36 to R58; A37 to L59; T38 to G60; Y39 to G61; L40 to T62; E41 to G63; L42 to A64; A43 to F65; S44 to E66; A45 to 167; V46 to E68; K47 to 169; E48 to N70; Q49 to G71; Y50 to Q72; P51 to L73; G52 to V74; 153 to F75; E54 to S76; 155 to K77; E56 to L78; S57 to E79; % R58 to N80; L59 to G81; G60 to G82; G61 to F83; T62 to P84; G63 to Y85; A64 to E86; F65 to K87; E66 to D88; 167 to L89; E68 to 190; 169 to E91; N70 to A92; G71 to 193; Q72 to R94; L73 to R95; V74 to A96; F75 to S97; S76 to N98; K77 to G99; L78 to E100; E79 to T101; N80 to LI02; G81 to E103; G82 to K104; F83 to 1105; P84 to T106; Y85 to N107; E86 to S108; K87 to R109; D88 to P110; L89 to Pill; 190 to C112; E91 to VI13; A92 to 1114; 193 to L115v (0130] In. another preferred embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 24mers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to R24; S2 to 125; G3 to V26; E4 to V27; P5 to E28; G6 to Y29; Q7 to C30; T8 ta£31;$9 to P32; V10 to C33; Al 1 to G34; P12 to F35; P13 to intellectual PROPERTY OFFICE of n.z. 2 5 OCT 2006 E36; P14 to A37; E15 to T38; E16 to Y39; V17 to L40; E18 to E41; P19 to L42; G20 to A43; S21 to S44; G22 to A45; V23 to V46; R24 to K47; 125 to E48; V26 to Q49; V27 to Y50; E28 to P51; Y29 to G52; C30 to 153; E31 to E54; P32 to 155; C33 to E56; G34 to S57; F35 to R58; E36 to L59; A37 to G60; T38 to G61; Y39 to T62; L40 to G63; E41 to A64; L42 to F65; A43 to E66; S44 to 167; A45 to E68; V46 to 169; K47 to N70; E48 to G71; Q49 to Q72; Y50 to L73; P51 to V74; G52 to F75; 153 to S76; E54 to K77; 155 to L78; E56 to E79; S57 to N80; R58 to G81; L59 to G82; G60 to F83; G61 to P84; T62 to Y85; G63 to E86; A64 to K87; F65 to D88; E66 to L89; 167 to 190; E68 to E91; 169 to A92; N70 to 193; G71 to R94; Q72 to R95; L73 to A96; V74 to S97; F75 to N98; S76 to G99; K77 to E100; L78 to T101; E79 to L102; N80 to E103; G81 to K104; G82 to 1105; F83 to T1Q6; P84 to N107; Y85 to S108; E86 to R109; K87 to PI 10; D88 to Pill; L89 to C112; 190 to V113; E91 to 1114; A92 to L115.

[0131] In another preferred embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 25mers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to 125; S2 to Y26; G3 to V27; E4 to E28; P5 to Y29; G6 to C30; Q7 to E31; T8 to P32; S9 to C33; V10 to G34; All to F35; P12 to E36; P13 to A37; P14 to T38; E15 to Y39; E16 to L40; V17 to E41; E18 to L42; P19 to A43; G20 to S44; S21 to A45; G22 to V46; V23 to K47; R24 to E48; 125 to Q49; V26 to Y50; Y27 to P51; E28 to G52; Y29 to 153; C30 to E54; E31 to 155; P32 to E56; C33 to S57; G34 to R58; F35 to L59; E36 to G60; A37 to G61; T38 to T62; Y39 to G63; L40 to A64; E41 to F65; L42 to E66; A43 to 167; S44 to E68; A45 to 169; V46 to N70; K47 to G71; E48 to Q72; Q49 to L73; Y50 to V74; P51 to F75; G52 to S76; 153 to K77; E54 to L78; 155 to E79; E56 to N80; S57 to G81; R58 to G82; L59 to F83; G60 to P84; G61 to Y85; T62 to E86; G63 to K87; A64 to D88; F65 to L89; E66 to 190; 167 to E91; E68 to A92; 169 to 193; N70 to R94; G71 to R95; Q72 to A96; L73 to S97; V74 to N98; F75 to G99; S76 to E100; K77 to T101; L78 to L102; E79 to E103; N80 to K104; G81 to 1105; G82 to intellectual property office of n.z. 2 5 OCT 2006 received T106; F83 to N107; P84 to S108; Y85 to R109; E86 to P110; K87 to PI 11; D88 to C112; L89 to V113; 190 to 1114; E91 to L115.

[0132] In another preferred embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 26mers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to V26; S2 to V27; G3 to E28; E4 to Y29; P5 to C30; G6 to E31; Q7 to P32; T8 to C33; S9 to G34; V10 toF35; All toE36;P12 to A37; P13 to T38; P14 to Y39; E15 to L40; E16 to E41; V17 to L42; E18 to A43; P19 to S44; G20 to A45; S21 to V46; G22to K47; V23 to E48; R24 to Q49; 125 to Y50; V26 to P51; V27 to G52; E28 to 153; Y29 to E54; C30 to 155; E31 to E56; P32 to S57; C33 to R58; G34 to L59; F35 to G60; E36 to G61; A37 to T62; T38 to G63; Y39 to A64; L40 to F65; E41 to E66; L42 to 167; A43 to E68; S44 to 169; A45 to N70; V46 to G71;K47 to Q72; E48 to L73; Q49 to Y74; Y50 toF75; P51 to S76; G52 to K77; 153 to L78; E54 to E79; 155 to N80; E56 to G81; S57 to G82; R58 to F83; L59 to P84; G60 to Y85; G61 to E86; T62 to K87; G63 to D88; A64 to L89; F65 to 190; E66 to E91; 167 to A92; E68 to 193; 169 to R94; N70 to R95; G71 to A96; Q72 to S97; L73 to N98; V74 to G99; F75 to El 00; S76 to T101; K77 to LI 02; L78 to E103; E79 to K104; N80 to 1105; G81 to T106; G82 to N107; F83 to S108; P84 to R109; Y85 to P110; E86 to Pill; K87 to C-112; D88 to V113; L89 to 1114; 190 to LI 15.

[0133] In another preferred embodiment,the isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 27mers (residues correspond to SEQ ED NO:2 and FIG. IB): Ml to V27; S2 to E28; G3 to Y29; E4 to C30; P5 to E31; G6 to P32; Q7 to C33; T8 to G34; S9 to F35; V10 to E36; All to A37; P12 to T38; P13 to Y39; P14 to L40; E15 toE41; E16 to L42; V17 to A43; E18 to S44; P19 to A45; G20 to V46; S21 to K47; G22 to E48; V23 to Q49; R24 to Y50; 125 to P51; V26 to G52; V27 to 153; E28 to E54; Y29 to 155; C30 to E56; E31 to S57; P32 to R58; C33 to L59; G34 to G60; F35 to G61; E36 to T62; A37 to G63; T38 to A64; Y39 to F65; L40 to E66; E41 to 167; L42 to E68; A43 to 169; S44 to N70; A45 intellectual property office of n.z. 2 5 OCT 2006 RECEIVED to G71; V46 to Q72; K47 to L73; E48 to V74; Q49 to F75; Y50 to S7 6; P51 to K77; G52 to L78; 153 to E79; E54 to N80; 155 to G81; E56 to G82; S57 to F83; R58 to P84; L59 to Y85; G60 to E86; G61 to K87; T62 to DE8; G63 to L89; A64 to 190; F65 to E91; E66 to A92; 167 to 193; E68 to R94; 169 to R95; N70 to A96; G71 to S97; Q72 to N98; L73 to G99; V74 to E100; F75 to T101; S76 to L102; K77 to E103; L78 to K104; E79 to 1105; N80 to T106; G81 to N1Q7; G82 to S108; F83 to R109; P84 to P110; Y85 to Pill; E86 to C112; K87 to VI13; D88 'i r to 1114; L89 to LI 15. ^ (0134] In another preferred embodiment, the isolated polypeptides described herein . comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 28mers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to E28; S2 to Y29; G3 to C30; E4 to E31; P5 to P32; G6 to C33; Q7 to G34; T8 to F35; S9 to E36; V10 to A37; All to T38; P12 to Y39; P13 to L40; P14 to E41; E15 to L42; E16 to A43; V17 to S44; E18 to A45; P19 to V46; G20 to K47; S21 to E48; G22 to Q49; V23 to Y50; R24 to P51; 125 to G52; V26 to 153; V27 to E54; E28 to 155; Y29 to E56; C30 to S57; E31 to R58; P32 to L59; C33 to G60; G34 to G61; F35 to T62; E36 to G63; A37 to A64; T38 to F65; Y39 to E66; L40 to 167; E41 to E68; L42 to 169; A43 to N70; S44 to G71; A45 to Q72; V46 to L73; K47 to V74; E48 to F75; Q49 to S76; Y50 to K77; P51 to L78; # G52 to E79; 153 to N80; E54 to G81; 155 to G82; E56 to F83; S57 to P84; R58 to Y85; L59 to E86; G60 to K87; G61 to D88; T62 to L89; G63 to 190; A64 to E91; F65 to A92; E66 to 193; 167 to R94; E68 to R95; 169 to A96; N70 to S97; G71 to N98; Q72 to G99; L73 to El00; V74 toTlOl; F75 to L102; S76 to E103; K77 to K104; L78 to 1105; E79 to T106; N80 to N107; G81 to S108; G82 to R109; F83 to PI 10; P84 to PI 11; Y85 to CI 12; E86 to VI13; K87 to II14; D88 to LI 15. {0135] In another preferred embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 29mers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to Y29; S2 to C30; G3 to E31; E4 to P32; P5 to C33; G6 to G34; I NTELLECfuAL~PR0PERTY~0^FRCE of n.z. 2 5 OCT 2006 Q7 to F35; T8 to E36; S9 to A37; V10 to T38; All to Y39; P12 to L40; P13 to E41; P14 to L42; E15 to A43; E16 to S44; V17 to A45; E18 to V46; P19 to K47; G20 to E48; S21 to Q49; G22 to Y50; V23 to P51; R24 to G52; 125 to 153; V26 to E54; V27 to 155; E28 to E56; Y29 to S57; €30 to R58; E31 to L59; P32 to G60; C33 to G61; G34 to T62; F35 to G63; E36 to A64; A37 to F65; T38 to E66; Y39 to 167; L40 to E68; E41 to 169; L42 to N70; A43 to G71; S44 to Q72; A45 to L73; V46 to V74; K47 to F75; E48 to S76; Q49 to K77; Y50 to L78; P51 to E79; G52 to N80; 153 to G81; E54 to G82; 155 to F83; E56 to P84; S57 to Y85; R58 to E86; L59 to K87; G60 to D88; G61 to L89; T62 to 190; G63 to E91; A64 to A92; F65 to 193; E66 to R94; 167 to R95; E68 to A96; 169 to S97; N70 toN98; G71 to G99; Q72toE100; L73 toTlOl; V74toL102; F75 to El 03; S76toK104; K77 to 1105; L78 to T106; E79 to N107; N80 to S108; G81 to R109; G82 to PI 10; F83 to Pill; P84 to C112; Y85 to VI13; E86 to 1114; K87 to L115. (0136] In another preferred embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 30mers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to C30; S2 to E31; G3 to P32; E4 to C33; P5 to G34; G6 to F35; Q7 to E36; T8 to A37; S9 to T38; V10 to Y39; Al 1 to L40; P12 to E41; P13 to L42; P14 to A43; E15 to S44; E16 to A45; V17 to V46; E18 toK47;P19 to E48; G20 to Q49; S21 to Y50; G22 to P51; V23 to G52; R24 to 153; 125 to E54; V26 to 155; V27 to E56; E28 to S57; Y29 to R58; C30 to L59; E31 to G60; P32 to G61; C33 to T62; G34 to G63; F35 to A64; E36 to F65; A37 to E66; T38 to 167; Y39 to E68; L40 to 169; E41 to N70; L42 to G71; A43 to Q72; S44 to L73; A45 to V74; V46 to F75; K47 to S76; E48 to K77; Q49 to L78; Y50 to E79; P51 to N80; G52 to G81; 153 to G82; E54 to F83; 155 to P84; E56 to Y85; S57 to E86; R58 to K87; L59 to D88; G60 to L89; G61 to 190; T62 to E91; G63 to A92; A64 to 193; F65 to R94; E66 to R95; 167 to A96; E68 to S97; 169 to N98; N70 to G99; G71 to E100; Q72 to T101; L73 to L102; V74 to E103; F75 to K104; S76 to 1105; K77 to T106; L78 to N107; E79 to S108; N80 to R109; G81 to PI 10; G82 to PI 11% F83 to €11^; P84 to V1B; Y85 to H14; E86to L115;

[0137] In another preferred embodiment,the isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 3 liners (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to E31; S2 to P32; G3 to C33; E4 to G34; P5 to F35; G6 to E36; Q7 to A37; T8 to T38; S9 to Y39; V10 to L40; All to E41; P12 to L42; P13 to A43; P14 to S44; E15 to A45; E16 to V46; V17 to K47; E18 to E48; P19 to Q49; G20 to Y50; S21 to P51; G22 to G52; V23 to 153; R24 to E54; 125 to 155; V26 to E56; V27 to S57; E28 to R58; Y29 to L59; C30 to G60; E31 to G61; P32 to T62; C33 to G63; G34 to A64; F35 to F65; E36 to E66; A37 to 167; T38 to E68; Y39 to 169; L40 to N70; E41 to G71; L42 to Q72; A43 to L73; S44 to V74; A45 to F75; V46 to S76; K47 to K77; E48 to L78; Q49 to E79; Y50 to N80; P51 to G81; G52 to G82; 153 to F83; E54 to P84; 155 to Y85; E56 to E86; S57 to K87; R58 to D88; L59 to L89; G60 to 190; G61 to E91; T62 to A92; G63 to 193; A64 to R94; F65 to R95; E66 to A96; 167 to S97; E68 to N98; 169 to G99; N70 to El 00; G71 to T101; Q72 to L102; L73 to E103; V74 to K104; F75 to 1105; S76 to T106; K77 to N107; L78 to S108; E79 to R109; N80 to PU0; G81 to Pill; G82 to CI 12; F83 to VI13; P84 to 1114 and Y85 to LI 15.

[0138] In another preferred embodimentjthe isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 32mers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to P32; S2 to C33; G3 to G34; E4 to F35; P5 to E36; G6 to A37; Q7 toT38; T8 to Y39; S9 to L40; V10 to E41; All to L42;P12 to A43; P13 to S44; P14 to A45; E15 to V46; E16 to K47; V17 to E48; E18 to Q49; P19 to Y50; G20to P51; S21 to G52; G22 to 153; V23 to E54; R24 to 155; 125 to E56; V26 to S57; V27 to R58; E28 to L59; Y29 to G60; C30 to G61; E31 to T62; P32 to G63; C33 to A64; G34 to F65; F35 to E66; E36 to 167; A37 to E68; T38 to 169; Y39 to N70; L40 to G71; E41 to Q72; L42 to L73; A43 to V74; S44 to F75; A45 to S76; V46 to K77; K47 to L78; E48 to E79; Q49 to N80; Y50 to G81; P51 to G82; G52 to F83; 153 to P84; E54 to Y85; 155 to E86; E56 to K87; S57 to D88; R58 to L89; L59 to 190; G60>to E91; G61to A92; T62 to 193; G63 to R94; A64 INTELLECTUAL PROPERTY OFFICE > OF N.Z. 1 2 5 OCT 2006 j receive!;'1 to R95; F65 to A96; E66 to S97; 167 to N98; E68 to G99; 169 to E100; N70 to T101; G71 to LI02; Q72 to E103; L73 to K104; V74 to 1105; F75 to T106; S76 toN107; K77 to S108; L78 to R109; E79 to P110; N80 to Pill; G81 to C112; G82 to VI13; F83 to 1114 and P84 to LI 15. (0139] ^ In another preferred embodiment,the isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 33mers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to C33; S2 to G34; G3 to F35; E4 to E36; P5 to A37; G6 to T38; Q7 to Y39; T8 to L40; S9 to E41; V10 to L42; Al 1 to A43; P12 to S44; P13 to A45; P14 to V46; E15 to K47; E16 to E48; V17 to Q49; E18 to Y50; P19 to P51; G20 to G52; S21 to 153; G22 to E54; V23 to 155; R24 to E56; 125 to S57; V26 to R58; V27 to L59; E28 to G60; Y29 to G61; C30 to T62; E31 to G63; P32 to A64; C33 to F65; G34 to E 66; F35 to 167; E36 to E68; A37 to 169; T38 to N70; Y39 to G71; L40 to Q72; E41 to L73; L42 to V74; A43 to F75; S44 to S76; A45 to K77; V46 to L78; K47 to E79; E48 to N80; Q49 to G81; Y50 to G82; P51 to F83; G52 to P84; 153 to Y85; E54 to E86; 155 to K87; E56 to D88; S57 to L89; R58 to 190; L59 to E91; G60 to A92; G61 to 193; T62 to R94; G63 to R95; A64 to A96; F65 to S97; E 66 to N98; 167 to G99; E68 to E100; 169 to T101; N70 to LI 02; G71 to E103; Q72 to K104; L73 to 1105; V74 to T106; F75 to N107; S76 to S108; K77 to R109; L78 to P110; E79 to Pill; N80 to C112; G81 to V113; G82 to II14 and F83 to LI 15. (0140] In another preferred embodiment,the isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 34mers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to G34; S2 to F35; G3 to E36; E4 to A37; P5 to T38; G6 to Y39; Q7 to L40; T8 to E41; S9 to L42; V10 to A43; All to S44; P12 to A45; P13 to V46; P14 toK47; E15 to E48; E16 to Q49; V17 to Y50; El 8 to P51; P19 to G52; G20 to 153; S21 to E54; G22 to 155; V23 to E56; R24 to S57; 125 to R58; V26 to L59; V27 to G60; E28 to G61; Y29 to T62; C30 to G63; E31 to A64; P32 to F65; C33 toE66;G34 to 16?; F354oE68^E36 tp 169; A37 to N70; T38 to G71; Y39 INTELLECTUAL PROPERTY office of n2. 2 5 OCT 2006 receive/l to Q72; L40 to L73; E41 to V74; L42 to F75; A43 to S76; S44 to K77; A45 to L78; V46 to E79; K47 to N80; E48 to G81; Q49 to G82; Y50 to F83; P51 to P84; G52 to Y85; 153 to E86; E54 to K87; 155 to D88; E56 to L89; S57 to 190; R58 to E91; L59 to A92; G60 to 193; G61 to R94; T62 to R95; G63 to A96; A64 to S97; F65 to N98; E66 to G99; 167 to E100; E68 to T101; 169 to L102; N70 to E103; i G71 to K104; Q72 to 1105; L73 to T106; V74 to N107; F75 to S108; S76 to R109; K77 to P110; L78 to Pill; E79 to CI 12; N80 to V113; G81 to 1114 and G82 to LI 15. 4) .(0141] In another preferred embodiment,the isolated polypeptides described herein . comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 35mers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to F35; S2 to E36; G3 to A37; E4 to T38; P5 to Y39; G6 to L40; Q7 to E41; T8 to L42; S9 to A43; V10 to S44; Al 1 to A45; P12 to V46; P13 to K47; P14 to E48; E15 to Q49; E16 to Y50; V17 to P51; E18 to G52; P19 to 153; G20 to E54; S21 to 155; G22 to E56; V23 to S57; R24 to R58; 125 to L59; V26 to G60; V27 to G61; E28 to T62; Y29 to G63; C30 to A64; E31 to F65; P32 to E66; C33 to 167; G34 to E68; F35 to 169; E36 to N70; A37 to G71; T38 to Q72; Y39 to L73; L40 to V74; E41 to F75; L42 to S76; A43 to K77; S44 to L78; A45 to E79; V46 to N80; K47 to G81; E48 to G82; Q49 to F83; Y50 to P84; P51 to # Y85; G52 to E86; 153 to K87; E54 to D88; 155 to L89; E56 to 190; S57 to E91; R58 to A92; L59 to 193; G60 to R94; G61 to R95; T62 to A96; G63 to S97; A64 to N98; F65 to G99; E66 to El00; 167 to T101; E68 to L102; 169 to E103; N70 to KL104; G71 to 1105; Q72 to T106; L73 to N107; V74 to S108; F75 to R109; S76 to PllO; K77 to PHI; L78 to C112; E79 to V113; N80 to 1114; G81 to L115.

[0142] In another preferred embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 36mers (residues correspond to SEQIDNO:2 and FIG. IB): M1 to E36; S2 to A37; G3 to T38; E4 to Y39; P5 to L40; G6 to E41; Q7 to L42; T8 to A43; S 9 to S44; V10 to A45; Al 1 to V46; P12 to K47; P13 to E48; P14 to Q49; El 5 to Y50; E16 to P51; V17 to G52; E18 to 153; P19 to E54; G20 to 155; S21 to E56; G22 to S57; V23 to R58; R24 to L59; 125 to G60; V26 to G61; V27 to T62; E28 to G63; Y29 to A64; C30 to F65; E31 to E66; P32 to 167; C33 to E68; G34 to 169; F35 to N70; E36 to G71; A37 to Q72; T38 to L73; Y39 to V74; 140 to F75; E41 to S76; L42 to K77; A43 to L78; S44 to E79; A45 to N80; V46 to G81; K47 to G82; E48 to F83; Q49 to P84; Y50 to Y85; P51 to E86; G52 to 0 K87; 153 to D88; E54 to L89; 155 to 190; E56 to E91; S57 to A92; R58 to 193; L59 to R94; G60 to R95; G61 to A96; T62 to S97; G63 to N98; A64 to G99; F65 to E100; E66 to T101; 167 to L102; E68 to E103; 169 to K104; N70 to 1105; G71 to T106; Q72 toN107; L73 to S108; V74 to R109; F75 to PllO; S76 to Pill; K77 to CI 12; L78 to V113; E79 to 1114; N80 to L115. £0143] In another preferred embodiment, the isolated polypeptides described herein ' comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 37mers (residues correspond to SBQ ID NO:2 and FIG. IB): Ml to A37; S2 to T38; G3 to Y39; E4 to L40; P5 to E41; G6 to L42; Q7 to A43; T8 to S44; S9 to A45; V10 to V46; All to K47; P12 toE48;P13 to Q49; P14 to ® Y50; E15 to P51; E16 to G52; V17 to 153; E18 to E54; P19 to 155; G20 to E56; S21 to S57; G22 to R58; V23 to L59; R24 to G60; 125 to G61; V26 to T62; V27 to G63; E28 to A64; Y29 to F65; C30 to E66; E31 to 167; P32 to E68; C33 to 169; G34 to N70; F35 to G71; A37 to L73; T38 to V74; Y39 to F75; L40 to S76; E41 to K77; L42 to L78; A43 to E79; S44 to N80; A45 to G81; V46 to G82; K47 to F83; E48 to P84; Q49 to Y85; Y50 to E86; P51 to K87; G52 to D88; 153 to L89; E54 to 190; 155 to E91; E56 to A92; S57 to 193; R58 to R94; L59 to R95; G60 to A96; G61 to S97; T62 to N98; G63 to G99; A64 to El 00; F65 to T101; E66 to L102; 167 to E103; E68 to K104; 169 to 1105; N70 to T106; G71 to N107; Q72 to S108; L73 to R109; V74 to PllO; F75 to Pill; S76 to C112; K77 to VI13; L78 to II14; E79 to LI 15.

IntbIIctua^^ OF N.Z. 2 5 OCT 20GS i received {0144] In another preferred embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 38mers (residues correspond to SEQ ID NO:2 and HG. IB): Ml to T38; S2 to Y39; G3 to 140; E4 to E41; P5 to L42; G6 to A43; Q7 to S44; T8 to A45; S9 to Y46; V10 to K47; All to E48; P12 to Q49; P13 to Y50; P14 to P51; E15 to G52; E16 to 153; V17 to E54; El 8 to 155; P19 toE56; G20 to S57; S21 to R58; G22 to L59; V23 to G60; R24 to G61; 125 to T62; V26 to G63; V27 to A64; E28 to F65; Y29 to E66; C30 to 167; E31 to E68; P32 to 169; C33 to N70; G34 to G71; F35 to Q72; E36 to L73; A37 to V74; T38 to F75; Y39 to S76; 140 to K77; E41 to L78; 142 to E79; A43 to N80; S44 to G81; A45 to G82; V46 to F83; K47 to P84; E48 to Y85; Q49 to E86; Y50 to K87; P51 to D88; G52 to L89; 153 to 190; E54 to E91; 155 to A92; E56 to 193; S57 to R94; R58 to R95 L59 to A96; G60 to S97; G61 to N98; T62 to G99; G63 to E100; A64 to T101 F65 to LI02; E66 to E103; 167 to K104; E68 to 1105; 169 to T106; N70 toN107: G71 to S108; Q72 to R109; L73 to PllO; V74 to Pill; F75 to C112; S76 to VI13; K77 to 1114; L78 to LI 15.

[0145] In another prefeired embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 39mers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to Y39; S2 to L40; G3 to E41; E4 to L42; P5 to A43; G6 to S44; Q7 to A45; T8 to V46; S9 toK47; V10 to E48; All to Q49; P12 to Y50; P13 to P51;P14 to G52; El 5 to 153; E16 to E54; V17 to 155; E18 to E56; P19 to S57; G20 to R58; S21 to L59; G22 to G60; V23 to G61; R24 to T62; J25 to G63; V26 to A64; V27 to F65; E28 to E66; Y29 to 167; C30 to E68; E31 to 169; P32 to N70; C33 to G71; G34 to Q72; F35 to L73; E36 to V74; A37 to F75; T38 to S76; Y39 to K77; L40 to L78; E41 to E79; L42 to N80; A43 to G81; S44 to G82; A45 to F83; V46 to P84; K47 to Y85; E48 to E86; Q49 to K87; Y50 to D88; P51 to L89; G52 to 190; 153 to E91; E54to A92; 155 to 193; E56 to R94; S57 to R95; R58 to A96; INTELLECTUAL property officl OF n.z. 2 5 OCT 2006 ECEIVED L59 to S97; G60 to N98; G61 to G99; T62 to E100; G63 to T101; A64 to LI 02; F65 to E103; E66 to K104; 167 to 1105; E68 to T106; 169 to N107; N70 to S108; G71 to R109; Q72 to PllO; L73 to Pill; V74 to CI 12; F75 to VI13; S76 to 1114; K77 to LI 15.

[0146] In another preferred embodiment, the isolated polypeptides > described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 40mers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to 140; S2 to E41; G3 to L42; E4 to A43; P5 to S44; G6 to A45; Q7 to V46; T8 to K47; S9 to E48; V10 to Q49; Al 1 to Y50; P12 to P51; P13 to G52; P14 to 153; E15 to E54; E16 to 155; V17 to E56; E18 to S57; P19 to R58; G20 to L59; S21 to G60; G22 to G61; V23 to T62; R24 to G63; 125 to A64; V26 to F65; V27 'v to E66; E28 to 167; Y29 to E68; C30 to 169; E31 to N70; P32 to G71; C33 to -Q72; G34 to L73; F35 to V74; E36 to F75; A37 to S76; T38 to K77; Y39 to L78; L40 to E79; E41 to N80; L42 to G81; A43 to G82; S44 to F83; A45 to P84; V46 to Y85; K47 to E86; E48 to K87; Q49 to D88; Y50 to L89; P51 to 190; G52 to E91; 153 to A92; E54 to 193; 155 to R94; E56 to R95; S57 to A96; R58 to S97; L59 to N98; G60 to G99; G61 to E100; T62 to T101; G63 to LI02; A64 to E103; F65 to K104; E66 to 1105; 167 to T106; E68 to N107; 169 to S108; N70 to R109; G71 to PI 10; Q72 to Pill; L73 to CI 12; V74 to VI13; F75 to II14; S76 to L115.

[0147] In another prefeired embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 41mers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to E41; S2 to L42; G3 to A43; E4 to S44; P5 to A45; G6 to V46; Q7 to K47;-T8 toE48; S9 to Q49; V10 to Y50; All toP51;P12 to G52;P13 to 153;P14 to E54; El 5 to 155; E16 to E56; V17 to S57; E18 to R58; P19 to L59; G20 to G60; S21 to G61; G22 to T62; V23 to G63; R24 to A64; 125 to F65; V26 to E66; V27 toI67;E28to®68;Y29toI#9; C3® toN70;E31 to G71; P32 to Q72; C33 to L73; INTF'' FfYTLIAL PROPERTY Q'rriCc OF N.Z. 2 5 OCT 2006 _ [receive 0 G34 to V74; F35 to F75; E36 to S76; A37 to K77; T38 to L78; Y39 to E79; L40 to N80; E41 to G81; L42 to G82; A43 to F83; S44 to P84; A45 to Y85; V46 to E86; K47 to K87; E48 to D88; Q49 to L89; Y50 to 190; P51 to E91; G52 to A92; 153 to 193; E54 to R94; 155 to R95; E56 to A92; S57 to S97; R58 to N98; L59 to G99; G60 to E100; G61 to T101; T62 to L102; G63 to E103; A64 to K104; F65 to 1105; E66 to T106; 167 to N107; E68 to S108; 169 to R109; N70 to PI 10; G71 to PI 11; Q72 to CI 12; L73 to VI13; V74 to II14; F75 to LI 15.

[0148] In another preferred embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 42mers (residues correspond to SEQ ID NO :2 and FIG. IB): Ml toL42; S2 to A43; G3 to S44; E4 to A45; P5 to V46; G6 to K47; Q7 to E48; T8 to Q49; S9 to Y50; V10 to P51; All to G52; P12 to 153; P13 to E54; P14 to 155; E15 to E56; E16 to S57; V17 to R58; El 8 to L59; P19 to G60; G20 to G61; S21 to T62; G22 to G63; V23 to A64; R24 to F65; 125 to E66; V26 to 167; V27 to E68; E28 to 169; Y29 to N70; C30 to G71; E31 to Q72; P32 to L73; C33 to V74; G34 to F75; F35 to S76; E36 to K77; A37 to L78; T38 to E79; Y39 to N80; L40 to G81; E41 to G82; L42 to F83; A43 to P84; S44 to Y85; A45 to E86; V46 to K87; K47 to D88; E48 to L89; Q49 to 190; Y50 to E91; P51 to A92; G52 to 193; 153 to R94; E54 to R95; 155 to A96; E56 to S97; S57 to N98; R58 to G99; L59 to El00; G60 to T101; G61 to L102; T62 to E103; G63 to K104; A64 to 1105; F65 to T106; E66 to N107; 167 to S108; E68 to R109; 169 to PllO; N70 to Pill; G71 to CI 12; Q72 to VI13; L73 to II14; V74 to LI 15.

[0149] In another preferred embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 43mers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to A43; S2 to S44; G3 to A45; E4 to V46; P5 to K47; G6 to E48; Q7 to Q49; T8 to Y50; S9 to P51; V10 to G52; All to 153; P12 to E54; P13 to 155; P14 to 56; E15 toS57; £.16 to R58; V17 to L59; El 8 to G68; P19 to G61; G20 to T62; intellectual PROPERTY OFFICE OF n.z. 2 5 OCT 2006 receivedl S21 to G63; G22 to A64; V23 to F65; R24 to E66; 125 to 167; V26 to E68; V27 to 169; E28 to N70; Y29 to G71; C30 to Q72; E31 to L73; P32 to V74; C33 to F75; G34 to S76; F35 to K77; E36 to L78; A37 to E79; T38 to N80; Y39 to G81; L40 to G82; E41 to F83; L42 to P84; A43 to Y85; S44 to E86; A45 to K87; V46 to D88; K47 to L89; E48 to 190; Q49 to E91; Y50 to A92; P51 to 193; G52 to R94; 153 to R95; E54 to A96; 155 to S97; E56to N98; S57 to G99; R58 to E100; L59 to TlOl; G60 to L102; G61 to E103; T62 to K104; G63 to 1105; A64 to T106; F65 to N107; E66 to S108; 167 to R109; E68 to PI 10; 169 to Pill; N70 0 toC112; G71 to V113; Q72 toI114; L73 to L115. {0150] In another preferred embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 44mers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to S44; S2 to A45; G3 to V46; E4 to K47; P5 to E48; G6 to Q49; Q7 to Y50; T8 to P51; S9 to G52; V10 to 153; Al 1 to E54; P12 to 155; P13 to E56; P14 to S57; E15 to R58; E16 to L59; V17 to G60; E18 to G61; P19 to T62; G20 to G63; S21 to A64; G22 to F65; V23 to E66; R24 to 167; 125 to E68; V26 to 169; V27 to N70; E28 to G71; Y29 to Q72; C30 to L73; E31 to V74; P32 to F75; C33 to S76; G34 to K77; F35 to L78; E36 to E79; A37 to N80; T38 to G81; Y39 to G82; ® L40 to F83; E41 to P84; L42 to Y85; A43 to E86; S44 to K87; A45 to D88; V46 to L89; K47 to 190; E48 to E91; Q49 to A92; Y50 to 193; P51 to R94; G52 to R95; 153 to A96; E54 to S97; 155 to N98; E56 to G99; S57 to E100; R58 to TlOl; L59 to LI02; G60 to E103; G61 to K104; T62 to 1105; G63 to T106; A64 to N107; F65 to S108; E66 to R109; 167 to PllO; E68 to Pill; 169 to C112; N70 to V113; G71 to 1114; Q72 to L115.

J0151] In another preferred embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 45mers (residues correspond to SEQ ID NO:2 and FIG. IB): iwellectual pr0pertv ofhul"! i of ni 1 2 5 OCT 2006 j M1 to A45; S2 to V46; G3 to K47; E4 to E48; P5 to Q49; G6 to Y50; Q7 to P51; T8 to G52; S9 to 153; V10 to E54; Al 1 to 155; P12 to E56; P13 to S57; P14 to R58; E15 to L59; E16 to G60; V17 to G61; E18 to T62; P19 to G63; G20 to A64; S21 to F65; G22 to E66; V23 to 167; R24 to E68; 125 to 169; V26 to N70; V27 to G71; E28 to Q72; Y29 to L73; C30 to Y74; E31 to F75; P32 to S76; C33 to K77; G34 to L78; F35 toE79; E36 to N80; A37 to G81; T38 to G82; Y39 to F83; L40 to P84; E41 to Y85; L42 to E86; A43 to K87; S44 to D88; A45 to L89; V46 to 190; K47 to E91; E48 to E92; Q49 to 193; Y50 to R94; P51 to R95; G52 to 0 A96; 153 to S97; E54 to N98; 155 to G99; E56 to E100; S57 to TlOl; R58 to LI 02; L59 to E103; G60 to K104; G61 to K105; T62 to T106; G63 toN107; A64 to S108; F65 to R109; E66 to PI 10; 167 to PI 11; E68 to CI 12; 169 to V113; N70 to 1114; G71 to LI 15. (0152] In another preferred embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting o£ one or more C35 peptide epitopes include the following 46mers (residues correspond to SEQDDNO:2and FIG. IB): Ml to V46; S2 to K47; G3 to E48; E4 to Q49; P5 to Y50; G6 to P51; Q7 to G52; T8 to 153; S9 to E54; V10 to 155; All to E56; P12 to S57; P13 to R58; P14 to L59; E15 to G60; E16 to G61; V17 to T62; E18 to G63; P19 to A64; G20 to F65; # S21 to E66; G22 to 167; V23 to E68; R24 to 169; 125 to N70; V26 to G71; V27 to Q72; E28 to L73; Y29 to V74; C30 to F75; E31 to S76; P32 to K77; C33 to L78; G34 to E79; F35 toN80; E36 to G81; A37 to G82; T38 to F83; Y39 to P84; L40 to Y85; E41 to E86; L42 to K87; A43 to D88; S44 to L89; A45 to 190; V46 to E91; K47 to A92; E48 to 193; Q49 to R94; Y50 to R95; P51 to A96; G52 to S97; 153 to N98; E54 to G99; 155 to E100; E56 to TlOl; S57 to L102; R58 to E103; L59 to K104; G60 to 1105; G61 to T106; T62 to N107; G63 to S108; A64 to R109; F65 to PI 10; E66 to PI 11; 167 to CI 12; E68 to V113; 169 to II14; N70 toL115

[0153] In another preferred embodiment, the isolated polypeptides described herein comprising or, -alternatively, consisting of, ©n£<§9i epitopes include the following 47mers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to K47; S2 to E48; G3 to Q49; E4 to Y50; P5 to P51; G6 to G52; Q7 to 153; T8 to E54; S9 to 155; V10 to E56; All to S57; P12 to R58; P13 to L59; P14 to G60; E15 to G61; E16 to T62; V17 to G63; E18 to A64; P19 to F65; G20to E66; S21 to 167; G22 to E68; V23 to 169; R24 to N70; 125 to G71; V26 to Q72; V27 to L73; E28 to V74; Y29 to F75; C30 to S76; E31 to K77; P32 to L78; C33 to E79; G34 to N80; F35 to G81; E36 to G82; A37 to F83; T38 to P84; Y39 to Y85; 0 L40 to E86; E41 to K87; L42 to D88; A43 to L89; S44 to 190; A45 to E91; V46 to A92; K47 to 193; E48 to R94; Q49 to R95; Y50 to A96; P51 to S97; G52 to N98; 153 to G99; E54 to E100; 155 to TlOl; E56 to L102; S57 to E103; R58 to K104; L59 to 1105; G60 to T106; G61 to N107; T62 to S108; G63 to R109; A64 to PllO; F65 to Pill; E66 to C112; 167 to V113; E68 to 1114; 169 to L115 {0154] In another preferred embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting o£ one or more C35 peptide epitopes include the following 48mers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to E48; S2 to Q49; G3 to Y50; E4 to P51; P5 to G52; G6 to 153; Q7 to E54; T8 to 155; S9 to E56; V10 to S57; All to R58; P12 to L59; P13 to G60; P14 to # G61; E15 to T62; E16 to G63; V17 to A64; E18 to F65; P19 to E66; G20 to 167; 521 to E68; G22 to 169; V23 to N70; R24 to G71; 125 to Q72; V26 to L73; V27 to V74; E28 to F75; Y29 to S76; C30 to K77; E31 to L78; P32 to E79; C33 to N80; G34 to G81; F35 to G82; E36 to F83; A37 to P84; T38 to Y85; Y39 to E86; L40 to K87; E41 to D88; L42 to L89; A43 to 190; S44 to E91; A45 to A92; V46 to 193; K47 to R94; E48 to R95; Q49 to A96; Y50 to S97; P51 to N98; G52 to G99; 153 to E100; E54 to TlOl; 155 to L102; E56 to El 03; S57 to K104; R58 to 1105; L59 to T106; G60 to N107; G61 to S108; T62 to R109; G63 to PI 10; A64 to PI 11; F65 to CI 12; E66 to VI13; 167 to II14; E68 to LI 15 [0155] In another preferred embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 49mers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to Q49; S2 to Y50; G3 to P51; E4 to G52; P5 to 153; G6 to E54; Q7 to 155; T8 to E56; S9 to S57; V10 to R58; Al 1 to L59; P12 to G60; P13 to G61; P14 to T62; El 5 to G63; E16 to A64; V17 to F65; E18 to E66; P19 to 167; G20 to E68; S21 to 169; G22 to N70; V23 to G71; R24 to Q72; 125 to L73; V26 to V74; V27 to F75; E28 to S76; Y29 to K77; C30 to L78; E31 to E79; P32 to N80; C33 to G81; G34 to G82; F35 to F83; E36 to P84; A37 to Y85; T38 to E86; Y39 to K87; 140 to D88; E41 to L89; L42 to 190; A43 to E91; S44 to A92; A45 to 193; Y46 to R94; K47 to R95; E48 to A96; Q49 to S97; Y50 to N98; P51 to <399; G52 to E100; 153 to TlOl; E54 to L102; 155 to E103; E56 to K104; S57 to 1105; R58 to T106; L59 to N107; G60 to S108; G61 to R109; T62 to PllO; G63 to PI 11; A64 to CI 12; F65 to VI13; E66 to II14; 167 to LI 15 [0156] hi another prefeired embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 50mers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to Y50; S2 to P51; G3 to G52; E4 to 153; P5 to E54; G6 to 155; Q7 to E56; T8 to S57; S9 to R58; V10 to L59; Al 1 to G60; P12 to G61; P13 to T62; P14 to G63; E15 to A64; E16 to F65; V17 to E66; E18 to 167; P19 to E68; G20 to 169; S21 to N70; G22 to G71; V23 to Q72; R24 to L73; 125 to V74; V26 to F75; V27 to S76; E28 to K77; Y29 to L78; C30 to E79; E31 to N80; P32 to G81; C33 to G82; G34 to F83; F35 to P84; E36 to Y85; A37 to E86; T38 to K87; Y39 to D88; L40 to L89; E41 to 190; 142 to E91; A43 to A92; S44 to 193; A45 to R94; V46 to R95; K47 to A96; E48 to S97; Q49 to N98; Y50 to G99; P51 to E100; G52 to TlOl; 153 to LI02; E54 to E103; 155 to K104; E56 to 1105; S57 to T106; R58 to N107; L59 to S108; G60 to R109; G61 to PI 10; T62 to PI 11; G63 to CI 12; A64 to VI13; F65 to II14; E66 to LI 15 | {0157] In another preferred embodiment, the isolated polypeptides described herein comprising or, atternatiyfelyl consisting, of, one or more C35 peptide Property OFHC^l \ INTELLECTUAL^ ^ 2 5 OCT 2006 rece r> epitopes include the following 5 liners (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to P51; S2 to G52; G3 to 153; E4 to E54; P5 to 155; G6 to E56; Q7 to S57; T8 toR58; S9 to L59; V10 to G60; All to G61; P12 to T62; P13 to G63;P14 to A64; E15 to F65; E16 to E66; V17 to 167; E18 to E68; P19 to 169; G20 to N70; S21 to G71; G22 to Q72; V23 to L73; R24 to V74; 125 to F75; V26 to S76; V27 to K77; E28 to L78; Y29 to E79; C30 to N80; E31 to G81; P32 to G82; C33 to F83; G34 to P84; F35 to Y85; E36 to E86; A37 to K87; T38 to D88; Y39 to L89; L40 to 190; E41 to E91; L42 to A92; A43 to 193; S44 to R94; A45 to R95; V46 to A96; K47 to S97; E48 to N98; Q49 to G99; Y50 to ElOO; P51 to TlOl; G52 to LI02; 153 to E103; E54 to K104; 155 to 1105; E56 to T106; S57 to N107; R58 to S108; L59 to R109; G60 to PllO; G61 to Pill; T62 to CI 12; G63 to VI13; A64 to 1114; F65 to LI 15 {0158] In another preferred embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 52mers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to G52; S2 to 153; G3 to E54; E4 to 155; P5 to E56; G6 to S57; Q7 to R58; T8 to L59; S9 to G60; V10 to G61; Al 1 to T62; P12 to G63; P13 to A64; P14 to F65; E15 toE66; E16 to 167; V17 to E68; E18 to 169; P19 to N70; G20 to G71; S21 to Q72; G22 to L73; V23 to V74; R24 to F75; 125 to S76; V26 to K77; V27 to L78; E28 to E79; Y29 to N80; C30 to G81; E31 to G82; P32 to F83; C33 to P84; G34 to Y85; F35 to E86; E36 to K87; A37 to D88; T38 to L89; Y39 to 190; 140 to E91; E41 to A92; L42 to 193; A43 to R94; S44 to R95; A45 to A96; V46 to S97; K47 to N98; E48 to G99; Q49 to ElOO; Y50 to TlOl; P51 to L102; G52 to E103; 153 to K104; E54 to 1105; 155 to T106; E56 to N107; S57 to S108; R58 to R109; L59 to PllO; G60 to Pill; G61 to €112; T62 to VI13; G63 to 1114; A64toL115 {0159] In another preferred embodiment, the isolated polypeptides described comprising or, alternatively, consisting of, one or more C35 peptide Intellectual ppop OF NZ. epitopes include the following 53mers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to 153; S2 to E54; G3 to 155; E4 to E56; P5 to S57; G6 to R58; Q7 to L59; T8 to G60; S9 to G61; VIO to T62; Al 1 to G63; P12 to A64; P13 to F65; P14 to E66; El 5 to 167; EI6 to E68; V17 to 169; E18 to N70; PI9 to G71; G20 to Q72; S21 to L73; G22 to V74; V23 to F75; R24 to S76; 125 to K77; V26 to L78; V27 to E79; E28 to N80; Y29 to G81; C30 to G82; E31 to F83; P32 to P84; C33 to Y85; G34 to E86; F35 to K87; E36 to D88; A37 to L89; T38 to 190; Y39 to E91; L40 to A92;lE41 to 193; L42 to R94; A43 to R95; S44 to A96; A45 to S97; V46 toN98; K47 to G99; E48 to ElOO; Q49 to TlOl; Y50 to L102; P51 to E103; G52 to K104; 153 to 1105; E54 to T106; 155 to N107; E56 to S108; S57 to R109; R58 to PllO; L59 to Pill; G60 to C112; G61 to V113; T62 to 1114; G63 to L115 [0160] In another preferred embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 54mers (residues correspond to SEQ ID NO:2 and Ml to E54; S2 to 155; G3 to E56; E4 to S57; P5 to R58; G6 to L59; Q7 to G60; T8 to G61; S9 to T62; VIO to G63; Al 1 to A64; P12 to F65; P13 to E66; P14 to 167; E15 to E68; E16 to 169; V17 to N70; E18 to G71; P19 to Q72; G20 to L73; S21 to V74; G22 to F75; V23 to S76; R24 to K77; 125 to L78; V26 to E79; V27 to N80; E28 to G81; Y29 to G82; C30 to F83; E31 to P84; P32 to Y85; C33 to E86; G34 to K87; F35 to D88; E36 to L89; A37 to 190; T38 to E91; Y39 to A92; L40 to 193; E41 to R94; 142 to R95; A43 to A96; S44 to S97; A45 to N98; V46 to G99; K47 to ElOO; E48 to TlOl; Q49 to LI02; Y50 to E103; P51 to K104; G52 to 1105; 153 to T106; E54 to N107; 155 to S108; E56 to R109; S57 to PI 10; R58 to PHI; L59 to CI 12; G60 to VI13; G61 to 1114; T62 to LI 15 [0161] In another preferred embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 55mers (residues correspond to SEQ ID NO:2 and FIG, IB): FIG. IB): M1 to 155; S2 to E56; G3 to S57; E4 to R58; P5 to L59; G6 to G60; Q7 to G61; T8 to T62; S9 to G63; VIO to A64; Al 1 to F65; P12 to E66; P13 to 167; P14 to E68; E15 to 169; E16 to N70; V17 to G71; E18 to Q72; P19 to L73; G20 to V74; S21 to F75; G22 to S76; V23 to K77; R24 to L78; 125 to E79; V26 to N80; V27 to G81; E28 to G82; Y29 to F83; C30 to P84; E31 to Y85; P32 to E86; C33 to K87; G34 to D88; F35 to L89; E36 to 190; A37 to E91; T38 to A92; Y39 to 193; L40 to R94; E41 to R95; L42 to A96; A43 to S97; S44 to N98; A45 to G99; V46 to ElOO; K47 to TlOl; E48 to L102; Q49 to E103; Y50 to K104; P51 to 1105; G52 to T106; 153 to N107; E54 to S108; 155 to R109; E56 to PI 10; S57 to P111; R58 to CI 12; L59 to VI13; G60 to II14; G61 to LI 15 {0162] In another preferred embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 56mers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to E56; S2 to S57; G3 to R58; E4 to L59; P5 to G60; G6 to G61; Q7 to T62; T8 to G63; S9 to A64; VIO to F65; Al 1 to E66; P12 to 167; P13 to E68; P14 to 169; E15 to N70; E16 to G71; V17 to Q72; E18 to L73; P19 to V74; G20 to F75; S21 to S76; G22 to K77; V23 to L78; R24 to E79; 125 to N80; V26 to G81; V27 to G82; E28 to F83; Y29 to P84; C30 to Y85; E31 to E86; P32 to K87; C33 to D88; G34 to L89; F35 to 190; E36 to E91; A37 to A92; T38 to 193; Y39 to R94; L40 to R95; E41 to A96; L42 to S97; A43 to N98; S44 to G99; A45 to ElOO; V46 to TlOl; K47 to L102; E48 to E103; Q49 to K104; Y50 to 1105; P51 to T106; G52 to N107; 153 to S108; E54 to R109; 155 to PllO; E56 to Pill; S57 to CI 12; R58 to V113; L59 to 1114; G60 to L115 [0163] In another preferred embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 57mers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to S57; S2 to R58; G3 to L59; E4to G60; P5 to G61; G6 to T62; Q7 to G63; T8 to A64; S9 to F65; V10 to F66; Al 1 to 167; P12 to F68; P13 to 169; P14 to I 25 OCT 2G0o 1 «rrci\/?j N70; E15 to G71; E16 to Q72; V17 to L73; E18 to V74; PI9 to F75; G20 to S76; S21 to K77; G22 to L78; V23 to E79; R24 to N80; 125 to G81; V26 to G82; V27 to F83; E28 to P84; Y29 to Y85; C30 to E86; E31 to K87; P32 to D88; C33 to L89; G34 to 190; F35 to E91; E36 to A92; A37 to 193; T38 to R94; Y39 to R95; L40 to A96; E41 to S97; L42 to N98; A43 to G99; S44 to ElOO; A45 to TlOl; V46 to L102; K47 to E103; E48 to K104; Q49 to 1105; Y50 to T106; P51 to N107; G52 to S108; 153 to R109; E54 to PI 10; 155 to Pill; E56 to CI 12; S57 to V113; R58 to 1114; L59 toL115

[0164] In another preferred embodiment, the isolated polypeptides described herein i comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 58mers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to R58; S2 to L59; G3 to G60; E4 to G61; P5 to T62; G6 to G63; Q7 to A64; T8 to F65; S9 to E66; VIO to 167; All to E68; P12 to 169; P13 to N70; P14 to G71; E15 to Q72; E16 to L73; V17 to V74; E18 to F75; P19 to S76; G20 to K77; S21 to L78; G22 to E79; V23 toN80; R24 to G81; 125 to G82; V26 to F83; V27 to P84; E28 to Y85; Y29 to E86; C30 to K87; E31 to E88; P32 to L89; C33 to 190; G34 to E91; F35 to A92; E36 to 193; A37 to R94; T38 to R95; Y39 to A96; L40 to S97; El to N98; L42 to G99; A43 to ElOO; S44 to TlOl; A45 to L102; V46 to El 03; K47 to K104; E48 to 1105; Q49 to T106; Y50 to N107; P51 to S108; G52 to R109; 153 to PllO; E54 to Pill; 155 to CI 12; E56 to VI13; S57 to II14; R58 to LI 15

[0165] In another preferred embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 59mers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to L59; S2 to G60; G3 to G61; E4 to T62; P5 to G63; G6 to A64; Q7 to F65; T8 to E66; S9 to 167; V10 to E68; Al 1 to 169; P12 to N70; P13 to G71; P14 to Q72; El5 to L73; E16 to V74; V17 to F75; E18 to S76; P19 to K77; G20 to L78; . tcrE79;lG22 to N80;Y23 tdG81; 124 to G82| 125 to F83; V26 to P84; V27 intellectual property OffiCc of im.z 2 5 OCT 2006 V H to Y85; E28 to E86; Y29 to K87; C30 to D88; E31 to L89; P32 to 190; C33 to E91; G34 to A92; F35 to 193; E36 to R94; A37 to R95; T38 to A96; Y39 to S97; L40 to N98; E41 to G99; 142 to ElOO; A43 to TlOl; S44 to LI02; A45 to El03; V46 to K104; K47 to 1105; E48 to T106; Q49 to N107; Y50 to S108; P51 to R109; G52 to PllO; 153 to PI 11; E54 to CI 12; 155 to VI13; E56 to II14; S57 to LI 15

[0166] In another prefeired embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 60mers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to G60; S2 to G61; G3 to T62; E4 to G63; P5 to A64; G6 to F65; Q7 to E66; T8 to 167; S9 to E68; V10 to 169; All to N70; P12 to G71; P13 to Q72; P14 to L73; El 5 to V74; E16 to F75; V17 to S76; E18 to K77; P19 to L78; G20 to E79; S21 to N80; G22 to G81; V23 to G82; R24 to F83; 125 to P84; V26 to Y85; V27 to E86; E28 to K87; Y29 to D88; C30 to L89; E31 to 190; P32 to E91; C33 to A92; G34 to 193; F35 to R94; E36 to R95; A37 to A96; T38 to S97; Y39 to N98; L40 to G99; E41 to ElOO; L42 to TlOl; A43 to L102; S44 to E103; A45 to K104; V46 to 1105; K47 to T106; E48 to N107; Q49 to S108; Y50 to R109; P51 to PllO; G52 to Pill; 153 to CI 12; E54 to VI13; 155 to 1114; E56 to LI 15

[0167] In another preferred embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 61mers (residues correspond to SEQ ID NO:2 and FIG. IB): Mi to G61; S2 to T62; G3 to G63; E4 to A64; P5 to F65; G6 to E66; Q7 to 167; T8 to E68; S9 to 169; V10 to N70; All to G71;P12 to Q72; P13 to L73; P14 to V74; El 5 to F75; El 6 to S76; VI7 to K77; El 8 to L78; P19 to E79; G20 to N80; S21 to G81; G22 to G82; V23 to F83; R24 to P84; 125 to Y85; V26 to E86; V27 to K87; E28 to D88; Y29 to L89; C30 to 190; E31 to E91; P32 to A92; C33 to 193; G34 to R94; F35 to R95; E36 to A96; A37 to S97; T38 to N98; Y39 to G99; L40 to ElOO; E41 to TlOl; L42 to L102; -A43 toE1Q3; S44to K104; A45 to. 1105; V46 to T106; K47 toN107; E48 to S108; Q49 to R109; Y50 to PI 10; P51 to Pill; G52 to CI 12; 153 to VI13; E54 to 1114; 155 to LI 15

[0168] In another preferred embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 62mers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to T62; S2 to G63; G3 to A64; E4 to F65; P5 to E66; G6 to 167; Q7 to E68; T8 to 169; S9 to N70; VIO to G71; Al 1 to Q72; P12 to L73; P13 to V74; P14 to F75; E15 to S76; E16 to K77; V17 to L78; E18 to E79; P19 to N80; G20 to G81; S21 to G82; G22 to F83; V23 to P84; R24 to Y85; 125 to E86; V26 to K87; V27 to D88; E28 to L89; Y29 to 190; C30 to E91; E31 to A92; P32 to 193; C33 to R94; G34 to R95; F35 to A96; E36 to S97; A37 to N98; T38 to G99; Y39 to ElOO; L40 to TlOl; E41 to L102; L42 to E103; A43 to K104; S44 to 1105; A45 to T106; V46 to N107; K47 to S108; E48 to R109; Q49 to PI 10; Y50 to PI 11; P51 to CI 12; G52 to VI13; 153 to II14; E54 to LI 15.

[0169] In another preferred embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 63mers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to G63; S2 to A64; G3 to F65; E4 to E66; P5 to 167; G6 to E68; Q7 to 169; T8 to N70; S9 to G71; V10 to Q72; All to L73; P12 to V74; P13 to F75; P14 to S76; El 5 to K77; E16 to L78; V17 to E79; E18 to N80; P19 to G81; G20 to G82; S21 to F83; G22 to P84; V23 to Y85; R24 to E86; 125 to K87; V26 to D88; V27 to L89; E28 to 190; Y29 to E91; C30 to A92; E31 to 193; P32 to R94; C33 to R95; G34 to A96; F35 to S97; E36 to N98; A37 to G99; T38 to ElOO; Y39 to TlOl; L40 to L102; E41 to E103; L42 to K104; A43 to 1105; S44 to T106; A45 to N107; V46 to S108; K47 to R109; E48 to PI 10; Q49 to PI 11; Y50 to CI 12; P51 to VI13; G52 to II14; 153 to LI 15

[0170] In another preferred embodiment, the isolated polypeptides described herein comprising or, alternatively consisting of, one or more C35 peptide INTELLECTUAL property OF N.Z 2 5 OCT 2006 RECEIVE office! epitopes include the following 64mers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to A64; S2 to F65; G3 to E66; E4 to 167; P5 to E68; G6 to 169; Q7 to N70; T8 to G71; S9 to Q72; VIO to L73; All to V74; P12 to F75; P13 to S76; P14 to K77; E15 to L78; E16 to E79; V17 to N80; E18 to G81; P19 to G82; G20 to F83; S21 to P84; G22 to Y85; V23 to E86; R24 to K87; 125 to D88; V26 to L89; V27 to 190; E28 to E91; Y29 to A92; C30 to 193; E31 to R94; P32 to R95; C33 to A96; G34 to S97; F35 to N98; E36 to G99; A37 to ElOO; T38 to TlOl; Y39 to LI 02; L40 to El 03; E41 to K104; L42 to 1105; A43 to T106; S44 to N107; A45 to S108; V46 to R109; K47 to PllO; E48 to Pill; Q49 to C112; Y50 to V113; P51 to 1114; G52 to LI 15; (0171] ]ri another preferred embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 65mers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to F65; S2 to E66; G3 to 167; E4 to E68; P5 to 169; G6 to N70; Q7 to G71; T8 to Q72; S9 to L73; V10 to V74; Al 1 to F75; P12 to S76; P13 to K77; P14 to L78; E15 to E79; E16 toN80; V17 to G81; E18 to G82; P19 to F83; G20 to P84; S21 to Y85; G22 to E86; V23 to K87; R24 to D88; 125 to L89; V26 to 190; V27 to E91; E28 to A92; Y29 to 193; C30 to R94; E31 to R95; P32 to A96; C33 to S97; G34 to N98; F35 to G99; E36 to ElOO; A37 to TlOl; T38 to L102; Y39 to E103; L40 to K104; E41 to 1105; L42 to T106; A43 to N107; S44 to S108; A45 to R109; V46 to PllO; K47 to Pill; E48 to CI 12; Q49 to VI13; Y50 to II14; P51 to LI 15;

[0172] In another preferred embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 66mers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to E66; S2 to 167; G3 to E68; E4 to 169; P5 to N70; G6 to G71; Q7 to Q72; T8 to L73; S9 to V74; VIO to F75; All to S76;P12toK77;P13.to L78; P14 to intellectual PROPERTY OFFiCi: of n.z. 2 5 OCT 2006 RECEIVE" E79; E15 to N80; E16 to G81; V17 to G82; E18 to F83; P19 to P84; G20 to Y85; S21 to E86; G22 to K87; V23 to D88; R24 to L89; 125 to 190; V26 to E91; V27 to A92; E28 to 193; Y29 to R94; C30 to R95; E31 to A96; P32 to S97; C33 to N98; G34 to G99; F35 to ElOO; E36 to TlOl; A37 to L102; T38 to E103; Y39 to K104; L40 to 1105; E41 to T106; L42 to N107; A43 to S108; S44 to R109; A45 to PllO; V46 to Pill; K47 to C112; E48 to V113; Q49 to 1114; Y50 to LI 15

[0173] In another preferred embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 67mers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to 167; S2 to E68; G3 to 169; E4 to N70; P5 to G71; G6 to Q72; Q7 to L73; T8 to V74; S9 to F75; VIO to S76; All to K77; P12 to L78; P13 to E79; P14 to N80; E15 to G81; E16 to G82; V17 to F83; E18 to P84; P19 to Y85; G20 to E86; S21 to K87; G22 to D88; V23 to L89; R24 to 190; 125 to E91; V26 to A92; V27 to 193; E28 to R94; Y29 to R95; C30 to A96; E31 to S97; P32 to N98; C33 to G99; G34 to ElOO; F35 to TlOl; E36 to LI02; A37 to E103; T38 to K104; Y39 to 1105; L40 to T106; E41 to N107; L42 to S108; A43 to R109; S44 to PI 10; A45 to PHI; V46 to CI 12; K47 to V113; E48 to 1114; Q49 to L115;

[0174] In another preferred embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting o^ one or more C35 peptide epitopes include the following 68mers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to E68; S2 to 169; G3 to N70; E4 to G71; P5 to Q72; G6 to L73; Q7 to V74; T8 to F75; S9 to S76; VIO to K77; Al 1 to L78; P12 to E79; P13 to N80; P14 to G81; E15 to G82; E16 to F83; V17 to P84; E18 to Y85; P19 to E86; G20 to K87; S21 to D88; G22 to L89; V23 to 190; R24 to E91; 125 to A92; V26 to 193; V27 to R94; E28 to R95; Y29 to A96; C30 to S97; E31 to N98; P32 to G99; C33 to ElOO; G34 to TlOl; F35 to L102; E36 to E103; A37 to K104; T38 to 1105; Y39 intellectual property office of n.z. 2 5 OCT 2005 RFr.EJVEC to T106; 140 to N107; E41 to S108; L42 to R109; A43 to PI 10; S44 to Pill; A45 to CI 12; V46 to VI13; K47 to II14; E48 to LI 15; i

[0175] In another preferred embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 69mers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to 169; S2 to N70; G3 to G71; E4 to Q72; P5 to L73; G6 to V74; Q7 to F75; T8 to S76; S9 to K77; VIO to L78; Al 1 to E79; P12 to N80; P13 to G81; P14 to G82; E15 to F83; E16 to P84; V17 to Y85; E18 to E86; P19 to K87; G20 to D88; S21 to L89; G22 to 190; V23 to E91; R24 to A92; 125 to 193; V26 to R94; V27 to R95; E28 to A96; Y29 to S97; C30 to N98; E31 to G99; P32 to ElOO; C33 to TlOl; G34 to L102; F35 to E103; E36 to K104; A37 to 1105; T38 to T106; Y39 to N107; L40 to S108; E41 to R109; L42 to PllO; A43 to Pill; S44 to C112; A45 to VI13; V46 to II14; K47 to LI 15. (0176] In another preferred embodiment, the isolated polypeptides described t herein comprising or, alternatively, consisting of! one or more C35 peptide epitopes include the following 70mers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to N70; S2 to G71; G3 to Q72; E4 to L73; P5 to V74; G6 to F75; Q7 to S76; T8 to KL77; S9 to L78; VIO to E79; Al 1 to N80; P12 to G81; P13 to G82; P14 to F83; El 5 to P84; E16 to Y85; V17 to E86; E18 to K87; P19 to D88; G20 to L89; S21 to 190; G22 to E91; V23 to A92; R24 to 193; 125 to R94; V26 to R95; V27 to A96; E28 to S97; Y29 to N98; C30 to G99; E31 to ElOO; P32 to TlOl; C33 to L102; G34 to E103; F35 to K104; E36 to 1105; A37 to T106; T38 to N107; Y39 to S108; L40 to R109; E41 to PllO; L42 to Pill; A43 to C112; S44 to VI13; A45 to 1114; V46 to L115. {0177] In another preferred embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 7 lmers (residues correspond to SEQ ID NO :2 and FIG. IB): l^teilectual""propertv^o s^rct OF N.i OCT 2C06 M1 to G71; S2 to Q72; G3 to L73; E4 to V74; P5 to F75; G6 to S76; Q7 to K77; T8 toL78; S9 toE79; V10toN80; All toG81; P12 to G82; P13 toF83; P14 to P84; E15 to Y85; E16 to E86; V17 to K87; E18 to D88; P19 to L89; G20 to 190; S21 to E91; G22 to A92; V23 to 193; R24 to R94; 125 to R95; V26 to A96; V27 to S97; E28 to N98; Y29 to G99; C30 to ElOO; E31 to TlOl; P32 to L102; .C33 to E103; G34 to K104; F35 to 1105; E36 to T106; A37 to N107; T38 to S108; Y39 to R109; L40 to PllO; E41 to Pill; L42 to CI 12; A43 to V113; S44 to 1114; A45 to LI 15. £0178] In another preferred embodiment, the isolated polypeptides described! herein comprising or, alternatively, consisting ofj one or more C35 peptide epitopes include the following 72mers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to Q72; S2 to L73; G3 to V74; E4 to F75; P5 to S76; G6 to K77; Q7 to L78; T8 to E79; S9 to N80; VIO to G81; Al 1 to G82; P12 to F83; P13 to P84; P14 to Y85; E15 to E86; E16 to K87; V17 to D88; E18 to L89; P19 to 190; G20 toE91; S21 to A92; G22 to 193; V23 to R94; R24 to R95; 125 to A96; V26 to S97; V27 toN98; E28 to G99; Y29 to ElOO; C30 to TlOl; E31 to L102; P32 to E103; C33 to K104; G34 to 1105; F35 to T106; E36 to N107; A37 to S108; T38 to R109; Y39 to PI 10; L40 to Pll 1; E41 to CI 12; L42 to VI13; A43 to II14; S44 to LI 15. |0179] In another preferred embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 73mers (residues correspond to SEQ ID NO:2 and FIG IB): Ml to L73; S2 to V74; G3 to F75; E4 to S76; P5 to K77; G6 to L78; Q7 to E79; T8 to N80; S9 to G81; V10 to G82; Al 1 to F83; P12 to P84; P13 to Y85; P14 to E86; E15 to K87; E16 to D88; V17 to L89; El 8 to 190; P19 to E91; G20 to A92; S21 to 193; G22 to R94; V23 to R95; R24 to A96; 125 to S97; V26 to N98; V27 to G99; E28 to E100; Y29 to TlOl; C30 to L102; E31 to E103; P32 to K104; C33 to 1105; G34 to T106; F35 to N107; E36 to S108; A37 to R109; T38 to PllO; SB9 to#1 llfL40 to CI 12; E41 to V113; L42 to I114; A43 to LI 15; intellectual property office of n2. 2 5 OCT 2006 {0180] In another preferred embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 74mers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to V74; S2 to F75; G3 to S76; E4 to K77; P5 to L78; G6 to E79; Q7 to N80; T8 to G81; S9 to G82; VIO to F83; Al 1 to P84; P12 to Y85; P13 to E86; P14 to K87; E15 to D88; E16 to L89; V17 to 190; E18 to E91; P19 to A92; G20 to 193; S21 to R94; G22 to R95; V23 to A96; R24 to S97; 125 to N98; V26 to G99; V27 to ElOO; E28 to TlOl; Y29 to L102; C30 to E103; E31 to K104; P32 to 1105; C33 to T106; G34 to N107; F35 to S108; E36 to R109; A37 to PI 10; T38 to Pill; Y39 to CI 12; L40 to VI13; E41 to 1114; L42 to LI 15. {0181] hi another preferred embodiment, the isolated polypeptides described' herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 75mers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to F75; S2 to S76; G3 to K77; E4 to L78; P5 to E79; G6 to N80; Q7 to G81; T8 to G82; S9 to F83; VIO to P84; All to Y85; P12 to E86; P13 to K87; P14 to D88; E15 to L89; E16 to 190; V17 to E91; E18 to A92; P19 to 193; G20 to R94; S21 toR95; G22 to A96; V23 to S97; R24 to N98; 125 to G99; V26 to ElOO; V27 to TlOl; E28 to L102; Y29 to E103; C30 to K104; E31 to 1105; P32 to T106; C33 to N107; G34 to S108; F35 to R109; E36 to PllO; A37 to Pill; T38 to CI 12; Y39 to VI13; L40 to 1114; E41 to L115; {0182] In another preferred embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 76mers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to S76; S2 to K77; G3 to L78; E4 to E79; P5 to N80; G6 to G81; Q7 to G82; T8 to F83; S9 to P84; V10 to Y85; Al 1 to E86; P12 to K87; P13 to D88; P14 to L89; El5 to 190; E16 to E91; V17 to A92; E18 to 193; P19 to R94; G20 to R95; S21 to A96; G22 to S97; V23 to N98; R24 to G99; I25^E100; V26 to TlOl; IMTFII FP.TIJAL PROPERTY OFHCEp OF N.Z 2 5 OCT 2006 V27 to LI02; E28 to E103; Y29 to K104; C30 to 1105; E31 to T106; P32 to N107; C33 to S108; G34 to R109; F35 to PllO; E36 to Pill; A37 to CI 12; T38 to VI13; Y39 to II14; L40 to LI 15; J0183] In another preferred embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 77mers (residues correspond to SEQ DDNO:2 and FIG. IB): Ml to K77; S2 to L78; G3 to E79; E4 to N80; P5 to G81; G6 to G82; Q7 to F83; T8 to P84; S9 to Y85; VIO to E86; All toK87; P12 to D88; P13 to L89; P14 to 190; E15 to E91; E16 to A92; V17 to 193; E18 to R94; P19 to R95; G20 to A96; S21 to S97; G22 to N98; V23 to G99; R24 to ElOO; 125 to TlOl; V26 to L102; V27 to E103; E28 to K104; Y29; 1105; C30 to T106; E31 toN107;P32to S108; C33 to R109; G34 to PllO; F35 to Pill; E36 to C112; A37 to V113; T38 to 1114; Y39 to LI 15; (0184] In another preferred embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 78mers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to L78; S2 to E79; G3 toN80; E4 to G81; P5 to G82; G6 to F83; Q7 to P84; T8 to Y85; S9 to E86; V10 to K87; Al 1 to D88; P12 to L89; P13 to 190; P14 to E91; E15 to A92; E16 to 193; V17 to R94; E18 to R95; P19 to A96; G20 to S97; S21 to N98; G22 to G99; V23 to ElOO; R24 to TlOl; 125 to L102; V26 to E103; V27 to KL104; E28 to 1105; Y29 to T106; C30 to N107; E31 to S108; P32 to R109; C33 to PI 10; G34 to PI 11; F35 to CI 12; E36 to VI13; A37 to II14; T38 to LI 15. (0185] In another preferred embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 79mers (residues correspond to SEQ ID NO:2 and FIG. IB): INTELLECTUAL PROPERTY QFFICifj OF N.Z 2 5 OCT 2006 M1 to E79; S2 to N80; G3 to G81; E4 to G82; P5 to F83; G6 to P84; Q7 to Y85; T8 to E86; S9 to K87; VIO to D88; All to L89; P12 to 190; P13 to E91; P14 to A92; E15 to 193; E16 to R94; V17 to R95; E18 to A96; P19 to S97; G20 to N98; S21 to G99; G22 to ElOO; V23 to TlOl; R24 to L102; 125 to E103; V26 to K104; V27 to 1105; E28 to T106; Y29 to N107; C30 to S108; E31 to R109; P32 to PllO; C33 to Pill; G34 to C112; F35 to V113; E36 to 1114; A37 to L115. [0186] In another preferred embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 80mers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to N80; S2 to G81; G3 to G82; E4 to F83; P5 to P84; G6 to Y85; Q7 to E86; T8 to K87; S9 to D88; VIO to L89; All to 190; P12 to E91; P13 to A92; P14 to 193; E15 to R94; E16 to R95; V17 to A96; E18 to S97; P19 to N98; G20 to G99; S21 to ElOO; G22 to TlOl; V23 to L102; R24 to E103; 125 to K104; V26 to 1105; V27 to T106; E28 to N107; Y29 to S108; C30 to R109; E31 to PllO; P32 to Pill; C33 to CI 12; G34 to V113; F35 to 1114; E36 to LI 15. {0187] In another preferred embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 8 lmers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to G81; S2 to G82; G3 to F83; E4 to P84; P5 to Y85; G6 to E86; Q7 to K87; T8 to D88; S9 to L89; V10 to 190; All to E91; P12 to A92; P13 to 193; P14 to R94; E15 to R95; E16 to A96; V17 to S97; E18 to N98; P19 to G99; G20 to ElOO; S21 to TlOl; G22 to L102; V23 to E103; R24 to K104; 125 to 1105; V26 to T106; V27 to N107; E28 to S108; Y29 to R109; C30 to PllO; E31 to Pill; P32 to CI 12; C33 to VI13; G34 to 1114; F35 to LI 15.

[0188] In another preferred embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 82mers (residues correspond to SEQ ID NO:2 and FKMB> INTELLECTUAL property of OF mi.

OCT 2008 Ml to G82; S2 to F83; G3 to P84; E4 to Y85; P5 to E86; G6 to K87; Q7 to D88; T8 to L89; S9 to 190; VIO to E91; All to A92; P12 to 193; P13 to R94; P14 to R95; El5 to A96; E16 to S97; V17 to N98; E18 to G99; P19 to ElOO; G20 to TlOl; S21 to LI02; G22 to E103; V23 to K104; R24 to 1105; 125 to T106; V26 to N107; V27 to S108; E28 to R109; Y29 to PllO; C30 to Pill; E31 to C112; P32 to V113; C33 to 1114; G34 to L115.

[0189] In another preferred embodiment, the isolated polypeptides > described I ! herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 83mers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to F83; S2 to P84; G3 to Y85; E4 to E86; P5 to K87; G6 to D88; Q7 to L89; T8 to 190; S9 to E91; V10 to A92; Al 1 to 193; P12 to R94; P13 to R95; P14 to A96; E15 to S97; E16 to N98; V17 to G99; E18 to ElOO; P19 to TlOl; G20 to L102; S21 to E103; G22 to K104; V23 to 1105; R24 to T106; 125 to N107; V26 to S108; V27 to R109; E28 to PI 10; Y29 to PI 11; C30 to CI 12; E31 to VI13; P32 to 1114; C33 to LI 15.

[0190] In anotherpreferred embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 84mers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to P84; S2 to Y85; G3 to E86; E4 to K87; P5 to D88; G6 to L89; Q7 to 190; T8 to E91; S9 to A92; VIO to 193; All to R94; P12 to R95; P13 to A96; P14 to S97; E15 to N98; E16 to G99; V17 to ElOO; E18 to TlOl; P19 to L102; G20 to El 03; S21 to K104; G22'to 1105; V23 to T106; R24 to N107; 125 to S108; V26 toR109; V27 to PllO; E28 to Pill; Y29 to CI 12; C30 to V113; E31 to 1114; P32toL115.

[0191] In another preferred embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 85mers (residues correspond to SEQ ID NO:2 and FIG. IB): INTELLECTUAL PROPERTY OFFICE OF M.Z.

M1 to Y85; S2 to E86; G3 to K87; E4 to D88; P5 to L89; G6 to 190; Q7 to E91; T8 to A92; S9 to 193; VIO to R94; Al 1 to R95; P12 to A96; P13 to S97; P14 to N98; El5 to G99; E16 to ElOO; V17 to TlOl; E18 to L102; P19 to El03; G20 to K104; S21 to 1105; G22 to T106; V23 to N107; R24 to S108; 125 to R109; V26 to PllO; V27 to Pill; E28 to C112; Y29 to V113; C30 to 1114; E31 toL115.

[0192] In another preferred embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 86mers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to E86; S2 to K87; G3 to D88; E4 to L89; P5 to 190; G6 to E91; Q7 to A92; T8 to 193; S9 to R94; V10 to R95; Al 1 to A96; P12 to S97; P13 to N98; P14 to G99; E15 to ElOO; E16 to TlOl; V17 to L102; E18 to E103; P19 to K104; G20 to 1105; S21 to T106; G22 to N107; V23 to S108; R24 to R109; 125 to PI 10; V26 to Pill; V27 to C112; E28 to VU3; Y29 to 1114; C30 to L115.

[0193] In another preferred embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 87mers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to K87; S2 to D88; G3 to L89; E4 to 190; P5 to E91; G6 to A92; Q7 to 193; T8 to R94; S9 to R95; V10 to A96; Al 1 to S97; P12 to N98; P13 to G99; P14 to Ei00; El5 to TlOl; E16 to L102; V17 to El03; E18 to K104; P19 to 1105; G20 to T106; S21 to N107; G22 to SI08; V23 to R109; R24 to PllO; 125 to Pill; V26 to C1.12; V27 to V113; E28 to 1114; Y29 to L115.

[0194] In another preferred embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 88mers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to D88; S2 to L89; G3 to 190; E4 to E91; P5 to A92; G6 to 193; Q7 to R94; T8 to R95; S9 to A96; V10 to S97; All to N98; P12 to G99; P13 to ElOO; P14 to TlOl; E15 to LI02; E16 to E103; V17 to K104; E18 to 1105; P19 to T106; INTELLECTUAL G20 to N107; S21 to S108; G22 to R109; V23 to PllO; R24 to Pill; 125 to CI 12; V26 to VI13; V27 to 1114; E28 to LI 15.

[0195] In another preferred embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 89mers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to L89; S2 to 190; G3 to E91; E4 to A92; P5 to 193; G6 to R94; Q7 to R95; T8 to A96; S9 to S97; VIO to N98; Al 1 to G99; P12 to ElOO; P13 to TlOl; P14 to L102; E15 to E103; E16 to K104; V17 to 1105; E18 to T106; P19 to N107; G20 to S108; S21 to R109; G22 to PllO; V23 to Pill; R24 to CI 12; 125 to V113; V26 to 1114; V27 to L115. {0196] hi another preferred embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C3 5 peptide epitdpes include the following 90mers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to 190; S2 to E91; G3 to A92; E4toI93; P5 to R94; G6toR95; Q7toA96; T8 to S97; S9 to N98; V10 to G99; Al 1 to ElOO; P12 to TlOl; P13 to L102; P14 to E103; El 5 to K104; E16 to 1105; V17 to T106; E18 to N107; P19 to S108; G20 to R109; S21 to PllO; G22 to Pill; V23 to C112; R24 to V113; 125 to 1114; V26 toL115. : {0197] hi another preferred embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 9 lmers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to E91; S2 to A92; G3 to 193; E4 to R94; P5 to R95; G6 to A96; Q7 to S97; T8 to N98; S9 to G99; V10 to ElOO; All to TlOl; P12 to L102; P13 to E103; P14 to K104; E15 to 1105; E16 to T106; V17 to N107; E18 to S108; P19 to R109; G20 to PllO; S21 to Pill; G22 to CI 12; V23 to V113; R24 to 1114; 125 to LI 15.

INTELLECTUAL property 0,-TiCE of N.Z. 2 5 OCT 2006 RECEIVED

[0198] Jh another preferred embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 92mers (residues correspond to SEQ ED NQ:2 and FIG. IB): Ml to A92; S2 to 193; G3 to R94; E4 to R95; P5 to A96; G6 to S97; Q7 to N98; T8 to G99; S9 to ElOO; VIO to TlOl; All to L102; P12 toE103; P13 to K104; P14toI105;E15toT106; E16toN107;V17toS108; E18toR109;P19toP110; G20 to Pill; S21 to C112; G22 to V113; V23 to 1114; R24 to L115. i J0199] In another preferred embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 93mers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to 193; S2 to R94; G3 to R95; E4 to A96; P5 to S97; G6 to N98; Q7 to G99; T8 to ElOO; S9 to TlOl; VIO to L102; Al 1 to E103; P12 to K104; P13 to 1105; P14 to T106; E15 to N107; E16 to S108; V17 to R109; E18 to PllO; P19 to Pill; G20 to CI 12; S21 to VI13; G22to 1114; V23 to LI 15. {0200] hi another preferred embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 94mers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to R94; S2 to R95; G3 to A96; E4 to S97; P5 to N98; G6 to G99; Q7 to ElOO; T8 to TlOl; S9 to L102; VIO to E103; All to K104; P12 to 1105; P13 to T106; P14 toN107; E15 to S108; E16 to R109; V17 to PI 10; E18 to Pill; P19 to CI 12; G20 to VI13; S21 to II14; G22 to LI 15.

[0201] In another preferred embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 95mers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to R95; S2 to A96; G3 to S97; E4 to N98; P5 to G99; G6 to ElOO; Q7 to TlOl; T8 to L102; S9 to E103; VIO to K104; All to 1105; P12 to T106; INTELLECTUAL PROPERTY OFFICE OF N.Z. 2 5 OCT 2006 RECEIVED P13 to N107; P14 to S108; E15 to R109; E16 to PllO; V17 to Pill; E18 to CI 12; P19 to VI13; G20 to 1114; S21 to L115. (0202] In anotherpreferred embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 96mers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to A96; S2 to S97; G3 to N98; E4 to G99; P5 to ElOO; G6 to TlOl; Q7 to L102; T8 to E103; S9 to K104; VIO to 1105; Al 1 to T106; P12 to N107; P13 to S108; P14 toR109; E15 to PI 10; E16 to Pill; V17 to CI 12; E18 to V113; P19 to II14; G20 to LI 15. {0203] In another preferred embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 97mers (residues correspond to SEQ'H>NO:2 and FIG. IB): Ml to S97; S2 to N98; G3 to G99; E4 to ElOO; P5 to TlOl; G6 to LI02; Q7 to El 03; T8 to K104; S9 to 1105; V10 to T106; Al 1 to N107; P12 to S108; P13 to R109; P14 to PllO; E15 to Pill; E16 to C112; V17 to V113; E18 to 1114; P19 to LI 15. (0204] In another preferred embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 98mers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to N98; S2 to G99; G3 to ElOO; E4 to TlOl; P5 to L102; G6 to E103; Q7 to K104; T8 to 1105; S9 to T106; V10 to N107; Al 1 to S108; P12 to R109; P13 to PI 10; P14 to PI 11; E15 to CI 12; E16 to VI13; V17 to II14; E18 to LI 15. (0205] In another preferred embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 99mers (residues correspond to SEQ ID NO:2 and FIG. IB): INTELLECTUAt PROPERTv Of- kl 2 5 OCT 2006 M1 to G99; S2 to ElOO; G3 to TlOl; E4 to L102; P5 to E103; G6 to K104; Q7 to 1105; T8 to T106; S9 to N107; VIO to S108; All to R109; P12 to PllO; P13 to Pill; P14 to CI 12; E15 to VI13; E16 to 1114; V17 to LI 15.

[0206] In another preferred embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following lOOmers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to ElOO; S2 to TlOl; G3 to L102; E4 to El03; P5 to 004; G6 to 1105; Q7 to T106; T8 to N107; S9 to S108; VIO to R109; Al 1 to PI 10; P12 to PI 11; P13 to CI 12; P14 to VI13; E15 to II14; E16 to LI 15.

[0207] In anotherpreferred embodiment, the isolated polypeptides described herein 1 comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following lOlmers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to TlOl; S2 to L102; G3 to E103; E4 to K104; P5 to 1105; G6 to T106; Q7 toN107; T8to SI 08; S9toR109; V10 to PI 10; All to PI 11; P12to C112;P13 to VI13; P14 to II14; E15 to LI 15.

[0208] In another preferred embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 102mers (residues correspond to SEQ ID NO:2 and FIG IB): Ml to LI02; S2 to E103; G3 to K104; E4 to 1105; P5 to T106; G6 to N107; Q7 to S108; T8 to R109; S9 to PllO; V10 to Pill; All to CI 12; P12 to VI13; P13 to 1114; P14 to LI 15.

[0209] In another preferred embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 103mers (residues correspond to SEQ ID NO:2 and FIG. IB): INTELLECTUAL PROPERTY 0rT-iC OF N.Z. 2 5 OCT 2006 RECEIVED M1 to E103; S2 to K104; G3 to 1105; E4 to T106; P5 to N107; G6 to S108; Q7 to R109; T8 to PllO; S9 to Pill; VIO to CI 12; All to VI13; P12 to 1114; P13 toL115. {0210] In anotherpreferred embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 104mers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to K104; S2 to 1105; G3 to T106; E4 to N107; P5 to S108; G6 to R109; Q7 to PI 10; T8 to PI 11; S9 to C112; V10 to VI13; Al 1 to II14; P12 to L115.

[0211] In another preferred embodiment, the isolated polypeptides < described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 105mers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to 1105; S2 to T106; G3 to N107; E4 to S108; P5 to R109; G6 to P110; Q7 to Pill; T8 to C112; S9 to V113; V10 to 1114; All to L115.

[0212] In anotherpreferred embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 106mers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to T106; S2 to N107; G3 to S108; E4 to R109; P5 to PllO; G6 to PHI; Q7 to C112; T8 to V113; S9 to 1114; V10 to LI 15. {0213] In another preferred embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 107mers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml toN107; S2 to S108; G3 to R109; E4 to PllO; P5 to Pill; G6 to CI 12; Q7 to V113; T8 to 1114; S9to L115.

[0214] In anotherpreferred embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide intellectual property office of n.z. 2 5 OCT 200S received . epitopes include the following 108mers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to S108; S2 to R109; G3 to PllO; E4 to Pill; P5 to C112; G6 to V113; Q7 to II14; T8 to LI 15.

[0215] In anotherpreferred embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 109mers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to R109; S2 to PllO; G3 to PI 11; E4 to CI 12; P5 to VI13; G6 to 1114; Q7 to LI 15. {0216] Inanotherpreferredembodiment,theisolatedpolypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following llOmers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to PllO; S2 to Pill; G3 to C112; E4 to V113; P5 to 1114; G6 to L115. {0217] In another preferred embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following lllmers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to Pill; S2 to CI 12; G3 to V113; E4 to 1114; P5 to L115.

[0218] Ihanotherpreferredembodiment,theisolatedpolypeptides described herein 1 comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 112mers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to CI 12; S2 to VI13; G3 to 1114; E4 to LI 15.

[0219] In anotherpreferred embodiment, the isolated polypeptides described herein > comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 113mers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to VI13; S2 to 1114; G3 to LI 15.

INTELLECTUAL PROPERTY OFFICE OF N.2. 2 5 OCT 2006 RECEIVED

[0220] In another preferred embodiment, the isolated polypeptides described herein comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 1 Miners (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to II14; S2 to LI 15.

Stimulation of CTL and HTL responses

[0221] Much more about tihe mechanismby which T cells recognize antigens has been elucidated during the past ten years, hi accordance with this understanding of the immune system, the present inventors have developed efficacious antibody compositions that induce a therapeutic or prophylactic immune response to certain tumor associated antigens, when administered via various art-accepted modalities. Moreover, by use of the antibodies, raised against peptide epitopes > disclose! herein, or by use of combinations of such antibodies in accordance with the principles disclosed herein, responses can be achieved in significant percentages of a non-genetically biased worldwide population. For an understanding of the value and efficacy of the claimed compositions, a brief review of immunology-related technology is' provided.

[0222] A complex of an HLA molecule and a peptidic antigen acts as the ligand recognized by HLA-restricted T cells (Buus, S. et al., Cell 47:1071, 1986; Babbitt, B. P. et al., Nature 317:359,1985; Townsend, A. and Bodmer, H., Annu. Rev.Immunol.7:60\y 1989; Germain, R.NAnnu. Rev. Immunol. 11:403,1993). Through the study of single amino acid substituted antigen analogs and the sequencing of endogenously bound, naturally processed peptides, critical residues that correspond to motifs required for specific binding to HLA antigen molecules have been identified.

[0223] Furthermore, x-ray crystallographic analyses of HLA-peptide complexes have revealed pockets within the peptide binding cleft of HLA molecules which accommodate, often on an allele-specific basis, residues borne by peptide ligands; INTELLECTUAL

[0220] In another prefixed embodiment, the isolated polypeptides of the present invention comprising or, alternatively, consisting of, one or more C35 peptide epitopes include the following 114mers (residues correspond to SEQ ID NO:2 and FIG. IB): Ml to II14; S2 to LI 15.

Stimulation of CTL and HTL responses

[0221] Much more about the mechanism by which T cells recognize antigens has been elucidated during the past ten years, hi accordance with this understanding of the immune system, the present inventors have developed efficacious peptide epitope compositions that induce a therapeutic or prophylactic immune response to certain tumor associated antigens, when administered via various art-accepted modalities. Moreover, by use of the peptide epitopes of the invention, or by use of combinations of peptide epitopes in accordance with the principles disclosed herein, responses can be achieved in significant percentages of a non-genetically biased worldwide population. For an understanding of the value and efficacy of the claimed compositions, a brief review of immunology-related technology is' provided. {0222] A complex of an HLA molecule and a peptidic antigen acts as the ligand recognized by HLA-restricted T cells (Buus, S. et al, Cell 47:1071, 1986; Babbitt, B. P. et al, Nature 317:359,1985; Townsend, A. and Bodmer, H., Annu. Rev. Immunol 7:601,1989; Germain, R. N., Annu. Rev. Immunol. 11:403,1993). Through the study of single amino acid substituted antigen analogs and the sequencing ofendogenouslybound,naturallyprocessed peptides, critical residues that correspond to motifs required for specific binding to HLA antigen molecules have been identified.

[0223] Furthermore, x-ray crystallographic analyses of HLA-peptide complexes have revealed pockets within the peptide binding cleft of HLA molecules which accommodate, often on an allele-speciflc basis, residues borne by peptide ligands; these residues in turn determine the HLA binding capacity of the peptides in which they are present. (See, e.g., Madden, D.R. Annu. Rev. Immunol. 13:587, 1995; Smith, etal., Immunity 4:203,1996; Fremont etal., Immunity 8:305,1998; Sterne/al., Structure2:245,1994; Jones, E.Y. Curr. Opin. Immunol. 9:75,1997; Brown, J. H. etal., Nature 364:33,1993; Guo, H. C. et al.,Proc. Natl. Acad. Sci. USA 90:8053,1993; Guo, H. C. et al, Nature 360:364,1992; Silver, M. L. et al., Nature 360:367,1992; Matsumura, M. et al., Science 257:927,1992; Madden et al., Cell 70:1035,1992; Fremont, D. H. et al, Science 257:919,1992; Saper, M. A,Bjorkman,P. J. and Wiley,D. C.,J. Mol. Biol. 219:277,1991.) Accordingly, the definition of class I and class II allele-specific HLA binding motifs, or class I or class II supermotifs allows identification of regions within a protein that have the predicted ability to bind particular HLA antigen(s). {0224] Moreover, the correlation of binding affinity with ixmnunogenicity, which is disclosed herein, is an important factor to be considered when evaluating candidate peptides. Thus, by a combination of motif searches of antigenic sequences, andby HLA-peptide binding assays, epitope-based vaccines have been identified. As appreciated by one in the art, after determining their binding affinity, additional work can be performed to select, amongst these vaccine peptides, e.g., epitopes can be selected having optional characteristics in terms of population coverage, antigenicity, and immunogenicity, etc. {0225] Various strategies can be utilized to evaluate immunogenicity, including: 1) EvaluationofprimaryT cell cultures from normal individuals (see, e.g., Wentworth, P. A. et al, Mol Immunol 32:603,1995; Celis, E. et al,Proc. Natl. Acad. Sci. USA 91:2105,1994; Tsai, V. etal., J. Immunol 158:1796,1997; Kawashima, I. et al., Human Immunol. 59:1,1998). This procedure involves the stimulation of peripheral blood lymphocytes (PBL) from normal subjects with a test peptide in the presence of antigen presenting celis in vitro over a period of several weeks. T cells specific for the peptide become activated during this time and are detected using, e.g., a ^ICr-release assay involving peptide sensitized target cells, and/or target cells that generate antigen endogenously. 2) Immunization of HLA transgenic mice (see, e.g., Wentworth, P.

A. etal, J. Immunol. 26:97,1996; Wentworth, P. A. etal., Int. Immunol 8:651, 1996; Alexander, J. etal, J. Immunol 159:4753,1997); in this method, peptides in incomplete Freund's adjuvant are administered subcutaneously to HLA transgenic mice. Several weeks following immunization, splenocytes are removed and cultured in vitro in the presence of test peptide for approximately one week. Peptide-specific T cells are detected using, e.g., a ^^Cr-release assay involvingpeptide sensitized target cells and target cells expressing endogenously generated antigen. 3) Demonstration of recall T cell responses from individuals exposed to the disease, such as immune individuals who were effectively treated and recovered from disease, and/or from actively ill patients (see, e.g., Rehermann, B. etal, J. Exp. Med. 181:1047,1995; Doolan,D. L. et al, Immunity 7:97,1997; Bertoni, R. et al, J. Clin. Invest. 100:503, 1997; Threlkeld, S. C. et al, J. Immunol. 159:1648,1997; Diepolder, H.M. etal, J. Virol 71:6011,1997). In applying this strategy, recall responses are detected by culturing PBL from subjects in vitro for 1-2 weeks in the presence of a test peptide plus antigen presenting cells (APC) to allow activation of "memory" T cells, as compared to "naive" T cells. At the end of the culture period, T cell activity is detected using assays for T cell activity including 51Cr release involving peptide-sensitized targets, T cell proliferation, or lymphokine release.

[0226] The following describes the peptide epitopes and corresponding nucleic acids of the invention in more detail.

Binding Affinity of Peptide Epitopes for HLA Molecules

[0227] As indicated herein, the large degree of HLA polymorphism is an important factor to be taken into account with the epitope-based approach to vaccine development. To address this factor, epitope selection encompassing identification of peptides; capable of binding at high or intermediate affinity to multiple HLA molecules is preferably utilized, most preferably these epitopes bind at high or intermediate affinity to two or more allele-specific HLA molecules.

[0228] CTL-inducing peptide epitopes of interest for vaccine compositions preferably include those that have an IC50 or binding affinity value for a class I HLA molecule(s) of 500 nM or better (i.e., the value is s 500 nM). HTL-inducing peptide epitopes preferably include those that have an IC50 or binding affinity value for class II HLA molecules of 1000 nM or better, (i.e., the valuers ^ l,OOOnM). For example, peptide binding is assessed by testing the capacity of a candidate peptide to bind to a purified HLA molecule in vitro. Peptides exhibiting high or intermediate affinity are then considered for further analysis. Selected peptides are generally tested on other members of the supertype family. In preferred embodiments, peptides that exhibit cross-reactive binding are then used in cellular screening analyses or vaccines.

[0229] The relationship between binding affinity for HLA class I molecules and immunogenicity of discrete peptide epitopes on bound antigens has been determined. As disclosed in greater detail herein, higher HLA binding affinity is correlated with greater immunogenicity.

[0230] Greater immunogenicity can be manifested in several different ways. Immunogenicity corresponds to whether an immune response is elicited at all, and to the vigor of any particular response, as well as to the extent of a population in which a response is elicited. For example, a peptide epitope might elicit an immune response in a diverse array of the population, yet in no instance produce a vigorous response. In accordance with these principles, close to 90% of high binding peptide have been found to elicit a response and thus be "immunogenic," as contrasted with about 50% of the peptides that bind with intermediate affinity. (See, e.g., Schaeffer et al. PNAS 1988) Moreover, not only did peptides with higher binding affinity have an enhanced probability of generating an immune response, the generated response tended to be more vigorous than the response seen with weaker binding peptides: As a result* less peptide is rcqMired to- ehcat a similar biological effect if a high affinity binding peptide is used rather than a lower affinity one. Thus, in preferred embodiments ofthe invention, high affinity binding epitopes are used.

The correlation between binding affinity and immunogenicity was analyzed by two different experimental approaches (see, e.g., Sette, et al., J. Immunol. 153:5586-5592,1994)). In the first approach, the immunogenicity of potential epitopes ranging in HLA binding affinity over a 10,000-fold range was analyzed in HLA-A*0201 transgenic mice. In the second approach, the antigenicity of approximately 100 different hepatitis B virus (HBV)-derived potential epitopes, all carrying A*0201 binding motifs, was assessed by using PBL from acute hepatitis patients. Pursuant to these approaches, it was determined that an affinity threshold value of approximately 500 nM (preferably 50 nM or less) determines the capacity of a peptide epitope to elicit a CTL response. These data are toe for class I binding affinity measurements for naturally processed peptide epitopes and for synthesized T cell epitopes. These data also indicate the important role of determinant selection in the shaping of T cell responses (see, e.g., Schaeffer et al. Proc. Natl. Acad. Sci. USA 86:4649-4653,1989).

An affinity threshold associated with immunogenicity in the context of HLA class H (i.e., HLA DR) molecules has also been delineated (see, e.g., Southwood et al. J. Immunology 160:3363-3373,1998. In order to define a biologically significant threshold of HLA class II binding affinity, a database of the binding affinities of 32 DR-restricted epitopes for their restricting element (i.e., the HLA molecule that binds the epitope) was compiled. In approximately half of the cases (15 of 32 epitopes), DR restriction was associated with high binding affinities, i.e. binding affinity values of 100 nM or less. In the other half ofthe cases (16 of 32), DR restriction was associated with intermediate affinity (binding affinity values in the 100-1000 nM range). In only one of 32 cases was DR restriction associated with an IC50 of 1000 nM or greater. Thus, 1000 nM is defined as an affinity threshold associated with immunogenicity in the context of DR molecules.

[0233] Vaccines described herein may also comprise epitopes that bind to MHC class H DR molecules. A greater degree of heterogeneity in both size and binding frame position of the motif, relative to the N and C termini of the peptide, exists for class II peptide ligands. This increased heterogeneity of HLA class II peptide ligands is due to the structure of the binding groove of the HLA class H molecule which, unlike its class I counterpart, is less physically constricted at both ends.

[0234] There are numerous additional supeimotifs and motifs in addition to the A2 supermotif and the A2.1-allele specific motif. By inclusion of one or more epitopes from other motifs or supermotifs, enhanced population coverage for major global ethnicities can be obtained.

Peptide Analogs

[0235] In general, CTL and HTL responses are not directed against all possible epitopes. Rather, they are restricted to a few "immunodominant" determinants (Zinkernagel, etal, Adv. Immunol. 27:5159,1979; Bennink, etal, J. Exp. Med. 168:19351939,1988; Rawle, etal, J. Immunol. 146:3977-3984,1991). It has been recognized that irrununodominance (Bertacerraf, etal, Science 175:273-279, 1972) could be explained by either the ability of a given epitope to selectively bind a particular HLA protein (determinant selection theory) (Vitiello, et al., J. Immunol. 131:1635, 1983); Rosenthal, et al, Nature 267:156-158,1977), or to be selectively recognized by the existing TCR (T cell receptor) specificities (repertoire theory) (Klein, J., Immunology, the Science of SelfNonself Discrimination, John Wiley & Sons, New York, pp. 270-310, 1982). It has been demonstrated that additional factors, mostly linked to processing events, can also play akey role in dictating, beyond strict immunogenicity, which ofthe many INTELLECTUAL property gff OF n.z. 2 5 OCT 2008 , RFOPIV | ^ U ILswai lUgm I If potential determinants will be presented as immunodominant (Sercarz, et al, Annu. Rev. Immunol. 11:729-766,1993).

[0236] The concept of dominance and subdominance is relevant to immunotherapy of both infectious diseases and malignancies. For example, in the course of chronic viral disease, recruitment of subdominant epitopes can be important for successful clearance of the infection, especially if dominant CTL or HTL specificities have been inactivated by functional tolerance, suppression, mutation of viruses and other mechanisms (Franco, et al., Curr. Opin. Immunol. 7:524-531, 1995). In the case of cancer and tumor antigens, CTLs recognizing at least some of the highest binding affinity peptides might be functionally inactivated. Lower binding affinitypeptides are preferentially recognized at these times, and may therefore be preferred in therapeutic or prophylactic anti-cancer vaccines.

[0237] In particular, it has been noted that a significant number of epitopes derived from known non-viral tumor associated antigens (TAA) bmd HLA class I with intermediate affinity (IC30 in the 50-500 nM range) rather than at high affinity (ICJ0 of less than 50 nM).

[0238] For example, it has been found that 8 of 15 known TAA peptides recognized by tumor infiltrating lymphocytes (TIL) or CTL bound in the 50-500 nM range. (These data are in contrast with estimates that 90% of known viral antigens were bound by HLA class I molecules with IC50 of 50 nM or less, while only approximatelylO% bound in the 50-500nMrange (Sette, etal, J. Immunol, 153:558-5592,1994). In the cancer setting this phenomenon is probably due to elimination or functional inhibition ofthe CTL recognizing several ofthe highest binding peptides, presumably because of T cell tolerization events.

[0239] Without intending to be bound by theory, it is believed that because T cells to dominant epitopes may have been clonally deleted, and selecting subdominant epitopes may allow existing T cells to be recruited, which will then lead to a therapeutic or prophylactic response. However, the binding of HLA *99-

[0240] Accordingly, there is a need to be able to modulate the binding affinity of particular immunogenic epitopes for one or more HLA molecules, to thereby modulate the immune response elicited by the peptide, for example to prepare analog peptides which elicit a more vigorous response. This ability to modulate both binding affinity and the resulting immune response in accordance with these principles greatly enhances the usefulness of peptide epitope-based vaccines and therapeutic agents.

[0241] Although peptides with suitable cross-reactivity among all alleles of a superfamily are identified by the screening procedures described above, cross-reactivity is not always as complete as possible, and in certain cases procedures to increase cross-reactivity of peptides can be useful; moreover, such procedures can also be used to modify other properties of the peptides such as binding affinity or peptide stability. Having established the general rules that govern cross-reactivity of peptides for HLA alleles within a given motif or supeimotif, modification (z'.e., analoging) ofthe structure ofpeptides of particular interest in order to achieve broader (or otherwise modified) HLA binding capacity can be performed. More specifically, peptides that exhibit the broadest cross-reactivity patterns, can be produced in accordance with title teachings herein.

[0242] In brief, the analoging strategy utilizes the motifs or supermotifs that correlate with binding to certain HLA molecules. Analog peptides can be created by substituting amino acid residues at primary anchor, secondary anchor, or at primary and secondary anchor positions. Generally, analogs are made for peptides that already bear a motif or supermotif. For a number of the motifs or supermotifs, residues are defined which are deleterious to binding to allele-specific HLA molecules or members of HLA supertypes that bind the respective motif or supermotif. Accordingly, removal of such residues that are detrimental to binding can be performed. For example, in the case ofthe A3 supertype, when all peptides that have such deleterious residues are removed from the population of peptides used in the analysis, the incidence of cross-reactivity increased from to 37% (see, e g., Sidney, J. et al, Hu. Immunol 45:79,1996)., Examples of C35 peptide epitope analogs described herein are found in Table 4. In a particularly preferred embodiment, the isolated polypeptides _ . comprise or, alternatively, consist of the following C35 peptide epitope analogs: for the peptide epitope G22 to C30 ofSEQ ID NO:2 and FIG. IB (i.e., GVRIWEYC), the analog with either alanine or glycine substituted for cysteine at the ninth amino acid residue (i.e., GVRIWEYA or GVRIWEYG); for the peptide epitope 125 to C33 ofSEQ!DNO:2 and FIG. IB (le., IWEYCEPC),the analog with either alanine or glycine substituted for the cysteine at the sixth amino acid residue and/or the ninth amino acid residue (i.e., IWEYAEPC, IWEYCEPA, IWEYGEPC, IWEYCEPG, IWEYAEPA, IWEYAEPG, IWEYGEPA, IWEYGEPG); for the peptide epitope K77 to Y85 ofSEQ ID NO: 2 and FIG. IB (i.e., KLENGGFPY), the analog with valine substituted for tyrosine at the ninth amino acid residue (i.e., KLENGGFPV); for peptide epitope K104 to CI 12 of SEQ ID NQ:2 and FIG. IB (i.e., KTTNSRPPC), the analogs with alanine, glycine or leucine substituted for cysteine at the ninth amino acid residue (i.e., KITNSRPPL, KITNSRPPA, KITNSRPPG); for peptide epitope K104 to VI13 of SEQ ID NO:2 and FIG. IB (i.e., KTTNSRPPCV), the analogs with alanine, glycine, serine or leucine substituted for cysteine at the ninth amino acid residue (i.e, KITNSRPPLV, KITNSRPPAV, KITNSRPPGV, KJTNSRPPSV), forthepeptide epitope 1105 to VI13 ofSEQ ID NO:2 and FIG. IB (i.e, ITNSRPPCV), the analogs wherein either leucine or methionine is substituted for threonine at the second amino acid residue and/or alanine, serine or glycine is substituted for cysteine at the eighth amino acid residue (i.e, ILNSRPPCV, MNSRPPCV, ITNSRPPAV, ITNSRPPGV, 1LNSRPPAV, ILNSRPPGV, MNSRPPAV, MNSRPPGV, JLNSRPPSV, MNSRPPSV, ITNSRPPSV), for the peptide epitope N107 to LI 15 ofSEQ ID NO:2 and FIG. IB (i.e., NSRPPCVJL), the analog with either alanine or glycine substituted for cysteine at the sixth amino acid residue (Le., NSRPPAVIL, NSRPPGVIL). The invention is further directed to polypeptides comprising or, alternatively, consisting^f one or more C35 %fitope analogst ,lii a preferred embodiment, INTELLECTUAL PROPERTY office OF N.Z. 2 5 OCT 2006 ECE polypeptides are described comprising one or more C35 epitope analogs and, in addition, one or more C35 peptide epitopes. In a particularly preferred embodiment, a fusion protein is described comprising at least one C35 peptide epitope analog selected from the group consisting of: for the peptide epitope G22 to C30 ofSEQ ID NO:2 and FIG. IB (Le., GVRIWEYC), the analog with either alanine or glycine substituted for cysteine at the ninth amino acid residue (i.e, GVRIWEYA or GVRIWEYG); for the peptide epitope 125 to C33 of SEQ ID NO:2 and FIG. IB (Le, IWEY CEPC), the analog with either alanine or glycine substituted for the cysteine at the sixfli amino acid residue and/or the ninth amino acid residue (Le, IWEYAEPC, IWEYCEPA, IWEYGEPC, IWEYCEPG, IWEYAEPA, IWEYAEPG, IWEYGEPA, IWEYGEPG); for the peptide epitope K77 to Y85 of SEQ ID NO: 2 and FIG IB (i.e, KLENGGFPY), the analog with valine substituted for tyrosine at the ninth amino acid residue (i.e, KLENGGFPV); for peptide epitope K104 to C112 of SEQ ID NO:2 and FIG. IB (Le, KTTNSRPPC), the analogs with alanine, glycine or leucine substituted for cysteine at the ninth amino acid residue (Le, K3TNSRPPL, KITNSRPPA, KUNSRPPG); for peptide epitope K104 to VI13 of SEQ ID NO:2 and FIG. IB (Le, KTTNSRPPCV), the analogs with alanine, glycine, serine or leucine substituted for cysteine at the ninth amino acid residue (Le, KTIKSRPPLV, KITNSRPPAV, KITNSRPPGV, KJTNSRPPSV); for the peptide epitope 1105 to VI13 ofSEQ ID NO:2 and FIG. IB (Le, ITNSRPPCV), the analogs wherein either leucine or methionine is substituted for threonine at the second amino acid residue and/or alanine, serine or glycine is substituted for cysteine at the eighth amino acid residue (i.e, ILNSRPPCV, IMNSRPPCV, JTNSRPPAV, ITNSRPPGV, ILNSRPPAV, ILNSRPPGV, MNSRPPAV, MNSRPPGV, ILNSRPPSV, MNSRPPSV, ITNSRPPSV), for the peptide epitope N107 to LI 15 ofSEQ ID NO:2 and FIG. IB (Le, NSRPPCV1L), the analog with either alanine or glycine substituted for cysteine at the sixth amino acid residue (Le, NSRPPAVIL, NSRPPGVIL), and at least one C35 peptide epitope selected from the group consisting of: INTELLECTUAL PR NO:2, S9 to V17 ofSEQ ID NO: 2, S21 to Y29 ofSEQ ID NO:2, G22 to C30 of SEQ ID NO: 2,125 to C33 ofSEQ ID NO:2, T38 to V46 ofSEQ ID NO:2, G61 to 169 ofSEQ ID NO:2, T62 to N70 ofSEQ ID NO:2, G63 to G71 ofSEQ ID NO:2, F65 to L73 ofSEQ ID NO: 2,167 to F75 ofSEQ ID NO:2, K77 to Y85 of SEQ ID NO:2, Q72 to E86 ofSEQ ID NO:2, G81 to L89of SEQ ID NO:2, G99 to Y113 ofSEQ ID NO:2, ElOO to VI13 of SEQ ID NO:2, K104 to CI 12 ofSEQ ID NO:2, K104 to VI13 ofSEQ ID NO: 2,1105 to VI13 ofSEQ ID NO:2, and N107 to LI 15 of SEQ ID NO:2.

[0243] Thus, one strategy to improve the cross-reactivity of peptides within a given supermotif is simply to delete one or more df the deleterious residues present within apeptide and substitute a small "neutral" residue such as Ala (that may not influence T cell recognition of the peptide). An enhanced likelihood of cross-reactivity is expected if, together with elimination of detrimental residues within a peptide, "preferred" residues associated with high affinity binding to an allele-specific HLA molecule or to multiple HLA molecules within a superfamily are inserted.

[0244] To ensure that an analog peptide, when used as a vaccine, actually elicits a CTL response to the native epitope in vivo (or, in the case of class H epitopes, elicits helper T cells that cross-react with the wild type peptides), the analog peptide maybe used to induce T cells in vitro from individuals ofthe appropriate HLA allele. Thereafter, the immunized cells' capacity to lyse wild type peptide sensitized target cells is evaluated. Alternatively, evaluation of the cells' activity can be evaluated by monitoring IFN release. Each of these cell monitoring strategies evaluate the recognition of the APC by the CTL. It will be desirable to use as antigen presenting cells, cells that have been either infected, or transfected with the appropriate genes, or, (generally only for class II epitopes, due to the different peptide processing pathway for HLA class II), cells that have been pulsed with whole protein antigens, to establish whether endogenously produced antigen is also recognized by the T cells induced by the analog peptide. It is to be noted that peptide/protein-pulsed dendritic cells can be used to present whole protein antigens for both HLA class I and class H.

[0245] Also described is a way to, create analogs of weak binding peptides, to thereby ensure adequate numbers of cellular binders. Class I binding peptides exhibiting binding affinities of500-5000nM, and carrying an acceptable but suboptimal primary anchor residue at one or both positions can be "fixed" by substituting prefeired anchor residues in accordance with the respective supertype. The analog peptides can then be tested for binding and/or cross-binding capacity.

[0246] Also described is a way to create analogs of peptides that are already cross-reactive binders and are vaccine candidates, but which bind weakly to one or more alleles of a supertype. If the cross-reactive binder carries a suboptimal residue (less preferred or deleterious) at a primary or secondary anchor position, the peptide can be analoged by substituting out a deleterious residue and replacing it with a prefeired or less preferred one, or by substituting out a less preferred residue and replacing it with a preferred one. The analog peptide can then be tested for cross-binding capacity.

[0247] Another embodiment for generating effective peptide analogs involves the substitution of residues that have an adverse impact on peptide stability or solubility in, e.g., a liquid environment. This substitution may occur at any position of the peptide epitope. For example, a cysteine (C) can be substituted out in favor of a-amino butyric acid. Due to its chemical nature, cysteine has the propensity to form disulfide bridges and sufficiently alto: the peptide structurally so as to reduce binding capacity. Substituting a-amino butyric acid for C not only alleviates this problem, but actually improves binding and crossbinding capability in certain instances (see, e.g., the review by Sette et al., In: Persistent Viral Infections. Eds. R. Ahmed and I. Chen, John Wiley & Sons, England, 1999). Substitution of cysteine with a-amino butyric acid may occur at any residue of a peptide epitope, i.e. at either anchor or non-anchor positions.

INTELLECTUAL PROPERTY 0 . .1 "J OF N.Z. | 2 5 OCT 2008 j RECEIVE {024&] Moreover, it has been shown that in sets of A*0201 motif-bearing peptides containing at least one preferred secondary anchor residue while avoiding the presence of any deleterious secondary anchor residues, 69% of the peptides will bind A*0201 with an IC50 less than 500 nM (Ruppert, J. et al. Cell 74:929,1993). The determination ofwhat was aprefeired or deleterious residue in Ruppert can be used to generate algorithms (see, e.g., 22) . Such algorithms are flexible in that cut-off scores may be adjusted to select sets of peptides with greater or lower predicted binding properties, as desired.

[0249] C35 epiotpes containing cysteine residues have a tendency to dimerize with other cysteine containing peptides. Thus, also described is a composition comprising a peptide epitope (e.g. a C35 peptide epitope listed in any of Tables 1-3 or 5-6, exclusive of El 00 to R109 ofSEQ ID NO:2) and a suitable reducing agent that protects the free sulfhydryl group of the cysteine residue but does not otherwise inhibit epitope binding. In a preferred embodiment the composition comprises the peptide epitope ITNSRPPCV or KTTNSRPPCV in combination with a suitable reducing agent. Suitable reducing agents include, but are not limited to, TCEP and dithiolhreitol (DTT).

[0250] . Also described is a way to create peptide epitope analogs in which the cysteine residues of the peptide epitope (e.g., a C3 5 peptide epitope listed in any of Tables 1-3 or 5-6, exclusive of ElOO to R109 of SEQ ID NO:2) have been substituted with any other amino acid to facilitate synthesis. (See Zarling, A.L. et al., J. Exp. Med. 192(12): 1755-1762 (2000)). Preferably, the cysteine residues are substituted with either alanine, serine or glycine residues, although any amino acid can be substituted provided that such substitution does not negatively effect binding to MHC or recognition by T cells. Thus, in a particularly preferred embodiment, the isolated polypeptides described herein comprise or, alternatively, consist of the following C35 peptide epitope analogs: for the peptide epitope G22 to C30 of SEQ ID 3SfO:2 and FIG. IB (i.e., GVRIVVEYC), the analog with either alanine or INTELLECTUAL PROPERTY GrRfc OF N.Z. 2 5 OCT 2006 glycine substituted for the cysteine at the ninth amino acid residue (i.e., GVRIWEYA or GVRIWEYG); for the peptide epitope 125 to C33 ofSEQ ID NO:2 and FIG; IB (i.e., IWEYCEPC), the analog with either alanine or glycine substituted for the cysteine at the sixth amino acid residue and/or the ninth amino acid residue (i.e., IWEYAEPC or IWEYGEPC or IWEYCEPA or IWEYCEPG or IWEYAEPA or IWEYAEPG or IWEYGEPA or IWEYGEPG); for the peptide epitope of K104 to CI 12 of SEQ ID NO:2 and FIG. IB (i.e., KTTNSRPPC) the analog with either alanine or glycine substituted for the cysteine at the ninth residue (i.e., KTTNSRPPA or KTTNSRPPG); for the peptide epitope K104 to VI13 of SEQ ID NO:2 and FIG. IB (i.e., KITNSRPPCV), the analog with either alanine, serine or glycine substituted for the cysteine at the ninth residue (i.e., KXTNSRPPAV, KJTNSRPPSV or K1TNSRPPGV); for the peptide epitope 1105 to VI13 of SEQ ID NO:2 and FIG. IB (i.e., ITNSRPPCV), the analog with either alanine, serine or glycine substituted for the cysteine at the eighth residue (i.e., 3TNSRPPAV, ITNSRPPSV or ITNSRPPGV); for the peptide epitope N107 to LI 15 (Le., NSRPPCVIL), the analog With either alanine or glycine substituted for the cysteine at the sixth amino acid residue (Le., NSRPPAV1L, NSRPPGVIL); for the multi-epitope peptide TlOl to V113 ofSEQ ID NO:2 and FIG. IB (i.e., TLEKTTNSRPPCV), the analog with either alanine or glycine substituted for the cysteine at the twelfth residue (i.e., TLEK3TNSRPPAV or TLEKITNSRPPGV); for the multi-epitope peptide ElOO to V113 ofSEQ ID NO:2 and FIG. IB (Le., ETLEKTTNSRPPCV), the analog with either alanine or glycine substituted for the cysteine at the thirteenth amino acid residue <ie., ETLEKTTNSRPPAV, ETLEKITNSRPPGV), for the multi-epitope peptide G99 to VI13 of SEQ ID NO:2 and FIG. IB (i.e., GETLEKTTNSRPPCV), the analog with either alanine or glycine substituted for the cysteine at the fourteenth amino acid residue (i.e., GETLEK3TNSRPPAV, GETLEKITNSRPPGV), for the multi-epitope peptide ■313 tolVltlSsoiffi^B('NO:2 and FIG. IB (Le., IRRASNGETLEKITNSRPPCV), the analog with either alanine or glycine substituted for the cysteine at the twentieth residue (i.e., IRRASNGETLEKITNSRPPAV or IRRASNGETLEKITNSRPPGV); for the multi-epitope peptide D88 to VI13 of SEQ ID NO:2 and FIG. IB (i.e., DL1EAIRRASNGETLEKITNSRPPCV), the analog with either alanine or glycine substituted for the cysteine at the twenty-fifih residue (i.e., DLIEAIRRASNGETLEKrrNSRPPAV or DLIEADRRASNGETLEKITNSRPPGV}; for the multi-epitope peptide P84 to VI13 of SEQ ID NO:2 and FIG. IB (i.e., PYEKDLIEAIREASNGETLEKrrNSRPPCV), the analog with either alanine or glycine substituted for the cysteine at the twenty-ninth residue (i.e., PYEKDLIEAIRRASNGETLEKITNSRPPAV or PYEKDLIEAIRRASNGETLEKrrNSRPPGV); for the multi-epitope peptide K77 to LI 15 of SEQ ID NO:2 and FIG. IB (i.e., KLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPCV), the analog with either alanine or glycine substituted for the cysteine at the thirty-sixth residue (i.e., KLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPAV or KLENGGFPYEKDLIEAIRRASNGETLEKlTNSRPPGVt: for the multi-epitope peptide Q72 to LI 15of SEQ ID NO:2 and FIG. IB (i.e., QLVFSKLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPCV), the analog with either alanine or glycine substituted for the cysteine at the forty-first residue (i.e., QLVFSKLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPAV or QLVFSKLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPGV); for the multi-epitope peptide F65 to LI 15 of SEQ ID NO:2 and FIG. IB (i.e., FEIEINGQLVFSKLENGGFPYEKDLIEAIRRASNGETLEK1TNSRPPCV), the analog with either alanine or glycine substituted for the cysteine at the forty-eighth residue (i.e., FEIEINGQLVFSKLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPAV or FEIEINGQLVFSKLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPGV); arid for the multi-epitope ff^tide L^lb Mi'S^BSQ ID NO^ahd FIG. IB (ie., LGGTGAFEIE1NGQLVFSKLENGGFPYEKDLIEAIRRASNGETLEK1TNS RPPCV), the analog with either alanine or glycine substituted for the cysteine at the fifty-fourth residue (i.e., LGGTGAFEIEINGQLVFSKLENGGFPYEKDLIEAIRRASNGETLEKmsrS RPPAV or LGGTGAFEIEINGQLVFSKLENGGFPYEKDLIEAIRRASNGETLEKITNS RPPGV) 10251] Also described is a way to create peptide epitope analogs in which the cysteine residues of the peptide epitope (e.g., a C35 peptide epitope listed in any of Tables 1-3 or 5-6, exclusive of ElOO to R109 of SEQ ID NO:2, having one or more cysteine residues) have been "cysteinylated" (i.e., reacted with a second cysteine residue). (See Pierce, R.A. et al., J. Immunol. 163(12):6360-6364 (1999)). As used herein, the term "cysteinylated" describes a cysteine residue, within apeptide (e.g. peptide epitope) of the present invention, which has been reacted with a second free cysteine, i.e. a cysteine not part of a larger peptide, at the free sulfhydryl group thereby creating a disulfide bond (-SH +HS- = -S-S-). {0252] Thus, in aparticularly preferred embodiment, the isolatedpolypeptides comprise or, alternatively, consist of the following C35 peptide epitope analogs: for the peptide epitope of K104 to VI13 of SEQ ID NO:2 and FIG. IB (i.e., KITNSRPPCV), the analog wherein the cysteine at the ninth residue has been cysteinylated and for the peptide epitope of 1105 to VI13 ofSEQ ID NO:2 and FIG. lB(i.e. ITNSRPPCV), the analog wherein the cysteine at the eighth residue has been cysteinylated.

[0253] Also described is a way to create peptide epitope analogs in which the serine, threonine and/or tyrosine residues of the peptide epitope (e.g, a C35 peptide epitope listed in any of Tables 1-3 or 5-6, exclusive of ElOO to R109 of SEQ ID NO:2) have been phosphorylated. Thus, INTELLECTUAL PROPERTY OF OF M.Z. 2 5 OCT 2008 0 *4 g I ^ U t I ¥ E . comprise or, alternatively, consist of the following C35 peptide epitope analogs: for the peptide epitope E4 to P12 of SEQ ID NO:2 and FIG. IB (i.e., EPGQTSVAP), the analog wherein the threonine at T8 and/or the serine at S9 have been phosphorylated; for the peptide epitope S9 to V17 of SEQ ID NO:2 and FIG. IB (i.e., SVAPPPEEV), the analog wherein the serine at S9 has been phosporylated; for the peptide epitope S21 to Y29 of SEQ ID NO:2 and FIG. IB (i.e., SGVRIVVEY), the analog wherein the serine at S21 and/or the tyrosine at Y29 are phosphorylated; for the peptide epitope G22 to C30 of SEQ 3DD NO:2 and FIG. IB (i.e., GVRIWEYC), the analog wherein the tyrosine at Y29 is phosphorylated; for the peptide epitope T38 to V46 of SEQ ID NO:2 and FIG. IB (Le., TYLELASAV), the analog wherein the threonine at T38, the tyrosine at Y39, and/or the serine at S44 are phosphorylated; for the peptide epitope G61 to 169 (Le., GTGAFEIEI), the analog wherein the threonine at T62 is phosphorylated); for the peptide epitope T62 to N70 ofSEQ ID NO:2 and FIG. IB (i.e., TGAFEIEIN), the analog wherein the threonine at T62 has been phosphorylated; for the peptide epitope K77 to Y85 ofSEQ ID NO:2 and FIG. IB (i.e., KLENGGFPY), the analog wherein the tyrosine at Y85 is phosphorylated; for the peptide epitope Q72 to E86 ofSEQ ID NO:2 and FIG. IB (Le., QLVFSKLENGGFPYE), the analog wherein the serine at S76 and/or the tyrosine at Y85 are phosphorylated; for the peptide epitope G81 to L89 of SEQ ID NO:2 or FIG. IB (i.e., GGFPYEKDL), the analog wherein the tyrosine at Y85 is phosphorylated; for the peptide epitope K104 to CI 12 of SEQ ID NO:2 and FIG. IB (i.e., KTTNSRPPC), the analog wherein the threonine at T106 and/or the serine at S108 are phosphorylated; for the peptide epitope K104 to VI13 of SEQ ID NO:2 and FIG. IB (i.e., KITNSRPPCV), the analog wherein the threonine at T106 and/or the serine at S108 are phosphorylated; for the peptide epitope 1105 to VI13 (i.e., ITNSRPPCV), the analog wherein the threonine at T106 and/or the serine at SI08 are phosphorylated; for the peptide epitope N107 to NSRPPCVIL^'the anategwherein theserine at S108 is INTELLECTUAL PROPERTY o OF N.2. 2 5 OCT 1C LUl phosphorylated; for the polyepitopic peptide TlOl to VI13 of SEQ 3D NO:2 and FIG. IB (i.e., TLEKITNSRPPCV), the analog wherein the threonines at TlOl and T106 and/or the serine at S108 are phosphorylated; for the polyepitopic peptide 193 to VI13 of SEQ ID NO:2 and FIG. IB (i.e., IRRASNGETLEKTTNSRPPCV), the analog wherein the serine at S97 and/or the threonine at TlOl and/or the threonine at T106 and/or the serine at S108 are phosphorylated; for the polyepitopic peptide D88 to VI13 of SEQ ID NO:2 and FIG. IB (i.e., DLIEAIRRASNGETLEKITNSRPPCV), the analog wherein the serine at S97 and/or the threonine at TlOl and/or the threonine at T106 and/or the serine at S108 are phosphorylated; for the polyepitopic peptide P84 to VI13 ofSEQ ID NO:2 and FIG. IB (i.e., PYEKDLIEAIRRASNGETLEKITNSRPPCV), the analog wherein the tyrosine at Y85 and/or the serine at S97 and/or fee threonine at TlOl and/or the threonine at T106 and/or the serine at S108 are phosphorylated; for the polyepitopic peptide K77 to VI13 of SEQ ID NO:2 and FIG. IB (i.e., KLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPCV), the analog wherein the tyrosine at Y85 and/or the serine at S97 and/or the threonine at TlOl and/or the threonine at T106 and/or the serine at S108 are phosphorylated; for the polyepitopic peptide Q72 to VI13 of SEQ ID NO:2 and FIG. IB (i.e., QLVFSKLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPCV), the analog wherein the serine at S76 and/or the tyrosine at Y85 and/or the serine at S97 and/or the threonine at TlOl and/or the threonine at T106 and/or the serine at S108 are phosphorylated; for the polyepitopic peptide F65 to VI13 of SEQ ID NO:2andFIG. IB (i.e., FEIEINGQLVFSKLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPCV), the analog wherein the serine at S76 and/or the tyrosine at Y85 and/or the serine at S97 and/or the threonine at TlOl and/or the threonine at T106 and/or the serine at S108 are phosphorylated; for the polyepitopic peptide L59 to VI13 of SEQ ID NO:2 and FIG. IB (i.e., I^GTGAFEIEINGQLVFSKLENGG®®KDLiEA|^RASMPiTLEK|rNS:_ RPPCV), the analog wherein the threonine at T62 and/or the serine at S76 and/or the tyrosine at Y85 and/or the serine at S97 and/or the threonine at TlOl and/or the threonine at T106 and/or the serine at S108 are phosphorylated.

[0254] . Also described is a way to create peptide epitope analogs in which the asparagine residues ofthe peptide epitope (e.g., a C35 peptide epitope listed in any of Tables 1-3 or 5-6, exclusive of ElOO to R109 of SEQ ID NO:2) have been converted to aspartic acid after translation. (See Skipper, J.C. et al, J. Exp. Med. 183(2):527-534 (1996)).

[0255] In preferred embodiments, the C35 peptide epitope analogs contain multiple modifications provided that such modifications do not inhibit binding to MHC molecules or recognition by T cells. Thus, preferred analogs include C35 peptide epitopes for which one or more residues have been modified as described herein to increase binding affinity to MHC molecules, one or more cysteine residues have been replaced with alanine or glycine residues to facilitate synthesis, and one or more serine, threonine or tyrosine residues have been phosphorylated.

[0256] Furthermore, additional amino acids can be added to the termini of a peptide epitope to provide for ease of linking peptide epitopes one to another, for coupling to a carrier support or larger polypeptide, for modifying the physical or chemical properties of the peptide or oligopeptide, or the like. Amino acids such as tyrosine, cysteine, lysine, glutamic or aspartic acid, or the like, can be introduced at the C- or N-terminus of the peptide or oligopeptide, particularly class I peptides. It is to be noted that modification at the carboxyl terminus of a CTL epitope may, in some cases, alter binding characteristics of the peptide, hi addition, the peptide or oligopeptide sequences can differ from the natural sequence by being modified by teraiinal-NH2 acylation, e.g., by alkanoyl (C,-C20) or thioglycolyl acetylation, terminal-carboxyl amidation, e.g., ammonia, methylamine, etc., polyethylene-glycol modification (i.e., ^QylatfSh.}1 C4eiminus, and thfe addition of a lipid tail (e.g+ a INTELLECTUAL PROPERTY OrFlCc' OF N.Z. ; 2 5 OCT 2005 I RECEIVE palmitoyl-lysme chain) to enhance presentation to T cells and immunogenicity. (See Brinckerhoff, L.H. et al., Int. J. Cancer 83(3):326-334 (1999); Le Gal, F.A. etal.,Int. J. Cancer98(2):22\-221 (2002). N-tenninal amides, in particular, will be more resistant to certain peptidases, thus preventing destruction of the peptide epitope in situ without affecting recognition. This will effectively increase the half-life of the peptide epitope and enhance its ability to stimulate immune cells. In some instances these modifications may provide sites for linking to a support or other molecule.

Preparation of Peptide Epitopes

[0257] Peptide epitopes can be prepared synthetically, by recombinant DNA technology or chemical synthesis, or from natural sources such as native tumors or pathogenic organisms. Peptide epitopes maybe synthesized individually or as polyepitopic polypeptides (e.g., homopolymers or heteropolymers). Although the peptide will preferably be substantially free of other naturally occurring host cell proteins and fragments thereof, in some embodiments the peptides may be synthetically conjugated to native fragments or particles.

[0258] In addition, one or more non-035 tumor associated peptides can be linked to one or more C35 peptide epitopes and/or C35 peptide epitope analogs to increase immune response via HLA class I and/or class II.

Especially preferred are polypeptides comprising a series of epitopes, known as "polytopes," and nucleic acids encoding same. The epitopes can be arranged in sequential or overlapping fashion (see, e.g., Thomson et al., Proc. Natl. Acad. Sci. USA 92:5845-5849 (1995); Gilbert et al., Nature/Biotechnology 15:1280-1284 (1997)), with or without the natural flanking sequences, and can be separated by unrelated linker sequences if desired. The polytope is processed to generate individual epitopes which are INTELLECTUAL PROPERTY office of N.Z. 2 5 OCT 2006 RECEIVE?" Thus, for example, C35 peptide epitopes and C35 peptide epitope analogs can be combined with peptides from other tumor rejection antigens (e.g., by preparation of hybrid nucleic acids or polypeptides) to form "polytopes." (Zeng, G. et al., Proc. Natl. Acad. Sci. 98(7)'3964-3969 (2001); Zeng, G. et al., J. Immunol. 165:1153-1159 (2000); Mancini, S. et al., J. Exp. Med. 189(5):87l-&76 (1999)). Exemplary tumor associated antigens that can be administered to induce or enhance an immune response are derived from tumor associated genes and encoded proteins including: MAGE-1, MAGE-2, MAGE-3, MAGE-4, MAGE-5, MAGE-6, MAGE-7, MAGE-8, MAGE-9, MAGE-10, MAGE-11, MAGE-12, MAGE-13, GAGE-1, GAGE-2, GAGE-3, GAGE-4, GAGE-5, GAGB-6, GAGE-7, GAGE-8, BAGE-1, RAGE-1, LB33/MUM-1, PRAME, NAG, MAGE-Xp2 (MAGE-B2), MAGE-Xp3 (MAGE-B3), MAGE-Xp4 (MAGE-B4), tyrosinase, brain glycogen phosphorylase, Melan-A, MAGE-C1, MAGE-C2, NY-ESO-1, LAGE-1, SSX-1, SSX-2(H()M-MEL-40), SSX-1, SSX-4, SSX-5, SCP-1 and CT-7. For example, specific antigenic peptides characteristic of tumors include those listed in Table A.

Table A Gene MHC Peptide Position MAGE-1 HLA-A1 EADPTGHSY 161-169 HLA-Cwl6 SAYGEPRKL 230-238 MAGE-3 HLA-A1 EVDPIGHLY 168-176 HLA-A2 FLWGPRALV 271-279 HLA-B44 MEVDPIGHLY 167-176 BAGE HLA-Cwl6 AARAVFLAL 2-10 GAGE-1,2 HLA-Cwl6 YRPRPRRY 9-16 RAGE HLA-B7 SPSSNRJQRNT 11-20 GnT-V HLA-A2 VLPDVFIRC(V) 2-10/11 MUM-1 HLA-B44 EEKLIWLF exon2/intron EEKLSWLF (wild-type) CDK4 HLA-A2 ACDPHSGHFV 23-32 ARDPHSGHFV (wild-type) JN&teriin HLA-A24 SYLDSGSP SYLDSGIHS (wild-type) Tyrosinase HLA-A2 MLLAVLYCL 1-9 HLA-A2 YMNGTMSQV 369-377 HLA-A2 YMDGTMSQV 369-377 HLA-A24 AFLPWHRLF 206-214 HLA-B44 SEIWRDIDF 192-200 HLA-B44 YEIWRDIDF 192-200 HLA-DR4 QNILLSNAPLGPQFP 56-70 HLA-DR4 DYSYLQDSDPDSFQD 448-462 Melan-A1,1®141 HLA-A2 (E)AAGIGILTV 26/27-35 HLA-A2 JLTVILGVL 32-40 gpioo^n? HLA-A2 KTWGQYWQV 154-162 HLA-A2 ITDQVPFSV 209-217 HLA-A2 YLEPGPVTA 280-288 HLA-A2 LLDGTATLRL 457-466 HLA-A2 VLYRYGSFSV 476-485 PRAME HLA-A24 LYVDSLFFL 301-309 MAGE-6 HLA-Cwl6 KISGGPRISYPL 292-303 NY-ESO-1 HLA-A2 SLLMWTTQCFL 157-167 HLA-A2 SLLMWTTQC 157-165 HLA-A2 QLSLLMWTT 155-163

[0260] Other examples of non-C35 HLA class I and HLA class II binding peptides will be known to one of ordinary skill in the art and can be used in the invention in a like manner to those disclosed herein. One of ordinary skill in the art can prepare polypeptides comprising one or more C35 peptide epitopes orC35 peptide epitope analogs and one or more of the aforementioned tumor rejection peptides, or nucleic acids encoding such polypeptides, according to standard procedures inmolecular biology. Examples ofpolytopes comprising C35 peptide epitopes or C35 peptide epitope analogs and various tumor rejection antigenic peptides are set forth in Tables B and C below.

[0261] Thus, polytopes are groups of two or more potentially immunogenic or immune response stimulating peptides which can be joined together in various arrangements (e.g. concatenated, overlapping). The polytope (or nucleic acid encoding the polytope) can be administered in a standard immunization protocol, e.g. to animals, to test the effectiveness ofthe polytope in stimulating, enhancing and/or provoking an immune response. The peptides can be joined directly or via INTELLECTUAL PRQPFRTV OF N.Z | 2 5 OCT 2C3S ! d er r*1•. ... ; the use of flanking sequences to form polytopes, and the use of polytopes as vaccines is well known in the art.

[0262] In a preferred embodiment, the isolated polypeptides comprise one or more C35 peptide epitopes or C35 peptide epitope analogs linked to one or more tumor rejection peptides. In aparticularly preferred embodiment, said one or more C35 peptide epitopes are selected from the group consisting of: amino acids E4 to P12 ofSEQ 3D NQ:2, amino acids S9 to V17 of SEQ ID NO:2, amino acids S21 to Y29 of SEQ ID NO:2, amino acids G22 to C30 of SEQ ID NO: 2, amino acids 125 to C33 of SEQ IDNO:2, amino acids T38 to V46 ofSEQ ID NO:2, amino acids G61 to 169 of SEQ ID NO:2, amino acids T62 to N70 of SEQ DD NO:2, amino acids G63 to G71 of SEQ ID NO:2, amino acids F65 to L73 of SEQ ID NO:2, ammo acids 167 to F75 of SEQ ID NO:2, amino acids K77 to Y85 of SEQ ID NO:2, amino acids Q72 to E86 of SEQ ID NO:2, amino acids G81 to L89 of SEQ ID NO:2, amino acids K104 to C112 of SEQ ID NO:2, amino acids K104 to VI13 ofSEQ ID NO:2, amino acids 1105 to VI13 of SEQ ID NO:2, amino acids N107 to LI 15 of SEQ ID NO:2, amino acids TlOl to V113 ofSEQ ID NO:2, amino acids ElOO to V113 ofSEQ ID NO:2, amino acids G99 to VI13 of SEQ ID NO:2, amino acids 193 to VI13 of SEQIDNO:2, amino acids D88 to VI13 ofSEQ ID NO:2, amino acids P84 to V113 ofSEQ ed NO:2, amino acids K77 to V113ofSEQIDNO:2, aminoacids Q72 to VI13 ofSEQ ID NO:2, amino acids F65 to VI13 ofSEQ ID NO:2, and L57 to VI13 ofSEQ ID NO:2; and said one or more tumor rejection peptides are selected from the group consisting of the antigenic peptides shown in Table A.

[0263] In another embodiment, one or more non-C35 cell penetrating peptides can be linked to one or more C35 peptide epitopes and/or C35 peptide epitope analogs to enhance delivery of C35 peptide epitopes to cells, e.g., dendritic cells. Especiallypreferred are polypeptides comprising a series ofC3 5 peptide epitopes or C35 peptide epitope analogs and cell penetrating peptides, and nucleic acids encoding same. The ^iidpe#®^f)^ptides can be arranged iii sequential or "intellectual property of n.z. 2 5 OCT 2008 RECEIVE overlapping fashion with or without the natural flanking sequences, and can be separated by unrelated linker sequences if desired. The polypeptide is processed to generate individual C35 epitopes which are recognized by the immune system, for generation of immune responses.

Thus, for example, C35 peptide epitopes and C35 peptide epitope analogs can be combined with cell-penetrating peptides. (Wang, R.-F. et al, Nature Biotechnology 20(2):U9-\5A (2002); Frankel, A.D. etal., Cell 55:1189-1193 (1988); Elliott, G. et al, Cell 88(2):223-233 (1997); Phelan, A. et al, Nature Biotechnology 16(5):440-443 (1998); Lin, Y.-Z. et al., J. Biol Chem. 270(24):14255-14258 (1995); Rojas,M. etal, Nature Biotechnology 16(4):370-375 (1998)). Exemplary cell penetrating peptides that can be administered to enhance delivery of C35 peptides to cells, such as dendritic cells, include: the Tat protein of human immunodeficiency virus, the HSV-1 structural protein VP22, and the 12-residue membrane-translocating sequence (MTS) modified from the 16-residue h region of the signal sequence of Kaposi fibroblast growth factor.

The one or more C35 peptide epitopes/analogs and one or more cell penetrating peptides can be joined together in various arrangements (e.g. concatenated, overlapping). The resulting polypeptide (or nucleic acid encoding the polypeptide) can be administered in a standard immunization protocol, e.g. to animals, to test the effectiveness ofthe polypeptide in stimulating, enhancing and/or provoking an immune response. The C35 peptide epitopes/analogs and one or more cell penetrating peptides can be joined directly or via the use of flanking sequences to fomi the polypeptides, and the use of such polypeptides as vaccines is well known in the art. Examples of polypeptides comprising C35 peptide epitopes or C35 peptide epitope analogs of the present invention and various cell penetrating peptides are set forth in Tables D and E below.

TABLED £35 Peptide/Epitope Exemplary Tumor Rejection Peptide Exemplary Polytopes S9-V17 ofSEQ ID NO:2 SVAfPPEEV amino acids 161-169 of MAGE-1 svapppeeveadptghsy.

EADPTGHSYSVAAPPPEEVEADPTGHSY amino acids 230-238 of MAGE-1 S VAPPPEEVS AYGEPRJCL.

SAYGEPRKL SVAPPPEEVSAYGEPRKL amino acids 168-176 of MAGE-3 SVAPPPEEVEVDPIGHLY. EVDPIGHLY SVAPPPEEVEVDPIGHLY amino acids 271-279 of MAGE-3 SVAPPPEEVFLWGPRALV. FLWGPRALVSVAPPPEEVFLWGPRALV amino acids 167-176 of MAGE-3 SVAPPPEEVMEVDPIGHLY. MEVDPIGHLYSVAPPPEEVMEVDPTGHLY amino acids 2-10 of BAGE SVAPPPEEVAARAVFLAL. AARAVFLALSVAPPPEEVAARAVFLAL amino acids 9-16 of GAGE-1,2 SVAPPPEEVYRPRPRRY. YRPRPRRYSVAPPPEEVYRPRPRRY amino acids 11-20 of RAGE SVAPPPEEVSPSSNRJRNT. SPSSNRTRNTSVAPpPEEVSPSSXTRTR^JT amino acids 23-32 of CDK4 SVAPPPEEVARDPHSGHFV. ARDPHSGHFVSVAPPPEEVARDPH55GHFV amino acids 29-37 of (3-catenin SVAPPPEEVSYLDSGTHS. SYLDSGIHSSVAPPPEEVSYLDSGTHS amino acids 1-9 of Tyrosinase SVAPPPEEVMLLAVLYCL. MLLAVLYCLSVAPPPEEVMLLAVTYCT, G35 Peptide/Epitope Exemplary Tumor Rejection Peptide Exemplary Polytopes amino acids 206-214 of Tyrosinase SV APPPEEVAFLPWHRLF. AFLPWHRLFSYAPPPEEVAFLPWHRLF amino acids 56-70 of Tyrosinase SVAPPPEEVONILLSNAPLGPOFP. ONnXSNAPLGPOFPSVAPPPEEVONTLLSNAPLGPOFP amino acids 448-462 of Tyrosinase SVAPPPEEVDYSYLODSDPDSFOD. DYSYLODSDPDSFODSVAPPPEEVDYSYLODSDPDSFOD amino acids 32-40 ofMelan-AMAKr"1 SVAPPPEEVJLTVILGVL. JLTVILGVLSVAPPPEEVILTVTLGVL amino acids 154-162 of gpl00Pmem SVAPPPEEVKTWGOYWOV.

KTWGO YW O V5VAPPPEEVKTWGO YWOV amino acids 209-217 of gpl00Pme,n SVAPPPEEVITDOVPFSV.

TTDO VPFSV SVAPPPEEVTTDOVPFS V amino acids 280-288 of gplOOPme"7 SVAPPPEEVYLEPGPVTA. YLEPGPVTASVAPPPEEVYLEPGPVTA amino acids 457-466 of gpl00Fmeli7 SVAPPPEEVLLDGTATLRL. LLDGTATLRLSVAPPPEEVLLDGTATLRL amino acids 476-485 of gpl00Pmel17 SVAPPPEEVVLYRY GSFSV. VLYRYGSFSVSVAPPPEEWLYRYGSFSV anrino acids 301-309 of FRAME SVAPPPEEVLYVDSLFFL. LYVDSLFFLSVAPPPEEVLYVDSLFFT, amino acids 292-303 of MAGE-6 SVAPPPBEVKISGGPRISYPL. KISGGPRISYPLSVAPPPEEVKISGGPRTSYPT, amino acids 157-167 ofNY-ESO-1 ■SVAPPPEEVSLLMWITOCFL. SLLMWrTQCFLSVAPPPEEVSLLMWITQCFL I C35 Peptide/Epitope Exemplary Tumor Rejection Peptide Exemplary Polytopes } amino acids 157-165 ofNY-ESO-1 SVAPPPEEVSLLMWITOC. SLLMWITQCSVAPPPEEVSLLMWITQC amino acids 155-163 ofNY-ESO-1 SVAPPPEEV OLSLLMWIT. OLSLLMWITSVAPPfEEVOLSLLMWIT amino acids 157-170 ofNY-ESO-1 and amino acids 281-295 of MAGE-3 SLLMWITOCFLPWSVAPPPBEVTSYVKVLHHMVKISG S21-Y29 ofSEQ ID NO:2 SGVRIWEY V r i t .11 n, ■■ i , 1 amino acids 161-169 of MAGE-1 SGVRIWEYEADPTGHSY. EADPTGHSYSGVR1WEYEADPTGHSY amino acids 230-238 of MAGE-1 SGVRTWEY SAY GEPRKL. SAYGEPRKLSGYRIWpYSAYGEPRKL amino acids 168-176 of MAGE-3 sgvriweyevdpighly. EVDPIGHLY SGVRIVyEYEVDPIGHLY amino acids 271-279 ofMAGE-3 SGVRIWEYFLWGPRALV. flwgpralvsgvriweyflwgpra.lv amino acids 167-176 ofMAGE-3 sgvrivveymevdpighly. mevdpighlysgvrtvyeymevdpighly amino acids 2-10 of BAGE sgvrtvveyaaravflal. aaravflalsgvriweyaaravflal amino acids 9-16 of GAGE-1,2 sgvrivveyyrprprrv.

YRPRPRRYSGVRIWEYYRPRPRRY amino acids 11-20 of RAGE SGVRIWEYSPSSNRIRNT. SPSSNRIRNTSGVRrWEYSPSSNRIRNT amino acids 23-32 of CDK4 SGVRIWEYACDPTTSGHFV. ACDPHSGHFVSGVRJWEYACDPHSGHFV C35 Peptide/Epitope Exemplary Tumor Rejection Peptide Exemplary Polytopes amino acids 29-37 of |}-catenin SGVRIWEYSYLDSGIHR SYLDSGIHFSGVRIWEYSYLDSGIHF amino acids 1-9 of tyrosinase SGVRIWEYMLLA VLY CL. MLLAVLYCLSGVRIWEYMLLA VLYCL amino acids 206-214 of tyrosinase SGVRIWEY AFLPWHRLF. AFLPWHRLFSQVRIVVEYAFLPWHRLF amino acids 56-70 of tyrosinase SGVRIWEYONILLSNAPLGPOFP. ONILLSNAPLGPOFPSGVRTWEYONILLSNAPLGPOFP amino acids 448-462 of tyrosinase SGVRIWEYDYSYLODSDPDSFOD. DYSYLODSDPDSFODSGVRIWEYDYSYLODSDPDSFOD amino acids 32-40 of Melan-A*^1"'1 SGVRIWEY JLTVILGVL. JLTVILGVLSGVRIWEYJLTVTLGVL amino acids 154-162 of gplOOPmeU7 SGVRIWEYKTWGOYWOV. KTWGOYWOVSGVRiyVEYKTWGQYWQV amino acids 209-217 of gplOO^117 SGVRIWEY ITDOVPFSV.

ITDOVPFSV SGVRIWEY ITDOVPFSV amino acids 280-288 of gplOOPrae117 SGVRIWEYYLEPGPVTA. YLEPGPVTASGVRIWEYYLEPGPVTA amino acids 457-466 of gpl00Pniel17 / SGVRIWEYLLDGTATLRL. LLDGTATLRLSGVRIWEYLLDGTATLRL amino acids 476-485 of gpl00Pmel17 SGVRIWEYVLYRYGSFSV. VLYRYGSFSVSGVRIWEYVLYRYGSFSV amino acids 301-309 of PRAME SGVRIWEYLYVDSLFFL. LYVDSLFFLSGVRIWEYLYVDSLFFL C35 Peptide/Epitope Exemplary Tumor Rejection Peptide Exemplary Polytopes amino acids 292-303 of MAGE-6 SGVRIWEYKISGGPRISYPL. KISGGPRISYPLSGVRIWEYKISGGPRISYPL amino acids 157-167 ofNY-ESO-1 SGVRIWEYSLLMWITOCFL SLLMWITOCFLSGVRIWEYSLLMWITOCFL amino acids 157-165 ofNY-ESO-1 SGVRIWEY SLLMWITOC. SLLMWITOCSGVRIWEYSLLMWITOC amino acids 155-163 ofNY-ESO-1 SGVRIWEYOLSLLMWTT. OLSLLMWITSGVRTWEYOLSLLMWIT amino acids 157-170 ofNY-ESO-1 and amino acids 281-295 ofMAGE-3 SLLMWITOCFLPVFSGVRIVVEYTSYVKVLHHMWTSG G22-C30 ofSEQ ID NO :2 GVRTVVEYC amino acids 161-169 "of MAGE-1 GVRIWEYCEADPTGHSY. EADPTGHSYGVRIWEYCEADPTGHSY amino acids 230-238 of MAGE-1 GVRIWEY CS A Y GEPRKL.

SAY GEPRKLGYRIVYEY CS AYGEPKKL amino acids 168-176 ofMAGE-3 GVRIWEY CEVDPIGHLY. EVDPIGHLYGVRIWEYQEVDPIGHLY amino acids 271-279 ofMAGE-3 GVRIWEY CFLWGPRALV. FLWGPRALVGVRTWEYCFLWGPRALV amino acids 167-176 ofMAGE-3 GVRTWEY CMEVDPIGHLY. MEVDPIGHLYGVRiyVEYCMEVDPIGITT ,V amino acids 2-10 of BAGE GVRIWEYCAARAVFLAL. AARAVFLALGVRIVyEYCA ARA VFLAL amino acids 9-16 of GAGE-1,2 GVRIWEYCYRPRPRRY. YRPRPRRY GVRTWEY CYRPRPRRY C35 Peptide/Epitope Exemplary Tumor Rejection Peptide Exemplary Polytopes amino acids 11-20 of RAGE gvriweycspssnrirnt. spssnrirntgvriweycspssnrirnt amino acids 23-32 of CDK4 GVRIWEYCACDPHSGHFV. ACDPHSGHFVGVRIWEYCACDPHSGHFV amino acids 29-37 of P-catenin gvriweycsyldsgihf. syldsgihfgvriweycsyldsgihf amino acids 1-9 of tyrosinase GVRIVVEYCMLLAVLYCL.

MLLAVLYCLGVRIWEY CMLLAVLY CL amino acids 206-214 of tyrosinase GVRIWEYCAFLPWHRLF. AFLPWHRLFQVRIWEYCAFLPWHRLF amino acids 56-70 of tyrosinase GVRIWEYCONILLSNAPLGPOFP. ONILLSNAPLGPOFPGVRTWEYCONILLSNAPLGPOFP amino acids 448-462 of tyrosinase GVRIWEYCDYSYLODSDPDSFOD. DYSYLODSDPDSFODGVRJVyEYCDYSYLODSDPDSFOD amino acids 32-40 of Melan-AMART'1 GVRIWEY CILTVILGVL. ILTVILGVLGVRIWEYCILTVILGVL amino acids 154-162 of gpl00Pmt'17 GVRIWEYCKTWGOYWOV. KTWGOYWOVGVRIWEYCKTWGOYWOV amino acids 209-217 ofgpl00PmeU7 GVRTWEYCITDOVPPSV. ITDOVPFSVGVRIWEYCITDOVPFSV amino acids 280-288 of gplOOPme117 GVRIWEYCYLEPGPVTA. YLEPGPVTAGVRIWEYCYLEPGPVTA amino acids 457-466 of gplOOProe"7 GVRIWEYCLLDGTATLRL. LLDGTATLRLGVRIWEYCLLDGTATLRL C35 Peptide/Epitope Exemplary Tumor Rejection Peptide Exemplary Polytopes > amino acids 476-485 of gplOO**™'" GVRIWEY CVLYRYGSFS V. VLYRYGSFSVGVRTWEYCVLYRYGSFSV amino acids 301-309 of PRAME GVRTWEYCLYVDSLFFL. LYVDSLFFLGVRIWEYCLYVDSLFFL amino acids 292-303 of MAGE-6 GVRTWEY CKISGGPRIS YPL. KISGGPRISYPLGVRIWEY CKISGGPRISYPL amino acids 157-167 ofNY-ESO-1 GVRIWEY CSLLMWITOCFL. SLLMWITOCFLGVRIWEYCSLLMWITOCFL amino acids 157-165 ofNY-ESO-1 GVRIWEY CSLLMWITOC. SLLMWITOCGVRTWEY CSLLMWITOC amino acids 155-163 ofNY-ESO-1 GVRIWEY COLSLLMWTT. OLSLLMWITGVRTWEYCOLSLLMWIT amino acids 157-170 ofNY-ESO-1 and amino acids 281-295 ofMAGE-3 SLLMWITOCFLPVF GVRIWEYCTSYVKVLHHMVKISG 125 to C33 ofSEQ ID NO:2 ,IWEYCEPC amino acids 161-169 of MAGE-1 IWEYCEPCEADPTGHSY.

EADPTGHS YIWEYCEPCEADPTGHS Y amino acids 230-238 of MAGE-1 IWEY CEPCSAY GEPRKL.

SAY GEPRKLIWEY CEPCSAY GEPRJCL amino acids 168-176 ofMAGE-3 IWEYCEPCEVDPIGHLY. EVDPIGHLYIWEYCEPCBVDPIGHLY amino acids 271-279 ofMAGE-3 IWEY CEPCFLWGPRALV.

FLWGPRALVTVyEY CEPCFLW GPRA LV amino acids 167-176 ofMAGE-3 IWEYCEPCMEVDPIGHLY. MEVDPIGHLYIWEYCEPCMEVDPTGm.Y 035 Peptide/Epitope Exemplary Tumor Rejection Peptide Exemplary Polytopes ammo acids 2-10 of BAGE IWEYCEPCAARA VFLAL. AARAVFLALIWEYCEPCAARAVFLAL amino acids 9-16 of GAGE-1,2 IWEYCEPCYRPRPRRY. YRPRPRRYIWEY CEPCYRPRPRRY amino acids 11-20 of RAGE tweycepcspssnrtrnt. SPSSNRIRNTTWEYCEPCSPSSNRIRNT amino acids 23-32 of CDK4 IWEY CEPCACDPHSGHFV. ACDPHSGHFVIWEYCEPCACDPHSGHFV amino acids 29-37 of p-catenin IWEY cepcs YLDSG1HF. SYLDSGIHFrWEYCEPCSYLDSGIHF amino acids 1-9 of tyrosinase iweycepc mllavlycl mllavlycliweycepcmllavlycl amino acids 206-214 of tyrosinase IWEY CEPCAFLPWHRLF. AFLPWHRLFIWEYqEpCAFLPWHRLF amino acids 56-70 of tyrosinase IWEY CEPCONILLSNAPLGPOFP. ONILLSNAPLGPOFPIWEY CEPCONILLSNAPLGPOFP amino acids 448-462 of tyrosinase IWEYCEPCDYSYLODSDPDSFOD. DYSYLODSDPDSFODIWEYCEPCDYSYT.QDSnPDSFQD amino acids 32-40 of Melan-AMART"1 IWEYCEPCJLTVTLGVL. JLTVILGVLIVyEYCEPCJLTVILGVL amino acids 154-162 of gplOO*1™117 IWEYCEPCKTWGOYWO V. KTWGOYWOVTVVEYCEPCKTWGQYWOV amino acids 209-217 of gpl00pmel17 IWEYCEPCITDOVPFSV. rroOVPFSVIWEYCEPCITDOVPFSV C35 Peptide/Epitope Exemplary Tumor Rejection Peptide Exemplary Polytopes 1 ! amino acids 280-288 of gpl00?™117 IWEY CEPCYLEPGP VTA. YLEPGPVTAIWEYCEPCYLEPGPVTA amino acids 457-466 of gpl00Fmel17 IWBYCEPCLLDGTATLRL. LLDGTATLRLIWEYCEPCLLDGTATLRL amino acids 476-485 ofgplOO^117 IWEYCEPCVLYRYGSFSV.

VLYRY GSFSVTWEYCEPCVLYRYGSFSV amino acids 301-309 of PRAME IWEY CEPCLYVDSLFFL. LYVDSLFFLIWEYCEPCLYVDSLFFL amino acids 292-303 of MAGE-6 rWEYCEPCKlSGGPRISYPL. KISGGPRISYPLrWEYCEPCKISGGPRISYPL amino acids 157-167 ofNY-ESO-1 IWEYCEPCSLLMWITOCFL. SLLMWITOCFLIVVEYCEPCSLLMWITOCFL amino acids 157-165 ofNY-ESO-1 IWEYCEPCSLLMWTTOC. SLLMwrrociwEYCEpqsLLMwrroc amino acids 155-163 ofNY-ESO-1 IWEY CEPCOLSLIMWIT. OLSLLMwrriyvEYqEpcvoLSLLMwrr amino acids 157-170 ofNY-ESO-1 and amino acids 281-295 ofMAGE-3 SLLMWITOCFLPVFIWEYCEPCTSYVKVLHHMViaSG T38-V46 ofSEQ ID NO:2 TYLELASAV amino acids 161-169 of MAGE-1 TYLELASAVEADPTGHSY EADPTGHSYTYLELASAVEADPTGHSY amino acids 230-238 of MAGE-1 TYLELASAVSAYGEPRKL.

SAY GEPRKLTYLELAS A V SAYGEPRKL amino acids 168-176 ofMAGE-3 TYLELASAVEVDPIGHLY. EVDPIGHLYTYLELASAVEVDPIGHLY C35 Peptide/Epitope Exemplary Tumor Rejection Peptide Exemplary Polytopes amino acids 271-279 ofMAGE-3 TYLELASAVFLWGPRALV.

FLW GPRALVTYLELASAVFLWGPRALV amino acids 167-176 of MAGE-3 TYLELASAVMEVDPIGHLY. MEVDPIGHLYTYLELASAVMEVDPIGHLY amino acids 2-10 of BAGE TYLELASAVAARAVFLAL. AARAVFLALTYLELASAVAARAVFLAL amino acids 9-16 of GAGE-1,2 TYLELASAVYRPRPRRY. YRPRPRRYTYLELASAYYRPRPRRY amino acids 11-20 of RAGE TYLELASAVSPSSNRIRNT. SPSSNRIRNTTYLELASAVSPSSNRIRNT amino acids 23-32 of CDK4 TYLELASAVACDPHSGHFV. ACDPHSGHFVTYLELASAVACDPHSGHFV amino acids 29-37 of p-catenin TYLELASAVSYLDSGIHF. SYLDSGIHFTYLELASAVSYLDSGTHF amino acids 1-9 of tyrosinase TYLELASAVMLLAVLYCT,.

MLLAVLY CLTYLELAS A VMLLA VLY CL amino acids 206-214 of tyrosinase TYLELASAVAFLPWHRLF. AFLPWHRLFTYLELASAVAFLPWHRLF amino acids 56-70 of tyrosinase TYLELAS AV ONILLSNAPLGPOFP. ONILLSNAPLGPOFPTYLELASAVONTLLSNAPLGPOFP amino acids 448-462 of tyrosinase TYLELASAVDYSYLODSDPDSFOD. DYSYLQDSDPDSFQDTYLELASAVDYSYLQDSDPDSFQD amino acids 32-40 of Melan-AMAKT'1 TYLELASAVJLTVILGVL. JLTVILGVLTYLELAS A VJLTVILGVT.

| C35 Peptide/Epitope Exemplary Tumor Rejection Peptide Exemplary Polytopes 1 \ amino acids 154-162 of gpl00pn"U7 TYLELASAVKTWGOYWOV. KTWGOYWOVTYLELASAVKTWGOYWOV amino acids 209-217 of gpl00Pmel17 TYLELASAVITDOVPFSV. ITDOVPFSVTYLELASAVITDOVPFSV amino acids 280-288 of gpl00Pmeln TYLELASAVYLEPGPVTA. YLEPGPVTATYLELASAVYLEPGPVTA amino acids 457-466 of gpl00Fm*n7 TYLELASAVLLDGTATLRL. LLDGTATLRLTYI .ELASAVLLDGTATLRL amino acids 476-485 of gpl00FmeU7 TYLELASAWLYRYGSFSV. VLYRYGSFSVTYLELASAWLYRYGSFSV amino acids 301-309 ofPRAME TYLELASAVLYVDSLFFL. LYVDSLFFLTYLELASAVLYVDST.FFI. amino acids 292-303 of MAGE-6 TYLELASAVKISGGPRTSYPL. KISGGPRISYPLTYLELASAVKISGGPRISYPT, amino acids 157-167 ofNY-ESO-1 TYLELASAVSLLMWITOCFL. SLLMWITOCFLTYLELASAySLLMWITOCFI. amino acids 157-165 ofNY-ESO-1 TYLELASAVSLLMWITOC. SLLMWTTOCTYLELASAVSLLMWITOC amino acids 155-163 ofNY-ESO-1 TYLELASAVOLSLLMWIT. OLSLLMWITTYLELAg AV OLSLLMWIT amino acids 157-170 ofNY-ESO-1 and amino acids 281-295 ofMAGE-3 SLLMWTTOCFLPVF TYLEIASAVTSYVKVI.HHMVKIfSG C35 Peptide/Epitope Exemplary Tumor Rejection Peptide Exemplary Polytopes G61-I69 of SEQ ID NO:2 fGTGAFEIEI amino acids 161-169 of MAGE-1 gtgafeieieadptghsy. eadptghsygtgafeieieadptghsy amino acids 230-238 of MAGE-1 GTGAFEIEIS AY GEPRKL. say geprklgxgafei^is ay geprkl amino acids 168-176 ofMAGE-3 gtgafeieievdptghly. evdpighlygtgafeieievdpighly amino acids 271-279 ofMAGE-3 gtgafeieiflwgpralv. flwgpralvgtgafeieiflwgpralv amino acids 167-176 ofMAGE-3 gtgafeieimevdpighly. mevdpighly gtgafeieimevdpighly amino acids 2-10 of B AGE gtgafeieiaaravflal. aaravflalgtgafeieiaara vflal amino acids 9-16 of GAGE-1,2 gtgafeieiyrprprry. yrprprrygtgapeieiyrprprry amino acids 11-20 of RAGE gtgafeieispssnrirnt. spssnrirntgtgafeieispssnriknt amino adds 23-32 of CDK4 GTGAFEIEIACDPHSGHFV. acdphsghfvgtqafeieiacdphsghfv amino acids 29-37 of P-catenin GTGAFEIBrSYLDSGIHF. syldsgihfgtgafeieisyldsgihf amino acids 1-9 of tyrosinase gtgafeieimllavlycl. mllavly clgtgafeieimlla vly cl amino acids 206-214 of tyrosinase GTGAFEIEIAFLPWHRLF. aflpwhrlfgtgafeieiaflpwhrlf CSS Peptide/Epitope Exemplary Tumor Rejection Peptide Exemplary Polytopes f i i J I 1 } amino acids 56-70 of tyrosinase GTGAFEIEIONILLSNAPLGPOFP. ONILLSNAPLQPOFPGTGAFEffilONILLSNAPLGPOFP amino acids 448-462 of tyrosinase GTGAFEIEIDYSYLODSDPDSFOD. DYSYLODSDPDSFODGTGAFEIEIDYSYLODSDPDSFOD amino acids 32-40 of Melan-AMART"1 GTGAFEIEIJLTVTLGVL. JLTVILGVLGTGAFEIEIJLTVILGVL amino acids 154-162 of gpl00pmel17 GTGAFEIEIKTWGOYWOV. KTWGOYWOVGTGAFEIEIKTWGOYWOV amino acids 209-217 of gpl00Pmel17 GTGAFEIEHTDOVPFSV. ITDOVPFSVGTGAFEffillTDOVPFSV amino acids 280-288 of gpl00?mdl7 GTGAFEIEIYLEPGPVTA. YLEPGPVTAGTGAFEIEIYLEPGPVTA amino acids 457-466 of gplOO*™117 GTGAFEIEILLDGTATLRL. LLDGTATLRLQTQAFEIEILLDGTATLRL amino acids 476-485 of gplOO*8"117 GTGAFEIEIVLYRYGSFSV. VLYRYGSFSVGTGAFElErVLYRYGSFSV amino acids 301-309 of PRAMB gtgafeie1lyvdslffl. lyvdslfflgtgafeieilyvdslffl amino adds 292-303 of MAGE-6 GTGAFEIEIKISGGPRISYPL. K1SGGPRISYPLGTGAFEIEIKISGGPRTSYPL amino adds 157-167 ofNY-ESO-1 GTGAFEIEISLIMWTTOCFL. SLLMWITOCFLGTGAFEIEISLLMWITQnFT, amino acids 157-165 of NY-ESO-1 GTGAFE1EISIXMWITOC. SLLMWITOCGTGAFEIEISLLMWITOn C3S Peptide/Epitope Exemplary Tumor Rejection Peptide Exemplary Polytopes amino acids 155-163 ofNY-ESO-1 GTGAFEIEIOLSLLMWIT. OLSLLMWITGTGAFEmrOLSLLMWIT amino acids 157-170 ofNY-ESO-1 and amino acids 281-295 ofMAGE-3 SLLMWTTOCFLPVFGTGAFEIEITSYVKVLHHMVKISG F65-L73 ofSEQ ID NO:2 FEIEINGQL . amino aeids 161-169 of MAGE-1 FEIEINGOLEADPTGHSY. EADPTGHSYFEIEINGQLBADPTGHSY amino acids 230-238 of MAGE-1 FEIEINGOLSAYGEPRICL.

SAY GEPRKLFEIEINGQLS AY GEPRKL amino acids 168-176 ofMAGE-3 FEIEINGOLEVDPIGHLY. EVDPIGHLYFEIEINGQLEVDPIGHLY amino acids 271-279 ofMAGE-3 FEIEINGOLFLWGPRALV. FLWGPRALVFEIEINGQLFL'WGPRALV amino acids 167-176 ofMAGE-3 FEIEINGOLMBVDPIGHLY. MEVDPIGHLYFEIEINGQLMEVDPIGHLY amino acids 2-10 of BAGE FEIFJNGOLAARAVFLAL. AARAVFLALFEIEINGQLAARA VFLAL amino acids 9-16 of GAGE-1,2 FEIEINGOLYRPRPRRY. YRPRPRRYFEipiNGQLYRPRPRRY amino acids 11-20 of RAGE FEIEINGOLSPSSNRIRNT. SPSSNRIRNTFEIEINGQLSPSSNRIRNT amino acids 23-32 of GDK4 feffilngolaedphsghfv. acdphsghfvfeie1ngqlacdphsghfv amino acids 29-37 of p-catenin FEIEINGOLSYLDSGIHF. SYLDSGIHFFEIEINGOLSYLDSGIHF C35 Peptide/Epitope Exemplary Tumor Rejection Peptide Exemplary Polytopes i. k t* i f t ir amino acids 1-9 of tyrosinase FEIEINGOLMLLAVLYCL. MLLAVLYCLFETEJNGOIMLLAVLYCL amino acids 206-214 of tyrosinase FEIEINGOLAFLPWHRLF. AFLPWHRLFFEIEINGOLAFLPWHRLF amino acids 56-70 of tyrosinase FEIEINGOLONILLSNAPLGPOFP. ONILLSNAPLGPOFPFEIEINGQLONILLSNAPLGPOFP amino acids 448-462 of tyrosinase FEIEINGOLDYSYLODSDPDSFOD. DYSYLODSDPDSFODFEIEINGOLDYSYLODSDPDSFOD amino acids 32-40 ofMelan-A1^™ FEIEINGOLJLTVILGVL. JLTVILGVLFEIEINGOLJLTVILGVL amino acids 154-162 of gplOOPmem FEffilNGOLKTWGOYWOV. KTWGOYWOVFEffilNGQLKTWGOYWQV amino acids 209-217 of gplOO*1*117 FEffilNGOLITDOVPFSV. ITDOVPFSVF?IEI^GOLITDOVPFSV amino acids 280-288 of gplOO*"1®117 FEIEINGOLYLEPGPVTA. YLEPGPVTAFEIEINQQLYLEPGPVTA amino acids 457-466 of gpl00PmeU7 FEffilNGOLLLDGTATLRL. LLDGTATLRLFEIEINGQLLLDGTATLRL amino acids 476-485 of gplOOPm5"7 FEIEINGOLVLYRY GSFSV. VLYRYGSFSVFEIEINGQLVLYRYGSFSV amino acids 301-309 of PRAME FEIEINGOLLYVDSLFFL. LYVDSLFFLFEIEINGQLLYVDSLFFL amino acids 292-303 of MAGE-6 FEIEINGOLKISGGPRISYPL. OSGGPRISYPLFEffilNGQLKISGGPRTSVPL €35 Peptide/Epitope Exemplary Tumor Rejection Peptide Exemplary Polytopes > amino acids 157-167 ofNY-ESO-1 FEIEINGOLSLLMWITOCFL. SLLMWITOCFLFEffilNGQLSLLMWITOCFL amino acids 157-165 ofNY-ESO-1 FEIEINGOLSLLMWITOC. SLLMWTTOCFEIEINGQLSLLMWITOC amino acids 155-163 ofNY-ESO-1 FEIEINGOLOLSLLMWIT. OLSLLMWTTFEIEINGQLOLSLLMWIT ammo acids 157-170 ofNY-ESO-1 and amino acids 281-295 of MAGB-3 SLLMWITOCFLPVFFEIEINGOLTSYVKVLHHMVKISG I67-F75 ofSEQ ID NO:2 IEINGQLVF i i» amino acids 161-169 of MAGE-1 IEINGOLVFEADPTGHSY. EADPTGHSYIEINGQLVFEADPTGHSY amino acids 230-238 of MAGE-1 IEINGOLVFSAY GEPRKL. SAYGEPRKLIE1NGQLVFSAYGEPRKL amino acids 168-176 ofMAGE-3 IEINGOLVFEVDPIGHLY. EVDPIGHLYTEINGOLVFEVDPIGHLY amino acids 271-279 ofMAGE-3 IETNGOLVFFLWGPRALV. FLWGPRALVIEINGQLVFFLWGPRALV amino acids 167-176 ofMAGE-3 IEDSfGOLVFMEVDPIGHLY. MEVDPIGHLYIEINGQI^yFMEVDPIGHLY amino acids 2-10 of BAGE IEINGOLVFAARA VFLAL. AARAVFLALIEINGQLYFAARAVFLAL amino acids 9-16 of GAGE-1,2 IEINGOLVFYRPRPRRY. YRPRPRRYIEINGQLVFYRPRPRRY amino acids 11-20 of RAGE IEINGOLVFSPSSNRIRNT. SPSSNRIRNTIEINGQLVFSPSSNRIRNT C3S Peptide/Epitope Exemplary Tnmor RejectlonPeptlde Exemplary Polytopes 11 1 1 ammo acids 23-32 of CDK4 TCTNGOT.VFCDPHSGHFV. ACDPHSGHFVIEINGOLVFACDPHSGHFV amino acids 29-37 of p-catenin IEINGOLVPSYLDSGTHF. SYLDSGIHFIEINGOLVFSYLDSGIHF amino acids 1-9 of tyrosinase IEINGOLVFMLLAVLYCL.

MLLAVLY CLIEINGQLVFMLLAVLYCL amino acids 206-214 of tyrosinase IETNGOLVFAFLPWHRLF. AFLPWHRLFffilNGQLWAFLPWHRLF amino acids 56-70 of tyrosinase IEINGOLVFON1LLSNAPLGPOFP. ONILLSNAPLGPOFPIEINGQLVFONTLLSNAPLGPOFP amino acids 448-462 of tyrosinase IETNGOLVFDYSYLODSDPDSFOD. DYSYLODSDPDSFODIEINGQ^VFDYSYLODSDPDSFOD amino acids 32-40 of Melan-AMART"1 IEINGOLVFJLTVILGVL. JLTVTLGVLIBINGOLVFJLTVILGVL amino acids 154-162 of gplOOPme117 IEINGOLYFKTWGOYWOV.

KTW GO YW OVIE1NGQLVFKTW GO YW OV amino acids 209-217 of gpl00Pmen7 IEINGOLVFITDOVPFSV. ITDOVPFSVIEINGOLVFITDOVPFSV amino acids 280-288 of gpl00pmeI17 IEINGOLVFYLEPGPVT A. YLEPGPVTAIBINGQLVFYLEPGPVTA amino acids 457-466 of gplOO*™*"7 1EINGOLVFLLDGTATLRL. LLDGTATLRLIEINGQLVFLLDGTATT^L amino acids 476-485 of gplOO^117 IEINGOLVFVLYRYGSFSV. VLYRYGSFSVIEINGQLVFVLYR.YGSFSV €35 Peptide/Epitope Exemplary Tumor Rejection Peptide Exemplary Polytopes amino acids 301-309 of PRAME IEINGOLVFLYVDSLFFL. LYVDSLFFLIEINGOLVFLYVDSLFFL amino acids 292-303 ofMAGE-6 ffilNGOLVFKISGGPRISYPL. KISGGPRISYPLIEINGQLVFKISGGPRISYPL amino acids 157-167 ofNY-ESOl IEINGOLVFSLLMWITOCFL. SLLMWITOCFLIEINGOLVFSLLMWrrOCFL amino acids 157-165 ofNY-ESO-1 IEINGOLVFSLLMWITOC. SLLMWITOCIEINGOLVFSLLMWITOC amino acids 155-163 ofNY-ESO-1 IEINGOLVFOLSLLMWIT. OLSLLMWITffilNGOLVFOLSLLMWIT amino acids 157-170 ofNY-ESO-1 and amino acids 281-295 ofMAGE-3 SLLMWITOCFLPVFffilNGOLVFTSYVKVLHHMVKISG K77-Y85 ofSEQ ID NO:2 KLENGGFPY amino acids 161-169 of MAGE-1 KLENGGFPYEADPTGHSY. EADPTGHSYKLENGGFPYEADPTGHSY amino acids 230-238 of MAGE-1 KLENGGFPYSAY GEPRKL. SAYGEPRKLKLENGGFPYSAYGEPRKL amino acids 168-176 ofMAGE-3 KLENGGFPYEVDPIGHLY. EVDPIGHLYKLENGGFPYEVDPIGHLY amino acids 271-279 ofMAGE-3 KLENGGFPYFLWGPRALV. FLWGPRALVKLE^GGFPYFLWGPRALV amino acids 167-176 ofMAGE-3 KLENGGFPYMEVDPIGHT.Y. MEVDPIGHLYKLENGGFPYMEVDPIGHLY amino acids 2-10 of BAGE KLENGGFPYAARA VFLAT,. AARAVFLALKLENGGFPYAARA VFLAL C35 Peptide/Epitope Exemplary Tumor Rejection Peptide Exemplary Polytopes i amino acids 9-16 of GAGE-1,2 KLENGGFPYYRPRPRRY. YRPRPRRYKLENGGFPYYRPRPRRY amino acids 11-20 of RAGE KLENGGFPYSPSSNRIRNT. SPSSNRERNTKLENGGFPYSPSSNEURNT amino acids 23-32 of CDK4 KLENGGFPYACDPHSGHFV. ACDPHSGHFVKLENGGFPYACDPHSGHFV amino acids 29-37 of P-catenin KLENGGFPYSYLDSGTHF. SYLDSGIHFKLENGGFPYSYLDSGIHF amino acids 1-9 of tyrosinase KLENGGFPYMLLAVLY CL. MLLAVLYCLKLENGGFPYMLLAVLY CL amino acids 206-214 of tyrosinase KLENGGFPYAFLPWFTRLF. AFLPWHRLFKLENGGFPYAFLPWHRLF amino acids 56-70 of tyrosinase KLENGGFPYONILLSNAPLGPOFP.. ONILLSNAPLGPOFPKLENGGFPY ONTLLSN APT.GPOFP amino acids 448-462 of tyrosinase KLENGGFPYDYSYLODSDPDSFOD. DYSYLODSDPDSFODTCLENGGFPYDYSYT,Or),<!r)PnSFOn amino acids 32-40 of Melan-AMART"' KLENGGFPYJLTVILGVL. JLTVILGVLKLENGGppYJLTVILGVT. amino acids 154-162 of gpl00Pnwm KLENGGFPYKTWGOYWOV. KTWGOYWOVKLEl^GGFPYKTWGOYWQV amino acids 209-217 of gpl00Fmel17 KLENGGFPYITDOVPFSV. rroQVPFSVKLENGGFPYTIDQVPFSV amino acids 280-288 of gpl00rmel17 KLENGGFPYYT.F.POPVTA YLEPGPVTAKLENGGFPYYLEPGPVTA C35 Peptide/Epitope Exemplary Tumor Rejection Peptide Exemplary Polytopes I f j, annuo acids 457-466 of gplOOPmein KLENGGFPYLLDGTATLRL.

LLD GTATLRLKLENQGFPYLLDGTATLRL amino acids 476-485 of gpl00pm<!,I7 KLENGGFPYVLYRYGSFSV.

VLYRY GSFSVKLENGGFPYVLYRYGSFSV amino acids 301-309 of PRAME KLENGGFPYLYVDSLFFL. LYVDSLFFLKLENGGFPYLYVDSLFFL amino acids 292-303 of MAGE-6 KLENGGFPYKISGGPRISYPL. KISGGPRISYPLKLENGGFPYKISGGPRISYPL amino acids 157-167 ofNY-ESO-1 KLENGGFPYSLLMWITOCFL. SLLMWITOCFLTCLENGGFPYSLLMWITOCFL amino acids 157-165 ofNY-ESO-1 KLENGGFPYSLLMWITOC. SLLMWITOCKLENGGFPYSLLMWITOC amino acids 155-163 ofNY-ESO-1 KLENGGFPYOLSLLMWIT. OLSLLMWTTKLENGGFPYOLSLLMWTT amino acids 157-170 ofNY-ESO-1 and amino acids 281-295 ofMAGE-3 SLLMWITOCFLPVF KLENGGFPYTSYVKVLHHMVKTSG Q72-E86 of SEQ ID NO:2 QLVFSKLENGGFPYE amino acids 161-169 ofMAGE-1 OLVFSKLENGGFPYEEADPTGHSY. EADPTGHSYQIfVFSKLENGGFPYEEADPTGHSY amino acids 230-238 ofMAGE-1 OLVFSKLENGGFPYES AY GEPRKL.

SAY GEPRKLOLVFSKLENGGFPYESA YGEPRKL amino acids 168-176 ofMAGE-3 OLVFSKLENGGFPYEEVDPIGHLY. EVDPIGHLYOLVFSKLENGGFPYEEVDPIGHLY amino acids 271-279 ofMAGE-3 OLVFSKLENGGFPYEFLWGPRALV. FLWGPRALVOLVFSKLENGGFPYEFLWGPRALV C35 Peptide/Epitope Exemplary Tumor Rejection Peptide Exemplary Polytopes * ■. i K j . amino acids 167-176 ofMAGE-3 OLVFSKLENGGFPYEMEVDPIGHLY. MEVDPIGHLYOLVFS^LENGGFPYEMEVDPIGHLY amino acids 2-10 of BAGE OLVFSKLENGGFPYEAARAVFLAL. AARAVFLALOLVFSKLENGGFPYEAARAVFLAL amino acids 9-16 of GAGE-1,2 OLVFSKLENGGFPYEYRPRPRRY. YRPRPRRY OLVFSELENGGFP YEYRPRPRRY amino acids 11-20 of RAGE OLVFSKLENGGFPYESPSSNRIRNT. SPSSNRIKNTOLVFSKLENGGFPYESPSSNRERNT amino acids 23-32 of CDK4 OLVFSKLENGGFPYEA CDPHSGHFV. ACDPHSGHFVOLVFSKLENGGFPYEACDPHSGHFV amino acids 29-37 of p-catenin OLVFSKLENGGFPYESYLDSGIHF. SYLDSGIHFOLVFSKLENGGFPYESYLDSGTHF amino acids 1-9 of tyrosinase OLVFSKLENGGFPYEMLLAVLYCL. MLLAVLYCLOLVFSKLENGGFPYEMLLAVLYCL amino acids 206-214 of tyrosinase OLVFSKLENGGFPYEAFLPWHRLF. AFLPWHRLF OLVF SKLENGGFPYEAFLPWTTR T .F amino acids 56-70 of tyrosinase OLVFSKLENGGFPYEONILLSNAPLGPOFP. onillsnaplgpofpolvfsklenggfpyeonttlsnaplgpofp amino acids 448-462 of tyrosinase OLVFSKLENGGFPYEDYSYLODSDPDSFOT) DYSYLODSDPDSFODQLVFSKLENGGFPYF.nvSYT.QBSr>pr>sfqn amino acids 32-40 of Melan-AMART*1 OLVFSKLENGGFPYFJLTVTLGVL. JLTVILGVLOLVFSKLENGGFP YEJLTVTT .GVT. amino acids 154-162 of gpl00Prael17 OLVFSKLENGGFPYRKTWGOYWOV KTWGOYWOVOLVFSKLENGGFPYEKTWGOYWOV | C35 Peptide/Epitope Exemplary Tumor Rejection Peptide Exemplary Polytopes i amino acids 209-217 of gpl00Pmen7 OLVFSKLENGGFPYEITDOVPFSV. TTDOVPFSVOLWSKLENGGFPYEITDOVPFSV amino acids 280-288 of gplOO*"*117 OLVFSKLENGGFPYEYLEPGPVTA. YLEPGPVTAOLVFSKLENGGFPYEYLEPGPVTA amino acids 457-466 of gpl00Pn*1!7 OLVFSKLENGGFPYELLDGTATLRL. LLDGTATLRLQLVFSKLENGGFPYELLDGTATLRL amino acids 476-485 ofgpl00PmeU7 OLVFSKLENGGFPYEVLYRYGSFSV. VLYRYGSFSVOLVFSELENGGFPYEVLYRYGSFSV amino acids 301-309 of PRAME OT.VFSKLENGGPPYELYVDSLFFL. LYVDSLFFLOLVFSKLENGGFPYELYVDSLFFL ammo acids 292-303 of MAGE-6 OLVFSKLENGGFPYEKISGGPRISYPL. KISGGPRISYPLOLVFSKLENGGFPYEKISGGPRISYPL amino acids 157-167 ofNY-ESO-1 OLVFSKLENGGFPYESLLMWITOGFL. SLLMWITOCFLOLVFSKLENGGFPYESLLMWITOCFL amino acids 157-165 ofNY-ESO-1 OLVFSKLENGGFPYRSLLMWITOn. SLLMWITQCOLVFSKLENGGFPYESLLMWITQC amino adds 155-163 ofNY-ESO-1 OLVFSKLENGGFPYEOLSLLMWIT. OLSLLMWITOLVFSKLENGGFPYEOLSLLMWIT amino acids 157-170 ofNY-ESO-1 and amino acids 281-295 ofMAGE-3 SLLMWITOCFLPVFOLVFSKLENGGFPYETSYVKVT.HHMWTSG C35 Peptide/Epitope Exemplary Tumor Rejection Peptide Exemplary Polytopes :G81'-L89 ofSEQ ID NO:2 GGFPYEKDL k amino acids 1<>1-169 ofMAGE-1 GGFPYEKDLEADPTGHSY.

EADPTGHS Y GGFPYEKDLEADPTGHS Y amino acids 230-238 ofMAGE-1 GGFPYEKDLSA YGEPRKL.

SAY GEPRKLGGFP YEKDLSAYGEPRKL amino acids 168-176 ofMAGE-3 GGFPYEKDLEVDPIGHLY. EVDPIGHLYGGFPYEKDLEVDPIGHLY amino acids 271-279 ofMAGE-3 GGFPYEKDLFLWGPRALV. FLWGPRALVGGFPYEKDLFLWGPRALV amino acids 167-176 ofMAGE-3 GGFPYEKDLMEVDPIGHLY. MEVDPIGHLYGGFPYEKDLMEVDPIGHLY amino acids 2-10 of BAGE GGFPYEKDLAARAVFLAL. AARAVFLALGGFPYEKDLAARAVFLAL amino acids 9-16 of GAGE-1,2 GGFPYEKDLYRPRPRRY. YRPRPRRY GGFPYEKDLYRPRPRRY amino acids 11-20 of RAGE GGFPYEKDLSPSSNRIRNT. spssnrirntggfpyekdlspssnriRnt amino acids 23-32 of CDK4 GGFPYEKDLACDPHSGHFV. ACDPHSGHFVGGFPYEKDLACDPHSGHFV amino acids 29-37 of P-catenin GGFPYEKDLSYLDSGIHF. SYLDSGIHFGGFPYEKDLSYLDSGIHF amino acids 1-9 of tyrosinase GGFPYEKDLMLLAVLYCL. MLLAVLYCLGGFPYEKDLMLLAVLYCL amino acids 206-214 of tyrosinase GGFPYEKDLAFLPWHRLF. AFLPWHRLFGGFPYEKDLAFLPWHPLF C35 Peptide/Epitope Exemplary Tumor Rejection Peptide Exemplary Polytopes amino acids 56-70 of tyrosinase GGFPYF.TCDT .("VNTT .T .SN APT GPOFP. ONILLSNAPLGPOFPGGFPYEKDLONILLSNAPLGPOFP amino acids 448-462 of tyrosinase GGFPYEKDLDYSYLODSDPDSFOD. DYSYLODSDPDSFODGGFPYEKDLDYSYLODSDPDSFOD amino acids 32-40 of Melan-AMART"1 GGEPYEKDLJLTVILGVL. JLTVILGVLGGFPYEKDLJLTVILGVL amino acids 154-162 of gpl00RBrtl7 GGFPYEKDLKTWGO YW O V. •KTWGOYWOVGGFPYEKDLKTWGOYWOV amino acids 209-217 of gpl00pm*u7 GGFPYEKrjLITDOVPFSV. ITDOVPFSVGGFPYEKDLITDOVPFSV amino acids 280-288 of gpl00Prael17 GGFPYEKDLYLEPGPVTA. YLEPGPVTAGGFPYEKDLYLEPGPVTA amino acids 457-466 of gpl00?mel17 GGFPYEKDLLLDGTATLRL. LLDGTATLRLGGFPYEKDLLLDGTATLRL amino acids 476-485 of gpl00pmel17 GGFP YEKDLVLYRYGSFS V.

VLYRY GSFSV GGFPYEKDLVLYRYGSFSV ammo acids 301-309 of PRAME GGFPYEKDLLYVDSLFFL. LYVDSLFFLQGFPYEKDLLYVDSLFFL amino acids 292-303 of MAGE-6 GGFPYEKDLKISGGPRISYPL. KISGGPRISYPLGGFPYEKDLKISGGPPTSYPT. amino acids 157-167 ofNY-ESO-1 GGFPYEKDLSLLMWITOCFL. SLLMWITOCFLGGFpyEKDLSLLMWITOCFL amino acids 157-165 ofNY-ESO-1 GGFPYEKDLSLLMWITOC. SLLMWITOCGGFPYEKDLSLLMWITOG C35 Peptide/Epitope Exemplary Tumor Rejection Peptide Exemplary Polytopes ammo acids 155-163 ofNY-ESO-1 GGFPYEKDLOLSLLMW1T. OLSLLMWTTGGFPYEKDLOLSLLMWIT amino acids 157-170 ofNY-ESO-1 and amino acids 281-295 ofMAGE-3 SLLMWITOCFLPVFGGFPYEKDI .TSYVKVLHHMVKISG K104-C112 of SEQ ID NO:2 KTTNSRPPC amino acids 161-169 ofMAGE-1 KITNSRPPCEADPTGHSY. EADPTGHSYKITNSRPPCEADPT 3HSY amino acids 230-238 ofMAGE-1 KITNSRPPCSAYGEPRKL. SAYGEPRKLKTTNSRPPCSAYGE PRKL amino acids 168-176 ofMAGE-3 KITNSRPPCEVDPTGHLY. EVDPIGHLYKITNSRPPCEVDPIG HLY amino acids 271-279 ofMAGE-3 KITNSRPPCFLW GPRALV. FLWGPRALVKITNSRPPCFLWGF RALV amino acids 167-176 ofMAGE-3 KITNSRPPCMEVDPIGHLY. MEVDPIGHLYKITNSRPPCMEVE PIGHLY amino acids 2-10 of BAGE KITNSRPPCAARA VFLAL. AARAVFLALKITNSRPPCAARA\ FLAL amino acids 9-16 of GAGE-1,2 KITNSRPPCYRPRPRRY. YRPRPRRYKITNSRPPCYRPRPRI LY amino adds 11-20 of RAGE KITNSRPPCSPSSNRIRNT. SPSSNRIRNTKITNSRPPCSPSSNR IRNT amino adds 23-32 of CDK4 KITNSRPPCACDPHSGHFV. ACDPHSGHFVKITNSRPPCACDP JSGHFV amino adds 29-37 of 0-catenin K3TNSRPPCSYLDSGIHF. SYLDSGfflFKTINSRPPCSYLDSG HF C35 Peptide/Epitope Exemplary Tumor Rejection Peptide Exemplary Polytopes amino acids 1-9 of tyrosinase KITNSRPPCMLLAVLYCL.

MLLAVLY CLKITNSRPPCMLLA VLY CL amino acids 206-214 of tyrosinase KITNSRPPCAFLPWHRLF. AFLPWHRLFKITNSRPPCAFLPWHRLF amino acids 56-70 of tyrosinase KITNSRPPCONILLSNAPLGPOFP. ONILLSNAPLGPOFPKITNSRPPCONILLSNAPLGPOFP amino acids 448-462 of tyrosinase KTTNSRPPCDYSYLODSDPDSFOD. DYSYLODSDPDSFODKTINSRPPCDYSYLODSDPDSFOD amino acids 32-40 of Melan-AMAST"1 KITNSRPPCJLTVILGVL. JLWILGVLKT^SRPPCJLTVILGVL amino acids 154-162 of gplOO^1"117 KITNSRPPCKTW.GOYWOV. KTWGOYWOVKITNSRPPCKTWGOYWOV amino acids 209-217 ofgpl00pmen7 KITNSRPPCITDOVPFSV. TTDOVPFSVTCITNSRPPCITDOVPFSV amino acids 280-288 of gplOO*"*117 KITNSRPPCYLEPGPVTA. YLEPGPVTAKITNSRPPCYLRPGPVTA amino acids 457-466 of gplOO*"*117 KITNSRPPCLLDGTATLRL. LLDGTATLRLKnrNSRPpCLLDGTATLRL amino acids 476-485 of gpl00Prael17 KITNSRPPCVLYRYGSFSV. VLYRYGSFSVPTNSRPPCVLYRYGSFSV amino acids 301-309 of PRAME KITNSRPPCLYVDSLFFL. LYVDSLFFLKITNSRPPCLYVDSLFFL amino acids 292-303 of MAGE-6 KITNSRPPCKISGGPRISYPL. KISGGPRISYPLKTTNSRPPCKISGGPRISYPL C35 Peptide/Epitope Exemplary Tnmor Rejection Peptide Exemplary Polytopes amino acids 157-167 ofNY-ESO-1 KITNSRPPCSLLMWITOCFL. SLLMWITQCFLKrrNSRPPCSLLMWrrQCFL amino acids 157-165 ofNY-BSO-1 KITNSRPPCSLLMWITOC. SLLMWITOCEJTNSRPPCSLLMWITOC amino acids 155-163 ofNY-ESO-1 KITNSRPPCOLSLLMWIT. OLSLLMWITKITNSRPPCOLSLLMWIT amino acids 157-170 ofNY-ESO-1 and amino acids 281-295 ofMAGE-3 SLLMWITbCFLPVFKITNSRPPCTSYVKVLHHMVKISG K104-V113 ofSEQ ID NO:2 KTINSRPPCV amino acids 161-169 of MAGE-1 KITNSRPPCVEADPTGHSY. EADPTGHSYKirNSRPPCVEADPTGHSY amino acids 230-238 of MA.GE-1 KTTNSRPPCVS AYGEPRKL.

SAY GEPRKLKITNSRPPCVS A YGEPRKL amino acids 168-176 ofMAGB-3 KITNSRPPCVEVDPIGHLY. EVDPIGHLYKITNSRPPCVEVDPIGHLY amino acids 271-279 ofMAGB-3 KTINSRPPCVFLWGPRALV. FLWGPRALVKJTNgRPPCVFLWGPRALV amino acids 167-176 ofMAGE-3 KITNSRPPCVMEVDPIGHLY. MEVDPIGHLYKITNSRPPCVMBVDPIGHLY amino acids 2-10 of BAGE KITNSRPPCVAARAVFLAL. AARAVFLALKITNSRPPCVAARAVFLAL amino acids 9-16 of GAGE-1,2 KITNSRPPCVYRPRPRRY. YRPRPRRYKITNSRPPCVYRPRPRRY amino acids 11-20 of RAGE KITNSRPPCVSPSSNRIRNT. SPSSNRIRNTKITNSRPPCVSPSSNRIRNT C35 Peptide/Epitope Exemplary Tumor Rejection Peptide Exemplary Polytopes ' ■ amino acids 23-32 of CDK4 KITNSRPPCVACDPHSGHFV. ACDPHSGHFVKITNSRPPCVACDPHSGHFV amino acids 29-37 of (3-catenin KITNSRPPCVSYLDSGIHF. SYLDSGIHFKTINSRPPCVSYLDSGIHF amino acids 1-9 of tyrosinase KITNSRPPCVMLLAVLYCL.

MLLA VLY CLKITNSRPPCVMLLAVLY CL amino acids 206-214 of tyrosinase KITNSRPPCVAFLPWHRLF. AFLPWHRLFKITNSRPPCVAFLPWHRLF amino acids 56-70 of tyrosinase KTTNSRPPCVONILLSNAPLGPOFP. ONILLSNAPLGPOFPKITNSRPPCVONILLSNAPLGPOFP amino acids 448-462 of tyrosinase KTTNSRPPCVDYSYLODSDPDSFOD. DYSYLODSDPDSFODKlTNSRPPqVDYSYLODSDPDSFOD amino acids 32-40 ofMelan-AMART"1 KITNSRPPCVJLTVILGVL. JLTVILGVLKrmSRPPCVJLTVILGVL amino acids 154-162 of gplOO5™117 KITNSRPPCVKTWGOYWOV. KTWGOYWOVKtTNSRPPCVKTWGOYWOV amino acids 209-217 of gpl00pfflel17 KITNSRPPCVITDOVPFSV. ITDOVPFSVKITNSRPPCVITDOVPFSV amino acids 280-288 of gplOO*1"117 KITNSRPPCVYLEPGPVTA. YLEPGPVTAKTTNSRPPCVYLEPGPVTA amino acids 457-466 of gplOO*1*117 KITNSRPPCVLLDGTATLRL. LLDGTATLRLIOTNSRPPCVLLDGTATLRT. amino acids 476-485 of gplOOPme117 KITNSRPPCWLYRYGSFS V.

VLYRY GSFS VKTTNSRPPCVVLYRY GSFS V C35 Peptide/Epitope Exemplary Tumor Rejection Peptide Exemplary Polytopes t ■ • amino acids 301-309 of PRAME KITNSRPPCVLYVDSLFFL. T YVDSLFFLKITNSRPPCVLYVDSLFFL amino acids 292-303 of MAGE-6 1KITNSRPPCVKISGGPRISYPL. KISGGPRISYPLKITNSRPPCVKISGGPRISYPL amino acids 157-167 ofNY-ESO-1 KTTNSRPPCVSLLMWITOCFL. SLLMWITOCFLKITNSRPPCVSLLMWITOCFL amino acids 157-165 ofNY-ESO-1 KITNSRPPCVSLLMWITOC. SLLMWITOCKITNSRPPCVSLLMWITOC amino acids 155-163 ofNY-ESO-1 KITNSRPPCVOLSLLMWIT. OLSLLMWITKITNSRPPCVOLSLLMWIT !• amino acids 157-170 ofNY-ESO-1 and amino acids 281-295 of MAGE-3 SLLMWITOCTLPWKTmSRPPCVTSYVKVLHHMWISG ,1105 - VI13 ofSEQ ID NO:2 sITNSRPPCV amino acids 161-169 ofMAGE-1 ITNSRPPCVEADPTGHSY. EADPTGHSYITN SRPPCVEADPTGHSY amino acids 230-238 ofMAGE-1 ITNSRPPCVSAY GEPRKL. SAYGEPRKLITNSRPPCVSAYGEPRKL amino acids 168-176 ofMAGE-3 ITNSRPPCVEVDPIGHLY. EVDPIGHLYITNSRPPCVEVDPIGHLY amino acids 271-279 ofMAGE-3 ITNSRPPCVFLWGPRALV. FLWGPRALVITNSRPPCVFLWGPRALV amino acids 167-176 ofMAGE-3 ITNSRPPCVMEVDPIGHLY. MEVDPIGHLYITNSRPPCVMEVDPIGHLY amino acids 2-10 of BAGE ITNSRPPCVAARA VFLAL. AARAVFLALITNSRPPCVAARA VFLAL L05 • - r-j.j, C235 Peptide/Epitope Exemplary Tumor Rejection Peptide Exemplary Polytopes amino acids 9-16 of GAGE-1,2 TTNSRPPCVYRPRPRRY. YRPRPRRYITNSRPPCVYRPRPRRY amino acids 11-20 of RAGE / ITNSRPPCVSPSSNRIRNT. SPSSNRIRNTIXNSRPPCVSPSSNRIRNT amino acids 23-32 of CDK4 ITNSRPPCVACDPHSGHFV. ACDPHSGHFVTTNSRPPCVACDPHSGHFY amino acids 29-37 of P-catenin TTNSRPPCVSYLDSGIHF. SYLDSGIHFITNSRPPCVSYLDSGIHF amino acids 1-9 of tyrosinase ITNSRPPCVMLLAVLY CL.

MLLA VLY CLITNSRPPCVMLLA VLY CL amino acids 206-214 of tyrosinase ITNSRPPCVAFLPWHRLF. AFLPWHRLFITNSRPPCVAFLPWHRLF amino acids 56-70 of tyrosinase ITNSRPPCVONILLSNAPLGPOFP. ONILLSNAPLGPOFPITNSRPPCVONILLSNAPLGPOFP ami no acids 448-462 of tyrosinase ITNSRPPCVDYSYLODSDPDSFOD. DYSYLODSDPDSFODITNSRPPCVDSYLODSDPDSFOD amino acids 32-40 ofMelan-AMART"1 ITNSRPPCV JLTVILGVL. JLTVILGVLITNSRPPCVJLTVILGVL amino acids 154-162 of gpl00PmeU7 ITNSRPPCVKTWGOYWOV.

KTW GO YW OVITNSRPPCVKTW GO YW Q V amino acids 209-217 of gpl00ftmU7 ITNSRPPCVITDOVPFSV. ITDOVPFSVITNSRPPCVITDOVPFSV amino acids 280-288 ofgplOOPn*"7 ITNSRPPCVYLEPGPVTA. YLEPGPVTAITNSRPPCVYLEPGPVTA 4 C35 Peptide/Epitope Exemplary Tumor Rejection Peptide Exemplary Polytopes ! amino acids 457-466 of gplOO*""117 ITNSRPPCVLLDGTATLRL. lldgtatlrlitnsrppcvlldgtatlrl amino acids 476485 of gpl00pmel17 ITNSRPPCWLYRY GSFSV.

VLYRYGSFSVITNSRPPCVVLYRY GSFS V amino acids 301-309 of PRAME ITNSRPPCVLYVDSLFFL. LYVDSLFFLITNSRPPCVLYVDSLFFL amino acids 292-303 of MAGE-6 ITNSRPPCVKISGGPRISYPL. KISGGPRISYPLITNSRPPCVKISGGPRISYPL amino acids 157-167 ofNY-ESO-1 ITNSRPPCV SLLMWTTOCFL. SLLMWITOCFLITNSRPPCVSLLMWITOCFL amino acids 157-165 ofNY-ESO-1 rmsRPPCvsLLMwrroc. SLLMWITOCITNSRPPCVSLLMWTTOC amino acids 155-163 ofNY-ESO-1 ITNSRPPCV OLSLLMWIT. OLSLLMWniTNSRPPCVOLSLLMWIT • amino acids 157-170 ofNY-ESO-1 and amino acids 281-295 ofMAGE-3 SLLMWTTOCFLPVmNSRPPCVTSYVKVLHHMW.TSG 1 TlOl - VI13 of SEQ ED NO:2 TLEKITNSRPPCV amino acids 161-169 of MAGEsl TLEKITNSRPPCVEADPTGHSY. EADPTGHSYTLEKTTNSRPPCVEADPTGHSY amino acids 230-238 ofMAGE-1 TLEKTTNSRPPCVSAYGEPRTCL.

SAY GEPRKLTLEKITNSRPPCVSAY GEPRKL amino acids 168-176 ofMAGE-3 TLEKITNSRPPCVEVDPIGHLY.

EVDPIGHLY TLEKITNSRPPCVEVDPIGHLY amino acids 271-279 ofMAGE-3 TLEKITNSRPPCVFLWGPRALV. FLWGPRALVTLEKITNSRPPCVFLWGPRALV C35 Peptide/Epitope Exemplary Tumor Rejection Peptide Exemplary Polytopes - amino acids 167-176 ofMAGE-3 TLEKITNSRPPCVMEVDPIGHLY. MEVDPIGHLYTLEKITNSRPPCVMEVDPIGHLY amino acids 2-10 of B AGE TLEKITNSRPPCVAARA VFLAL. AARAVFLALTLEICFTNSRPPCVAARAVFLAL amino acids 9-16 of GAGE-1,2 TLEKITNSRPPCVYRPRPRRY. YRPRPRRYTLEKITNSRPPCVYRPRPRRY amino acids 11-20 of RAGE TLEKITNSRPPCVSPSSNRIRNT. SPSSNRIRNTTLEKrmSRPPCVSPSSNRIRNT amino acids 23-32 of CDK4 TLEKITNSRPPCVACDPHSGHFV. ACDPHSGHFVTLEIOTNSRPPCVACDPHSGHFV amino acids 29-37 of P-catenin TLEKITNSRPPCVSYLDSGIHF. SYLDSGIHFTLEKITNSRPPCVSYLDSGIHF amino acids 1-9 of tyrosinase TLEKJTNSRPPCVMLLAVLYCL.

MLLA VLYCLTLEKITNSRPPCVMLLA VLY CL amino acids 206-214 of tyrosinase TLEKITNSRPPCVAFLPWHRLF. AFLPWHRLFTLEKITNSRPPCVAFLPWHRLF amino acids 56-70 of tyrosinase TLEKITNSRPPCVONILLSNAPLGPOFP. ONELLSNAPLGPOFPTLEKITNSRPPCVONILLSNAPLGPOFP amino acids 448-462 of tyrosinase TLEKITNSRPPCVDYSYLODSDPDSFOD. DYSYLODSDPDSFODTLEKITNSRPPCVDYSYLODSDPDSFOD amino acids 32-40 of Melan-A1^7"1 TLEK3TNSRPPCVJLTVILGVL. JLTVILGVLTLEKITOSRPPCVJLTVILGVL amino acids 154-162 of gpl00PnBl17 TLEKITNSRPPCVKTWGOYWOV. KTWGOYWOVTLEKITNSRPPCVKTWGOYWOV :• • C35 Peptide/Epitope Exemplary Tumor Rejection Peptide Exemplary Polytopes amino acids 209-217 of gplOO*™117 TLEKITNSRPPCVITDOVPFSV. TTDOVPFSVTLEOTNSRPPCVITDOVPFSV amino acids 280-288 of gpl0GPrneU1 TLEKITNSRPPCVYLEPGPVTA. YLEPGPVTATLEKITNSRPPCVYLEPGPVTA amino acids 457-466 of gplOO*""117 TLEKITNSRPPCVLLDGTATLRL. LLDGTATLRLTLEKITNSRPPCVLLDGTATLRL amino acids 476-485 of gpl00ftnen7 TLEKITNSRPPCVVLYRY GSFSV.

VLYRY GSFS VTLEOT^SRPPCVVLYRYGSFS V amino acids 301-309 of FRAME TLEKTTNSRPPCVLYVDSLFFL. LYVDSLFFLTLEKITNSRPPCVLYVDSLFFL amino acids 292-303 of MAGE-6 TLEKITNSRPPCVKISGGPRISYPL. KISGGPRISYPLTLEKITNSRPPCVKISGGPRISYPL amino acids 157-167 of NY-ESP-1 TLEKITNSRPPCVSLLMWITOCFL. SLLMWITOCFLTLEKITNSRPPCVSLLMWITOCFL amino acids 157-165 ofNY-ESO-1 TLEKITNSRPPCVSLLMW1TOC. SLLMWITOCTLEKITNSRPPqVSLLMWITOC amino acids 155-163 ofNY-ESO-1 TLEKITNSRPPCVOLSLLMWrr. OLSLLMWITTLEKITNSRPPCVOLSLLMWIT amino acids 157-170 ofNY-ESO-1 and amino acids 281-295 ofMAGE-3 SLLMWITOC3fLPVFTLEKITNSRPPCVTSYVKVT.HHMWTSG C35 Peptide/Epitope Exemplary Tumor Rejection Peptide Exemplary Polytopes I93~ VI13 of SEQ ID NO:2 IRRASNGETLEKITNSRPP CV amino acids 161-169 ofMAGE-1 IRRASNGETLEK1TNSRPPCVEADPTGHSY. EADPTGHSYIRRASNGETLEKITISrSRPPCVEADPTGHSY amino acids 230-238 ofMAGE-1 IRRASNGETLEKrrNSRPPCVSAY GEPRKL. SAYGEPRKLIRRASNGETLEKITNSRPPCVSAYGEPRKL amino acids 168-176 ofMAGE-3 IRRASNGETLEKITNSRPPCVEVDPIGHLY. EVDPIGHLYIRRASNGETLEKITNSRPPCVEVDPIGHLY amino adds 271-279 ofMAGE-3 IRRASNGETLEKITNSRPPCVFLWGPRALV. FLWGPRALVIRRASNGETLEKITNSRPPCVFLWGPRALV amino acids 167-176 ofMAGE-3 IRRASNGETLEKITNSRPPCVMEVDPIGHLY. MEVDPIGHLYIRRASNGETLEKITNSRPPCVMEVDPIGHLY amino acids 2-10 of BAGE IRRASNGETLEKITNSRPPCVAARAVFLAL. AARAVFLALIRRASNGETLEKITNSRPPCVAARA VFLAL amino acids 9-16 of GAGE-1,2 IRRASNGETLEKITNSRPPCVYRPRPRRY. YRPRPRRYIRRASNGETLEKITNSRPPCVYRPRPRRY amino acids 11-20 of RAGE IRRASNGETLEKITNSRPPCVSPSSNRIRNT. SPSSNRIRNTtRRASNGETLEKITNSRPPCVSPSSNRTONT amino acids 23-32 of CDK4 IRRASNGETLEKITNSRPPCVARDPHSGHFV. ARDPHSGHFVIRRASNGETLEKITNSRPPCVARDPHSGHFV amino acids 29-37 of p-catenin IRRASNGETLEKITNSRPPCVSYLDSGIHS. SYLDSGIHSIRRASNGETLEKITNSRPPCVSYLDSGTHS amino acids 1-9 of tyrosinase IRRASNGETLEKITNSRPPCVMLLAVLYCL.

MLLAVLY C3JRRASNGETLEKITNSRPPCVMI,LA VT YCT. amino acids 206-214 of tyrosinase IRRASNGETLEKITNSRPPCVAFLPWHRLF. AFLPWHRLFIRRASNGETLEKITNSRPPCVAFLPWHRLF C35 Peptide/Epitope Exemplary Tumor Rejection Peptide Exemplary Polytopes i i 1 i i i I amino acids 56-70 of tyrosinase IRRASNGETLEKITNSRPPCVONILLSNAPLGPOFP. ONHJ,SNAPLGPOFPIRRASNGETLE]HTNSRPPCrVONILLSNAPLGPQFP amino acids 448-462 of tyrosinase IRRASNGETLEKITNSRPPCVDYSYLODSDPDSFOD. DYSYLODSDPDSFODIRRASNGETLEKITNSRPPCVDYSYLODSDPDSFOD amino acids 32-40 of Melan-A1^™ IRRASNGETLEKTTNSRPPCVILTVILGVL. JLTVTLGVLIRRASNGETLEKITNSRPPCVJLTVn.GVL amino acids 154-162 of gpl00pimI17 IRRA SNGETLEKITNSRPPCVKTWGO YWO V. KTWQOYWOVIRPASNGETLEKITNSRPPCVKTWGOYWOV amino acids 209-217 of gpl00pmel17 IRRASNGETLEKITNSRPPCVTLITDOVPFSV. lTDOYPFSVIRRASNGETLEKITNSRPPCVILrrDOVPFSV amino acids 280-288 of gpl00Pms117 IRRASNGETLEKITNSRPPCVYLEPGPVTA. YLEPGPVTAJRRASNGETLEIOTNSRPPCVYLEPGPVTA amino acids 457-466 of gpl00Pm'117 IRRASNGETLEKTTNSRPPCVLLDGTATLRL. LLDGTATLRLIRRASNGETLEKITNSRPPCVLLDGTATLRL amino acids 476-485 of gpl00Fmel17 IRRASNGETLEKITNSRPPCWLYRYGSFSV.

VLYRY GSFS VIRRASN GETLEKITNSRPPCVVT ,YR YGSFS V amino acids 301-309 of PRAME IRRASNGETLEKITNSRPPCVLYVDSLFFL. LYVDSLFFLIRRASNGETLEKITNSRPPCVLYVDST,FFL amino acids 292-303 of MAGE-6 IRRASNGETLEKITNSRPPCVKISGGPRISYPT,. KISGGPRISYPLIRRASNGETLEKITNSRPPqWTSGGPRISYPT, amino acids 157-167 ofNY-ESO-1 milASNGETLEKITNSRPPCVSLLMWITOCFL. SLLMWITOCFLIRRASNGETLEKITNSRPPCVSLLMWITOCFT, amino acids 157-165 ofNY-ESO-1 IRRASNGETLEKITNSRPPCVSLLMWITOC. SLLMWITQCIRRASNGETLEK1TNSRPPCVSLLMWITQC ft! ' | C35 Peptide/Epitope Exemplary Tumor Rejection Peptide Exemplary Polytopes J 1 u i amino acids 155-163 6f NY-ESO-1 TRRA SNGETLEKITNSRPPCVOLSLLMWIT. OLSTXMWITIRRASNGETLEKITNSRPPCVOLSLLMWIT ^ ' T *~t ■ T 1 ' i' amino acids 157-170 of NY-ESO-1 and amino acids 281-295 ofMAGB-3 sllmwitocflpvfirrasngetlekitnsrppcvtsyvkvlhhmvkisg i- 11 'D88-V113 ofSEQ IDNO:2 ■DLIEAIRRASNGETLEKIT ;:nsrppcv f { amino acids 161-169 ofMAGE-1 DLIEAIRRASNGETLEKITNSRPPCVEADPTGHSY. EADPTGHSYDLIEAIRRASNGETLEKITNSRPPCVEADPTGHSY amino acids 230-238 ofMAGE-1 DLIEAIRRASNGETLEKTTNSRPPCVSAY GEPRKL. RAYGEPRKLDLIEAIRRASNGETLEKITNSRPPCVSAYGEPRKL amino acids 168-176 ofMAGE-3 DLIEAIRRASNGETLEKrrNSRPPCVEVDPIGHLY. EVDPIGHLYDLIEATRRASNGETLEKITNSRPPCVEVBPIGHLY amino acids 271-279 ofMAGE-3 DLIEAIRRASNGETLEKITNSRPPCVFLWGPRALV. FLWGPRALVDLIBAIRRASNGETLEKITNSRPPCVFLWGPRALV amino acids 167-176 ofMAGE-3 DLIEAIRRASNGETLEKITNSRPPCVMEVDPIGHLY. MEVDPIGHLYDLffiAIRRASNGETLEKITNSRPPCVMEVDPIGHLY amino acids 2-10 of BAGE DLIEAIRRASNGETLEKTTNrSRPPCVAARAVFLAL. AARAVFLALDLIEAIRRASNGETLEK1TNSRPPCVAARAVFLAL amino acids 9-16 of GAGE-1,2 DLIEAIRRASNGETLEKITNSRPPCVYRPRPRRY. YRPRPRRYDLIEAIRRASNGETLEKITNSRPPCVYRPRPRRY amino acids 11-20 of RAGE DLIEAIRRASNGETLEKITNSRPPCVSPSSNRIRNT. SPSSNRIRNTDLffiAIRRASNGETLEKITNSRPPCVSPSSNRIRNT amino acids 23-32 of CDK4 DLIEAIRRASNGETLEKITNSRPPCVARDPHSGFFFV. ARDPHSGHFVDLIEAIRRASNGETLEKITNSRPPCVARDPHSGHFV amino acids 29-37 of p-catenin DLIEAIRRASNGETLEKITNSRPPCVSYLDSGIHS. SYIDSGIHSDLIEAIRRASNGETLEKITNSRPPCV SYLDSGIHS C35 Peptide/Epitope Exemplary Tumor Rejection Peptide Exemplary Polytopes amino acids 1-9 of tyrosinase DLIEAIRRASNQETLEKITNSRPPCVMLLAVLYCL. MLLAVLYCLDLIEAIRRASNGETLEKTTNSRPPCVMLLAVLYCL amino acids 206-214 of tyrosinase DLIEAIRRASNGETLBKITNSRPPCVAFLPWHRLF. AFLPWHRLFDLIEAIRRASNGETLEKITNSRPPCVAFLPWHRLF amino acids 56-70 of tyrosinase DLffiAIRRASNGETLEKITNSRPPCVONILLSNAPLGPOFP. ONILLSNAPLGPOFPDLIEAIRRASNGETLEK1TNSRPPCVONILLSNAPLGPOFP amino acids 448-462 of tyrosinase DLIEAIRRASNGETLEKrrNSRPPCVDYSYLODSDPDSFOD. DYSYLODSDPDSFODDLIEAIRRASNGETLEKITNSRPPCVDYSYLODSDPDSFOD amino acids 32-40 of Melan-AMART*1 DLIEAIRRASNGETLEKITNSRPPCVJLTVILGVL. JLTVILGVLDLIEAIRRASNGETLEKITNSRPPCVJLTVILGVL amino acids 154-162 of gpl00Pm4'17 DLIEAIRRASNGETLEKITNSRPPCWTWGOYWOV. ICTWGOYWOVDLIEAIRRASNGETLEKTTNSRPPCVKTWGOYWOV amino acids 209-217 of gpl00pmel17 DLIEAIRRASNGETLEKITNSRPPCVITDOVPFSV. rTDOVPFSVDLIEAIRRASNGETLEKTTNSRPPCVITDOVPFSV amino acids 280-288 ofgpl00Pme"7 DL1EAIRRASNGETLEKITNSRPPCVYLEPGPVTA. YLEPGPVTADLIEAIRRASNGETLEKITNSRPPCVYLEPGPVTA amino acids 457-466 of gpl00pmem DLffiAIRRASNGETLEKITNSRPPCVLLDGTATLRL. LLDGTATLRLDLIEAIRRASNGETLEKITNSRPPCVLLDGTATLPL amino acids 476-485 of gpl00pmel!7 DLIEAIRRASNGETLBKITNSRPPCWLYRYGSFSV. VLYRYGSFSVDLIEAIRRASNGETLEKITNSRPPCWLYRYGSFSV amino acids 301-309 of PRAME DLIEAIRRASNGETLEKITNSRPPCVLYVDSLFFL. LYVDSLFFLDLIEAIRRASNGETLEKrrNSRPPCVLYVDSLFFT. amino acids 292-303 of MAGE-6 DLffiAIRRASNGETLEKITNSRPPCVKISGGPRISYPL. KISGGPRISYPLDLIEAIRRASNGETLEKTTNSRPPCYKISGGPRTRYPT. | £35 Peptide/Epitope Exemplary Tumor Rejection Peptide Exemplary Polytopes J amino acids 157-167 ofNY-ESO-1 DLIEAIRRASNGETLEKITNSRPPCVSLIMWITOCFL. STXMWTTOCFLDLlEAIRRASNGETLEKITNSRPPCVSLLMWrrOCFL amino acids 157-165 ofNY-ESO-1 DLIEATRRASNGETLEKTTNSRPPCVSLLMWITOC. SLLMWITOCDLIEAIRRASNGETLEIQTNSRPPCVSLLMWITOC amino acids 155-163 ofNY-ESO-1 DLTEATRRASNGETLEKITNSRPPCVOLSLLMWIT. OLSII.MWTTDLIEAIRRASNGETLEEITNSRPPCVOLSLLMWIT i amino acids 157-170 ofNY-ESO-1 and amino acids 281-295 ofMAGE-3 SLLMWITOCFLPVFDLIEAIRRASNGETLEKITNSRPPCVTSYVKVLHHMVKISG P84 - VI13 of SEQ ID NO:2 PYEKDLIEAIRRASNGET LEKJTNSRPPCV ammo acids 161-169 ofMAGE-1 PYEKDLIEAIRRASNGETLEmNSRPPCVEADPTGHSY. EADPTGHSYPYEKDLffiAIRRASNGETLEKITNSRPPCVEADPTGHSY amino acids 230-238 of MA.GE-1 PYEKDLIEAIRRASNGETLEKITNSRPPCVSAYGEPRTCL. SAYGEPRKLPYEKDLIEAIRRASNGETLEKITNSRPPCVSAYGEPRKL amino acids 168-176 ofMAGE-3 PYEKDLIEArRRASNGETLEKITNSRPPCVEVDPIGHLY. EVDPIGHLYPYEKDLIEAIRRASNGETLEKm^SRPPCVEVDPIGHLY amino acids 271-279 ofMAGE-3 PYEKDLIEAIRRASNGETLEKITNSRPPCVFLWGPRALV. FLWGPRALVPYEKDLIEAIRRASNGETLEKITNSRRPCVFLWGPRAT.V amino acids 167-176 ofMAGE-3 PYEKDLIEAIRRASNGETLEKrrNSRPPCVMEVDPrGHLY. MEVDPIGHLYPYEKDLIEAIRRASNGETLEKITN'SRPPCVMEVDPTGHLY amino acids 2-10 of B AGE PYEKDLIEAIRRASNGETLEKnNSRPPCVAARAVFLAL.

AARAVFLALPYEKDL1EAIRRASNGETLEKITNSRPPCVAAR AVFT.AT, amino acids 9-16 of GAGE-1,2 PYEKDLIEAIRRASNGETLEKITNSKPPCVYRPRPRPY. yrprprrypyekdlieairrasngetlekitnsrppcvyrprprry amino acids 11-20 of RAGE PYEKDLIEAIRRASNGETLEKITNSRPPCVSP.qSNRTT?NT. SPSSNRlRNTPYEKDLffiAIRRASNGETLEKITNSRPPCVSPSSNRJRNT C35 Peptide/Epitope Exemplary Tumor Rejection Peptide Exemplary Polytopes amino acids 23-32 of CDK4 PYEKDLmAIRRASNQETLEiaTNSRPPCVARDPHSGHFV. ARDPHSGHFVPYEKDLffiAIRRASNGETLEKITNSRPPCV ARDPHSGHFV amino acids 29-;37 of p-catenin PYEKDLIEAIRRASNGETLEK1TNSKPPCVSYLDSGIHS. SYLDSGIHSPYEKDLffiAIRRASNGETLEKITNSRPPqVSYLDSGfflS amino acids 1-9 of tyrosinase PYEKDLIEAIRRASNGETLEKTTOSRPPGVMLLAVLYCL. MLLAVLYCLP YEKDLIEAIRRASNGETLEKITNSRPPCVMLL A VLY CL amino acids 206-214 of tyrosinase PYEKDLEAIRRASNGETLEKITNSRPPCVAFLPWHRLF. AFLPWHRLFPYEKDLIEAIRRASNGETLEKITNSRPPCVAFLPWHRLF amino acids 56-70 of tyrosinase PYEKDLIEAIRRASNGETLEKTTNSRPPCVONTLLSNAPLOPOFP. ONILLSNAPLGPOFPPYEKDLIEAIRRASNGETLEKITNSRPPCVONILLSNAPLGPOFP amino acids 448-462 of tyrosinase PYEKDLIEAIRRASNGETLEKrrNSRPPCVDYSYLODSDPDSFOD. DYSYLODSDPDSFODPYEKDLffiAIRRASNGETLEKITNSRPPCVDYSYLODSDPDSFOr) amino acids 32-40 ofMelan-AMART"1' PYEKDLIEAIRRASNGETLEKITNSRPPCVJLTVILGVL. JLTVILGVLP YEKDLTEAIRRASNGETLEK1TNS'RPPCVIT..TVTT .GVL amino acids 154-162 of gplOO*"*117 PYEKDLffiAIRRASNGETLEKITNSRPPCVKTWGOYWOV. KTWGOYWOVPYEKDLIEAIRRASNGETLEKlTNrSRPPCVKTWGOYWOV amino acids 209-217 of gpl00Pme,n PYEKDLIEAIRRASNGETLEKrrNSRPPCVITDOVPFSV. ITDOVPFSVPYEKDLlEAIKRASNGETLEKirNSRPPCVTTnOVPFSV amino acids 280-288 of gplOO*1™117 PYEKDLffiAIRRASNGETLEKITlSrSRPPCVYLEPGPVTA. YLEPGPVTAPYEKDLIEAIRRASNGETLEKlTNSRPPqVYLEPGPVTA amino acids 457-466 of gplOOPme117 PYEKDLffiAIRRASNGETLEKITNSRPPCVLLDGTATT.PT. LLDGTATLRLPYEKDLEEAIRRASNGETLEKITNrSRPPqVTXDGTATT.RT. amino acids 476-485 of gpl00PnwU7 PYEKDLIEAIRRASNGETLEKITNSRPPCVVLYRYGSFSV. VLYRYGSFSVPYEKDLIEAIRRASNGETLEKITNSRPPCWLYRYGSFSV C35 Peptide/Epitope Exemplary Tumor Rejection Peptide Exemplary Polytopes amino acids 301-309 of PRAME PYEKDLIEAIRRASNGETLEKrmSRPPCVLYVDSLFFL. LYVDSLFFLPYEKDLIEAIRRASNGETLEKITNSRPPCVLYVDSLFFL amino acids 292-303 ofMA.GE-6 PYEKDLIEAIRRASNGETLEKITNSRPPCVKISGGPRISYPL. KISGGPRISYPLPYEKDLIEAIRRASNGETLEKITNSRPPCVKISGGPRISYPL amino acids 157-167 ofNY-ESO-1 PYEKDLIEAIRRASNGETLEKITNSRPPCVSLLMWITOCFL. 55LLMWITOCFLPYEKDLTEAIRRASNGETLEKITNSRPPCVSLLMWITOCFL amino acids 157-165 ofNY-ESO-1 PYEKDLffiAIRRASNGETLEKITNSRPPCVSLLMWITOC. SLLMWITOCPYEKDLIEAIKRASNGETLEKITNSRPPCVSLLMWITOC amino acids 155-163 ofNY-ESO-1 PYEKDLffiArRjRASNGETT.EKITNSRPPCVOLSLLMWIT. OLSLLMWITPYEKOLIEATRRASNGETLEKITNSRPPCVOLSLLMWIT amino acids 157-170 ofNY-ESO-1 and amino acids 281-295 ofMAGE-3 SLLMWITOCFLPVFPYEKDLIEAIRRASNGETLEiaTNSRPPCVTSYVKVLHHMVKISG ;K77 - VI13 of SEQ ID NO:2 KLEN GGFP YEKDLIEAIR jRASNGETLEKITNSRPPCV amino acids 161-169 ofMAGE-1 KLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPCVEADPTGHSY. EADPTGHSYKLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPCV EADPTGHSY amino acids 230-238 ofMAGE-1 KLENGGFPYEKDLIEAIRRASNGETLEKrmSRPPCVSAYGEPRKL. SAYGEPRKLKLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPCVSAYGEPRKL amino acids 168-176 ofMAGE-3 KLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPCVEVDPIGHLY. EVDPIGHLYKLENGGFPYEEDLIEAIRRASNGETLEErrNSRPPCVEVDPTGHT.Y amino acids 271-279 ofMAGE-3 KLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPCVFLWGPRALV. FLWGPRALVKLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPCVFLWGPRALV amino acids 167-176 ofMAGE-3 KLENGGFPYEKDLIEAmRASNGETLEKITNSRPPCVMEVDPIGHLY. MEVDPIGHLYKLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPCVMEVDPTGHLY amino acids 2-10 of BAGE KLENGGFPYEKDLIEAIRRASNGETLEKrrNSRPPCVAARA VFLAL. AARAVFLALKLENGGFPYEKDLIEAIRRASNGETLEKTTMSRPPnVA AR A VFT.AL £35 Peptide/Epitope Exemplary Tumor Rejection Peptide Exemplary Polytopes amino acids 9-16 of GAGE-1,2 TTT.P.'KfGGFPYEKDLIEAIRRASNGETLEIQTNSRPPCVYRPRPRRY.

YRPRPRRYKLENGGFPYEKDLffiAIRRASNGETLEKrmSRPPCVYRPKPRRY amino acids 11-20 of RAGE KIF>TOGFPYEKDLffiAIRRASNGETLEKITNSRPPCVSPSSNRIRNT.

SPSRNRIRNTELENGGFPYEKDLIEAIRRASNGETLEKITHSRPPCVSPSSNRIRKT amino acids 23-32 of CDK4 KLENGGFPYEKDLffiAIRRASNGETLEKITNSRPPCVARDPHSGHFV.

ARDPHSGHFVKLENGGFPYEKDLffiAIRRASNGETLEKITNSRPPCVARDPHSGHFV amino acids 29-37 of P-catenin KLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPCVSYLDSGIHS.

SYLDSGIHSKLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPCVSYLDSGIHS amino acids 1-9 of tyrosinase KLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPCVMLLAVLY CL.

MLLA VLY CLKLENGGFP YEKDLIEArflRASNGETLEKITNSRPPCVMLLA VLY CL amino acids 206-214 of tyrosinase KLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPCVAFLPWHRLF.

AFLPWHRLFKLENGGFPYBKDLIEAIRRASNGETLEKITNSRPPCVAFLPWHRLF amino acids 56-70 of tyrosinase KLENGGFP YEKDLIEAIRRASNGETLEKITNSRPPCV ONTLLSNA PLGPOFP.

ONILLSNAPLGPOFPKLENGGFPYEKDLIEATRRA55NGETLEKITNSRPPCVONTT .T .SNAPIG PQFP amino acids 448-462 of tyrosinase KLENGGFP YEKDLIEAIRRASNGETLEKITNSRPPCVDYSYLODSDPDSFQT) DYSYLODSDPDSFODKLENGGFPYEKDLIEAlRRAS5NGETLEKTTMSRPPCVDY«rYr.Or>RT> PDSFQD amino acids 32-40 ofMelan-AMART"1 KLENGGFPYEKDLIEAIRRASNGETLEKrmSRPPCVJLTVILGVL.

JLTVILGVLKLENGGFPYEKDLffiAIRRASNGETLEKrrNSRPPCVJLTVTT.GVT. amino acids 154-162 of gpl00Pm'n7 KLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPCVK.TWGOYWOV.

KTWGOYWOVKLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPCVKTWGOYWOV amino acids 209-217 of gpl00Pm5in KLENGGFP YEKDLIEAIRRASNGETLEK1TNSRPPCVTLTTDOVPFSV ITDOVPFSVKLENGGFPYEKDLIEAIRRASNGETLEKrrNSRPPCVILTTDOVPFSV C35 Peptide/Epitope Exemplary Tumor Rejection Peptide Exemplary Polytopes 4 amino acids 280-288 of gplOO*1™117 KLENGGFPYEKDLIEAIRRASNGETLEKrrNSRPPCVYLEPGPYTA.

YLEPGPVTAKLENGGFPYEKDLIEAIRRASNGETLEKITNSKPPCVYLEPGPVTA amino acids 457466 of gpl00pm!m KLENGGFPYEKDLIEAIRRASNGETLEKITOSRPPCVLLDGTATLRL.

LLDGTATLRLKLENGGFPYEKDLIEAIRRASNGETLEOTNrSRPPCVLLDGTATLRL amino acids 476485 of gplOO®""117 KLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPCVVLYRYGSFSV.

VLYRYGSFSVKLENGGFPYEKDLIEAIRRASNGETLETCrTOSRPPCWLYRYGSFSV amino acids 301-309 of PRAME KLENGGFPYEKDLIEAIRRASNGETLEKrrNSRPPCVLYVDSLFFL.

LYVDSLFFLKLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPCVLYVDSLFFL amino acids 292-303 of MAGE-6 KLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPCVfCISGGPRISYPL. kisggprisyplklengofpyrttdt .tp. a TRRASNGETLEKITNSRPPCVKISGGPRISYPL amino acids 157-167 of NY-ESO-l KLENGGFPYEKDLlEAmRASNGETLEKlTNSRPPCVSTJMWTTOCFT,.

SLLMWITOCFLKLENGGFPYEKDLIEAIRRASNGETLEKTTNr§RPPCVSLT,MWTTOCFL amino acids 157-165 ofNY-ESO-1 KLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPCVSLLMWTTGC.

SLLMWITOCKLENGGFPYEKDLIEAIRRASNGETLEKrrNSRPPCVSLLMWTTOC amino acids 155-163 ofNY-ESO-1 KLENGGFPYEKDLIEAIRRASNGETLEiaTNSRPPCVOLSLLMWIT.

OLSLLMWITKLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPCVOLSLLMWrr amino acids 157-170 ofNY-ESO-1 and amino acids 281-295 ofMAGE-3 SLLMWITOCFLPVFKLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPCVTSYVKVLHHM VKISG Q72-V113 ofSEQ ID NO:2 qlvfsklenggfpyekd LIEAIRRASN QETLEKITN SRPPCV amino acids 161-169 ofMAGE-1 OLVFSKLENGGFPYEKDLIEAIRRASNGETLEKrTOSRPPnVF,adptgtt2v EADPTGHSYOLVFSKLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPCVEADPTGHSY amino acids 230-238 ofMAGE-1 OLVFSKLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPCVSAYGEPR-KL.

SAY GEPRKLOLVFSKLENGGFP YEKDLIEAIRRASNGETT.EKTTN'SR PPCV55 A Y GFPR K"T. amino acids 168-176 ofMAGE-3 OLVFSEXENGGFPYEKDLIEArRRASNGETLEICITNSRPpGVF.VDPTGTTTY, evdpighlyolvfsklenggfpyekdlieairrasngett.ekttmsrppcvevdpighly \ C35 Peptide/Epitope Exemplary Tumor Rejection Peptide Exemplary Polytopes i s i !' i : i r 1 i 1: j: amino acids 271-279 ofMAGE-3 OLVFSKLENGGFPYEKDLffiAIRRASNGETLEKITNSRPPCVFLWGPRALV.

FLWGPRALVOLVFSKLENGGFPYBKDIJEAffiRASNGETLEKrmSRPPCVFLWGPRALV amino acids 167-176 ofMAGE-3 OLVFSKLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPCVMEVDPIGHLY.

MEVDPIGHLYOLVFSKLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPCVMEVDPIGHLY amino acids 2-10 of BAGE OLVFSKLENGGFPYEKDLIEAIRRASNGETLEK1TNSRPPCVAARAVFLAL.

AARAVFLALOLVFSELENGGFPYEKDLIEAIRRASNGETLEKITNSRPPCVAARAVFLAL amino acids 9-16 of GAGE-1,2 OLVFSKLENGGFPYEKDLIEATRRASNGETLEKITNSRPPCVYRPRPRRY.

YRPRPRRY OLVFSKLEN GGFPYEKDLIEAIRRASNGETLEKITNSRPPCVYRPKPRRY amino acids 11-20 of RAGE OLVFSKLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPCVSPSSNPTRNT.

SPSSNRIRNrOLVFSKLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPCVSPSSNRIRNT amino acids 23-32 of CDK4 OLVFSKLENGGFPYEKDLTEAIRRASNGETLEKrmSRPPCVARDPHSGHFV.

ARDPHSGHFVOLVFSKLENGGFPYEKDLIEAIRBASNGETLEKITNSRPPCVARDPHSGHFV amino acids 29-37 of p-catenin OLVFSKLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPCVSYLDSGIHS.

SYLDSGmSOLVFSKLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPCVSYLDSGIHS amino acids 1-9 of tyrosinase OLVFSKLENGGFPYEICDLIEAIRRASNGETLEKITNSRPPCVMLLAVLYCL.

MLLAVLY CLOLVFSKLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPCVMLLAVLY CL amino acids 206-214 of tyrosinase OLVFSKLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPCVAFLPWHRLF.

AFLPWHRLFOLVFSKLENGGFPYEKDLIEAIKRASNGETLEKrmSRPPCVAFLPWHRLF amino acids 56-70 of tyrosinase OLVFSKLENGGFPYEKDLIEAlRRASNGETLEKITNSRPPCVOMTTJr.RNAPT.GPQ-pP, ONILLSNAPLGPOFPOLVFSKLENGGFPYEKDLIEArRRASNGETLEICTTN55RPPCVONTT.T.S NAPLGPQFP C35 Peptide/Epitope Exemplary Tumor Rejection Peptide Exemplary Polytopes amino acids 448-462 of tyrosinase OLVFSKLENGGFPYEKDLIEAIRRASNGETLEK1TNSRPPCVDYSYLODSDPDSFOD.

DYSYLODSDPDSFODOLVFSKLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPGVDYSY LQDSDPDSFQD amino acids 32-40 of Melan-A"^1'1 OLVFSKLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPCVJLTVTLGVL.

JLTVTLGVLOLVFSKLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPCVJLTVDLGVL amino aoids 154-162 of gplOO*""117 OLVFSKLENGGFP YEKDLIEAIRRASNGETLEK1TNSRPPCVKTW GOYW OV.

KTWGOYWOVOLVFSKLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPCVKTWGOYWOV amino acids 209-217 of gpl00!>mn7 OLVFSKLENGGFPYEKDLIEAIRRASNGETLEKITOSRPPCVITDOVPFSV.

ITDOVPFSVOLVFSKLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPCVITDOVPFSV amino acids 280-288 of gpl00Pmel17 OLVFSICLENGGFPYEEDLIEAIRRASNGETLEK3TNSRPPCVYLEPGPVTA.

YLEPGPVTAOLVFSKLENGGFPYEKDLffiAIRRASNGETLEKITNSRPPOVYLEPGPVTA amino acids 457-466 of gpl00Pmel17 OLVFSKLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPCVLLDGTATTJH..

LLDGTATLRLOLVFSKLENGGFPYEKDLIEAiRRASNGETLEKITNSRPPCVTXDGTATLRL amino acids 476-485 of gplCD*"*"7 OLVFSKLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPCWLYRYGSFSV.

VLYRYGSFSVOLVFSKLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPnWT.YRYGRFSV amino acids 301-309 of PRAME OLVFSKLENGGFPYEKDmAIRRASNGETLEKITNSRPPGVI.WnRT.FFT.

LYVDSLFFLOLVFSKLENGGFPYEKDLIEAIRRASNGBTLBKrrNSRPPCVLYVDST .FFT. amino acids 292-303 of MAGE-6 OLVFSKLENGGFPYEKDLIEATRRASNGETLEKTTNSRPPCVKTSGGPRTSYPT., KISGGPRISYPLOLVFSKLENGGFPYEKDLIEAIRRASNGETLEKlTNSRPPGVTrrSGGPRTSYPT. amino acids 157-167 ofNY-ESO-1 OLVFSKLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPCVSLLMWTTOGFT..

SLLMWTTQCFLOLVFSiCLENGGFPYEKDLIEAIRRASNGETLEKrmSRPPCVSLLMWrrQCFL C35 Peptide/Epitope Exemplary Tumor Rejection Peptide Exemplary Polytopes amino acids 157-165 ofNY-ESO-1 OLVFSKLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPCVSLLMWIT0C.

ST.LMWITOCOLVFSKLENGGFPYEKDLIEAIRPASNGETLEKITNSRPPCVSLLMWITOC amino acids 155-163 ofNY-ESO-1 OLVFSKLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPCVOLSLLMWIT.

OT.SLLMWITOLWSKLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPCVOLSLLMWIT amino acids 157-170 ofNY-ESO-1 and amino acids 281-295 ofMAGE-3 STXMWITOCFLPVFOLVFSKLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPCVTSYVKV LHHMVKISG F65 to VI13 ofSEQ ID NO:2 FEIBINGQLVFSKLENGGF PYEKDLIEAIRRASNGET 1LEKITNSRPPCV 1 amino acids 161-169 ofMAGE-1 FEIE1NGOLVFSKLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPCVEADPTGHSY.

EADPTGHSYFEIEINGOLVFSKLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPCVEADP TGHSY amino acids 230-238 ofMAGE-1 FETEINGOLVFSKLENGGFPYEKDLIEAmRASNGETLEKITNSRPPCVSAYGEPRKL. 55AYGEPRKLFEIEINGOLVFSKLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPCVSAYG EPRKL amino acids 168-176 ofMAGE-3 FEIEINGOLVFSKLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPCVEVDPTGHLY.

EVDPIGHLYFEIEINGOLVFSKLENGGFPYEKDLIEAIRRASNGETLEKTTNSRPPCVEVDPI GHLY amino acids 271-279 ofMAGE-3 FEIEINGOLVFSKLENGGFPYEKDLIEAIRRASNGETLEEITNSRPPCVFLWGP'R ALV.

FLWGPRALVFEDBINGOLVFSKLENGGFPYEKDLIEAIRRASNGETLEICTTNSRPPCWT.WG PRALV amino acids 167-176 ofMAGE-3 FETEINGOLVFSKLENGGFPYEKDLIEAmRASNGETLEKITNSPPPnVMF.VnPTGm.Y.

MEVDPIGHLYFEIEINGOLVFSKLENGGFPYE'FCDLTEArRRASNGRTT.F.KTrNrSRPPrrVVrRV DPIGHLY C35 Peptide/Epitope Exemplary Tumor Rejection Peptide Exemplary Polytopes amino acids 2-10 of BAGE FEIEINGOLVFSKLENGGFPYEKDLIEAIRRASNGETLEKTrNSRPPCVAARAVFLAL.

A ARA VFLALFEIEINGOLVFSKLENGGFPYEKDL1BAIRRASNGETLEKITNSRPPCVAARA VFLAL amino acids 9-16 of GAGB-1,2 FFJEINGOLVFSKLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPCVYRPRPRRY.

YRPRPRRYFEIEINGOLVFSKLENGGFPYEKDLIEAIRRASNGETLEKTTNSRPPCVYRPRPRRY amino acids 11-20 of RAGE FEIE1NGOLVFSKLENGGFPYEKDLIEA1RRASNGETLEKTTNSRPPCVSPSSNRIRNT.

SPSSNRTRNTFEIEINGOLVFSKLENGGFPYEKDLIEAIRRASNGETT.EKITNTSRPPCVSPSSN RIRNT amino acids 23-32 of CDK4 FEIElNGOLVFSKLENGGFPYEKDLIEAIRPASNGETLEKTrNSRPPnVARDPTTSGHFV.

ARDPHSGHFVFE1EINGOLVFSKLENGGFPYEKDLIEAIRRASNGETLEKTTNSRPPCVARD PHSGHFV amino acids 29-37 of P-catenin FEIEINGOLVFSKLENGGFPYEKDLIEAIRRASNGETLEKrrNSRPPCVSYTJDRGTFfS.

SYLDSGIHSFEIEINGOLVFSKLENGGFPYEKDLIEAIRRASNGETT.EKITNrSRPPCVSYLDS GIHS amino acids 1-9 of tyrosinase FEIEINGOLVFSKLENGGFPYEKDLIEAIRRASNGETLKaTNSRPPCVMLT.AVT.YCT,, MLLAVLY CLFEIEINGOLVFSKLENGGFPYEKDLIEAIRRASNGETT EKITNSRPPCVMLLA VLYCL amino acids 206-214 of tyrosinase FEIEINGOLVFSKLENGGFPYEKDLIEAIRRASNGETLEKTTNSRPPCVAFT.PWHPTP.

AFLPWHRLFFEIEINGOLVFSKLENGGFPYEKDLTEAIRRASNGRTT .EKTTNSRPPCV AFLP WHRLF r— : V C35 Peptide/Epitope Exemplary Tumor Rejection Peptide Exemplary Polytopes ammo acids 56-70 of tyrosinase FEEEINGOLVFSKLENQGFPYEKDLIEAIRRASNQETLEKmSrSRPPCVONILLSNAPLGPOFP.

ONILLSNAPLGPOFPFEffilNGOLVFSKLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPC VQNILLSNAPLGPQFP amino acids 448-462 of tyrosinase FElElNGOLVFSKLENGGFPYEKDLIEAIRRASNGETLEKTnSISRPPCVDYSYLODSDPDSFOD.

DYSYLODSDPDSFODFEIEINGOLVFSKLENGGFPYEKDLIEAIRRASNGETLEKITOSRPP CVDYSYLQDSDPDSFQD amino acids 32-40 of Melan-AMART*1 'FElEINGOLVFSKLENGGFPYEKDLIEAIRRASNGETr.EKITNSRPPCVJLTVn.GVL.

JLTVILGVLFEIEINGOLVFSKLENGGFPYEKDLTEAIRRASNGErLEKITNSRPPCVJLTVILGVL amino acids 154-162 of gpl00Pmel17 FEIEINGOLVFSKLENGGFPYEKDLIEAIRRASNGETLEKnNSRPPCVKTWGOYWOV.

KTWGOYWOVFEIEINGOLVFSKLENGGFPYEKDLIEATRRASNGETLEKITNSRPPCVKTW GQYWQV amino acids 209-217 of gplOO*"*117 FEIEINGOLVFSKLENGGFPYEKDLIEAIRRASNGETI-EK3TNSRPPCVTTDOVPFSV.

ITDOVPFSVFEIEINGOLVFSKLENGGFPYEKDLIEArRRASNGETT,EKITNSRPPCVTTDOV PFSV amino acids 280-288 of gpl00PraeI17 FEIEINGOLVFSKLENGGFPYEKDLIEAIRRASNGETLEFCITNSRPPCVYT.EPGPVTA.

YLEPGPVTAFEIEINGOLVFSKLENGGFPYEKDLIEATR'RASNGETT.EKTTN.SRPPr.VYT.EPG PVTA amino acids 457-466 of gpl00pmetl7 FEffilNGOLVFSKLENGGFPYEKDLlEAIRRASNGETLEiaTNSRPPCVLLDGTATLRT,.

LLDGTATLRLFEIEINGOLVFSKLENGGFPYEKDLTEAIRRASNGETT .TflOTNSRPPfTVT .T T)G TATLRL C35 Peptide/Epitope Exemplary Tumor Rejection Peptide Exemplary Polytopes amino acids 476-485 of gplOO*"1®117 FEIEINGOLVFSKLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPCWLYRYGSFSV.

VLYRYGSFSVFEIEINGOLVFSKLENGGFPYT!,T?:r>T.TF.AIRRASNGETLEKlTNSRPPCWLY RYGSFSV amino acids 301-309 of PRAME FEIEINGOLVFSKLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPCVLYVDSLFFL.

LYVDSLFFLFEIEINGOLVFSKLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPCVLYVDS LFFL amino acids 292-303 of MAGE-6 FEmiNGOLVFSKLENGGFPYEKDLTEArRRASNGETLEKTTNSPPPCVKISGGPRISYPL.

KISGGPRISYPLFEIEINGOLVFSKLENGGFPYEKDLIEAIKRASNGETLEKITNSRPPCVE3S GGPRISYPL amino acids 157-167 ofNY-ESO-1 FEIEINGOLVFSKLENGGFPYEKDLIEAmRASNGETLEKITNSRPPCVILSLLMWrrOCFL.

SLLMWITOCFLFEIEINGOLVFSKLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPCVSLL MW1TQCFL amino acids 157-165 ofNY-ESO-1 FEIEINGOLVFSKLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPCVSLLMWITOC.

SLLMWITOCFEIEINGOLVFSKLENGGFPYEKDLTEAIRRASNGETLEKITNSPPPCVSLT.M WITQC amino acids 155-163 ofNY-ESO-1 FEIEINGOLVFSKLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPCVOLSLLMWrr.

OLSLLMWITFEIEINGOLVFSKLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPCVOLSLT. MWTT amino acids 157-170 ofNY-ESO-1 and amino acids 281-295 ofMAGE-3 SLLMWITOCFLPVFFEIEINGOLVFSKLENGGFPYEKDLTEATRR ASNGETI .ETCTTNSRPPfTV TSYVKVLHHMVKISG CSS Peptide/Epitope Exemplary Tumor Rejection Peptide Exemplary Polytopes L59 - VI13 of SEQ ID NO:2 LGFGTGAFEIEINQQLVFS KLEHGGFPYEKJDLIEAIR RASNGETLEKTTNSKPPCV amino acids 161-169 ofMAGE-1 LGGTGAFEIEINGOLVFSKLENGGFPY^DLIEAIRRASNGETLEKITNSRPPCVEADPTGHSY, EADPTGHSYLGGTGAFEIEINGOLVFSKLENGGFPYEKDLIEAIRRASNGETLEKrTNSRPP CVEADPTGHSY amino acids 230-238 ofMAGE-1 LGGTGAFEIEINGOLVFSKLENGGFPYEKDLIEAIRRASNGETLEKTTNSRPPCV2AYGFPPTrr.J SAYGEPRKLLGGTGAFEIETNGOLVFSKLENGGFPYEKDLIEAIRRASNGF.TT.EKTTNSRPP CVSAYGEPRKL amino acids 168-176 ofMAGE-3 LGGTGAFEIEINGOLVFSKLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPCVEVDPTGHT.Y.

EVDPIGHLYLGGTGAFEIEINGOLVFSKLENGGFPYF.Kr)T.TP.ATT?RASNGETLFKTTNaRPPr: VEVDPIGHLY amino acids 271-279 ofMAGE-3 LGGTGAFEffilNGOLVFSKLENGGFPYEKDLTEATRRASNGETLEKTmSRPPCVFLWGPRALV.

FLWGPRALVLGGTGAFEIEINGOLVFSKLENGGFPYEKDLIEAIRRASNGETT.F.KTTNS-RPP cvflwgpralv amino acids 167-176 ofMAGE-3 LGGTGAFEIEINGOLVFSKLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPCVMEVDPTG HLY, MEVDPIGHLYLGGTGAFEIEINGOLVFSKLENGGFPYEKDLIEAIRRASNGETT,F,KTTNS-RP PCVMEVDPIGHLY amino acids 2-10 of BAGE LGGTGAFEIEINGOLVFSKLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPCVAAPAVFT.AT,.

AARAVFLALLGGTGAFEIEINGOLVFSKLENGGFPYEKDLIEAIRU A SNGP.TT JOnTMRRW CVAARAVFLAL C35 Peptide/Epitope Exemplary Tumor Rejection Peptide Exemplary Polytopes amino acids 9-16 of GAGE-1,2 T.GGTGAFEIEINGOLVFSKLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPCYYRPRPKRY; 1 yrprprrylggtgafeieingolvfsklenggfpyekdlieairrasngetlekitnsrppkS YYRPKPKRY -jg amino acids 11-20 of RAGE t/3GTGAFEIEINGOLVFSKLENGGFPYEKDLIEAIRRASNGBTLEKnNSRPPCVSPSSNRIRN^ spssnrirntlggtgafeieingolvfsklenggfpyekdlieatrrasngetlekitnsrih CVSPSSNRIR2sfT h amino acids 23-32 of CDK4 LGGTGAFEIEINGOLVFSKLENGGFPYEKDLIEAIRRASNGETLEKrTNSRPPCVARDPHM HFV, ■ ARDPHSGHFVLGGTGAFEIEINGOLVFSKLENGGFPYEKDLIEAIRRASNGETLEKITNS^ PCVARPPHSGHFV j| amino acids 29-37 of p-catemn LGGTGAFEIEINGOLVFSEXENGGFPYEKDLIEAmRASNGETLEKrrNSRPPCVSYLDSGIlJ! f.4 SYLDSGIHSLGGTGAFErEINGOLVFSKLENGGFPYEKDLIEATRRASNGETLEKITNSRPEC VSYLDSGIHS f amino acids 1-9 of tyrosinase LGGTGAFEIEINGOLVFSKLENGGFPYEKDLIEAIRRASNGETLEKrrNSRPPCVMrT.AVTYrit MLLAVLYCLLGGTGAFEIEINGOLVFSKLENGGFPYEEDLIEAIRRASNGETLEiaTNSR|^ CVMLLAVLYCL |1; amino acids 206-214 of lyrosinase LGGTGAFEKINGOLVFSKLENGGFPYEKDLIEAIRRASNGETLEKrrtSrSRPPCVAFLPWHRli' AFLPWHRLFLGGTGAFEIEINGOLVFSKLENGGFPYEKDLIEAIRRASNGETLEKTTNSRii CVAFLPWHRLF 1 C35 Peptide/Epitope Exemplary Tumor Rejection Peptide Exemplary Polytopes amino acids 56-70 of tyrosinase lggtgafereingolvfsklenggfpyekdlieairrasngetlekitnsrppcvonillsna plgpqfp, ,sf. onillsnaplgpofplggtgafe1e1ngolvfsklenggfpyekdlieairrasngetlekto NSRPPCV ONILLSNAPLGPQFP • ff amino acids 448-462 of tyrosinase lggtgafeieingolvfsklenggfpyekdlieairrasngetlekitnsrppcvdysylcj| sdpdsfqd, jj dysylodsdpdsfodlggtgafeieingolwsklenggfpyekdlteairrasngetleB tnsrppgvdysylqdsdpdsfqd j§ amino acids 32-40 ofMelan-A^7'1 lggtgafeieingolvfsklenggfpyekdlieairrasngetlekitnsrppcvjltvilgvS JLTVILGVLLGGTGAFEIEINGOLVFSKLENGGFPYEKDLIEAIRRASNGETLEKrrNSRPiS vjltvilgvl h amino acids 154-162 of gplOO*"*117 LGGTGAFEIEINGOLVFSKLENGGFPYEKDLIEAIRRASNGETLEKITNrSRPPCVKTWGO^ wqv, v ktwgoywovlggtgafeieingolvfsklenggfpyekdlieairrasngetlekitns# PCVKTWGOYWOV amino acids 209-217 of gpl00fmel17 LGGTGAFEIEINGOLVFSKLENGGFPYEKDLIEAIRRASNGETLEKrmSRPPCVITDOVPF^ itdovpfsvlggtgafeieingolvfsklenggfpyekdlffiairrasngetlektrnsrp^ vttdqvpfsv amino acids 280-288 of gpl00Pmel17 lggtgafeieingolvfsklenggfpyekdt.tratrpasngetlekttnsrppcvyt.epgpv^ YLEPGPVTALGGTGAFEIEINGOLWSKLENGGFPYEKDLTF.ATRPASNGTm.ETCTrNrSPPP CVYLEPGPVTA -= — »>'! C35 Peptide/Epitope Exemplary Tumor Rejection Peptide Exemplary Polytopes amino acids 457-466 of gpl00PmeU7 I.GGTQAFErEINGOLVFSKLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPCVLLDGTAT LRL, . LLDGTATLRLLGGTGAFEIEINGOLVFSKLENGGFPYEKDLIEAIRRASNGETLEKITNSi& PCVLLDGTATLRL Jfj amino acids 476-485 of gpl00Pme"7 T.GGTGAFEIETNGOLVFSKLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPCVVLYRY^Ij FSV' X VLYRYGSFSVLGGTGAFEIEINGOLVFSKLENGGFPYEKDLIEAIRRASNGETLEKITNS®! PCWLYRYGSFSV ( amino acids 301-309 ofPRAME lggtgafeieingolvfsklenggfpyekdlieairrasngetlekitnsrppcvlyvdslfS LYVDSLFFLLGGTGAFBIEINQOLVFSKLENGGFPYEKDLIEAtRRASNOim.KK:rrNr<n?t^ VLYVDSLFFL amino acids 292-303 of MAGE-6 LGGTGAFEffilNGOLVFSKLENGGFPYEKDLIEAIKRASNGETLEKITNSRPPCVKISGG^! SYPL, •4\ -4t ! kisggprisypllggtgafeieingolvfsklenggfpyekdlieairrasngetlekitnMj PPCVKISGGPRISYPL Jj amino acids 157-167 ofNY-ESO-1 LGGTGAFEIEINGOLVFSKLENGGFPYEKDLTEAIRRASNGFTT.EKITNSRPPnVSLLM^ Q CFL, -||i 'r A* SLLMWITOCFLLGGTGAFEffiMGOLWSKLENGGFPYEKDLIEAIRRASNGETLEKlTNSi pPCVSLLMWITQCFL F amino acids 157-165 ofNY-ESO-1 LGGTGAFEIEINGOLVFSKLENGGFPYEKDLIEAIRRASNGETLFKITNSRPPCVSLLMWTT^; SLLMWITOCLGGTGAFEIEINGOLVFSKLBNGGFPYEKDLIEAmRASNGFTI.EKITNSRPP evsllmwttq^ r C3S Peptide/Epitope Exemplary Tumor Rejection Peptide Exemplary Polytopes amino acids 155-163 ofNY-ESO-1 LGGTGAFEffilNGOLVFSKLENGGFFYEKDLIEAffiRASNGETLEKITNrSRPPCVOLSLLMWM • ?? OLSLLMWITLGGTGAFEIEINGOLVFSKLENGGFPYEKDLIEAIRRASNGETLEKITNSR# CVQLSLLMWIT amino acids 157-170 of NY-BSO-1 and amino acids 281-295 ofMAGE-3 SLLMWITOCFLPVFLGGTGAFEIEINGOLVFSKLENGGFPYEKDLIEAIRRASNGETLEKIT NSRPPCVTSYVKVLHHMVKISG G99 -VI13 of SEQ ID NO:2 GETLEKITNSRPPCV amino acids 161-169 ofMAGE-1 GETLEKITNSRPPCVEADPTGHSY.

EADPTGHS YGETLEKITNSRPPCVE ADPTGHSY amino acids 230-238 ofMAGE-1 GBTLEKITNSRPPCVSAYGEPRKL.

SAY GEPRKLGETLEKITKSRPPCVSAYGEPRKL amino acids 168-176 of MAGE-3 GETLEKITNSRPPCVEVDPIGHLY. EVDPIGHLYGETLEKITNSRPPCVEVDPIGHLY amino acids 271-279 ofMAGE-3 GETLEKITNSRPPCVFLWGPRALV. FLWGPRALV GETLEKTTNSRPPCVFLWGPRALV amino acids 167-176 of MAGE-3 GETLEK1TNSRPPCVMEVDPIGHLY. 1 MEVDPIGHLYGETLEKITNSRPPCVMEVDPTGHLY j amino acids 2-10 of BAGE GETLEKITNSRPPCVAARAVFLAL. J AARAVFLALGETLEK1TNSRPPCVAARAVFLAL | amino acids 9-16 of GAGE-1,2 GETLEKITNSRPPCVYRPRPRRY.

YRPRPRRY GETLEKITNSRPPCVYRPRPRRY j amino acids 11-20 of RAGE n GETLEK1TNSRPPCVSPSSNRIRNT.

SPSSNRIRNTGETLEKITNSRPPCVSPSSNRTRNT amino acids 23-32 of CDK.4 GETLEKITNSRPPCV ARDPHSGHFV. ARDPHSGHFVGETLEKITNSRPPCVARDPHSGHFV amino acids 29-37 of p-catenin GETLEKITlSfSRPPCVSYLDSGfflS. SYLDSGIHSGETLEKITNSRPPCVSYLDSGIHS amino acids 1-9 of Tyrosinase GETLEKITNSRPPCVMLLAVLYCL. MIXAVLYCLGETLEKITNSRPPCVMLLAVLYCL amino acids 206-214 of Tyrosinase GETLEKITNSRPPCVAFLPWHRLF.

AFLP WHRLFGETLEKITNSRPPCVAFLPWHRLF ! amino acids 56-70 of Tyrosinase GETLEKITNSRPPCVONILLSNAPLGPOFP. QNILLSNAPLGPQFPGETLEKITNSKPPCVQNILLSNAPLGPQFP amino acids 448-462 of Tyrosinase GETLEKITNSPPPCVDYSYLODSDPDSFOD. DYSYLQDSDPDSFQDGETLBKITNSRPPCVDYSYLQDSDPDSFQD amino acids 32-40 of Melan-AMAET'1 GETLEKITNSRPPCVJLTVILGVL. JLTVILGVLGETLEKITNSRPPCVJLTVILGVL amino acids 154-162 of gpl00?mein GETLEKITNSRPPCVKTWGOYWOV. i KTWGQYWQVGETLEKITNSRPPCVKTWGQYWQV j amino acids 209-217 of gplOO*"0117 SVAPPPEEVTTDOVPFSV. ITDOVPFSVSVAPPPEEVITDOVPFSV amino acids 280-288 of gpl00PmeI17 S V APPPEEVYLEPGP VTA. YLEPGPVTASVAPPPEEVYLEPGPVTA amino acids 457-466 of gpl00Prael17 GETLEKTTNSRPPCVLLDGTATLRL. LLDGTATLRLGETLEKITNSRPPCVLLDGTATLRL amino acids 476-485 of gpl00pme"7 GETLEKITNSRPPCWLYRY GSFSV. VLYRYGSFSVGETLEKITNSRPPCWLYRYGSFSV amino acids 301-309 of PRAME GETLEKITNbRPPCVLYVDSLFFL. LYVDSLFFLGETLEKITNSRPPCVLYVDSLFFL amino acids 292-303 of MAGE-6 GETLEKITNSRPPCVKISGGPRISYPL. KISGGPRISYPLGETLEKITNSRPPCVBQSGGPRISYPL amino acids 157-167 of NY-ESO-1 GETLEKITNSRPPCVSLLMWITOCFL 1 SLLMWrrQCFLGETLEKITNSRPPCVSLLMWITQCFL amino acids 157-165 ofNY-ESO-1 GETLEKITNSRPPCVSLLMWITOC. .! SLLMWITQCGETLEKrmSRPPCVSLIMWITQC 1 amino acids 155-163 ofNY-ESO-1 GETLEKITNSRPPCVOLSLLMWIT. QLSLLMWITGETLEKTTNSRPPCV QLSLLMWIT amino acids 157-170 of NY-ESO-1 and amino acids 281-295 ofMAGE-3 SLLMWITOCFLPVFGETLEKITNSRPPCVTSYVKVLHHMVKISG ElOO -V113 ofSEQ ID NO:2 ETLEKTTNSKPPCV amino acids 161-169 ofMAGE-1 ETLEKTTNSRPPCVADPTGHS Y. EADPTGHSYETLEK3TNSRPPCVEADPTGHSY amino acids 230-238 of MA.GE-1 ETLEKITNSRPPCVSAYGEPRKL. SAYGEPRKLETLEKITNSRPPCVSAYGEPRKL amino acids 168-176 ofMAGE-3 ETLEK1TNSRPPCVEVDPIGHLY.

EVDPIGHLY ETLEKITNSRPPCVBVDPIGHLY amino acids 271-279 ofMAGE-3 ETLEKITNSRPPCVFLW GPRALV. FLWGPRALVETLEKITNSKPPCVFLWGPRALV amino acids 167-176 ofMAGE-3 ETLEKITNSRPPCVMEVDPIGHLY. MEVDPIGHLYETLEKITNSRPPCVMEVDPIGHLY amino acids 2-10 of B AGE ETLEOTNSRPPCVAARAVFLAL. AARAVFLALETLEKITNSRPPCVAARAVFLAL amino acids 9-16 of GAGE-1,2 ETLEKITNSRPPCVYRPRPRRY. YRPRPRRYETLEKTTNSRPPCVYRPRPRRY •amino acids 11-20 of RAGE ETLEKITNSRPPCVSPSSNRIRNT. SPSSNRTRNTETT.EKTTNSRPPCVSPSSNRIRNT amino acids 23-32 of ODK4 ETLEKTTNSRPPCVARDPHSGHFV.

ARDPHSGHFVETLEKITNSRPPCVARDPHSGHFV | amino acids 29-37 of p-catenin ETLEKITNSRPPCVSYLDSGIHS. SYLDSGIHSETLEKITNSRPPCVSYLDSGIHS amino acids 1-9 of Tyrosinase ETLEKITNSRPPCVMLLAVLYCL.

MLLAVLY CLETLEKITNSRPPCVMLLAVLYCL amino adds 206-214 of Tyrosinase ETLEKITNSRPPCVAFLPWHRLF.

AFLP WHRLFETLEKITNSRPPCVAFLPWHRLF amino acids 56-70 of Tyrosinase ETLEKITNSRPPCVONTLLSNAPLGPOFP. ONILLSNAPLGPOFPETLEKITNSRPPCVONILLSNAPLGPOFP amino adds 448-462 of Tyrosinase ETLEKITNSRPPCVDYSYLODSDPDSFOD. DYSYLODSDPDSFODETLEKITNSRPPCVDYSYLODSDPD53FOD amino acids 32-40 of Melan-AMART"1 ETLEKITNSRPPCVJLTVILGVL. JLTVILGVLETLEKrrNSRPPCVJLTVILGVL i amino acids 154-162 of gpl00pmel17 ETLEKITNSRPPCVKTWGOYWOV. KTWGOYWOVETLEKITNSRPPCVKTWGOYWOV i amino acids 209-217 of gplOO**117 ETLEKITNSRPPCVTTDOVPFSV. ITDOVPFSVETLEKITNSRPPCVITDOVPFSV ammo acids 280-288 of gpl00Pm'u7 ETLEKITNSRPPCVYT.F.PGPVTA. YLEPGPVTAETLEKIXNSRPPCyYLEPGPVTA i amino acids 457-466 of gplOO1"™"7 ETLEKITNSRPPCVLLDGTATLRL. LLDGTATLRLETLEKITNSRPPCVLLDGTATLRL amino acids 476-485 of gpl00flMl17 ETLEKITNSRPPCWLYRY GSFSV.

YLYRY GSFSVETLEKITNSRPPpWLYRYGSFSV amino acids 301-309 of PRAME etlekitnsrppcvlyvdslffl. lyvdslffletlekitnsrppcvlyvdslfft. amino acids 292-303 of MAGE-6 ETLEKITNSRPPCVTCISGGPRISYPL. KISGGPRISYPLETLEKrmSRPPCVKTSGGPRTSYPT. amino acids 157-167 ofNY-ESO-1 ETLEKITNSRPPCVSLLMWITOCFL. SLLMWTTOCFLETLEIQTNSRPPCV SLLMWITOCFL ammo acids 157-165 ofNY-ESO-1 ETLEKITNSRPPCVSLLMWITOC. i SLLMWITQCETLEK1TNSRPPCVSLLMWITQC J amino acids 155-163 ofNY-ESO-1 ETLEKITNSRPPCV OLSLLMWIT. ] OLSLLMWITETLEKITNSRPPCVOLSLLMWIT amino acids 157-170 ofNY-ESO-1 and amino acids 281-295 ofMAGE-3 SLLMWITOCFLPVFETLEKITNSRPPCVTSYVTCVLTTT7MVKTSG TABLEC C35 Epitope Analog Exemplary Tumor Rejection Peptide Exemplary Polytope Analog of S77-Y85 ofSEQ ID NO:2 having valine substituted for tyrosine at ninth amino acid residue (KLENGGFPY) amino acids 161-169 ofMAGE-1 KLENGGFPVEADPTGHSY.

FADPTGHSYKLENGGFPVEADPTGHSY :i> amino acids 230-238 of MAGE-1 KLENGGFPVSAYGEPRKL. J* S AYGEPRKLKLENGGFPVS AY GEPRKL amino acids 168-176 ofMAGE-3 KLENGGFPVEVDPIGHLY. EVDPIGHLYKLENGGFPVEVDPIGHLY amino acids 271-279 ofMAGE-3 KLENGGFPVFLWGPRALV. FLWGPRALVKLENGGFPVFLWGPRALV amino acids 167-176 ofMAGE-3 KLENGGFPVMEVDPIGHLY. MEVDPIGHLYKLENGGFPVMEVDPIGHLY amino acids 2-10 of BAGE KLENGGFPVAARAVFLAL. AARAVFLALKLENQQFPYAARAVFLAL amino acids 9-16 of GAGE-1,2 .

KLENGGFPVYRPRPRRY. YRPRPRRY^LENGGFPVYRPRPRRY amino acids 11-20 of RAGE KLENGGFPVSPSSNRIRNT. SPSSNRtRNTKLENGGFPVSPSSNMRNT amino acids 23-32 of CDK4 KLENGGFPVARDPHSGHFV. ARDPHSGHFVKLENGGFPVARDPHSGHFV amino acids 29-37 of p-catenin KLENGGFPVSYLDSGIHS. SYLDSGIHSKLENGGFPVSYLDSGIHS amino acids 1-9 of Tyrosinase KLENGGFPVMLLAVLYCL. ? MLLAVLYCLKLENGGFPVMLLAVLYCL ! C35 Epitope Analog Exemplary Tumor Rejection Peptide Exemplary Polytope amino acids 206-214 of Tyrosinase KLKNGGFPVAFLPWHRLR AFLPWHRLFKLENGGFPVAFLPWHRLF amino acids 56-70 of Tyrosinase KLENGGFPVONILLSNAPLGPOFP. ONTLLSNAPLGPOFPKLENGGFPVONILLSNAPLGPOFP amino acids 448-462 of Tyrosinase KLENGGFPVDYSYLODSDPDSFOD. S DYSYLODSDPDSFODKLENGGFPVDYSYLODSDPDSFOD amino acids 32-40 of Melan-AMART*1 KLENGGFPVJLTVILGVL. JLTVILGVLKLENGGFPVJLTVILGVL amino acids 154-162 of gpl00pme"7 KLENGGFPVKTWGOYWOV. ! KTWGQYWQVKLENGGFPVKTWGQYWQV ;! amino acids 209-217 of gpl00Pmel t7 KLENGGFPVITDOVPFSV. 1 ITDQVPFSVKLENGGFPVITDQVPFSV j| amino acids 280-288 of gpl00Pn*117 KLENGGFP VYLEPGP VTA. H YLEPGPVTAKLENGGFPVYLEPGPVTA amino acids 457-466 of gplOQpme117 KLENGGFPVLLDGTATLRL.

LLDGTATLRLKLENGGFPVLLDGTATLRL 1 amino acids 476-485 of gplOOPme"7 KLENGGFP WLYRYGSFSV.

VLYRYGSFSVKLENGGFPWLYRYGSFSV r. 1 amino acids 301-309 of PRAME KLENGGFP VLYVDSLFFL.

LYVDSLFFLKLE^QGFPVLYVDSLFFL ■! amino acids 292-303 of MAGE-6 KLENGGFP VKISGGPRISYPL.

KISGGPRISYPLKLENGGFPVTOSGGPRISYPL - ? amino acids 157-167 ofNY-ESO-1 KLENGGFPVSLLMWITOCFL. ? SLLMWITQCFLKLENGGFPVSLLMWITQCFL C35 Epitope Analog Exemplary Tumor Rejection Peptide Exemplary Polytope amino acids 157-165 of NY-ESQ-1 KLENGGFPVSLLMWITOC. SLLMWITOCKLENGGFPVSLLMWITOC amino acids 155-163 ofNY-ESO-1 KLENGGFPVOLSLLMWIT. i OLSLLMWITKLENGGFFVOLSLIMWIT amino acids 157-170 of NY-ESO-land amino acids 281-295 ofMAGE-3 SLLMWITOCFLPVFKLENGGFPVTSYVKVLHHMVK1SG Analog of K104 - CI 12 of SEQ ID NO:2 having leucine substituted for cysteine at the ninth amino acid residue (KITNSRPPL) amino acids 161-169 ofMAGE-1 KTTNSRPPLEADPTGHSY. EADPTGHSYKITNSRPPLEADPTGHSY amino acids 230-238 ofMAGE-1 KITNSRPPLS AY GEPRKL. saygeprklptnsrpplsaygeprkl amino acids 168-176 ofMAGE-3 i " ' t KTTNSRPPLEVDPTGHLY.

EVDPIGHLYKITlsrSRPPLEVDPIGHLY amino acids 271-279 ofMAGE-3 KTTNSRPPLFLWGPRALV. 5 FLWGPRALVKITNSRPPLFLWGPRALV amino acids 167-176 ofMAGE-3 KITNSRPPLMEVDPIGHLY. MEVDPIGHLYKITNSRPpLMEVDPIGHLY amino acids 2-10 of BAGE KITNSRPPLAARA VFLAL. AARAVFLALKTTNSRPPLAARAVFLAL amino acids 9-16 of GAGE-1,2 KITNSRPPLYRPRPRRY. YRPRPRRYKITNSRPPLYRPRPRRY amino acids 11-20 of RAGE - 1 KTTNSRPPLSPSSNRIRNT.

SPSSNRTRNTFaTNSRPPLSPSSMRIRNT amino acids 23-32 of CDK4 kitnsrpplardphsghfv.

ARDPHSGHFVKITNSRPPLARDPHSGHFV 4 C35 Epitope Analog Exemplary Tumor Rejection Peptide Exemplary Polytope amino acids 29-37 of p-catenin KTTNSRPPLSYLDSQIHS. SYLDSGIHSKITNSRPPLSYLDSGIHS amino acids 1-9 of Tyrosinase KITNSRPPLMLLAVLYCL. mllavlyclkitnsrpplmllavlycl amino acids 206-214 of Tyrosinase KTTNSRPPLAFLPWHRLR AFLPWHRLFKITNSRPPLAFLPWHRLF amino acids 56-70 of Tyrosinase KITNSRPPLONILLSNAPLGPOFP.

QNTLLSNAPLGPOFPK1TNSRPPLONIIXSNAPLGPOFP : amino acids 448-462 of Tyrosinase KTTNSRPPLDYSYLODSDPDSFOD. DYSYLODSDPDSFODKITNSRPPLDYSYLODSDPDSFOD amino acids 32-40 of Melan-AMART"1 KITN SRPPLJLTVILGVL. JLTVTLGVLKITNSRPPLJLTVTLGVL amino acids 154-162 of gplOO^'117 KITNSRPPLKTWGOYWOV. KTWGOYWOVKIT^SRPPLKTWGOYWOV amino acids 209-217 of gplOO*™"117 KinSTSRPPLITDOVPFSV. < ITDOVPFSVKrjN^IUPPLrrDOVPFSV amino acids 280-288 of gpl00Pratl17 KITNSRPPLYLEPGPVTA. YLEPGPVTAKITNSRPPLYLEPGPVTA amino acids 457-466 of gpl00pm>117 KITNSRPPLLLDGTATLRL. 1 LLDGTATLRLKITNSRPPLLLDGTATLRL ] amino acids 476-485 of gpl00JnM"7 KITNSRPPLVLYRYGSFSV. 1 VLYRY GSFS VKrnSTSRPPLVLYRYGSFS V j amino acids 301-309 of PRAME KITNSRPPLLYVDSLFFL. J LYVDSLFFLKITNSRPPLLYVDSLFFL | C35 Epitope Analog Exemplary Tumor Rejection Peptide Exemplary Polytope { amino acids 292-303 of MAGE-6 KTTNSRPPLKTSGGPRISYPL. ktsggprisyplkitnsrpplkisggprisypl amino acids 157-167 ofNY-ESO-1 KITNSRPPLSLLMWITOCFL. i 55LLMWITOCFLKTFNSRPPLSLLMWITOCFL j amino acids 157-165 ofNY-ESO-1 PCTTNSRPPLSLLMWITOC. J SLLMWITQCKjtTNSRPPLSLLMWITQC ! amino acids 155-163 ofNY-ESO-1 TOTNSRPPLOLSLLMW1T. 1 QLSLU^WTIKITNSRPPLQLSLLMWrr .[ amino acids 157-170 ofNY-ESO-1 and amino acids 281-295 ofMAGE-3 SLLMWITOCFLPVFKITNSKPPLTSYVKVLHHMVKISG 1 Analog of 1105 -VI13 of SEQ ED NO:2 having leucine substituted for threonine at the second amino acid residue and alanine substituted for cysteine at the eighth amino acid residue (ILNSRPPAV) amino acids 161469 ofMAGE-1 TLNSRPPAVEADPTGHSY. 1 EADPTGHSYILNSRPPAVEADPTGHSY j amino acids 230-238 ofMAGE-1 ILNSRPPAVS AY GEPRKL. I SAY GEPRKLILNSRPPA VSAY GEPRKL f amino acids 168-176 ofMAGE-3 TLNSRPPAVEVDPIGHLY. 1 EVDPIGHLYILNSR?PAVEVDPIGHLY i amino acids 271-279 ofMAGE-3 TLNSRPPAVFLWGPRALV. ■ " !? FLWGPRALVtLNSRPpAVFLWGPRALV 1 amino acids 167-176 ofMAGE-3 ILNSRPPAVMEVDPIGHLY. i MEVDPIGHLYILNSRPPAVMEVDPIGHLY amino acids 2-10 of BAGE ILNSRPPAVAARAVFLAL.

A ARA VFLALILNSRPPA VAARA VFLA T, ; amino acids 9-16 of GAGE-1,2 ILNSRPPAVYRPRPRRY. " ? YRPRPRRYfLNSRPPAVYRPRPRRY i C35 Epitope Analog Exemplary Tumor Rejection Peptide Exemplary Polytope amino acids 11-20 of RAGE TLNSRPPAVSPSSNRIRNT. SPSSNRtRNTJLNSRPpAVSPSSNRIRNT amino acids 23-32 of CDK4 ILNSRPPAVARDPHSGHFV. A'RDPHSGHFyiLNSRPPAVAKDPHSGHFV amino acids 29-37 of P-catenin ILNSRPPAVSYLDSG1HS. SYLDSGIHSILNSRPPAVSYLDSGMS amino acids 1-9 Of Tyrosinase TLNSRPPAVMLLAVLYCL.

MLLA VLY CLILN SRPP AVMLLAVLYCL i amino adds 206-214 of Tyrosinase ILNSRPPAV AFLPWHRLF. AFI.PWHRLFILNSRPPAVAFLPWHRLF amino adds 56-70 of Tyrosinase TLNSRPPAVONILLSNAPLGPOFP. ONTLLSNAPLGPOFPILNSRPPAV ONILLSNAPLGPOFP amino acids 448-462 of Tyrosinase ILNSRPPAVDYSYLODSDPDSFOD. DYSYLODSDPDSFODILNSRPPAVDYSYLODSDPDSFOD amino adds 32-40 of Melan-AMART*1 1LNSRPPAVJLTVTLGVL. JLTVILGVLILNSRPPAVJLTVILGVL amino acids 154-162 ofgplOO*"1®117 ILNSRPPAVKTWGOYWOV. KTWGOYWOVJLNSRpPAVKTWGOYWOV amino acids 209-217 of gpl00Fmel17 1LNSRPPAVITDOVPFSV. ITDOVPFSVILNSRPPAVTTDOVPFSV amino adds 280-288 of gplOO*"*1'7 1 1 I ILNSRPPAVYLEPGPVTA.

YLEPGPVTAILNSRPPAVYLEPGPVTA amino acids 457-466 ofgpl00Pme"7 ILNSRPPAVLLDGTATLRL. ' LLDGTATLRLILNSRPPAVLLDGTATLRL C35 Epitope Analog Exemplary Tumor Rejection Peptide Exemplary Polytope amino acids 476-485 of gpl00Pme"7 ILNSRPPAWLYRYGSFSV. VLYRYGSFSVTLNSRPPAVVLYRYGSFSV amino acids 301-309 of PRAMB ILNSRPPAVLYVDSLFFL. LYVDSLFFLILNSRPPAVLYVDSLFFL amino acids 292-303 ofMAGE-6 ILNSRPPAVKISGGPRISYPL. KISGGPRISYPLILNSRPPAVKISGGPRISYPL amino acids 157-167 of NY-ESO-1 ILNSRPPAVSLLMWITOCFL. SLLMWITOCFLILNSRPPAWSLLMWITOCFL amino acids 157-165 ofNY-ESO-1 ILNSRPPAVSLLMWITOC. SLLMWITOCILNSRPPAVSLLMWITOC amino acids 155-163 ofNY-ESO-1 ILNSRPPAVOLSLLMWTT. j OLSLLMWITILNSRPPAVOLSLIMWIT t amino acids 157-170 ofNY-ESO-1 and amino adds 281-295 ofMAGE-3 SLLMWITOCFLPVFILNSRPPAVTSYVKVLHHMVKISG Analog of 1105 - VI13 of SEQ ID NO:2 having methionine substituted for threonine at the second amino acids residue and alanine substituted for cysteine at the eighth amino acid residue (IMNSRPPAV) amino acids 161-169 ofMAGE-1 IMNSRPPAV EADPTGHSY. EADPTGHSYIMNSRPPAVEADPTGHSY amino acids 230-238 ofMAGE-1 IMNSRPPAV SAYGEPRKL. SAYGEPRKLJM^SRPPAV SAYGEPRKL amino acids 168-176 ofMAGE-3 IMNSRPPAVEVDPIGHLY. EVDPIGHLYIMNSRPPAV EVDPIGHLY amino acids 271-279 ofMAGB-3 ■■ -li IMNSRPPAVFLWGPRALV.

FLWGPRALVTMNSRPPAV FLWGPRALV amino acids 167-176 ofMAGB-3 IMNSRPPAVMEVDPIGHLY. MEVDPIGHLYIMNSRPPAVMEVDPIGHLY C3S Epitope Analog Exemplary Tumor Rejection Peptide Exemplary Polytope amino acids 2-10 of BAGE IMNSRPP AVAARAVFLAL. AARAVFLALIMNSRPPAVAARAVFLAL amino acids 9-16 of GAGE-1,2 IMNSRPP AVYRPRPRRY. YRPRPRRYMNSRPPAVYRPRPRRY amino acids 11-20 of RAGE IMNSRPPAVSPSSNRIRNT. SPSSNRIRNTIMNSRPPAVSPSSNRIRNT amino acids 23-32 of CDK4 IMNSRPPAVARDPHSGHFV. ARDPHSGHFVIMNSRPPAVARDPHSGHFV amino acids 29-37 of (3-catenin A IMNSRPP AVSYLDSGIHS.

SYLDSGfflSMNSRPPAVSYLDSGIHS ' amino acids 1-9 of Tyrosinase IMN SRPP A VMLLAVLY CL.

MLLAVLYCLIMNSRPPAVMLLAVLY CL J amino acids 206-214 of Tyrosinase IMNSRPP AVAFLPWHRLF. -1 AFLPWHRLFIMNSRPPAVAFLPWHRLF | amino acids 56-70 of Tyrosinase IMNSRPPAVONILLSNAPLGPOFP.

QNILLSNAPLGPQFPIMNSRPPAVQNILLSNAPLGPQFP j amino acids 448-462 of Tyrosinase 1MNSRPPAVDYSYLODSDPDSFOD. 1 DYSYLQDSDPDSFQDIMNSRPPAVDYSYLQDSDPDSFQD 1 amino acids 32-40 of Melan-AMAKr'1 IMNSRPPAVJLTVILGVL. JLTVILGVLIMNSRPPAVJLTVILGVL amino acids 154-162 of gpl00FlIwm IMNSRPP AVKTW GOYWO V. KTWGOYWOVM^SKPPAVKTWGOYWOV amino acids 209-217 of gplOO*"""7 IMNSRPP AVITDOVPFSV. : ITDQVPFSV1MNSRPPAVITDQVPFSV C35 Epitope Analog Exemplary Tumor Rejection Peptide Exemplary Polytope amino acids 280-288 of gpl00Pn*m IMNSRPPAVYLEPGPVTA, YLEPGPVTAIMNSRPPAVYLEPGPVTA amino acids 457-466 of gpl00Pm"17 IMNSRPP A VLLDGTATLRL. LLDGTATLRLIMNSRPPAVLLDGTATLRL amino acids 476-485 of gplOO^"®117 IMNSRPP A VVLYRYGSFSV. 1 VLYRYGSFSVIMNSRPPAWLYRYGSFSV amino acids 301-309 of PRAMB IMNSRPPAVLYVDSLFFL. LYVDSLFFLIM^SRPPAVLYVDSLFFL amino acids 292-303 of MAGB-6 IMNSRPP AVKISGGPRTSYPL.

KISGGPRISYPLIMNSRPPAVKISGGPRISYPL 1 amino acids 157-167 ofNY-ESO-1 IMNSRPP AVSLLMWITOCFL. SLLMWrrOCFLITNSRPPAVSLLMWrrOCFL amino acids 157-165 ofNY-ESO-1 IMNSRPPAVSLLMWITOC. SLLMWITOCIMNSRPPAVSLLMWrrOC amino acids 155-163 ofNY-ESO-1 IMNSRPPAVOLSLLMWIT.

OLSLLM WITTMNSRPP A V OLSLLMWIT : amino acids 157-170 ofNY-ESO-1 and amino acids 281-295 ofMAGE-3 SLLMWITOCFLPVFIMNSRPPAVTSYVKVLHHMVKISG Analog of 1105 - VI13 of SEQ ED NO:2 having serine substituted for cysteine at the eighth amino acid residue (ITNSRPPSV) amino acids 161-169 ofMAGE-1 ITNSRPPSV EADPTGHSY. EADPTGHSYITNSRPPSVEADPTGHSY amino acids 230-238 ofMAGE-1 ITNSRPPSV SAYGEPRKL. SAYGEPRKLITNSRPPSV SAYGEPRKL amino acids 168-176 ofMAGE-3 ITNSRPPSVEVDPIGHLY.

EVDPIGHLYTTNSRPPSV EVDPTGHLY — , -— amino acids 271-279 ofMAGE-3 ITNSRPPSVFLWGPRALV. FLWGPRALVITNSRPPSV FLWGPRALV ammo acids 167-176 ofMAGE-3 TTNSRPPSVMEVDPIGHLY. MEVDPIGHLYnTSfSRPPSVMEVDPIGHLY amino acids 2-10 of BAGE TTNSRPPSVAARAVFLAL. AARAVFLALITNSRPPSVAARAVFLAL amino acids 9-16 of GAGE-1,2 ITNSRPPSVYRPRPRRY. , YRPRPRRYTTNSRPPSVYRPRPRRY amino acids 11-20 of RAGE TTWSRPPSVSPSSNRIRNT. SPSSNRIRNTITNSRPPSVSPSSNRIRNT amino acids 23-32 of CDK4 TTNSRPPSVARDPHSGHFV. 3 ARDPHSGHFVTINSRPPSVARDPHSGHFV ■■■] amino acids 29-37 of p-catenin TTNSRPPSVSYLDSGIHS. SYLDSGIHSITNSRPPSVSYLDSGIHS amino acids 1-9 of Tyrosinase ITNSRPPSVMLLAVLYCL.

MLLAVLYCLITNSRPPSVMLLAVLY CL I amino acids 206-214 of Tyrosinase TTNSRPPSVAFLPWHRLF. AFLPWHRLFITNSRPPSVAFLPWHRLF amino acids 56-70 of Tyrosinase ITNSRPPSV ONILLSNAPLGPOFP. ONILLSNAPLGPOEPITNSRPPSVONILLSNAPLGPOFP % amino adds 448-462 of Tyrosinase ITNSRPPSVDYSYLODSDPDSFOD. ' i DYSYLODSDPDSFODITNSRPPSVDYSYLODSDPDSFOD amino adds 32-40 of Melan-AMAM"1 ITNSRPPSVJLTVILGVL. JLTVTLGVLITNSRPPSVJLTVILGVT, 1 amino adds 154-162 of gplOO®"""117 ITNSRPPSVKTWGOYWOV. ?: KTWGQYWQVITNSRPPSVKTWGQYWQV ' amino acids 154-162 of gplOO*"*117 GVRIWEYAKTWGOYWOV. * KTWGOYWOVGVRIWEYAKTWGOYWOV 'ij amino acids 209-217 of gplOO1^"7 gvriv veyattdovpfs v.

ITDQVPFSVGVRIWEYAITDQVPFSV j amino acids 280-288 of gpl00pmeU7 GVRIWEYAYIEPGPVTA. ii YLEPGPVTAGVRIWEYAYLEPGPVTA fj amino acids 457-466 of gplOO*™5'17 gvptwryat.t .dgtatt.pt. S lldgtatlrlgvrtvveyalldgtatlrl -i amino acids 476-485 of gpl00PmeU7 TCT P.NGGFPWT .YRYGSPSV. 1 VLYRYGSFSVKLENGGFPVYLYRYGSFSV f amino acids 301-309 of PRAME '4 GVRIWEYALYVDSLFFL. i lyvdsleflgvriweyalyvdslffl \ amino acids 292-303 of MAGE-6 GVRTV VEYAKISGGPRIS YPL. % KISGGPRISYPLGVRIVVEYAKISGGPRrSYPL 1 amino acids 157-167 ofNY-ESO-1 GVRIWEYASLLMW1TOCFL. * SLLMWTTOCFLGVRIWEYASLLMWTTOCFL amino acids 157-165 ofNY-ESO-1 GVRIWEYASLLMWITOC. SLLMWITOC GVRiWEYAsi^Mwrroc amino acids 155-163 ofNY-ESO-1 • gvrivVeyaolsllmwit.

OLSLLMWIT GVSJVWAOLSLLMWIT amino acids 157-170 of NY-ESO-land amino acids 281-295 ofMAGE-3 . sllmwttocflpvf gvriweyatsyvkvlhhmvktsg 9 amino acids 271-279 ofMAGE-3 KITNSRPPSVFLWGPRALV. FLWGPRALVKITNSRPPSV FLWGPRALV amino acids 167-176 ofMAGE-3 KITNSRPPSVMKVDPIGHLY. MEVDPIGHLYJCITNSRPPSVMEVDPIGHLY amino acids 2-10 of BAGE /> KTINSRPPSVAARA VFLAL.

AARAVFLALKTTNSRPPSVAARAVFLAL amino acids 9-16 of GAGE-1,2 KITNSRPPSVYRPRPRRY. YRPRPRRYKriNSRPPSVYRPRPRRY amino acids 11-20 of RAGE KITNSRPPSVSPSSNRIRNT. SPSSNRIRNTKITNSRPPSVSPSSNRIRNT amino acids 23-32 of CDK4 KITNSRPPSVARDPHSGHFV. ARDPHSGHFVKITNSRPP55VARDPHSGHFV amino acids 29-37 of p-catenin KITNSRPPSVSYLDSGIHS. SYLDSGIHSK1TNSRPPSVSYLDSGIHS amino acids 1-9 of Tyrosinase KITNSRPP SVMLLAVLY CL.

MLLAVLYCLKITNSRPPS VMLLAVLY CL amino acids 206-214 of Tyrosinase KITNSRPPSVAFLPWHRLF.

AFLPWHRLFKITNrSRPPSVAFLPWHRLF , amino acids 56-70 of Tyrosinase i KTINSRPPSVONILLSNAPLGPOFP. QNILLSNAPLGPQFPKITNSRPPSVONDLLSNAPLGPQFP amino acids 448-462 of Tyrosinase KITNSRPPSVDYSYLODSDPDSFOD.

DYSYLQDSDPDSFQDKITNSRPPSVDYSYLQDSDPDSFQD , amino acids 32-40 of Melan-AMAEr'1 KITNSRPPSVJLTVILGVL. 1 JLTVILGVLKITNSRPPSVJLTVILGVL amino acids 154-162 of gpl00Prael17 "I KTINSRPPSVKTWCfOYWOV.

K.TW GOYW OVKITNSRPPS VTCTWGO YWOV amino acids 209-217 of gpl00Pmel17 KrmSRPPSVTTDOVPFSV. ITDOVPFSVKITNSRPPSVITDOVPFSV amino acids 280-288 of gpl00rmelt7 KITNSRPPSVYLEPGPVTA. • t YLEPGPVTAKJTNSRPPSVYLEPGPVTA amino acids 457-466 of gpl00Pmel17 KITNSRPPSVLLDGTATLRL. LLDGTATLRLKITNSRPPSVLLDGTATLRL amino acids 476-485 of gplOOPme117 KITNSRPPSVVLYRYGSFSV. VLYRYGSFSVKITNSRPPSVVLYRYGSFSV amino .acids 301-309 of FRAME KITNSRPPSVLYVDSLFFL. LYVDSLFFLKITNSRPPSVLYVDSLFFL amino acids 292-303 of MAGE-6 KITNSRPPSVKISGGPRtSYPL. KlSGGPRtSYPLKITNSRPPSVKISGGPRISYPL amino acids 157-167 ofNY-ESO-1 KITNSRPPSVSLLMWITOCFL. :! SLLMWITQCFLKITNSRPPSVSLLMWITQCFL ■ 1 > amino acids 157-165 ofNY-ESO-1 KTTNSRPPSVSLLMWITOC. ^ 1 SLLMWrrOCKlTNSRPPSVSLLMWTTOC amino acids 155-163 ofNY-ESO-1 KITNSRPPSVOLSLLMWIT. OLSLLMWITKJTNSRPPSVOLSLLMWIT amino acids 157-170 ofNY-ESO-1 and amino acids 281-295 ofMAGE-3 SLLMWrrOCFLPVFJaTNSRPPSVTSYWVLHHMVTCTSG Analog of G22 - C30 ofSEQ ID NO:2 having alanine substituted for cysteine at the ninth amino acid residue (GVMWEYA) amino acids 161-169 ofMAGE-1 GVRTWEYAEADPTGHSY. EADPTGHSYGVRIWEYAEADPTGHSY amino acids 230-238 ofMAGE-1 GVRTWEYASAYGEPRKL. : * SAYGEPRKLGVRIWEYASAYGEPRKL amino acids 168-176 of MAGE-3 GVRTWEYAEVDPIGHLY. EVDPIGHLYGVRTWEYAEVDPIGHLY • • amino acids 271-279 ofMAGE-3 GVRTVVEYAFLWGPRALV. FLWGPRALVGVRIWEYAFLWGPRALV amino acids 167-176 ofMAGE-3 GVRTWEYAMEVDPIGHLY. MEVDPIGHLY GVRIWEYAMEVDPIGHLY amino acids 2-10 of BAGE GVRIWEYAAARAVFLAL. AARAVFLALGVRIWEYAAARAVFLAL amino acids 9-16 of GAGE-1,2 GVRIWEYAYRPRPRRY. YRPRPRRYQVRty VEYAYRPRPRRY amino acids 11-20 of RAGE GVRIWEYASPSSNRIRNT. SPSSNRIRNTGVRIVVEYASPSSNRIRNT amino acids 23-32 of CDK4 GVRIWEYAARDPHSGHFV. ARDPHSGHFVGVRIWEYAARDPHSGHFV amino acids 29-37 of p-catenin GVRIWEYASYLDSGIHS. • SYLDSGfflSGVRIWEYASYLDSGIHS amino acids 1-9 of Tyrosinase GVRIWEYAMLLAVLY CL.

MLLAVLY CLGVRTWEYAMLLAVLYCL amino acids 206-214 of Tyrosinase GVRIWEYAAFLPWHRLF. AFLPWHRLFGVRIWEYAAFLPWHRLF amino acids 56-70 of Tyrosinase GVRIWEYAONILLSNAPLGPOFP. ONILLSNAPLGPOFPGVRIWEYAONILLSN APLGPOFP amino acids 448-462 of Tyrosinase GVRIWEYADYSYLODSDPDSFOD. j DYSYLQDSDPDSFQDGVRIWEYADYSYLQDSDPDSFQD amino acids 32-40 of Melan-AMART'1 GVR1WEYAJLTVILGVL.

JLTVILGVLGVRIWEYAJLTVTT.GVT, ; amino acids 154-162 of gpl00PmeI'7 GVRIWEYAKTWGOYWOV. KITWGOYWOVGVRIWEYAKTWGOYWOV amino acids 209-217 of gpl00Fmen1 GVRTWEYATTDOVPFSV.

ITD O VPFS V GVRIWEYAITDO VPFS V amino acids 280-288 of gpl00Fme,n GVRTWEYAYLEPGPVTA. YLEPGPVTAGVRTWEyAYLEPGPVTA amino acids 457-466 of gpl00Pmsl17 GVRIWEYALLDGTATLRL. LLDGTATLRLGVRIWEYALLDGTATLRL amino acids 476-485 of gplOOPmel!7 KLENGGFPWLYRYGSFSV.

VLYRYGSFSVKLENGGFPWLYRYGSFS V amino acids 301-309 of PRAME GVRTWEYALYVDSLFFL. LYVDSLFFLGVRIWEYALYVDSLFFL amino acids 292-303 ofMAGE-6 GVRTWEYAKISGGPRISYPL.

KISGGPRISYPLGVRIWEYAKISGGPR1SYPL * amino acids 157-167 ofNY-BSO-1 GVRTWEYASLLMWITOCFL. SLLMWITOCFLGVRrWEYASLLMWITOCFL amino acids 157-165 ofNY-ESO-1 GVRIWEYASLLMWITOQ - sllmwitoc gvriweyasllmwitoc amino acids 155-163 ofNY-ESO-1 GVRIWEYAOLSLLMWIT. OLSLLMWIT GVRIWEYAOLSLLMWIT amino acids 157-170 of NY-ESO-land amino acids 281-295 ofMAGE-3 sllmwttocflpvf gvriweyatsyvkvlhhmvktsg Analog of 125 - C33 ofSEQ ID NO:2 having alanine amino acids 161-169 ofMAGE-1 IWEYAEPAEADPTGHSY. EADPTGHSYIWEYAEPAEADPTGHSY substituted for cysteine at the sixth and ninth amino acids residues (IWEYAEPA) amino acids 230-238 ofMAGE-1 IWEYAEPASAYGEPRKL.

SAYGEPRKLIWEYAEPAS A YGEPRKL amino acids 168-176 ofMAGE-3 TWEYAEPAEVDPIGHLY. EVDPIGHLYIWEYAEPAEVDPIGHLY amino acids 271-279 ofMAGE-3 IWEYAEPAFLWGPRALV. FLWGPRALVrWEYAEPAFLWGPRALV amino acids 167-176 ofMAGE-3 IWEYAEPAMEVDPIGHLY. MEVDPIGHLYTWEYAEPAMEVDPIGHLY amino acids 2-10 of BAGE IWEYAEPAAARAVFLAL. i AARAVFLALIWEYAEPAAARAVFLAL amino acids 9-16 of GAGE-1,2 IWEYAEPAYRPRPRRY. | YRPRPRRYIWEYAEPAYRPRPRRY amino acids 11-20 of RAGE TWEYAEPASPSSNRIRNT.

SPSSNRIRNTIWEYAEPASPSSNR3RNT . ■ amino acids 23-32 of CDK4 IWEYAEPAARDPHSGHFV. ARDPHSGHFVTWEYAEPAARDPHSGHFV amino acids 29-37 of p-catenin IWEYAEPASYLDSGIHS. SYLDSGIHSIWEYAEPASYLDSGfflS amino acids 1-9 of Tyrosinase IVVEYAEPAMLLAVLYCL. MLLAVLYCLIWEYAEPAMLLAVLYflT. amino acids 206-214 of Tyrosinase IWEYAEP AAFLPWHRLF. AFLPWHRLFTWEYAEPAAFLPWHRT.F amino acids 56-70 of Tyrosinase TWEYAEPAONILLSNAPLGPOFP. ONILLSNAPLGPOFPIWEYAEPAONHiSNAPLGPOFP amino acids 448-462 of Tyrosinase TWEYAEPADYSYLODSDPDSFOD. DYSYLODSDPDSFODIWEYAEPAJDYSYLODSDPDSFOD amino acids 32-40 of Melan-AMART"1 IWEYAEPAVJLTVILGVL. : TLTVILGVLIWEYAEPAJLTVILGVL amino acids 154-162 of gpl00Fmel17 TVVEYAEPAKTWGOYWOV. KTWGOYWOVTVVEYAEPAKTWGOYWOV amino acids 209-217 of gpl00proem IWEYAEPAITDOVPFSV. ITDOVPFSVIWEYAEPAITDOVPFSV amino acids 280-288 of gpl00Pmel17 TWEYAEPAYLEPGPVTA. YLEPGPVTAIWEYAEPAYLEPGPVTA amino acids 457-466 of gpl00Pmel17 TWEYAEPALLDGTATLRL. LLDGTATLRLIWEYAEPATXDGTATLRL amino acids 476-485 of gpl00Pm5"7 IWEYAEPAVLYRYGSFSV. VLYRYGSFSVIWEYAEPAVLYRYGSFSV amino acids 301-309 of PRAME IWEYAEPALYVDSLFFL. LYVDSLFFLIVVEYAEPALYVDSLFFL amino acids 292-303 of MAGE-6 IWEYAEPAKISGGPRISYPL. KISGGPRISYPLIVVEYAEPAKISGGPRISYPL amino acids 157-167 ofNY-ESO-1 1WEYAEPASLLMWITOCFL. SLLMWITOCFLIWEYAEPASLLMWITOCFL amino acids 157-165 ofNY-ESO-1 TWEYAEPASLLMWTTOC1 SLLMWITOCIWEYAEPASLLMWITOC amino acids 155-163 ofNY-ESO-1 rWEYAEPAOLSLIMWIT.

OLSLLMWIT IWEYAEPAOLSLLMWIT amino acids 157-170 of NY-ESO-land amino acids 281-295 ofMAGE-3 ST JMWITOCFLPVF TVVEYAEPATSYVKVLHHMVKISG Analog of K104 - CI 12 of SEQ ID NQ:2 having alanine substituted for cysteine at Hie ninth amino acid residue (KITNSRPPA) • amino acids 161-169 ofMAGE-1 KITNSRPPABADPTGHSY.

EADPTGHSY KITNSRPPAEADPTGHSY amino acids 230-238 of MAGE-1 KITNSRPPASAYGEPRKL. ' SAYGEPRKLKITNSRPPASAYGEPRKL amino acids 168-176 ofMAGE-3 KITNSRPPAEVDPIGHLY. EVDPTGHLYKITNSRPPAEVDPIGHLY amino acids 271-279 ofMAGE-3 KITNSRPPAFLWGPRALV. FLWGPRALVKITNSRPPAFLWGPRALV amino acids 167-176 ofMAGE-3 KITNSRPPAMEVDPIGHLY. MEVDPIGHLYKITNSRPPAMEVDPIGHLY amino acids 2-10 of BAGE KITNSRPPAAARA VFLAL. AARAVFLALKITNSRPPAAARA VFLAL amino acids 9-16 of GAGE-1,2 KITNSRPPAYRPRPRRY. YRPRPRRYKITNSRPPAYRPRPRRY amino acids 11-20 of RAGE KITNSRPPASPSSNRIRNT. SPSSNRIRNTKlTNSRPpASPSSNRIRNT amino acids 23-32 of CDK4 KITNSRPPAARDPHSGHFV. ARDPHSGHFVKITNSRPPAARDPHSGHFV amino acids 29-37 of P-catenin KTTNSRPPASYLDSGIHS. SYLDSGIHSKITNSRPPjASYLDSGIHS amino acids 1-9 of Tyrosinase KITNSRPPAMLLAVLYCL. MLLAVLYCLKITNSRPPAMLLAVLYCL amino acids 206-214 of Tyrosinase KITNRRPPAAFLPWHRLF. AFLPWHRLFKITNSRPPAAFLPWHRLF amino acids 56-70 of Tyrosinase KITNSRPPAONILLSNAPLGPOFP.

ONILLSNAPLGPOFP KITNSRPPAONILLSNAPLGPOFP amino acids 448-462 of Tyrosinase KITNSRPPADYSYLODSDPDSFOD. DYSYLODSDPDSFQDKITNSRPPADYSYLODSDPDSFQD amino acids 32-40 of Melan-AMART"1 KITNSRPPAJLTVILGVL. JLTVTLGVLKITNSRPPAJLTVILGVL amino acids 154-162 of gplOO^1"117 KITNSRPPAKTWGOYWOV. TCTWGOYWOVKITNSRPPAKTWGOYWOV amino acids 209-217 of gplOO5"*117 KITNSRPPAITDOVPFSV. ■ ' lTDOVPFSVKITNSRPPAITDOVPFSV amino acids 280-288 of gpl00?mel17 KITNSRPPAYLEPGPVTA. ": YLEPGPVTAKITNSRPPAYLEPGPVTA amino acids 457-466 of gpl00pmeH7 KITNSRPPALLDGTATLRL. LLDGTATLRLKITNSRPPALLDGTATLRL amino acids 476-485 ofgpl00Pme"7 KITNSRPPAVLYRYGSFS V. VLYRYGSFSVKITNSRPPAVLYRYGSFSV amino acids 301-309 ofPRAME KITNSRPPALYVDSLFFL. LYVDSLFFLKITNSRPPALYVDSLFFL amino acids 292-303 of MAGE-6 KITNSRPPAKISGGPRISYPL. KISGGPRISYPLKITNSRPPAKISGGPRISYPL amino acids 157-167 ofNY-ESO-1 KITNSRPPASLLMWITOCFL. SLLMWITOCFLKITNSRPPASLLMWITQCFT. amino acids 157-165 ofNY-ESO-1 KITNSRPPASLLMWITOC. SLLMWITOCKITNSRPPASLLMWITOC amino acids 155-163 ofNY-ESO-1 KITNSRPPAOLSLLMWTT. OLSLLMWITKITNSRPPAOLSLLMWIT ammo acids 157-170 ofNY-ESO-1 and amino acids 281-295 ofMAGE-3 SLLMWITOCFLPVFKITNSRPPATSYVKVLHHMVKISG TABLED C35 Epitope Exemplary Cell-Penetrating Peptide Sequence (CPP) Exemplary Polypeptide Containing C35 Epitope and CPP S9 - V17 of SEQ ID NO:2 SVAPPPEEV HSV-1 tegument protein VP22 SVAPPPEEVMTSMtSVKSGPRBVPRDEYEDLYYTPSSGMASPDSPPDTSRRGALOTRSRORGEV RFVQYDESDYALYGGSSSEDDEHPEVPRTRRPVSGAVLSGPGPARAPPPPAGSGGAGRTPTTA PRAPRTQRVATKAPAAPAAETTRGRKSAQPESAALPDAPASTAPTRSKTPAQGLARKLHFSTA PPNPDAPWTPRVAGFNKRVFCAAVGRLAAMHARMAAVQLWDMSRPRTDEDLNELLGITTIR VTVCEGKNLLQRANELVNPDWQDVDAATATRGRSAASRPTERPRAPARSASRPRRPVE, MTSRRSVKSGPREVPRDEYEDLYYTPSSGMASPDSPPDTSRRGALQTRSRQRGEVRFV QYDES DYALYGGSSSEDDEHPEVPRTRRPVSGAVLSGPGPARAPPPPAGSGGAGRTPTTAPRAPRTQR VATKAPAAPAAETTRGRKSAQPESAALPDAPASTAPTRSKTPAQGLARKLHFSTAPPNPDAPW TPRVAGFNKRYFCAAVGRLAAMHARMAAVQLWDMSRPRTDEDLNELLGITT1RVTVCEGKN LLORANELVNPDWODVDAATATRGRSAASRPTERPRAPARSASRPRRPVESVAPPPEEVMTS RRSVKSGPREVPKDEYEDLYYTPSSGMASPDSPPDTSRRGALQTRSRQRGEVRFVQYDESDYA LYGGSSSEDDEHPEVPRTRRPVSGAVLSGPGPARAPPPPAGSGGAGRTPTTAPRAPRTQRVATK APAAPAAETTRGRKSAQPESAALPDAPASTAPTRSKTPAQGLARKLHFSTAPPNPDAPWTPRV AGFNKRVFCAAVGRLAAMHARMAAVQLWDMSRPRTDEDLNELLGITTIRVTVCEGKNLLQR ANELVHPD W QD VD AATATRGRSAASRPTERPRAPARS ASRPRRP VE membrane-translocating sequence (MST) from h region of the signal sequence of Kaposi fibroblast growth factor SVAPPPEEVAAVLLPVLLAAP. AAVLLPVLLAAPSVAPPPEEVAAVLLPVLLAAP C35 Epitope Exemplary Cell-Penetrating Peptide Sequence (CPP) Exemplary Polypeptide Containing C35 Epitope and CPP S21 - Y29 of SEQ ID NO:2 SGVRIWEY HSV-1 tegument protein VP22 SGVRIWEYMTSRRSVKSGPREVPRDEYEDLYYTPSSGMASPDSPPDTSRRGALOTRSRORGE VRPVQYDESDYALYGGSSSEDDEHPEVPRTRRPVSGAVLSGPGPARAPPPPAGSGGAGRTPTT APRAPRTQRVATKAPAAPAAETTRGRKSAQPESAALPDAPASTAPTRSKTPAQGLARKLHFST APPNPD APWTPRVAGFNKRVFCAAV GRLAAMHARMAAV QLWDMSRPRTDEDLNELLGITTl RVTVCEGKNLLQRANELVNPDWQDVDAATATRGRSAASRPTERPRAPARSASRPRRPVE, ' MTSRRSVKSGPREVPRDEYEDLYYTPSSGMASPDSPPDTSRRGALQTRSRQRGEVRFVQYDES DYALYGGSSSEDDEHPEVPRTRRPVSGAVLSGPGPARAPPPPAGSGGAGRTPTTAPRAPRTQR VATKAPAAPAAETTRGRKSAQPESAALPDAPASTAPTRSKTPAQGLARKLHFSTAPPNPDAPW TPRVAGFNKRVFCAAVGRLAAMHARMAAVQLWDMSRPRTDEDLNELLGITTIRVTVCEGKN LLORANELVNPDWQDVDAATATRGRSAASRPTERPRAPARSASRPRRPVESGVRIVVEYMTS RRSVKSGPREVPRDEYEDLYYTPSSGMASPDSPPDTSRRGALQTRSRQRGEVRFVQYDESDYA LYGGSSSEDDEHPEVPRTRRPVSGAVLSGPGPARAPPPPAGSGGAGRTPTTAPRAPRTQRVATK APAAPAAETTRGRKSAQPESAALPDAPASTAPTRSKTPAQGLARKLHFSTAPPNPDAPWTPRV AGFNKRVF CAA V GRLAAMHARMAAV QLWDMSRPRTDEDLNELLGITTIRVTV CEGKNLLQR ANELVNPD W QD VDAATATRGRS AASRPTERPRAPARSASRPRRP VE membrane-translocating sequence (MST) from h region of the signal sequence of Kaposi fibroblast growth factor SGVRIWEYAAVLLPVLLAAP. AAVLLPVLLAAPSGVRIWEYAAVLLPVLLAAP C35 Epitope Exemplary Cell-Penetrating Peptide Sequence (CPP) Exemplary Polypeptide Containing C35 Epitope and CPP G22 - C30 erf SEQ ID NO:2 GVRIWEYC HSV-1 tegument protein VP22 GVRIVVEYCMTSRRSVKSGPREVPRDEYEDLYYTPSSGMASPDSPPDTSRRGALOTRSRORGE VRFVQYDESDYALYGGSSSEDDEHPEVPRTRRPVSGAVLSGPGPARAPPPPAGSGGAGRTPTT APRAPRTQRVATKAPAAPAAETTRGRKSAQPESAALPDAPASTAPTRSKTPAQGLARKLHFST APPNPDAPWTPRVAGFNKRVFCAAVGRLAAMHARMAAVQLWDMSRPRTDEDLNELLGITTI RVTV CEGKNLLQRANELVNPD V V QDVD AATATRGRSAASRPTERPRAP ARSASRPRRP VE, MTSRRSVKSGPRBVPRDEYEDLYYTPSSGMASPDSPPDTSRRGALQTRSRQRGEVRFVQYDES DYALYGGSSSEDDEHPEVPRTRRPVSGAVLSGPGPARAPPPPAGSGGAGRTPTTAPRAPRTQR VATKAPAAPAAETTRGRKSAQPESAALPDAPASTAPTRSKTPAQGLARKLHFSTAPPNPDAPW TPRVAGFNKRVFCAAVGRLAAMHARMAAVQLWDMSRPRTDEDLNELLGITTIRVTVCEGKN LLORANELVNPDWODVDAATATRGRSAASRPTERPRAPARSASRPRRPVEGVRIWEYCMTS RRSVKSGPREVPRDEYEDLYYTPSSGMASPDSPPDTSRRGALQTRSRQRGEVRFVQYDESDYA LYGGSSSEDDEHPEVPRTRRPVSGAVLSGPGPARAPPPPAGSGGAGRTPTTAPRAPRTQRVATK APAAPAAETTRGRKSAQPESAALPDAPASTAPTRSKTPAQGLARKLHFSTAPPNPDAPWTPRV AGFNKRVFCAAVGRLAAMHARMAAVQLWDMSRPRTDEDLNELLGITTIRVTVCEGKNLLQR ANELVNPD W QDVD AATATRGRSAASRPTERPRAP ARSASRPRRP VE membrane-translocating sequence (MST) from h region of the signal sequence of Kaposi fibroblast growth factor GVRIWEY CAAVLLPVLLA AP. A AVLLPVLLAAPGVRIWEYCA A VLLPVLLA AP C35 Epitope Exemplary Cell-Penetrating Peptide Sequence (CPP) Exemplary Polypeptide Containing C35 Epitope and CPP 125-C33 ofSEQ ID NO:2 IWEYCEPC HSV-1 tegument protein VP22 TVVEYOTPCMTSRRSVKSGPREVPRDEYEDLYYTPSSGMASPDSPPDTSRRGALOTRSRORGEV RFVQYDESDYALYGGSSSEDDEHPBVPRTRRPVSGAVLSGPGPARAPPPPAGSGGAGRTPTTA PRAPRTQRVATKAPAAPAAETTRGRKSAQPESAALPDAPASTAPTRSKTPAQGLARKLHFSTA PPNPDAPWTPRVAGFNKRVFCAAVGRLAAMHARMAAVQLWDMSRPRTDEDLNELLGITTIR VTVCEGKNLLQRANELVNPDWQDVDAATATRGRSAASRPTERPRAP ARSASRPRRP VE, MTSRRSVKSGPREVPRDEYEDLYYTPSSGMASPDSPPDTSRRGALQTRSRQRGEVRFVQYDES DYALYGGSSSEDDEHPEVPRTRRPVSGAVLSGPGPARAPPPPAGSGGAGRTPTTAPRAPRTQR VATKAPAAPAAETTRGRKSAQPESAALPDAPASTAPTRSKTPAQGLARKLHFSTAPPNPDAPW TPRVAGFNKRVFCAAVGRLAAMHARMAAVQLWDMSRPRTDEDLNELLGITTIRVTVCEGKN LLORANELVNPDWODVDAATATRGRSAASRPTERPRAP ARSASRPRRPVEIWEYCEPCMTS RRSVKSGPREVPRDEYEDLYYTPSSGMASPDSPPDTSRRGALQTRSRQRGEVRFVQYDESDYA LYGGSSSEDDEHPEVPRTRRPVSGAVLSGPGPARAPPPPAGSGGAGRTPTTAPRAPRTQRVATK APAAPAAETTRGRKSAQPESAALPDAPASTAPTRSKTPAQGLARKLHFSTAPPNPDAPWTPRV AGFNKRVFCAAVGRLAAMHARMAAVQLWDMSRPRTDEDLNELLGITTIRVTVCEGKNLLQR ANELVNPDWQDVDAATATRGRSAASRPTERPRAPARSASRPRRPVE membrane-translocating sequence (MST) from h region of the signal sequence of Kaposi fibroblast growth factor IWEYCEPCAAVLLPVLLAAP.

A A VTXP VLLAAPIVVEYCEPCAAVLLPVLL A AP C35 Epitope Exemplary Cell-Penetrating Peptide Sequence (CPP) Exemplary Polypeptide Containing C35 Epitope and CPP T38 - V46 of SBQ ID N0:2 TYLELASAV HSV-1 tegument protein VP22 TVT .RT.AS A VMTSRRSVKSGPREVPRDEYEDLYYTPSSGMASPDSPPDTSRRGALOTRSRORGE VRFVQYDESDYALYGGSSSEDDEHPEVPRTRRPVSGAVLSGPGPARAPPPPAGSGGAGRTPTT APRAPRTQRVATKAPAAPAAETTRGRKSAQPESAALPDAPASTAPTRSKTPAQGLARKLHFST APPNPDAPWTPRVAGFNKRVFCAAVGRLAAMHARMAAVQLWDMSRPRTDEDLNELLGITTI RVTVCBGKNLLQRANELVNPDWQDVBAATATRGRSAASRPTERPRAPARSASRPKRPVE, MTSRRSVKSGPREVPRDEYEDLYYTPSSGMASPDSPPDTSRRGALQTRSRQRGEVRFVQYDES DYALYGGSSSEDDEHPEVPRTRRPVSGAVLSGPGPARAPPPPAGSGGAGRTPTTAPRAPRTQR VATKAPAAPAAETTRGRKSAQPESAALPDAPASTAPTRSKTPAQGLARKLHFSTAPPNPDAPW TPRVAGFNKRVF CAA V GRLAAMHARMAAV QLWDMSRPRTDEDLNELLGITTIRVTV CEGKN LLORANELVNPDWODVD AATATRGRSAASRPTERPRAP ARSASRPRRP VETYLELASAVMTS RRSVKSGPREVPRDEYEDLYYTPSSGMASPDSPPDTSRRGALQTRSRQRGEVRFVQYDESDYA LYGGSSSEDDEHPEVPRTRRPVSGAVLSGPGPARAPPPPAGSGGAGRTPTTAPRAPRTQRVATK APAAPAAETTRGRKSAQPESAALPDAPASTAPTRSKTPAQGLARKLHFSTAPPNPDAPWTPRV AGFNKRVFCAAVGRLAAMHARMAAVQLWDMSRPRTDEDLNELLGITTIRVTVCEGKNLLQR ANELVNPDWQD VD AATATRGRSAASRPTERPRAP ARSASRPRRP VE membrane-translocating sequence (MST) from h region of the signal sequence of Kaposi fibroblast growth factor TYLELASAVAAVLLPVLLAAP.

AAVLLPVLLAAP TYLELASAVAAVLLPVLLAAP C35 Epitope Exemplary Cell-Penetrating Peptide Sequence (CPP) Exemplary Polypeptide Containing C35 Epitope and CPP G61-169 ofSEQ ID NO:2 GTGAFEIEI HSV-1 tegument protein VP22 GTGAFEIEIMTSRRSVKSGPRBVPRDEYEDLYYTPSSGMASPDSPPDTSRRGALOTRSRORGEV RFVQYDESDYALYGGSSSEDDEHPEVPRTRRPVSGAVLSGPGPARAPPPPAGSGGAGRTPTTA PRAPRTQRVATKAPAAPAAETTRGRKSAQPESAALPDAPASTAPTRSKTPAQGLARKLHFSTA PPNPDAPWTPRVAGFNKRVFCAAVGRLAAMHARMAAVQLWDMSRPRTDEDLNELLGITT1R VTVCEGKNLLQRANELVNPDVVQDVD AATATRGRSAASRPTERPRAP ARSASRPRRPVE, MTSRRSVKSGPREVPRDEYEDLYYTPSSGMASPDSPPDTSRRGALQTRSRQRGEVRFVQYDES DYALYGGSSSEDDEHPEVPRTRRPVSGAVLSGPGPARAPPPPAGSGGAGRTPTTAPRAPRTQR VATKAPAAPAAETTRGRKSAQPESAALPDAPASTAPtRSKTPAQGLARKLHFSTAPPNPDAPW TPRVAGFNKRVF C AAV GRLAAMHARMAAV QLWDMSRPRTDEDLNELLGITTIRVTV CEGKN LLORANELVNPDWODVDAATATRGRSAASRPTERPRAPARSASRPRRPVEGTGAFF.TF,TMTSR RSVKSGPREVPRDEYEDLYYTPSSGMASPDSPPDTSRRGALQTRSRQRGEVRFVQYDESDYAL YGGSSSEDDEHPEVPRTRRPVSGAVLSGPGPARAPPPPAGSGGAGRTPTTAPRAPRTQRVATK APAAPAAETTRGRKSAQPESAALPDAPASTAPTRSKTPAQGLARKLHFSTAPPNPDAPWTPRV AGFNKRVF CAA V GRLAAMHARMAAV QLWDMSRPRTDEDLNELLGITTIRVTV CEGKNLLQR ANELVNPDVVQDVDAATATRGRSAASRPTERPRAP ARSASRPRRPVE membrane-translocating sequence (MST) from h region of the signal sequence of Kaposi fibroblast growth factor GTGAFEIEIAAVLLPVLLAAP. AAVTXPVLLAAPGTGAFEIEIAAVLLPVLLAAP C35 Epitope Exemplary Cell-Penetrating Peptide Sequence (CPP) Exemplary Polypeptide Containing C35 Epitope and CPP F65 - L73 ofSEQ DD NO:2 FEIBINGQL HSV-1 tegument protein VP22 FEIEINGOLMTSRRSVKSGPREVPRDEYEDLYYTPSSGMASPDSPPDTSRRGALOTRSRORGEV RFVQYDESDYALYGGSSSEDDEHPEVPRTRRPVSGAVLSGPGPARAPPPPAGSGGAGRTPTTA PRAPRTQRVATKAPAAPAAETTRGRKSAQPESAALPDAPASTAPTRSKTPAQGLARKLHFSTA PPNPDAPWTPRVAGFNKRVFCAAVGRLAAMHARMAAVQLWDMSRPRTDEDLNELLGITTIR VTVCEGKNLLQRANELVNPDVVQDVD AATATRGRSAASRPTERPRAP ARSASRPRRPVE, MTSRRSVKSGPREVPRDEYEDLYYTPSSGMASPDSPPDTSRRGALQTRSRQRGEVRFVQYDES DYALYGGSSSEDDEHPEVPRTRRPVSGAVLSGPGPARAPPPPAGSGGAGRTPTTAPRAPRTQR VATKAPAAPAAETTRGRECSAQPESAALPDAPASTAPTRSKTPAQGLARKLHFSTAPPNPDAPW TPRVAGFNKRVFCAAVGRLAAMHARMAAVQLWDMSRPRTDEDLNELLGITTIRVTVCEGKN LLORANELVNPDWODVDAATATRGRSAASRPTERPRAPARSASRPRRPVEFEIEINGOLMTSR RSVKSGPREVPRDEYEDLYYTPSSGMASPDSPPDTSRRGALQTRSRQRGEVRFVQYDESDYAL YGGSSSEDDEHPEVPRTRRPVSGAVLSGPGPARAPPPPAGSGGAGRTPTTAPRAPRTQRVATK APAAPAAETTRGRKSAQPESAALPDAPASTAPTRSKTPAQGLARKLHFSTAPPNPDAPWTPRV AGFNKRVFCAAVGRLAAMHARIvIAAVQLWDMSRPRTDEDLNELLGITTIRVTVCEGKNLLQR ANELVNPDWQDVD AATATRGRSAASRPTERPRAP ARSASRPRRPVE membrane-translocating sequence (MST) from h region of the signal sequence of Kaposi fibroblast growth factor FEIEINGOLAAVLLPVLLAAP. AAVLLPVLLAAPFEIEINGOLAAVLLPVLLAAP C35 Epitope Exemplary Cell-Penetrating Peptide Sequence (CPP) Exemplary Polypeptide Containing C35 Epitope and CPP 167 - F75 of SBQ ID NO:2 BEJNGQLVF hsv-1 tegument protein vp22 ieingolvfmtsrrsvk.sgprevprdeyedlyytpssgmaspdsppdtsrrga"LOTRRRORGF;v rfvqydesdyalyggssseddehpevprtrrpvsgavlsgpgparappppagsggagrtptta praprtqrvatkapaapaaettrgrksaqpesaalpdapastaptrsktpaqglarklhfsta ppnpdapwtprvagfnkrvfcaavgrlaamharmaavqlwdmsrprtdedlnellgittir vtvcegknllqranelvnpdwqdvdaatatrgrsaasrpterpraparsasrprrpve, mtsrrsvksgprevprdeyedlyytpssgmaspdsppdtsrrgalqtrsrqrgevrfvqydes. dyalyggssseddehpevprtrrpvsgavlsgpgparappppagsggagrtpttapraprtqr vatkapaapaaettrgrksaqpesaalpdapastaptrsktpaqglarexhfstappnpdapw tprvagfnkrvfcaavgrlaamharmaavqlwdmsrprtdedlnellgittirvtvcegkn lloranelvnpd w od vd a atatrgrs aasrpterprap ars a f?r pr r p vf.tfjngot ,vfmts rrsvksgprevprdeyedlyytpssgmaspdsppdtsrrgalqtrsrqrgevrfvqydesdya lyggssseddehpevprtrrpvsgavlsgpgparappppagsggagrtpttapraprtqrvatk apaapaaettrgrksaqpesaalpdapastaptrsktpaqglarklhfstappnpdapwtprv agenkrvf caa v grlaamharmaav qlwdmsrprtdedlnellgittirvtv cegknllqr anelvnpdvvqdvd aatatrgrsaasrpterprap arsasrprrpve membrane-translocating sequence (MST) from h region of flie signal sequence of Kaposi fibroblast growth factor ieingolvfaavllpvllaap. aavllpvllaapieingolvfaavllpvllaap C35 Epitope Exemplary Cell-Penetrating Peptide Sequence (CPP) Exemplary Polypeptide Containing C35 Epitope and CPP K77 - Y85 ofSEQ ID NO:2 KLENGGFPY HSV-1 tegument protein VP22 KLENGGFP YMTSRRSVKSGPREVPRDEYEDLYYTPSSGMASPDSPPDTSRRGALOTRSRORGE VRFVQYDESDYALYGGSSSfiDDEHPEVPRTRRPVSGAVLSGPGPARAPPPPAGSGGAGRTPTT APRAPRTQRVATKAPAAPAAETTRGRKSAQPESAALPDAPASTAPTRSKTPAQGLARKLHFST APPNPDAP WTPRVAGFNKRVFCAA V GRLAAMHARMAAV QLWDMSRPRTDEDLNELLGITO RVTVCEGKNLLQRANELVNPDWQDVD AATATRGRSAASRPTERPRAP ARSASRPRRPVE, MTSRRSVKSGPREVPRDEYEDLYYTPSSGMASPDSPPDTSRRGALQTRSRQRGEVRFVQYDES DYALYGGSSSEDDEHPEVPRTRRPVSGAVLSGPGPARAPPPPAGSGGAGRTPTTAPRAPRTQR VATKAPAAPAAETTRGRKSAQPESAALPDAPASTAPTRSKTPAQGLARKLHFSTAPPNPDAPW TPRVAGFNKRVFCAAVGRLAAMHARMAAVQLWDMSRPRTDEDLNELLGITTIRVTVCEGKN LLORANELVNPDVVODVDAATATRGRSAASRPTERPRAP ARSASRPRRP VEKLENGGFPYMTS RRSVKSGPREVPRDEYEDLYYTPSSGMASFDSPPDTSRRGALQTRSRQRGEVRFVQYDESDYA LYGGSSSEDDEHPEVPRTRRPVSGAVLSGPGPARAPPPPAGSGGAGRTPTTAPRAPRTQRVATfc APAAPAAETTRGRKSAQPESAALPDAPASTAPTRSKTPAQGLARKLHFSTAPPNPDAPWTPRV AGFNKRVFCAAVGRLAAMHARMAAVQLWDMSRPRTDEDLNELLGITTIRVTVCEGKNLLQR ANELVNPD W QD VDAATATRGRSAASRPTERPRAPARS ASRPRRP VE membrane-translocating sequence (MST) from h region ofthe signal sequence of Kaposi fibroblast growth factor KLENGGFPYAAVLLPVLLAAP. j AAVLLP VLLAAPKLENGGFP YAA VLLP VLLA AP 1 C35 Epitope Exemplary Cell-Penetrating Peptide Sequence (CPP) Exemplary Polypeptide Containing C35 Epitope and CPP Q72 - E86 ofSEQ ID NO:2 QLVFSKLENGGFPYE HSV-1 tegument protein VP22 olvrsklenggfpyemtsrrsvksgprevprdeyedlyytpssgmaspdsppdtsrrgalotrs rqrgevrfvqydesdyalyggssseddehpevprtrrpvsgavlsgpgparappppagsggag rtpttapbaprtqrvatkapaapaaettrgrksaqpesaalpdapastaptrsktpaqglark lhfstappnpdapwtprvagfnkrvfcaavgrlaamharmaavqlwdmsrprtdedlnell gitmvtvcegknllqranelvnpdvvqdvdaatatrgrsaasrpterpraparsasrprrpve, mtsrrsvksgprevprdeyedlyytpssgmaspdsppdtsrrgalqtrsrqrgevrfvqydes dyalyggssseddehpevprtrrpvsgavlsgpgparappppagsggagrtpttapraprtq1l vatkapaapaaettrgrksaqpesaalpdapastaptrsktpaqglarklhfstappnpdap% tprvagfnkrvf caa v grla amharm a a v qlwdmsrprtdedlnellgittirvtv cegkn lloranelvnpdwodvdaatatrgrsaasrpterpraparsasrprrpveolvfsklenggf pyemtsrrsvksgprevprdeyedlyytpssgmaspdsppdtsrrgalotrsrorgevrfvoy desdyalyggssseddehpevprtrrpvsgavlsgpgparappppagsggagrtpttapraprt qrvatkapaapaaettrgrksaqpesaalpdapastaptrsktpaqglarklhfstappnpda pwtprvagfnkrvfcaavgrlaamharmaavqlwdmsrprtdedlnellgittirvtvceg knllqranelvnpdwqdvdaatatrgrsaasrpterpraparsasrprrpve membrane-translocating sequence (MST) from h region of the signal sequence of Kaposi fibroblast growth factor OLVFSKLENGGFPYEAAVLLPVLLAAP. AAVLLPVLLAAPOLVFSKLENGGFPYEAAVLLPVLLAAP C35 Epitope Exemplary Cell-Penetrating Peptide Sequence (CPP) r: Exemplary Polypeptide Containing C35 Epitope and CPP G81 - L89 of SEQ ID NO:2 GQFPYEKDL HSV-1 tegument protein VP22 GGFPYEKDLMTSRRSVKSGPREVPRDEYEDLYYTPSSGMASPDSPPDTSRRGALOTRSRORGE VRFVQYDESDYALYGGSSSEDDEHPEVPRTKRPVSGAVLSGPGPARAPPPPAGSGGAGRTPTT APRAPRTQRVATKAPAAPAAETTRGRKSAQPESAALPDAPASTAPTRSKTPAQGLARKLHFST APPNPDAPWTPRVAGFNKRVF'CAAVGRLAAMHARMAAVQLWDMSRPRTDEDLNELLGITTI RVTVCEGKNLLQRANELVNPDWQDVD AATATRGRSAASRPTERPRAP ARSASRPRRPVE, MTSRRSVKSGPREVPRDEYEDLYYTPSSGMASPDSPPDTSRRGALQTRSRQRGEVRFVQYDES DYALYGGSSSEDDEHPEVPRTRRPVSGAVLSGPGPARAPPPPAGSGGAGRTPTTAPRAPRTQR VATKAPAAPAAETTRGRKSAQPESAALPDAPASTAPTRSKTPAQGLARKLHFSTAPPNPDAPW TPRVAGFNKRVFCAAVGRLAAMHARMAAVQLWDMSRPRTDEDLNELLGITTIRVTVCEGKN LLORANELVNPDWODVDAATATRGRSAASRPTERPRAPARSASRPRRPVEGGFPYEKDLMTS RRSVKSGPREVPRDEYEDLYYTPSSGMASPDSPPDTSRRGALQTRSRQRGEVRFVQYDESDYA LYGGSSSEDDEHPEVPRTRRPVSGAVLSGPGPARAPPPPAGSGGAGRTPTTAPRAPRTQRVATK APAAPAAETTRGRKSAQPESAALPDAPASTAPTRSKTPAQGLARKLHFSTAPPNPDAPWTPRV AGFNKRVFCAAVGRLAAMHARMAAVQLWDMSRPRTDEDLNELLGITTER.VTVCEGKNLLQR ANELVNPDWQDVD AATATRGRSAASRPTERPRAP ARSASRPRRPVE membrane-translocating sequence (MST) from h region of the signal sequence of Kaposi fibroblast growth factor GGFPYEKDLAAVLLPVLLAAP. AAVLLPVLLAAPGGFPYEKDLAAVLLPVLLAAP 035 Epitope Exemplary Cell-Penetrating Peptide Sequence (CPP) Exemplary Polypeptide Containing C35 Epitope and CPP K104. CI 12 of SEQ ID NO:2 KITNSRPPC HSV-1 tegument protein VP22 TCTTNSRPPCMTSRRSVKSGPREVPRDEYEDLYYTPSSGMASPDSPPDTSRRGALOTRSRORGEV RFVQYDESDYALYGGSSSEDDEHPEVPRTRRPVSGAVLSGPGPARAPPPPAGSGGAGRTPTTA PRAPRTQRVATKAPAAPAAETTRGRKSAQPESAALPDAPASTAPTRSKTPAQGLARKLHFSTA PPNPDAPWTPRVAGFNKRVFCAAVGRLAAMHARMAAVQLWDMSRPRTDEDLNELLGITTIR VTVCEGKNLLQRANELVNPDWQDVD AATATRGRSAASRPTERPRAP ARSASRPRRPVE, MTSRRSVKSGPREVPRDEYEDLYYTPSSGMASPDSPPDTSRRGALQTRSRQRGEVRFVQYDES DYALYGGSSSEDDEHPEVPRTRRPVSGAVLSGPGPARAPPPPAGSGGAGRTPTTAPRAPRTQR VATKAPAAPAAETIRGRKSAQPESAALPDAPASTAPTRSKTPAQGLARKLHFSTAPPNPDAPW TPRVAGFNKRVFCAAVGRLAAMHARMAAVQLWDMSRPRTDEDLNELLGITTIRVTVCEGKN TI.ORANELVNPDWODVDAATATRGRSAASRPTERPRAPARSASRPRRPVEKiTNSRPPCMTS RRSVKSGPREVPRDEYEDLYYTPSSGMASPDSPPDTSRRGALQTRSRQRGEVRFVQYDBSDYA LYGGSSSEDDEHPEVPRTRRPVSGAVLSGPGPARAPPPPAGSGGAGRTPTTAPRAPRTQRVATK APAAPAAETTRGRKSAQPESAALPDAPASTAPTRSKTPAQGLARKLHFSTAPPNPDAPWTPRV AGFNKRVFCAAVGRLAAMHARMAAVQLWDMSRPRTDEDLNELLGITTIRVTVCEGKNLLQR ANELVNPDVVQDVDAATATRGRSAASRPTERPRAPARSASRPRRPVE membrane-translocating sequence (MST) from b. region of Hie signal sequence of Kaposi fibroblast growth factor TOTNSRPPCAAVLLPVLLAAP. AAVLLPVLLAAPK3TNSRPPCAAVLLPVLLAAP C35 Epitope Exemplary Cell-Penetrating Peptide Sequence (CPP) Exemplary Polypeptide Containing C35 Epitope and CPP K.104 - VI13 of SEQ ID NO:2 KITNSRPPCV HSV-1 tegument protein VP22 KTTNSRPPCVMTSRR.SVKSGPREVPRDEYEDLYYTPSSGMASPDSPPDTSRRGALOTRSRORGE VRFVQYDESDYALYGGSSSEDDEHPEVPRTRRPVSGAVLSGPGPARAPPPPAGSGGAGRTPTT apraprtqrvatkapaapaaettrgrksaqpesaalpdapastaptrsktpaqglarklhfsT APPNPDAPWTPRVAGFNKRVFCAAVGRLAAMHARMAAVQLWDMSRPRTDEDLNELLGITTI rvtvcegknllqranelvnpdvvqdvdaaTAtrgrsaasrpterpraparsasrprrpve, MTSRRSVKSGPREVPRDEYEDLYYTPSSGMASPDSPPDTSRRGALQTRSRQRGEVRPVQYDES DYALYGGSSSEDDEHPEVPRTRRPVSGAVLSGPGPARAPPPPAGSGGAGRTPTTAPRAPRTQR VATKAPAAPAAETTRGRKSAQPESAALPDAPASTAPTRSKTPAQGLARKLHFSTAPPNPDAPW TPRVAGFNKRVFCAAVGRLAAMHARMAAVQLWDMSRPRTDEDLNELLGITTIRVTVCEGKNi lloranelvnpdwodvdaatatrgrsaasrpterpraparsasrprrpvekitnsrppcvmt! SRRSVKSGPREVPRDEYEDLYYTPSSGMASPDSPPDTSRRGALQTRSRQRGEVRFVQYDESDY. alyggssseddehpevprtrrpvsgavlsgpgparappppagsggagrtpttapraprtqrvat kapaapaaettrgrksaqpesaalpdapastaptrsktpaqglarklhfstappnpdapwtpr vagfnkrvfcaavgrlaamharmaavqlwdmsrprtdedlnellgittirvtvcegknllq ranelvnpdwqdvdaatatrgrsaasrptbrpraparsasrprrpve membrane-translocating sequence (MST) from h region ofthe signal sequence of Kaposi fibroblast growth, factor kttnsrppcvaavllpvllaap. a a vllpVllaapkitnsrppcvaavllpvllaap C35 Epitope Exemplary Cell-Penetrating Peptide Sequence (CPP) Exemplary Polypeptide Containing C35 Epitope and GPP 1105 - VI13 ofSEQ ID NO:2 ITNSRPPCV hsv-1 tegument protein vp22 itnsrppcvmtsrrsvksgprevprdeyedlyytpssgmaspdsppdtsrrgalotrsrorgev rfvqydesdyalyggssseddehpevprtrrpvsgavlsgpgparappppagsggagrtptta praprtqrvatkapaapaaettrgrksaqpesaalpdapastaptrsktpaqglarklhfsta ppnpdapwtprvagfnkrvfcaavgrlaamharmaavqlwdmsrprtdedlnellgittir vtvcegknllqranelvnpdwqdvdaatatrgrsaasrpterpraparsasrprrpve, mtsrrsvksgprevprdeyedlyytpssgmaspdsppdtsrrgalqtrsrqrgevrfvqydes dyalyggssseddehpevprtrrpvsgavlsgpgparappppagsggagrtpttapraprtqr vatkapaapaaettrgrksaqpesaalpdapastaptrsktpaqglarklhfstappnpdapw tprvagfnkrvfcaavgrlaamharmaavqlwdmsrprtdedlnellgittirvtvcegkn lloranelvnpdwodvdaatatrgrsaasrpterprap arsasrprrp veitnsrppcvmts rrsvksgprevprdeyedlyytpssgmaspdsppdtsrrgalqtrsrqrgevrfvqydesdya lyggssseddehpevprtrrpvsgavlsgpgparappppagsggagrtpttapraprtqrvatk apaapaaettrgrksaqpesaalpdapastaptrsktpaqglarklhfstappnpdapwtprv agfnkrvfcaavgrlaamharmaavqlwdmsrprtdedlnellgittirvtvcegknllqr akelvnpdwqdvdaatatrgrsaasrpterpraparsasrprrpve membrane-translocating sequence (MST) from h region of the signal sequence of Kaposi fibroblast growth, factor itnsrppcvaavllpvllaap. aavllpvllaapitnsrppcvaavllpvllaap C35 Epitope Exemplary Cell-Penetrating Peptide Sequence (CPP) Exemplary Polypeptide Containing C35 Epitope and CPP T101-V113 ofSEQ ID no:2 TLEKITNSRPPCVIL hsv-1 tegument protein vp22 tlekitnsrppcvmtsrrsvksgprevprdeyedlyytpssgmaspdsppdtsrrgalotrsro rgevrfvqydesdyalyggssseddehpevprtrrpvsgavlsgpgparappppagsggagrt pttapraprtqrvatkapaapaaettrgrksaqpesaalpdapastaptrsktpaqglakklh fstappnpdapwtprvagfnkrvfcaavgrlaamharmaavqlwdmsrprtdedlnellgi TnRVTVCEGKNLLQRANELVNPDWQDVDAATATRGRSAASRPTERPRAPARSASRPKRPVEs. mtsrrsvksgprevprdeyedlyytpssgmaspdsppdtsrrgalqtrsrqrgevrfvqydes dyalyggssseddehpevprtrrpysgavlsgpgparappppagsggagrtpttapraprtqr vatkapaapaaettrgrksaqpesaalpdapastaptrsktpaqglarklhfstappnpdapw tprvagfnkrvfcaavgrlaamharmaavqlwdmsrprtdedlnellgittirvtvcegkn LLORANELVNPDVVODVD AATATRGRSAASRPTERPRAP ARSASPPRRPVF.TT/RKTTNSPPPCV mtsrrsvksgprevprdeyedlyytpssgmaspdsppdtsrrgalqtrsrqrgevrfvqydes dyalyggssseddehpevprtrrpvsgavlsgpgparappppagsggagrtpttapraprtqr' vatkapaapaaettrgrksaqpesaalpdapastaptrsktpaqglarklhfstappnpdapw tprvagfnkrvfcaavgrlaamharmaavqlwdmsrprtdedlnellgittirvtvcegkk llqranelvnpdwqdvdaatatrgrsaasrpterpraparsasrprrpve membrane-translocating sequence (MST) from h region of the signal sequence of Kaposi fibroblast growth factor tlekitnsrppcvaavllpvllaap. aavllpvllaaptlekttnsrppcvaavllpvllaap C35 Epitope Exemplary Cell-Penetrating Peptide Sequence (CPP) Exemplary Polypeptide Containing C35 Epitope and CPP 193 - VI13 of SEQ ID no:2 IRRASNGETLEKITNSRPP CV hsv-1 tegument protein vp22 mrasngetlekitnsrppcvmtsrrsvksgprevprdeyedlyytpssgmaspdsppdtsrpga lqtrsrqrgevrfvqydesdyalyggssseddehpevprtrrpvsgavlsgpgparappppag sggagrtpttapraprtqrvatkapaapaaettrgrksaqpesaalpdapastaptrsktpaq glarklhfstappnpdapwtprvagfnkrvfcaavgrlaamharmaavqlwdmsrprtde dlnbllgittirvtvcegknllqranelvnpdwqdvd aatatrgrsaasrpterprap arsa srprrpve, mtsrrsvksgprevprdeyedlyyipssgmaspdsppdtsrrgalqtrsrqrgevrfvqydes dyalyggssseddehpevprtrrpvsgavlsgpgparappppagsggagrtpttapraprtqr vatrapaapaaettrgrksaqpesaalpdapastaptrsktpaqglarklhfstappnpdapw tprvagfnkrvfcaavgrlaamharmaavqlwdmsrprtdedlnellgittirvtvcegkn lloranelvnpdwqdvdaatatrgrsaasrpterpraparsasrprrpveirrasngetleki TOKPPPCVMTSRRSVKSGPPEVPPDEYEDLYVTPSSOM A SPDSPPTDTSR P 0 A T OTP ST? OP OP.V kfvqydesdyalyggssseddehpevprtrrpvsgavlsgpgparappppagsggagrtptta praprtqrvatkapaapaaettrgrksaqpesaalpdapastaptrsktpaqglarklhfsta ppnpdapwtprvagfnkrvfcaavgrlaamharmaavqlwdmsrprtdedlnellgittir vtvcegknllqranelvnpdwqdvdaatatrgrsaasrpterpraparsasrprrpve membrane-translocating sequence (MST) from h region ofthe signal sequence of Kaposi fibroblast growth factor irrasngetlekitnsrppcvaavllpvllaap. aavllpvllaapirrasngetlekitnsrppcva a vllpvtxa ap C35 Epitope Exemplary Cell-Penetrating Peptide Sequence (CPP) Exemplary Polypeptide Containing C35 Epitope and CPP D88 - VI13 of SEQ ID NO:2 DLIEAIRRASNGETLEKTrN SRPPCV hsv-1 tegument protein vp22 dlieamrasngetlekitnsrppcvmtsrrsvksgprevprdeyedlyytpssgmaspdsppdt srrgalqtrsrqrgevrfvqydesdyalyggssseddehpevprtrrpvsgavlsgpgparap pppagsggagrtpttapraprtqrvatkapaapaaettrgrksaqpesaalpdapastaptrs ktpaqglarexhfstappnpdapwtprvagfnkrvfcaavgrlaamharmaavqlwdmsr prtdedlnellgittirvtvcegknllqranelvnpdwqdvdaatatrgrsaasrpterpra p arsasrprrpve, mtsrrsvksgprevprdeyedlyytpssgmaspdsppdtsrrgalqtrsrqrgevrfvqydes dyalyggssseddehpevprtrrpvsgavlsgpgparappppagsggagrtpttapraprtqr vatkapaapaaettrgrksaqpesaalpdapastaptrsktpaqglarklhfstappnpdapw tprvagfnkrvfcaavgrlaamharmaavqlwdmsrprtdedlnellgittirvtvcegkn lloranelvnpdwgdvdaatatrgrsaasrpterpraparsasrprrpvedlieairrasnge tlekitnsrppcvmtsrrsvksgprevprdeyedlyytpssgmaspdsppdtspr a a T.OTR rr o rgevrfvqydesdyalyggssseddehpevprtrrpvsgavlsgpgparappppagsggagrt pttapraprtqrvatkapaapaaettrgrksaqpesaalpdapastaptrsktpaqglarklh fstappnpdapwtprvagfnkrvfcaavgrlaamharmaavqlwdmsrprtdedlnellgi ttirvtvcegknllqranelvnpdwqdvdaatatrgrsaasrpterpraparsasrprrpve' membrane-translocating sequence (MST) from h region of the signal sequence of Kaposi fibroblast growth factor dlieairrasngetlekitnsrppcvaavllpvllaap. aavllpvllaapdlieairrasngetlekitnsrppcva avt jpvlla ap C35 Epitope Exemplary Cell-Penetrating Peptide Sequence (CPP) Exemplary Polypeptide Containing C35 Epitope and CPP P84 - VI13 ofSEQ ID NO:2 PVRKPLIEAIRRASNGETL EKTTNSRPPCV hsv-1 tegument protein vp22 pyekdlieairrasngetlekitnsrppcvmtsrrsvksgprevprdeyedlyytpssgmaspds ppdtsrrgalqtrsrqrgevrfvqydesdyalyggssseddehpevprtrrpvsgavlsgpgp arappppagsggagrtpttapraprtqrvatkapaapaaettrgrksaqpesaalpdapasta PTRSKTPAQGLARKLHFSTAPPNPDAPWTPRVAGFNKRVFCAAVGRLAAMHARMAAVQLWDi MSRPRTDEDLNELLGITTIRVTVCEGKNLLQRANELVNPDWQDVDAATATRGRSAASRPTER PRAPARSASRPRRPVE, • mtsrrsvksgprevprdeyedlyytpssgmaspdsppdtsrrgalqtrsrqrgevrfvqydes dyalyggssseddehpevprtrrpvsgavlsgpgparappppagsggagrtpttapraprtqr vatkapaapaaettrgrksaqpesaalpdapastaptrsktpaqglarklhfstappnpdapw tprvagfnkrvfcaavgrlaamharmaavqlwdmsrprtdedlnellgittirvtvcegkn lloranelvnpdwodvdaatatrgrsaasrpterpraparsasrprrpvepyekdlieatrpJI sngetlekitnsrppcvmtsrrs vksgprevprdeyedlyytprsgm aspdsppdtrrr gat .f)t rsrqrgevrfvqydesdyalyggssseddehpevprtrrpvsgavlsgpgparappppagsgg* agrtpttapraprtqrvatkapaapaaettrgrksaqpesaalpdapastaptrsktpaqgla rklhfstappnpdapwtprvagfnkrvfcaavgrlaamharmaavqlwdmsrprtdedln ellgitilrvtvcegknllqranelvnpdvvqdvdaatatrgrsaasrpterpraparsasrp rrpve membrane-translocating sequence (MST) from h region of the signal sequence of Kaposi fibroblast growth factor pyekdlieairrasngetlekitnsrppcvaavllpvli.aap. aavllpvllaappyekdlieairrasngetlekitnsrppcva a vt.tpvt.t .a ap C35 Epitope Exemplary Cell-Penetrating Peptide Sequence (CPP) Exemplary Polypeptide Containing C35 Epitope and CPP ! K77 -VI13 ofSEQ ID NO:2 KLENGGFPYEKDLIEAffiR ASNGETLEKITNSRPPCV hsv-1 tegument protein vp22 klenggfpyekdlieairrasngetlekitnsrppcvmtsrrsvksgprevprdeyedlyytpss gmaspdsppdtsrrgalqtrsrqrgevkfvqydesdyalyggssseddehpevprtrrpvsga vlsgpgparappppagsggagrtpttapraprtqrvatkapaapaaettrgrksaqpesaalP" dapastaptrsktpaqglarklhfstappnpdapwtprvagfnkrvfcaavgrlaamharm aavqlwdmsrprtdedlnellgittervtvcegknllqranelvnpdvvqdvdaatatrgrs aasrpterpraparsasrprrpve, mtsrrsvksgprevprdeyedlyytpssgmaspdsppdtsrrgalqtrsrqrgevrfvqydes dyalyggssseddehpevprtrrpvsgavlsgpgparappppagsggagrtpttapraprtqr vatkapaapaaettrgrksaqpesaalpdapastaptrsktpaqglarklhfstappnpdapw tprvagfnkrvfcaavgrlaamharmaavqlwdmsrprtdedlnellgittirvtvcegkn lloranelvnpdwodvdaatatrgrsaasrpterpraparsasrprrpveklenggfpyekd l1eairrasngetlekitnsrppcvmtsrrsvksgprevprdeyedlyytpssgmaspdsppdts rrgalqtrsrqrgevrfvqydesdyalyggssseddehpevprtrrpvsgavlsgpgparapp ppagsggagrtpttapraprtqrvatkapaapaaettrgrksaqpesaalpdapastaptrsk tpaqglarklhfstappnpdapwtprvagfnkrvfcaavgrlaamharmaavqlwdmsrp rtdedlnellgittirvtvcegknllqranelvnpdwqdvd aatatrgrsaasrpterprap arsasrprrpve membrane-translocating sequence (MST) fromh region of die signal sequence of Kaposi fibroblast growth factor KLENGGFPYEKDLIEAIRRASNGETLEKrrNSRPPCVAAVLLPVLLAAP. AAVLLPVLLAAPKLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPCV AAVLLPVLLAAP C35 Epitope Exemplary Cell-Penetrating Peptide Sequence (CPP) Exemplary Polypeptide Containing C35 Epitope and CPP Q72 - V113 ofSEQ ID NO:2 QLVFSKLENGGFPYEKDLI EAIKRASNGBIXEKTmSR PPCV hsv-1 tegument protein vp22 OLVFSKLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPCVMTSRRSVKSGPREVPRDEYEDLY YTPSSGMASPDSPPDTSRRGALQTRSRQRGEVRFVQYDESDYALYGGSSSEDDEHPEVPRTRR PVSGAVLSGPGPARAPPPPAGSGGAGRTPTTAPRAPRTQRVATKAPAAPAAETTRGRKSAQPE SAALPDAPASTAPTRSKTPAQGLARKLHFSTAPPNPDAPWTPRVAGFNKRVFCAAVGRLAAM HARMAAV QLWDMSRPRTDEDLNELLGITTIRVTV CEGKNLLQRANELVNPD VV QD VDAATA TRGRSAASRPTERPRAP ARSASRPRRPVE, MTSRRSVKSGPREVPRDEYEDLYYTPSSGMASPDSPPDTSRRGALQTRSRQRGEVRFVQYDES DYALYGGSSSEDDEHPEVPRTRRPVSGAVLSGPGPARAPPPPAGSGGAGRTPTTAPRAPRTQR VATKAPAAPAAETTRGRKSAQPESAALPDAPASTAPTRSKTPAQGLARKLHFSTAPPNPDAPW TPRVAGFNKRVFCAAVGRLAAMHARMAAVQLWDMSRPRTDEDLNELLGi'1'l'lRVTVCEGKN LLORANELVNPDWODVDAATATRGRSAASRPTERPRAPARSASRPRRPVEOLVFSKLENGGR PYEKDLTEAIRRASNGETLEKITNSRPPCVMTSRRSVKSGPREVPRDEYEDLYYTPSSGMASPDS ppdtsrrgalqtrsrqrgevrfvqydesdyalYggssseddehpevprtrrpvsgavlsgpgP' ARAPPPPAGSGGAGRTPTTAPRAPRTQRVATKAPAAPAAETTRGRKSAQPESAALPDAPASTA PTRSKTPAQGLARKLHFSTAPPNPDAPWTPRVAGFNKRVFCAAVGRLAAMHARMAAVQLWD MSRPRTDEDLNELLGITHRVTVCEGKNLLQRANELVNPDWQDVDAATATRGRSAASRPTER PRAPARSASRPRRPVE membrane-translocating sequence (MST) from h region of die signal sequence of Kaposi fibroblast growth factor OLVFSICLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPCVAAVLLPVLLAAP.

AAVLLPVLLAAPOLVFSKLENGGFPYEKDLIEAIRRASNGETLEKTTN'SRPPCV AAVI.TPVT.T.A AP C35 Epitope Exemplary Cell-Penetrating Peptide Sequence (CPP) Exemplary Polypeptide Containing C35 Epitope and CPP F65 - VI13 of SEQ ID NO:2 FEffilNGQLVFSKLENGGF PYEKDLIEAIRRASNGETL EKITOSRPPCV HSV-1 tegument protein VP22 FKTRTNGQLVFSKLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPCVMTSRRSVKSGPREVPRD^ EYEDLYYTPSSGMASPDSPPDTSRRGALQTRSRQRGEVRFVQYDESDYALYGGSSSEDDEHPEj VPRTRRPVSGAVLSGPGPARAPPPPAGSGGAGRTPTTAPRAPRTQRVATKAPAAPAAETTRGR KSAQPESAALPDAPASTAPTRSKTPAQGLARKLHFSTAPPNPDAPWTPRVAGFNKRVFCAAVG RLAAMHARMAAVQLWDMSRPRTDEDLNELLGITTIRVTVCEGKNLLQRANELVNPDWQDV DAATATRGRSAASRPTERPRAP ARSASRPRRPVE, MTSRRSVKSGPREVPRDEYEDLYYTPSSGMASPDSPPDTSRRGALQTRSRQRGEVRFVQYDESI DYALYGGSSSEDDEHPEVPRTRRPVSGAVLSGPGPARAPPPPAGSGGAGRTPTTAPRAPRTQ^ VATKAPAAPAAETTRGRKSAQPESAALPDAPASTAPTRSKTPAQGLARKLHFSTAPPNPDAPw! TPRVAGFNKRVFCAAVGRLAAMHARMAAVQLWDMSRPRTDEDLNELLGITTIRVTVCEGKN LLORANELVNPDWODVD AATATRGRSAASRPTERPRAP ARSASRPRRP VEFEIEINGOLVFSK LENGGFPYEKDLIEAIRRASNGETLEKITNSRPPCVMTSRRSVKSGPREVPRDEYEDLYYTPSSG MASPDSPPDTSRRGALQTRSRQRGEVRFVQYDESDYALYGGSSSEDDEHPEVPRTRRPVSGAV LSGPGPARAPPPPAGSGGAGRTPTTAPRAPRTQRVATKAPAAPAAETTRGRKSAQPESAALPD APASTAPTRSKTPAQGLARKLHFSTAPPNPDAPWTPRVAGFNKRVFCAAVGRLAAMHARMA AV QLWDMSRPRTDEDLNELLGITTIRVTV CEGKNLLQRANELVNPD W QD VD AATATRGRSA ASRPTERPRAPARSASRPRRPVE membrane-translocating sequence (MST) from h region of the signal sequence of Kaposi fibroblast growth factor FEIEINGOLVFSKLENGGFPYEKDLIEAIRRASNGETLEKITNrSRPPCVAAVT.LPVLLAAP.

AAVLLPVLLAAPFEIEINGQLVFSKLENGGFPYEKDLIEAIRRASNGETLEglTNSRPPCVAAVLL PVLLAAP C35 Epitope Exemplary Cell-Penetrating Peptide Sequence (CPP) Exemplary Polypeptide Containing C35 Epitope and CPP L59 -VI13 ofSEQ ID NO:2 LGGTGAFEIEINGQLVFSK LENGGFPYEKDLIEAIRRA SKGETLEKITNSRPPCVIL HSV-1 tegument protein VP22 T .GOTG A FRIETNGOLVFSKLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPCVMTSRRS VKSGP- REVPRDEYEDLYYTPS S GM ASPDSPPDTSRJR.GALQTRSRQRGEVRFV Q YDESD YALY GGS S SE DDEHPEVPRTRRPVSGAVLSGPGPARAPPPPAGSGGAGRTPTTAPRAPRTQRVATKAPAAPAA ETTRGRKSAQPESAALPDAPASTAPTRSKTPAQGLARKLHFSTAPPNPDAPWTPRVAGFNKRV FCAAVGRLAAMHARMAAVQLWDMSRPRTDEDLNELLGITTIRVTVCEGKNLLQRANELVNP DWQDVD AATATRGRSAASRPTERPRAP ARSASRPRRPVE, MTSRRSVKSGPREVPRDEYEDLYYTPSSGMASPDSPPDTSRRGALQTRSRQRGEVRFVQYDES DYALYGGSSSEDDEHPEVPRTRRPVSGAVLSGPGPARAPPPPAGSGGAGRTPTTAPRAPRTQR VATKAPAAPAAETTRGRKSAQPESAALPDAPASTAPTRSKTPAQGLARKLHFSTAPPNPDAPW TPRVAGFNKRVFCAAVGRLAAMHARMAAVQLWDMSRPRTDEDLNELLGITTIRVTVCEGKN ULORANFLVNPDWODVD AATATRGRSAASRPTERPRAP ARSASRPRRPVELGGTGAFEIEING OLVFSKLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPCVMTSRRSVKSGPREVPRDEYEDLY YTPSSGMASPDSPPDTSRRGALQTRSRQRGEVRFVQYDESDYALYGGSSSEDDEHPEVPRTRR PVSGAVLSGPGPARAPPPPAGSGGAGRTPTTAPRAPRTQRVATKAPAAPAAETTRGRKSAQPE SAALPD APASTAPTRSKTPAQGLARKLHFSTAPPNPDAPWTPRVAGFNKRVF CAA V GRLA AM HARMAAVQLWDMSRPRTDEDLNELLGITnRVTVCEGKNLLQRANELVNPDWQDVDAATA TRGRSAASRPTERPRAPARSASRPRRPVE membrane-translocating sequence (MST) from h region ofthe signal sequence of Kaposi fibroblast growth factor LGGTGAFE3EINGOLVFSKLENGGFPYEKDLIEAIRRASNGETLEKITNSRPPCVAAVLLPVLLAAP.

AAVLLPVLLAAPLGGTGAFEIEINGOLVFSKLENGGFPYEKDLTEAIRRASNGETLEKITNSRPPCV AAVLLPVLLAAP G99- VI13 ofSEQ IDNO:2 GETLEKtTNSBPPCV HSV-1 tegument protein VP22 GETLEKITNSRPPCVMTSRRSVKSGPREVPRDEYEDLYYTPSSGMASPDSPPDTSRRGALOTRS RQRGEVRFVQYDESDYALYGGSSSEDDEHPEVPRTRRPVSGAVLSGPGPARAPPPPAGSGGAG RTPTTAPRAPRTQRVATKAPAAPAAETTRGRKSAQPESAALPDAPASTAPTRSKTPAQGLARK LHFSTAPPNPDAPWTPRVAGFNKRVFCAAVGRLAAMHARMAAVQLWDMSRPRTDEDLNELL GnilRVTVCEGKNLLQRANELVNPDVVQDVDAATATRGRSAASRPTERPRAP ARSASRPRRPVE, MTSRRSVKSGPRBVPRDEYEDLYYTPSSGMASPDSPPDTSRRGALQTRSRQRGEVRFVQYDES D YALY GGSSSEDDEHPEVPRTRRP V SGAVLSGPGPARAPPPPAGSGGAGRTPTTAPRAPRTQR VATKAPAAPAAETTRGRKSAQPESAALPDAPASTAPTRSKTPAQGLARKLHFSTAPPNPDAPW TPRVAGFNKRVFCAAVGRLAAMHARMAAVQLWDMSRPRTDEDLNELLGITnRVTVCEGKN; LLORANELVNPDWQDVD AATATRGRSAASRPTERPRAP ARSASRPRRP VEGETLEKITNSRPP.1 CVMTSRRSVKSGPREVPRDEYEDLYYTPSSGMASPDSPPDTSRRGALQTRSRQRGEVRFVQYD ESDYALYGGSSSEDDEHPEVPRTRRPVSGAVLSGPGPARAPPPPAGSGGAGRTPTTAPRAPRTQ RVATKAPAAPAAETTRGRKSAQPESAALPDAPASTAPTRSKTPAQGLARKLHFSTAPPNPDAPi WTPRV AGFNKRVF C AA V GRLAAMHARMAAV QLWDMSRPRTDEDLNELLGITTIRVTV CEGK NLLQRANELVNPDVVQDVDAATATRGRSAASRPTERPRAP ARSASRPRRPVE membrane-translocating sequence (MST) from h region ofthe signal sequence of Kaposi fibroblast growth factor GETLEKITNSRPPCVAAVLLPVLLAAP. AAVLLPVLLAAPGETLEKITNSRPPCVAAVLLPVLLA AP ElOO - VI13 of SBQ ID NO:2 ETLEKITNSRPPCV HSV-1 tegument protein VP22 ett.rkttnrrppcvmtsrrsvksgprevprdeyedlyytpssgmaspdsppdtskrgalotrsr qrgevrfvqydesdyalyggssseddehpevprtrrpvsgavlsgpgparappppagsggagR tpttapraprtqrvatkapaapaaettrgrksaqpesaalpdapastaptrsktpaqglarkl hfstappnpdapwtprvagfnkrvfcaavgrlaamharmaavqlwdmsrprtdedlnell gittirvtvcegknllqranelvnpdwqdvdaatatrgrsaasrpterpraparsasrprrpve,: MTSRRSVKSGPREVPRDEYEDLYYTPSSGMASPDSPPDTSRRGALQTRSRQRGEVRFVQYDES dyalyggssseddehpevprtrrpvsgavlsgpgparappppagsggagrtpttapraprtqrI VATKAPAAPAAETTRGRKSAQPESAALPDAPASTAPTRSKTPAQGLARKLHFSTAPPNPDAPW TPRVAGFNKRVFCAAVGRLAAMHARMAAVQLWDMSRPRTDEDLNELLGITTIRVTVCEGKN' LLORANELVNPDVVODVDAATATRGRSAASRPTERPRAPARSASRPRRPVEETLEKITNSRPPC VMTSRRSVKSGPREVPRDEYEDLYYTPSSGMASPDSPPDTSRRGALQTRSRQRGEVRFVQYDE SDYALYGGSSSEDDEHPEVPRTRRPVSGAVLSGPGPARAPPPPAGSGGAGRTPTTAPRAPRTQR VATKAPAAPAAETTRGRKSAQPESAALPDAPASTAPTRSKTPAQGLARKLHFSTAPPNPDAPW TPRVAGFNKRVTCAAVGRLAAMHARMAAVQLWDMSRPRTDEDLNELLGi'iTiRVTVCEGKN LLQRANELVNPDVVQDVDAATATRGRSAASRPTERPRAP ARSASRPRRPVE membrane-translocating sequence (MST) from h region of the signal sequence of Kaposi fibroblast growth factor ETLEKITNSRPPCVAAVLLPVLLAAP. AAVLLPVLLAAPETLEKITNSRPPCVAAVLLPVLLAAP TABLEE C35 Epitope Analog Exemplary Cell-Penetrating Peptide Sequence (CPP) Exemplary Polypeptide Containing C35 Epitope Analog and CPP Analog of S77 -Y85 of SEQ JD NO:2 having valine substituted for tyrosine at ninth amino acid residue (KLENGGFPY) HSV-1 tegument protein VP22 KLENGGFPVMTSRRSVKSGPREVPRDEYEDLYYTPSSGMASPDKPPDTSRRGALOTRS'RO'R GF. VRFV QYDESD YALY GGSSSEDDEHPEVPRTRRPVSGAVLSGPGPARAPPPPAGSGGAGRTPTT APRAPRTQRVATKAPAAPAAETTRGRKSAQPESAALPDAPASTAPTRSKTPAQGLARKLHPST APPNPDAPWTPRVAGFNKRVFCAAVGRLAAMHARMAAVQLWDMSRPRTDEDLNELLGITTI RVTVCEGKNLLQRANELVNPDWQDVD AATATRGRSAASRPTERPRAP ARSASRPRRPVE, MTSRRSVKSGPREVPRDBYEDLYYTPSSGMASPDSPPDTSRRGALQTRSRQRGEVRFVQYDES DYALYGGSSSEDDEHPEVPRTRRPVSGAVLSGPGPARAPPPPAGSGGAGRTPTTAPRAPRTQR VATKAPAAPAAETTRGRKSAQPESAALPDAPASTAPTRSKTPAQGLARiCLHFSTAPPNPDAPW TPRVAGFNKRVFCAAVGRLAAMHARMAAVQLWDMSRPRTDEDLNELLGITTIRVTVCEGKN LLORANELVNPDWODVDAATATRGRSAASRPTERPRAPARSASRPRRPVRTCLENGGFPVMTS RRSVKSGPREVPRDEYEDLYYTPSSGMASPDSPPDTSRRGALQTRSRQRGEVRFVQYDESDYA lyggssseddehpevprtrrpvsgavlsgpgparappppagsggagrtpttapraprtqrvatk APAAPAAETTRGRKSAQPESAALPDAPASTAPTRSKTPAQGLARKLHFSTAPPNPDAPWTPRV AGFNKRVFCAAVGRLAAMHARMAAVQLWDMSRPRTDEDLNELLGITTIRVTVCEGKNLLQR ANELVNPDVVQDVD AATATRGRSAASRPTERPRAP ARSASRPRRPVE ■» membrane-translocating sequence (MST) from h region of the signal sequence of Kaposi fibroblast growth factor KLENGGFPVAAVLLPVLLAAP.

AAVLLPVLLAAPKLENGGFPVAAVLLPVLLAAP ' 1 C35 Epitope Analog Exemplary Cell-Penetrating Peptide Sequence (CPP) Exemplary Polypeptide Containing C35 Epitope Analog and CPP Analog of K104 - CI 12 of SBQ ID NO:2 having leucine substituted for cysteine at the ninth amino add residue (KTTNSRPPL) hsv-1 tegument protein vp22 kitmsrpplmtsrrsvksgprevprdeyedlyytpssgmaspdsppdtsrrgalotrsrorgev rfvqydesdyalyggssseddehpevprtrrpvsgavlsgpgparappppagsggagrtptta praprtqrvatkapaapaaettrgrksaqpesaalpdapastaptrsktpaqglarklhfsta ppnpdapwtprvagfnkrvfcaavgrlaamharmaavqlwdmsrprtdedlnellgittir vtvcegknllqranelvnpdwqdvdaatatrgrsaasrpterprap arsasrprrpve, mtsrrsvksgprevprdeyedlyytpssgmaspdsppdtsrrgalqtrsrqrgevrfvqydes d yaly ggss seddehpevprtrrp v s gaylsgpgp arapppp ags ggagrtpttapraprtqr vatkapaapaaettrgrksaqpesaalpdapastaptrsktpaqglarklhfstappnpdapw tprvagfnkrvfcaavgrlaamharmaavqlwdmsrprtdedlnellgittirvtvcegkh lloranelvnpdwodvd aatatrgrsaasrpterpraparsasrprrpvekitnsrpplmts rrsvksgprevprdeyedlyytpssgmaspdsppdtsrrgalqtrsrqrgevrfvqydesdya lyggssseddbhpevprtrrpvsgavlsgpgparappppagsggagrtpttapraprtqrvatk. apaapaaettrgrksaqpesaalpdapastaptrsktpaqglarklhfstappnpdapwtprv agfnkrvfcaavgrlaamharmaavqlwdmsrprtdedlnellgittirvtvcegknllqr anelvnpdwqdvdaatatrgrsaasrpterpraparsasrprrpve membrane-translocating sequence (MST) from li region of the signal sequence of Kaposi fibroblast growth factor kttosrpplaavllpvllaap. aavllpvllaapkitnsrpplaavllpvllaap C35 Epitope Analog Exemplary Cell-Penetrating Peptide Sequence (CPP) Exemplary Polypeptide Containing C35 Epitope Analog and CPP .

Analog of 1105 - vi13 of SEQ ID NO:2 having leucine substituted for threonine at the second amino acid residue and alanine substituted for cysteine at the eighth amino acid residue (elnsrppcv) hsv-1 tegument protein vp22 ilnsrppavmtsrrsvksgprevprdeyedlyytpssgmaspdsppdtsrrgalotrsrorgev rfvqydesdyalyggssseddehpevprtrrpvsgavlsgpgparappppagsggagrtptta praprtqrvatkapaapaaettrgrksaqpesaalpdapastaptrsktpaqglarklhfsta ppnpdapwtprvagfnkrvfcaavgrlaamharmaavqlwdmsrprtdedlnellgittir vtvcegknllqranelvnpdvvqdvd aatatrgrsaasrpterprap arsasrprrpve, mtsrrsvksgprevprdeyedlyytpssgmaspdsppdtsrrgalqtrsrqrgevrfvqydes dyalyggssseddehpevprtrrpvsgavlsgpgparappppagsggagrtpttapraprtqr vatkapaapaaettrgrksaqpesaalpdapastaptrsktpaqglarklhfstapfnpdapw tprvagfnkrvfcaavgrlaamharmaavqlwdmsrprtdedlnellgittirvtvcegkn lloranelvnpdwodvdaatatrgrsaasrpterprap arsasrprrp veilnsrppavmts rrsvksgprevprdeyedlyytpssgmaspdsppdtsrrgalqtrsrqrgevrfvqydesdya lyggssseddehpevprtrrpvsgavlsgpgparappppagsggagrtpttapraprtqrvatk apaapaaettrgrksaqpesaalpdapastaptrsktpaqglarklhfstappnpdapwtprv agfnkrvfcaavgrlaamharmaavqlwdmsrprtdedlnellgittirvtvcegknllqr anelvnpd wqd vdaatatrgrsaasrpterpraparsasrprrpve membrane-translocating sequence (MST) ftomhiegioii ofthe signal sequence of Kaposi fibroblast growth factor ilnsrppavaavllpvllaap. aavllpvllaapilnsrppavaavllpvllaap C35 Epitope Analog Exemplary Cell-Penetrating Peptide Sequence (CPP) Exemplary Polypeptide Containing C3S Epitope Analog and CPP Analog of H05 - VI13 of SEQ ID NO:2 having methionine substituted for threonine at the second amino acid residue and alanine substituted for cysteine at the eighth amino acid residue (IMNSRPPCV) HSV-1 tegument protein VP22 IMNSRPPAVMTSRRSVKSGPKEVPRDEYEDLYYTPSSGMASPDSPPDTSRRGALOTRSRORGE VKFVQYDESDYALYGGSSSEDDEHPEVPRTRRPVSGAVLSGPGPARAPPPPAGSGGAGRTPTT APRAPRTQRVATKAPAAPAAETTRGRKSAQPESAALPDAPASTAPTRSKTPAQGLARKLHFST APPNPDAPWTPRVAGFNKRVFCAAVGRLAAMHARMAAVQLWDMSRPRTDEDLNELLGITTI RVTVCEGKNLLQRANELVNPDWQDVD AATATRGRSAASRPTERPRAP ARSASRPRRPVE, MTSRRSVKSGPREVPRDEYEDLYYTPSSGMASPDSPPDTSRRGALQTRSRQRGEVRFVQYDES DYALYGGSSSEDDEHPEVPRTRRPVSGAVLSGPGPARAPPPPAGSGGAGRTPTTAPRAPRTQR; VATKAPAAPAAETTRGRKSAQPESAALPDAPASTAPTRSKTPAQGLARKLHFSTAPPNPDAPW TPRVAGFNKRVFCAAVGRLAAMHARMAAVQLWDMSRPRTDEDLNELLGITTIRVTVCEGKN LLORANELVNPDWODVDAATATRGRSAASRPTERPRAP ARSASRPRRP VEIMNSRPPAVMTS RRSVKSGPREVPRDEYEDLYYTPSSGMASPDSPPDTSRRGALQTRSRQRGEVRFVQYDESDYA" LYGGSSSEDDEHPEVPRTRRPVSGAVLSGPGPARAPPPPAGSGGAGRTPTTAPRAPRTQRVATK APAAPAAETTRGRKSAQPESAALPDAPASTAPTRSKTPAQGLARKLHFSTAPPNPDAPWTPRV. AGFNKRVFCAAVGRLAAMHARMAAVQLWDMSRPRTDEDLNELLGITTIRVTVCEGKNLLQR ANELVNPDWQDVDAATATRGRSAASRPTERPRAP ARSASRPRRPVE membrane-translocating sequence (MST) from h region ofthe signal sequence of Kaposi fibroblast growth factor IMNSRPP AVAAVLLPVLLAAP. AAVLLPVLLAAPIMNSRPPAVAAVLLPVLLAAP Analog of 1105 - VI13 of SEQ ID NO:2 having serine substituted for cysteine at the eighth, axnino acid residue (ITNSRPPSV) HSV-1 tegument protein VP22 ITNSRPPSVMTSRRSVKSGPREVPRDEYEDLYYTPSSGMASPDSPPDTSRRGALOTRSRORGEV RFVQYDESDYALYGGSSSEDDEHPEVPRTRRPVSGAVLSGPGPARAPPPPAGSGGAGRTPTTA PRAPRTQRVATKAPAAPAAETTRGRKSAQPESAALPDAPASTAPTRSKTPAQGLARKLHFSTA PPNPDAPWTPRVAGFNKRVFCAAVGRLAAMHARMAAVQLWDMSRPRTDEDLNELLGITTTR VTVCEGKNLLQRANELVNPDWQDVD AATATRGRSAASRPTERPRAP ARSASRPRRPVE, MTSRRSVKSGPREVPRDEYEDLYYTTSSGMASPDSPPDTSRRGALQTRSRQRGEVRFVQYDES DYALYGGSSSEDDEHPEVPRTRRPVSGAVLSGPGPARAPPPPAGSGGAGRTPTTAPRAPRTQR VATKAPAAPAAETTRGRKSAQPESAALPDAPASTAPTRSKTPAQGLARKLHFSTAPPNPDAPW TPRVAGFNKRVFCAAVGRLAAMHARMAAVQLWDMSRPRTDEDLNELLGITTIRVTVCEGKri LLQRANELVNPDWQDVD AATATRGRSAASRPTERPRAPARSASRPRRPVEITNSRPPSVMTSR RSVKSGPREVPRDEYEDLYYTPSSGMASPDSPPDTSRRGALQTRSRQRGEVRFVQYDESDYAL YGGSSSEDDEHPEVPRTRRPVSGAVLSGPGPARAPPPPAGSGGAGRTPTTAPRAPRTQRVATK APAAPAAETTRGRKSAQPESAALPDAPASTAPTRSKTPAQGLARKLHFSTAPPNPDAPWTPRV AGFNKRVF C AAV GRLAAMHARMAAV QLWDMSRPRTDEDLNELLGITTIRVTVCEGKNLLQR ANELVNPDWQDVD AATATRGRSAASRPTERPRAP ARSASRPRRPVE membrane-translocating sequence (MST) from h region of the signal sequence of Kaposi fibroblast growth factor ITNSRPPSVAAVLLPVLLAAP. AAVLLPVLLAAPITNSRPPSVAAVLLPVLLAAP Analog of K104 - VI13 of SEQ ID NO:2 having serine substituted for cysteine at the ninth amino acid residue (KJTNSRPPSV) HSV-1 tegument protein VP22 KTTNSRPPSVMTSRRSVKSGPREVPRDEYEDLYYTPSSGMASPDSPPDTSRRGALOTRSRORGE VRFVQYDESDYALYGGSSSEDDEHPEVPRTRRPVSGAVLSGPGPARAPPPPAGSGGAGRTPTT APRAPRTQRVATKAPAAPAAETTRGRKSAQPESAALPDAPASTAPTRSKTPAQGLARKLHFST APPNPDAPWTPRVAGFNKRVFCAAVGRLAAMHARMAAVQLWDMSRPRTDEDLNELLGITTI RVTVCEGKNLLQRANELVNPDWQDVD AATATRGRSAASRPTERPRAP ARSASRPRRPVE, MTSRRSVKSGPREVPRDEYEDLYYTPSSGMASPDSPPDTSRRGALQTRSRQRGEVRFVQYDES DYALYGGSSSEDDEHPEVPRTRRPVSGAVLSGPGPARAPPPPAGSGGAGRTPTTAPRAPRTQR VATKAPAAPAAETTRGRKSAQPESAALPDAPASTAPTRSKTPAQGLARKLHFSTAPPNPDAPW TPRVAGFNKRVFCAAVGRLAAMHARMAAVQLWDMSRPRTDEDLNELLGITTIRVTVCEGKN LLORANELVNPDWODVD AATATRGRSAASRPTERPRAP ARSASRPRRPVFXITNSRPPSVMT SRRSVKSGPREVPRDEYEDLYYTPSSGMASPDSPPDTSRRGALQTRSRQRGEVRFVQYDESDY ALYGGSSSEDDEHPEVPRTRRPVSGAVLSGPGPARAPPPPAGSGGAGRTPTTAPRAPRTQRVAT KAPAAPAAETTRGRKSAQPESAALPDAPASTAPTRSKTPAQGLARKLHFSTAPPNPDAPWTPR VAGFNKRVFCAAVGRLAAMHARMAAVQLWDMSPJPRTDEDLNELLGITTIRVTVCEGKNLLQ RANELVNPDWQDVDAATATRGRSAASRPTERPRAPARSASRPRRPVE membrane-translocating sequence (MST} from h region of the signal sequence of Kaposi fibroblast growth factor KITNSRPPSVAAVLLPVLLAAP. AAVTXPVLLAAPKTTNSRPPSVA AVLLPVLLA AP Analog of G22 to C30 of SEQ ID NO:2 having alanine substituted for cysteine at ninth amino acid residue (GVRIWEYA) HSV-1 tegument protein VP22 GVRIWEYAMTSRRSVKSGPREVPRDEYEDLYYTPSSGMASPDSPPDTSRRGALOTRSRORGE VRFVQYDESDYALYGGSSSEDDEHPEVPRTRRPVSGAVLSGPGPARAPPPPAGSGGAGRTPTT APRAPRTQRVATKAPAAPAAETTRGRKSAQPESAALPDAPASTAPTRSKTPAQGLARKLHFST APPNPDAPWTPRVAGFNKRVFCAAVGRLAAMHARMAAVQLWDMSRPRTDEDLNELLGITTI RVTV CEGKNLLQRANELVNPD W QDVD AATATRGRSAASRPTERPRAP ARSASRPRRP VE, MTSRRSVKSGPREVPRDEYEDLYYTPSSGMASPDSPPDTSRRGALQTRSRQRGEVRFVQYDES DYALYGGSSSEDDEHPEVPRTRRPVSGAVLSGPGPARAPPPPAGSGGAGRTPTTAPRAPRTQR VATKAPAAPAAETTRGRKSAQPESAALPDAPASTAPTRSKTPAQGLARKLHFSTAPPNPDAPW TPRVAGFNKRWCAAVGRLAAMHARMAAVQLWDMSRPRTDEDLNELLGITTIRVTVCEGKN LLORANELVNPDWODVDAATATRGRSAASRPTERPRAP ARSASRPRRP VEGVRJWEYAMTS RRSVKSGPREVPRDEYEDLYYTPSSGMASPDSPPDTSRRGALQTRSRQRGEVRFVQYDESDYA LYGGSSSEDDEHPEVPRTRRPVSGAVLSGPGPARAPPPPAGSGGAGRTPTTAPRAPRTQRVATK APAAPAAETTRGRKSAQPESAALPDAPASTAPTRSKTPAQGLARKLHFSTAPPNPDAPWTPRY; AGFNKRVFCAAVGRLAAMHARMAAVQLWDMSRPRTDEDLNELLGrri'lRVTVCEGKNLLQR ANELVNPD W QDVD AATATRGRSAASRPTERPRAP ARSASRPRRP VE membrane-translocating sequence (MST) from h region of the signal sequence of Kaposi fibroblast growth factor GVRTWEY AAAVLLPVT ,L A AP. AAVLLPVLLAAPGVRIWEYAAAVLLPVLLAAP Analog of 125 to C33 ofSEQ ID NO:2 having alanine substituted for cysteine at the sixth, and ninth amino acid residues (IWEYAEPA) HSV-1 tegument protein VP22 tweyaepamtsrrsvksgprevprdeyedlyytpssgmaspdsppdtsrrgalotrsrorge vrfvqydesdyalyggssseddehpevprtrrpvsgavlsgpgparappppagsggagrtptf apraprtqrvatkapaapaaettrgrksaqpesaalpdapastaptrsktpaqglarklhfst appnpdapwtprvagfnkrvfcaavgrlaamharmaavqlwdmsrprtdedlnellgitti rvtvcegknllqranelvnpdwqdvd aatatrgrsaasrpterprap arsasrprrpve, mtsrrsvksgprevprdeyedlyytpssgmaspdsppdtsrrgalqtrsrqrgevrfvqydes dyalyggssseddehpevprtrrpvsgavlsgpgparappppagsggagrtpttapraprtqe vatkapaapaaettrgrksaqpesaalpdapastaptrsktpaqglarklhfstappnpdapw tprv agfnkrvf c a av grlaamharmaav qlwdmsrprtdedlnellgittirvtv cegkn lloranelvnpdwodvd aatatrgrsaasrpterprap ARSASRPRRPVF.TWKYARPAMTS rrsvksgprevprdeyedlyytpssgmaspdsppdtsrrgalqtrsrqrgevrfvqydesdya lyggssseddehpevprtrrpvsgavlsgpgparappppagsggagrtpttapraprtqrvatk apaapaaettrgrksaqpesaalpdapastaptrskTpaqglarklhfstappnpdapwtprv agfnkrvfcaavgrlaamharmaavqlwdmsrprtdedlnellgittirvtvcegknllqr anelvnpdwqdvdaatatrgrsaasrpterprap arsasrprrpve membrane-translocating sequence (MST) from h region of the signal sequence of Kaposi fibroblast growth factor iweyaepaaavllpvllaap. aavllpvllaapiweyaepaaavllpvllaap Analog of K104 -CI 12 of SEQ ID NO:2 having alanine substituted for cysteine at the ninth amino acid residue (KITNSRPPA) hsv-1 tegument protein vp22 kitnsrppamtsrrsvksgprevprdeyedlyytpssgmaspdsppdtsrrgalotrsrorgev rfvqydesdyalyggssseddehpevprtrrpvsgavlsgpgparappppagsggagrtptta praprtqrvatkapaapaaettrgrksaqpesaalpdapastaptrsktpaqglarklhfsta ppnpdapwtprvagfnkrvfcaavgrlaamharmaavqlwdmsrprtdedlnellgittir vtvcegknllqranelvnpdwqdvd aatatrgrsaasrpterprap arsasrprrpve, mtsrrsvksgprevprdeyedlyytpssgmaspdsppdtsrrgalqtrsrqrgevrfvqydes dyalyggssseddehpevprtrrpvsgavlsgpgparappppagsggagrtpttapraprtqr vatkapaapaaettrgrksaqpesaalpdapastaptrsktpaqglarxlhfstappnpdapw tprvagfnkrvfcaavgrlaamharmaavqlwdmsrprtdedlnellgittirvtvcegkn lloranelvnpdvvqdvd aatatrgrsaasrpterprap arsasrprrp vekitosrppamts rrsvksgprevprdeyedlyytpssgmaspdsppdtsrrgalqtrsrqrgevrfvqydesdya lyggssseddehpevprtrrpvsgavlsgpgparappppagsggagrtpttapraprtqrvatk apaapaaettrgrksaqpesaalpdapastaptrsktpaqglarklhfstappnpdapwtprv agfnkrvf caav grlaamharmaav qlwdmsrprtdedlnellgittirvtvcegknllqr anelvnpdwqdvdaatatrgrsaasrpterpraparsasrprrpve membrane-translocating sequence (MST) from h region of the signal sequence of Kaposi fibroblast growth factor kitnsrppaaavllpvllaap. aavllpvllaap kitnsrppaaavllpvlla ap Analog ofK104-V113 of SBQ ID NO:2 having alanines substituted for cysteine at Hie ninth amino acid residue (KITNSRPPAV) HSV-1 tegument protein VP22 K1TNSRPPAVMTSRRSVKSGPREVPRDEYEDLYYTPSSGMASPDSPPDTSRRGALOTRSRORGE VRWQYDESDYALYGGSSSEDDEHPEVPRTRRPVSGAVLSGPGPARAPPPPAGSGGAGRTPTT APRAPRTQRVATKAPAAPAAETTRGRKSAQPESAALPDAPASTAPTRSKTPAQGLARKLHFST APPNPDAPWTPRVAGFNKRVFCAAVGRLAAMHARMAAVQLWDMSRPRTDEDLNELLGITTI RVTVCEGKNLLQRANELVNPDWQDVD AATATRGRSAASRPTERPRAP ARSASRPRRPVE, MTSRRSVKSGPREVPRDEYEDLYYTPSSGMASPDSPPDTSRRGALQTRSRQRGEVRFVQYDES DYALYGGSSSEDDEHPEVPRTRRPVSGAVLSGPGPARAPPPPAGSGGAGRTPTTAPRAPRTQR VATKAPAAPAAETTRGRKSAQPESAALPDAPASTAPTRSKTPAQGLARKLHFSTAPPNPDAPW TPRVAGFNKRVFCAAV GRLAAMHARMAAV QLWDMSRPRTDEDLNELLGri"i'LRVTV CEGKN LLORANELVNPDVVODVD AATATRGRSAASRPTERPRAP ARSASRPRRP VEKTTNSRPPAVMT SRRSVKSGPREVPRDEYEDLYYTPSSGMASPDSPPDTSRRGALQTRSRQRGEVRFVQYDESDY ALYGGSSSEDDEHPEVPRTRRPVSGAVLSGPGPARAPPPPAGSGGAGRTPTTAPRAPRTQRVAT KAPAAPAAETTRGRKSAQPESAALPDAPASTAPTRSKTPAQGLARKLHFSTAPPNPDAPWTPR VAGFNKRVFCAAVGRLAAMHARMAAVQLWDMSRPRTDEDLNELLGITTIRVTVCEGKNLLQ RANELVNPD W QDVD AATATRGRSAASRPTERPRAP ARSASRPRRPVE membrane-translocating sequence (MST) from h region of Hie signal sequence of Kaposi fibroblast growth factor KITNSRPPAVAAVLLPVLLAAP.

AAVLLPVLLAAP KITNSRPPAVAAVLLPVLLAAP

[0266] The peptides described herein can be a variety of lengths, and either in their neutral (uncharged) forms or in forms which are salts. The peptides can contain modifications such as glycosylation, side chain oxidation, or phosphorylation, generally subject to the condition that modifications do not destroy the biological activity ofthe peptides.

[0267] The peptides can be prepared in a wide variety of ways. For the preferred relatively short size, the peptides can be synthesized in solution or on a solid support in accordance with conventional techniques. Various automatic synthesizers are commercially available and canbe used in accordance with known protocols. (See, for example, Stewart & Young, SOLID PHASE Peptide Synthesis, 2d. ed., Pierce Chemical Co., 1984). Further, individual C35 peptide epitopes and C35 peptide epitope analogs can be joined using chemical ligation to produce larger homopolymer or heteropolymer polypeptides j

[0268] Alternatively, recombinant DNA technology can be employed wherein a nucleotide sequence which encodes an immunogenic peptide of interest is inserted into an expression vector, transformed or transfected into an appropriate host cell and cultivated under conditions suitable for expression. These procedures are generally known in the art, as described generally in Sambrook et al, Molecular Cloning, aLaboratory Manual, Cold Spring Harbor Press, Cold Spring Harbor, New York (1989). Thus, recombinant polypeptides, which comprise one or more peptide epitope sequences described herein, can be used to present the appropriate T cell epitope.

[0269] The nucleotide coding sequence for C35 peptide epitopes or C35 peptide epitope analogs of the preferred lengths contemplated herein can be synthesized by chemical techniques, for example, the phosphotriester method ofMatteucci, et al, J. Am. Chem. Soc. 103:3185 (1981). Peptide analogs can be made simply by substituting the appropriate and desired nucleic acid base(s) for those that encode the native peptide sequence; exemplary nucleic acid substitutions are those that encode an amino acid defined by the motifs/supermotifs herein.

Hf§y±CTUAL PROPERTVO^'5 OF HI, 2 5 OCT 2006 coding sequence can then be provided with appropriate linkers and ligated into expression vectors commonly available in the art, and the vectors used to transform suitable hosts to produce the desired fusion protein. A number of such vectors and suitable host systems are now available. For expression of the fusion proteins, the coding sequence will be provided with operably linked start and stop codons, promoter and terminator regions and usually a replication system to provide an expression vector for expression in the desired cellular host. For example, promoter sequences compatible with bacterial hosts are provided in plasmids containing convenient restriction sites for insertion of the desired coding sequence. The resulting expression vectors are transformed into suitable bacterial hosts. Of course, yeast, insect or mammalian cell hosts may also be used, employing suitable vectors and control sequences.

[0270] It is generally preferable that the peptide epitope be as small as possible while still maintaining substantially all of the immunologic activity of the native protein. When possible, it may be desirable to optimize HLA class I binding peptide epitopes of the invention to a length of about 8 to about 13 amino acid residues, preferably 9 to 10. It is to be appreciated that a longer polypeptide, e.g., a C3 5 polypeptide fragment or a synthetic polypeptide, can comprise one or more C35 peptide epitopes or C35 peptide epitope analogs in this size range (see the Definition Section for the term "epitope" for further discussion of peptide length).

HLA class II binding epitopes are preferably optimized to a length of about 6 to about 30 amino acids in length, preferably to between about 13 and about 20 residues. Preferably, the epitopes are commensurate in size with endogenously processed pathogen-derived peptides or tumor cell peptides that are bound to the relevant HLA molecules. The identification and preparation of peptides of various lengths can be carried out using the techniques described herein.

[0271] Alsp described is the administration of peptides described herein linked as a polyepitopic polypeptide, e.g., homopolymers or heteropolymers, or as a minigene that encodes a polyepitopic polypeptide.

'^^CTui~PROPFRr of w.2. 2 5 OCT 2006 RECEIV {0272} Another preferred embodiment is obtained by identifying native C35 polypeptide regions that contain ahigh concentration of class I and/or class It C35 peptide epitopes. Such a sequence is generally selected on the basis that it contains the greatest number of C35 epitopes per amino acid length. It is to be appreciated that epitopes can be present in a frame-shifted manner, e.g. a 10 amino acid long peptide could contain two 9 amino acid long epitopes and one 10 amino acid long epitope; upon intracellular processing, each epitope can be exposed and bound by an HLA molecule upon administration of such a peptide. Thus a larger, preferably multi-epitopic, polypeptide can be generated synthetically, recombinantly, or via cleavage from the native source.

Assays to Detect T-Cell Responses

[0273] Once HLA binding peptides are identified, they can be tested for the ability to elicit a T-cell response. The preparation and evaluation ofmotif-bearing peptides are described, e.g., in PCT publications WO 94/20127 and WO 94/03205, the entire contents of which are hereby incorporated by reference. Briefly, peptides comprising epitopes from a particular antigen are synthesized and tested for their ability to bind to relevant HLA proteins. These assays may involve evaluation of peptide binding to purified HLA class I molecules in relation to the binding of a radioiodinated reference peptide. Alternatively, cells expressing empty class I molecules (i.e. cell surface HLA molecules that lack any bound peptide) may be evaluated for peptide binding by immunofluorescent staining and flow microfluorimetiy. Other assays that may be used to evaluate peptide binding include peptide-dependent class I assembly assays and/or the inhibition of CTL recognition by peptide competition. Those peptides that bind to an HLA class I molecule, typically with an affinity of 500 nM or less, are further evaluated for their ability to serve as targets for CTLs derived from infected or immunized individuals, as well as for their capacity to induce primary in vitro or in vivo CTL responses that can give rise to CTL populations capable of reacting with selected target cells associated with pathology.

[0274] Analogous assays are used for evaluation of HLA class H binding peptides. HLA class II motif-bearing peptides that are shown to bind, typically at an affinity of1000 nM or less, are further evaluated for the ability to stimulate HTL responses.

[0275] Conventional assays utilized to detect T cell responses include proliferation assays, lymphoMne secretion assays, direct cytotoxicity assays, and limiting dilution assays. For example, antigen-presenting cells that have been incubated with a peptide can be assayed for the ability to induce CTL responses in responder cell populations. Antigen-presenting cells can be normal cells such as peripheral blood mononuclear cells or dendritic cells. Alternatively, mutant, non-human mammalian cell lines that have been transfected with a human class I MHC gene, and that are deficient in their ability to load class I molecules with internally processed peptides, are used to evaluate the capacity of the peptide to induce in vitro primary CTL responses. Peripheral blood mononuclear cells (PBMCs) can be used as the source of CTL precursors. Antigen presenting cells are incubated with peptide, after which the peptide-loaded antigen-presenting cells are then incubated with the responder cell population under optimized culture conditions. Positive CTL activation can be determined by assaying the culture for the presence of CTLs that lyse radio-labeled target cells, either specific peptide-pulsed targets or target cells that express endogenously processed antigen from which the specific peptide was derived. Alternatively, the presence of epitope-specific CTLs can be determined by BFNy in situ EIIS A. {0276] Additionally, a method has been devised which allows direct quantification of antigen-specific T cells by staining with fluorescein-labelled HLA tetrameric complexes (Altman, J. D. et al, Proc. Natl Acad. Sci. USA 90:10330, 1993; Altman, J. D. et al, Science 274:94, 1996). Other options include staining for intracellular lymphokines, and interferon release assays or EUSPOT assays. Tetramer staining, intracellular lymphoMne staining and ELISPOT assays all appear to be at least 10-fold more sensitive than more conventional assays (Lalvani, A. et al., J. Exp. Med. 186:859,1997; Dunbar, P.

R. et al., Curr. Biol. 8:413, 1998; Murali-Krishna, K. et al., Immunity 8:177, 1998).

[0277] Helper T lymphocyte (HTL) activation may also be assessed using techniques known to those in the art, such as T cell proliferation or lymphokine secretion (see, e.g. Alexander et al., Immunity 1:751-761,1994).

[0278] Alternatively, immunization of HLA transgenic mice can be used to determine immunogenicity ofpeptide epitopes. Several transgenic mouse strains, e.g., mice with human A2.1, All (which can additionally be used to analyze HLA-A3 epitopes), and B7 alleles have been characterized. Other transgenic mice strains (e.g., transgenic mice for HLA-A1 and A24) are being developed.

Moreover, HLA-DR1 and HLA-DR3 mouse models have been developed. In accordance with principles in the art, additional transgenic mouse models with other HLA alleles are generated as necessary.

[0279] Such mice can be immunized with peptides emulsified in Incomplete Freund's Adjuvant; thereafter any resulting T cells can be tested for their capacity to recognize target cells that have been peptide-pulsed or transfected with genes encoding the peptide of interest. CTL responses can be analyzed using cytotoxicity assays described above. Similarly, HTL responses can be analyzed using, e.g., T cell proliferation or lymphokine secretion assays.

Vaccine Compositions

[0280] Vaccines that contain an immunologically effective amount of one or more C35 peptide epitopes and/or C35 peptide epitope analogs are also described. The peptides can be delivered by various means or formulations, all collectively referred to as "vaccine" compositions. Such vaccine compositions, and/or modes of administration, can include, for example, naked cDNA in cationic lipid formulations; lipopeptides intellectual, propertv of n.z. 2 5 OCT 2008 (e.g.,Vitiello, A. et al., J. Clin. Invest. 95:341,1995), naked cDNA or peptides, encapsulated e.g., in poly(DL-lactide-co-glycolide) ("PLG") microspheres (see, e.g., Eldridge, etal.,Molec. Immunol. 28:287-294,1991: Alonso etal., Vaccine 12:299-306,1994; Jones etal., Vaccine 13:675-681,1995); peptide compositions contained in immune stimulating complexes (ISCOMS) (see, e.g., Takahashi et al.,Nature 344:873-875,1990; Hu etal., Clin Exp Immunol. 113:235-243,1998); multiple antigen peptide systems (MAPs) (see e.g. , Tam, J. P., Proc. Natl. Acad.

Sci. U.S.A. 85:5409-5413, 1988; Tam, J.P., J. Immunol. Methods 196:17-32, 1996); viral, bacterial, or, fungal delivery vectors (Perkus, M. E. et al., In: Concepts in vaccine development, Kaufmann, S. H. E., ed., p. 379, 1996; Qiakrabarti, S, et al., Nature 320:535, 1986; Hu, S. L. et al., Nature 320:537, 1986; Kieny, M.-P. et al., AIDS Bio/Technology 4:790,1986; Top, F. H. et al., J. Infect. Dis. 124:148, 1971; Chanda, P. K. et al., Virology 175:535, 1990); particles of viral or synthetic origin (e.g., Kofler, N. et al., J. Immunol. Methods. 192:25,1996; Eldridge, J. H. et al, Sem. Hematol. 30:16,1993; Falo, L. D., Jr. et al, Nature Med. 7:649, 1995); adjuvants (Warren, H. S., Vogel, F. R., and Chedid, L. A. Annu. Re\>. Immunol. 4:369, 1986; Gupta, R. K. et al, Vaccine 11:293,1993); liposomes (Reddy, R. etal, J. Immunol. 148:1585,1992; Rock, K.L., Immunol Today 17:131,1996); or, particle-absorbed cDNA (Ulmer, J. B. et al, Science 259:1745,1993; Robinson, H. L., Hunt, L. A., and Webster, R. G., Vaccine 11:957,1993; Shiver, J. W. et al, In: Concepts in vaccine development, Kaufinann, S. H. E., ed., p. 423,1996; Cease, K. B., and Berzofsky, J. A., Annu. Rev. Immunol. 12:923, 1994 and Eldridge, J. H. et al, Sem. Hematol. 30:16, 1993), etc. Toxin-targeted delivery technologies, also known as receptor mediated targeting, such as those of Avant Immunotherapeutics, Inc. (Needham, Massachusetts) or attached to a stress protein, e.g., HSP 96 (Stressgen Biotechnologies Corp., Victoria, BC, Canada) can also be used. [0281] Vaccines may also comprise nucleic acid mediated modalities.

DNA or RNA encoding one or more of the polypeptides of the invention can be administered to a patient. This approach is described, for instance, in Wolff et.

INTELLECTUAL property OF M.2. 2 5 OCT 2006 al., Science 247:1465 (1990) as well as U.S. Patent Nos. 5,580,859; 5,589,466; 5,804,566; 5,739,118; 5,736,524; 5,679,647; and, WO 98/04720. Examples of DNA-based delivery technologies include "naked DNA", facilitated (bupivicaine, polymers, peptide-mediated) delivery, cationic lipid complexes, and particle-mediated ("gene gun") or pressure-mediated delivery (see, e.g., U.S. Patent No. 5,922,687). Accordingly, peptide vaccines can be expressed by viral or bacterial vectors. Examples of expression vectors include attenuated viral hosts, such as vaccinia or fowlpox. For example, vaccinia virus is used as a vector to express nucleotide sequences that encode the peptides ofthe invention. Upon introduction into an acutely or chronically infected host or into a non-infected host, the recombinant vaccinia virus expresses the immunogenic peptide, and thereby elicits an immune response. Vaccinia vectors and methods useful in immunization protocols are described in, e.g., U.S. Patent No. 4,722,848. Another vector is BCG (Bacille Calmette Guerin). BCG vectors are described in Stover et al,Nature 351:456-460 (1991). A wide variety of other vectors useful for therapeutic administration or immunization of the peptides e.g. adeno and adeno-associated virus vectors, alpha virus vectors, retroviral vectors, Salmonella typhi vectors, detoxified anthrax toxin vectors, and the like, are apparent to those skilled in the art from the description herein. {0282] Furthermore, vaccines can comprise one or more C35 peptide epitopes* Accordingly, a C35 peptide epitope or C35 peptide epitope analog canbe present in a vaccine individually or; alternatively, the peptide epitope or analog can exist as multiple copies of the samepeptide epitope or analog (ahomopolymer), or as multiple different peptide epitopes or analogs (a heteropolymer). Polymers have the advantage of increased probability for immunological reaction and, where different peptide epitopes or analogs are used to make up the polymer, the ability to induce antibodies and/or T cells that react with different antigenic determinants of the antigen targeted for an immune response. The composition maybe anaturallyoccurring region of an antigen or can be prepared, e.g., recombinantly or by chemical synthesis.

INTELLECTUAL PROPERTY OrTiCE OF N.Z. 2 5 OCT 2008 li ta

[0283] Carriers that can be used with vaccines are well known in the art, and include, e.g., thyroglobulin, albumins such as human serum albumin, tetanus toxoid, polyamino acids such as poly L-lysine, poly L-glutamic acid, influenza virus proteins, hepatitis B virus core protein, and the like. The vaccines can contain a physiologically tolerable diluent such as water, or a saline solution, preferably phosphate buffered saline. Generally, the vaccines also include an adjuvant. Adjuvants such as incomplete Freund's adjuvant, aluminum phosphate, aluminum hydroxide, or alum are examples of materials well known in the art. Additionally, as disclosed herein, CTL responses can be primed by conjugating peptides of the invention to lipids, such as tripalmitoyl-S-glyceryl-cysteinyl-seryl-serine (P3CSS).

[0284] Upon immunization with a peptide composition described herein^ via injection (e.g., subcutaneous, intradermal, intramuscular, aerosol, oral, transdermal, transmucosal, intrapleural, intrathecal), or other suitable routes, the immune system of the host responds to the vaccine by producing antibodies, CTLs and/or HTLs specific for the desired antigen. Consequently, the host becomes at least partially immune to subsequent exposure to the TAA, or at least partially resistant to further development of tumor associated antigen-bearing cells and thereby derives a prophylactic or therapeutic benefit.

[0285] In certain embodiments, components that induce T cell responses are combined with components that induce antibody responses to the target antigen of interest. A preferred embodiment of such a composition comprises class I and class II epitopes in accordance with the invention. Alternatively, a composition comprises a class I and/or class n epitope in accordance with the invention, along with a PADRE™ molecule (Epinrmune, San Diego, CA).

[0286] Vaccine compositions can comprise antigen presenting cells, such as dendritic cells, as a vehicle to present peptides ofthe invention. For example, dendritic cells are transfected, e.g., with a minigene construct in accordance with the invention, in order to elicit immune responses. Minigenes are discussed in greater detail in a following section. Vaccine compositions can INTELLECTUAL PROPERTY GhiCE OF AI.Z. 2 5 OCT 2008 r> r? r* fr i % / r be created in vitro, following dendritic cell mobilization and harvesting, whereby loading of dendritic cells occurs in vitro.

[0287] The vaccine compositions may also be used in combination with antiviral drugs such as interferon-a, or immune adjuvants such as IL-12, GM-CSF, etc.

[0288] Preferably, the following principles are utilized when selecting epitppe(s) for inclusion in a vaccine, either peptide-based or nucleic acid-based formulations. Each of the following principles can be balanced in order to make the selection. When multiple epitopes are to be used in a vaccine, the epitopes may be, but need not be, contiguous in sequence in Ihe native antigen from which the epitopes are derived.

[0289] 1) Epitopes are selected which, upon administration, mimic immune responses that have been observed to be correlated with prevention or clearance of TAA-expressing tumors. For HLA Class I, this generally includes 3-4 epitopes derived from at least one TAA.

[0290] 2) Epitopes are selected that have the requisite binding affinity established to be correlated with immunogenicity: for HLA Class I an IC50 of 500 nM or less, or for Class H an IC50 of 1000 nM or less. For HLA Class I it is presently preferred to select a peptide having an IC50 of200 nM or less, as this is believed to better correlate not only to induction of an immune response, but to in vitro tumor cell killing as well.

[0291] 3) Supermotifbearing-peptides, or a sufficient array of allele-specific motif-bearing peptides, are selected to give broad population coverage. In general, it is preferable to have at least 80% population coverage. A Monte Carlo analysis, a statistical evaluation known in the art, can be employed to assess the breadth of population coverage.

[0292] 4) When selecting epitopes from cancer-related antigens, it can be preferable to include analog peptides in the selection, because the patient may have developed tolerance to the native epitope. When selecting epitopes for r,NTELLECTUAl PROPERTY DiriG; OF N.Z. 2 5 OCT 2005 Ps E C E S V infectious disease-related antigens it is presently preferable to select either native or analog epitopes.

[0293] 5) Of particular relevance are "nested epitopes." Nested epitopes (or epitope analogs) occur where at least two epitopes or analogs (or an epitope and an analog) overlap in a given polypeptide sequence. A polypeptide comprising "transcendent nested epitopes" is a polypeptide that has both HLA class I and HLA class II epitopes and/or analogs in it. When providing nested epitopes, it is preferable to provide a sequence that has the greatest number of epitopes or analogs per provided sequence. Preferably, one avoids providing a polypeptide that is any longer than the combined length of the peptide epitopes or analogs. When providing a polypeptide comprising nested epitopes, it is important to evaluate the polypeptide in order to insure that it does not have pathological or other deleterious biological properties; this is particularly relevant for vaccines directed to infectious organisms. Thus, in a preferred embodiment, the vaccine compositions comprise one or more multi-epitope polypeptides selected from the group consisting of: 1105 to VI13 of SEQ ID NO:2 and FIG. IB, TlOl to VI13 of SEQ ID NO:2 and FIG. IB, ElOO to VI13 ofSEQ ID NO:2 and FIG. IB, G99 to VI13 ofSEQ ID NO:2 and FIG. IB, 193 to VI13 ofSEQ ID NO:2 and FIG. IB, D88 to VI13 of SEQ ID NO:2 and FIG. IB, P84 to VI13 of SEQ ID NO:2 and FIG. IB, K77 to VI13 ofSEQ ID NO:2 and FIG. IB, Q72 to VI13 ofSEQ ID NO:2 and FIG. IB, F65 to VI13 ofSEQ ID NO:2 and FIG. IB, and L59 to VI13 ofSEQ ID NO:2 and FIG. IB.

[0294] 6) IfapolypeptidecomprisingmorethanoneC35peptideepitopeor C35 peptide epitope analog is created, or when creating a minigene, an objective is to generate the smallest polypeptide that encompasses the epitopes/analogs of interest. This principle is similar, if not the same as that employed when selecting a polypeptide comprising nested epitopes. However, with an artificial polyepitopic polypeptide, the size minimization objective is balanced against the need to integrate any spacer sequences between epitopes in the polyepitopic polypeptide. Spacer or linker amino acid residues can be introduced to avoid INTELLECTUAL PROPERTY GFBC OF HI. 2 5 OCT 200S i r- 1 nc junctiona! epitopes (an epitope recognized by the immune system, not present in the target antigen, and only created by the man-made juxtaposition of epitopes), or to facilitate cleavage between epitopes and thereby enhance epitope presentation. Junctional epitopes are generally to be avoided because the recipient may generate an immune response to that non-native epitope. Of particular concern is a junctional epitope that is a "dominant epitope." A dominant epitope may lead to such a zealous response that immune responses to other epitopes are diminished or suppressed.

Minigene Vaccines

[0295] Anumber of different approaches are available which allow simultaneous delivery of multiple epitopes. Nucleic acids encoding multiple C35 peptide epitopes or analogs are a useful embodiment of the invention; discrete .epitopes/analogs or polyepitopic polypeptides can be encoded. The epitopes or analogs to be included in a minigene are preferably selected according to the guidelines set forth in the previous section. Examples of amino acid sequences that can be included in a minigene include: HLA class I epitopes or analogs, HLA class II epitopes or analogs, a ubiquitination signal sequence, and/or a targeting sequence such as an endoplasmic reticulum (ER) signal sequence to facilitate movement of the resulting peptide into the endoplasmic reticulum.

[0296] The use of multi-epitope minigenes is also described in, e.g., Ishioka et al., J. Immunol. 162:3915-3925, 1999; An, L. and Mutton, J. L., J. Virol. 71:2292,1997; Thomson, S. A. etal., J. Immunol. 157:822,1996; Whitton, J. L. et al., J. Virol 67:348,1993; Hanke, R. et al, Vaccine 16:426,1998. A similar approach can be used to develop minigenes encoding TAA epitopes.

[0297] For example, to create a DNA sequence encoding the selected epitopes (minigene) for expression in human cells, the amino acid sequences of the epitopes may be reverse translated. A human codon usage table can be used to guide the codon choice for each amino acid. These epitope-encoding DNA sequences may be directly adjoined, so that when translated, a continuous polypeptide sequence is created. However, to optimize expression and/or immunogenicity, additional elements can be incorporated into the minigene design such as one or more spacer or linker amino acid residues between epitopes. HLA presentation of CTL and HTL epitopes may be improved by including synthetic (e.g. poly-alanine) or naturally-occurring flanking sequences ( adjacent to the CTL or HTL epitopes; these larger polypeptides comprising the epltope(s)/analog(s) are within the scope of the invention.

[0298] The minigene sequence may be converted to DNA by assembling oligonucleotides that encode the plus and minus strands of the minigene. Overlapping oligonucleotides (30-100 bases long) may be synthesized, phosphorylated, purified and annealed under appropriate conditions using well known techniques. The ends of the oligonucleotides can be joined, for example, using T4 DNA ligase. This synthetic minigene, encoding the epitope polypeptide, can then be cloned into a desired expression vector.

[0299] Standard regulatory sequences well known to those of skill in the art are preferably included in the vector to ensure expression in the target cells. Several vector elements are desirable: a promoter with a downstream cloning site for minigene insertion; a polyadenylation signal for efficient transcription termination; an E. coli origin of replication; and saE. co&" selectable marker (e.g. ampicillin or kanamycin resistance). Numerous promoters can be used for this purpose, e.g., the human cytomegalovirus (hCMV) promoter. See, e.g., U.S. Patent Nos. 5,580,859 and 5,589,466 for other suitable promoter sequences. 10300] Optimized peptide expression and immunogenicity can be achieved by certain modifications to a minigene construct. For example, in some cases introns facilitate efficient gene expression, thus one or more synthetic or naturally-occurring introns can be incorporated into the transcribed region ofthe minigene. The inclusion of mRNA stabilization sequences and sequences for replication in mammalian cells may also be considered for increasing minigene expression.

[0301] Once an expression vector is selected, the minigene is cloned into the polylinker region downstream of the promoter. This plasmid is transformed into an appropriate bacterial strain, and DNA is prepared using standard techniques. The orientation and DNA sequence of the minigene, as well as all other elements included in the vector, are confirmed using restriction mapping and DNA sequence analysis. Bacterial cells harboring the correct plasmid can be stored as cell banks.

[0302] hi addition, immunostimulatory sequences (ISSs or CpGs) appear to play a role in the immunogenicity of DNA vaccines. These sequences may be included in the vector, outside the minigene coding sequence to enhance immunogenicity.

[0303] hi some embodiments, a bi-cistronic expression vector which allows production ofboth the minigene-encoded epitopes and a second protein (e.g., one that modulates immunogenicity) can be used. Examples of proteins or polypeptides that, if co-expressed with epitopes, can enhance an immune response include cytokines (e.g., IL-2, IL-12, GM-CSF), cytokme-inducing molecules (e.g., LeIF), costimulatory molecules, or pan-DR binding proteins (PADRE™, Epimmune, San Diego, CA). Helper T cell (HTL) epitopes such as PADRE™ molecules can be joined to intracellular targeting signals and expressed separately from expressed CTL epitopes. This can be done in order to direct HTL epitopes to a cell compartment different than that of the CTL epitopes, on^ that provides for more efficient entry of HTL epitopes into the HLA class II pathway, thereby improving HTL induction. In contrast to HTL or CTL induction, specifically decreasing the immune response by co-expression of immunosuppressive molecules (eg. TGF-P) may be beneficial in certain diseases.

[0304] Therapeutic quantities of plasmid DNA can be produced for example, by fermentation in E. coli, followed by purification. Aliquots from the working cell bank are used to inoculate growth medium, and are grown to saturation in shaker flasks or a bioreactor according to well known techniques. Plasmid DNA is purified using standard bioseparation technologies such as solid phase anion- exchange resins available, e.g., from QIAGEN, Inc. (Valencia, California). If required, supercoiled DNA can be isolated from the open circular and linear forms using gel electrophoresis or other methods.

Purified plasmid DNA can be prepared for injection using a variety of formulations. The simplest of these is reconstitution of lyophilized DNA in sterile phosphate-buffer saline (PBS). This approach, known as "naked DNA," is currently being used for intramuscular (IM) administration in clinical trials. To maximize the immunotherapeutic effects of minigene vaccines, alternative methods of formulating purified plasmid DNA may be used. A variety of such methods have been described, and new techniques may become available. Cationic lipids, glycolipids, and fusogenic liposomes can also be used in the formulation (see, e.g., WO 93/24640; Mannino & Gould-Fogerite, BioTechniques 6(7): 682 (1988); U.S. Patent No. 5,279,833; WO 91/06309; and Feigner, et al., Proc. Nat'lAcad. Sci. USA 84:7413 (1987). In addition, peptides and compounds referred to collectively as protective, interactive, non-condensing compounds (PINC) can also be complexed to purified plasmid DNA to influence variables such as stability, intramuscular dispersion, or trafficking to specific organs or cell types.

Target cell sensitization can be used as a functional assay of the expression and HLA class I presentation of minigene-encoded epitopes. For example, the plasmid DNA is introduced into a mammalian cell line that is a suitable target for standard CTL chromium release assays. The transfection method used will be dependent on the final formulation, electroporation can be used for "naked" DNA, whereas cationic lipids allow direct in vitro transfection. A plasmid expressing green fluorescent protein (GFP) can be co-transfected to allow enrichment of transfected cells using fluorescence activated cell sorting (FACS). The transfected cells are then chromium-51 (51Cr) labeled and used as targets for epitope-specific CTLs. Cytolysis of the target cells, detected by slCr release, indicates both the production and HLA presentation of, minigene- encoded CTL epitopes. Expression of HTL epitopes may be evaluated in an analogous manner using assays to assess HTL activity.

[0307] In vivo immunogenicity is a second approach for functional testing of minigene DNA formulations. Transgenic mice expressing appropriate human FT,A proteins are immunized with the DNA product. The dose and route of administration are formulation dependent (e.g., IM for DNA in PBS, intraperitoneal (IP) for lipid-complexed DNA). Eleven to twenty-one days after immunization, splenocytes are harvested and restimulated for one week in the presence of peptides encoding each epitope being tested. Thereafter, for CTLs, standard assays are conducted to determine if there is cytolysis ofpeptide-loaded, 51Cr-labeled target cells. Once again, lysis of target cells that were exposed to epitopes corresponding to those in the minigene, demonstrates DNA vaccine function and induction of CTLs. Immunogenicity of HTL epitopes is evaluated in transgenic mice in an analogous manner.

[0308] Alternatively, the nucleic acids can be administered using ballistic delivery as described, for instance, in U.S. Patent No. 5,204,253. Using this technique, particles comprised solely of DNA are administered. In a further alternative embodiment for ballistic delivery, DNA can be adhered to particles, such as gold particles.

Combinations of CTL Peptides with Helper Peptides

[0309] Vaccine compositions comprising CTL peptides can be modified to provide desired attributes, such as improved serum half-life, broadened population coverage or enhanced immunogenicity.

[0310] For instance, the ability of a peptide to induce CTL activity can be enhanced by linking the CTL peptide to a sequence which contains at least one HTL epitope.

[0311] Although a CTL peptide can be directly linked to a T helper peptide INTElxECTUA! WFRu particularlypreferred CTL epitope/HTL epitope conjugates are linked by a spacer w < < < 2 5 OCT 2M VE molecule. The spacer is typically comprised of relatively small, neutral molecules, e.g., amino acids or amino acid mimetics, which are substantially uncharged under physiological conditions. The spacers are typically selected from, e.g., Ala, Gly, or other neutral spacers of nonpolar amino acids or neutral polar amino acids. It will be understood that the optional spacer need not be comprised of the same residues and thus may be a hetero- or homo-oligomer. When present, the spacer will usually be at least one or two residues, commonly three to 13, more frequently three to six residues. The CTL peptide epitope may be linked to the T helper peptide epitope, directly or via a spacer, at either it's amino or carboxyl terminus. The amino terminus of eitherthe CTL peptide or the HTL peptide can be acylated.

[0312] la certain embodiments, the T helper peptide is one that is recognized by T helper cells present in the majority of the population. This can be accomplished by selecting amino acid sequences that bind to many, most, or all of the HLA class II molecules. These are known as "loosely HLA-restricted" or "promiscuous" T helper sequences. Examples of amino acid sequences that are promiscuous include sequences from antigens such as tetanus toxoid at positions 830-843 (QYIKANSKFIGITE), Plasmodium falciparum CS protein at positions 378-398 (DIEKEQAKMEELASSVFlSr^VNS), and Streptococcus 18kD protein at positions 116 (GAVDSILGGVATYGAA). Other examples include peptides bearing a DR 1 -4-7 supermotif, or either of the DR3 motifs.

[0313] Alternatively, it is possible to prepare synthetic peptides capable of stimulating T helper lymphocytes, in a loosely HLA-restricted fashion, using amino acid sequences that may not be found in nature. Synthetic compounds fell within the family of molecules called Pan-DR-binding epitopes (e.g., PADRE™, Epimmune Inc., San Diego, CA). PADRE™ peptides are designed to bind multiple HLA-DR (human HLA class D) molecules. For instance, a pan-DR-binding epitope peptide having the formula: aKXVAAZTLKAAa, where "X" is either cyclohexylalanine, phenylalanine, or tyrosine; "Z" is either tryptophan, tyrosine, histidine or asparagine; and "a" is either D-aianine or L-alanine, has been found to bind to numerous allele-specific HLA-DR molecules. Accordingly, these molecules stimulate a T helper lymphocyte response from most individuals, regardless of their HLA type. Certain pan-DR binding epitopes comprise all "L" natural amino acids; these molecules can be provided as peptides or in the fbim of nucleic acids that encode the peptide.

[0314] HTL peptide epitopes can be modified to alter their biological properties. HTL peptide epitopes can be modified in the same manner as CTL peptides. For instance, they may be modified to include D-amino acids or be conjugated to other molecules such as lipids, proteins, sugars and the like. Peptides comprising D-amino acids generally have increased resistance to proteases, and thus have an extended serum half-life.

[0315] In addition, polypeptides comprising one or more peptide epitopes of the invention can be conjugated to other molecules such as lipids, proteins or sugars, or any other synthetic compounds, to increase their biological activity. For example, a T helper peptide can be conjugated to one or more palmitic acid chains at either the amino or the carboxyl termini.

Combinations of CTL Peptides with T Cell Priming Materials

[0316] In some embodiments it maybe desirable to include in the pharmaceutical compositions ' at least one component which primes cytotoxic T •** lymphocytes. Lipids have been identified as agents capable of facilitating the priming m vitro CTL response against viral antigens. For example, palmitic acid residues canbe attached to the 8- and a-amino groups of a lysine residue and then linked to an immunogenic peptide. One or more linking moieties can be used such as Gly, Gly-Gly-, Ser, Ser-Ser, or the like. The lipidated peptide can then be administered directly in a micelle or particle, incorporated into a liposome, or emulsified in an adjuvant, e.g., incomplete Freund's adjuvant. A preferred immunogenic composition comprises palmitic acid attached to 8- and a-amino INTELLECTUAL PROPERTY Officii OF N.Z. 2 5 OCT 2006 pr tr* pt" is i groups of Lys via a linking moiety, e.g., Ser-Ser, added to the amino terminus of an immunogenic peptide.

[0317] In another embodiment of lipid-facilitated priming of CTL responses, E. coli lipoproteins, such as tripalmitoyl-S-glyceryl-cysteinyl-seryl-serine (P3CSS) can be used to prime CTL when covalently attached to an appropriate peptide.

(See, e.g., Deres, et al, Nature 342:561,1989). Thus, peptides can be coupled to P3CSS, and the lipopeptide administered to an individual to specifically prime a CTL response to the target antigen. Moreover, because the induction of neutralizing antibodies can also be primed with P3CSS-conjugated epitopes, two such compositions can be combined to elicit both humoral and cell-mediated responses.

Vaccine Compositions Comprising Dendritic Cells Pulsed with CTL and/or HTL Peptides

[0318] An embodiment of a vaccine composition comprises ex vivo administration of a cocktail of epitope-b earing peptides to PBMC, or isolated DC therefrom, from the patient's blood. A pharmaceutical to facilitate harvesting of DC can be used, such as Progenipoietin™ (Monsanto, St. Louis, MO) or GM-CSF/IL-4. After pulsing the DC with peptides and prior to reinfiision into patients, the DC are washed to remove unbound peptides. In this embodiment, a vaccine comprises peptide-pulsed DCs -which present the pulsed peptide epitopes in HLA molecules on their surfaces.

[0319] The DC can be pulsed ex vivo with a cocktail of peptides, some of which stimulate CTL responses to one or more antigens of interest, e.g., tumor associated antigens (TAA) such as HER2/neu, p53, MAGE 2, MAGE3, and/or carcinoembiyonic antigen (CEA). Collectively, these TAA are associated with breast, colon and lung cancers. Optionally, a helper T cell (HTL) peptide such as PADRE™, can be included to facilitate the CTL response. Thus, a vaccine INTELLECTUAL PROPERTY C OF N.z 2 5 OCT 2005 oer.FlVE comprising epitopes from HER2/neu, p53, MAGE2, MAGES, and carcinoembryonic antigen (CEA) is used to treat minimal or residual disease in patients with malignancies such as breast, colon or lung cancer; any malignancies that bear any of these TAAs can also be treated with the vaccine. A TAA vaccine can be used following debulking procedures such as surgery, radiation therapy or chemotherapy, whereupon the vaccine provides the benefit of increasing disease free survival and overall survival in the recipients.

Thus, in preferred embodiments, a vaccine is a product that treats a majority of patients across a number of different tumor types. A vaccine comprising a plurality of epitopes, preferably supermotif-bearing epitopes, offers such an advantage.

Administration of Vaccines for Therapeutic or Prophylactic Purposes The polypeptides comprising one or more peptide epitopes including pharmaceutical and vaccine compositions thereof, are useful for administration to mammals, particularly humans, to treat and/or prevent disease. In one embodiment, vaccine compositions (peptide or nucleic acid) of the invention are administered to a patient who has a malignancy associated with expression of one or more TAAs, or to an individual susceptible to, or otherwise at risk for developing TAA-related disease. Upon administration an immune response is elicited against the TAAs, thereby enhancing the patient's own immune response capabilities. In therapeutic applications, peptide and/or nucleic acid compositions are administered to a patient in an amount sufficient to elicit an effective immune response to the TAA-expressing cells and to thereby cure, arrest or slow symptoms and/or complications. An amount adequate to accomplish this is defined as "therapeutically effective dose." Amounts effective for this use will depend on, e.g., the particular composition administered, the manner of administration, the stage and severity ofthe disease being treated, the weight and. general state of health of the patient, and the judgment of the prescribing physician. prophylactic agents. Generally the dosage for an initial prophylactic immunization generally occurs in a unit dosage range where the lower value is about 1,5,50,500, or 1000 ng of peptide and the higher value is about 10,000; 20,000; 30,000; or 50,000 pg of peptide. Dosage values for a human typically range from about 500 fig to about 50,000 fig of peptide per 70 kilogram patient. This is followed by boosting dosages of between about 1.0 ftg to about 50,000 pg ofpeptide, administered at defined intervals from about four weeks to six months after the initial administration of vaccine. The immunogenicity of the vaccine may be assessed by measuring the specific activity of CTL and HTL obtained from a sample of the patient's blood.

[0323] As noted above, polypeptides comprising CTL and/or HTL epitopes <, induce immune responses when presented by HLA molecules and contacted with a CTL or HTL specific for an epitope comprised by the peptide. The manner in which the peptide is contacted with the CTL or HTL is not critical to the invention. For instance, the peptide can be contacted with the CTL or HTL either in vitro or in vivo. If the contacting occurs in vivo, peptide can be administered directly, or in other forms/vehicles, e.g., DNA vectors encoding one or more peptides, viral vectors encoding the peptide(s), liposomes, antigen presenting cells such as dendritic cells, and the like, as described herein.

[0324] Accordingly, for pharmaceutical compositions in the form of peptides or polypeptides, the peptides or polypeptides can be administered directly. Alternatively, the peptide/polypeptides can be administered indirectly presented on APCs, or as DNA encoding them. Furthermore, the polypeptides, peptide epitopes or DNA encoding them can be administered individually or as fusions of one or more peptide sequences.

[0325] For therapeutic use, administration should generally begin at the first

[0322] The vaccine compositions can be used purely as diagnosis of TAA-related disease. This is followed by boosting doses at le lSITELLECTUAL PR0Ptfi > v u 2 5 OCT 2C03 RF a ii Ikra until symptoms are substantially abated and for a period thereafter. In chronic disease states, loading doses followed by boosting doses maybe required.

[0326] The dosage for an initial therapeutic immunization generally occurs in a unit dosage range where the lower value is about 1, 5, 50, 500, or 1,000 |xg of peptide and the higher value is about 10,000; 20,000; 30,000; or 50,000 fig of peptide. Dosage values for a human typically range from about 500 fig to about 50,000 fig ofpeptideper 70 kilogram patient. Boosting dosages of between about 1.0 fig to about 50,000 fig of peptide, administered pursuant to a boosting regimen over weeks to months, can be administered depending upon the patient's response and condition. Patient response can be determined by measuring the specific activity of CTL and HTL obtained from the patient's blood.

[0327] In certain embodiments, polypeptides, peptides and compositions i are used in serious disease states. In such cases, as a result of the minimal amounts of extraneous substances and the relative nontoxic nature of the peptides, it is possible and may be desirable to administer substantial excesses of these peptide compositions relative to Ihese stated dosage amounts.

[0328] For treatment of chronic disease, a representative dose is in the range disclosed above, namely where the lower value is about 1,5,50,500, or 1,000 fig of peptide and the higher value is about 10,000; 20,000; 30,000; or 50,000 fig of peptide, preferably from about 500 fig to about 50,000 fig of peptide per 70 kilogram patient. Initial doses followed by boosting doses at established intervals, e.g., from four weeks to six months, may be required, possibly for a prolonged period of time to effectively immunize an individual. In the case of chronic disease, administration should continue until at least clinical symptoms or laboratory tests indicate that the disease has been eliminated or substantially abated, and for a follow-up period thereafter. The dosages, routes of administration, and dose schedules are adjusted in accordance with methodologies known in the art.

[0329] The pharmaceutical compositions for therapeutic treatment are intended for parenteral, topical, oral, intrathecal, or local administration. Preferably, the INTELLECTUAL PROPERTY 0.-0F N Z 2 5 OCT 2GGS pharmaceutical compositions are administered parentally, e.g., intravenously, subcutaneously, intradermally, or intramuscularly.

[0330] Thus, in a preferred embodiment Compositions for parenteral administration which comprise a solution ofthe immunogenic peptides dissolved or suspended in an acceptable carrier, preferably an aqueous carrier. A variety of aqueous carriers may be used, e.g., water, buffered water, 0.8% saline, 0.3% glycine, hyaluronic acid and the like. These compositions maybe sterilized by conventional, well known sterilization techniques, or may be sterile filtered. The resulting aqueous solutions may be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile solution prior to administration. The compositions may contain pharmaceutically acceptable auxiliary substances or pharmaceutical excipients as may be required to approximate physiological conditions, such as pH-adjusting and buffering agents, tonicity adjusting agents, wetting agents, preservatives, and the like, for example, sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, sorbitan monolaurate, triethanolamine oleate, etc.

[0331] The concentration of peptides and polypeptides < in the pharmaceutical formulations can vary widely, i.e., from less than about Ovl%, usually at or at least about 2% to as much as 20% to 50% or more by weight, and will be selected primarily by fluid volumes, viscosities, etc., in accordance with the particular mode of administration selected.

[0332] A human unit dose form of the peptide and polypeptide composition is typically included in a pharmaceutical composition that also comprises a human unit dose of an acceptable earner, preferably an aqueous carrier, and is administered in a volume of fluid that is known by those of skill in the art to be used for administration of such compositions to humans (see, e.g., Remington's Pharmaceutical Sciences, 17th Edition, A. Gennaro, Editor, Mack Publishing Co., Easton, Pennsylvania, 1985).

[0333] The peptides and polypeptides can also be administered ft INTELLECTUAL PROPERTY via liposomes, which serve to target the peptides and polypeptides to a particuljar of n.z 2 5 OCT 2003 gr"*0 a « # r* tissue, such as lymphoid tissue, or to target selectively to infected cells, as well as to increase the half-life of the peptide composition. Liposomes include emulsions, foams, micelles, insoluble monolayers, liquid crystals, phospholipid dispersions, lamellar layers and the like. In these preparations, the peptides and polypeptides to be delivered is incorporated as part of a liposome, alone or in conjunction with a molecule which binds to a receptor prevalent among lymphoid cells (such as monoclonal antibodies which bind to the CD45 antigen) or with other therapeutic or immunogenic compositions. Thus, liposomes either filled or decorated with a desired peptide of the invention can be directed to the site of lymphoid cells, where the liposomes then deliver the peptide compositions.

Liposomes are formed from standard vesicle-forming lipids, which generally include neutral and negatively charged phospholipids and a sterol, such as cholesterol. The selection of lipids is generally guided by consideration of, e.g., liposome size, acid lability and stability ofthe liposomes in the blood stream. A variety of methods are available for preparing liposomes, as described in, e.g., Szoka, et al., Ann. Rev. Biophys.

Bioeng. 9:467 (1980), andU.S. PatentNos. 4,235,871,4,501,728,4,837,028, and 5,019,369.

[0334] Fortargetingcompositionsoftheinventiontocellsoftheimmunesystem, a ligand can be incorporated into the liposome, e.g., antibodies or fragments thereof specific for cell surface determinants of the desired immune system cells.

A liposome suspension containing a peptide may be administered intravenously, locally, topically, etc. in a dose which varies according to, inter alia, the manner of administration, the peptide being delivered, and the stage of the disease being treated.

[0335] For solid compositions, conventional nontoxic solid carriers may be used which include, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium carbonate, and the like. For oral administration, a pharmaceutically acceptable nontoxic composition is formed by incorporating any of the normally {Intellectual"? ' *• OF N2.

Jo I employed excipients, such as those carriers previously listed, and generally 10-95% of active ingredient, that is, one or more peptides often at a concentration of 25%-75%.

[0336] For aerosol administration, the immunogenic peptides are preferably supplied in finely divided form, along with a surfactant and propellant Typical percentages ofpeptides are 0.01 %-20% by weight, often 1%-10%. The surfactant must, of course, be pharmaceutically acceptable, and preferably soluble in the propellant. Representative of such agents are the esters or partial esters of fatty acids containing from 6 to 22 carbon atoms, such as caproic, octanoic, lauric, palmitic, stearic, linoleic, linolenic, olesteric and oleic acids with an aliphatic polyhydric alcohol or its cyclic anhydride. Mixed esters, such as mixed or natural glycerides maybe employed. The surfactant may constitute 0.1 %-20% by weight of the composition, preferably 0.25-5%. The balance of the composition is ordinarily propellant, although an atomizer may be used in which no propellant is necessary and other percentages are adjusted accordingly. A carrier can also be included, e.g., lecithin for intranasal delivery.

[0337] Antigenic peptides have been used to elicit a CTL and/or HTL response ex vivo, as well. The resulting CTLs or HILs can be used to treat chronic infections, or tumors in patients that do not respond to other conventional forms of therapy, or who do not respond to a therapeutic peptide or nucleic acid vaccine in accordance with the invention. Ex vivo CTL or HTL responses to a particular antigen (infectious or tumor-associated) are induced by incubating in tissue culture the patient's, or genetically compatible, CTLor HTL precursor cells together with a source of antigen-presenting cells (APC), such as dendritic cells, and the appropriate immunogenic peptide. After an appropriate incubation time (typically about 7-28 days), in which the precursor cells are activated and expanded into effector cells, the cells are infused back into the patient, where they will destroy (CTL) or facilitate destruction (HTL) of their specific target cell (an infected cell or a tumor cell).

INTELLECTUAL PROPERTY OFFiCc < OF NX 2 5 OCT 2006 RECEIVED] A number of computer algorithms have been described for identification of peptides in a larger protein that satisfy the requirements of peptide binding motifs for specific MHC class I or MHC class II molecules. Because of the extensive polymorphism of MHC molecules, different peptides will often bind to different MHC molecules. Tables 1-6 list C35 peptides predicted to be MHC bindingpeptides using three different algorithms. Specifically, Tables 1 and 5 list C35 HLA Class I and II epitopes predicted using the rules found at the SYFPEITHI website fwvsiwvg://3 5/http://! 34.2.96.221/scripts/hlaserver.dll/ EpPredict.htm) and are based on the book "MHC Ligands and Peptide Motifs" by Rammensee, H.G., Bachmann, J. and Stevanovic, S. (Chapman & Hall, New York 1997). Table2UstspredictedMHCbindingpeptidesderivedfromtheC35 sequence using the NIH BIMAS program available on the web ftrttp://himas.dcrt.nih.gov/cri-bin/molbio/ken ttarker comboform). Finally, Tables 3 and 6 list predicted C35 peptides identified by the Tepitope program, a program for prediction of peptides that may bind to multiple different MHC class II molecules. Using Tepitope, four C35 peptides were identified as likely candidates for binding to a variety of HLA class II molecules. These peptides are, in general, longer than those binding to HLA class I and more degenerate in terms of binding to multiple HLA class n molecules. Due to the relatedness of the HLA molecules and the inherent limitations of the binding algorithms, it is expected that many of these C35 peptide epitopes predicted to bind to a specific HLA molecules will also bind to one or more other HLA molecules.

TABLE1 C35 peptides predicted by SYFPEITHI website (score reflects ligation strength): Class I MHC HLA-A*0201 nonamers Position Score 123456789 9 SVAPPPEEV 23 88 DLIEAIRRA 21 37 ATYLELASA 19 97 SNGETLEKI 18 105 ITNSRPPCV 18 2 SGEPGQTSV 17 45 AVKEQYPGI 17 38 TYLELASAV 16 61 GTGAFEIEI 16 85 YEKDLIEAI 16 65 FEIEINGQL 107 NSRPPCVIL 41 ELASAVKEQ 14 58 RLGGTGAFE 14 59 LGGTGAFEI 14 66 EIEINGQL V 14 68 EINGQLVFS 14 81 GGFPYEKDL 14 94 RRASNGETL 14 HLA-A*0201 decamers Pos Score 123456789 0 58 RLGGTGAFEI 22 96 ASNGETLEKI 19 104 KITNSRPPCV 19 37 ATYLELASAV 17 VEPGSGVRIV 33 CGFEATYLEL 44 SAVKEQYPGI 92 AIRRASNGET 39 YLELASAVKE 53 IEIE SRLGGT 65 FEIEINGQL V 105 ITNSRPPCVI 1 MSGEPGQTSV 63 GAFEIEINGQ 68 EINGQLVFSK 69 INGQLVFSKL 83 FP YEKDLIE A 88 DLIE AIRRAS 18 17 16 16 16 14 14 14 14 14 93 IRRASNGETL 14 72 QLVFSKLENG 13 89 LIE AIRRASN 13 8 TSVAPPPEEV 12 16 EVEPGSGVRI 12 50 YPGIEIESRL 12 60 GGT GAFEIEI 12 81 GGFPYEKDLI 12 106 TNSRPPCVIL 12 HLA-A*0203 nonamers Pos Score 123456789 FEATYLELA HLA-A*0203 decamers Pos Score 1234567 890 36 EATYLELASA 18 HLA-Al nonamers Pos Score 123456789 77 KLENGGFPY 2 SGEPGQTSV 21 SGVRIWEY 16 EVEPGSGVR 29 YCEPCGFEA 42 LASAVKEQY 31 EPCGFEATY 34 GFEATYLEL 39 YLELASAVK 29 18 18 17 17 17 16 16 84 P YEKDLIE A 14 66 EIEINGQL V 13 13 PPEEVEPGS 12 46 VKEQYPGIE 12 52 GIEIESRLG 12 96 ASNGETLEK 12 HLA-Al decamers Pos Score 1234567890 GSGVRIVVEY 29 YCEPCGFEAT 19 76 SKLENGGFPY 18 2 SGEPGQTSVA 17 52 GIEIESRLGG 17 66 EIEINGQLVF 41 ELASAVKEQY 16 46 YKEQYPGIEI 16 16 EVEPGSGVRI CEPCGFEATY 39 YLELASAVKE 77 KLENGGFPYE 14 86 EKDLIEAIRR 14 98 NGETLEKITN 14 34 GFEATYLELA 12 64 AFEIEINGQL 12 101 TLEKITNSRP 12 IILA-A26 nonamers Pos Score 123456789 68 EINGQLVFS 24 100 88 54 41 45 31 34 73 16 77 66 21 37 ETLEKITNS 24 DLIEAIRRA 23 EIESRLGGT 22 ELASAVKEQ 21 AVKEQYPGI EPCGFEATY 19 GFEATYLEL 19 LVFSKLENG 19 EVEPGSGVR 18 KLENGGFPY 18 EIEINGQLV 17 SGVRIWEY 16 ATYLELASA 16 24 RIVVEYCEP 9 SVAPPPEEV 14 22 GVRIVVEYC 51 PGIEIESRL 70 NGQLVFSKL 57 SRLGGTGAF 65 FEIEINGQL IVVEY CEP C 48 EQYPGIEIE 67 IEINGQL VF 75 FSKLENGGF 81 GGFPYEKDL 104 KITNSRPPC 105 ITNSRPPCV 14 14 14 13 13 12 12 12 12 12 12 12 HLA-A26 decamers Pos Score 1234567890 41 ELASAVKEQY 27 66 EIEINGQLVF 26 68 EINGQLYFSK 23 26 VVEYCEPCGF 21 16 EVEPGSGVRI 88 DLIEAIRRAS 19 100 ETLEKITNSR 19 74 VFSKLENGGF 18 33 CGFEATYLEL 17 54 EIESRLGGTG 17 56 ESRLGGTGAF 17 GSGVRIVVEY 16 31 EPCGFEATYL 16 64 69 61 73 9 45 72 77 79 AFEIEINGQL INGQLVF SKL GTG AFEIEIN LVFSKLENGG SVAPPPEEVE IVVEYCEPCG AVKEQYPGIE QLVFSKLENG KLENGGFPYE ENGGFPYEKD EPGQTSVAPP QTSVAPPPEE CEP CGFEATY 36 EATYLELASA 37 ATYLELASAV 14 14 13 13 13 13 13 13 12 12 12 12 12 76 SKLENGGFPY 12 89 LIEAIRRASN 12 HLA-A3 nonamers Pos Score 123456789 39 YLELASAVK 77 KLENGGFPY 16 EVEPGSGVR 58 RLGGTGAFE 67 IEINGQLVF 96 ASNGETLEK 92 AIRRASNGE 9 SVAPPPEEV 101 TLEKITNSR 22 GVRIVVEYC 28 24 22 19 18 17 16 16 31 45 72 21 68 69 88 91 37 55 57 79 87 104 EPCGFEATY AVKEQYPGI QLVFSKLEN SGVRIWEY EINGQLVFS INGQLVFSK DLIE AIRRA EAIRRASNG IVVEYCEPC ATYLELASA IESRLGGTG 14 14 14 14 14 13 13 13 SRLGGTGAF 13 ENGGFPYEK 13 KDLIEAIRR 13 KITNSRPPC 13 -265 24 RIVVEYCEP 42 LASAVKEQY. 66 EIEINGQLV 89 LIE AIRRAS 90 IEAIRRASN 94 RRASNGETL HLA-A3 decamers Pos Score 1234567890 EINGQLVFSK 22 EVEPGSGVRI TYLELASAVK ELASAVKEQY EIEINGQL VF SVAPPPEEVE 12 12 12 12 12 12 68 16 38 41 66 9 58 RLGGTGAFEI 19 39 YLELASAVKE 18 92 AIRRASNGET 18 95 RASNGETLEK 18 45 AVKEQYPGIE 17 54 EIESRLGGT G 16 88 DLIEAIRRAS 16 89 LIEAIRRASN 16 26 VVEYCEPCGF 37 ATYLELASAV 22 GVRIVVEYCE 14 77 KLENGGFPYE 14 93 IRRASNGETL 14 IVVEYCEPCG 13 CEPCGFEATY 13 52 GIEIESRLGG 13 76 SKLENGGFPY 13 78 LENGGFPYEK 13 101 TLEKITNSRP 13 104 KITNSRPPCV 13 24 RIVVEYCEPC 12 72 QLVFSKLENG 12 HLA-B*0702 nonamers Pos Score 123456789 18 EPGSGVRIV 19 107 NSRPPCVIL 18 4 EPGQTSVAP 11 APPPEEVEP 31.

EPCGFEATY 34 GFEATYLEL 13 94 RRASNGETL 13 12 PPPEEVEPG 12 19 PGSGVRIVV 12 32 PCGFEATYL 12 83 FP YEKDLIE 12 106 TNSRPP CVI 12 HLA-B*0702 decamers Pos Score 1234567890 31 EPCGFEATYL 24 50 YPGIEIESRL 21 18 EPGSGVRIVV 83 FPYEKDLIEA 16 4 EPGQTSVAPP 11 APPPEEVEPG 93 IRRASNGETL 14 106 TNSRPPCVIL 14 69 INGQLVFSKL 13 33 CGFEATYLEL 12 64 AFEIEINGQL 12 HLA-B*08 octamers Pos Score 12 3 4 5 6 7 8 83 FPYEKDLI 66 EIEINGQL 16 52 GIEIESRL 18 EPGSGVRI 14 54 EIESRLGG 14 91 EAIRRASN 95 RASNGETL 14 100 ETLEKITN 14 33 CGFEATYL 12 45 AVKEQYPG 12 58 RLGGTGAF 12 68 EINGQLVF 12 71 GQLVFSKL 12 75 FSKLENGG 12 82 GFPYEKDL 12 107 NSRPPCVI 12 108 SRPPCVIL 12 HLA-B*08 nonamers Pos Score 123456789 75 FSKLENGGF 83 .

FPYEKD LIE 45 AVKEQYPGI 85 YEKDLIEAI 107 NSRPPCVIL 100 ETLEKITNS 54 EIESRLGGT 65 FEIEINGQL 91 EAIRRASNG GSGVRIVVE 34 GFEATYLEL 51 PGIEIESRL 81 GGFPYEKDL 19 18 18 17 14 14 14 12 12 12 12 HLA-B*1510 nonamers Pos Score 123456789 107 NSRPPCVIL 34 GFEATYLEL 13 51 P GIEIESRL 13 81 GGFPYEKDL 13 94 RRASNGETL 13 HLA-B*2705 nonamers Pos Score 123456789 57 SRLGGTGAF 26 94 RRASNGETL 67 IEINGQLVF 19 87 KDLIE AIRR 19 51 P GIEIESRL 17 81 GGFPYEKDL 65 FEIEINGQL 69 INGQLYF SK 96 ASNGETLEK 16 EVEPGSGVR 34 GFEATYLEL 50 YP GIEIBSR 70 NGQLVFSKL 101 TLEKITN S R 23 VRIVVEYCE 32 PCGFEATYL . 39 YLELASAVK 79 ENGGFPYEK 93 IRRASNGET 21 SGVRIWEY 17 16 16 16 .14 14 14 14 14 13 27 VEY CEPCGF 13 75 FSKLENGGF 13 86 EKDLIE AIR 13 107 NSRPPCVIL 13 17 VEPGSGVRI 12 31 EPCGFEATY 12 77 KLENGGFPY 12 HLA-B*2709 nonamers Pos Score 123456789 94 RRASNGETL 57 .SRLGGTGAF 81 GGFPYEKDL 16 34 GFEATYLEL 14 51 PGIEIESRL 13 65 FEIEINGQL 13 23 VRIVVEYCE 12 107 NSRPPCVIL 12 HLA-B*5101 nonamers Pos Score 123456789 18 EPGSGVRIV 21 81 GGFPYEKDL 21 51 PGIEIESRL 70 NGQLVFSKL 19 PGSGVRIVV 19 31 EPCGFEATY 19 2 SGEPGQTSV 18 42 LASAVKEQY 18 59 LGGTGAFEI 18 21 83 97 13 38 45 63 94 12 33 50 66 SGVRIWEY 14 FPYEKDLIE 14 SNGETLEKI 14 PPEEVEP GS 13 TYLELASAV 13 AVKEQYPGI 13 GAFEIEIN G 13 RRASNGETL 13 PPPEEVEPG 12 CGFEATYLE 12 YPGIEIESR 12 EIEINGQLV 12 85 YEKDLIE Al 12 95 RASNGETLE 12 105 ITNSRPPCV 12 HLA-B*5101 octamers Pos Score 12 3 4 5 6 7 8 83 FPYEKDLI 95 RASNGETL 23 VAPPPEEV 21 18 EPGSGVRI 21 33 CGFEATYL 21 98 NGETLEKI 19 19 PGSGVRIV 18 60 GGTGAFEI 18 62 TGAFEIEI 18 63 GAFEIEIN 14 71 GQLVFSKL 14 48 EQYPGIEI 13 67 IEINGQLV 13 106 TNSRPPCV 12 Class n MHC HLA-DRBl *010115 -mers Pos Score 123456789012345 72 QLVFSKLENGGFPYE 29 37 ATYLELASAVKEQYP 26 26 VVEYCEPCGFEATYL 63 G AFEIEING QLVFS K 24 RIVVEYCEPCGFEAT 24 36 EATYLELASAVKEQY 24 39 YLELASAVKEQYPGI 24 53 IEIES RLGGTGAFEI 24 56 ESRLGGTGAFEIEIN 14 PEEVEPGSGVRIVVE 43 ASAVKEQYPGIEIES 20 GSGVRIVVEYCEPCG 62 TGAFEIEINGQLVFS 32 PCGFEATYLELASAV 47 KEQYPGIEIESRLGG 64 AFEIEINGQLVFSKL 82 GFPYEKDL IE AIRRA 34 GFEATYLELASAVKE 54 EIESRLGGTGAFEIE 90 IE AIRRASNGETLEK 99 GETLEKITNSRPPCV 31 EPCGFEATYLELASA 49 QYPGIEIESRLGGTG 24 23 23 19 19 19 19 18 18 18 18 17 17 58 RLGGTG AFEIEING Q 17 66 EIEINGQLVFSKLEN 17 67 IEINGQLVFSKLENG 17 68 EINGQLVFSKLENGG 17 84 P YEKD LIEAIRRASN 17 86 EKDLIEAIRRASNGE 17 FEATYLELASAVKEQ 16 74 VFS KLENGGFP YEKD 16 87 KD LIE AIRRASNGET 16 91 EAIRRASNGETLEKI 16 I MSGEPGQTS VAPPPE 4 EPGQTSVAPPPEEVE II APPPEEVEPGSGVRI 12 PPPEEVEPGSGVRIV 29 YCEPCGFEATYLELA ' PGQTSVAPPPEEVEP 14 6 GQTSVAPPPEEVEPG 14 44 SAVKEQYPGIEIESR 14 52 GIEIESRLGGTGAFE 14 61 GTGAFEIEINGQLVF 13 50 YPGIEIESRLGGTGA 12 HLA-DRB1*0301 (DR17) 15 - mers Pos Score 123456789012 3 45 64 AFEIEINGQLVFSKL 26 39 YLELASAVKEQYP GI 72 QLVFSKLENGGFPYE 23 62 TGAFEIEINGQLVFS 22 24 RIVVEYCEPCGFEAT 19 71 GQLVFSKLENGGFPY 19 86 EKDLIEAIRRASNGE 7 QTSVAPPPEEVEPGS 23 VRIVVEYCEPCGFEA 50 YPGIEIESRLGGTGA 90 IE AIRRASNGETLEK 20 GSGVRIVVEYCEPCG 87 KD LIE AIRRASNGET 99 GETLEKITNSRPPCV 28 EYCEPCGFEATYLEL 37 ATYLELASAVKEQYP 48 EQ YPGIEIESRLGGT 78 LENGGFP YEKDLIEA 14 PEEVEPGSGVRIVVE 70 NGQLVFSKLENGGFP 43 AS AVKEQYPGIEIES 19 18 18 18 18 17 17 16 14 14 14 13 13 12 52 GIEIESRLGGTGAFE 12 54 EIE S RLGGTGAFEIE 12 74 VFSKLENGGFPYEKD 12 82 GFP YEKDLIE AIRRA 12 HLA-DRB1*0401 (DR4Dw4) 15 - mers Pos Score 123456789012345 36 EATYLELASAVKEQY 28 62 TGAFEIEING QLVFS 28 86 EKDLIEAIRRASNGE 26 87 KDLIEAIRRASNGET 26 90 IE AIRRASNGETLEK 26 72 QLVFSKLENGGFPYE 22 82 GFP YEKDLIE AIRRA 22 50 YPGIEIESRLGGTGA 99 GETLEKITNSRPPCV 26 VVEYCEPCGFEATYL 32 PCGFEATYLELASAV Al KEQYPGIEIESRLGG 80 NGGFP YEKD LIE AIR 14 PEEVEPGSGVRIVVE GSGVRIVVEYCEPCG 22 GVRIVVEYCEPCGFE 37 ATYLELASAVKEQYP 39 YLELAS AVKEQYPGI 56 ESRLGGTGAFEIEIN 64 AFEIEINGQLVFSKL 66 EIEINGQLVFSKLEN 10 VAPPPEEVEPGSGVR 12 PPPEEVEPGSGVRIV 16 16 16 16 14 14 14 14 14 14 14 14 12 12 16 EVEPGS GVRIVVEYC 29 YCEPCGFEATYLELA CEPCGFEATYLELAS 31 EPCGFEATYLELASA 34 GFEATYLELASAVKE FEATYLELASAVKEQ 42 LASAVKEQYPGIEIE 48 EQYPGIEIESRLGGT 49 QYPGIEIESRLGGTG 53 IEIESRLGGTGAFEI 58 RLGGTGAFEIEINGQ 59 LGGTGAFEIEINGQL 61 GTGAFEIEINGQLVF 63 GAFEIEINGQLVFSK 67 IEINGQL.VFSKLENG 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 68 EINGQLVFSKLENGG 12 69 INGQL VFSKLENGGF 12 85 YEKDLIEAIRRASNG 12 93 IRRASNGETLEKITN 12 94 RRASNGETLEKITNS 12 96 ASNGETLEKITNSRP 12 97 SNGETLEKITNSRPP 12 TABLE2 HLA peptide motif search results j User Parameters and Scoring Information | method selected to limit number of results (explicit number | number of results requested | 20 | HLA molecule type selected .1 Al | length selected for subsequences to be scored -1- : | echoing mode selected lor input sequence il * i ]| echoing format || numbered lines j '| length of user's input peptide sequence I 115 : :| number of subsequence scores calculated J.. I0? ! ;|number of top-scoring subsequences reported back in scoring output tat >le|| 20 j Rank Start Position Subsequence Residue listing Score (Estimate of Half Time of Disassociatton of . a Molecule Containing This Subsequence) 1 77 KLENGGFPY 225.000 : 2 16 EVEPGSGVR 90.000 3 29 ' YCEPCGFEA 45.000 : 4 . 39 YLELASAVK i 36.000 : 2 SGEPGQTSV 2.250 6 ' 26 .. J WEYCEPCG 1.800 1 96 : ASNGETLEK 1400 8 101 ; TLEKITNSR 0.900 9 89 : LIEAIKRAS osiio | 54 EIESRLGGT o.9oo ; 11 66 EIEINGQLV 0.900 j 12 52 GIEIESKLG 0.900 13 86 . EKDLIEAIR 0.500 14 1 42 LRSAVKEQY 0.500 IS 1 31 \ EPCGFEATY 0.250 16 1 69 .

... . INGQLVFSK 1 0^250 If | 34 . J GFEATYLEL J 0.225 it | 98 L.

NGETLEECCT 1 0,225 _J 19 I . 6i L.

GTGAFEIEI L 0.125 | 79 L.

ENGGFPYEK 1 0.100 Echoed User Peptide Sequence (length = 115 residues) HLA peptide motif search results | User Parameters and Scoring Information | method selected to limit number of results explicit number j number of resul ts requested j HLA molecule type selected Al | length selected for subsequences to be scored to | echoing mode selected for input sequence Y j | echoing lonnat numbered lines j | length of user's input peptide sequence 115 j :| number of subsequence scores calculated W6 j [number of top-scoring subsequences reported back in scoring output table i Scoring Results Rank' Start Position Subsequence Residue Listing Score (Estimate of Half Time of Disassociatton of ] a Molecule Containing This Subsequence) j 1 66 EIEInGQLVF 45.000 ! 2 16 EVEPgSGVRI 18.000 j 3" 29 YCEPCGFEAT 9.000 | 4 26 .

VVEYCEPCGF ; 9.00b i 52 j GIEIeSRLGG 4.500 - ; 6 2 j SGEPgQTSVA 2.250 ! 7 89 LIEAiRRASN 1.800 8 GSGVrlWEY 1.500 9 86 EKDLiEAIRR 1.250 i • 98 ; NGET1EKITN ; 1.125 | 11 95 RASNgETLEK ; 1.000 j 12 68 EINGqLVFSK 1.000 13 54 EIESrLGGTG 0.900 14 41 ELASaVKEQY 0.500 j | 100 | ETLElcITNSR 0.250 i 16 | -46 l| VKEQyPGIEI 0.225 .! 17 j 39 <| YtELaSRVKE 0.180 i 18 j 77 j KLENgGFEYE 0.180 j 19 [ 76 ;[ SKLEnGGFPY 0.125 j 48 I EQYPglEIES O § i Echoed User Peptide Sequence (length = 115 residues) HLA peptide motif search results | User Parameters and Scoring Information | method selected to limit number ol results Jexpiicit number | number of results requested | 20 j HLA molecule type selected j A 0201 | length selected for subsequences to be scored 1 | echoing mode selected for input sequence 1... .Y | echoing format J numbered lines | length ol user's input peptide sequence j lis | number of subsequence scores calculated .] 107 |number of top-scoring subsequences reported back in scoring output tab!e!| 20 Scoring Results Rank Start Position Subsequence Residue Listing / Score (Estimate ol Halt Time of Disassociation of a Molecule Containing This Subsequence) 1 9 SVAPPPEEV v/ 2.982 2 104 KITNSRPPC 2.391 3 105 ITNSRPPCV 1.642 4 IVVEYCEPC V 1.485 . 65 FEIEINGQL 1.018 6 47 KEQYPGIEI 0.710 7 88 DLIEAIRRA 0.703 8 59 LGGTGAFEI 0.671 9 61 GTGRFEIEI 0.551 81 GGFPYEKOL 0.516 ll 37 ATYLELASA 0.508 12 FEATYLELA 0.501 ! « EEVEPGSGV 0.416 1 14 1 17 VEPGSGVRI 0345 1 | 91 SNGETLEKI 0.313 1 | 70 | NGQLVFSKL 0.265 i | 22 | GVRIVVEYC j 0-203 1 i* | 45 | AVKEQYPGI j 0.196 { 19 1 85 | YEKDL1EAI | 0.151 | 20 j 38 | TYLELASAV | 0.147 Echoed User Peptide Sequence (length =115 residues) HLA peptide motif search results j User Parameters and Scoring information | method selected to limit number of results explicit number j number of results requested | HLA molecule type selected A_0201 j length selected tor subsequences to be scored j j echoing mode selected for input sequence j .Y i'| echoing format j numbered lines j j length of user's input peptide sequence j 115 | number of subsequence scores calculated 106 jnumber of top-scoring subsequences reported back in scoring output table Scoring Results Rank Start Position, Subsequence Residue ' Listing Score (Estimate of Halt lime of Disassociation of. a Molecule Containing This Subsequence) 1 58 RLGGtGAFEI 60.-510 2 104 KITNSRPPCV 33.472 3 65 FEIEiNGQLV .506 4 83 FPYEkDLIEA ; 4.502 ■ 5 n 33 CGFEaTYLEh 3.173 . . \ 6 } ' 1 MSGEpGQTSV j 3.165 37 ATYLeLASAV 3.091 S 50 YPGIelESRL 0.641 9 69 INGQ1VFSKL 0.450 1? VEPGSGVRIV 0.434 11 24 RIWeYCEPC 0335 12 53 IEIEsRLGGT 0.352 13 60 GGTGaFEIEI 0.259 14 | 8 TSVApPPEEV 0.222 { 44 SAVKeQYPGI 0.217 16 j 21 : SGVRiWEYC 0.2<tt ) \1 j 55 IESR1GGTGA i| 0.164 1 is | 80 NGGFpYEKDL J 0-139 1 lv 1 81 ...

GGFPyEKDLI "j 0.123 j 20 j 105 ITNSrPPCVI i| 0.101 Echoed User Peptide Sequence (length = 115 residues) HLA peptide motif search results | User Parameters and Scoring Information j method selected to limit number of results (explicit number j number of results requested | 20 | HLA molecule type selected | A_0205 j length selected for subsequences to be scored JL .. 9 j echoing mode selected for input sequence 1 v i -|_ echoing format j| numbered lines | ,| length of user's input peptide sequence .1 j i| number of subsequence scores calculated II 107 ; jnumber of top-scoring subsequences reported back in scoring output tal 3lel( 20 I Scoring Results Rank Start Position Subsequence Residue . Listing Score (Estimate of Half Time of Disassociation of | a Molecule Containing This Subsequence) I 1 65 FEIEXNGQL 8.820 . 2 IVVEYCEPC 3.060 i 3 9 SVAPPPEEV 2.otio | 4 104 KITNSRPPC 1.500 i 81 GGFPYEKDL 1J260 j 6 45 AVKEQYPGI ; L200 ; 7 70 NGQLVFSKL 0.700 1 8 47 KEQYPGIEI 0.420 9 105 ITNSRPPCV 0.340 i 37 ATYLELASA 0.300 i 11 FEATYLELA 0.252 12 17 VEPGSGVRI 0.238 \ 13 61 GTGAFEIEI 0.200 14 97 SNGETLEKI 0.150 | CEPCGFEAT 0.140 j 16 |' fc5 | ' YEKDLIEAI o.iie : 17 51 .j PGIEIESRL__ o.io5 j is | 59 | LGGTGAFEI L ...... .... j 19 | 22 | GVRIVVEYC 1 O.10O i 1 15 | EEVEPGSGV 1 0.084" I Echoed User Peptide Sequence (length = 115 residues) HLA peptide motif search results ] User Parameters and Scoring Information | method selected to limit number ot results explicit number 1 number of results requested | HLA molecule type selected A_0205 | length selected for subsequences to be scored j echoing mode selected for input sequence , Y ;| echoing format | numbered lines j | length of user's input peptide sequence 3 . . 1 | number of subsequence scores calculated { 106 {number of top-scoring subsequences reported bade in scoiing output table: i Scoring Results Rank.

Start Position Subsequence Residue Listing Score (Estimate of Half Time of Disassociation of i a Molecule Containing This Subsequence) 1 33 CGFEaTYLEL 6300 j 2 104 KITNSRPPCV 6.000' 3 45 FEIEiNGQLV £520 . | 4 53 IEIESRLGGT i.428 | 83 FPYEkOLIEA 1.350 ! 6 5fc RLGGtGAFEI 1.200 ' j 7 69 INGQ1VFSKL 1.190 & 50 YPGIelESRL i.050 ' ; 9 37 ATYteLASAV 0.600 i 1 MSGEpGQTSV 0.510 j U ao DGGFpYEKM, 0.42b ; 12 106 THSRpPCVIL 6.350 " ; 13 24 RIVVeYCEPC 0.300 , 14 44 SAVKeQYPGI 0.200" 17 VEPGSGVRIV o.iso 1 16 | 105 ITNSrPPCVI 0.170 j 17 j 07 SHGEtLEKIT 0.150 ' i | 18 | 55 IESR1GGTGA <).119 "■ j 19 j M GGTGaFEIEI 0.100 j 20 | 91 AIRRaSNGET 0.100 ! Echoed User Peptide Sequence (length = 115 residues) HLA peptide motif search results | User Parameters and Scoring Information 1 method selected to limit number of results (explicit number 1 number of results requested f~ 26 ] HLA molecule type selected || A24 I length selected for subsequences to be scored it ?_ . ■ -j echoing mode selected for input sequence || Y | echoing format || numbered lines j j length of user's input peptide sequence II .115 i j number of subsequence scores calculated _J. . ™ ' {number of top-scoring subsequences reported back in scoring output ti iblejj 20 Scoring Results ; Rank Start Position Subsequence Residue ■ Listing Score (Estimate of Halt Time of Disassociation of' a Molecule Containing This Subsequence) | 1 34 GFEATYLEL 33.000 ... 2 49 QYfGIEIES ; 11.550 3 70 NGfiLVFSKL 11.088 j 4 38 TYLELASAV .800 " ~ • 82 GFPYEKDLI ; '7.500 , i 6 . 81 GGFPYEKDL 4.800 j 7 " i07 NSRPPCVIL 4.800 8 75 FSKLENGGF : 2.000 9 97 SNGETLEKI 1.320 45 AVKEQYPGI 1.200 11 61 GTGAFEIEI 1.100 ! 12 59 LGGTGAFEI 1.100 13 <j5 FEIEINGQL 1.66$ 14 51 PGIEIESRL l.OOS IS 106 TNSRPPCVX l.OOO s 16 84 PYEKDLIEA 0.825 17 $4 RRASNGETL 0.800 j 18 28 EYCEPCGFE 0.600 ' " i 19 j 32 PCGFEATYL 0.400 J 20 .J 47 j KEQYEGIEI i| 0.330 1 Echoed User Peptide Sequence (length = 115 residues) HLA peptide motif search results | User Parameters and Scoring Information | method selected to limit number of results explicit number J number of results requested I 20 j HLA molecule type selected A24 j length, selected tor subsequences to be scored j j echoing mode selected for input sequence j y i "| echoing format j numbered lines; j length of user's input peptide sequence j 1 j number of subsequence scores calculated j 106 •; .jnumber of top-scoring subsequences reported bade in scoring output table] i Scori Bg Results Rank Start Position: Subsequence Residue ' Listing Score (Estimate of Half Time of Disassociation of i a Molecule Containing This Subsequence) 1 64 AEEIelNGQL ' 42.O00 ! 2 74 vesklenggf) .000 3 84 i PSfEKdLIEBfi 9.000 ; 4 " 69 , iRgqivfsecl' 7.392 | 28 EYCEpCGFEA; 6.600 6 50 • YPGIelESRL .600 i 'i 33 CGFEaTYLEL i .280 ; 8 106 TNSRpPCVIL 4. OOf) > 31 EPCGfEATYL 4.6'O"6 " i SO NGGFpYEKDL 4.000 ; ...... t 11 26 VVEYCEPCGF 3.OO0 12 66 EIEInGQLVF 3.000 ! 13 58 RLGGtGAFEI 2.200 14 56 ESRLgGTGAF 2.6*00 16 EVEPgSGVRI i.800 i 16 96 | RSBGeTLEKI 1.650 1 17 . 105 | ITNSrPPCVI i.500 ! 1 « 44 j SAVKeQYPGI 1.500 ! |» i 81 ..

[ GCFPyEKDLI ] 1-200 J | 20 [ 60 i| GGTGaFEIEI 1 1.100 • Echoed User Peptide Sequence (length = 115 residues) HLA peptide motif search results | User Parameters and Scoring Information | method selected to limit number of results explicit number | number of results requested | HLA molecule type selected ; A3 | length selected for subsequences to be scored 9 | echoing mode selected for input sequence j Y | echoing format | numbered lines j j length of user's input peptide sequence j 115 j number of subsequence scores calculated j 167 jnumber ot top-scoring subsequences reported back in scoring output table] 1 Scoring Results Rank Start Position; Subsequence Residue Listing Score (Estimate of Half Time of Disassociation of i a Molecule Containing This Subsequence) 1 77 KLENGGFPY;- 36,000 ' i 2 39 YfiELASAVK'i .000 ■; 3 101 TLEKlTHSRi 6.000 4 61 (rffAFEIEI. 0.540 . 69 I&GQLVFSK: 0360 6 . 96 ASNGETLEK 0.300 ! 7 22 GVRIVVEYC 0.270 j 8 79 ENGGFPYEK 0.162 £ IVVEYCEPC 0.135 45 : AVKEQYPGI ' 0.090 ! 11 37 .

ATYLELASA 0.075 j 12 42 LASAVKEQY 0.060 5 13 104 KITNSRPPC 0.060 14 50 YEGIEIESR 0.060 72 QLVFSKLEN j O.O60 16 16 EVEPGSGVR 0.054 ! I 31 EPCGFEATY 0.054 i 1 18 9 SVAPPPEEV 0.045 | 19 J 87 KDLIEAIRR 0.036 | 20 | 27 VEYCEPCGF 0.03O 1 Echoed User Peptide Sequence (length —115 residues) HLA peptide motif search results | User Parameters and Scoring Information | method selected to limit number of results explicit number j number of results requested | HLA molecule type selected A3 1 length selected for subsequences to be scored ; _[ echoing mode selected for input sequence j Y | echoing format j numbered lines j | length of user's input peptide sequence j 115 ; | number of subsequence scores calculated J 1W jnumber of top-scoring subsequences reported bade in scoring output table) l- Scoring Results [lank Start Position Subsequence Residue Listing Score (Estimate of Half Time ofiJisassociation of -a Molecule Containing This Subsequence) 1 68 EINGqLVFSK 8.100 2 58 RLGGtGRFEI 2.700 3 41 ELASaVKEQY 1.800 4 = 78 lifcHGgFPYEK o.si'o 95 RASNgETLEK 0.400 6 GSGVrlWEY 0.270 ; 7 i'oo ETLEklTNSR 0.203 ; 8 26 WEYcEPCGF 0.200" 9 77 KLENgGFPYE O.180" 66 EIEInGQLVF 0.i20 11 24 RIVVeYCEPC 0.090 1 12 104 KITNsRPPCV 0.060 ' 13 37 ATYLeLASAV 0.050 14 38 TXLElftSflVK 0.045 ; b 83 | FPYEkDLIEA 0.045 , 16 105 ,j IINSrPPCTI 0045 j 17 | 72 GLVFsKLEHG _ 0.045 18 j 30 | CEECgFERTY 0.036 19 j 22 J GVRIVVEYCE 0.027 j 16 J EVEPgSGVRI 0.027 ■ : Echoed User Peptide Sequence (length = 115 residues) HLA peptide motif search results User Parameters and Scoring Information method selected to limit number of results explicit number number oi results requested HLA molecule type selected A_1101 length selected tor subsequences to be scored 9 echoing mode selected for input sequence < y echoing format j numbered lines j length of user's input peptide sequence ] 115 number of subsequence scores calculated 107 i number of top-scoring subsequences reported back in scoring output table: Scoring Results i Rank: Start Position Subsequence Residue ' Listing Score (Estimate of Half Time of Disassociation of; a Molecule Containing This Subsequence) 1 39 YLELASAVK ... . . 0.400 . i i 69 INGQLVFSK 6.120 ; 3 16 EVEPGSGVR o.i2o ; 4 101 TLEKITNSR. 0.080 61 GTGAFEIEI : 0.060 i 6 50 YPGIE1ESR ; 0.040 7 96 ASNGETLEK 0.040 8 87 KDLIEAIRR : 0.036 $ 77 KLENGGFPY 0.036 j ; 79 ENGGFPYEK 0.024 ll 9 SVAPPPEEV 0.020 i 12 45 AVKEQYPGI .0.020 ! 13 37 ATYLELASA 0.020 14 34 GFEATYLEL 0.012 105 ITNSRPPCV 0.010 ! 16 22 GVRIVVEYC | 0.006 i 1? 38 TYLELASAV ) 0.0W | 18 82 GFPYEKDLI ! 0.006 | |19 | 29 YCEPCGFEA 0.006 \ I 20 J 73 ;| LVFSKLENG 0.004 ] Echoed User Peptide Sequence (length = 115 residues) HLA peptide motif search results | User Parameters and Scoring Information | method selected to limit number of results explicit number j number of results requested , j HLA molecule type selected A_3101 j length selected for subsequences to be scored j 9 . | echoing mode selected for input sequence j ^ i j echoing format ] numbered lines ] j length of user's input peptide sequence j 115 j | number of subsequence scores calculated j [ 167 ! jnumber of top-scoring subsequences reported back in scoring output table] iO j Scoring Results : Rank Start Position Subsequence Residue Listing Score (Estimate of Half Time of Disassociation of j a Molecule Containing This Subsequence) 1 101 TLEKITNSR 2.000 2 16 EVEPGSGVR 0.600 " " ; 3 • 50 YPGIEIESR 0.400 4 87 KDLIEAIRR 0.240 3S> YLELASAVK 0.200 ; 6 77 KLENGGFPY 0.180 " j 7 37 ATYLELASA 0.060 8 69 INGQLVFSK 0.024 9 45 AVKEQYPGI 0.020 <>1 GTGAFEIEI 0.020 j 11 0 SVAPPPEEV 0.020 12 24 RIVVEYCEP 0.012 13 | 34 GFEATYLEL O.0l2 : 14 | 73 LVFSKLENG 0.012 IS | 38 TYLELASAV 0.012 ; j 16 j 105 ITNSRPPCV 0.010 ; | 17 | 72 QLVFSKLEH l| _ __ 0-WtS _ i j 18 | 82 GFPYEKDLI | 0.006 _ j j 1S> j 104 KITNSRPPC j 0-006 _ __ : j 20 j 79 ENGGFPYEK :J _0-006_ _ _ : Echoed User Peptide Sequence (length = 115 residues) HLA peptide motif search results { User Parameters and Scoring Information I method selected to limit number of results -|explicit number 1 number of results requested | 20 j HLA molecule type selected | A 3302 " | length selected for subsequences to be scored II 9 i | echoing mode selected tor input sequence 1 Y ! j echoing foimat J numbered lines | j length ot user's input peptide sequence "1| 115 i j number of subsequence scores calculated JL ™^..\ |number of top-scoring subsequences reported back in scoring output tabtejj 20 ! Scoring Results ; Rank Start Position Subsequence Residue Listing Score (Estimate of Hair Time of Disassociation of a Molecule Containing This Subsequence) j 1 16 EVEPGSGVR 45.000 2" 101 TLEKITNSR 9.000 ; 3 50 YPGIEIESR 3/100 "" . 4 66 EIEIHGQLV 1.500 ! " " 56 ESKLGGTGA lioo . • 6 54 EIESRLGGT | 1.500 i 7 68 EIHGQLVFS 1.500 .! 8 86 EKDLIEAIR 0.900 "" ; 9 41 ELASAVKEQ 0.900 88 DLIEAIRRA 0.900 11 96 ASNGETLEK 0.500 ; ii 22 GVRIVVEYC oioo 13 1 | MSGEPGQTS 0.500 * 1 14 " 89 | LIEAIRRfiS 0.500 1 15 | 107 | NSRPPCVIL 1 GJOO j 16 1 9 j SVAPPPEEV ■ 1 o.5oi) "": 1 ,7 |' 38 j __ TYLELASAV 1. 0.500 i I 18 I 25 | IWEYCEPC_ 1 J0.500 _ j 1 19 1 45 j AVKEQYPGI i 0.500 t | 20 j 49 j QYPGIEIES il oioo j Echoed User Peptide Sequence (length = 115 residues) HLA peptide motif search results | User Parameters and Scoring Information | method selected to limit number of results [explicit number j number of results requested | 20 | HLA molecule type selected | A 3302 | length selected tor subsequences to be scored 1 ? -J | echoing mode selected for input sequence i v f | echoing format | numbered iines | | length of user's input peptide sequence 1 j j number of subsequence scores calculated j 107 j jnumber of top-scoring subsequences reported back in scoring output table 1 ^0 _ ' Scoring Results •: Rank Start Position: Subsequence Residue Listing Score (Estimate of Half Time of Disassociation of a Molecule Containing This Subsequence) j 1 16 EVEPGSGVR 45.000 2 101 TLEKITNSR 9.000 ' ; 3 50 YPGIEIESR 3.000 4 66 EIEINGQLV ; 1.500 " : 56 ESRLGGTGA 1.500 . j 6 54 EIESRLGGT ! 1.500 ~"1 7 68 EIHGQLVFS 1.500 ! S 86 EKDLIEAIR ' 0.900 9 41 ELASAVKEQ 0.900 88 DLIEAIRRA 0.900 11 96 ASNGETLEK 0300 12 22 GVRIVVEYC 0300 13 1 MSGEPGQTS 0.500 14 89 LIEAIRRAS 0.500 | 107 NSRPPCVIL oisoo 16 | 9 j| SVAPPPEEV o.5oo ' : 1 17 | 38 1 TYLELASAV H 0.500 1 18 I 25 :| IVVEYCEPC '-| _ _ 0.500 1 19 I 45 'I AVKEQYPGI •} _ 0.500 | j 20 | 49 :| QYPGIEIES i| 0.500 _ j Echoed User Peptide Sequence (length = 115 residues) HLA peptide motif search results | User Parameters and Scoring information j method selected to limit number of results explicit number [ number of results requested j HLA molecule type selected A68.1 j length selected for subsequences to be scored j 9 j echoing mode selected for input sequence : y ; j echoing fonnaF ] numbered lines | 'j length of usert input peptide sequence ; 115 j j number of subsequence scores calculated j 107 { jnumber of top-scoring subsequences reported back in scoring output table! ; Scoring Results Rank Start Position Subsequence Residue Listing Score (Estimate of Half Time of Disassociation of ; a Molecule Containing This Subsequence) 1 16 EVEPGSGVR POO.OOO 2 9 SVAPPPEEV 12.006 » 3' 50 YPGIEIESR io.o'oo 4 96 ASNGETLEK 9.006 101 TLEKITNSR .000" . ; 6 45 AVKEQYPGI 4.000 7 79 ENGGFPYEK 3.600 ; 8 39 YLELASAVK 3.000 9 6] GTGAFEIEI 3.000 86 EKDLIEAIR 2350 ; 11 69 INGQLVFSK 1.200 12 87 KDLIEAIRR 1.000 j 13 105 ITNSRPPCV i.o65 (4 37 ATYLELASA 1.000 56 ESRLGGTGA ■ 0.906 ; 16 IVVEYCEPC 0.806 17 73.

I LVFSKLENG 0.800 lis OO OO DLIEAIRRA 0.600 i 18 [ EPGSGVRIV 1" a«8_ __ ; 50 |" 26 j WEYCEPCG | 0.600 j Echoed User Peptide Sequence (Length = 115 residues) HLA peptide motif search results User Parameters and Scoring Information method selected to limit number of results explicit number number of results requested HLA molecule type selected A68.1 length selected for subsequences to be scored j 9 echoing mode selected for input sequence echoing format | numbered lines length of user's input peptide sequence ! 115 number of subsequence scores calculated j number of top-scoring subsequences reported back ia scoring output table! ; Scoring Results Rank Start Position Subsequence Residue Listing Score (.Estimate of Half Time of Disassociation of: a Moleculc Containing This Subsequence) 1 16 evepgsgvr 900.000 2 9 svapppeev 12.000 " i 3 50 ypgieiesr L io.oioO 4 96 asngetlek 9.OT0 101 tlekitnsr .000 . ; 6 45 avkeqypgi 4.000 " ! 7 79 enggfpyek 3.600 i 8 39 . ylelasavk 3.000 9 61 gtgafeiei ; 3.000 • 86 ekdlieair 2.250 ; 11 69 ingqlvfsk 1.200 12 • 8? kdlieairr i.ooo ! 13 105 itnsrppcv 1.000 14 37 atylelasa 1.000 56 esrlggtga • 0.900 ; ]<) ivveycepc 0.800 1? 73. lvfskleng O.8O0 18 88 " dlieairra 0.600 ! 18 epgsgvriv 0.600 i | 20 \ 26 | vveyce pcg | 0.600 Echoed User Peptide Sequence (length = 115 residues) HLA peptide motif search results User Parameters and Scoring Information method selected to limit number of results number of results requested explicit number HLA molecule type selected A68.1 length selected lor subsequences to be scored echoing mode seleetedforinpuFsequence~~ IF , Y_ J numbered lines i echoing format length of visa's inputpeptide sequence number of subsequence scores calculated TTF C "TOT jnumber of top-scoring subsequences reported back in scoring output tabid Scoring Results Rank Start Position Subsequence Residue ' Listing Score (Estimate of Half Time of Disassociation of; a Molecule Containing This Subsequence) I 100 ETLEklTNSR 300.000 2 16 EVEPgSGVRI 18.000 : 3 68 EINGqLVFSK 9.000 4 EEVEpGSGVR 9.000 95 RASNgETLEK 3.000 6 85 YEKD1IEAIR 1 2.250 7 9 SVAPpPEEVE 1.800 & 86 EKDIdEAIRR : 1300 9 73 LVFSkLENGG 1.200 IWEyCEPCG , 1300 11 105 ITNSrPPCVI 1.000 11 37 ATYLelASAV . l.OOO 13 7& IiENGgFPYEK 0.900 14 8 TSVftpPPEEV 0.600 22 GVRIVVEYCE 0.600 16 18 EPGSgVRIW 0.600 17 | 1 MSGEpGQTSV 0.600 ; j 18 | 38 TYLE1ASAVK >( 0.600 ; J 19 J 49 j QYPGiEIESR .(_ _ U.500 _ ! I 20 | 45 'j AVKEqYPGIE j 0.400 _ 1 Echoed User Peptide Sequence (length = 115 residues) HLA peptide motif search results User Parameters and Scoring Information method selected to limit number of results explicit number number of results requested io HLA molecule type selected B14 length selected tor subsequences to be scored 1. _? echoing mode selected for input sequence .X. 5 echoing format | numbered lines ] length of user's input peptide sequence 115 number of subsequence scores calculated io7 s number of top-scoring subsequences reported back in scoring output table : Scoring Results Rank Start Position; Subsequence Residue Listing Score (Estimate of Half lime of Disassociation of, a Molecule Containing This Subsequence) i 1 94 i RRASNGETL .000 2 57 SRLGGTGAF .000 3 100 ETLEKITNS . 3.3?S ! 4 105 ITNSRPPCV 2.000 i 88 DLIEAIRRA 1350" <5 18 EPGSGVRIV i.2ot> : 7 70 NGQLVFSKL l.OOO ! t 81 GGFPYEKDL 1.000 9 54 EIESRLGGT 0.900 : 97 SNGETLEKI 0.600 ll 91 EAIRRASNG 0.450 : 12 68 EINGQLVFS 0.450 1 13 65 FEIEINGQL 6.300 14 23 VRIVVEYCE 0.300 21 SGVRIWEY 6.300 16 51 ; PGIEIBSRL 0.300 J t17 104 KITNSRPPC 1. _ _ 0.250 I.18 48 EQYPGIEIE 1... _ . 0325 '. !.'» • 93 IRRASHGET 1 0300 | 20 107 NSRPPCVIL 1 . . 0.200 Echoed User Peptide Sequence (length = 115 residues) •-305- HLA peptide motif search results | User Parameters and Scoring Information ! method selected to limit number of results t •|cxplicit number ] number of results requested f 20 | HLA molecule type selected 4 Bl4 | length selected for subsequences to be scored 3 V> | echoing mode selected for input sequence |— y. ) | echoing format 1| numbered lines ] j length of user's input peptide sequence | 115 j j number of subsequence scores calculated l| 106 j Jnumber of top-scoring subsequences reported back in scoring output table| 20 j Scoring Results < Rank Start Positlon- Subsequence Residue Listing Score (Estimate of Half Time of Disassociation of j a Molecule Containing This Subsequence) 1 103 EKITnSRFPC 6.750 2 33 CGFEaTYLEL .000 j 3 93 IRRASNGETL 4.000 4 18 EPGSgVRIW 3.000 : 6 88 DLIEalRRAS 2.250 _ <; 6 104 KITNSRPPCV 2.000 j 1 106 TOSRpPCVIL 1.000 8 50 YPGIelESRL i.ooo 9 69 INGQ1VFSKL LOW I It) 37 ATYLeLASAV 1.000 I 11 31 EPCGfEATYL 0.900 j 12 48 EQYPglEIES 0.750 : 13 76 SKLEnGGFPY 0.750 14 - 83 FPYEkDLIEA 0.750 8 TSVApPPEEV 0.6i)0 i 16 96 ASNGeTLEKI " : 0.600 | 1 1? 44 SAVKeQYPGI 0.600 j 1 18 57 SRLGgTGRFE 0.500 I.1* 53 IEIESRLGGT 0.450 i | 20 21 SGVRi VVEYC 0300 i Echoed User Peptide Sequence (length 5= 115 residues) HLA peptide motif search results | User Parameters and Scoring Information | method selected to limit number of results explicit number j number of results requested | HLA molecule type selected : B_2705 | length selected tor subsequences to be scored j 9 | echoing mode selected for input sequence j V : j echoing format j numbered lines | .j length of user's input peptide sequence | 115 i | number of subsequence scores calculated { 107 i jnumber of top-scoring subsequences reported back in scoring output table] 1 Scoring Results j Rank Start Position Subsequence Residue Listing Score (Estimate of Half Time of Disassociation of, a Molecule Containing This Subsequence) 1 94 RRASNGETL 6000.006 2 57 SRLGGTGAF lOOO.OOO" ' 3 93 IRRASNGET '6'.06'6 ; 4 27 VEYCEPCGF 75.000 77 KLENGGFPY 45.000 . 6 39 YLELASAVK 3O.O00 " ; 7 66 FBIEINGQL .000 •. 8 47 KEQYPGIEI 27.000 9 69 INGQLVFSK 26.000 23 VRIVVEYCE 2O.O00 11 101 TLEKITNSR .006 12 67 TEINGQLVF .006 13 107 NSRPPCVIL .000 14 96 ASNGETLEK .000 IS 85 YEKDLIEAI 9.000 16 17 VEPGSGVRI • 9.000 i 1 17 !l 81 j GGFPYEKDL 1 7.56b ; | 18 ,| 106 | THSRPPCVI | 6~000 1 ^ [ 97 j SNGETLEKI | (WOO _ j 20 1 w | FSKLENGGF j 5.000 . i Echoed User Peptide Sequence (length = 115 residues) HLA peptide motif search results | User Parameters and Scoring Information j method selected to limit number of results Jexplicit number j number of results requested •1 20 j HLA roolecuJe type selected j B 2705 j length selected for subsequences to be scored ..J !? _J [ echoing mode selected for input sequence —1- >" I ;| echoing format j| numbered lines j j length of user's input peptide sequence 11 ns J j number of subsequence scores calculated ..J ._«* Jnumber of top-scoring subsequences reported bade in scoring output tablelj 20 ! Scoring Results Rank Start Position! Subsequence Residue : Listing Score (Estimate of Half Time of Disassociation of i a Molecule Containing This Subsequence) 1 93 IRRAsNGETI. i 2000.000 2 94 RRASnGETLE 60.000 3 78 LENGgFPYEK .000 4 95 RASNgETLEK : .000 58 RLGGtGAFEI ; 27.000 6 33 CGFEaTYtEL L 25.000 j 7 • 106 TNSRpPCVIL .000 8 71 GQLVfSKLEN .000 9 23 VRIWEYCEP .006 i id 57 SRLGgTGAFE .000 , 11 69 ' IHGQ1VFSKL .000 12 | 30 CEPCgFEATY .000 13 | 85 YEK01IEAIR .000 14 | 37 ! ATYLeLASAV .000 IS | ' 48 1 EQYPglEIES .000 [16 | 50 i XPGIelESRL .000 J <04 L KITNsRPPCV 9.000 I.18. 1 65 J FEXEiNGQLV . JL 9.000 i 1 ?* 1 81 ..

L GGFPyEKDI.1 i. • 7-SOO : \ 20 | 83 1 FPYEkDLIEA 1 .000 i Echoed User Peptide Sequence (length = 115 residues) HLA peptide motif search results User Parameters and Scoring Information method selected to limit number of results explicit number number of results requested HLA molecule type selected • B_3501 length selected tor subsequences to be scored , 9 echoing mode selected for input sequence j Y j echoing fonnat ] numbered lines' length of uset*s input peptide sequence j 115 j number of subsequence scores calculated j 107 number of top-scoring subsequences reported back in scoring output tablej ! | Scoring Results Rank Start Position Subsequence Residue Listing Score (Estimate of Half Time of Disassociation of i a Molecule Containing This Subsequence) . 1 31 EPCGFEATY 40".0"00 2 75 FSKLENGGF 22.500 3 107 NSRPPCVIL .000 4 42 LftSAVKEQY 6.000 IS EPGSGVRIV 4.000 . j 6 45 AVKEQYPGI 2.400 j 1 21 • SGVRIWEY 2.000 56 ESRLGGTGA 1.500 9 77 KLENGGFPY 1.200 81 GGFPYEKDL 1.000 Jl 1 MSGEPGQTS 1.000 12 70 NGQLVFSKL 1.000 13 97 SNGETLEKI 0.800 | 14 | 83 FPYEKDLIE 0.400 1 » | 61 GTGAFEIEI 0.400 j 1* 1 & LGGTGAFEI (MOO : ^ 17 r| 106 TNSRPPCVI 0.400 .

,| I S j 50 YPGIEIESR 0300 , j | 1$ | 22 GVRIVVEYC 0300 1 20 j ll APPPEEVEP 0300 Echoed User Peptide Sequence (length = 115 residues) HLA peptide motif search results | User Parameters and Scoring Information | method selected to limit number of results explicit number j number of results requested j HLA molecule type selected B_350l | length selected for subsequences to be scored j echoing mode selected far input sequence j V j echoing format j numbered lines 1| length of user's input peptide sequence j ni i ij number of subsequence scores calculated j ib6 ! '.jnumber of top-scoring subsequences reported back in scoring output table) .

Scorii ng Results Rank Start Position Subsequence Residue Listing Score (Estimate of Half Time of Disassociation of a Molecule Containing This Subsequence) 1 31 EPCGfEATYL .C00 2 50 YPGIelESRL .000 3 56 ESBLgGTGAF i5.000 4 GSGVrlWEY .000 83 FPYEkDLIEA 6.000 6 18 EPGSgVRIW 4.0bo . 7 33 CGFEaTYLEL 2.000 8 I MSGEpGQTSV 2.000 9 96 ASNGeTLEKI 2.000 41 EIASaVKEQY 2.O0O 11 44 SAVKeQYPGI 1.200 12 69 INGQ1VFSKL l.OO'o 13 8 TSVApPPEEV 1.600 14 80 NGGFpYEKDL 1.000 IS 106 TMSRpPCVIL .. . 1.000 16 58 . RLGGtGAFEI 0.800 17 81 GGFPyEKDiX .. 1- - 0.600 ! 18 26 WEYcEPCGF . ...1 .. __ .. 0.450 : Z6 EATY1ELASA L ... 0.45O • lb 12 PPPEeVEPGS J . _ 0.4ob Echoed User Peptide Sequence (length = 115 residues) HLA peptide motif search results | User Parameters and Scoring Information I method selected to limit number ol'results (explicit number number of results requested HLA molecule type selected length selected tor subsequences to be scored B_3901 5 r echoing mode selected for input sequence c echoing format length of user's input peptide sequence j| numbered lines ZL 115 "J number of subsequence scores calculated i| 107 •jnumber of top-scoring subsequences reported back in scoring output table | 3T Scoring Results Rank Start Position Subsequence Residue Listing Score (Estimate of Half Time of Disassociation of! a Molecule Containing This Subsequence) : 1 94 rrasngetl .000 2 34 gfeatylel 9.000 ! 3 38 tylelasav 4.000 ' : 4 66 eieingqlv 3.000 2 sgepgqtsv 3.000 6 97 sngetleki , 3.000 ; 1 70 ngqlvfskl 3.000 * 81 ggfpyekdl 3.000 9 ' 18 epgsgvriv 1.500 65 feieingql 130 ; ll 57 srlggtgaf 1.000 j 12 106 tnsrppcvi l.ooo IS 9 svapppeev l.OOO | 14 | 59 lggtgafei l.OOO | 15 | 105 itnsrppcv l.OOO 1 IJ« 4 107 nsrppcvil 0.900 J | 17 I 45 avkeqypgi oioo j J is j 51 pgieiesrl 0.600 j j 19 | 88 dlieairra 0.600 1 | 20 J 100 etlekitns 0.600 ; Echoedt User Peptide Sequence (length = 115 residues) HLA peptide motif search results | User Parameters and Scoring Information | method selected to limit number of results explicit number | number of results requested J HLA molecule type selected [~~ B_3901 | length selected for subsequences to be scored | j echoing mode selected tor input sequence _j Y j echoing format | numbered lines > ;( length of user's input peptide sequence j 115 | number of subsequence scores calculated j [ 106 '(number of top-scoring subsequences reported back in scoiing output tablej Scoring Results i Rank Start Position Subsequence Residue Listing Score (Estimate of Hall Time of Disassociation of a Molecule Containing This Subsequence) 1 33 : CGFEaTYLfeL 12.000 , 2 64 AFEIelNGQL 9.000 3 . 93 IRRASNGETL 4-5°° i 4 46 VKEQyPGIEI 3.000 16 EVEPgSGVRI 3.000 6 106 TNSRpPCVIL 3.000 ; 7 69 IMGQ1VFSKL 3.000 S 31 UPCGfEATYL 3.000 9 44 SAVKeQYPGI 2.006 ■ 1 MSGEpGQTSV 2.000 ll 8 TSVApPPEEV 2.000 : 12 37 ATYLeLRSAV 2.600 13 80 NGGFpYEKDL 1.500 1 14 50 YPGIelESRL | 1.500 1 « 96 J ASNGeTLEKI 1 liSSd i 1<5 58 .

RLGGtGAFEI |j 1-000 ; 1J7 | 105 1.

ITNSrPPCVI 1 ___ 1.000 ! 1. 81 .

.L.

GGFPyEKDLI j 1.000 { I..19 j 104 .L.

KITKsRPPCV | • jioO ! ,| 20 1 « t FPYEkDLIEfi.

I 0.600 ! Echoed User Peptide Sequence (length = 115 residues) HLA peptide motif search results ] User Parameters and Scoring Information | method selected to limit number of results ^explicit number | number of results requested | HLA molecule type selected B40 ( length selected for subsequences to be scored 9 •j echoing mode selected for input sequence Y 1 | echoing format numbered lines j [ length of user's input peptide sequence 1X5 | j number of subsequence scores calculated 167 ! jnumber of top-scoring subsequences reported back in scoring output tablei ""} I Scoring Results Rank Start Position Subsequence Residue Listing Score (Estimate of Half Time of Disassociation of '■ a Molecule Containing This Subsequence) j 1 65 FEIEINGQL 80.000 i 2 3 GEPGQTSVA j i = : o j 3 FEATYLELA. 40.000 • 4 " EEVEPGSGV 24.600 | " 67 IEINGQLVF fiooo . i 6 81 GGFPYEKDL 8.OO0 ! 7 27 VEYCEPCGF 8.600 1 8 47 KEQYPGIEI ri.OGO 9 17 VEPGSGVRI 4.000 CEPCGFEAT ib'oo i 11 99 GETLEKITN 2.400 i 12 90 1EAIRRASN 2.400 1 13 37 ATYLELASA 2.000 14 85 YEKDLIEAI | _ 2.000 is Si IEXESRLGG ,J 1.600 [ 1<> 40 LELASAVKE 'j 0.8Q0 _j | 17 .j 107 NSRPPCVIL !j 0.750 ,j 18 j 29 YCEPCGFEA | 0300 j 19 | 70 NGQLVFSKL -| 0.500 j j 20 | 78 LENGGFPYE j 0.400 j Echoed User Peptide Sequence (length—115 residues) rwja HLA peptide motif search results | User Parameters and Scoring Information ! method selected to limit number of results » jcxplicit number number of results requested j 20 HLA molecule type selected | B40 length selected for subsequences to be scored ) echoing mode selected for input sequence 1 r ; echoing format || numbered lines j length of user's input peptide sequence jl_ ?15 Zj number of subsequence scotes calculated l.. number of top-sconng subsequences reported back in scoring output t ablejj 20 i Scoiing Results Rank Start Position Subsequence Residue • Listing Score (Estimate of Half lime of Disassociation of! a Molecule Containing This Subsequence) j 1 55 IESR1GGTG& .000 2 53 IEIEsRLGGT 16.000 3 65 FEIEiNGQLV 16.000 j 4 67 IEIHgQLVFS i6.000 " 09 GETLeKITOS : OO ' b ®l • O 6 FEATyLELAS 8.000 1 87 KDLIeAIRRA .000 1 8 17 VEPGSGVRIV 4.000 | 9 CEPCgFEATY 4.000 33 CGFEaTYLEL i 2.000 i 11 EEVEpGSGVR : 1.600 ! I 12 81 GGFPyEKOLI 1.600 i 1 13 27 VEYCePCGFE i.200 | 14 | 83 FPYEkOlIEA 1.000 | 15 f 40 LELAsAVKEQ O.80O ! j ie j 3 GEPGqTSVAP 0.800 ' | 17 [ 90 IEAIrfeASNG 0.800 • j 18 j 106 THSRpPCVIL 0.750 j 1 »M * ...

TSVBpPPEEV O.600 | 20 | 2 SGEPgQTSVA oioo ; Echoed User Peptide Sequence (length = 115 residues) •<•314- HLA peptide motif search results j User Parameters and Scoring Information j method selected to limit number of results explicit number | number of results requested j HLA molecule type selected B_5201 •j length selected tor subsequences to be scored 9 :| echoing mode selected for input sequence j * i .| echoing format j numbered lines j j length of user's input peptide sequence | ll5 ! j number of subsequence scores calculated j 107 i jnumber of top-scoting subsequences reported back in scoring output tablej , Scori ag Results Rank Start Position Subsequence Residue Listing Score (Estiniate of Half Time of Disassociation of; a Molecule Containing This Subsequence) 1 18 EPGSGVRIV 75.000 2 67 IEINGQLVF 22."500 3 59 LGGTGAFEI 11-250 4 98 NGETLEKIT 11.000 • PGSGVRIVV .660 . ' : 6 - 106 TNSRPPCVI .606 ( 1 48 EQYEGIEIE 9.900 8 2 SGEPGQTSV 9.666 9 81 GGFPYEKDL 6.600 : 38 TYLELASAV 4.800 : tl 27 : VEYCEPCGF 3.750 i 12 | 83 FPYEKDLIE 3.000 13 1 " VEPGSGVRI- 3.000 14 | 70 MGQLVFSKL 2.400 j *5 ' YEKDLIEAI 2.200 16 1 3 [ GEPGQTSVA 1 . . 2.200 j 17 | 82 '| GFPYEKDLI 1 _ 1200 18 j 97 | SNGETLEKI 1 IM ' " 19 1 61 . j GTGAFEIEI 1 1.800 j 105 j ITNSRPPCV 1 ijoo Echoed User Peptide Sequence (length = 115 residues) HLA peptide motif search results User Parameters and Scoring Information method selected to limit number of results explicit number number of results requested HLA molecule type selected B_5201 length selected tor subsequences to be scored ] echoing mode selected lor input sequence j Y i echoingformat j numbered lines j length of user's input peptide sequence { 115 j number of subsequence scores calculated j t&6 j number of top-scoring subsequences reported bade in scoring output table: j Scoring Results Rank.

Start Position Subsequence Residue Listing Score (Estimate of Half Time of Disassociation of a Molecule Containing This Subsequence) 1 18 EPGSgVRIW 100.000 2 • 17 VEPGSGVRIV 45.000 i 81 GGFPyEKDU 33.000 4 105 ITSSrPPCVI .000 37 ATYLeLASAV 12.000 6 . 66 EIEInGQLVF 9.000 7 33 CGFEaTYLEL 9.000 8 60 GGTGaFEIEI 7.500 1 9 2 SGEPgQTSVA 6.600 83 FPYEkDLIEA 3300 ii 1 ; > MSGEpGQTSV 2.700 12 97 SNGEtLEKIT 2.640 i 13 65 FEIEiNGQLV 2.640 14 50 YPGIelESRL 2.400 1 " | 48 EQYPglElES 2.400 :l }6 1 106 .. 1 | TNSRpPCVIIi 2.000" i 1 11 | 96 j ASNGeTLEKl [ 1.815 ; I « | 58 | _ RLGOteRFEI^ | 1.500 j t.'V 1 8 j TSV^pPPEEV | 1.320 | 20 1 59 j LGGTgAFEIE 1 1.238 j Echoed User Peptide Sequence (length = 115 residues) HLA peptide motif search results User Parameters and Scoring Information method selected to limit number of results explicit number number of results requested HLA molecule type selected B60 length selected for subsequences to be scored echoing mode selected for input sequence ] y echoing format numbered lines < length ot user's input peptide sequence j lis number of subsequence scores calculated j 107 • number of top-scoring subsequences reported back in scoring output table] Scoring Results Rank Start Position Subsequence Residue Listing Score (Estimate of Half Time of Disassociation of a Molecule Containing This Subsequence) 1 65 FEIEINGQL 387-200 2 17 VEPGSGVRI 17.600 3 EEVEPGSGV 16.000 4 47 KEQYPGIEI 16.000 ~ ; 83 YEKDLIEAI 8.800 6 ■ 107 NSRPPCVIL 8.000 7 FEATYLELA 8.000 8 70 NGQLVFSKL 4.840 9 3 GEPGQTSVA 4.000 81 GGFPYEKDL 4.000 11 CEPCGFEAT 4.000 12 67 IEINGQLVF 3.266 13 90 IEAIRRASN 2.400 14 99 | GETLEKITN 2.400 | 40 :| LEIASAVKE i.760 16 *j • 53 -j IEIESRLGG 1.600 17 j 51 I PGIEIESRL a%8 j 18 j 55 I lESRLGGTG 0.880 } 19 | 34 j GFEWYtEL 0.800 j 20 j 94 °| RRASNGETL 0.800 .

Echoed User Peptide Sequence (length = 115 residues) HLA peptide motif search results User Parameters and Scoring Information method selected to limit number of results [explicit number number of results requested j 10 HLA molecule type selected :| B60 length selected lor subsequences to be scored J 10 echoing mode selected for input sequence ...J ..y _ -i echoing format J numbered lines , length of user's input peptide sequence i number of subsequence scores calculated ...1 m.. : number of top-scoring subsequences reported bade in scoring output t able| 20 , Scoring Results Rank Start Position.

Subsequence Residue : Listing Score (Estimate of Half Time of Disassociation of a Molecule Containing This Subsequence) 1 65 FEIEiNGQiV 16.000 2 106 TNSRpPCVII. 16.000 3 s3 1EIESRLGGT 8.000 4 33 CGFEaTXLEL 8.oob 17 VEPGSGVRIV 8.000 6 55 iesriggtga 8.000 7 6$ ingqivfskl 4.840 8 • 50 TfPGIelESRL 4.840 9 80 NGGB^pYEKDL 4.000 31 .

EPCGfEATYI. iooo 11 FEATyLELAS 3.520 12 67 lEINgQLVFS 3.200 13 87 KDLIeAIRRA 1.100 1 «« 78 LENGgFPYEK Oioo 1 >5 EEVEpGSGVR 0.800 1 * 9<) GETLeKITHS 0.800 I.17 CEPCgFEATY 0.800 118 ; 90 lEMrRASNG 0.800 I» i 3 :■ GEPGqTSVAP 0.800 ^ | 20 40 | LELAsAVKEQ 0.800 Echoed User Peptide Sequence (length = 115 residues) HLA peptide motif search results | User Parameters and Scoring Information 1 method selected to limit number of results (explicit number number of results requested | 20 j HLA molecule type selected | B6l | length selected for subsequences to be scored L .._9 • j echoing mode selected for input sequence L _ JL .. _j :| echoing foimat | numbered lines | | length of user's input peptide sequence 1 115 ; | number of subsequence scores calculated | 107 » jnumber of top-scoring subsequences reported back in scoring output table j 20 " i Scoring Results ! Rank Start Position Subsequence Residue : Listing Score Estimate of Half Time of Disassociation of < a Molecule Containing This Subsequence) j EEVEPGSGV 8OVOOO ; S FEATYLELA 40.000 "" i 3 3 GEPGQTSVA 22.006 ■; 4 65 FEIEINGQL 16.000 85 YEKDLXEAI 16.000 . | 17 VEPGSGVRI ; 8.000 1 " 47 KEQYPGIEI 8.000 " '! 8 CEPCGFEAT 4.060 ! 9 99 GETLEKITN 2.640 j 90 IEAIRRASN 2.400 11 27 j VEYCEPCGF j 1.600 12 67 IEINGQLVP 1.600 : | 13 | 2 SGEPGQTSV 1.606 | 14 | 18 EPGSGVRIV 1.000 | 15 j 105 ITNSRPPCV ;| 1.000 j j 16 | 37 ATYLELASA :| 1.000 , 1 17 i 53 IEIESRLGG j 0.800 .

I 18 | 40 LELASAVRE | 0.800 1 1 19 1 81 GGFPYEKDL j . _ _ 0,660 -| 20 } 29 YCEPCGFEA ;| 0-500 J Echoed User Peptide Sequence (length = 115 residues) HLA peptide motif search results User Parameters and Scoring Information method selected to limit number of results explicit number number of results requested ; HLA molecule type selected i B61 length selected lor subsequences to be scored ] echoing niode s^ectedfor input sequence ] Y 1 echoing foimat j numbered lines | length of user's input peptide sequence j lis ■ ] number of subsequence scores calculated j 106 j number of top-scoring subsequences reported back in scoiing output table] _ . _i .. « — | Scoring Results j Rank Start Position' Subsequence Residue Listing Score (Estimate of Half Time of Disassociation of • a Molecule Containing This Subsequence) 1 65 FEIEiNGQLV 80.000 i 1 17 VEPGSGVRIV 40.606 j 3 55 IESR1GGTG& 20X00 j 4 87 KDLIeRIRRR io.tioo I 53 IEIEsRLGGT 8.000 . t 6 : 14 PEEVePGSGV 4.000 j 1 99 GETLeKITNS 3.520 ; 8 37 ATYkeLASAV lobo 9 8 TSVapPPEEV iooo • 67 XEINgQLVFS i.600 j 11 FERTyLEIAS 1.600 [ 12 1 MSGEpGQTSV 1.000 ! 1. 13 18 EPGSqVRIVV l.trao : 1 14 36 EATYIELMA 1.000 : 1 «. 83 PPYEJcDLIEfi :| J.OOO j j 16 .

EEVEpGSGVR :| _ _ 0.800 _ | 1 17 1 27 VEYCePCGFE i| O.iiQO 1 1 30 CEPCgFEATY • _ | __ 0-800 1 19 1 90 IEArrR&SNG '| 0.800 j | 20 :| 40 • ^ LELRsAVKEQ ;| _0.800 J Echoed User Peptide Sequence (length = 115 residues) HLA peptide motif search results | User Parameters and Scoring Information j method selected lo limit number of results explicit number j number of results requested j HLA molecule type selected • B62 j length selected tor subsequences to be scored i 9 j echoing mode selected for input sequence J Y ; j echoing format | numbered lines j j length of user's input peptide sequence | 115 j •j number of subsequence scores calculated ] 107 {number of top-scoring subsequences reported back in scoring output table] 1 | Scoring Results Rank Start Position Subsequence Residue Listing Score (Estimate of Hall Time of Disassociation of' a Molecule Containing This Subsequence) 1 77 fCLEHGGFFY 24.000 2 21 SGVRIWEY 4.800 3 75 FSKLENGGF 3.600 4 31 EPCGFEATY £640 *8 DLIEAIRRA 2.200 <! 42 LASAVKEQY 2.000 7 48 EQYPGIEIE 0.960 8 • 71 GQLVFSKLE 0.800 9 6 GQTSVAPPP 0.800 67 IEINGQLVF 0.686 11 22 GVRIVVEYC 0.660 12 58 RLGGTGAFE 0.480 1 13 57 SRLGGTGAF 0.480 1 14 18 EPGSGVRIV 0.400 i '5 59 LGGTGAFEI 0.400 | 16 56 ESRLGGTGA O.360 i 17 | 45 AVKEQYPGI | WJ30 | IS j 104 KITNSRPPC | 0.250 _ i j 19 j 72 QLVFSKLEN j 0.240 _ . _ • | 20 j 61 GTGAFEIEI | ■ ^ 0.240 j Echoed User Peptide Sequence {length -115 residues) HLA peptide motif search results ) User Parameters and Scoring Information j method selected to limit number oi results explicit number j number of results requested j HLA molecule type selected B62 j length selected lor subsequences to be scored i 0 L .... echoing mode selected for input sequence y i 1 echoing format numbered lines j | length oi user's input peptide sequence 115 i j number of subsequence scores calculated 106 j (number of top-scoring subsequences reported back in scoring output table Scoring Results Rank Start Position Subsequence Residue ! Listing Score (Estimate of Half Time of Disassociation of a Molecule Containing This Subsequence) 1 41 EIASaVKEQY 40.000 2 58 RLGGtGAFEI 9.600 3 66 EIEInGQLVF ! '7.920 4 - 56 - ESRLgGTGAF 6.000 GSGVrlWEY 4.fi66 6 92 AIRRaSNGET 1-500 7 48 EQYPglEIES 1.152 6 26 VVEYCEPCGF O.60O 9 24 RlWeYCEPC oioo 104 KITNSRPPCV 0.500 1 ll 71 GQLVfSKLEN 0.480 12 76 SKLEnGGFPY 0.440 13 $8 DLIEalRRAS 0.440 14 6 GQTSvAPPPE 0.400 1 MSGEpGQTSV 0.264 16 18 EPGSGVRIVV 0.264 ; | 17 J 69 INGQ1VFSKL 'J 0.260 { IS j 21 SGVRiWEYC ij 0.220 : | 19 | 30 CEPCgFEATY :| 0.220 j 20 | 74 VFEK1ENGGF :j 0.200 Echoed User Peptide Sequence (length = 115 residues) J~322- HLA peptide motif search results User Parameters and Scoring Information method selected to limit number of results explicit number number of results requested HLA molecule type selected B7 length selected for subsequences to be scored j 9 echoing mode selected for input sequence j y echoing format ] numbered lines | 1 1 1 P< I <0 1 i i i j US | number of subsequence scores calculated ] 107 | number of top-scoring subsequences reported back in scoring output tablej . „._.20 j Scoring Results Rank Start Position Subsequence Residue Listing Score (Estimate of Half Time of Disassociation of! a Molecule Containing This Subsequence) 1 . to? NSRPPCVIL 60.000 2 45 AVKEQYPGI 6.000 j 3 - 22 GVRIVVEYC .000 4 70 ,NGQLVFSKL 4.000 ; 81 GGFPYEKDL 4.00O 6 18 EPGSGVRIV 4.000 ! 7 9 SVAPPPEEV 1.500 : 8 56 ESRLGGTGA 1.000 , 9 106 TNSRPPCVI 0.600 lo , 11 APPPEEVEP 0.600 | 11 IVVEYCEPC 0.500 J 12 65 FEIEINGQL 0.400 13 61 GTGAFEIEI 0.400 14 31 EPCGFEATY 0.400 ; 94 RRASNGETL 0.400 , 16 59 LGGTGAFEI 0.400 17 51 PGIEIESRL 0.400 j ife 32 PCGFEATYL i i 1 t f | 19 97 SNGETLEK3 ! 0.400 i | 20 92 " AIRRASNGE 1 0300 ! Echoed User Peptide Sequence (length = 115 residues) HLA peptide motif search results User Parameters and Scoring Information j method selected to limit number of results explicit number | number of results requested " | HLA molecule type selected B7 | length selected tor subsequences to be scored io j echoing mode selected for input sequence V ] .j echoing format numbered linesi | length of user's input peptide sequence .. "5 1 | number of subsequence scores calculated 106 1 [number of top-scoring subsequences reported back in scoring output table . j | Scoiing Results Rank Start Position Subsequence Residue Listing Score (Estimate of Half Time of Disassociation of a Molecule Containing This Subsequence) 1 50 YPGIelESRL 8O.OO0 2 31 EPCGfEATYL 80.000 3 18 EPGSgVRIW 6.000 4 106 TOSRpPCVIL 6.000 80 NGGFpYEFCDL 4.000 6 69 INGQ1VFSKL 4.000 7 ' 93 IRRASNGETL "4.000 8 33 CGFEaTYLEL 4.000 0 92 AIRRaSNGET 3.000 83 FPYEkDLIEA 2.000 n 44 SAVKeQYPGX 1.200 . 12 % ASNGeTLEKX 1.200 13 11 APPPeEVEPG 0.600 14 16 EVEPgSGVRI d.«)6 'IS" 37 ATYLeLASAV 0.600 16 105 ITNSrPPCVI 0.600 1 I? 22 GVRIWEYCE 1 0.500 j 1 « 60 GGTGaFEIEI 0.400 , J 19 j 81 j_ GGFPyEKDLI 0.400 ; I 20 I 58 ,| RLGGtGAFEI | 0.400 _ Echoed User Peptide Sequence (length = 115 residues) HLA peptide motif search results J User Parameters and Scoring Information j method selected to limit number of results explicit number . j number of results requested ! j HLA molecule type selected > B8 :| length selected for subsequences to be scored : 8 ;j echoing mode selected tor input sequence J V i j echoing ibimat ] numbered lines j "j length of user's input peptide sequence j .. . 1" __i j number of subsequence scores calculated j 108 j jnumber of top-scoring subsequences reported back in scoring output tablej .2(L ...J Scoring Results • Rank Start Position Subsequence Residue Listing Score (Estimate of Half Time of Disassociation of' a Molecule Containing This Subsequence) 1 83 fpyekoli 6.000 j 2 107 nsrppcvi 1.000 , 3 91 embrasn 0.800 ! 4 . gsgvriw 0.600 i 18 epgsgvri 0.400 : 6 95 rasngetl 0.400 { 7 100 etlekitn 0300 ! 8 105 itnsrppc 0.200 j 9 vapppeev 0.120 j 73 lvfsklen 0.100 " i 11 . 43 asavkeqy o.ioo i 12 22 gvriwey o.ioo" •; 13 36 eatylela 0.080 14 31 epcgfeat 0.080 1 15 1 66 eieingql 0.080 . •| 16 j 4 EPGQTSTO j 0.080 j 3 17 | 33 J CGFEATO | 0.060 J j 18 j 71 ^ _ gqwfskl _ jj __ °:06?L i •j 19 | 56 :| esrlggtg j 0.040 [ .| 20 J 106 ;( TNSRPPCV .]. 0.030 _ _ _ j Echoed User Peptide Sequence (length = 115 residues) HLA peptide motif search results | User Parameters and Scoring Information j method selected to limit number of results (explicit number . | number of results requested { 20 ~ i j HLA molecule type selected •| BS ,-| length selected for subsequences to be scored .1 _ J ;| echoing mode selected ibr input sequence J Y -j echoing format •j numbered lines i j length ol user's input peptide sequence it I" j 1- I 1' W i II 1 0 1 || .108 J jnumber of top-scoring subsequences reported back in scoring output tablej] 20 j Scoring Results 1 Rank Start Position Subsequence Residue Listing Score (Estimate of Half Time of Disassociation of! a Molecule Containing This Subsequence) ' 1 83 FPYEKDLI 6.000 j 2 107 NSRPPCVI 1.000 ~ j 3 91 EAIRRflSN 0.800 i 4 .

GSGVRIW 0.600 ; 18 EPGSGVRI o.4oo ; 6 95 RASNGETL 0.400 ! 7 100 ETLEKITN 0300 i 8 105 ITNSRPPC 0.200 ; VAPPPEEV 0.120 ; 73 LVFSKLEN 0.100 [ 11 43 ASAVKEQY 0.100 i 1 12 22 GVRIWEY o.ioo i 13 36 EATYLELA 0.080 I U i 31 EPCGFEAT 0.080 | 15 \ <66 1 EIEIKGQL 0.080 , 116 1 4 [ EPGQTSVA 1 . ... 0.080 j 117 1 33 | _ CQFEAro 1 0.060 J 1 * I 71 | GQWFSKL _ 0.060 -I19 1 56 j ESBLGGTG 1 . - 0.040 ! .( 20 1 106 j THSRPPCV i- . 0.630 j Echoed UserJPeptide Sequence (length = 115 residues) HLA peptide motif search results j User Parameters and Scoring Information J method selected to limit number of results explicit number j number of results requested j HLA molccule type selected ! Cw_0702 j length selected for subsequences to be scored , ; j echoing mode selected for input sequence j !| echoing format | numbered lines j j length of usei's input peptide sequence j 115 j j number ofsubsequence scores calculated j 106 | jnumber of top-scoring subsequences reported back in scoring output table! i Scoring Kesutts Rank Start Position Subsequence Residue Listing Score Estimate of Half Time or Disassociation of j a Molecule Containing This Subsequence) j 1 GSGVrlWEY- 38.400 2 CEPCgFEATY. _ 16.000 . i 3 41 ELASaVKEQS f6.000 j 4 50 YPGIelESRL W20 ' ; 76 SKLEnGGFPY 4.000 „ : 6 69 INGQ1VFSKL : 2.880 | 7 • 18 EPGSgVRIW 2.400 8 • 33 CGFEaTYLEL 1.440 'i 0 1 SO NGGFpYEKDIi 1.440 56 ESRLgGTGAF lioo i 11 ' 93 IRRASNGETL 000 ; 12 : (A AFEIelNGQL 1.200 13 66 EIEInGQLVF 1.000 | 1 FEATyLELAS 0.960 1 V 87 KDLIeAIRBA | ' 0.800 1 16 97 | SNGEtLEKIT 1 • ..?■«*! J 1 * 17 | VEPGSGVRIV | 0.&tio 1 " 21 j_ SGVRi VVEYC | O.800 I i«r 28 | EYCEpCGFEA i 1 f i 1 p 1 20 48 | EQYPglEIES | _ 0.672 _/ __ Echoed User Peptide Sequence (length «= 115 residues) HLA peptide motif search results j User Parameters and Scoring Information | metliod selected to limit number of results [explicit number - j number of results requested :| 20 j HLA molecule type selected J B8 j length selected for subsequences to be scored | 10 j echoing mode selected for input sequence ii * i j echoing format [[numbered lines j j length of user's input peptide sequence i lis i j number of subsequence scores calculated . 1 1 jnumber of top-sconng subsequences reported back: in scoring output ta .blejj 20 s | Scorii ng Results ' Rank' Start Position Subsequence Residue Listing Score (Estimate of Half Time of Disassociation of) a Molecule Containing This Subsequence) 1 50 YPGIelESRL 0.800 i 2 P IRRASNGETL 0.400" j 3 31 EPCGfEATYL 0320 4 ' 104 KITNSRPPCV 0300 i ifc EPGSgVRIW 0.240 , ; 6 56 ESRLgGTGAF j 0.200 | 7 44 SAVKeQYPGI 0.200 ! 8 92 AIRRaSNGET 0.200 ( 9 69 INGQ1VFSKL 0.200 j 106 TNSRpPCVIL j 0.200 11 42 LASAvKEQYP 0.160 i 12 33 CGFEaTYLEL 0.060 | 13 105 ITNSrPPCVl 0.050 14 I 58 RLGGtGAFEI 0.050 : j 96 ASHGeTLEKI 0.050 i i6 | 1 MSGEpGQTSV ' 0.045 { 17 J 16 FSKLeNGGFP 0.046 J | 18 | 80 .j NGGFpVEKDL 0.040 ; J 19 | 72 | GLVFsKLENG ') 0.040 , j 20 | 53 J IEIEsRLGGT ij 0.030 j Echoed User Peptide Sequence (length = 115 residues) HLA peptide motif search results j User Parameters and Scoring Information ! melhod selected to limit number of results (explicit number j number of results requested *| io j HLA molecule type selected i| B 2702 i length selected for subsequences to be scored - L »_ " | echoing mode selected for input sequence -J! * i •j echoing format || numbered lines! | length of user's input peptide sequence !i 115 1 t number of subsequence scores calculated i| W7 Jnumber of top-scoring subsequences reported back in scoring output ta BTe| a Scoring Results Rank Start Position Subsequence Residue Listing Score (Estimate of Half Time of Disassociation of; a Molecule Containing This Subsequence) , 1 57 SRLGGTGAF 200.000 2 94 RRASNGETL 1 SO.OOO ! 3 93 IERASNG£T_ .000 ' j 4 : 27 VEYCEPCGF : .000 77 KLENGGFPY . 9.000 . ' 6 67 IEIHGQLVF 3.006 ! 1 47 KEQYPGIEI 2.700 j S 23 VRIVVEYCE 2.000 9 42 LASAVKEQY 1.000 75 FSKLENGGF l.OOO i I 11 : 85 YEKDLIEAI 0.900 ! 12 17 VEPGSGVRI 0.900 i 13. 65 FEIEINGQL 0.900 | 14 | 97 SNGETLEKI 0.600 J 15 | 106 TNSRPPCVI 0.600 ; j 16 | 37 ATYLELASA 0.500 1 | 17 | 2l SGVRIWEY 0.506 ; | 18 .j 107 NSRPPCVIL 0.300 ! j 19 | 30 CEPCGFEAT 0.300 j j 20 1 48 EQYPGIEIE 0.300 j Echoed User Peptide Sequence (length = 115 residues) HLA peptide motif search results User Parameters and Scoring Information method selected to limit number of results explicit number number of results requested HLA molecule type selected B_2702 length selected for subsequences to be scored ■ ! echoing mode selected for input sequence | Y : echoing format j numbered lines j length of user's input peptide sequence { 115 j number of subsequence scores calculated j 106 ( number of top-scoring subsequences reported back in scoring output tablej > Scoring Results Rank Start Position' Subsequence Residue Listing Score (Estiniate of Half Time of JDisassociation of: a Molecule Containing This Subsequence) 1 93 IRRASNGETL 6t>.000 i 2 94 RRASnGETLE 6.000 ' ' " i 3 CEPCg PEATY 3.000 ! 4 " . 58 RLGGtGAFEI 2.700 i 23 VRIVvEYCEP 2.000 . : 6 57 i SRLGgTGAFE 2.000" i 7 : 48 EQYPglEIES 1.500 8 26 WEYcEPCGF l.OOO ' 6 GSGVrlVVEY i.000 , 71 GQLVfSKLEN 1.000 1 11 41 ELASaVKEQY 0.900 j 12 33 GGFEaTYLEL 0.750 13 81 GGFPyEKDLI 0.750 14 106 TNSRpPCVIL 0.600 1 y 69 INGQ1VFSKL 0.600 _j 11* 83 J FPYEkDLIEA 0.500 •j 17 37 ;| ATXLeliASAV 0.500 1 18 55 :| IESR1GGTGA 0.300 tJ9 96 | ASNGeTLEKI | 0.300 | 20 56 | ESRLgGTGAF j 0.300 Echoed User Peptide Sequence (length = 115 residues) HLA peptide motif search results 1 User Parameters and Scoring Information 1 method selected to limit number of results (explicit number i number of results requested | 26 i HLA molecule type selected lj B 3701 """ J... length selected for subsequences to be scored -4 -. t. echoing mode selected tor input sequence i v I..... . echoing tbimat ^numbered lines j J—.. . length of user's input peptide sequence H its 1 number of subsequence scores calculated I 106 ! Jnumber of top-scoring subsequences reported back in scoring output ta&ielj "iO "j Scoring Results Rank Start Position.

Subsequence Residue Listing Score (Estiniate of Half Time of Disassociation of a Molecule Containing This Subsequence) 1 65 FEIBiNGQLV .000 2 67 IEINgQLVFS .000 3 81 GGFPyEKDLI .000 4 87 KDLIeAIKRA 4.000 "" i CEPCgFEATY 2.OO0 6 17 VEPGSGVRIV i ZOOO 7 50 YPGIelESRL L500 ' " ' 3 64 AFEIelNGQL L500 9 69 INGQ1VFSKL 1300 99 GETLeKITNS 1.000 11 60 GGTGaFEIEI 1.000 12 46 VKEQyPGIEI 1.000 13 53 IElEsRLGGT 1.000 14 16 EVEPgSGVHI i.O'oo | 44 SRVKeQYPGI 1.000 16 | 105 ITSSrPPCVI 1.660 J 17 | 96 -j ASNGeTLEKI i.iiw j 18 j 80 | NGGFpYEKDL 1.000 " , 1 19 I 55 | IESR1GGTGA ii 1.000 ; 1 20 ] 31 \ EPCGfEATYL ,| 1.000 i Echoed User Peptide Sequence (length = 115 residues) HLA peptide motif search results | User Parameters and Scoring Information | method selected to limit number of results explicit number | number of results requested | HLA molecule type selected [" B_3801 J length selected lor subsequences to be scored j 9 || echoing mode selected for input sequence Y | ( echoing format j numbered lines j .| length of user's input peptide sequence ) ™. lis :j number of subsequence scores calculated ; 107 i Jnumber of top-scoring subsequences reported back in scoring output tablej ! | Scoring Results Rank Start Position Subsequence Residue Listing Score (Estimate of Half Time of Disassociation of i a Molecule Containing This Subsequence) ! I 34 : GFEATYLEL 6.OO0 1 70 HGQLVFSKL 1.560 : 3 38 TYLELASAV 1.040 4 81 GGFPYEKDL j 1.000 { $7 SNGETLEKI 0.720 " . 6 66 EIEINGQLV j 0.600 ! 7 2 SGEPGQTSV 0.600 i 8 82 GFPYEKDLI 0.600 £ 49 QYPGIEIES 0.520 io 18 EPGSGVRIV 0.400 ; ll 31 EPCGFEATY 0.406 "" j 12 89 LtEAIRRAS 0.390 13 98 NGETLEKIT 0.390 14 77 KLENGGFPY 0.300 . 6l GTGAFEIEI .0300 16 107 NSRPPCVIL , OJUO j 17 1 75 FSKLENGGF 1 (jjoo ; IS 106 TNSRPPCVI 0.301} i 1 l9.. 29 YCEPCGFEA 0.300 ' ! 1 20 54 EIESRLGGT OJOO 1 Echoed User Peptide Sequence (length = 115 residues) HLA peptide motif search results ] User Parameters and Scoring Information j method selected to limit oumbcrofresults explicit number | number of results requested j HLA molecule type selected BJ3801 j length selected for subsequences to be scored 1 | echoing mode selected tor input sequence Y ' .j echoing foanat numbered lines j length of user's input peptide sequence 115 j number of subsequence scores calculated 166 > jnumber of top-sconng subsequences reported back in scoring output table £5' "] Scoring Results Rank Start Position' Subsequence Residue Listing Score (Estimate of Half Time of Disassociation of: a Molecule Containing This Subsequence) 1 64 AFEIelNGQL 7.800 2 31 EPCGfEftTYL 4.800 3 66 EIEInGQLVP 3.000 4 26 VVEYCEPCGF 3.066 S 50 YPGIelESRL 2,601} 6 74 VFSK1ENGGF 2.00Q 7 33 CGFEaTYLEL 2.000 g 69 INGQlVFSfO, L560 9 106 TNSRpPCVIL 1.000 80 NGGFpYEKDL 1.000 ll 16 EVEPgSGVRI 0.900 12 96 ASNGeTLEKI 0.720 13 34 GFE!\£YLEL& 0.600 14 60 GGTGaFEIEI 0.600 | 15 j 58 RLGGtGAFEI 0.600 j 16 | 18 EPGSgVRIW 0.520 J 17 | 83 FPYEkDLIEA 0.400 ; j 18 j 28 EYCEpCGFER !| 0.400 1 19 I 1 MSGEpGQTSV :| 0.400 | 20 | 2 SGEPgQTSVA ;| 0.300 Echoed User Peptide Sequence (length = 115 residues) HLA peptide motif search results User Parameters and Scoring Information . method selected to limit number of results explicit number number of results requested HLA molecule type selected BJ3902 length selected for subsequences to be scored i 9 ) echoing mode selected for input sequence 1 ' Y 't echoing format | numbered lines j length of user's input peptide sequence j 115 j number of subsequence scores calculated j 107 J number of top-scoring subsequences repotted back in scoring output table] | Scoring Results Rank Start Position Subsequence Residue Listing Score (Estimate of Hall rime of Disassociation of' a Molecule Containing This Subsequence) ! 70 ngqlvfskl 2.400 2 81 ggfpyekdl 2.400 i 94 rrasngetl 2.000 4 34 gfeatylel 2.000 ' ' 107 nsrppcvil 0.600 6 57 srlggtgaf 0.5O0 7 65 feieingql O.480 ' : 8 51 pgieiesrl 0.240 9 32 pcgfeatyl 0.200 75 fsklenggf 0.150 11 • 86 ekdlieair 0.120 12 6 gqtsvappp 6.120 13 71 gqlvfskle 0.120 J4 46 vkeqypgie 0.120 | 89 lieairras o.iSo •1 16 !i 21 | sgvriwey :j 0.120 j L" I 98 [ ngetlekit | O.120 | 1 18 | 36 [ eatylelas -J 0.120 i I w i 38 | tylelasav | 0.120 | 20 1 3J | epcgfeaty | 0.120 i Echoed User Peptide Sequence (length = 115 residues) HLA peptide motif search results User Parameters and Scoring information method selected to limit number of results (explicit number number of results requested ( 20 HLA mo lecule type selected [ BJ5902 length selected for subsequences to be scored «| 9 echoing mode selected tor input sequence ij Y echoing format |j numbered lines length of user's input peptide sequence it U5 j number ot subsequence Scores calculated i 107 number ot top-scoring subsequences reported back in scaring output ts £>tej 20 Scoring Results Rank Start Position Subsequence Residue Listing Score (Estimate of Half lime of Disassociation of' a Molecule Containing This Subsequence) I 70 NGQLVFSKL 2.400 " ' 2 81 GGFPYEKDL 2.400 3 94 RRASNGETL 2.000 4 34 GFEATYLEL 2.000 ~ 107 NSRPPCVIL 0.6OO 6 57 SRLGGTGAF 0.500 7 65 FEIEINGQL 0.480 } 8 ' 51 PGIEIESRL 0.240 9 32 PCGFEATYL 0.200 75 FSKLENGGF 0.150 11 • 86 EKDLIEAIR 0.120 12 6 GQTSVAPPP 0.i20 13 71 GQLVFSKLE 0.120 14 46 VKEQYPGIE 0.120 89 LIEAIRRAS 0.120 16 21 ij _ SGVRIWEY : 0.120 ; 17 98 ;[ NGETLEKIT _ 0.120 j 18 :| 36 | EATYLEIAS 0.120 ; 19 :| 38 | TYLELASAV 0.120 "j 31 I EPCGFEAtr -j 0.120 j Echoed User Peptide Sequence (length = 115 residues) HLA peptide motif search results | User Parameters and Scoring Information | method selected to limit number of results explicit number | number of results requested | HLA molecule type selected j 6_3£02 ,| length selected for subsequences to be scored : 16 .j echoing mode selected for input sequence | Sf i | echoing format j numbered lines | || length of user's input peptide sequence j 115 | j number of subsequence scores calculated J lod ; ■Jnumber of top-scoring subsequences reported bade in scoring output tablej I Scoring Results Rank Start Position- Subsequence Residue . Listing Score (Estimate of Half Time of Disassociation of a Molecule Containing This Subsequence) 1 69 TOGQ1VFSKL 2.4Q0 "" 2 64 AFEIelNGQL 2.400 3 50 YPGIelESRL Z400 ; 4 80 j NGGFpYEKDL . 2.400 106 TNSRpPCVIL 2.000 1 6 31 EPCGfEATYL 2.000 i 7 33 CGFEaTYLEL 2.000 8 48 EQYPglEIES i.200 9 76 SKLEnGGFPY i.ooo 71 GQLVfSKLEN 1.000 ll ■ 46 VKEQyPGIEX 1.000 12 103 EKITnSRPPC l.OOO 13 93 IRRAsNGETL 6.600 14 66 EIEInGQLVF 0.500 . 26 WEYcEPCGF 0.500 16 74 >| VFSK1ENGGF 0.500 | 17 56 ;|2 ESRLgGTGAF 0.150 ! 18 | 24 RivveTfCEPC 6.120 1 19 j 34 6FEA«uaA | 0.120 j j 60 .| CGTGaFEIEI | 0.120 i Echoed User Peptide Sequence (length = 115 residues) FfT/A peptide motif search results | User Parameters and Scoring Information r method selected to limit number of results (explicit number i number of results requested j 20 i HLA molecule type selected !| B 4403 i...... length selected for subsequences to be scored -J ... i echoing mode selected for input sequence J echoing format g numbered lines• ii... .... length of user's input peptide sequence L ..lli i number of subsequence scores calculated »_ 107 jnumber of top-scoring subsequences reported back in scoring output ta] blejj 20 ; Scoring Results Rank1 Start Position.

Subsequence Residue Listing Score (.Estimate ol Hall Time of disassociation of a Molecule Containing This Subsequence) 1 67 rEIMGQtiVF 200.v00 2 27 veycepcgf 40.0(H) 3 21 sgvriwey 36.000 4 65 FEIEINGQlr .00li featylela 12.000 6 3 gepgqtsva ; 9.000 7 eevepgsgv 8.000 8 17 vepgsgvri 6.000 S i 42 lasavkeqy 4.500 . 31 epcgfeaty 4.500 11 85 yekdlieai 4.000 12 3d cepcgfeat 4.000 13 47 keqypgiei 4.000 14 90 ieairrasn 3.600 53 ieiesrlgg ioOo 16 40 leiasavke < 1.800 •1 J7..S §9 getlekitk 1-200 I 1S 75 - j fsklenggf 1.000 1 19 57 SRLGGTGAF oioo j 20 78 J lenggfpye | 0.600 Echoed User Peptide Sequence (length —115 residues) HLA peptide motif search results User Parameters and Scoring Information method selected to limit number of results explicit number number of results requested HLA molecule type selected B_4403 length selected ibr subsequences to be scored echoing mode selected for input sequence 1 Y « echoing format j numbered lines j length of user's input peptide sequence j lis i number of subsequence scores calculated j 106 ! number of top-scoring subsequences reported back in scoring output tablej Scoring Results Rank Start Position Subsequence Residue Listing Score (Estimate of Half Time of Disassociatian of a Molecule Containing This Subsequence) 1 CEPCgFEATY 120.000 | 2 53 IEIEsRLGGT .60() 3 67 IEINgQLVFS .0M) 4 65 FEIEiNGQLV .b<j(j ' " : VEPGSGVRIV 18.00(5 6 GSGVrlWEY 9.00i) 7 99 GETLeKITNS 9.000 8 FEKTyLELAS 8.006 9 55 IESR1GGTGA 6.OO0 40 LELAsAVKEQ .4O0 11 87 KDLIeAIRRA 2.250 \2 76 SKLEnGGFPY 1.800 13 90 lEAIrRASNG i.sOo 14 21 SGVRi VVEYC 1.800 1 * 56 ESRLgGTGAF . 1.500 1 16 41 EIASaVKEQY 6.900 1 17 EEVEpGSGVR 0.800 | 18 | 96 ASNGeTLEKI 0.675 1 19 1 3 GEPGqTSVAP 0.600 I 20 ] 78 IiENGgFPYEK |j 0.600 Echoed User Peptide Sequence (length = 115 residues) HLA peptide motif search results { User Parameters and Scoring Information | method selected to limit mimber of results [explicit number j number ot results requested ] 20 | HLA molecule type selected ■j B_5101 ,| length selected for subsequences to be scored il $ | echoing mode selected tor input sequence j| y j ;| echoing format | numbered lines j | length of user's input peptide sequence II lis 1 | number of subsequence scores calculated | 107 j (number of top-sconng subsequences reported back: in scoring output ta slg| 20 j Scoring Results Rank Start Position Subsequence Residue Listing Score (Estimate of Half lime oC Disassociation of a Molecule Containing This Subsequence) 1 18 EPGSGVRIV 484.000 2 59 LGCTGAFEI 114.400 3 2 SGEPGQTSV 48.400 i 4 81 GGFPYEKDL 44.000 70 NGQLVFSKL 22.000 . j 6 31 EPCGFEATY 7.260 7 " 97 SNGETLEKI .856 > 8 36 EATYLELAS .000 9 19 PGSGVRIVV 4.840 ' 66 EIEINGQLV 4.840 " : ll 45 AVKEQYPGI 4.400 12 82 GFPYEKDIiI 4.400 1 13 61 GTGAFEIEI ; 4.000 14 106 TOSRPPCVI 4.000 is 83 FPYEKOLIE 2.860 16 . lbs ITNSRPPCV ; 2.600 i 11 42 LASAVKEQY j 2.595 j lis 51 PGIEIESRL 2.420 i 19 j 4 EPGQTSVAP zioo j :|. 9 SVAPPPEEV 2.200 r ; Echoed User Peptide Sequence (length «= 115 residues) HLA peptide motif search results | User Parameters and Scoring Information i i method selected to limit number,of results '[explicit number i number of results requested | 20 i HLA molecule type selected h b sioi . .

I length selected for subsequences to be scored _JL _!?_ I .... echoing mode selected for input sequence 11 v —1 1.... echoing format jf numbered lines 1 1 l 0 1 u Cu ij s! Ii 1 "5 1 number of subsequence scores calculated J. ...

Jnumber of top-scoring subsequences reported back: in scoring output tal >le| 20 Scoring Results ; Rank Start Position, Subsequence Residue Listing Score (Estimate of Half Time of Disassociation of a Molecule Containing This Subsequence) i 1 18 EPGSgVRIW 440.000 2 44 SAVKeQYPGI 220.000 1 3 31 EPCGfEATYL 220,000 " ; 4 $1 GGFPyEKOLI 176.000 " ; S 50 YPGIelESRL 1573W 6 60 GGTGaFEIEI 88.006" i 7 33 CGFEaTYLEL 48.400 " ! S 83 FPYEkDLIEA 31.460 y 80 NGGFpYEKDL 22.000 { 36 EATY1ELASA 11.000 : ii 16 EVEPgSGVRI 8.800 " • 12 96 ASNGeTLEKI .856 13 105 ITNSrPPCVI .200 ; 14 37 ATYLeLASAV 4.OO0 i MSGEpGQTSV 3.461 i 16 21 SGVRi VVEYC 2.420 " ; | 17 | 58 j RLGGtGAFEI 2.420 " | j 18 | 4 <| EFGQtSVfipp j 2J2UQ J 1 19 j 8 [ TSVApPPEEV j 2.200 : j 20 I 2 •( SGEPgQTSVa =1 2-000 1 Echoed User Peptide Sequence {length = 115 residues) HLA peptide motif search results User Parameters and Scoring Information method selected to limit number of results .'(explicit number number of results requested j 20 HLA molecule type selected ij B_5102 ! length selected for subsequences to be scored • JL 9 '■ echoing mode selected for input sequence 9 v ! echoing format || numbered lines j length oE user's input peptide sequence 8- »5 I number of subsequence scores calculated . 11 ... 107 . 1 number of top-scoring subsequences reported back in scoring output t *Wej| 20 j Scoring Results Rank Start Position Subsequence Residue Listing Score (Estiniate ot UaltTime of Disassociatton of ] a Molecule Containing This Subsequence) I 18 EPGSGVRIV 242.000 2 81 GGFPYEKDL no.oob 3 59 LGGTGAFEI 96.800 4 70 HGQLVFSKL 48.400 2 SGEPGQTSV 24.200 6 51 PGIEIESKL 13.200 j 7 83 FPYEKDLIE 11.000 8 97 SNGETLEKI .648 ! 38 TYLELASAV 6.600 PGSGVRIVV 4.840 11 106 TNSRPPCVI 4.400 12 61 GTGAFEIEI 4.000 13 82 GFPYEKDLI 4.000 14 31 EPCGFEATY 3.630 63 t GAFEIEING 2.750 ] 36 EATYLELAS 2.500 17 50 YPGIEIESR 2.420 j j 18 1 45 j AVKEQYPGI 2.420 j j 19 j 9 ,| SVAPPPEEV 2.200 ; 1 20 .j 105 J ITNSRPPCV 2.000 | Echoed User Peptide Sequence (length = 115 residues) *341- HLA peptide motif search results User Parameters and Scoring Information method selected to limit number of results .(explicit number number of results requested 20 HLA molecule type selected J B 5102 length selected tor subsequences to be scored #. 10 echoing mode selected for input sequence _ 8 * i echoing format J numbered lines j length of user's input peptide sequence . !l j number of subsequence scores calculated | . 166' 1 number of top-scoring subsequences reported back in scoring output taf>Ie[ 20 ""~j Scoring~Results Rank Start Position Subsequence Residue ' Listing Score (Estimate of HaifTiiniie of Disassociation of < a Molecule Containing This Subsequence) 1 44 SAVKeQYEGI 726.000 2 50 YPGIelESRL 4OO.OO0 3 81 GGFPyEKDLI 4o6rdoo 4 18 EPGSgVRIW 220.000 . 31 EPCGfEflTYL 12X000 6 33 CGFEaTYLEL 121.000 7 &3 FPYEkDLIEA fio.boO 8 60 GGTGaFEIEI 88.000 ' i> . 80 HGGFpYEKDL 22.000 37 ATYLeLASAV 11.000 ll $6 ASNGeTLEKI .64& : 12 21 SGVRiVVEYC 8.785 13 8 TSVApPPEEV 6.600 14 S6 EMY1ELASA . _5.000 58 . RLGGtGAFEI 4.840 16 16 | EVEPgSGVRI 4.000 17 105 j ITNSrPPCVT 4.000 18 ,'| 65 | FEIEiNGQt>V 3.1$4 19 | 63 | GAFEiEINGQ '| __ ___ _3.025 | 1 j HSGEpGQTSV ij 2.662 Echoed User Peptide Sequence (length = tlS residues) HLA peptide motif search results User Parameters and Scoring Information melhod selected to limit number ot results explicit number number of results requested HLA molecule type selected ' B_5103 length selected for subsequences to be scored : echoing mode selected tor input sequence j V echoing format j numbered lines• length of user's input peptide sequence j • 115 . number of subsequence scores calculated j 106 number oi top-scoring subsequences reported bade in scoring output table] [_" 20 Scorl ng Results Rank Start Position Subsequence Residue : Listing Score (Estimate of Half Xime of bisassociation of a Molecule Containing This Subsequence) 1 44 SAVfCeQYPGI 110.000 2 SI GGFPyEKDLI 52800 3 18 EPGSgVRIW 44.00(3 " "" 4 60 GGTGaFEIEI 44.000 33 CGFEaTYLEL 7.920 6 37 ATYLeL&SAV 6.600 7 31 EPCGfEATYL 6.600 IS 83 FPYEkDLIEA . 6.600 9 80 NGGFpYEKDL ; 6.000 to 50 YPGIelESRL 6.000 11 36 EATY1ELASA .000 12 21 SGVRi.WEYC 2.420 13 2 SGEPgQTSVA 2.420 14 1 MSGEpGQTSV 2.420 104 KITNSRPPCV £'420 16 58 RLGGtGAFEI 2.420 17 96 ASKGeTLEKI 2200 18 8 J TSVApPPEEV ! 2JZOO 19 16 EVEPgSGVRI = 2.200 | 2(> 105 ITNSrPPCVI 2.OO0 ' Echoed User Peptide Sequence (length = 115 residues) HLA peptide motif search results User Parameters and Scoring Information method selected to limit number of results explicit number number ot results requested HLA molecule type selected ' BJ103 length selected tor subsequences to be scored : lO echoing mode selected for input sequeace j V echoing format j numbered lines i length of user's input peptide sequence j • 115 = number ot subsequence scores calculated J 106 number of top-scoring subsequences reported back in scoring output tablej L ® Scoring Results Rank Start Position Subsequence Residue ; Listing Score (Estimate of Half Time of Disassociation of a Molecule Containing This Subsequence) 1 44 SAVKeQYPGI 110.000 ' 2 81 GGFPyEKDLI ' 52.800 a 18 EPGSgVRIW 44.000 * 4 60 GGTGaFEIEI 44.000 33 CGFEaTYLEL 7.920 6 37 ATYLeLASAV 6.600 7 31 EPCGfEATYL : 6.600 ii 83 FPYEkDLIEA . 6.600 y 80 NGGFpYEKDL • 6.000 id 50 YPGIelESRL ; 6.000 u 36 EATY1ELASA .000 12 21 SGVRi.WEYC 2.420 13 2 SGEPgQTSVA 2.420 14 I MSGEpGQTSV 2.420 104 KITNSRPPCV 2.420 16 58 RLGGtGAFEI 2.420 17 96 ASNGeTLEKI ^ 2200 It 8 TSVApPPEEV ! 2200 ' 1$ 16 .

EVEPgSGVRI 2.200 ; 105 ITNSrPPCVI 2.000 Echoed User Peptide Sequence (length = 115 residues) - *344- HLA peptide motif search results | User Parameters and Scoring Information 1 method selected to limit numbec ot results .(explicit number 1 number ot results requested j 20 1 HLA molecule type selected j B 5801 L_. length selected for subsequences to be scored .1 * L. .. echoing mode selected for input sequeace .J X ! ii echoing format j| numbered lines ] L... .. length of user's input pqjtide sequence 1. 115 _J I number of subsequence scores calculated 1 107 ; (nninber of top-scoring subsequences reported back in scoring output U ibleij 20 i | ~ ' Scoring Results Rank Start Position: Subsequence Residue Listing Score (Estimate of Half Time of Disassociation of! a Molecule Containing This Subsequence) 1 75 FSKLENGGF 40.000 " ] 2 42 LASAVKEQY 4.500 3 107 NSRPPCVIL 4.000 ' ; 4 61 GTGAFEIEI 3.000 " ; 105 ITNSRPPCV 3.000 . : 6 37 : ATYLELASA 2.400 7 1 MSGEPGQTS 0.880 ! 8 67 IEINGQLVF 0.660 9 56 ESRLGGTGA 0.600 21 SGVRIWEY 0.540 . '" j 11 . 27 VEYCEPCGF 0.400 " • 12 63 GAFEIEING 0.330 "" ! 13 100 ETLEKITNS 0.317 14 $5 RASNGETLE 0.300 '15'.

GSGVRIVVE 6.240 16 ' 96 ASNGETLEK '6^20 17 44 SAVKEQYPG 0220 18 2 SGEPGQTSV 0200 » 1 '« VAPPPEEVE oioo ( 57 !j SRLGGTGAF oioo Echoed User Peptide Sequence (length = 115 residues) HLA peptide motif search results 1 User Parameters and Scoring Information 1 method selected to limit number of results (explicit number 1 number of results requested | 20 1 1 HLA molecule type selected j & 5801 j length selected for subsequences to be scored 1 w : ;j echoing mode selected for inpk sequence 1 * 1 :| echoing format | numbered lines i ■j length of user's input pqptide sequence 1 115 ! j number of subsequence scores calculated L j jnumber of top-scoring subsequences reported bade in scoring output table |_ ?J> ! Scoring Results j Rank.

Start Position.

Subsequence Residue Listing Score (Estimate or Half Time of Disassociation of a Molecule Containing This Subsequence) j 1 56 ESRLgGTGAF 12.000 " " i 2 GSGVrlWEY IO^OO " i 3 1 MSGEpGQTSV 4X)O0 • 4 105 ITNSrPPCVI 3.000 " = 37 ATYfceLASAV 3.000 . ' j 6 96 ASNGeTLEKI • 2.640 " j 7 44 SAVKeQYPGI 2.000 8 8 TSVA0PPEEV 2.000 ! 74 VFSK1ENGGF 0.800 " { to 61 GTGAfEIEIN 0.480 ll 26 WEVcEPCGF 6400 1 h 36 EATV1EIASA 0.360 13 95 RASNgETLEK 0.330 14 63 GAFEiEINGQ 0.264 8"3 FPYEkDLIBA 0.240 16 ■ 29 YCEPCGFEAT 0.240 j 17 • 33 CGFEaTYLEL 0.220 • 43 ASAVkEQYPG |_ 0.220 ~ ~ ; J 19 | 75 :| FSKLeNGGFP 0.200 1 20 -j 7 ij QTSVaPPPEE oaoif : Echoed User Peptide Sequeace (length = 115 residues) HLA peptide motif search results User Parameters and Scoring Information method selected to limit number of results ^explicit number number of results requested i 20 HLA molecule type selected ij Cw 0301 length selected foe subsequences to be scored II 9 echoing mode selected for input sequence echoing format |j numbered lines length ot user's input peptide sequence || US number of subsequence scores calculated || 107 number of top-scoring subsequences reported bade in scoiing output tt i&Ie§ " 20" ! Scoring Results Rank Start Position: Subsequence Residue Listing Score (Estimate of Half Time of Disassociation of a Molecule Containing This Subsequence) i 65 FEIEINGQL .006 2 81 GGFPYEKDL 18.000 3 70 NGQLVFSKL s iz.ooo 4 57 SRLGGTGAF .00O 34 GFEATYLEL .000 6 94 : RRASNGETL ; .760 7 27 VEYCEPCGF .000 8 67 IEINGQLVF .000 $ 107 NSRPPCVIL 2.000 = 51 SGIEIESRL 1.800 11 , EEVEPGSGV 1.800 12 38 TYLELASAV 1.800 13 21 SGVRIWEY 1.500 14 IVVEYCEPC 1.500 J 88 DLIEAIRRA i i.500 | 16 37 ATYLELASA ; 1.000 1 17 45 AVKEQYPGI J 0.750 J.18 J 97 SHGETLEKI 0.750 j 19 \ 106 THSRPPCVI 0.750 ,| 29 YCEPCGFER. 0.500 Echoed User Peptide Sequence (length = 115 residues) HLA peptide motif search results } . User Parameters and Scoring Information ] method selected to limit number of results explicit number j number of results requested | HLA molecule type selected Cwj)301 " | length selected for subsequences to be scored j | echoing mode selected for input sequence Y [ echoing format numbered lines | | length of user's input peptide sequence 115 j | number of subsequence scores calculated 106 i ■jnumber of top-scoring subsequences reported back in scoring output tabtejj 20 j Scoring Results Rank Start Position Subsequence Residue ! Listing Score (Estimate of Half Time of Disassociation of1 a Molecule Containing This Subsequence) J 44 SAVKeQYPSI 50.000 " " 2 33 CGFEaTYLEL 45.000 3 6S INGQlVFSKlt 12.000 4 81 GGFPyEKDLI • 3.750 106 TOSRpPCVIL , i.ooO 6 29 YCEPCGFEAT : isoo 7 • 16 EVEPgSGVRI 2.500" : 8 65 FEIEiHGQLV Z160 9 - 31 .

EPCGfEATYL looo 64 RFEXelNGQL 2.000 11 53 IEIEsRLGGT 1.500 12 83 FPYEkDLIEA 1.500 13 . 76 SKLEnGGFPY 1.500 14 21 SGVRi VVEYC 1.500 37 J ATYLeLftSAV 1-200 16 80 NGGFpYEKDL i ioo . 17 50 YPGIelESRL j llzOO j 18 $3 IRRAsHGETL 1.152 • t9 23 VRIVvEYCEP "l.OOO " ; j 20 | 8 TSVApPPEEV i.ooib Echoed User Peptide Sequence {length = 115 residues) HLA peptide motif search results User Parameters and Scoring Information method selected to limit number of results (explicit number number of results requested j 20 HLA molecule type selected 1| Cw_0401 j length selected lor subsequences to be scored 4 9 echoing mode selected for input sequence Jl _ Y j echoing format jf numbered lines ] length of user's Input peptide sequence II 1 number of subsequence scores calculated t number of top-scoring subsequences reported bade in scoring output ta ble|| 20 j Scoring Results : Rank.

Start Position Subsequence Residue ; listing Score (Estimate of Half Time of Disassociation of a Molecule Containing This Subsequence) j 1 34 GFEATYLEL 240,000 2 38 .

TYLELASAV .000 i 82 GFPYBKMII .000 ■ ■ 4 18 < EPGSGVRIV .000 31 EPCGFEATY 12.000. . ; 6 81 GGFPYEKDL j 4.800 7 107 NSRPPCVIL 4.800 i 8 70 NGQLVFSKL 4.400 9 " 75 FSKLENGGF 2.000 97 SNGETLEKI 1.584 : 11 64 AFEIEINGQ 1.000 12 84 PYEKOLIEA 1.000 i 13 49 QYPGIEIES 1.000 14 21 SGVRXVVEV 1.000 j 15 2 SGEPGQTSV 0.660 1 I..16 1 28 , EYCEPCGFE 0.600 j 1 » r.. 45. ..

AVKEQYPGI 0.600 • U8 i 9 ...

SVAPPPEEV | 6.60O ' 1 19 . | 105 ITNSRPPCV j oiio 1 ; | 20 I n KLENGGFPY j 6.500 ; Echoed User Peptide Sequence (length = 115 residues) HLA peptide motif search results User Parameters and Scoring Information metliod selected to limit number ot results •[explicit number number of results requested | 20 HLA molecule type selected j Cw_0401 length selected for subsequences to be scored if 10 echoing mode selected for input sequeace 1 « echoing fonnat Ij numbered lines | length of user's input peptide sequence l| 115 | number of subsequence scores calculated L__. » number of top-scoring subsequences reported back in scoring output tal alejj 20 j Scoring Results Rank Start Position Subsequence Residue Listing Score (Estimate of Half Time of Disassociation of a Molecule Containing This Subsequence) 1 64 AFEIelNGQL 200.000 2 74 VFSEttENGGF 100.000 3 50 YPGIelESRL 86.()00 4 31 EPCGEEATM, 80.000 18 EPGSgVRIW .000 6 34 ; GFEft.tYI.ELA i'o.000 7 28 EX'CEpCGFEA 6.000 8 33 CGFEaTYLEL .760 9 84 PYEKdLIEAI .000 83 FPXEkDLIEA i 4.800 11 69 INGQ1VFSKL 4.400 12 SO NGGFpYEKDL 4.000 13 106 TNSRpPCVIL 4.000 14 56 ESRLgGTGAF 2.000 66 EIEInGQLVF ZOOO 16 26 WEYcEPCGF 2.000 17 ! 96 ASNGeTLEKI 1.320 i 18 49 OYPGiEIESR 1.1W 19 GSGVrlWEY 1.000 38 TOEIASAVK 0.^2 ! Echoed User Peptide Sequence (length =115 residues) HLA peptide motif search results User Parameters and Scoring Information method selected to limit number of results explicit number number of results requested HLA molecule type selected Cw_0602 " length selected tor subsequences to be scored 9 echoing mode selected ibr input sequence I —J i , echoing format 1 numbered lines j length of user's input peptide sequence ,! 115 | number of subsequence scores calculated j 107 ! number of top-scoring subsequences reported back in scoring output tablej M j Scoring Results Rank Start Position Subsequence Residue 1 listing Score (Estimate of Half'lime ot Disassociation of: a Molecule Containing This Subsequence) 1 85 YEKDLIEAI 6.600 2 65 FEIEINGQL 6.600 3 21 SGVRIWEY : 6.000 4 31 EPCGFEATY 3.300 4 61 GTGAFEIEI 3.000 6 38 TYLELASAV j . .A 3.000 ; 7 18 EPGSGVRIV '2.420 8 81 GGFPYEKDL 2.200 9 94 RRASNGETL 2.200 97 SNGETLEKI ; 2.000 11 70 NGQLVFSKL 2.060 12 34 GFEATYLEL 2.000 107 NSRPPCVIL 2.000 14 105 ITNSRPPCV i.iiio I 15 47 KEQXPGIEI 1.100 , j 16 66 EIEINGQLV lm~ ~ j 17 | 42 LASAVKEQY T.ioo ! J 18 | 77 KLENGGFPY i.ioo i 19 1 15 ..

EEVEPGSGV UxJo | 26 ) 45 AVKEQYPGI 1.000 : Echoed User Peptide Sequence (length = 115 residues) HLA peptide motif search results User Parameters and Scoring Information method selected to limit number of results "[explicit number number of results requested HLA molecule type selected length selected for subsequences to be scored "j Gw 0702' y echoing format T ~i numbered lines I length of user's input peptide sequence number of subsequence scores calculated Tir W i number of top-scoring subsequences reported back in scoring output tablej 20 Scoring Results Rank Start Position- Subsequence Residue > listing Score (Estimate of Half lime of Disassociation of; a Molecule Containing This Subsequence) 1 31 EPCGFEATY 24.000 2 21 SGVRIWEY 19.200 3 42 LASAVKEQY 8.800 '■ 4 77 KLENGGFPY 4.000 • 49 QYPGIEIES 2.880 ■ 6 57 SRLGGTGAF 2.400 1 18 EPGSGVRIV 2.400 i 8 94 RRASNGETL 2.400 0 85 YEKDLIEAI 1.478 : 34 GFEATYLEL 1.440 j 11 38 TYLELASAV 1.440 12 70 NGQLVFSKL 1.440 "'j 13 . 65 FEIEINGQL 1.200 14 81 GGFPYEKDL 1.008 IS 67 IEIHGQLVF 1.000 : 16 | 97 SNGETLEKI 0.960 ] 17 j 61 GTGAFEIEI : 0.960' | [ 18 j 101 NSRPPCVIL 0.840 J 19 j 22 GVRIVVEYC 0.800 ; =12b\ 35 FEATYLELA 0.800 i Echoed User Peptide Sequence (length = 115 residues) HLA peptide motif search results User Parameters and Scoring Information method selected to limit number ot results .(explicit number j number of results requested ■j 26 HLA molecule type selected length selected for subsequences to be scored i i echoing mode selected for input sequence 8 r J echoing format | numbered lines | length of user's input peptide sequence 1.. W 1 numberof subsequence scores calculated number of top-scoring subsequences reported back in scoring output tablej 20 j Scoring Results : Rank.

Start Position Subsequence Residue Listing Scorc (Estimate of Half Time of Disassociation of, a Molecule Containing This Subsequence) ! 1 GSGVrIVVEY: 38.400 i 2 : CEPCgFEATY. 16X)00 3 4l ELASaVKEQY; 16.065 j 4 50 YEGIelESRL 7.920 6 76 SKLEnGGFFY 4.0& 6 69 IHGQ1VFSKL 2.880 ) -7 1$ EPGSgVRIW 2.466 | 8 33 CGFEaTYLEL 1440 j 9 80 NGGFpYEKDL 1.440 : 56 ESRLgGTGAF 1.200 i U ' 93 IRRASNGETL v 000 , 12 64 AFEIelKGQL 1.200 j 13 66 EIEInGQLVF r.ooo 14 | FEATyLELAS 0.960 j 87 f KDLIeAIRRA 0.800 i 16 j 97 | SNGEtLEKIT 0.800 j : 17 :j 17 | VEPGSGVRIV oioo j 18 j[ 21 j SGVRiWEYC 0.800 ' ; :| 28 -j EYCEpCGFEA 0.116 | :| 48 :| EQYPglEIES $ 0.672 ; Echoed User Peptide Sequence (length = 115 residues) TABLE3 IMPORTANT MOTE: Tepiiope was programmed fo evaluate Cys residues as Ala, since for synthesis and assay limitations it was not possible to systematically test peptides containing Cys. So, whenever the predicted sequences contain Cys residues, we suggest you should have them synthesized REPLACING Cys WITH Ala RESIDUES.

File Name: C3S Predication Pai-anatars: Quantitative Threshold [%]: 3 Inhibitor threshold [log of fold change}: -1 Inhibitor Residues [number']: 1 0 30 DRB1*0101: SGVRZWErCEPCGF DRB1*0301: SGVRIVVEYCEPCGF DRB1*0401: SGVRIWEYCEPCGF DKB1*0701: SGVRIWEYCEPCGF DRB1*08Q1; SGVRIWEYCEECGF DRB1* 1101: SGVRI VVEYCEPCGF BRB1+1S01: SGVRI VVEYCEPCGF DKB5*0101: SG^JHEWESGEPCGF (binding frame for 135*0101 contains 1 inhibitory residue -100 fold) Quantitative Analysis of 1SGVRIWEYCEPCGF' Threshold (%}: 10 09 08 07 -06 05 04 03 02 01 dbbi*oioi xxxxxxxxxxxxxxxmxxxxxiaaaaaaaaacx drb1*0102 xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx »RB1*0301 XXXXXXXXXXXXXXXXXX drb1'*0401 xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx drb1*0402 xx DBB1*0404 XXXXXXXXXXXXXXXXXX DRB1*0410 XXXXXXXXXXXXXXXXXXXXXXXXXXXXXX drbi*042i xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx DRBl*070l xxxxxxxxxx DRB1*0801 XXXXXXXXXXXXXXXXXXXXXXXXXX PRB1*0802 XXXXXX drbi*0804 xxxxxxxxxxxxxx DRB1*0806 XXXXXXXXXXXSCXKXXXXXXXXXXXXXXXX »rb1*u01 xxxxxxxxxx dbb1*1104 xxxxxxxxxx DRB1*1106 XXXXXXXXXX DBS1*\107 XXXXXXXXXXXXXXXXXX drb1*1305 xraexxxxxxxxxxxxxxx DRB1*1307 XXXXXXXXXX DRB1*1311 XXXXXXXXXX DRB1*1321 XXXXXXXXXXXXXXXXXXXXX3CKXXXXXXX DEtBl*1501 XXXXXXXXXX DBB1*1502 XXXXXXXXXX DRBS*Q101 XXXXXXXXXXXXXXXXXXXXXXXXXXXXXX.

JTile Name: C35 Prediction parameters : Quantitative Threshold [%]: 3 Inhibitor Threshold [log of fold change]: -1 Inhibitor Residues [number]: 1 DRB1*0101: DRB1*0301: DRB1*0401: DRB1*0701: DRB1*0801: DRB1*1101: DRB1*X501: t®BS*0101: (binding frame for *0401 contains 2 inhibitory residues -10 fold each) 60 70 SRI4GGTSAFEIEINGQLVF SRLGGTGAFEIEINGQX.VF SRLGGIGAFEIEINGQLVF SRLGGTGAFEIEINGQLVF SRLGGTGAFEIEINGQLVF SRLGGTGAFEXEINGQLVF SRLGGTGAFEIEINGQLVF Quantitative Analysis of • SRLGGTGAFEIEINGQLVF' threshold (%) : 10 09 08 07 06 OS 04 03 02 01 DRB1*0101 DRB1*0102 DRB1*0301 DKB1*0401 DR81*0402 DRBl*0404 DBB1*0405 DRB1*0410 DRB1*0421 DRB1*0701 DRB1*0801 DRB1*0802 DRB1*0804 I>KB1*0806 DRB1*1101 DBB1*1104 DRB1*1106 DRB1*1107 DRB1*1305 DRB1*1307 DRB1*1311 DEB1*1321 DEB1*1501 DHB1*1502 DRB5*0101 XXXXXXXXXXX3Q0CXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXJ3CXXXXXXXXXXX XXXXXXXXXX. ..

XXXXXXXXXX XX XXXXXXXXXXXXXJOOCXXXXXXXXXXXXXXXXXX.. .. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX xxxxxx xxxxxx xxxxxxxxxxxxxxxxxxxxxx XXXXXXXXXXXJCXXXXXXXXXXXXXX xxxxxxxxxxxxxxxxxxxxxxxxxx XX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XX - XXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXX File Kama: C35 Prediction Parameters: Quauatitative Threshold [%] : 3 Inhibitor- Threshold (log of fold change]: -1 Inhibitor Residues [nuabar]; 1 DKB1*0101: DRBi*0301: DRB1+0401: DRB1*0701 : DKB1*0801: DRB1+1101: DKB1*1501: DRBS*0101: GAFEIEINGQLVFSKIiENGGF GAFEIEINGQLVFSKLENGGF GAFEIEINGQLVFSECLENGGF GAFEIEINGQLVFSKLENGGF GAFEIEINGQLVFSKLENGGF GAFEIEINGQLVFSKLENGGF GAFEIEINGQXiVFSKXiENGGF (binding frame for *0401 contains 2 inhibitory residues —10 fold each) Quantitative Analysis of ' GRFEXEINGQLVFSKLENGGF' Threshold (%) : 10 09 0 8 07 OS OS 04 03 02 01 D8B1*0101 DRB1*0102 DKB1*0301 DRB1*0401 DRB1*0402 D8B1*0404 DEB1*0405 BBB1*0410 DRB1*0421 ORBl*0701 DRB1*0801 DRBX*Oa02 DRB1*0804 DRB1*0806 DRB1*1101 DRB1*1104 DRB1*1106 DBB1*1107 t®Bl*1305 DRB1*1307 DHB1*1311 DR81*1321 DKB1*1501 DRB1*1502 DBB5* 0101 XXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxxxxxxx XXXXXXXXXX xxxxxx xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx XXXXXXXXXXXXXXXXXX xxxxxx xxxxxx XXXXXXXXXXXXXXXXXXXXXX.

XXXXXXXXXXXXXXXXXXXXXXXXXX xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx XXXXXXXXXXXXXXXXXX xxxxxxxxxxxxxxxxxxxxxxxxxx XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXX xxxxxxxxxxxxxx. xxxxxxxxxxxxxxxxxxxxxxxxxx File Name: C35 Prediction Parameters: Quantitative threshold [%J: 5 Inhibitor Threshold [log of fold change]: -1 Inhibitor Residues [number]: 1 go 100- DRB1*0101: FPYEKDLIEAIRRRSNGETLE DRBl*0301i FpyEKDIrlEAIRRASNGETLE DBB1*0701• FPYEKDLIEAIRRASNGETLE DRB1*0801: FPYEKDLIEMRRASNGETLE DRB1*1101: FPYEKDLIEAIRRASNGETLE DHB1*1501: FPYEKDLtEAIKRASNGETLE DRB5*0101: FPYEKDLIEAIRRASNGETLE Quantitative Analysis of 1FPYEKDLIEAIKRASNGETLE' Threshold (%}: 10 09 08 07 06 05 04 03 02 01 DKB1*0101 XXXXXXXXXXXXXXXXXX DRB1*0102 XXXXXXXXXXXXXXXXXXXXXXXXXX DRB1*0301 XXXXXXXXXXXXXXXXXXXXXX .

DRB1*0401 XXXXXXXXXXXXXXXXXXXXXXXXXX DRB1*0402 XXXXXXXXXXXXXXXXXX DRB1*0404 XXXXXXXXXXXXXXXXXXXXXXXXXX DRB1*Q405 XXXXXXXXXXXXXXXXXXXXXXXXXX DBB1*0410 XXXXXXXXXXXXXXXXXXXXXXXXXXXXXX DRB1*Q421 XXXXXXXXXXXXXXXXXXXXXXXXXX DRB1*0701 XXXXXXXXXX DRBl*0801 XXXXXXXXXXXXXXXXXX DRB1*0802 XXXXXXXXXXXXXXXXXX DEB1*Q804 XXXXXXXXXXXXXXXXXXXXXX DRB1*0806 XXXXXXXXXXXXXXXXXXXXXX . .

DRB1*1101 XXXXXXXXXX DRB1*1104 XXXXXXXXXXXXXXXXXX DRB1*1106 XXXXXXXXXXXXXXXXXX DKB1*1107 XXXXXXXXXXXXXXXXXXXXXX DEB1*1305 XXXXXX DRB1U307 XXXXXXXXXXXXXXXXXXXXXX - - BRB1*1311 XXXXXXXXXXXXXXXXXX DBB1*1321 XXXXXXXXXXXXXXXXXXXXXX DRB1*1501 XXXXXXXXXXXXXXXXXXXXXXXXXXXXXX DRB1*1502 XXXXXXXXXXXXXXXXXXXXXXXXXXXXXX DRB5*G101 XXXXXXXXXXXXXX Altered Peptide Ligands Identification of immunodominant epitopes of C35 for MHC class I antigens using specific human T cell lines is a key step toward their successful use in cancer vaccines. Modified C35 peptide epitopes containing amino acid substitutions at MHC binding residues have the potential to be used for enhancement of immune function. Such altered peptide ligand, or heteroclitic peptides, canbecome strongT cell agonists even at 100-fold lower concentrations that the original peptide (Dressel, A. et al., "Autoantigen recognition by human CD8 T Cell clones: enhanced agonist response induced by altered peptide ligand," J. Immunol. 759:4943-51 (1997). These altered peptide ligand can be of two forms: those modifications that enhance T cell receptor contact with the peptide (must be determined experimentally) and those that enhance HLA binding ofthe peptide by improving the anchor residues. Table 4 specifies modifications (hat enhance HLA Class I binding by introducing favorable anchor residues or replacing deleterious residues.

TABLE 4 Modifications that Enhance HLA Class I Binding (Unless otherwise indicated, examples apply to peptides of 9 amino acids; for 10-mers the amino acid at position 5 is disregarded and the resultant 9-mer is evaluated (http://bimas.dcrt.nih.gov/cgi-bin/molbio/hla_coefficient viewing page. The modifications listed below are provided by way of example based on current data in existing databases and are not intended in any way to be an inclusive list of all potential alterations of peptides binding all potential HLA molecules, both known and unknown to date.) HLA A*0101 Any altered peptide that has S or T at position 2 Any altered peptide that has D or E at position 3 Any altered peptide that has P at position 4 Any altered peptide that has A, F, I, L, Ms P, V, or Y at position 7 Any altered peptide tliat has F, K, R, or Y at anchor position 9 Any altered peptide where deleterious residues at the following positions are replaced: PI: P P2: D,E, F, G, H, K, M, N, P, Q, R, W, Y P3: E,K,R, W P4: K,R P7: D, E, G, R P9: D, E, P HLA A*02QI Any altered peptide that has F, I, K, L, M, V, W, or Y at position 1 Any altered peptide that has I, L, M, Q, or V at anchor position 2 Any altered peptide that has F, L, M, W, or Y at position 3 Any altered peptide that has D or E at position 4 Any altered peptide that has F at position 5 Any altered peptide that has F, I, L, M, V, W or Y at auxiliary anchor position 6 An}' altered peptide that has F, or W at position 7 Any altered peptide that has F, W, or Y at position 8 Any altered peptide that has I, L, T or V at anchor position 9 Any altered peptide where deleterious residues at the following positions are replaced: PI: D,E,H,P P2: C, F, H, K, N, P, R, S, W, Y P3: D,E,K,R P7: D, E, G, R P8: I.V- P9: D, E, F, G, H, K, N, P, Q, R, S, W, Y HLA-A*0205 Any altered peptide that has F, I, K, L, M, V, W, or Y at position 1 Any altered peptide that has E, I, L, M, Q, or V at anchor position 2 Any altered peptide that has F, L, M, W, or Y at position 3 Any altered peptide that has D or E at position 4 Any altered peptide that has F, Y at position 5 Any altered peptide that has F, I, L, M, V, W or Y at auxiliary anchor position 6 Any altered peptide that has F, ot W at position 7 Any altered peptide that has F, W, or Y at position 8 Any altered peptide that has I, L, T or V at anchor position 9 Any altered peptide where deleterious residues at the following positions aie replaced: PI: D, E, P P2: C, D, F, G, H, K, N, P, R, S, W, Y P3: D, E, K, R P7:D,E,R P9: D, E, F, G, H, K, N, P, Q, R, S, W, Y HLA-A*03 Any altered peptide that has G or K at position 1 Any altered peptide that has I, L, M, Q, T or V at anchor position 2 Any altered peptide that has F, I, L, M, V, W, or Y at position 3 Any altered peptide that has E, G or P at position 4 Any altered peptide that has F, I, P, V, W, Y at position 5 Any altered peptide that has F, I, L, M, or V at position 6 Any altered peptide that has F, I, L, M, W, or Y at position 7 Any altered peptide that has F, I, K, L, Q or Y at anchor position 9 Any altered peptide where deleterious residues at the following positions are replaced: PI: D,E, P P2: D, E, F, G, H, K, N, R, S, W, Y P7: G,K, R P9: D}E,G,H,N,P,Q,S,T HLA-A*1101 Any altered peptide that has G, K or R at position 1 Any altered peptide that has I, L, M, Q, T, V, Y at anchor position 2 Any altered peptide that has F, I, L, M, V, W, Y at position 3 Any altered peptide that has F, I, L, M, W or Y at position 7 J Any altered peptide that has K or R at anchor position 9 Any altered peptide where deleterious residues at the following positions are replaced: PI: D, E, P P2: D, E, G, H, K, N, R, S, W P7: K, R P9: C, D, E, G, N, P, Q, S, T HLA-A24 Any altered peptide that has K orR at position 1 Any altered peptide that has F or Y at anchor position 2 Any altered peptide that has E, I, L, M, N, P, Q, or Vat position 3 Any altered peptide that has D, E, or P at position 4 Any altered peptide that has I, L, or V at position 5 Any altered peptide that has F at position 6 Any altered peptide that has N or Q at position 7 Any altered peptide that has E or K at position 8 Any altered peptide that has F, I, L, or M at anchor position 9 Any altered peptide where deleterious residues at the following positions are replaced: PI: P P2: D, E, H, K, R P9: D,E,G,H,K,P,Q,R HLA-A*3101 Any altered peptide that has K or R at position 1 Any altered peptide that has F, I, L, M, Q, T, V, or Y at anchor position 2 Any altered peptide that has F, I, L, M, V W, or Y at position 3 , Any altered peptide that has F, I, L, M, or V at position 6 Any altered peptide that has F, I, L, M, W, or Y at position 7 Any altered peptide that has K or R at anchor position 9 Any altered peptide where deleterious residues at the following positions are replaced: PI: D,E,P P2: D, E, P7: K, R P9: C, G, N, P, Q, S, T HLA-A*33©2 Any altered peptide that has D or E at position. 1 Any altered peptide that has I, L, M, S, V or Y at anchor position 2 Any altered peptide that has R at anchor position 9 Any altered peptide where deleterious residues at the following positions are replaced: PI: K,P,R P2:D,E,K,R P9: D,E,F,6,N,P,W,Y HLA-B7 Any altered peptide that has A at position 1 Any altered peptide that has A, P or V at anchor position 2 Any altered peptide that has M or R at position 3 Any altered peptide that has P at position 5 Any altered peptide that has R at position 6 Any altered peptide that has I, L, M or V at anchor position 9 Any altered peptide where deleterious residues at the following positions are replaced: PI: P P2: D,E,F,H,K,R,W,Y P3: D,E .

P9: D, E, F, G, H, K, N, P, Q, R, S, W, Y HLA-B8 Any altered peptide that has D or E at position 1 Any altered peptide that has A, C, L, or P at anchor position 2 Any altered peptide that has K or R at position 3 Any altered peptide that has D or E at position 4 Any altered peptide that has K or R at position 5 Any altered peptide that has I, L, M, or V at anchor position 9 Any altered peptide where deleterious residues at the following positions are replaced: PI: K,P,R P2: D, E, F, G, H, K, Q, R, W, or Y P3: D, E P5: D,E P9: D, E, F, G, H, K, N, P, Q, R, S, W, Y HLA-B8 (8-mer peptides) Any altered peptide fiat has D or E at position 1 Any altered peptide that has A, C, L, or P at anchor position 2 Any altered peptide that has K. or R at position 3 Any altered peptide that has D or E at position 4 Any altered peptide that has K or R at position 5 Any altered peptide that has I, L, M, or V at anchor position 8 Any altered peptide where deleterious residues at the following positions are replaced: PI: K,P,R P2: D, E, F, G, H, K, Q, R, W, or Y P3: D,E P5: D,E P8: D, E, F, G, H, K, N, P, Q, R, S, W, Y HLA-B14 Any altered peptide that has D or E at position 1 Any altered peptide that has K or R at anchor position 2 Any altered peptide that has F, I, L, M, P, V, W, Y at position 3 Any altered peptide that has H or R at position 5 Any altered peptide that has I, L, M, R, or V at position 6 Any altered peptide that has T at position 7 Any altered peptide that has I, L, M, or V at anchor position 9 Any altered peptide where deleterious residues at the following positions are replaced: PI: P P2: D, E, F, W, or Y P3: E,R P5: E,W, Y P9: D, E, G, H, K, N, P, Q, R HLA-B*2702 Any altered peptide that has K or R at position 1 Any altered peptide that has E, L, M, N, Q or R at anchor position 2 Any altered peptide that has F, W, or Y at position 3 Any altered peptide that has F, I, L, W or Y at anchor position 9 Any altered peptide where deleterious residues at the following positions are replaced: PI: D,E,P P2: D, F, G, H, K, W, or Y P7: K P9: D, E, G, K, N, P, Q, R, S HLA-B27*05 (8-mer peptides) Any altered peptide that has K or R at position 1 Any altered peptide (hat has E, L, M, N, Q or R at anchor position 2 Any altered peptide that has F, W, or Y at position 3 Any altered peptide that has F, I, K, L, M, R, V or Y at anchor position 8 Any altered peptide where deleterious residues at the following positions are replaced: PI: D,E,P P2: D,F, G, H,K,W, orY P7: K P9: D,E,G,K,N,P,Q,R,S HLA-B*3501 (8-mer peptides) Any altered peptide that has K or R at position 1 Any altered peptide that has A, P, or S at anchor position 2 Any altered peptide that has K or R at position 3 Any altered peptide feat has D or E at position 4 Any altered peptide that has D or E at position 5 Any altered peptide that has F, I, L, M, V, W or Y at anchor position 8 Any altered peptide where deleterious residues at the following positions are replaced: PI: P P2: D,E,F,H,K,R,W,Y P3: D,E P8: D, E, F, G, H, KL, Ps Q, R HLA-B*3701 Any altered peptide that has D or E at anchor position 2 Any altered peptide that has I or V at position 5 Any altered peptide that has F, L, or M at position 8 Any altered peptide that has F, I, L, M, V or Y at anchor position 9 Any altered peptide where deleterious residues at the following positions are replaced: PI: P P9: D,E, G,H,K,P,Q,R HLA-B*3801 Any altered peptide that has F, H, P, W or Y at anchor position 2 Any altered peptide that has D or E at position 3 Any altered peptide that has D, E, or G at position 4 Any altered peptide that has A, I, L, M, or V at position 5 Any altered peptide that has K or Y at position 8 Any altered peptide that has F, I, L, M, or V at anchor position 9 Any altered peptide where deleterious residues at the following positions are replaced: PI: P P2: D,E,K,R P3: K,R P9: D, E, G, H, K, P, Q, R HLA-B*3901 (8-iaer peptides) Any altered peptide that has H or R at anchor position 2 Any altered peptide that has D, E, F, I, L, M, V, W, or W at position 3 Any altered peptide that has D or E at position 4 Any altered peptide that has I, L, M, or V at position 6 Any altered peptide that has I, L, M or V at anchor position 8 Any altered peptide where deleterious residues at the following positions are replaced: PI: P P2: D,E P3: K,R P6: D, E, K, R P8: D, E, G, H, K, P, Q, R HLA-B*3902 Any altered peptide that has K or Q at anchor position 2 Any altered peptide that has F, I, L, M, V, W, or Y at position 5 Any altered peptide that has F, L, or M at anchor position 9 Any altered peptide where deleterious residues at the following positions are replaced: PI: P P2: D,E ?3: K,R P9: D, E, G, H, K, P, Q, R HLA-B40 Any altered peptide that has A or G at position 1 Any altered peptide that has D or E at anchor position 2 Any altered peptide that has A, F, I, L, M, V, W, or Y at position 3 Any altered peptide that has P at position 4 Any altered peptide that has P at position 5 Any altered peptide that has A, L, M, or W at anchor position 9 Any altered peptide where deleterious residues at the following positions are replaced: pj. p P2: F, H, I, K, L, M, Q, R, V, W, or Y P3: D, E, K, R P9: D, E, G, H, K, N, P, Q, R HLA-B44*03 Any altered peptide that has A, D, or S at position 1 Any altered peptide that has D or E at anchor position 2 Any altered peptide that has A, I, L, M, or V at position 3 Any altered peptide that has F, I, or P at position 4 Any altered peptide that has A, K, or V at position 5 Any altered peptide that has A, L, T, or V at position 6 Any altered peptide that has F, K, or T at position 7 Any altered peptide that has K at position 8 Any altered peptide that has F, W or Y at anchor position 9 Any altered peptide where deleterious residues at the following positions are replaced: PI: P P2: F, H, I, K, L, M, Q, R, V, W, Y P9: D, E, G, H, K, N, P, Q, R HLA-B*5101 (8-mer peptides) Any altered peptide that has D, E, F, I, L, M, V, or Y at position 1 Any altered peptide that has A, G or P at anchor position 2 Any altered peptide that has F, W or Y at position 3 Any altered peptide that has D, E, G, I, K, or V at position 4 Any altered peptide that has A, G, I, S, T, or V at position 5 Any altered peptide that has i, K, L, N, or Q at position 6 Any altered peptide that has D , EC, Q, or R at position 7 Any altered peptide that has I, L, M, or V at anchor position 8 Any altered peptide where deleterious residues at the following positions are replaced: PI: K,P,R P2: D, E, H, K P8: D, E, F, G, H, K, N, P, Q, R, S, W, Y HLA-B*5102 Any altered peptide that has F or Y at position 1 Any altered peptide that has A, G, orP at anchor position 2 Any altered peptide that has F, I, L, V, W, or Y at position 3 Any altered peptide that has E, G, H, K, L, N, Q, R, or T at position 4 Any altered peptide feat has G, N, Q, T, or V at position 5 Any altered peptide feat has J, N, Q, or T at position 6 Any altered peptide feat has E, K, Q, or R at position 7 Any altered peptide feat has K, R, T, or Y at position 8 Any altered peptide feat has I, L, M, or V at anchor position 9 Any altered peptide where deleterious residues at the following positions are replaced: PI: P P2: D, E, H, K, R P3: D,E, K,R P9: D, E, F, G, H, K, N, P, Q, R, S, W, Y HLA-B*5102 (8-mer peptides) Any altered peptide feat has F or Y at position 1 Any altered peptide feat has A, G, or P at anchor position 2 Any altered peptide feat has F, I, L, V, W, or Y at position 3 Any altered peptide feat has E, G, H, K, L, V, W, or Y at position 4 Any altered peptide feat has G, N, Q, T, V at position 5 Any altered peptide feat has Ia N, or Q at position 6 Any altered peptide that has Q, or R at position 7 Any altered peptide feat has I, L, M, or V at position 8 Any altered peptide where deleterious residues at the followiag positions are replaced: PI: P P2: D, E, H, K, R P3: D, E, K, R P8: t>,E,F,G,H,K,N,?,Q,R,S,W)Y HLA-B*5103 Any altered peptide that has D, T, or V at position 1 r Any altered peptide that has A, G, or P at anchor position 2 Any altered peptide that has D, F, L, or Y at position 3 Any altered peptide that has E, G, L, N, Q, R, T, or V at position 4 Any altered peptide that has A, G, M, N, Q, R, K or V at position. 5 Any altered peptide that has I, K, or T atposition 6 Any altered peptide that has M or V at position 7 Any altered peptide that has I, L, M, or V at anchor position 9 Any altered peptide where deleterious residues at the followiag positions are replaced: PI: P P2: D,E,H,K,R P9: D,E,F,G,H,K,N,P,Q,R,S,W,Y HLA-B*5201 (8-mer peptides) Any altered peptide that has I, L, M, or V at position 1 Any altered peptide that has G, P, or Q at anchor position 2 Any altered peptide that has D, F, I, L, P, W, or Y atposition 3 Any altered peptide that has A, E, I, K,L, P, or V at position 4 Any altered peptide that has A, F, G, I, L, M, T or V at position 5 Any altered peptide that has K, L, N, S or T at position 6 Any altered peptide that has E, K, Q, or Y at position 7 Any altered peptide that has F, I, L, M, or V at anchor position 8 Any altered peptide where deleterious residues at the followiag positions are replaced: PI: P P2: H,K,R P3: R PS: D, E, G, H, K, K, P, Q, R, S HLA-B*5801 Any altered peptide that has I, K, or R at position 1 Any altered peptide that has A, S, or T at anchor position 2 Any altered peptide that has D at position 3 Any altered peptide that has E, K, or P at position 4 Any altered peptide that has F, I, L, M, or V at position. 5 Any altered peptide that has F, I, L, or V at position 6 Any altered peptide that has L, M, N, or Y at position 7 Any altered peptide that has K, N, R, or T at position 8 Any altered peptide that has F, W, or Y at anchor position 9 Any altered peptide where deleterious residues at the following positions are replaced: P1:D,E,P P2: D, E, F, H, I, K, L, M, N, Q, R, V, W, Y P9: D,E,G,H,K,N,P,Q,R,S HLA-B*60 Any altered peptide that has D or E at anchor position 2 Any altered peptide that has A, I, L, M, S, or V at position 3 Any altered peptide that has L, I, or V at position 5 Any altered peptide that has I, L, M, V, or Y at position 7 Any altered peptide that has K, Q, or R at position 8 Any altered peptide that has I, L, M, or V at anchor position 9 Any altered peptide where deleterious residues at the following positions are replaced: PI: P P2: F, H, I, K, L, M, Q, R, V, W, Y P9: D, E, F, G, H, K, N, P, Q, R, S, W, Y HLA-B*61 Any altered peptide that has G or R at position 1 Any altered peptide that has D or E at anchor position 2 Any altered peptide that has A, F, I, L, M, T, V, W, or Y at position 3 Any altered peptide that has I at position 6 Any altered peptide that has Y at position 7 Any altered peptide that has A, I, L, M, or V at anchor position 9 Any altered peptide where deleterious residues at the following positions are replaced: PI: P P2: F, H, I, K, L, M, Q, R, V, W, Y P9: D, E, F, G, H, K, N, P, Q, R, S, W, Y HLA-B*61 (8-mer peptides) Any altered peptide that has G or R at position 1 Any altered peptide that has D or E at anchor position 2 Any altered peptide that has A, F, I, L, M, T, V, W, or Y at position 3 Any altered peptide that has I at position 6 Any altered peptide that has Y at position 7 Any altered peptide that has A, I, L, M, or V at anchor position 8 Any altered peptide where deleterious residues at the following positions are replaced: PI: P P2: F, H, I, K, L, M, Q, R, V, W, Y P8: D,E,F,G,H,K,N,P,Q,R3S,W,Y HLA-B*62 Any altered peptide that has I at position 1 Any altered peptide that has I, L, Q at anchor position 2 Any altered peptide that has G, K, R at position 3 Any altered peptide that has D, E, G, or P at position 4 Any altered peptide that has F, G, I, L, or V atposition 5 Any altered peptide that has I, L, T, V at position 6 Any altered peptide that has T, V, or Y at position 7 Any altered peptide (hat has F, W, Y at anchor position 9 Any altered peptide where deleterious residues at the following positions are replaced: PI: P P2: D, E, F, H, K, K, R, S, W, Y P3: D, E P6: D, E, K, R P9: D,E,G,H,K,N,P,Q,R,S HLA-CW0301 Any altered peptide that has A or R at anchor position. 2 Any altered peptide that has F, I, L, M, V, or Y at position 3 Any altered peptide that has E, P, or R at position 4 Any altered peptide that has N at position 5 Any altered peptide that has F, M, or Y at position 6 Any altered peptide that has K, M, R, or S at position 7 Any altered peptide that has T at position 8 Any altered peptide that has F, I, L, M at anchor position 9 Any altered peptide where deleterious residues at the following positions are replaced: PI: P P3: D, K,R P6:D,E,K,R P9: D,E,G,H,K,N,P,Q,R,S, HLA-CW0401 Any altered peptide that has F, P, W, or Y at anchor position 2 Any altered peptide (hat has D, or H at position 3 Any altered peptide that has D or E at position 4 Any altered peptide that has A, H, M, R, or T at position 5 Any altered peptide (hat has I, L, M, or V at position 6 Any altered peptide that has A at position 7 Examples of predicted human Class I MHC binding peptides - continued Rank Start position Subsequence Score (estimated half time of dissociation) Any altered peptide that has H, K, or S at position 8 Any altered peptide that has F, L, L, M, V or Y at anchor position 9 Any altered peptide where deleterious residues at the following positions are replaced: PI: P P2: D,E,H,K,R P9: D, E, G, H, K, N, P, Q, R, S HLA-Cw0602 Any altered peptide that has F, I, K, or Y at position 1 Any altered peptide that has A, P, Q, or R at anchor position 2 Any altered peptide that has F, I, K, L, or M at position 5 Any altered peptide that has I, L, or V at position 6 Any altered peptide that has K, N, Q, or R at position 7 Any altered peptide that has I, L, M, V, or Y at anchor position 9 Any altered peptide where deleterious residues at the following positions are replaced: PI: P P9: D, E, G, H, K, N,P, Q, R, S

[0340] Examples of predicted human Class I MHC binding peptides from the C35 aa sequence and how they might be changed to improve binding: HLA-A*0101 Rank Start position Subsequence Score (estimated half time of dissociation) 1 77 KLENGGRPY 225.000 2 16 EVEPGSGVR 90.000 3 29 YCEPCGFEA 45.000 4 39 YLELASAVK 36.000 2 SGEPGQTSV 2.250 G is deleterious atP2 example of improved peptide STEPGQTSV 22.50 G replaced with T @ P2 Exaraples of predicted human Class I MHC binding peptides — continued Rank Start position Subsequence Score (estimated half time of dissociation) example of improved peptide STEPGQISY HLA-A*0101 (10-mer peptides) 1 2 3 4 66 16 29 26 52 EIEENGQLVF EVEPGSGVRI YCEPCGFEAT VVEYCEPCGF GffilESRLGG 5625.00 V at P9 replaced with Y, P7 enhanced 45.000 18.000 9.000 9.000 2.250 example of improved peptide GTEPSRLGY HLA-A*0201 (9-mer peptides) 1 2 3 4 9 104 105 25 65 SVAPPPEEV KITNSRPPC ITNSRPPCV IVVEYCEPC FEIEINGQL 1125.000 replace I with X @P2 replace G with Y @P9 P5 enhanced with P 2.982 2.391 1.642 1.485 1.018 example of improved peptide FLIEINWYL 16619.000 HLA-A*0201 (10-mer peptides) 1 58. 2 104 3 65 4 83 RLGGTGAFEI KITNSRPPCV FEIEINGQLV FPYEKDLIEA example of improved peptide FLYEKDLIEA example of improved peptide FLYEKDLIEV 60.510 33.472 25.506 4.502 P is deleterious at P2 689.606 replace P with L % P2 9654.485 replace A with V @ P9 Examples of predicted human Class I MHC binding peptides - continued Rank Start position Subsequence Score (estimated half time of dissociation.) 33 CGFEATYLEL 3.173 HLA-A*0205 1 2 3 4 65 25 9 104 81 FEIEINGQL IVVEYCEPC SVAPPPEEV KTTNSRPPC GGFPYEKDL example of improved peptide GVFPYEKDL 8.820 3.060 2.000 1.500 1.260 G is deleterious at P2 50.400 replace G with V @ P2 HLA-A*0205 (10-mer peptides) 1 33 CGEFATYLEL example of improved peptide CVEFATYLEL 2 ' 104 3 65 4 53 83 example of improved peptide 6.300 G is deleterious at P2 11.200 replace G with V@P2 KITNSRPPCV 6.000 FE1EINGQLV 2.520 .

IEIESRLGGT 1.428 FPYEKDLIEA 1.350 P is deleterious at P2 FVYEKDLBEA 54.000 replace P with V @ P2 HLA-A24 1 34 2 49 GFEATYLEL QYPGIEIES example of improved peptide QYPGIEIEL 33.000 11.550 3 70 4 38 82 462.000 enhanceP9 NGQLZFSKL 11.088 TYLELASAV 10.800 GFPYEKDLI 7.500 Examples of predicted human Class I MHC binding peptides - continued Rank Start position Subsequence Score (estimated half time of dissociation) HLA-A24 (10-mer peptides) 1 64 AFEIEINGQL 42.000 2 74 VFSKLENGGF 10.000 3 84 P YEKDLIEAI 9.000 4 69 INGQLVFSKL 7.392 example of improved peptide IYGQLVFSKL 369.6 enhance P2 28 EYCEPCGFEA 6.600 HLA-A3 1 77 KLENGGFPY 36.000 example of improved peptide KLENGGFPK 180.000 enhance P9 2 39 YLELASAVK 20.000 3 101 TLEKITNSR 6.000 4 61 GTGAFEIEI 0.540 69 INGQLVFSK 0.360 N is deleterious @P2 example of improved peptide ILGQLVFSK 180.000 replace N with L @ P2 HLA-A3 (10-mer peptides) 1 68 EINGQLVFSK 8.100 2 58 . RLGGTGAFEI 2.700 3 41 ELASAVKBQY 1.800 4 78 LENGGFPYEK 0.810 B is deleterious @ P2 example of improved peptide LLNGGFPYEK 270.000 replace E with L @ P2 95 RASNGETLEK 0.400 Examples of predicted human Class I MHC binding peptides - continued Rank Start position Subsequence Score (estimated half time of dissociation) HLA-A*1101 1 39 YLELASAVK 0.400 2 69 INGQLVFSK 0.120 Nis deleterious @ P2 example of improved peptide IVGQLVFSK 6.000 replace N with V @ P2 3 16 EVEPGSGVR 0.120 4 101 TLEKtTNSR 0.080 61 GTGAFEIEI 0.060 HLA-A*1101 (10-mer peptides) 1 95 RASNGETLEK 1.200 2 38 TYLELASAVK 0.600 3 68 EINGGLVFSK 0.360 4 78 LENGGFPYEK 0.120 E is deleterious @ P2 example of improved peptide LVNGGFPYEK 4.000 replace E with V @ P2 100 ETLEKTINSR 0.090 HLA-A*3101 1 101 TLEKTTNSR 2.000 2 16 EVEPGSGVR 0.600 3 50 YPGIEIESR 0.400 4 87 KZXLIEAERR 0.240 D is deleterious @ P2 example of improved peptide KIL1EAIRR 12.000 replace D with I @ P2 39 YLELASAVK 0.200 Examples of predicted human Class I MHC binding peptides—continued Rank Start position Subsequence Score (estimated half time of dissociation) HLA-A*3302 1 16 EVEPGSGVR 45.000 2 101 TLEKITNSR 9.000 3 50 YPGIEIESR 3.000 4 66 EIEINGQLV 1.500 56 ESRLGGTGA 1.500 HLA-A*3302 (10-mer peptides) 1 49 QYPGIEIESR 15.000 2 100 ETLEKITNSR 9.000 3 16 EVEPGSGVRI 1.500 4 28 EYCEPCGFEA 1.500 68 EINGQLVFSK 1.500 HLA-A68.1 1 16 EVEPGSGVR 900.000 2 9 SVAPPPEEV 12.000 3 50 YPGIEIESR 10.000 example of improved peptide YVGIEIESR 400.000 enhance P2 4 96 ASNGETLEK. 9.000 101 TLEKITNSR 5.000 HLA-A68.1 (10-mer peptides) 1 100 ETLEKITNSR 300.000 2 16 EVEPGSGVRI 18.000 3 68 EINGGLVFSK 9.000 4 15 EEVEPGSGVR 9.000 E is deleterious @ P2 Examples of predicted human Class I MHC binding peptides ~ continued Rank Start position Subsequence Score (estimated half time of dissociation) example of improved peptide EWEPGSGR 1200.00 replace E with V @P2 95 - . RASNGETLEK 3.000 HLA-B14 1 94 RRASNGETL 20.000 2 57 SRLGGTGAF 5.000 example of improved peptide SRLGGTGAL 100.000 enhance P9 3 100 ETLEKITNS 3.375 4 105 ITNSRPPCV 2.000 88 DLIEAIRRA 1.350 HLA-B14 (10-mer peptides) 1 • 103 EKITNSRPPC 6.750 example of improved peptide ERITNSRPPL 900.000 enhance P10 2 33 CGFEATYLEL 5.000 3 93 IRRASNGETL 4.000 4 18 EPGSGVRIVV 3.000 88 DLIEAIRRAS 2.250 HLA-B4Q 1 65 FEIEINGQL 80.000 2 3 GBPGQTSVA 40.000 3 35 FEATYLELA 40.000 4 15 EEVEPGSGV 24.000 example of improved peptide EEVEPGSGL 120.000 enhance P9 67 IEINGQLVF 16.000 Examples of predicted human Class I MHC binding peptides — continued Rank Start position Subsequence Score (estimated half time of dissociation) HLA-B40 (10-mer peptides) 1 55 IESRLGGTGA 20.000 2 53 IEIESRLGGT 16.000 example of improved peptide IEIESRLGGL 80.000 enhance P10 3 65 FEEEINGQLV 16.000 4 67 IEINGQLVFS 16.000 99 GETLEKITNS 8.000 HLA-B60 1 65 FEIEFNGQL 387.200 2 17 VEPGSGVRI 17.600 example of improved peptide VEPGSGVRL 352.000 enhance P9 3 15 EEVEPGSGV 16.000 4 47 KEQYPGIEI 16.000 85 YEKDLIEAI 8.800 HLA-B60 (10-mer peptides) 1 65 FEIEINGQLV 16.000 example of improved peptide FEIEINGQLL 320.000 enhance P10 2 106 TNSRPPCVIL 16.000 3 53 IEIESRLGGT 8.000 4 33 CGFEATYLEL 8.000 17 VEPGSGVRIV 8.000 HLA-B61 1 15 2 35 EEVEPGSGV FEATYLELA 80.000 40.000 Examples of predicted human Class I MHC binding peptides - continued Rank Start position Subsequence Score (estimated half time of dissociation) example of improved peptide FEATYLELV 160.000 enhance P9 3 3 GEPGQTSVA 22.000 . 4 65 feieingql 16.000 85 yekdlieai 16.000 HLA-B61 (10-mer peptides) 1 65 FEIEINGQLV 80.000 2 17 VEPGSGVRIV 40.000 3 55 IESRLGGTGA 20.000 4 87 KDLIEAIRRA 10.000 example of improved peptide KELIEAIRRV 160.000 enhance P2, P10 53 IEIESRLGGT 8.000 HLA-B62 1 77 KLENGGFPY 24.000 2 21 SGVRIWEY 4.800 3 75 FSKLENGGF 3.000 4 31 EPCGFEATY 2.640 P is deleterious @ P2 example of improved peptide EQCGFEATY 105.6 replace P with Q @ P2 88 DLIEAIRRA 2.200 HLA-B62 (10-mer peptides) 1 41 ELASAVKEQY 40.000 2 58 RLGGTGAFEI 9.600 3 66 EIEINGQLVF 7.920 4 56 ESRLGGTGAF 6.000 S is deleterious @ P2 Examples of predicted human Class I MHC binding peptides - continued Rank Start position Subsequence Score (estimated half time of dissociation) example of improved peptide EQRLGGTGAF 480.000 replace S with Q @ P2 20 GSGVRIVVEY 4.S00 S is deleterious @ P2 example of improved peptide GQGVRIWEY 384.000 replace S with Q @P2 HLA-B7 1 107 NSRPPCVIL 60.000 example of improved peptide NPRPPCVEL 1200.000 enhance P2 2 45 AVKEQYPGI 6.000 3 22 GVRIVVEYC 5.000 4 70 NGQLVFSKL 4.000 81 GGFPYEKDL 4.000 HLA-B7 (10-mer peptides) 1 50 YPGIEIESRL 80.000 2 31 EPCGFEATYL 80.000 3 18 EPGSGVRIVV 6.000 example of improved peptide EPGSGVRIVL 120.000 enhance F10 4 106 TNSRPPCVIL 6.000 80 NGGFPYEKDL 4.000 HLA-B8 1 107 NSRPPCVIL 4.000 2 45 AVKEQYPGI 1.500 3 105 ITNSRPPCV 0.600 4 56 ESRLGGTGA 0.400 100 ETLEKITNS 0.300 S is deleterious @ P9 Examples of predicted human Class I MHC binding peptides—continued Rank Start position Subsequence Score (estimated balftims of dissociation) example of improved peptide ETLEKITNL 12.000 replace S with L @ P9 HLA-B8 (8-mer peptides) 1 83 FPYEKDLI 2 107 NSRPPCVI 3 91 EAIRRASW example of improved peptide EAIRRASL 4 18 GSGVRIW EPGSGVRI 6.000 1.000 0.800 N is deleterious @ P8 32.000 replace N with L @ P9 0.600 0.400 HLA-B8 (10-mer peptides) 1 50 YPGIEIESRL 2 93 IREASNGETL example of improved peptide IA RASNGETL 0.800 0.400 3 31 4 104 18 16.000 replace R with A @ P2 EPCGFEATYL 0.320 KITNSRPPCV 0.300 EPGSGVRIVV 0.240 HLA-B*2702 1 57 2 94 SRLGGTGAF RRASNGETL example of improved peptide RRASNGETF 200.000 180.000 93 27 77 600.000 enhance P9 IRRASNGET 20.000 VEYCEPCGF 15.000 KLENGGFPY 9.000 Examples of predicted human Class I MHC binding peptides — continued Rank Start position Subsequence Score (estimated half time of dissociation) HLA-B*2702 (10-mer peptides) 1 93 IRRASNGETL 2 94 RRASNGETLE 3 30 CEPCGFEATY 4 58 RLGGTGAFEI 23 VRIVVEYCE? example of improved peptide VRIWEYCEY HLA-B*2705 1 94 RRASNGETL 2 57 SRLGGTGAF 3 93 IRRASNGET example of improved peptide IRBASNGEL 4 27 VEYCEPCGF 77 KLENGGFPY HLA-B*2705 (10-mer peptides) 1 93 IRRASNGETL 2 94 RRASNGETLE example of improved peptide RRASNGETLL 3 78 LENGGFPYEK 4 95 RASNGETLEK 58 RLGGTGAFEI HLA-B*3501 1 31 2 75 60.000 6.000 3.000 2.700 2.000 P is deleterious @P 10 200.000 replace P with Y @ P10 6000.000 1000.000 200.000 2000.000 enhance P9 75.000 45.000 2000.000 60.000 E is deleterious @ P2 6000.000 replace E with L @ P2 .000 30.000 27.000 EPCGFEATY 40.000 FSKLENGGF 22.500 Examples of predicted bnman Class I MHC binding peptides - continued Rank Start position Subsequence Score (estimated half time of dissociation) example of improved peptide FPKLENGGM 3 107 4 42 18 NSRPPCVIL LASAVKEQY EPGSGVRIV 120.000 enhance P2,P9 15.000 6.000 4.000 HLA-B*3501 (10-mer peptides) 1 2 3 4 31 50 56 20 83 EPCGFEATYL YPGIEIESRL ESRLGGTGAF GSGVRIVVEY FPYEKDLIEA example of improved peptide FPYEKDLIEM .000 20.000 15.000 10.000 6.000 120.000 enhance P10 HLA-B*3701 1 65 FEIEINGQL example of improved peptide FDIEINGQL 2 47 3 85 4 17 35 KEQYPGEBI YEKDLIEAI VEPGSGVRI FEATYLELA .000 60,000 enhance P2 10.000 10.000 10.000 5.000 HLA-B*3701 (10-mer peptides) 1 65 FEIEINGQLV example of improved peptide FDIEINGQH .000 2 3 67 81 200.000 enhance P2, P10 EEINGQLVFS 5.000 GGFPYEKDLI 5.000 Examples of predicted human Class IMHC binding peptides — continued Rank Start position Subsequence Score (estimated half time of dissociation) 4 87 KDLIEAIRRA 4.000 30 CEPCGFEATY 2.000 HLA-B*3801 1 34 GFEATYLEL 6.000 example of improved peptide GHEATYLEL 90.000 enhance P2 2 70 NGQLVFSKL 1.560 3 38 TYLELASAV 1.040 4 81 GGFPYEKDL 1.000 97 SNGETLEKI 0.720 HLA-B*3801 (10-mer peptides) 1 64 AFEIEINGQL 7.800 example of improved peptide AHEIEINGQL 117.000 enhance P2 2 31 EPCGFEATYL 4.800 ^ 3 66 EIEINGQLVF 3.000 4 26 VVEYCEPCGF 3.000 50 YPGIEIESRL 2.600 HLA-B*3901 1 94 RRASNGETL 15.000 example of improved peptide RHASNGETL 90.000 enhance P2 2 34 • GFEATYLEL 9.000 3 38 TYLELASAV 4.000 4 66 EIEINGQLV 3.000 2 SGEPGQTSV 3.000 Examples of predicted human Class I MHC binding peptides—continued Rank Start position Subsequence Score (estimated half time of dissociation) HLA-B*3901 (10-mer peptides) 1 33 CGFEATYLEL example of improved peptide CHFEATYLEL 12.000 2 64 3 93 4 46 16 360.000 enhance P2 AFEIE1NGQL 9.000 IRRASNGETL 4.500 VKEQYPGIEI 3.000 EVEPGSGVRI 3.000 HLA-B*3902 1 70 NGQLVFSKL example of improved peptide NKQLVFSKL 2 81 3 94 4 34 107 GGFPYEKDL RRASNGETL GFEATYLEL NSRPPCVIL 2.400 24.000 enhance P2 2.400 2.000 2.000 0.600 HLA-B*3902 (10-mer peptides) 1 69 INGQLVFSKL 2.400 2 64 AJFEIEINGQL 2.400 3 50 YPGIEIESRL 2.400 4 80 NGGFPYEKDL 2.400 106 TNSRPPCVIL 2.000 HLA-BM403 1 67 IEINGQLVF example of improved peptide IEINGQLVY 200.000 27 900.000 enhance P9 VEYCEPCGF 40.000 Examples of predicted human Class I MHC binding peptides - continued Rank Start position Subseqqeace Score (estimated half time of dissociation) 3 21 4 65 35 SGVRIWEY FEIEINGQL FEATYLELA 36.000 20.000 12.000 BQLA-B*4403 (10-mer peptides) 1 30 CEPCGFBATY 2 53 IEIESRLGGT example of improved peptide IEEESRLGGY 120.000 30.000 3 67 4 65 17 900.000 enhance P10 IEINGQLVFS 30.000 FEDBINGQLV 20.000 VEPGSGVRIV 18.000 HLA-B*5101 1 18 2 59 EPGSGVRIV LGGTGAFEI 484.000 114.400 example of improved peptide LPGTGAFEI 3 2 4 81 70 572.000 enhance P2 SGEPGQTSV 48.400 GGFPYEKDL 44.000 NGQLVFSKL 22.000 HLA-B*5I0I (10-mer peptides) 1 18 EPGSGVRIW 2 44 SAVKEQYPGI example of improved peptide SPVKEQYPGI 440.000 220.000 3 31 4 81 50 440,000 enhance P2 EPCGFEATYL 220.000 GGFPYEKDLI 176.000 YPGIEIESRL 157.300 Examples of predicted human Class I MHC binding peptides ~ continued Rank Start position Subsequence Score (estimated half time of dissociation') HLA-B*5102 1 18 EPGSGVRIV 242.000 2 81 GGFPYEKDL 110.000 example of improved peptide GPFPYEKDI 2200.000 enhance P2,P9 3 59 LGGTQAFEI 96.800 4 70 NGQLVFSKL 48.400 2 SGEPGQTSV 24.200 HLA-B*5102 (10-mer peptide) 1 44 SAVKEQYPGI 726.000 example of improved peptide SPVKEQYPGI 1452.000 enhance P2 2 50 YPGIEIESRL 400.000 3 81 GGFPYEKDLI 400.000 4 18 EPGSGVRIVV 220.000 31 " EPCGFEATYL 121.000 HLA-B*5103 1 59 LGGTGAFEI 48.400 example of improved peptide LAFTGAFEI 145.200 enhance P2 2 2 SGEPGQTSV 44.000 3 18 EPGSGVRIV 44.000 4 70 NGQLVFSKL 7.260 81 GGFPYEKDL 7.200 Examples of predicted human Class I MHC binding peptides — continued Rank Start position Subsequence Score (estimated half time of dissociation) HLA-B*5103 (10-mer peptide) 1 44 SAVKEQYPGI 110.000 2 81 GGFPYEKDLI 52.800 3 18 EPGSGVRIW 44.000 example of improved peptide EAGSGVRIW 110.000 enhance P2 4 60 GGTGAFEIEI 44.000 33 CGFEATYLEL 7.920 HLA-B*5201 1 18 WPGSGVRIV 75.000 2 67 LEINGQLVF 22.500 example of improved peptide LQ1NGQLVI 450.000 enhance P2, P9 3 59 LGGTGAFEI 11.250 4 98 NGETLEKIT 11.000 19 PGSGVRIVV 10.000 HLA-B*5201 (10-mer peptides) 1 18 EPGSGVRIW 100.000 2 17 VEPGSGVRIV 45.000 example of improved peptide VQPGSGVRIV 450.000 enhance P2 3 81 GGFPYEKDLI 33.000 4 105 ITNSRPPCVI 15.000 37 ATYLELASAV 12.000 Examples of predicted human Class I MHC binding peptides — contiaued Rank Start position Subsequence Score (estimated half time of dissociation) HLA-B*5801 1 75 FSKLENGGF 40.000 example of improved peptide FSKLENGGW 80.000 enhance P9 2 42 LASAVKEQY 4.500 3 107 NSRPPCVIL 4.000 4 61 GTGAFEIEI 3.000 105 ITNSRPPCV 3.000 HLA-B*5801 (10-mer peptides) 1 56 ESRLGGTGAF 12.000 2 20 GSGVRIVVEY 10.800 example of improved peptide GSGVRIWEW 144.000 enhance P10 3 1 MSGEPGQTSV 4.000 4 105 ITNSRPPCVI 3.000 37 ATYLELASAV 3.000 HLA-Cw*0301 1 65 FEIEINGQL 30.000 2 81 GGFPYEKDL 18.000 3 70 NGQLVFSKL 12.000 4 57 SRLGGTGAF 10.000 34 GFEATYLEL 10.000 HLA-Cw*0301 (10-mer peptides) 1 44 SAVKEQYPGI 50.000 example of improved peptide SAVKEQYPGL 100.000 enhance P10 2 33 CGFEATYLEL 45.000 Examples of predicted human Class I MHC binding peptides — continued Rank Start position Subsequeo.ee Score (estimated half time of dissociation) 3 69 4 81 106 INGQLVFSKL GGFPYEKDLI TNSRPPCVIL 12.000 3.750 3.000 HLA-Cw*0401 1 2 3 4 34 38 82 18 31 GFEATYLEL TYLELASAV GFPYEKDLI EPGSGVRIV EPCGFEATY example of improved peptide EFCGFEATL 240.000 .000 .000 .000 12.000 200.000 enhance P2,P9 HLA-Cw*0401 (10-mer peptides) 1 64 AFEIEINGQL 2 74 VFSKLENGGF example of improved peptide VFSKLENGGL 3 50 4 31 18 YPGIEIESRL EPCGFEATYL EPGSGVRIW 200.000 100.000 200.000 enhance P10 80.000 80.000 10.000 HLA-Cw*0602 1 85 2 65 3 21 4 31 61 YEKDLIEAI FEIEINGQL SGVRIWEY EPCGFEATY GTGAGEIEI 6.600 6.600 6.000 3.300 3.000 Examples of predicted human Class I MHC binding peptides - continued Rank Start position Subsequence Score (estimated half time of dissociation) HLA-Cw*0702 1 31 EPCGFEATY 24.000 2 21 SGVRIWEY 19.200 3 42 LASAVKEQY 8.800 4 77 KLENGGFPY 4.000 49 QYPGIBIES 2.880 HLA-Cw*0702 (10-mer peptides) 1 20 GSGVRIVVEY 38.400 2 30 CEPCGFEATY 16.000 3 41 ELASAVKEQY 16.000 4 50 YPGIEIESRL 7.920 76 SKLENGGFPY 4.000 Table 5 Predicted C35 HLA Class I epitopes* HLA restriction element Inclusive amino acids Sequence A*0201 9-17 SVAPPPEEV A*0201 -17 VAPPPEEV A*0201 16-23 EVEPGSGV A*0201 16-25 EVEPGSGVRI A*0201 36-43 EATYLELA A*0201 37-45 ATYLELASA A*0201 37-46 ATYLELASAV A*0201 39-46 YLELASAV A*0201 44-53 SAVKEQYPGI A*0201 45-53 AVKEQYPGI A*0201 52-59 GIEIESRL A*0201 54-62 EIESRLGGT A*0201 58-67 RLGGTGAFEI A*0201 61-69 GTGAFEIEI A*0201 66-73 EIEINGQL A*0201 66-74 EIEINGQLV A*0201 88-96 DLIEAIRRA A*0201 89-96 LEAIRRA A*0201 92-101 AIRRASNGET A*0201 95-102 RASNGETL A*0201 104-113 KITNSRPPCV A*0201 105.-113 ITNSRPPCV A*0201 105-114 ITNSRPPCVI A*3101 16-24 EVEPGSGVR B*3501 -38 EPCGFEATY A*30101 supermotif 96-104 ASNGETLEK ♦predicted using rules found at the SYFPEITHI website ("wvsiwvg://35/httD://134.2.96.221/scriDts/hlaserver.dll/Er>Predict.htm') and are based on the book "MHC Ligands and Peptide Motifs" by Rammensee, H.G., Bachmann, J. and S. Stevanovic. Chapman & Hall, New York, 1997.

Table 6 Predicted C35 HLA class II epitopes* Sequence Inclusive amino acids SGVRIVYEYCEPCGF 21-35 Restriction elements DRB1*0101 DRB1*0102 DRB1*0301 DRB1*0401 DRB 1*0404 DRB1*0405 DRB 1*0410 DRB1*0421 DRB1*0701 DRB1*0801 DRB1*0804 DRB1*0806 DRBiniOl DRB 1*1104 DRB1*1106 DRB 1*1107 DRB 1*1305 DRB1*1307 DRB1*1321 DRB1*1501 DRB1*1502 DRB5*0101 SRLGGTGAFEIEINGQLVF 57-75 DRB1*0101 DRB1*0102 DRB1*0301 DRB1*0401 DRB1*0402 DRBl*042i DRB1*0701 DRB1*0804 DRB1*0806 DRB1*1101 DRB1*1104 DRB1*1106 DRB1*1305 DRB1*1321 DRB1*1501 DRB1*1502 DRB5*0101 GAPEIEINGQLVFSKLENGGF 63-83 FPYEKDLIEAIRRASNGETLE 83-103 DRB1*0101 DRB1*0102 DRB1*0301 DRB1*0401 DRB1*0402 DRB 1*0404 DRB1*0405 DRB1*0410 DRB1*0421 DRB1*0701 DRB 1*0804 DRB1*0806 DRB1*1101 DRB1*1104 DRB 1*1106 DRB1*1107 DRB 1*1305 DRB1*1307 DRB1*1311 DRB1*1321 DRB1*1501 DRB1*1502 DRB5*0101 DRB1*0101 DRB 1*0102 DRB1*0301 DRB1*0401 DRB1*0402 DRB1*0404 DRB1*0405 DRB1*0410 DRB1*0421 DRB1*0701 DRB1*0801 DRB1*0802 DRB1*0804 DRB 1*0806 DRB1*1101 DRB1*1104 DRB1*1106 DRB1*1107 DRB1*1305 DRB1*1307 DRB1*1311 DRB1*1321 DRB1*1501 DRB1*1502 DRB5*0101 *Class II MHC epitopes predicted using TEPITOPE software. Sturniolo, T., et al. 1999. Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class Ilmatrices. Nature Biotechnology 17:555-571. .[0341] "Epitopes" refer to C35 polypeptide fragments having antigenic or immunogenic activity in an animal, especially in a human, or that are capable of eliciting a T lymphocyte response in an animal, preferably a human. A preferred embodiment relates to a C35 polypeptide fragment comprising a C35 peptide epitope, as well as the polynucleotide encoding this fragment. A further preferred embodiment relates to a C35 polypeptide fragment consisting of an epitope, as well as the pofynucleotide encoding this fragment. In specific preferred embodiments the epitope comprises a C35 fragment listed in any of Tables 1-3 or 5-6, exclusive of E-100 to R-109 ofSEQ ID NO:2.

In another preferred embodiment the epitope consists of a C35 fragment listed in any of Tables 1-3 and 5-6 exclusive of E-100 to R-109 of SEQ ID NO:2. A region of a protein molecule to which an antibody can bind is defined as an "antigenic epitope." In contrast, an "immunogenic epitope" is defined as a part of a protein that elicits T cell response. (See, for instance, Geysen etal, Proc. Natl Acad. Sci. USA 81:3998- 4002 (1983)). Thus, a further preferred embodiment is an immunogenic C35 peptide fragment that is capable of eliciting a T cell response when bound to the peptide binding cleft of an MHC molecule. In a specific preferred embodiment, the immunogenic C35 peptide fragment comprises an epitope listed in any of Tables 1-3 or 5-6 exclusive of E-100 to R-109 of SEQ ID NO:2. In another preferred INTELLECTUAL PROPERTY OFFICE OF N.Z. 2 5 oct 2006 RECEIVED embodiment, the immunogenic C35 peptide fragment consists of an epitope listed in any of Tables 1-3 or 5-6 exclusive of E-100 to R-109 of SEQ ID NO:2. Further embodiments ofthe invention are directed to pharmaceutical formulations and vaccine compositions comprising said immunogenic C35 peptide fragments or the polynucleotides encoding them.

[0342] Fragments which function as epitopes may be produced by any conventional means. (See, e.g., Houghten, R. A., Proc. Natl. Acad. Sci. USA 82:5131-5135 (1985) further described in U.S. Patent No. 4,631,211.) molecules can be modified at the known peptide anchor positions in predictable ways that act to increase MHC binding affinity. Such "epitope enhancement" has been employed to improve the immunogenicity of a number of different MHC class I or MHC class II binding peptide epitopes (Berzofsky, J. A. et al., Immunol. Rev. 170:151-72 (1999); Ahlers, J.D. et al, Proc. Natl. Acad. Sci U.SA. 94:10856-61 (1997); Overwijk, etal, J.Exp. Med. 188:211-S6 (1998);Parkhurst, M.R. et al., J. Immunol. 157:2539-48 (1996)). Accordingly, also described are such enhanced C35 peptide epitope analogs and the polynucleotides encoding such analogs.

[0344] Antigenic epitopes preferably contain a sequence of at least seven, more preferably at least nine, and most preferably between about 15 to about 30 amino acids. Antigenic epitopes are useful to raise antibodies, including monoclonal antibodies, that specifically bind the epitope. (See, for instance, Wilson et al., Cell 37:161-118 (1984); Sutcliffe, J. G. et al, Science 219:660-666 (1983).)

[0345] Similarly, immunogenic epitopes can be used to induce B cells and T cells according to methods well known in the art. (See Sutcliffe et al, supra; Wilson etal, supra; Chow, M. et al., Proc. Natl. Acad. Sci. USA &2:910-914; andBittle, F. J. et al, J. Gen. Virol <5(5:2347-2354(1985).) The immunogenic epitopes may be presented together with a carrier protein, such as an albumin, to an animal system (such as rabbit or mouse) or, if it is long enough (at least about 25 amino

[0343] The sequence of peptide epitopes known to bind to specific MHC INTELLECTUAL PROPERTY OFFICE OF N.Z. 2 5 OCT 2006 acids), without a carrier: However, immunogenic epitopes comprising as few as 9 amino acids have been shown to be sufficient to raise antibodies capable of binding to, at the very least, linear epitopes in a denatured polypeptide (e.g., in Western blotting.)

[0346] As usedherein, the term "antibody" (Ab) or "monoclonal antibody" (Mab) is meant to include intact molecules as well as antibody fragments (such as, for example, Fab and F(ab')2 fragments) which are capable of specifically binding to protein. Fab and F(ab')2 fragments lack the Fc fragment of intact antibody, clear more rapidly from the circulation, and may have less non-specific tissue binding than an intact antibody! (Wahl et al., J. Nucl. Med. 24:316-325 (1983).) Thus, for some applications these fragments are preferred, as well as the products of a Fab or other immunoglobulin expression library. Moreover, antibodies of the present invention include chimeric, single chain, and humanized antibodies.

Diagnostic and Therapeutic Uses of Antibodies

[0347] The present invention further relates to C35 antibodies, C35 antibody fragments and antibody conjugates and single-chain immunotoxins reactive with human carcinoma cells, particularly human breast and bladder carcinoma cells.

[0348] Table 7 provides a list of C35-specific monoclonal antibodies that have been isolated and characterized for use in different applications.

TABLE 7: C35 -Specific Murine Monoclonal Antibodies Fusion Hybridoma ELISA Isotype Western Blot Flow Cytometry Immunohisto-chemistry alpha 1F5 positive IgM positive positive 1F7 positive IgM positive 1F11 positive IgM positive 2D9 positive IgM positive positive positive Fusion Hybridoma ELISA Isotype Western Blot Flow Cytometry Immunohisto-chemistry beta 2G3 positive IgGl 2G8 positive 2G10 positive IgG3 2G11 positive IgG3 3F9 positive IgGl 4D11 positive IgGl 4G3 positive IgG3 7C2 positive IgM 8B11 positive IgM 8G2 positive IgM 10F4 positive IgGl 11B10 positive IgM positive 12B10 positive 16C10 positive IgM 16F10 positive ELISA assay on bacterially-synthesized C35 blank = not determined

[0349] As used in this example, the following words or phrases have the meanings specified.

[0350] As used in this example, "joined" means to couple directly or indirectly one molecule with another by whatever means, e.g., by covalent bonding, by non-covalent bonding, by ionic bonding, or by non-ionic bonding. Covalent bonding includes bonding by various linkers such as thioether linkers or thioester linkers. Direct coupling involves one molecule attached to the molecule of interest Indirect coupling involves one molecule attached to another molecule not of interest which in turn is attached directly or indirectly to the molecule of interest

[0351] As used in this example, "recombinant molecule" means a molecule produced by genetic engineering methods. ;-400- t0352] As used in this example, "fragment" is defined as at least a portion ofthe variable region of the immunoglobulin molecule which binds to its target, i.e. the antigen binding region. Some ofthe constant region of the immunoglobulin may be included.

[0353]. As used in this example, an "immunoconjugate" means any molecule or ligand such as an antibody or growth factor chemically or biologically linked to a cytotoxin, a radioactive agent, an anti-tumor drug or a therapeutic agent. The antibody or growth factor may be linked to the cytotoxin, radioactive agent, anti-tumor drug or therapeutic agent at any location along the molecule so long as it is able to bind its target. Examples of immuoconjugates include immunotoxins and antibody conjugates.

[0354] As used in this example, "selectively killing" means killing those cells to which the antibody binds.

[0355] As used in this example, examples of "carcinomas" include bladder, breast, colon, liver, lung, ovarian, and pancreatic carcinomas.

[0356] As used in this example, "immunotoxin" means an antibody or growth factor chemically or biologically linked to a cytotoxin or cytotoxic agent.

[0357] As used in this example, an "effective amount" is an amount of the antibody, immunoconjugate, recombinant molecule which kills cells or inhibits the proliferation thereof.

[0358] As used in tins example, "competitively inhibits" means being capable of binding to the same target as another molecule. With regard to an antibody, competitively inhibits mean that the antibody is capable of recognizing and binding the same antigen binding region to which another antibody is directed.

[0359] As used in this example, "antigen-binding region" means that part of the antibody, recombinant molecule, the fusion protein, or the immunoconjugate of the invention which recognizes the target or portions thereof. . [0360] As used in this example, "therapeutic agent" means any agent useful for therapy including anti-tumor drugs, cytotoxins, cytotoxin agents, and radioactive agents.

[0361] As used in this example, "anti-tumor drug" means any agent useful to combat cancer including, but not limited to, cytotoxins and agents such as antimetabolites, alkylating agents, anthracyclines, antibiotics, antimitotic agents, procarbazine, hydroxyurea, asparaginase, corticosteroids, mytotane (0,P'-(DDD)), interferons and radioactive agents.

[0362] As used in this example, "a cytotoxin or cytotoxic agent" means any agent that is detrimental to cells. Examples include taxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin and analogs or homologs thereof.

[0363] As used in this example, "radioisotope" includes any radioisotope which is effective in destroying a tumor. Examples include, but are not limited to, cobalt-60 and X-rays. Additionally, naturally occurring radioactive elements such as uranium, radium, and thorium which typically represent mixtures of radioisotopes, are suitable examples of a radioactive agent.

[0364] As used in this example, "administering" means oral administration, administration as a suppository, topical contact, intravenous, intraperitoneal, intramuscular or subcutaneous administration, or the implantation of a slow-release device such as a miniosmotic pump, to the subject.

[0365] As used in this example, "directly" means the use of antibodies coupled to a label. The specimen is incubated with the labeled antibody, unbound antibody is removed by washing, and the specimen may be examined.

[0366] As used in this example, "indirectly" means incubating the specimen with an unconjugated antibody, washing and incubating with a fluorochrome-conjugated antibody. The second or "sandwich" antibody thus reveals the presence of the first.

[0367] As used in this example "reacting" means to recognize and bind the target. The binding may be non-specific. Specific binding is preferred.

[0368] As used in this example, "curing" means to provide substantially complete tumor regression so that the tumor is not palpable for a period of time, i.e., >/= 10 tumor volume doubling delays (TVDD = the time in days that it takes for control tumors to double in size).

[0369] As used in this example, "tumor targeted antibody" means any antibody which recognizes the C35 antigen on tumor (i.e., cancer) cells.

[0370] As used in this example, "inhibit proliferation" means to interfere with cell growth by whatever means. .[0371] As used in this example, "mammalian tumor cells" include cells from animals such as human, ovine, porcine, murine, bovine animals.

[0372] As used in this example, "pharmaceutically acceptable carrier" includes any material which when combined with the antibody retains the antibody's immunogenicity and is non-reactive with the subject's immune systems. Examples include, but are not limited to, any of the standard pharmaceutical carriers such as a phosphate buffered saline solution, water, emulsions such as oil/water emulsion, and various types of wetting agents. Other carriers may also include sterile solutions, tablets including coated tablets and capsules.

[0373] Typically such carriers contain excipients such as starch, milk, sugar, certain types of clay, gelatin, stearic acid or salts thereof magnesium or calcium stearate, talc, vegetable fats or oils, gums, glycols, or other known excipients. Such carriers may also include flavor and color additives or other ingredients. Compositions comprising such carriers are formulated by well known conventional methods.

[0374] The present invention relates to C35 antibodies that are highly specific for carcinoma cells. More particularly, the antibodies react with a range of carcinomas such as breast, bladder, lung, ovary and colon carcinomas, while showing none or limited reactivity with normal human tissues or other types of tumors such as, for example, sarcomas or lymphomas.

[0375] The term "C35 antibody" as used herein includes whole, intact polyclonal and monoclonal antibody materials, and chimeric antibody molecules. The C35 antibody described above includes any fragments thereof containing the active antigen-binding region of the antibody such as Fab, F(ab')2 and Fv fragments, using techniques well established in the art [see, e.g., Rousseaux et al, "Optimal Conditions For The Preparation of Proteolytic Fragments From Monoclonal IgG of Different Rat IgG Subclasses", in Methods Enzymol, 121:663-69 (Academic Press 1986)]. The C35 antibody of the invention also includes fusion proteins.

Also included within the scope of the invention are anti-idiotypic antibodies to the C35 antibody of the invention. These anti-idiotypic antibodies can be produced using the C35 antibody and/or the fragments thereof as immunogen and are useful for diagnostic purposes in detecting humoral response to tumors and in therapeutic applications, e.g., in a vaccine, to induce an anti-tumor response in patients [see, e.g., Nepom et al., "Anti-idiotypic Antibodies And The Induction Of Specific Tumor Immunity", in Cancer And Metastasis Reviews, <5:487-501 (1987)].

In addition, the present invention encompasses antibodies that are capable of binding to the same antigenic determinant as the C3 5 antibodies and competing with the antibodies for binding at that site. These include antibodies having the same antigenic specificity as the C35 antibodies but differing in species origin, isotype, binding affinity or biological functions {e.g., cytotoxicity). For example, class, isotype and other variants of the antibodies of the invention having the antigen-binding region of the C3 5 antibody can be constructed using recombinant class-switching and fusion techniques known in the art [see,e.g., Thammana et al, "Immunoglobulin Heavy Chain Class Switch From IgM to IgG In A Hybridoma", Eur. J. Immunol, 13:614 (1983); Spira etal., "The Identification of Monoclonal Class Switch Variants by Subselection and ELISA Assay", /. Immunol Meth. 74:307-15 (1984); Neubergerefa/., "Recombinant Antibodies Possessing Novel Effector Functions", Nature 312:614-608 (1984); andOi etal, "Chimeric Antibodies", Biotechniques 4 (3):214-21 (1986)]. Thus, other chimeric antibodies or other recombinant antibodies (e.g., fusionproteins wherein the antibody is combined with a second protein such as a lymphokine or a tumor a404- inhibitory growth factor) having the same binding specificity as the C35-specific antibodies fell wittiin the scope of this invention.

[0378] Genetic engineering techniques known in the art maybe used as described herein to prepare recombinant immunotoxins produced by fusing antigen binding regions of antibody C35 to a therapeutic or cytotoxic agent at the DNA level and producing the cytotoxic molecule as a chimeric protein. Examples of therapeutic agents include, but are not limited to, antimetabolites, alkylating agents, anthracyclines, antibiotics, and anti-mitotic agents. Antimetabolites include methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine. Alkylating agents include mechlorethamine, thioepa chlorambucil, melphalan, carmustine (BSNU) and lomustine (CCNU), cyclothosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis-dichlorodiamine platinum (13) (DDP) cisplatin. Anthracyclines include daunorubicin (formerly daunomycin) and doxorubicin (also referred to herein as adriamycin). Additional examples include mitozantrone and bisantrene. Antibiotics include dactinomycin (formerly actinomycin), bleomycin, mitbramycin, and anthramycin (AMC). Antimytotic agents include vincristine and vinblastine (which are commonly referred to as vinca alkaloids). Other cytotoxic agents include procarbazine, hydroxyurea, asparaginase, corticosteroids, mytotane (0,P'-(DDD)), interferons. Further examples of cytotoxic agents include, but are not limited to, ricin, doxorubicin, taxol, cytochalasin B, gramicidin D, ethidium bromide, etoposide, tenoposide, colchicin, dihydroxy anthracin dione, 1-dehydrotestosterone, and glucocorticoid.

[0379] • Clearly analogs andhomologs of such therapeutic and cytotoxic agents are encompassed by the present invention. For example, the chemotherapuetic agent aminopterinhas acorrelative improved analognamely methotrexate. Further, the improved analog of doxorubicin is an Fe-chelate. Also, the improved analog for 1-methylnitrosourea is lomustine. Further, the improved analog of vinblastine is vincristine. Also, the improved analog of mechlorethamine is cyclophosphamide. ^ -405-

[0380] Recombinant immunotoxins, particularly single-chain immunotoxins, have an advantage over drug/antibody conjugates in that they are more readily produced than these conjugates, and generate a population of homogenous molecules, i.e. single peptides composed of the same amino acid residues. The techniques for cloning and expressing DNA sequences encoding the amino acid sequences corresponding to C35 single-chain immunotoxins, e.g synthesis of oligonucleotides, PCR, transforming cells, constructing vectors, expression systems, and the like are well-established in the art, and most practitioners, are familiar with the standard resource materials for specific conditions and procedures [see, e.g., Sambrook et al, eds., Molecular Cloning, A Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory Press (1989)].

[0381] The following include preferred embodiments of the immunoconjugates ofthe invention. Other embodiments which are known in the art are encompassed by the invention. The invention is not limited to these specific immunoconjugates, but also includes other immunoconjugates incorporating antibodies and/or antibody fragments according to the present invention.

[0382] The conjugates comprise at least one drug molecule connected by a linker of the invention to a targeting ligand molecule that is reactive with the desired target cell population. The ligand molecule can be an immunoreactive protein such as an antibody, or fragment thereof, a non-irmnunoreactive protein or peptide ligand such as bombesin or, a binding ligand recognizing a cell associated receptor such as a lectin or steroid molecule.

[0383] Further, because the conjugates ofthe invention canbe used for modifying a given biological response, the drug moiety is not to be construed as limited to classical chemical therapeutic agents. For example, the drug moiety may be a protein or polypeptide possessing a desired biological activity. Such proteins may include, for example, a toxin such as abrin, ricin A, pseudomonas exotoxin, or diphtheria toxin; a protein such as tumor necrosis factor, alpha -interferon, beta -interferon, nerve growth factor, platelet derived growth factor, tissue plasminogen activator; or, biological response modifiers such as, for example, lymphokines, interleukin-1 ("IL-1"), interleukin-2 ("IL~2"), interleukin-6 ("IL-6"), granulocyte macrophase colony stimulating factor ("GM-CSF"), granulocyte colony stimulating factor ("G-CSF"), or other growth factors.

[0384] The preferred drugs for use in the present invention are cytotoxic drugs, particularly those which are used for cancer therapy. Such drugs include, in general, alkylating agents, anti-proliferative agents, tubulin binding agents and the like. Preferred classes of cytotoxic agents include, for example, the anthracycline family of drugs, the vinca drugs, the mitomycins, the bleomycins, the cytotoxic nucleosides, the pteridine family of drugs, diynenes, and the podophyllotoxins. Particularly useful members of those classes include, for example, adriamycin, caiminomycin, daunorubicin, aminopterin, methotrexate, methqpterin, dichloromethotrexate, mitomycin C, porfiromycm, 5-fluorouracil, 6-mercaptopurine, cytosine arabinoside, podophyllotoxin, or podophyllotoxin derivatives such as etoposide or etoposide phosphate, melphalan, vinblastine, ■vincristine, leurosidine, vindesine, leurosine and the like. As noted previously, one skilled in the art may make chemical modifications to the desired compound in order to make reactions of that compound more convenient for purposes of preparing conjugates ofthe invention.

[0385] As noted, one skilled in the art will appreciate that the invention also encompasses the use of antigen recognizing immunoglobulin fragments. Such immunoglobulin fragments may include, for example, the Fab', F(ab*)2, F[v ]or Fab fragments, or other antigen recognizing immunoglobulin fragments. Such immunoglobulin fragments can be prepared, for example, by proteolytic enzyme digestion, for example, by pepsin or papain digestion, reductive alkylation, or recombinant techniques. The materials and methods for preparing such immunoglobulin fragments are well-known to those skilled in the art. See generally, Parham, J. Immunology 131:2895 (1983); Lamoyi et al, J. Immunological Methods 56:235 (1983); Parham, id., 53, 133 (1982); and Matthew et al., id., 50,239 (1982).

[0386] The immunoglobulin can be a "chimeric antibody" as that term is recognized in the art. Also, the immunoglobulin may be a Afunctional" or "hybrid" antibody, that is, an antibody which may have one arm having a specificity for one antigenic site, such as a tumor associated antigen while the other arm recognizes a different target, for example, a hapten which is, or to which is bound, an agent lethal to the antigen-bearing tumor cell. Alternatively, the bifunctional antibody may be one hi which each arm has specificity for a different epitope of a tumor associated antigen of the cell to be therapeutically or biologically modified. In any case, the hybrid antibodies have a dual specificity, preferably with one or more binding sites specific for the hapten of choice or one or more binding sites specific for a target antigen, for example, an antigen associated with a tumor, an infectious organism, or other disease state.

[0387] Biological bifunctional antibodies are described, for example, in European Patent Publication, EPA 0105 360, to which those skilled in the art are referred. Such hybrid or bifunctional antibodies may be derived, as noted, either biologically, by cell fusion techniques, or chemically, especially with cross-Unking agents or disulfide bridge-forming reagents, and may be comprised of whose antibodies and/or fragments thereof. Methods for obtaining suchhybrid antibodies are disclosed, for example, inPCT apphcation W083/03679, published Oct. 27,1983, and published European Apphcation EPA 0 217 577, published Apr. 8,1987. Particularly preferred bifunctional antibodies are those biologically prepared from a "polydome" or "quadroma" or which are synthetically prepared with cross-linking agents such as bis-(maleimideo)-methyl ether ("BMME"), or with other cross-linking agents familiar to those skilled in the art.

[0388] In addition the immunoglobulin may be a single chain antibody ("SCA"). These may consist of single chain Fv fragments ("scFv") in which the variable light ("V[L]") and variable heavy ("V[H]") domains are linked by a peptide bridge or by disulfide bonds. Also, the immunoglobulin may consist of single V[H ]domains (dAbs) which possess antigen-binding activity. See, e.g., G. .hb Winter and C. Milstein, Nature 349:295 (1991); R. Glockshuber et al, Biochemistry 29:1362 (1990); and, E. S. Ward et al, Nature 341:544 (1989).

[0389] Especially preferred for use in the present invention are chimeric monoclonal antibodies, preferably those chimeric antibodies having specificity toward a tumor associated antigen. As used in this example, the term "chimeric antibody" refers to a monoclonal antibody comprising a variable region, Le. binding region, from one source or species and at least a portion of a constant region derived from a different source or species, usually prepared by recombinant DNA techniques. Chimeric antibodies comprising amurine variable . region and a human constant region are preferred in certain applications of the invention, particularly human therapy, because such antibodies are readily prepared and may be less immunogenic than purely murine monoclonal antibodies. Suchmurine/human chimeric antibodies are the product of expressed immunoglobulin genes comprising DNA segments encoding murine immunoglobulin variable regions and DNA segments encoding human immunoglobulin constant regions. Other forms of chimeric antibodies encompassed by the invention are those in which the class or subclass has been modified or changed from that of the original antibody. Such "chimeric" antibodies are also referred to as "class-switched antibodies". Methods for producing chimeric antibodies involve conventional recombinantDNA and gene transfection techniques now well known in the art. See, e.g., Morrison, S. L. et al, Proc. Nat'lAcad. Sci. 81:6851 (1984).

[0390] Encompassed by the term "chimeric antibody" is the concept of "humanized antibody", that is those antibodies in which the framework or "complementarity" detemiining regions ("CDR") have been modified to comprise the CDR of an immunoglobulin of different specificity as compared to that of the parent immunoglobulin. In a preferred embodiment, a murine CDR is grafted into the framework region of a human antibody to prepare the "humanized antibody". See, e.g., L. Riechmann et al, Nature 332:323 (1988); M. S. Neuberger et al, Nature 314:26$ (1985). Particularly preferred CDR'S correspond to those representing sequences recognizing the antigens noted above for the chimeric and bifunctional antibodies. The reader is referred to the teaching of EPA 0 239 400 .(published Sep. 30,1987), for its teaching of CDR modified antibodies.

[0391] One skilled in the art will recognize that a bifunctional-chimeric antibody can be prepared which would have the benefits of lower immunogenicity of the chimeric or humanized antibody, as well as the flexibility, especially for therapeutic treatment, of the bifunctional antibodies described above. Such bifunctional-chimeric antibodies can be synthesized, for instance, by chemical synthesis using cross-linking agents and/or recombinant methods of the type described above. In any event, the present invention should not be construed as limited in scope by any particular method of production of an antibody whether bifunctional, chimeric, bifunctional-chimeric, humanized, or an antigen-recognizing fragment or derivative thereof.

[0392] hi addition, the invention encompasses within its scope immunoglobulins (as defined above) or immunoglobulin fragments to which are fused active proteins, for example, an enzyme of the type disclosed in Neuberger, et al., PCT application, W086/01533, published Mar. 13, 1986. The disclosure of such products is incorporated herein by reference.

[0393] As noted, "bifunctional", "fused", "chimeric" (includinghumanized), and "bifunctional-chimeric" (including humanized) antibody constructions also include, within their individual contexts constructions comprising antigen recognizing fragments. As one skilled in the art will recognize, such fragments could be prepared by traditional enzymatic cleavage of intact bifunctional, chimeric, humanized, or chimeric-bifunctional antibodies. If, however, intact antibodies are not susceptible to such cleavage, because of the nature of the construction involved, the noted constructions can be prepared with immunoglobulin fragments used as the starting materials; or, if recombinant techniques are used, the DNA sequences, themselves, can be tailored to encode the desired "fragment" which, when expressed, can be combined in vivo or in vitro, by chemical or biological means, to prepare the final desired intact immunoglobulin "fragment". It is in this context, therefore, that the term "fragment" is used. {0394] Furthermore, as noted above, the immunoglobulin (antibody), or fragment thereof, used in the present invention may be polyclonal or monoclonal in nature. Monoclonal antibodies are the preferred immunoglobulins, however. The preparation of such polyclonal or monoclonal antibodies now is well known to those skilled in the art who, of course, are fully capable of producing useful immunoglobulins which can be used in the invention. See, e.g., G. Kohler and C. Milstein, Nature 256: 495 (1975). In addition, hybridomes and/or monoclonal antibodies which are produced by such hybridomas and which are useful in the practice of the present invention are publicly available from sources such as the American Type Culture Collection ("ATCC") 10801 University Blvd., Manassas, VA. 20110.

[0395] Particularly preferred monoclonal antibodies for use in the present invention are those which recognize tumor associated antigens.

Diagnostic Techniques

[0396] Serologic diagnostic techniques involve the detection and quantitiation of tumor-associated antigens that have been secreted or "shed" into the serum or other biological fluids of patients thought to be suffering from carcinoma. Such antigens can be detected in the body fluids using techniques known in the art such as radioimmunoassays (RIA) or enzyme-linked immunosorbent assays (ELISA) wherein an antibody reactive with the "shed" antigen is used to detect the presence of the antigen in a fluid sample [see, e.g., Uotila et al., "Two-Site Sandwich ELISA With Monoclonal Antibodies To Human AFP", J. Immunol. Methods 42:11 (1981) and Allum et al, supra at pp. 48-51]. These assays, using the C35 antibodies disclosed herein, can therefore be used for the detection in biological fluids of the antigen with which the C35 antibodies react and thus the detection of human carcinoma in patients. Thus, it is apparent from the foregoing *411- that the C35 antibodies of the invention can be used in most assays involving antigen-antibody reactions. These assays include, but are not limited to, standard RLA. techniques, both liquid and solid phase, as well as ELISA assays, ELISPOT, immunofluorescence techniques, and other immunocytochernical assays [see, e.g., Sikora et al. (eds.), Monoclonal Antibodies, pp. 32-52 (Blackwell Scientific Publications 1984)].

[0397] The invention also encompasses diagnostic kits for carrying out the assays described above. In one embodiment, the diagnostic kit comprises the C35 monoclonal antibody, fragments thereof; fusion proteins or chimeric antibody of the invention, and a conjugate comprising a specific binding partner for the C35 antibody and a label capable of producing a detectable signal. The reagents can also include ancillary agents such as buffering agents and protein stabilizing agents (e.g., polysaccharides). The diagnostic kit can further comprise, where necessary, other components ofthe signal-producing system including agents for reducing background interference, control reagents or an apparatus or container for conducting the test.

[0398] In another embodiment, the diagnostic kit comprises a conjugate of the C35 antibodies of the invention and a label capable of producing a detectable single. Ancillary agents as mentioned above can also be present.

[0399] The C35 antibody of the invention is also useful for in vivo diagnostic applications for the detection of human carcinomas. One such approach involves the detection of tumors in vivo by tumor imaging techniques. According to this approach, the C35 antibody is labeled with an appropriate imaging reagent that produces a detectable signal. Examples of imaging reagents that can be used include, but at not limited to, radiolabels such as <131> \ <111> In, <123> I, <99m> Tc, <32> P, <125> I, <3> H, and <14> C, fluorescent labels such as fluorescein and rhodamine, and chemiluninescers such as luciferin. The antibody can be labeled with such reagents using techniques known in the art. For example, see Wensel and Meares, Radioimmunoimaging And Radioimmunotherapy, Elsevier, New York (1983) for techniques relating to the 1412- radiolabeling of antibodies [see also, Colcher et al.', "Use of Monoclonal Antibodies as Radiopharmaceuticals for Hie Localization of Human Carcinoma Xenografts in Athymic Mice", Meth. Enzymol. 121:802-16 (1986)].

[0400] In the case of radiolabeled antibody, the antibody is administered to the patient, localizes to the tumor bearing the antigen with which the antibody reacts, and is detected or "imaged" in vivo using known techniques such as radionuclear scanning using, e.g., a gamma camera or emission tomography [see, e.g., Bradwell et al., "Developments In Antibody Imaging", in Monoclonal Antibodies ^ for Cancer Detection and Therapy, Baldwin, et al. (eds.), pp. 65-85 (Academic Press 1985)]. the antibody is administered to the patient in a pharmaceutically acceptable carrier such as water, saline, Ringer's solution, Hank's solution or nonaqueous carriers such as fixed oils. The carrier may also contain substances that enhance isotonicily and chemical stability ofthe antibody such as buffers or preservatives. The antibody formulation is administered, for example, intravenously, at a dosage sufficient to provide enough gamma emission to allow visualization of the tumor target site. Sufficient time should be allowed between . administration of the antibody and detection to allow for localization to the tumor target. For a general discussion of tumor imaging, see Allum et al, supra, at pp. 51-55.

Therapeutic Applications of C35 Antibodies

[0401] The properties of the C35 antibody suggest a number of in vivo therapeutic applications.

[0402] First, the C35 antibody can be used alone to target and kill tumor cells in vivo. The antibody can also be used in conjunction with an appropriate therapeutic agent to treat human carcinoma. For example, the antibody can be used in combination with standard or conventional treatment methods such as chemotherapy, radiation therapy or can be conjugated or linked to a therapeutic •4413- drag, or toxin, as well as to a lymphokine or a tumor-inhibitory growth factor, for delivery of the therapeutic agent to the site of the carcinoma.

[0403] Techniques for conjugating such therapeutic agents to antibodies are well known [see, e.g., Arnon et al., "Monoclonal Antibodies for Immunotargeting of Drugs in Cancer Therapy", in Monoclonal Antibodies and Cancer Therapy, Reisfeld et al (eds.), pp. 243-56 (Alan R. Liss, Inc. 1985); Hellstrom et al., "Antibodies For Drug Delivery", in Controlled Drug Delivery (2nd Ed.), Robinson etal. (eds.), pp. 623-53 (Marcel Dekker, Inc. 1987); Thorpe, "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review", in Monoclonal Antibodies '84: Biological And Clinical Applications, Pinchera et al. (eds.), pp. 475-506 (1985); and Thorp eetal., "The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates", Immunol. Rev., 62:119-58 (1982)].

[0404] Alternatively, the C35 antibody can be coupled to high-energy radiation, e.g., a radioisotope such as <131> I, which, when localized at the tumor site, results in a killing of several cell diameters [see, e.g., Order, "Analysis, Results, and Future Prospective of The Therapeutic Use of Radiolabeled Antibody in Cancer Therapy", in Monoclonal Antibodies For Cancer Detection And Therapy, Baldwin et al. (eds.), pp. 303-16 (Academic Press 1985)]. According to yet another embodiment, the C35 antibody can be conjugated to a second antibody to form an antibody heteroconjugate for the treatment of tumor cells as described by Segal in U.S. Pat. No. 4,676,980.

[0405] Still other therapeutic applications for the C35 antibody of the invention include conjugation or linkage, e.g., by recombinant DNA techniques, to an enzyme capable of converting a prodrug into a cytotoxic drug and the use of that antibody-enzyme conjugate in combination with the prodrug to convert the prodrug to a cytotoxic agent at the tumor site [see, e.g., Senter et al., "Anti-Tumor Effects of Antibody-alkaline Phosphatase", Proc. Natl. Acad. Sci. USA 85:4842-46(1988); "Enhancement ofthe in vitro and in vivo Antitumor Activites of Phosphorylated Mitocycin C and Etoposide Derivatives by Monoclonal Antibody-Alkaline Phosphatase Conjugates", Cancer Research 49:5789-5792 (1989); and Senter, "Activation of Prodrugs by Antibody-Enzyme Conjugates: A New Approach to Cancer Therapy," FASEB J. 4:188-193 (1990)]. .[0406] Still another therapeutic use for the C35 antibody involves use, either in the presence of complement or as part of an antibody-drug or antibody-toxin conjugate, to remove tumor cells from the bone marrow of cancer patients. According to this approach, autologous bone marrow may be purged ex vivo by treatment with the antibody and the marrow infused back into the patient [see, e.g., Ramsay et al., "Bone Marrow Purging Using Monoclonal Antibodies", J. Clin. Immunol., 8(2):81-88 (1988)].

[0407] Furthermore, chimeric C35, recombinant immunotoxins and other recombinant constructs of the invention containing the specificity of the antigen-binding region of the C3 5 monoclonal antibody, as described earlier, may be used therapeutically. For example, the single-chain immunotoxins of the invention, may be used to treat human carcinoma in vivo.

[0408] Similarly, a fusion protein comprising at least the antigen-binding region ofthe C35 antibody joined to at least a functionally active portion of a second protein having anti-tumor acitivty, e.g., a lymphokine or oncostatin can be used to treat human carcinoma in vivo. Furthermore, recombinant techniques known in the art can be used to construct bispecific antibodies wherein one of the binding specificities of the antibody is that of C35, while the other binding specificty of the antibody is that of a molecule other than C35.

[0409] Finally, anti-idiotypic antibodies of the C35 antibody may be used therapeutically in active tumor immunization and tumor therapy [see, e.g., Hellstrom et al., "Immunological Approaches To Tumor Therapy: Monoclonal Antibodies, Tumor Vaccines, And Anti-Idiotypes", in Covalently Modified Antigens And Antibodies In Diagnosis And Therapy, supra at pp. 35-41],

[0410] Also described is a method for selectivelykilling tumor cells expressing the antigen that specifically binds to the C35 monoclonal antibody or functional equivalent. This method comprises reacting the immunoconjugate (e.g.

INTELLECTUAL PROPERTY OFFICE OF N.2. ^415- tlie immuJiotoxiii) ofthe invention with said tumor cells. These tumor cells may he from a human carcinoma. 10411] Also described is a method of treating carcinomas (for example human carcinomas) in vivo. This method comprises administering to a subject a pharmaceutically effective amount of a composition containing at least one of the immunoconjugates (e.g. the immunotoxin) of the invention.

[0412] The subject may be a human, equine, porcine, bovine, murine, canine, feline, and avian subjects. Other warm blooded animals are also included.

[0413] Also described is a method for curing a subject suffering from a cancer. The subject maybe a human, dog, cat, mouse, rat, rabbit, horse, goat, sheep, cow, chicken. The cancer may be identified as a breast, bladder, retinoblastoma, papillary cystadenocarcinoma of the ovary, Wilm's tumor, or small cell lung carcinoma and is generally characterized as a group of cells having tumor associated antigens on the cell surface. This method comprises administering to the subj ect a cancer killing amount of a tumor targeted antibody joined to a cytotoxic agent. Generally, the joining of the tumor targeted antibody with the cytotoxic agent is made under conditions which permit the antibody so joined to bind its target on the cell surface. By binding its target, the tumor targeted antibody acts directly or indirectly to cause or contribute to the killing of the cells so bound (hereby curing the subject.

[0414] Also described is a method of inhibiting the proliferation of mammalian tumor cells which comprises contacting the mammalian tumor cells with a sufficient concentration of the immunoconjugate of the invention so as to inhibit proliferation of the mammalian tumor cells.

[0415] Also described are methods for inhibiting the growth of human tumor cells, treating a tumor in a subject, and treating a proliferative type disease in a subject. These methods comprise administering to the subject an effective amount of the composition ofthe invention.

[0416] It is apparent therefore that the present invention encompasses pharmaceutical compositions, combinations and methods for treating human carcinomas. For example, the invention includes pharmaceutical compositions for use in the treatment of human carcinomas comprising a pharmaceutically effective amount of a C35 antibody and a pharmaceutically acceptable carrier.

[0417] The compositions may contain the C35 antibody or antibody fragments, either unmodified, conjugated to a therapeutic agent (e.g., drug, toxin, enzyme or second antibody) or in a recombinant form (e.g., chimeric C35, fragments of chimeric C35, bispecific C35 or single-chain immunotoxin C35). The compositions may additionally include other antibodies or conjugates fortreating carcinomas (e.g., an antibody cocktail).

[0418] The antibody, antibody conjugate and immunotoxin compositions of the invention can be administered using conventional modes of administration including, but not limited to, intravenous, intraperitoneal, oral, intralymphatic or administration directly into the tumor. Intravenous administration is preferred.

[0419] The compositions of the invention may be in a variety of dosage forms which include, but are not limited to, liquid solutions or suspension, tablets, pills, powders, suppositories, polymeric microcapsules or microvesicles, liposomes, and injectable or infusible solutions. The preferred form depends upon the mode of administration and the therapeutic application.

J0420] The compositions of the invention also preferably include conventional pharmaceutically acceptable carriers and adjuvants known in the art such as human serum albumin, ion exchangers, alumina, lecithin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, and salts or electrolytes such as protamine sulfate.

[0421]. The most effective mode of administration and dosage regimen for the compositions of this invention depends upon the severity and course of the disease, the patient's health and response to treatment and the judgment of the treating physician. Accordingly, the dosages of the compositions should be titrated to the individual patient. Nevertheless, an effective dose of the compositions of this invention may be in the range of from about 1 to about 2000 mg/kg. {0422] The molecules described herein may be in a variety of dosage forms which include, but are not limited to, liquid solutions or suspensions, tablets, pills, powders, suppositories, polymeric microcapsules or microvesicles, liposomes, and injectable or infusible solutions. The preferred form depends upon the mode of adxnixiistration and the therapeutic application.

[0423] The most effective mode of administration and dosage regimen for the molecules of the present invention depends upon the location of the tumor being treated, the severity and course ofthe cancer, the subject's health and response to treatment and the judgment of the treating physician. Accordingly, the dosages of the molecules should be titrated to the individual subject.

[0424] The interrelationship of dosages for animals of various sizes and species and humans based on mg/kg of surface area is described by Freireich, E. J., et al. Cancer Chemother., Rep. 50 (4): 219-244 (1966). Adjustments in the dosage regimen may be made to optimize the tumor cell growth inhibiting and killing response, e.g., doses maybe divided and administered on a daily basis or the dose reduced proportionally depending upon die situation (e.g., several divided doses may be administered daily or proportionally reduced depending on the specific therapeutic situation.

[0425] It would be clear that the dose of the composition of the invention required to achieve cures may be further reduced with schedule optimization.

[0426] In accordance with the practice of the invention, the pharmaceutical carrier maybe a lipid carrier. The lipid carrier may be a phospholipid. Further, the lipid carrier may be a fatty acid. Also, the lipid carrier may be a detergent. As used herein, a detergent is any substance that alters the surface tension of a liquid, generally lowering it.

[0427] In one example of the invention, the detergent may be a nonionic detergent Examples of nonionic detergents include, but are not limited to, polysorbate 80 (also known as Tween 80 or (polyoxyethylenesorbitan monooleate), Brij, and Triton (for example Triton WR-1339 and Triton A-20).

[0428] Alternatively, the detergent may be an ionic detergent. An example of an ionic detergent includes, but is not limited to, alkyltrimethylammonium bromide.

[0429] Additionally, in accordance with the invention, the lipid carrier may be a liposome. As used in this application, a "liposome" is any membrane bound vesicle which contains any molecules of the invention or combinations thereof.

Vaccine Formulations

[0430] The C35 epitopes can be produced in quantity by recombinant DNA methods and formulated with an adjuvant that promotes a cell-mediated immune response. The present invention encompasses the expression of the C35 polypeptides, or C35 epitopes (including cytotoxic or helper T cell eliciting epitopes), in either eucaryotic or procaryotic recombinant expression vectors; and the formulation of the same as immunogenic and/or antigenic compositions. Such compositions are described in, for example, U.S. Patent Appl. No. 08/935,377, the entire contents of which are incorporated herein by reference. In accordance with the present invention, the recombinantly expressed C35 epitope may be expressed, purified and formulated as a subunit vaccine. Preferably, the DNA encoding the C3 5 epitope may also be constructed into viral vectors, preferably pox virus, adenovirus, herpesvirus, and alphavirus vectors, for use in vaccines. In this regard, either a live recombinant viral vaccine, an inactivated recombinant viral vaccine, or a killed recombinant viral vaccine can be formulated. (i) Expression of C35 in Procaryotic and Eucaryotic Expression Systems

[0431] The present invention encompasses expression systems, both eucaryotic and procaryotic expression vectors, which may be used to express the C35 .=##19- epitope. The C35 epitope may be expressed in both truncated or full-length forms, in particular for the formation of subunit vaccines. ,.[0432] The present invention encompasses the expression of nucleotide sequences encoding the C35 polypeptide and immunologically equivalent fragments. Such immunologically equivalent fragments may be identified by making analogs of the nucleotide sequence encoding the identified epitopes that are truncated at the 5' and/or 3' ends of the sequence and/or have one or more internal deletions, expressing the analog nucleotide sequences, and determining whether the resulting fragments immunologically are recognized by the epitope-specific T lymphocytes and induce a cell-mediated immune response, or epitope-specific B lymphocytes for inductions of a humoral immune response.

[0433] The invention encompasses the DNA expression vectors that contain any of the foregoing coding sequences operatively associated with a regulatory element that directs expression of the coding sequences and genetically engineered host cells that contain any of the foregoing coding sequences operatively associated with a regulatory element that directs the expression ofthe coding sequences in the host cell. As used herein, regulatory elements include but are not limited to, inducible and non-inducible promoters, enhancers, operators and other elements known to those skilled in the art that drive and regulate expression.

[0434] The C35 epitope gene products or peptide fragments thereof, may be produced by recombinant DNA technology using techniques well known in the art. Thus, methods for preparing the C35 epitope gene polypeptides and peptides of the invention by expressing nucleic acid containing epitope gene sequences are described herein. Methods which are well known to those skilled in the art can be used to construct expression vectors containing epitope gene product coding sequences and appropriate transcriptional and translational control signals. These methods include, for example, in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. See, for example, the techniques described in Sambrook et al, Molecular Cloning: A Laboratory Manual, 2nd EcL, ^420- (1989), Cold Spring Harbor Laboratory Press, and Ausubel et al., 1989, supra. Alternatively, RNA capable of encoding glycoprotein epitope gene product sequences maybe chemically synthesized using, for example, synthesizers. See, for example, the techniques described in "Oligonucleotide Synthesis", 1984, Gait, M.J. ed., IRL Press, Oxford, which is incorporated by reference herein in its entirety.

[0435] The invention also encompasses nucleotide sequences that encode peptide fragments of the C35 epitope gene products. For example, polypeptides or peptides corresponding to the extracellular domain of the C35 epitope may be useful as "soluble" protein which would facilitate secretion, particularly useful in the production of subunit vaccines. The C35 epitope gene product or peptide -fragments thereof, can be linked to a heterologous epitope that is recognized by a commercially available antibody is also included in the invention. A durable fusion protein may also be engineered; i.e., a fusion protein which has a cleavage site located between the C35 epitope sequence and the heterologous protein sequence, so that the selected C35 can be cleaved away from the heterologous moiety. For example, a collagenase cleavage recognition consensus sequence may be engineered between the C35 epitope protein or peptide and the heterologous peptide or protein. The epitopic domain can be released from this fusion protein by treatment with collagenase. In a preferred embodiment of the invention, a fusion protein of glutathione-S-transferase and the C35 epitope protein may be engineered.

[0436] The C35 epitope proteins of the present invention for use in vaccine preparations, in particular subunit vaccine preparations, are substantially pure or homogeneous. The protein is considered substantially pure or homogeneous when at least 60 to 75% ofthe sample exhibits a single polypeptide sequence. A substantially pure protein will preferably comprise 60 to 90% of a protein sample, more preferably about 95% and most preferably 99%. Methods which are well known to those skilled in the art can be used to determine protein purity or homogeneity, such as polyacrylamide gel electrophoresis of a sample, followed by visualizing a single polypeptide band on a staining gel. Higher resolutionmay be determined using HPLC or other similar methods well known in the art. v[0437] The present invention encompasses C35 polypeptides which are typically purified from host cells expressing recombinant nucleotide sequences encoding these proteins. Such protein purification can be accomplished by a variety of methods well known in the art. In a preferred embodiment, the C35 epitope protein ofthe present invention is expressed as a fiision protein with glutathione-S-transferase. The resulting recombinant fusion proteins purified by affinity chromatography and the epitope protein domain is cleaved away from the heterologous moiety resulting in a substantially pure protein sample. Other methods known to those skilled in the art may be used; see for example, the techniques described in "Methods In Enzymology", 1990, Academic Press, Inc., San Diego, "Protein Purification: Principles and Practice", 1982, Springer-Verlag, New York, which are incorporated by reference herein in their entirety. (ii) Eucaryotic and Procaryotic Expression Vectors

[0438] The present invention encompasses expression systems, both eucaryotic and procaryotic expression vectors, which may be used to express the C35 epitope. A variety of host-expression vector systems may be utilized to express the C35 epitope gene of the invention. Such host-expression systems represent vehicles by which the C35 coding sequence may be produced and subsequently purified, but also represent cells which may, when transformed or transfected with the C35 nucleotide coding sequences, exhibit the C35 epitope gene product ofthe invention in situ. These include but are not limited to microorganisms such as bacteria (e.g., E.'coli, B. subtilis) transformed with recombinant bacteriophage DNA plasmid DNA or cosmid DNA expression vectors containing the C35 epitope gene product coding sequence; yeast (e.g., Saccharomyces, Pichia) transformed with recombinant yeast expression vectors containing the C35 epitope gene product coding sequence; insect cell systems infected with recombinant virus expression vectors (e.g., baculovirus) containing the C35 epitope gene product coding sequence; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing C35 epitope gene product coding sequence; or mammalian cell systems (e.g., COS, CHO, BHK, 293, 3T3) harboring recombinant expression constructs containing promoters derived from the genome of mammalian cells (e.g., metallotbionein promoter) or from mammalian viruses (e.g., the adenovirus late promoter; the vaccinia virus 7.5K promoter). (iii) Host Cells The present invention encompasses the expression of the C35 epitope in animal and insect cell lines. In a preferred embodiment of the present invention, the C35 epitope is expressed in a baculovirus vector in an insect cell line to produce an unglycosylated antigen. In another preferred embodiment of the invention, the C35 epitope is expressed in a stably transfected mammalian host cell, e.g., CHO cell line to produce a glycosylated antigen. The C35 epitopes which are expressed recombinantly by these cell lines may be formulated as subunit vaccines. The present invention is further directed to host cells that overexpress the C35 gene product. The cell may be a host cell transiently or stable transected or transformed with any suitable vector which includes a polynucleotide sequence encoding the C35 polypeptide or a fragment thereof and suitable promoter and enhancer sequences to direct overexpression of the C35 gene product. However, the overexpressing cell may also be a product of an insertion, for example via homologous recombination, of a heterologous promoter or enhancer which will direct overexpression of the endogenous C35 gene. The term "overexpression" refers to a level of expression which is higher than a basal \ level of expression typically characterizing a given cell under otherwise identical conditions. ,[0440] A host cell strain may be chosen which modulates the expression of the inserted sequences, or modifies and processes the C35 gene product in the specific fashion desired. Such modifications (e.g., glycosylation) and processing (e.g. cleavage) of protein products may be important for the function of the protein. Different host cells have characteristic and specific mechanisms for the post-translational processing and modification of proteins and gene products. Appropriate cell lines or host systems can be chosen to ensure the correct modification of the foreign protein expressed. To this end, eucaryotic host cells which possess the cellular machinery for proper processing of the primary transcript, glycosylation, phosphorylation, and prenylation of the C35 gene product may be used. Such mammalian host cells include but are not limited to CHO, VERO, BHK, HeLa, COS, MDCK, 293,3T3 and WI38 cell lines.

[0441] For long term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which stably express the C35 target epitope may be engineered. Rather than using expression vectors which contain viral origins of replication, host cells can be transformed with DNA controlled by appropriate expression control elements (e.g., promoter, enhancer, sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker. Following the introduction of the foreign DNA, engineered cells maybe allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media. The selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci which in turn can be cloned and expanded into cell lines. This method may advantageously be used to engineer cell lines. This method may advantageously be used to engineer cell lines which express the C35 epitope gene products. Such cell lines would be particularly useful in screening and evaluation of compounds that affect the endogenous activity of the C35 epitope gene product M24-

[0442] A number of selection systems may be used, including but not limited to the herpes simplex virus thymidine kinase (Wigler, et al, 1977, Cell 11:223), I hypoxanthine-guanine phosphoribosyltransferase (Szybalska & Szybalski, 1962, Proc. Natl. Acad. Sci. USA 48:2026), and adenine phosphoribosyltransferase (Lowy, et al., 1980, Cell 22:817) genes can be employed in tk", hgprt' or aprt" cells, respectively. Also, antimetabolite resistance can be used as the basis of selection for the following genes: dhfr, which confers resistance to methotrexate (Wigler, et al., 1980, Proc. Natl. Acad. Sci. USA 77:3567; OUare, et al., 1981, Proc. Natl. Acad. Sci. USA 75:1527); gpt, which confers resistance to mycophenolic acid (Mulligan & Berg, 1981, Proc. Natl. Acad. Sci. USA 78:2072); neo, which confers resistance to the aminoglycoside G-418 (Colberre-Garapin, et al., 1981, J. Mol. Biol. 150:1); and hygro, which confers resistance to hygromycin(Santerre, etal, 1984, Gene30:147).

[0443] Alternatively, any fusion protein may be readily purified by utilizing an antibody specific for the fusion protein being expressed. For example, a system described by Janknecht et al allows for the ready purification of non-denatured fusion proteins expressed in human cell lines (Janknecht, etal, 1991,Proc. Natl Acad. Set USA 88:8972-8976). In this system, the gene of interest is subcloned into a vaccinia recombination plasmid such that the gene's open reading frame is translationally fused to an ammo-terminal tag consisting of six histidine residues. Extracts from cells infected with recombinant vaccinia virus are loaded onto Ni2+*nitriloacetic acid-agarose columns and histidine-tagged proteins are selectively eluted with imidazole-containing buffers. (iv) Expression of C35 Epitope in Recombinant Viral Vaccines

[0444] In another embodiment ofthe present invention, either a live recombinant viral vaccine or an inactivated recombinant viral vaccine expressing the C35 epitope can be engineered. A live vaccine may be preferred because multiplication in the host leads to a prolonged stimulus of similar kind and ^425- magnitude to that occurring in natural infections, and therefore, confers substantial, long-lasting immunity. Production of such live recombinant virus vaccine formulations maybe accomplished using conventional methods involving propagation of the virus in cell culture or in the allantois of the chick embryo followed by purification.

[0445] . In this regard, a variety of viruses may be genetically engineered to express the C35 epitope. For vaccine purposes, it may be required that the recombinant viruses display attenuation characteristics. Current live virus vaccine candidates for use in humans are either cold adapted, temperature sensitive, or attenuated. The introduction of appropriate mutations (e.g., deletions) into the templates used for transfection may provide the novel viruses with attenuation characteristics. For example, specific multiple missense mutations that are associated with temperature sensitivity or cold adaptation can be made into deletion mutations and/or multiple mutations can be introduced into individual viral genes. These mutants should be more stable than the cold or temperature sensitive mutants containing single point mutations and reversion frequencies should be extremely low. Alternatively, recombinant viruses with "suicide" characteristics maybe constructed. Such viruses go through only one or a few rounds of replication in the host.

[0446] For purposes ofthe invention, any virus may be used in accordance with the present invention which: (a) displays an attenuated phenotype or may be engineered to display attenuated characteristics; (b) displays a tropism for mammals, in particular humans, or maybe engineered to display such a tropism; and (c) may be engineered to express the C35 epitope of the present invention.

[0447] Vaccinia viral vectors may be used in accordance with the present invention, as large fragments of DNA are easily cloned into its genome and recombinant attenuated vaccinia variants have been described (Meyer, et al., 1991, J. Gen. Virol. 72:1031-1038). Orthomyxoviruses, including influenza; Paramyxoviruses, including respiratory syncytial virus and Sendai virus; and Rhabdoviruses maybe engineered to express mutations whichresult in attenuated phenotypes (see U.S. Patent Serial No. 5,578,473, issued November 26,1996). These viral genomes may also be engineered to express foreign nucleotide sequences, such as the C35 epitopes of the present invention (see U.S. Patent Serial No. 5,166,057, issued November 24, 1992, incorporated herein by reference in its entirety). Reverse genetic techniques can be applied to manipulate negative and positive strand RNA viral genomes to introduce mutations which result in attenuated phenotypes, as demonstrated in influenza virus, Herpes Simplex virus, cytomegalovirus and Epstein-Barr virus, Sindbis virus and poliovirus (see Palese et al., 1996, Proc. Natl. Acad. Sci. USA 93:11354-11358). These techniques may also be utilized to introduce foreign DNA i-e-> the C35 epitopes, to create recombinant viral vectors to be used as vaccines in accordance with the present invention. See, for instance, U.S. Patent Appl. No. 08/935,377, the entire contents of which are incorporated herein by reference. In addition, attenuated adenoviruses and retroviruses may be engineered to express the C35 epitope. Therefore, a wide variety of viruses may be engineered to design the vaccines of the present invention, however, by way of example, and not by limitation, recombinant attenuated vaccinia vectors expressing the C35 epitope for use as vaccines are described herein. [0448] In one embodiment, a recombinant modified vaccinia variant, Modified Virus Ankara (MVA) is used in a vaccine formulation. This modified virus has been passaged for 500 cycles in avian cells and is unable to undergo a full infectious cycle in mammalian cells (Meyer, et al., 1991, J. Gen. Virol. 72:1031-1038). When used as a vaccine, the recombinant virus goes through a single replication cycle and induces a sufficient level of immune response but does not go further in the human host and cause disease. Recombinant viruses lacking one or more of essential vaccinia virus genes are not able to undergo successive rounds of replication. Such defective viruses can be produced by co-transfecting vaccinia vectors lacking a specific gene(s) required for viral replication into cell lines which permanently express this gene(s). Viruses lacking an essential gene(s) will be replicated in these cell lines but when administered to the human host will not be able to complete a round of replication. Such preparations may transcribe and translate—in this abortive cycle — a sufficient number of genes to induce an immune response.

[0449] Alternatively, larger quantities of the strains can be administered, so that these preparations serve as inactivated (killed) virus, vaccines. For inactivated vaccines, it is preferred that the heterologous C35 gene product be expressed as a viral component, so that the C35 gene product is associated with the virion. The advantage of such preparations is that they contain native proteins and do not undergo inactivation by treatment with formalin or other agents used in the manufacturing of killed virus vaccines.

[0450] In another embodiment of the invention, inactivated vaccine formulations are prepared using conventional techniques to "kill" the recombinant viruses. Inactivated vaccines are "dead" in the sense that their infectivity has been destroyed. Ideally, the infectivity of the virus is destroyed without affecting immunogenicity. In order to prepare inactivated vaccines, the recombinant virus may be grown in cell culture or in the allantois of the chick embryo, purified by zonal ultracentrifugation, inactivated by formaldehyde or P-propiolactone, and pooled The resulting vaccine is usually inoculated intramuscularly.

[0451] Inactivated viruses may be formulated with a suitable adjuvant in order to enhance the immunological response. Such adjuvants may include but are not limited to mineral gels, e.g., aluminum hydroxide; surface active substances such as lysolecithin, pluronic polyols, polyanions; peptides; oligonucleotides, oil emulsions; and potentially useful human adjuvants such as BCG and Corynebacterium parvum. (v) Methods of Treatment and/or Vaccination

[0452] Since the C35 epitopes of the present invention can be produced in large amounts, the antigen thus produced and purified has use in vaccine preparations. The C35 epitope maybe formulated into a subunit vaccine preparation, or may be engineered into viral vectors and formulated into vaccine preparations. Alternatively, the DNA encoding the C35 epitope may be administered directly as a vaccine formulation. The "naked" plasmid DNA once administered to a subject invades cells, is expressed, processed into peptide fragments, some of which can be presented in association with MHC molecules on the surface of the invaded cell, and elicits a cellular immune response so that T lymphocytes will attack cells displaying the C35 epitope. The C35 epitope also has utility in diagnostics, e.g., to detect or measure in a sample of body fluid from a subject the presence of tumors that express C35 or the presence of antibodies or T cells that have been induced by C35 expressing tumor and thus to diagnose cancer and tumors and/or to monitor the cellular immune response ofthe subject subsequent to vaccination

[0453] The recombinant viruses of the invention can be used to treat tumor-bearing mammals, including humans, to generate an immune response against the tumor cells. The generation of an adequate and appropriate immune response leads to tumor regression in vivo. Such "vaccines" can be used either alone or in combination with other therapeutic regimens, including but not limited to chemotherapy, radiation therapy, surgery, bone marrow transplantation, etc. for the treatment of tumors. For example, surgical or radiation techniques could be used to debulk the tumor mass, after which, the vaccine formulations of the invention can be administered to, ensure the regression and prevent the progression of remaining tumor masses or micrometastases in the body. Alternatively, administration ofthe "vaccine" can precede such surgical, radiation or chemotherapeutic treatment.

[0454] Alternatively, the recombinant viruses of the invention can be used to immunize or "vaccinate" tumor-free subjects to prevent tumor formation. With the advent of genetic testing, it is now possible to predict a subject's predisposition for certain cancers. Such subjects, therefore, may be immunized using a recombinant vaccinia virus expressing the C35 antigen.

[0455] The immunopotency of the C35 epitope vaccine formulations can be determined by monitoring the immune response in test animals following immunization or by use of any immunoassay known in the art. Generation of a cell-mediated and/or humoral immune response may be taken as an indication of an immune response. Test animals may include mice, hamsters, dogs, cats, monkeys, rabbits, chimpanzees, etc., and eventually human subjects.

[0456] Suitablepreparationsofsuchvaccinesincludeinjectables,eitherasliquid solutions or suspensions; solid forms suitable for solutionin, suspension in, liquid priorto injection, may also beprepared. The preparation may also be emulsified, or the polypeptides encapsulated in liposomes. The active immunogenic ingredients are often mixed with excipients which are pharmaceutically acceptable and compatible with the active ingredient. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol, or the like and combinations thereof. In addition, if desired, the vaccine preparation may also include minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, and/or adjuvants which enhance the effectiveness of the vaccine.

[0457] Examples of adjuvants which may be effective, include, but are not limited to: aluminum hydroxide, N-acetyl-muramyl-L-threonyl-D-isoglutamihe (thr-MDP), N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine, N-acetylmuramyl-D-alanyl-D-isoglutaminyl-L-alanine-2-(r-2'-dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)-ethylamine, GM-CSF, QS-21 (investigational drug, Progenies Pharmaceuticals,Inc.), DETOX (investigational drug, Ribi Pharmaceuticals), BCG, and CpG rich oligonucleotides.

[0458] The effectiveness of an adjuvant may be determined by measuring the induction of the cellular immune response directed against the C35 epitope.

[0459] The vaccines of the invention may be multivalent or univalent. Multivalent vaccines are made from recombinant viruses that direct the expression of more than one antigen. Multivalent vaccines comprised of multiple T cell epitopes, both cytotoxic and helper, are preferred.

[0460] The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. The composition can be a liquid solution, suspension, emulsion, tablet, pill, capsule, sustained release formulation, or powder. Oral formulation can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc.

[0461] Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent. Where the composition is administered by inj ection, an ampoule of sterile diluent canbe provided so that the ingredients may be mixed prior to administration.

[0462] In a specific embodiment, a lyophilized C35 epitope ofthe invention is provided in a first container; a second container comprises diluent consisting of an aqueous solution of 50% glycerin, 0.25% phenol, and an antiseptic (e.g., 0.005% brilliant green).

[0463] Use of purified C35 antigens as vaccine preparations can be carried out by standard methods. For example, the purified C35 epitopes should be adjusted to an appropriate concentration, formulated with any suitable vaccine adjuvant and packaged for use. Suitable adjuvants may include, but are not limited to: mineral gels, e.g., aluminum hydroxide; surface active substances such as lysolecithin, pluronic polyols; polyanions; peptides; oil emulsions; alum, and MDP. The immunogen may also be incorporated into liposomes, or conjugated to polysaccharides and/or other polymers for use in a vaccine formulation. In instances where the recombinant antigen is a hapten, i.e., a molecule that is antigenic in that it can react selectively with cognate antibodies, but not immunogenic in that it cannot elicit an immune response, the hapten may be covalently bound to a carrier or immunogenic molecule; for instance, a large protein such as serum albumin will confer immunogenicity to the hapten coupled to it. The hapten-carrier may be formulated for use as a vaccine.

[0464] Many methods may be used to introduce the vaccine formulations described above into a patient. These include, but are not limited to, oral, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, transdermal, epidural, pulmonary, gastric, intestinal, rectal, vaginal, or urethral routes. When the method of treatment uses a live recombinant vaccinia vaccine formulation ofthe invention, it may be preferable to introduce the formulation via the natural route of infection of the vaccinia virus, i.e., through a mucosal membrane or surface, such as an oral, nasal, gastric, intestinal, rectal, vaginal or urethral route, or through the skin. To induce a CTL response, the mucosal route of administration may be through an oral or nasal membrane. Alternatively, an intramuscular or intraperitoneal route of administration maybe used. Preferably, a dose of 106 - 107 PFU (plaque forming units) of cold adapted recombinant vaccinia virus is given to a human patient.

[0465] Theprecisedoseofvaccinepreparationtobeemployedinthe formulation will also depend on the route of administration, and the nature of the patient, and should be decided according to the j udgment of the practitioner and each patient's circumstances according to standard clinical techniques. An effective immunizing amount is that amount sufficient to produce an immune response to the antigen in the host to which the vaccine preparation is administered,

[0466] Where subsequent orbooster doses arerequired, amodified vaccinia virus such as MVA can be selected as the parental virus used to generate the recombinant. Alternatively, another virus, e.g., adenovirus, canary pox virus, or a subunit preparation can be used to boost. Immunization and/or cancer immunotherapy may be accomplished using a combined immunization regimen, e.g., immunization with a recombinant vaccinia viral vaccine of the invention and a boost of a recombinant adenoviral vaccine. In such an embodiment, a strong secondary CD8+ T cell response is induced after priming and boosting with different viruses expressing the same epitope (for such methods of immunization and boosting, see, e.g., Murata et al, Cellular Immunol. 173:96-107). For example, a patient is first primed with a vaccine formulation of the invention •*432- comprising a recombinant vaccinia virus expressing an epitope, e.g., a selected tumor-associated antigen or fragment thereof. The patient is then boosted, e.g., 21 days later, with a vaccine formulation comprising a recombinant virus other than vaccinia expressing the same epitope. Such priming followed by boosting induces a strong secondary T cell response. Such a priming and boosting immunization regimen is preferably used to treat a patient with a tumor, metastasis or neoplastic growth expressing the tumor associate, e.g., C3 5, antigen

[0467] In yet another embodiment, the recombinant vaccinia viruses can be used as abooster immunization subsequent to aprimaryimmunization with inactivated tumor cells, a subunit vaccine containing the C35 antigen or its epitope, or another recombinant viral vaccine, e.g., adenovirus, canary pox virus, or MVA.

[0468] In an alternate embodiment, recombinant vaccinia virus encoding C35 epitopes or fragment thereof may be used in adoptive immunotherapeutic methods for the activation of T lymphocytes that are histocompatible with the patient and specific for the C35 antigen (for methods of adoptive immunotherapy, see, e.g., Rosenberg, U.S. Patent No. 4,690,915, issued September 1, 1987; Zarling, et al, U.S. Patent No. 5,081,029, issued January 14, 1992). Such T lymphocytes may be isolated from the patient or a histocompatible donor. The T lymphocytes are activated in vitro by exposure to the recombinant vaccinia virus ofthe invention. Activated T lymphocytes are exp anded and inoculated into the patient in order to transfer T cell immunity directed against the C35 antigen epitope.

[0469] The invention also provides a pharmaceutical pack or kit comprising one or more containers comprising one or more of the ingredients of the vaccine formulations of the invention. Associated with such containers) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.

Cancer Diagnosis and Prognosis 10470] There are two classes of genes affecting tumor development. Genes influencing the cancer phenotype that act directly as a result of changes (e.g., mutation) at the DNA level, such as BRCA1, BRCA2, and p53, are one class of genes. Another class of genes affect the phenotype by modulation at the expression level. Development of breast cancer and subsequent malignant progression is associated with alterations of a variety of genes of both classes. Identification of quantitative changes in gene expression that occur in the malignant mammary gland, if sufficiently characterized, may yield novel molecular markers which may be useful in the diagnosis and treatment of human breast cancer.

[0471] The present inventors have identified a new breast cancer marker,C35, that is differentially expressed in primary infiltrating intraductal mammary carcinoma cells. Low expression levels of C35 in normal mammary epithelial cells suggest that overexpression of C35 indicates breast cancer malignant progression. It is possible that C35 may also be overexpressed in tumors of certain other tissue types including bladder and lung.

[0472] The present inventors have demonstrated that certain tissues in mammals with cancer express significantly enhanced levels ofthe C35 protein and mRNA encoding the C3 5 protein when compared to a corresponding "standard" mammal, i.e., a mammal of the same species not having the cancer. Further, it is believed that enhanced levels ofthe C35 protein, or of antibodies or lymphocytes specific for the C35 protein, can be detected in certain body fluids (e.g., sera, plasma, urine, and spinal fluid) from mammals with cancer when compared to sera from mammals ofthe same species not having the cancer. Thus, the present invention provides adiagnostic method useful for tumor diagnosis, which involves assaying the expression level of the gene encoding the C35 protein in mammalian cells or body fluid and comparing the gene expression level with a standard C35 gene expression level, whereby an increase in the gene expression level over the standard is indicative of certain tumors. Alternatively, the expression levels of antibodies or lymphocytes specific for C35 protein or C35 polypeptides can be determined in blood or other body fluids and compared with a standard of expression of C35-specific antibodies or lymphocytes.

[0473] Where a tumor diagnosis has already been made according to conventional methods, the present invention is useful as a prognostic indicator, whereby patients exhibiting enhanced C35 gene expression may experience a worse clinical outcome relative to patients expressing the gene at a lower level.

J0474] By "assaying the expression level of the gene encoding the C35 protein" is intended qualitatively or quantitatively measuring or estimating the level of the C35 protein or the level of the mRNA encoding the C35 protein in a first biological sample either directly (e.g., by determining or estimating absolute protein level or mRNA level) or relatively (e.g., by comparing to the C35 protein level or mRNA level in a second biological sample).

[0475] Preferably, the C35 protein level or mRNA level in the first biological sample is measured or estimated and compared to a standard C35 protein level or mRNA level, the standard being taken from a second biological sample obtained from an individual not having the cancer. As will be appreciated in the art, once a standard C35 protein level or mRNA level is known, it can be used repeatedly as a standard for comparison.

[0476] By "biological sample" is intended any biological sample obtained from an individual, cell line, tissue culture, or other source which contains C35 protein or mRNA. Biological samples include mammalian body fluids (such as sera, plasma, urine, synovial fluid and spinal fluid) which contain secretedmature C35 protein, and ovarian, prostate, heart, placenta, pancreas, liver, spleen, lung, breast, bladder and umbilical tissue which may contain precursor or mature forms of C35.

[0477] The present invention is useful for detecting cancer in mammals. In particular, the invention is useful during diagnosis of the following types of cancers in mammals: breast, bladder, ovarian, prostate, bone, liver, lung, pancreatic, and splenic. Preferred mammals include monkeys, apes, cats, dogs, cows, pigs, horses, rabbits and humans. Particularly preferred are humans. 1(0478] Total cellular RNA can be isolated from a biological sample using the single-step guanidinium-thiocyanate-phenol-chloroform method described in ChomczynskiandSacchi,^4na/. Biochem. 162:156-159 (1987). LevelsofmRNA encoding the C35 protein are then assayed using any appropriate method. These include Northern blot analysis (Harada et al., Cell 55:303-312 (1990)), SI nuclease mapping (Fujita et al., Cell 49:351-367 (1987)), the polymerase chain reaction (PCR), reverse transcription in combination with the polymerase chain reaction (RT-PCR) (Makino et al., Technique 2:295-301 (1990)), and reverse transcription in combination with the ligase chain reaction (RT-LCR).

[0479] Assaying C35 protein levels in biological sample can occur using antibody-based techniques. For example, C35 protein expression in tissues can be studied with classical immunohistological methods (Jalkanen, M., et al., J. Cell. Biol. 101:976-985 (1985); Jalkanen,M., etal.J. Cell. Biol. 705:3087-3096 (1987)).

[0480] Other antibody-based methods useful for detecting C35 protein expression include immunoassays, such as enzyme linked immunosorbent assay (ELISA), ELISPOT, and the radioimmunoassay (RIA).

[0481] Suitable labels are known in the art and include emyme labels, such as, Glucose oxidase, and radioisotopes, such as iodine (125I, mI), carbon (14C), sulfur (35S), tritium (3H), indium (mIn), and technetium ("mTc), and fluorescent labels, such as fluorescein and rhodamine, and biotin.

[0482] C35-specific T cells may be detected in a variety of proliferation and lymphokine secretion assays following activation by C35 presented by antigen presenting cells according to methods known in the art Tetrameric complexes of a C35 peptide epitope bound to soluble MHC molecules can be employed to directly stain and enumerate C35-specific T cells in a population of cells (Lee, P.P. et al., Nature Medicine 5:677-85 (1999) the entire contents of which is hereby incorporated by reference. ;*^436-

[0483] In addition to assaying secreted protein levels in a biological sample, proteins can also be detected in vivo by imaging. Antibody labels or markers for in vivo imaging of protein include those detectable by X-radiography, NMR or ESR For X-radiography, suitable labels include radioisotopes such as barium or cesium, which emit detectable radiation but are not overtlyharmful to the subject. Suitable markers for NMR and ESR include those with a detectable characteristic spin, such as deuterium, which may be incorporated into the antibody by labeling of nutrients for the relevant hybridoma. ;.[0484] A protein-specific antibody or antibody fragment which has been labeled with an appropriate detectable imaging moiety, such as a radioisotope (for example,13'I, U2lh,99mTc), a radio-opaque substance, or a material detectable by nuclear magnetic resonance, is introduced (for example, parenterally, subcutaneously, or intraperitoneally) into the mammal. It will be understood in the art that the size of the subject and the imaging system used will determine the quantity of imaging moiety needed to produce diagnostic images. In the case of a radioisotope moiety, for a human subject, the quantity of radioactivity injected will normally range from about 5 to 20 millicuries of 99mTc. The labeled antibody or antibody fragment will then preferentially accumulate at the location of cells which contain the specific protein. In vivo tumor imaging is described in S.W. Burchiel et al, "Inununophaimacokinetics of Radiolabeled Antibodies and Their Fragments." (Chapter 13 in Tumor Imaging: The Radiochemical Detection of Cancer, S.W. Burchiel andB. A. Rhodes, eds., Masson Publishing Inc. (1982).) Fusion Proteins

[0485] Any C35 polypeptide can be used to generate fusion proteins. For example, the C35 polypeptide, when fused to a second protein, can be used as an antigenic tag. Antibodies raised against the C35 polypeptide can be used to indirectly detect the second protein by binding to the C35. Moreover, because '=437- secreted proteins target cellular locations based on trafficking signals, the C35 polypeptides can be used as a targeting molecule once fused to other proteins. As used herein, the term "fusionprotein" does notmean C35 polypeptide fragments.

[0486] Examples of domains that can be fused to C35 polypeptides include not only heterologous signal sequences, but also other heterologous functional regions. The fusion does not necessarily need to be direct, but may occur through linker sequences. In a prefeired embodiment, the fusion protein of the present invention comprises at least one C35 peptide epitope or C35 peptide epitope analog joined to at least one additional C35 peptide epitope or C35 peptide epitope analog. In a particularly preferred embodiment, the fusion proteins ofthe present invention comprise homopolymers of the same C35 peptide epitope or C35 peptide epitope analog, as well as heteropolymers of different C35 peptide epitopes and C35 peptide epitope analogs.

[0487] In certain preferred embodiments, C35 fusion polypeptides may be constructed which include additional N-terminal and/or C-terminal amino acid residues. In particular, any N-terminally or C-terminally deleted C3 5 polypeptide disclosed herein may be altered by inclusion of additional amino acid residues at the N-terminus to produce a C35 fusion polypeptide. In addition, C35 fusion polypeptides are contemplated which include additional N-terminal and/or C-terminal amino acid residues fused to a C35 polypeptide comprising any combination of N- and C-terminal deletions set forth above.

[0488] Moreover, fusion proteins may also be engineered to improve characteristics ofthe C35 polypeptide. For instance, a region of additional amino acids, particularly charged amino acids, may be added to the N-terminus of the C35 polypeptide to improve stability and persistence during purification from the host cell or subsequent handling and storage. Also, peptide moieties may be added to the C35 polypeptide to facilitate purification. Such regions may be removed prior to final preparation of the C35 polypeptide. The addition of peptide moieties to facilitate handling of polypeptides are familiar and routine techniques in the art.

[0489] Moreover, C35 polypeptides, including fragments, and specifically epitopes, can be combined with parts of the constant domain of immunoglobulins (IgG), resulting in chimeric polypeptides. These fusion proteins facilitate purification and show an increased half-life in vivo. One reported example describes chimeric proteins consisting of the first two domains of the human CD4-polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. (EP A 394,827; Trauneckeref al, Nature 337:84-86 (1988).) Fusion proteins having disulfide-linked dimeric structures (due to the IgG) can also be more efficient in binding and neutralizing other molecules, than the monomelic secreted protein or protein fragment alone. (Fountoulakis et al, J. Biochem. 270:3958-3964 (1995).)

[0490] Similarly, EP-A-0 464 533 (Canadian counterpart 2045869) discloses fusion proteins comprising various portions of constant region of immunoglobulin molecules together with another human protein or part thereof. In many cases, the Fc part in a fusion protein is beneficial in therapy and diagnosis, and thus can result in, for example, improved pharmacokinetic properties. (EP-A 0232 262.) Alternatively, deleting the Fc part after the fusion protein has been expressed, detected, and purified, would be desired. For example, the Fc portion may hinder therapy and diagnosis if the fusion protein is used as an antigen for immunizations. In drug discovery, for example, human proteins, such as hIL-5, have been fused with Fc portions for the purpose of high-throughput screening assays to identify antagonists of hIL-5. (See, D. Bennett et al, J. Molecular Recognition 8:52-58 (1995); K. Johanson et al, J. Biol Chem. 270:9459-9471 (1995).)

[0491] Moreover, the C35 polypeptides can be fused to marker sequences, such as a peptide which facilitates purification of C3 5. In preferred embodiments, the marker amino acid sequence is ahexa-histidine peptide, such as the tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA, 91311), among others, many of which are commercially available. As described in Gentz et al, Proc. Natl Acad. Sci. USA 86:821-824 (1989), for instance, hexa-histidine provides for convenient purification of the fusion protein. Another peptide tag useful for purification, the "HA" tag, corresponds to an epitope derived from the influenza hemagglutinin protein. (Wilson et al., Cell 57:767 (1984).)

[0492] Thus, any of these above fusions can be engineered using the C35 polynucleotides or the C35 polypeptides.

Vectors, Host Cells, and Protein Production

[0493] The present invention also relates to vectors containing the C35 polynucleotide, host cells, and the production of C35 polypeptides by recombinant techniques. The vector maybe, for example, aphage, plasmid, viral, or retroviral vector. Retroviral vectors may be replication competent or replication defective. In the latter case, viral propagation generally will occur only in complementing host cells.

[0494] C35 polynucleotides may be joined to a vector containing a selectable marker for propagation in a host Generally, a plasmid vector is introduced in a precipitate, such as a calcium phosphate precipitate, or in a complex with a charged lipid. If the vector is a virus, it may be packaged in vitro using an appropriate packaging cell line arid then transduced into host cells.

[0495] The C35 polynucleotide insert should be operatively linked to an appropriate promoter, such as the phage lambda PL promoter, the E. coli lac, trp, phoA and tac promoters, the SV40 early and late promoters and promoters of retroviral LTRs, to name a few. Other suitable promoters will be known to the skilled artisan. The expression constructs will fiirther contain sites for transcription initiation, termination, and, in the transcribed region, a ribosome binding site for translation. The codingportion ofthe transcripts expressed by the constructs will preferably include a translation initiating codon at the beginning and a termination codon (UAA, UGA or UAG) appropriately positioned at the aid of the polypeptide to be translated.

[0496] As indicated, the expression vectors will preferably include at least one selectable marker. Such markers include dihydrofolate reductase, G418 or neomycin resistance for eukaryotic cell culture and tetracycline, kanamycin or ampicillin resistance genes for culturing in E. coli and other bacteria. Representative examples of appropriate hosts include, but are not limited to, bacterial cells, such as E. coli, Streptomyces and Salmonella typhimurium cells; fungal cells, such as yeast cells; insect cells such as Drosophila S2 and Spodoptera Sf9 cells; animal cells such as CHO, COS, 293, and Bowes melanoma cells; and plant cells. Appropriate culture mediums and conditions for the above-described host cells are known in the art. [04971 Among vectors preferred for use in bacteria include pHE-4 (and variants thereof); pQE70, pQE60 andpQE-9, available from QIAGEN, Inc.; pBluescript vectors, Phagescript vectors, pNH8A, pNH16a, pNH18A, pNH46A, available from Stratagene Cloning Systems, Inc.; and ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 available from Pharmacia Biotech, Inc. Among preferred eukaryotic vectors are pWLNEO, pSV2CAT, pOG44, pXTl and pSG available from Stratagene; and pSVK3, pBPV, pMSG and pSVL available from Pharmacia. Other suitable vectors will be readily apparent to the skilled artisan. Preferred vectors are poxvirus vectors, particularly vaccinia virus vectors such as those described in U.S. Patent Appl. No. 08/935,377, the entire contents of which are incorporated herein by reference.

[0498] Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-dextran mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection, or other methods. Such methods are described in many standard laboratory manuals, such as Davis et al, Basic Methods In Molecular Biology (1986).

[0499] C35 polypeptides can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, - —*41- affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography ("HPLC") is employed for purification.

[0500] C35 polypeptides can also be recovered from: products purified from natural sources, including bodily fluids, tissues and cells, whether directly isolated or cultured; products of chemical synthetic procedures; and products produced by recombinant techniques from a prokaiyotic or eukaryotic host, including, for example, bacterial, yeast, higher plant, insect, and mammalian cells. Depending upon the host employed in a recombinant production procedure, the C35 polypeptides may be glycosylated or may be non-glycosylated. hi addition, C35 polypeptides may also include an initial modified methionine residue, in some cases as a result of host-mediated processes. Thus, it is well known in the art that the N-terminal methionine encoded by the translation initiation codon generally is removed with high efficiency from any protein after translation in all eukaryotic cells. While the N-tenninal methionine on most proteins also is efficiently removed in most prokaryotes, for some proteins, this prokaiyotic removal process is inefficient, depending on the nature of the amino acid to which the N-terminal methionine is covalently linked.

[0501] In addition to encompassing host cells containing the vector constructs discussed herein, the invention also encompasses primary, secondary, and immortalized host cells of vertebrate origin, particularly mammalian origin, that have been engineered to delete or replace endogenous genetic material (e.g. C35 coding sequence), and/or to include genetic material (e.g., heterologous polynucleotide sequences) that is operably associated with C35 polynucleotides of the invention, and which activates, alters, and/or amplifies endogenous C35 polynucleotides. For example, techniques known in the art may be used to operably associate heterologous control regions (e.g., promoter and/or enhancer) and endogenous C35 polynucleotide sequences via homologous recombination (see, e.g., U.S. Patent No. 5,641,670, issued June 24, 1997; International Publication No. WO 96/29411, published September 26, 1996; International i-442- Publication No. WO 94/12650, published August 4,1994; Koller et al., Proc.

Acad. Sci. USA 86:8932-8935 (1989); andZijlstraetal., Nature 342:435-438 (1989), the disclosures of each of which are incorporated by reference in their entireties).

[0502] Having generally described the invention, the same will be more readily understood by reference to the following examples, which are provided by way of illustration and are not intended as limiting.

EXAMPLES EXAMPLE 1 Differential Expression of C35 in Human Breast Carcinoma

[0503] The present inventors have characterized a full-length cDNA representing a gene, C35, that is differentially expressed in human breast and bladder cancer (FIG. IA). A 348 base pair DNA fragment of C35 was initially isolated by subtractive hybridization of poly-A RNA from tumor and normal mammary epithelial cell lines derived from the same patient with primary infiltrating intraductal mammary carcinoma. (Band, V. et al., Cancer Res. 50:1351-1351 (1990). Employing primers based on this sequence and that of an overlapping EST sequence (Accession No. W57569), a cDNA that includes the full-length C35 coding sequence was then amplified and cloned from the SKBR3 breast tumor cell line (ATCC, HTB-19). This C35 cDNA includes, in addition to the 348 bp coding sequence, 167 bp of 3' untranslated region.

[0504] Differential expression of the C35 sequence is demonstrated in FIG. 2A which compares expression levels of clone C35 in poly-A RNA from cell lines derived from normal mammary epithelium, from two primary breast tumor nodules, and from two metastatic lung tumor nodules isolated approximately one year later from the same patient (Band, V. et al., Cancer Res. 50:1351-1351 (1990)). Quantitative analysis indicates that the sequence is expressed at a more ...» -443- than 10 fold higher level in tumor cells than in normal mammary epithelium. Low expression levels in a panel of other normal tissues is demonstrated by the Northern hybridization results of FIG. 2B. Even though three times as much poly-A RNA was loaded from normal tissues as from the tumor cell lines, little or no expression of RNA homologous to C35 was detected after a comparable 15 hour exposure. Only after an extended 96 hour exposure was low level expression of some homologous sequences detected in normal spleen and kidney tissues. Analysis of expression of C35 homologous sequences in poly-A RNA from three primary infiltrating ductal breast carcinoma from different patients as well as a sample of normal breast epithelium is shown in FIG. 2C. hi comparison to normal breast epithelium, sequences homologous to C35 are overexpressed as much as 45 and 25 fold in two of the three primary breast tumors.

[0505] The present inventors previously conducted an analysis of an immunoprotective tumor antigen expressed in several independently derived murine tumors and, at much reduced levels, in normal mouse tissues. (See U.S. Patent Application filed March 28,2000, titled "Methods of Producing a Library and Methods of Directly Selecting Cells Expressing Inserts of Interest," the entire contents of which are hereby incorporated herein by reference). In this case, a factor of 9 difference between expression levels in tumor and normal tissues was associated with induction of an immunoprotective tumor-specific response. As discussed above, the expression level of C35 in some human breast cancers relative to normal tissue exceeds a factor of 9, suggesting that C35 might also be immunoprotective against breast cancer in these individuals.

EXAMPLE 2 C35 Specific CTL are Cytolytic for C35 Positive Breast Tumor Cells

[0506] Although a gene product may be overexpressed in tumor cells, as is the case for C35, it is immunologically relevant only if peptides derived from that gene product can be processed and presented in association with MHC molecules of the tumor cells. It is conceivable that for any given gene product either no peptides are produced during the cellular degradation process that satisfy the requirements for binding to the MHC molecules expressed by that tumor, or, even if such peptides are generated, that defects in transport or competition for MHC molecules by other tumor peptides would preclude presentation of any peptides from that specific gene product. Even if relevant tumor peptides are processed and presented in association with human MHC in the tumor cells, it must in all cases be determined whether human T cells reactive to these peptides are well-represented in the repertoire or whether T cells may have been rendered tolerant, perhaps due to expression of the same or a related antigen in some other non-homologous normal tissue. For both these reasons, therefore, it is essential to confirm that MHC-restricted, human tumor antigen-specific T cells can be induced by C35 and that they are indeed crossreactive on human tumor cells. Relevant information on this point can be obtained through in vitro stimulation of human T cell responses with recombinant C35 or C35 peptides presented by autologous antigen presenting cells. [0507J A major technical problem in evaluating T cell responses to recombinant gene products is that a strong immune response against the expression vector can block or obscure the recombinant specific response. This is particularly a problem with primary responses that may require multiple cycles of in vitro stimulation. To minimize vector specific responses, it is possible to alternate stimulation by antigen presenting cells infected with different viral vectors recombinant for the same gene product. Convenient vectors include: retroviruses, adenovirus, and pox viruses.

[0508] Human PBMC were purified using Ficoll-Hypaque and subjected to rosetting with neuraminidase-treated sheep erythrocytes to isolate monocytes (erythrocyte rosette negative, ER~) andT lymphocytes (ER+). Dendritic cells were generated from the ER" fraction by culture for 7 days in rhGM-CSF (1000 U/ml) andrhIL-4 (1000U/ml) with fresh medium and cytokines being added every other day. At day 7, immature dendritic cells were transduced with retrovirus ^445- expressing human C35 in the presence of polybrene (1 ug/ml) for 6 hours. Cells were washed and incubated under maturation conditions for 4 days in the presence of 12.5% monocyte conditioned medium, 1000 U/ml rhGM-CSF and 1000 rhU/ml IL-4 and 1% autologous serum. At this point, the dendritic cells were incubated with autologous T lymphocytes (cryopreserved ER+ fraction) at a ratio of 1 DC:50 T cells for 14 days. Viable T cells were restimulated with autologous, irradiated EBV-B B cells infected at a multiplicity of infection of 1 overnight (16 hours) with a vaccinia recombinant expressing human C35 in the presence of cytokines IL-2 (20U/ml), IL-12 (20 U/ml) and EL-18 (10 ng/ml). Cells were restimulated two more times with autologous EBV-B cells infected with C35-bearing retrovirus in the presence of IL-2 arid IL-7 (10 ng/ml). Cytotoxic activity was measured after a total of 4 stimulations by 51Cr release assay using 5000 targets/well in a 4 hour assay. The results shown in Table 8 below demonstrate specific cytotoxic activity of C35 stimulated T cells against 21NT breast tumor cells that express relatively elevated levels of C35 but not against MDA-MB-231 tumor cells that express the same low levels of C35 as normal nontransformed epithelial cells.

C35-specific CTL are Cytolytic for C35 Positive Breast Tumor Cells Table 8 Target Cells E:T :1 10:1 HLA Haploype (Effectors:A2, All; B8, B35) (% specific lysis) Autologous EBV-B MDA-MB-231 C35 low (lx) 21NT C35 high (12x) K562 A2, All; B8, B35 A2; B8 2 3 1 A26, A31;B35, B38 22 2 0 EXAMPLE3 C35 Expression on the Membrane of Breast Carcinoma Cells

[0509] To determine whether the C35 polypeptide product is expressed on the surface of tumor cells, a C35 specific antiserum was prepared. BALB/c mice were immunized with syngeneic Line 1 mouse tumor cells that had been transduced with retrovirus encoding human C35. Mice were bled following a series of two or more immunizations. The immune sera were employed to detect surface expression of C35 protein by flow cytometry on three breast tumor cell lines representing high (21NT), intermediate (SKBR3), and low (MDA-MB-231 levels of expressionof the C35 transcript in Northern blots (see FIGS. 4A-4C). 1 x 10s breast tumor cells were stained with 3.5 microliters of C35 specific antiserum or control, pre-bleed BALB/c serum. After a 30 minute incubation, cells were washed twice with staining buffer (PAB) and incubated with FITC-goat anti-mouse IgG (1 ug/sample) for 30 minutes. Samples were washed and analyzed on an EPICS Elite flow cytometer. The results presented in FIGS. 4A-4C demonstrate membrane expression of the C35 antigen recognized by the specific immune serum at high levels on tumor line 2 INT (FIG. 4A), intermediate levels for tumor line SKBR3 (FIG. 4B), and undetectable levels in tumor line MDA-MB-231 (FIG. 4C). The high level of reactivity of antibody to membranes of tumor cells, that express elevated levels of C35 transcripts suggests that C35 specific antibodies may serve as effective immunotherapeutic agents for the large number of breast carcinoma that overexpress this gene product (see FIGS. 2A-2C and 3).

EXAMPLE 4 A Deregulated Ribosomal Protein L3 Gene Encodes a Shared Murine Tumor Rejection Antigen

[0510] The present inventors have developed novel antigen discovery technology that allows for the selection of genes encoding CTL epitopes from a cDNA * library constructed in a poxvirus. Using tins technology the present inventors have determined that a shared murine tumor antigen is encoded by an alternate allele of the ribosomal protein L3 gene. The immunogenic L3 gene is expressed at significant albeit reduced levels in normal tissues including thymus. Immunization with a vaccinia recombinant of the immunogenic L3 cDNA induces protective immunity against tumor challenge. It is of particular interest that a deregulated allele of a housekeeping gene can serve as an immunoprotective antigen and that thymic expression doies not preclude immunogemcityofanupregulatedtumorproduct. These observations emphasize that tolerance to a self-protein is not absolute but must be defined in relation to quantitative levels of expression. The ribosomal protein described may be representative of a class of shared tumor antigens that arise as a result of deregulated expression of aself-protein without compromising immune tolerance to normal tissues. Such antigens would be suitable for immunotherapy of cancer in vital organs.

Methods

[0511] Total RNA was isolated from BCA 39 tumor cells using the Perfect RNA Total RNA Isolation Kit (5 Prime 3 Prime, Inc., Boulder, CO). Poly A+ mRNA was isolated from the total RNA using Dynabeads (Dynal, Lake Success, NY). Two micrograms of poly A+ mRNA was converted to double stranded cDNA using the Great Lengths cDNA Synthesis Kit (Clontech, Palo Alto, CA). The double stranded cDNA was then inserted in vaccinia virus vector v7.5/tk. {0512] Balb/cByJ (Jackson Labs) mice were immunized intraperitoneally with 2 X 106 irradiated (6,500 cGy) BCA 34 cells. Two weeks later the mice were boostedby subcutaneous injection of 2 X106 irradiated BCA 34 cells. One week following the second immunization splenocytes were harvested, divided into 12 parts and cultured in 12 well plates with 6 X 105 irradiated (10,000 cGy), mitomycin C treated BCA 34 cells per well. At weekly intervals viable T cells were purified using Lympholyte-M (Accurate Chemical, Westbury, NY) and cultured in 12 well plates at 1.5 X106 T cells per well. To each well was also added 4 X106 irradiated (5000 cGy) Balb/c spleen, along with 6 X105 irradiated, mitomycin C treated BCA 34 cells.

[0513] A specific vaccinia recombinant that encodes the well characterized ovalbumin 257-264 peptide (SHNFEKL) that is immunodominant in association withH-2Kb was diluted with non-recombinant virus so that it initially constituted either 0.2%, 0.01%, or 0.001% of total viral pfu. An adherent monolayer of MC57G cells (H -2b) were infected with this viral mix at m.o.i =1 (approximately 5 x 105 cells/well). Following 12 hours infection, ovalbumin peptide-specific CTL, derived by repeated in vitro stimulation of ovalbumin primed splenic T cells with the inrnmnodominant SHNFEKL peptide, were added. During this incubation those adherent cells which were infected with a recombinant particle that expresses the ovalbumin peptide are targeted by specific cytotoxic T cells and undergo a lytic event which causes them to be released from the monolayer. Following incubation with CTL, the monolayer is gently washed, and both floating cells and the remaining adherent cells are separately harvested. Virus extracted from each cell population was titred for the frequency of recombinant (BRdU resistant) viral pfu. Virus extracted from floating cells was then used as input to another enrichment cycle with fresh adherent MC57G cells and ovalbumin peptide-specific CTL. It was observed that following enrichment of Wovato greater than 10% of total virus, further enrichment of the recombinant virus was accelerated if the m.o.i. in succeeding cycles was reduced from 1 to 0.1.

[0514] Confluent monolayers of BCN in wells of a 12 well plate were infected with rnoi=1.0 vaccinia BCA39 cDNA library. At 12 hours post-infection the monolayers were washed 3X with media, and 2.5 X 106 CTL were added to the wells in a 250 pi volume. The T cells and targets were incubated at 37 °C for 4 hours. Following the incubation the supernatant was harvested, and the monolayer gently washed 3X with250jxl media. Virus was released from the cells by freeze/thaw, and titers determined by plaque assay on BSC1 cells. The selected virus population (floating cells in cultures that received specific T cells) was amplified onBSCl cells in one well of a 12 well plate for 2 days. The virus was then harvested and titered This viral stock was subjected to three additional enrichment cycles. The selected virus population was not amplified prior to the next cycle.

[0515] Virus from the fourth enrichment cycle was divided into 40 pools of 5 pfu each. Each pool was amplified on BSC1 cells in a 96 well plate, with 1 pool / well. After 4 days the virus was harvested (P1), and used to infect monolayers of BCN in a 96 well plate at moi=5, with 1 pool per well. As a control, a monolayer of BCN was infected with moi-5 vNotl/tk (Merschlinsky et al., Virology 190:522 (1992)). At 5 hours post-infection, 2X104 washed CTL were added to each well. The final volume in each well was 225 fil. The cells were incubated at 37°C for 18 hours. The cells were then pelleted by centrifugation, 150(Jtl supernatant was harvested and tested for IFNg by ELBA. Twenty seven of the forty pools of 5 pfu were positive for the ability to stimulate CTL. Suggesting, by Poisson analysis, that specific recombinants were enriched to greater than 20%. Individual clones were picked from 5 positive pools and assayed as above.

[0516] Monolayers of B/C.N in a 6 well plate were infected with moi=1.0 of v7.5/tk, vF5.8,orvH2.16. At 14 hours post-infection cells ware harvested along with the control targets: B/C.N, BCA 34, and BCA 39. The target cells were labeled with 100 microcuries slChromium (Dupont, Boston, MA) for 1 hour at 37 °C, and 104 cells were added to wells of a 96 well round bottom plate in quadruplicate. Tumor specific CTL were added to target cells at the indicated ratios. Cells were incubated at 37°C for 4 hours. Supernatants were harvested and 51Cr release determined. Spontaneous release was derived by incubating target cells with media alone. Maximal release was determined by incubating target cells with 5% Triton X 100. Percentage of specific lysis was calculated using the formula: % specific lysis= ((experimental release-spontaneous release) / (maximal release-spontaneous release)) X 100. In each case the mean of quadruplicate wells was used in the above formula.

[0517] Two micrograms of total RNA was converted to cDNA using a dT primer and Superscript II Reverse Transcriptase (BRL, Gaithersburg, MD). cDNA was used as the template for a PCR using L3 specific primers; L3.F1.S (CGGCGAGATGTC TCACAGGA) and L3.F1.AS (ACCCCACCATCTGCACAAAG); and Klentaq DNA Polymerase Mix (Clontech) in a 20 microliter final volume. Reaction conditions included an initial denaturation step of 94°C for 3 minutes, followed by 30 cycles of: 94°C 30 seconds, 60°C for 30 seconds, 68°C for 2 minutes. These PCR products contained the region ofL3 between position 3 and 1252. The PCR products ware purified using Centricon 100 columns (Amicon, Beverly, MA), digested with Sau3AI, and resolved on a 3% Agarose/ethidium bromide gel.

[0518] Adult female Balb/cByJ mice (2 mice per group) were immunized by subcutaneous injection of 5X106 pfu of vH2.16, or v7.5/tk. Seven days following the immunization splenocytes were harvested and cultured in 12 well plates along with 1 micromolar peptide L34S_56(I54). After seven days the viable T cells were purified using Lympholyte-M, and 1X106 T cells were added to wells of a 12 well plate along with 1 micromolar peptide and 4 X106 irradiated (5000 cGy) Balb/c spleen cells per well. {0519] Adult female Balb/cByJ mice were immunized by subcutaneous injection of 10X106 pfu of VH2.16, vPKIa, v7.5/tk or Phosphate Buffered Saline. Secondary immunizations were given 21 days later. Mice were challenged with tumor by subcutaneous injection of 2X105 BCA 34 cells twenty one (primary immunization only) or fourteen days following immunization.

Results and Discussion

[0520] Prospects for development ofbroadly effective tumor vaccines have been advaroed by evidence-that several self-proteins can be recognized as tumor antigens by immune T cells (VandenEynde et al, J. Exp. Med. 173:1373 (1991); M. B. Bloom et al, J. Exp. Med. 755:453 (1997); Van Der Bruggen et al, Science 254:1643 (1991); Gaugler etal., J.Exp. Med. 179:921 (1994);Boeleta7., Immunity 2:167 (1995); Van Den Eynde et al, J. Exp. Med. 752:689 (1995); Kawakami et al, Proc. Natl. Acad. Sci. US.A. 91:3515 (1994); Kawakami et al., Proc. Natl. Acad. Sci. U.S.A. 97:6458 (1994); Brichard et al, J. Exp. Med. 178:489 (1993)). Suchnormal, nonmutated geneproducts may serve as common target antigens in tumors of certain types arising in different individuals. Clinical evidence for induction of protective immunity following vaccination with such shared tumor antigens is, currently, very limited (Marchand et al., Int. J. Cancer 80:219 (1999); Rosenberg etal, Nat. Med. 4:321 (1998); Overwijk etal, Proc. Natl. Acad. Sci. 96:2982 (1999); Brandle et al., Eur. J. Immunol. 25:4010 (1998)). It is, moreover, not at all clear whether the T cell responses to these self-proteins represent a surprising breakdown in immunological tolerance or are a consequence of qualitative or quantitative changes in the expression of die self-proteins in tumor cells. In die latter case, normal tissue tolerance could be maintained and vaccine induced immunity to self-proteins whose expression is systematically altered in tumors might be applicable even to cancer of vital organs.

[0521] The present inventors have shown that a ribosomal protein allele that is systematically deregulated in multiple murine tumors during the transformation r process is a tumor rejection antigen and that the principal correlate of immunogenicity is a dramatic change in quantitative expression in tumors relative to normal tissues and thymus.

[0522] Previously, the present inventors have reported that cross-protective immunity is induced among three independently derived murine tumor cell lines (Sahasrabudhe et al, J. Immunology 757:6302 (1993)). These tumors, BCA 22, BCA 34, and BCA 39 were derived by in vitro mutagenesis of independent subcultures of the B/C.N line, a cloned, immortalized, anchorage-dependent, cd^dai^ia^3t>ile^ * fibroUBSt -cell line derived from a Balb/e embryo (Collins et al., Nature 299:169 (1982); Lin et al., JNCI74:1025 (1985)). Strikingly, immunization with any of these tumor cell lines, but not with B/C.N provided protection against challenge with not only homologous tumor cells, but also against challenge with the heterologous tumor cell lines. Following immunization with any of these three tumor cell lines, CD8+ cytolytic T lymphocyte (CTL) lines and clones could be generated which in vitro displayed crossreactive specificity for the same three tumors, but not for the non-tumorigenic B/C.N cells from which they derived.

In order to move from an immunological definition to a molecular definition of this shared tumor antigen(s), the present inventors developed a novel and efficient method for the identification of genes that encode CTL target epitopes. In this approach a cDNA library from the BCA 39 tumor cell line was constructed in a modified vaccinia virus expression vector (Merchlinsky et al., Virology 235:444 (1997); E. Smith et al, Manuscript in preparation). Five hundred thousand plaque forming units (pfu) of this library were used to infect a monolayer of antigen-negative B/C.N cells at a multiplicity of infection (moi) of 1. Following 12 hours infection, BCA 34 tumor specific CTL were added to the target cell monolayer at an effector to target ratio that gives approximately 50% lysis in a standard 5lCr release assay. CTL specific for the heterologous BCA 34 tumor cell line were used in order to facilitate the identification of antigen(s) which are shared between these two tumor cell lines. Since adherence is an energy dependent process, it was expected that cells that undergo a CTL mediated lytic event would come off of the monolayer and could be recovered in the supernatant By harvesting virus from floating cells following cell mediated lymphocytotoxicity (CML), it was possible to enrich for viral recombinants that had sensitized the host cell to lysis. An essential feature of this procedure is that it lends itself to repetition. The virus harvested following one cycle of enrichment can be used as input for additional cycles of selection using fresh monolayers and fresh CTL until the desired level of enrichment has been achifv^Hiftamodefe^^iflient with CTL specific foe a known recombinant, it , was possible to demonstrate that specific recombinants could be enriched from an initial dilution of 0.001% to approximately 20% in 6 cycles of selection (Table 9). At this level it is a simple matter to pick individual plaques for further characterization.

Table 9 Multiple Cycles of Enrichment for Wova A vaccinia cocktail composed of wild type vNotl/tk (tk+) spiked with the indicated concentrations of Wova (tk-) was subjected to CML Selection (12) Enrichment % Wova in Floating Cells Cycle # Expt. 1 Expt. 2 Expt. 3 moi=l 0 0.2 0.01 0.001 1 2.1 0.3 nd 2 4.7 1.1 nd 3 9.1 4.9 nd 4 14.3 17.9 1.4 24.6 3.3 6 18.6 moi=0.1 48.8 39.3 %Wova = (Titer with BudR/Titer without BudR) X100 nd = not determined

[0524] The poxvirus expression library was subjected to 4 cycles of selection with tumor-specific CTL. Individual plaques of the selected viral recombinants were expanded and used to infect separate cultures ofB/C.N cells. These cells were assayed for the ability to stimulate specific CTL to secrete interferon gamma (IFN-gamma) (FIG. 5 A), or for sensitization to lysis by the tumor-specific CTL (FIG.5B). yen viral cloneg were isolated^ all of which conferred uppnB/C.N the ability to stimulate a line of tumor-specific CTL to secrete IFNy. All 10 clones contained the same sized (1,300 bp) insert (Smith et al, unpublished data). Sequence analysis confirmed that clones F5.8 and H2.16 contained the same full-length cDNA. It appeared, therefore, that all ten clones were recombinant for the same cDNA. In all, 6 of 6 CTL lines that were generated by immunization with BCA 34 demonstrated specificity for this antigen.

[0525] A search of GenBahk revealed that this cDNA is highly homologous to the murine ribosomal protein L3 gene (Peckham et al., Genes and Development 3:2062 (1989)). Sequencing the entire H2.16 clone revealed only a single nucleotide substitution that coded for an amino acid change when compared to the published L3 gene sequence. This CI 70T substitution generates a Threonine to Isoleucine substitution at amino acid position 54. The F5.8 clone also contained this nucleotide substitution.

[0526] Since CTL recognize antigen as peptide presented by a Major Histocompatibility Complex (MHC) molecule, it was of interest to identify the peptide epitope recognized by these class I MHC-restricted tumor-specific CD8+ T cells. It was considered likely that the altered amino acid (lie 54) would be included in the peptide recognized by the CTL. This hypothesis was supported by the demonstration that a vaccinia virus clone recombinant for only the first 199 bp (63 amino acids) of H2.16 (vH2199) was able to sensitize B/C.N to lysis by tumor-specific CTL (Smith et al, unpublished data). A Computer screen of peptide-binding motifs suggested that there are two epitopes encoded within this region that could associate with high affinity to the class I MHC molecule Kd (FIG. 12) (Parker et al, J. Immunology 152:163 (1994)). These two peptides, L345_54 (154) and L348.56 (154) were synthesized and tested for the ability to sensitize B/C.N cells to lysis by tumor-specific CTL. As shown in FIG. 7A, peptide L348_J6 (154) sensitized B/C.N to lysis, while L345.54 (154), and the wild type L348.5€ (T54) did not. It was determined that 10 nM L348.56 (154) was sufficient to sensitize targets to lysis by CTL, whereas 100 mM L348.56 (T54) did not (FIG. 7B). These results demonstrate that peptide L348_56 (154) is a target epitd^fefe^tfz^%^e%mldr-s|)ecific^TL- To analyze expression ofthe different L3 gene products, oligo-dT primed cDNA was synthesized from RNA of tumors and the B/C.N cell line from which they derived. The first strand cDNA was subjected to PCR amplification using a pair of primers which amplify nearly the entire mouse L3 mRNA. Sequence analysis of these PCR products showed that B/C.N and BCB13 L3 cDNA contained a C at position 170 (same as published sequence). BCB13 is a tumor cell line that was derived from the B/C.N cell line, but that is not immunologically cross-protective with the BCA tumor cell lines (Sahasrabudhe etal., J. Immunology 151:6302 (1993)). Sequence analysis ofthe PCR products from the crossreactive BCA 39, BCA 34, and BCA 22 tumors suggested that these cell lines express two different species of L3 mRNA. One species contains aCat 170, and the other contains a Tat 170, as in the H2.16 clone. Thesequence of all L3 cDNAs were identical except for this one base substitution.

There are two possible ways to account for the origin of the new L3 RNA in tumor cells. Either Hie L3 (C17OT) gene expressed in these tumors is a somatic mutant ofthe wild type gene or there are multiple germ line alleles of L3, at least one of which gives rise to an immunogenic product when deregulated during the process of tumor transformation. We considered the first hypothesis unlikely because the crossreactive BCA 39, BCA 34, and BCA 22 tumors were independently derived. It would be remarkable if the same mutant epitope was generated in all three tumors. On the other hand, Southern blots of different restriction digests of genomic DNA from BCA 39 and B/C.N suggested that there are multiple copies of the L3 gene in the mouse genome (Smith et al, unpublished data). The L3 gene has also been reported to be multi-allelic in both the rat and the cow (Kuwano et al, Biochemical and Biophysical Research Communications 187:58 (1992); Simonic et al, Biochemica et Biophysica Acta 1219:106 (1994)). Further analysis was required to test the hypothesis that different L3 alleles in the germ line are subject to differential regulation in tumors and normal cells. i

[0529] ThenucleotidesequenceofthepublishedL3frompositionl68tol71is GACC. The sequence of H2.16 in this same region is GATC (FIG. 8A). This new palindrome is the recognition sequence for a number of restriction endonucleases, including Sau3AI As shown in the restriction map of FIG. 8 A, a Sau3A I digest of L3 is expected to generate fragments of200,355,348,289, and 84 base pairs, while a Sau 3AI digest of H2.16 would generate a 168bp fragment in place of the 200 bp fragment This difference in the Sau 3AI digestion products was used to confirm that the three BCA cell lines express at least two different L3 alleles. The L3 RT-PCR products from all 5 cell lines and thymus RNA were digested with Sau 3AI and analyzed on an agarose gel. As shown in FIG. 8B all 3 BCA lines express both versions of L3. Remarkably, when this assay was repeated using greater amounts of starting material, the 168 bp fragment was also detectable in the digests of B/C.N, BCB13 and normal thymus cDNA (Smith etal, unpublished data). To enhance the sensitivity of this assay, the PCR was repeated using a P32 end-labeled 5J L3 specific primer. The radiolabeled PCR products were digested with Sau3AI and resolved on an agarose gel. As shown inFIG. 8C, B/C.N, BCB13 and thymus contain the 168bp fragment. Quantitative analysis indicates that the ratio of 200bp: 168bp fragments in the BCA tumors is 2:1 while the ratio of the same fragments detected in B/C.N, BCB13, and thymus is approximately 20:1. Low levels of expression of this immunogenic L3 allele was also observed when RNA from kidney, heart, and skeletal muscle was analyzed (Smith et al, unpublished data). These results suggest that gene deregulation associated with the transformation process in the crossreactive tumors leads to the expression of higher levels of this germ line L3 (C170T) allele, and that this altered L3 gene was not generated by somatic mutation of the L3 gene that is predominantly expressed in normal tissues. The present inventors have termed this new L3 allele (C170T), the immunogenic L3 allele (iL3).

[0530] It is particularly intriguing that the immunogenic L3 allele is also expressed,siltMfc atfoltt reduced level, in normal thymus. This level of expression is evidently not sufficient to tolerize all T cells with functional avidity for the level of deregulated iL3 expressed in some tumors. The observation that although B/C.N and BCB13 express low levels of iL3, they are not susceptible to lysis by the tumor specific CTL suggests, however, that higher affinity T cells have been tolerized. This appears to be the first instance in which a tumor antigen has been reported to be expressed in the thymus. These observations emphasize that tolerance to a self-protein is not absolute but must be defined in relation to quantitative levels of expression (Targoni et al, J. Exp. Med. 187:2055 (1998); C. J. Harrington et al, Immunity 5:571 (1998)).

[0531] If broadly effective vaccines are to be developed based on expression of shared tumor antigens, then it is critical to demonstrate that such antigens can be immunoprotective. The largest number of shared antigens have been identified for human tumors, but clinical Immunotherapy trials employing these antigens have so far been inconclusive, in part because of uncertainty regarding optimal vaccination strategies (Pardoll, D.M., Nat. Med. 4:525 (1998)). In mice, where immunotherapeutic strategies could be more thoroughly investigated, very few shared tumor antigens have been identified. It was, therefore, of considerable interest to determine whether immunizatidn with iL3 recombinant vaccinia virus would induce tumor specific CTL and protect mice from tumor challenge (Overwijk et al., Proc. Natl. Acad. Sci. 96:2982 (1999); Moss, B., Science 252:1662 (1991); Irvine et al, J. Immunology 154:4651 (1995); McCabe et al, Cancer Research 55:1741 (1995); Estin et al, Proc. Natl. Acad. Sci. 55:1052 (1988); J. Kantor etal, JNCI54:1084 (1992); V. Bronte etal, Proc. Natl Acad. Sci. 94:3183 (1997)). Immunization of Balb/c mice with vaccinia virus recombinant for the iL3 gene (H2.16) generated CTL that were able to lyse both BCA 34 and BCA 39 tumor cells, but not B/C.N in vitro (FIG. 9A). Mice immunized twice or even once with vaccinia virus recombinant for iL3 were.able to reject challenge with BCA 34 tumor cells (FIGS. 9B and 9C). Mice immunized with empty viral vector, or control vaccinia recombinant for the ) this tumor challenge (Olsen, S.R. and Uhler, M.D., J. Biol Chem. 266:11158 (1991); Mueller et al, Manuscript in Preparation). These results demonstrate that the iL3 self-protein is an immunoprotective tumor antigen.

[0532] The present inventors have developed a new strategy to identify genes that encode CTL epitopes based on CTL-mediated selection from a tumor cDNA library in a modified vaccinia virus vector (Merchlinsky et al, Virology 238:444 (1997);E. Smith etal, manuscript in preparation). We have applied this strategy to identify a deregulated housekeeping gene that encodes a tumor rejection antigen shared by three independently derived murine tumors. This ribosomal protein maybe representative of a larger class of immunoprotective shared tumor antigens that become immunogenic as a result of deregulated expression of self-proteins without compromising immune tolerance to normal tissues. Such antigens would be well suited for immunotherapy of cancer in vital organs.

EXAMPLE5 Expression and Immunogenicity of C35 Tumor Antigen

[0533] RNA transcripts of the novel C35 tumor gene are overexpressed in 70% (12/17) ofprimary human breast carcinomas examined and 50% (5/10) ofbladder carcinomas examined when compared to expression in normal human tissues. The foil-length gene encodes a novel 115 amino acid protein of unknown function. A monoclonal antibody, 2C3, has been selected that stains the surface membrane of cells expressing C35 by flow cytometric analysis. In addition, human cytotoxic T lymphocytes (CTL) have been generated in vitro that specifically lyse C35+ breast and bladder tumors. The ability to generate C35-specific CTL in vitro from normal human donors suggests the absence of tolerance to the overexpressed protein. Overexpression of C35 in tumors of different individuals and the ability to induce humoral and cellular immune responses make C35 a promising candidate for immunotherapy. :rvfjjgj vfws.

; Material and Methods r-

[0534] Cell lines: Human mammary carcinoma cell lines BT20, BT474, MCF7, MDA-MB231, SKBR3, T47D (supplied by ATCC) were grown in KPMI-1640 (BioWhitaker, Walkersville, MD) supplemented with 10% fetal bovine serum (Biofluids, Rockville, MD). An immortalized line derived from normal breast epithelium, H16N2, two metastastic tumors, 21-MT1 and 21-MT2, and two primary tumors, 21-NT and 21-PT all derived from the same patient, and grown inDFCImedium (Band, V. and Sager, R., "Tumor Progression in Breast Cancer" in Neoplastic Transformation in Human Cell Culture, J.S. Rhim and A. Dritscbilo eds., The Human Press Inc., Totowa, NJ. (1991), pp. 169-78) were generously provided by Dr. Vimla Band, New England-Tufts Medical Center. The bladder tumor cell line ppTllA3 was derived from the immortalized nontumorigenic cell line SV-HUC. These bladder cell lines were generously provided by Dr. Catherine Reznikoff, University of Wisconsin Clinical Cancer Center, and grown in F12 medium supplemented with 1% FBS, 0.025 units insulin, 1 ug hydrocortisone, 5 ug transferrin, 2.7 g dextrose, 0.1 uM nonessential amino acids, 2 mM L-glutaxnine, 100 units penicillin, and 100 ug streptomycin per 500ml. Normal proliferating breast epithelial cells (MEC) were purchased from Clonetics (BioWhittaker) and maintained according to the supplier's directions.

[0535] KNAextraction and Northern Blot Analysis: Cell lines were harvested for RNA extraction at approximately 80% confluency. Cells were harvested and lysed in QG buffer from Qiagen RNAeasy kit. Total RNA was extracted as per manufacturer's protocol and stored at -80°C as precipitates with GITC and alcohol. Tissue samples, were provided by the Cooperative Human Tissue Network as snap frozen samples, which were homogenized in lysis buffer for use in the RNAeasy protocol. For Northern blots, mRNA was extracted from total RNA (30 ug total RNA/well) using Dynal's (Lake Success, NY) oligo-dT25 3% formaldehyde. The mRNA was blotted onto Genescreen Plus (NEN) in 10X SSC overnight by capillary blot, then baked for 2 hours at 80°C. Membranes wereprobed with random-primed 32P-labeledcDNAprobes (Prime-It, Stratagene, LaJolla, CA) at 106 cpm/ml Quickhyb solution (Stratagene), at 68°C as per manufacturer's protocol. Blots were exposed to Xray film and/or phosphorimager screens overnight. Expression on all blots was normalized to a housekeeping gene, such as GAPDH or beta actin.

[0536] Subtractive Hybridization: PCRSelectcDNASubtractionKit(Clontech, Palo Alto, CA), based on Representational Difference Analysis as first described by Lisitsyn et al.(Lisitsyn, N. and Wigler, N.M., Science259:946-51 (1993)), was employed as per manufacturer's protocol to generate cDNAs enriched for genes overexpressed in tumor compared to normal breast cell lines. Briefly, oligo-dT-primed double stranded cDNA was synthesized from 2 ug high quality, DNase-treated niRNA from tumor and normal cells. Adaptors were ligated to short blunt-end (Rsal digested) tumor sequences and hybridized with excess Rsal digested normal fragments. Following 32 hour hybridization, suppression PCR (Clontech) allowed preferential amplification of overexpressed tumor sequences using adaptor sequences as primers. The products of the PCR amplification were cloned into pT7Blue3 (Novagen, Madison, WI) to generate a subtracted library. Clones were grown in LB/ampicillin (lOOug/ml) in 96-well format, inserts were PCR amplified from the overnight cultures and PCR products were spotted on Genescreen Plus using BioDot manifold (BioRad, Hercules, CA). Duplicate dot blots were then probed with random-primed tumor or normal cDNA, or, alternatively, the PCR products of the forward and reverse subtractive hybridizations. Clones that appeared to be overexpressed in the tumor cDNA and forward subtraction (tumor minus normal) were analyzed by Northern Blot (as described above) to confirm differential gene expression.

[0537] cDNA library and full length gene: Oligo-dT primed double stranded cDNA was generated from SKBR3 cell line using SMART cDNA Synthesis (Clontech *^#«iiWnes),T'felk>^eddby :.phen0lxhloroform:isoamyl alcohol extraction. Primers were synthesized (C35 sense: 5'-GCGATGACGGGGGAGCC, and C35 antisense: 5'-CCACGGAATCTTCTATTCTTTCT; Fisher Oligos, The Woodlands, TX) to amplify the coding region of C35, based on the open reading frame deduced from EST homologies, Accession# W57569,inparticular. PCRproducts were cloned into pT7Blue 3 (Novagen).

[0538] Vaccinia and Retroviral C35 recombinants: The coding sequence ofC35 was subcloned from the library into vaccinia transfer plasmid, pVTKO at BamHI/Sall sites in a defined orientation. Recombinant virus was generated by transfection of pVTK0.C35 along with NotI and Apal digested V7.5/TK viral DNA into fowlpox virus infected BSC-1 cells. As described elsewhere (U.S. Utility Patent Application No. 08/935,377; PCT/US98/24029; T Cells Specific for Target Antigens and Vaccines Based Thereon), this is an efficient method for construction of vaccinia virus recombinants. The C35 gene was also cloned into a retroviral vector pLXSN, and viral stocks were generated by co-transfection of 293-GP cells with pVSVg for pseudotyping. Supematants including infectious virus were collected 48 hours later.

[0539] Generation ofC35-spedfic2C3 monoclonal antibody and FACSanalysis: Linel mouse small cell lung carcinoma cells were infected with C35-retrovirus, and 103 - 2 x 104 cells were injected into three BALB/cByJ mice. Following 21 days, serum was harvested from retro-orbital bleeds and checked for reactivity with human tumor cells known to express low (MDA-MB-231) or very high (21NT) levels of C3 5 mRNA. Spleens were also harvested for the production of hybridomas by the fusion of spleen cells with P3 myeloma cells using standard mouse hybridoma technology. ELISA was used to screen HAT resistant clones • for the presence of Ig. High producers were isotyped, quantitated, and used to screen C35+ and C35- cell lines by flow cytometry. Hybridoma clone supematants containing 1 ug IgG were incubated with 106 cells in PAB (PBS, 1% BSA, 0.1% azide) for 30 min on ice, followed by 3 washes with PAB, and inci^atiori^ a0tp®oii®®es4gG conjugated to FJTC (Southern Biotechnology, Birmingham, AL) for 30 minutes on ice. One hybridoma clone, 2C3, recapitulated the surface staining seen with the immune serum (FIGS. 14A-14B) and was selected for expansion and antibody purification (BioExpress, West Lebanon, NY).

[0540] Generation of human C35-specific T cell line: Peripheral blood derived from a healthy female donor (HLA A2, 11, B35, 44) was separated into erythrocyte-rosette positive fraction'(a source of total T lymphocytes) and negative fraction (a source of monocytes). The T lymphocytes were cryopreserved for later use while the monocytes were incubated under conditions to generate dendritic cells (DC). Maturation of DCs was induced as described by Bhardwaj and colleagues (Bender, A. et ah, J. Immunol. Meth. 196:121-35 (1996); Reddy, A. et al., Blood 90:3640-46 (1997); Engelmayer, J. et al., J. Immunology 163:6762-68 (1999)) with some modifications. hGM-CSF and hIL-4 (lOOOU/ml) were added every other day. At day 7, non-adherent, immature DC were incubated wilh a retrovirus recombinant for C35 for 6 hours in the presence of GM-CSF and IL-4. At this point, the retroviral supernatant was washed out and immature dendritic cells were subjected to maturation conditions, which again included GM-CSF, IL-4 as well as 12.5% monocyte conditioned medium (MCM). After 4 days, these mature, C35-expressing DC were used to stimulate autologous T cells at a ratio of 1 DC:50 T cells for a period of 14 days. A fresh pool of autologous DC were generated for restimulation of the T cells, but this time they were infected after 48 hours of maturation in MCM with a vaccinia virus recombinant for C35. Cytokines IL-2 (20 U/ml), IL-12 (20 U/ml) and IL-18 (10 ng/ml) were added and a 1:50 ratio of DC:T cells was maintained. Following ^ 12 days culture, T cells were stimulated for 7 additional days with EBV-B cells infected with C35 recombinant retrovirus and with addition of JL-2 (20 U/ml) and IL-7 (lOng/ml). Cytokines were all purchased from R&D Systems (Minneapolis, MN). At this point, the cells were >90% CD8+ and were tested for activity in a standard 51Cr Release assay. Briefly, one million target cells were incubated wilh 1640, supplemented with 10% human AB serum (BioWhittaker). Activity ofthe CTL is expressed as the percent of specific lysis, measured as (51Cr released into the supernatant upon lysis of labeled targets by CTL - spontaneous release)/(maximal release - spontaneous release).

Results Characterization of C35: The sequence of clone C35, differentially expressed in human breast tumor cells, is not homologous to any known gene in Genbank, but homologous EST sequences (prototype Accession# W57569) were identified. Homologous human EST fragments are present inNCICGAP (Cancer Genome Anatomy Project) libraries, including tumors of brain, lung and kidney (A# AA954696), Soares ovary (A# AA285089) and parathyroid tumors (A# W37432), an endometrial tumor (A#AA337071), and colon carcinoma (A# AA313422). An open reading frame was identified that encodes a 115 amino acid protein (FIG. 10A). The full-length gene was isolated from a cDNA library of the breast adenocarcinoma cell line SKBR3. Sequencing of full-length transcripts from the cell lines SKBR3, 21MT2-D, and H16N2 confirmed that there were no point mutations in the cDNA; the transcript is 100% homologous in C35hi cell lines, as well as C35l0 cell lines. The C35 gene aligns on human chromosome 17ql2 (A# AC040933) and mouse chromosome 11 (A# AC064803). Exons were deduced from homologies with cDNA EST sequences, as well as GRAIL predictions. Interestingly, the gene for C35 is within 1000 base pairs of the Her2/neu oncogene and within2000bp of the gene for Growth Factor Receptor-Bound Protein 7 (GRB7), a tyrosine kinase that is involved in activating the cell cycle and that is overexpressed in esophageal carcinomas (Tariaka, S. et al., J Clin. Invest. 102:821-27 (1998)) (FIG. 10B). Her2/neu protein overexpression has been correlated with gene amplification in 30% breast tumors and is associated with poor clinical prognosis (Slamon, D J. et al., Science Predicted protein motifs in the C35 amino acid sequence include: casein kinase Uphosphorylation sites at amino acids 38 to 41 (TYLE), 76 to 79 (SKLE), and 97 to 100 (SNGE); an N-myristoylation site at amino acids 60 to 65 (GGTGAF); and a cAMP- and cGMP-dependent protein kinase phosphorylation site at amino acids 94 to 97 (REAS). Finally, Hie C35 protein contains a prenylation motif at the COOH-terminus, amino acids 112 to 115 (CVIL). Prenylation, the covalent attachment of a hydrophobic isoprenoid moiety, is a post-translational modification that promotes membrane association and also appears to mediate protein-protein interactions (Fu, H.-W. and Casey, P. J., Recent Progress in Hormone Research 54:315-43 (1999)). Prenylation has been shown to be required for localization and transforming potential ofthe oncogenic Ras family proteins to the cell surface (Jackson, J.H. etal, Proc. Natl. Acad. Sci. U.S.A. 87:3042-46 (1990); Hancock, J.F. et al., Cell 57:1167-77 (1989)). Inhibitors of prenylation have been shown to possess anti-tumor activities, such as slowing tumor growth (Garcia, A.M. et al, J. Biol. Chem. 2(55:18415-18 (1993)) and to promote rejection in animal models (Kohl, N.E. et al., Nature Med. 1:192-91 (1995)). Three O-glycosylation sites are predicted at or near the amino terminus — thr8, ser2, and ser9 using NetOGlyc2.0.

C35 Transcript is Overexpressed in Breast and Bladder Carcinoma: An \ ideal target antigen for tumor immunotherapy would be abundantly expressed in multiple independent carcinomas, and would be absent or minimally expressed in normal proliferating and vital tissues. Differential expression of C35 was confirmed by Northern blot analysis. C35 is expressed in 7/10 human tumor cell lines at levels 10-25X higher than expression in a normal immortalized breast epithelial cell line, H16N2 (FIG. 11 A). Importantly, C35 expression is shared among lines derived from both primary (21NT, 21PT) and metastatic (21MT1, 21MT2) lesions of a single patient, suggesting its expression may be associated with early events in the process of tumor transformation. In addition, the overexpression of C35 is shared among independently derived human mammary c^cindfaa:^#^^^BBiing S®E^i,47D»llndBT474. Interestingly, the C35 expression pattern in SKBR3, MDA MB231, H16N2 and tumors derived from the same patient correlates with Her2/neu expression, which may be associated with the close genomic proximity of the two genes and the incidence of HER2/neu gene amplification.

[0544] To investigate whether C35 expression in patient derived tumors is clinically relevant for development of a cancer vaccine, mRNA was extracted from snap frozen human tissue samples obtained fromjthe Cooperative Human Tissue Network (CHTN). 70% ofprimarybreasttumor samples overexpress C35 transcript (FIG. 11B), and 35% (7/20) of these breast adenocarcinomas overexpress at levels 10-70 fold higher than normal breast Overexpression of C3 5 is also seen in 50% of bladder carcinoma primary specimens examined (FIG. 12), while 20% (3/14) of primary bladder carcinoma express at levels greater than 10 fold higher than normal bladder. Overexpression of C35, at levels 9X or greater, was not detected in panels of ovarian (0/7), prostate (0/5), or colon (0/15) carcinomas (data not shown).

[0545] 2C3 Monoclonal Antibody reacts with C35+ cells: In order to confirm differential expression of the gene product encoded by C35, a monoclonal antibody against the shared tumor antigen was selected. Hybridomas were produced by immunizing mice with a poorly immunogenic BALB/cByJ tumor cell line, which had been transduced with a retroviral human C35 recombinant Hybridoma clones were screened for their ability to stain C35-H- breast and bladder tumor cell lines (FIGS. 13A and 13B). Non-tumorigenic breast H16N2 and bladder SV-HUC epithelial cell lines did not show a significant shift in fluorescence intensity when compared to the isotype control. In contrast, 2C3 monoclonal antibody specifically stained C35+ breast tumors, SKBR3 and 21-NT-D, and bladder tumor ppTl 1 A3. The staining was carried out on cells that were neither fixed nor permeabilized, indicating that 2C3 antibody recognizes a surface molecule.

Mribition of tumor growth with C35 antibodies:

[0546] Antibodies are useful tools to detect diagnostic markers of cancer, but they may also have potential use for therapeutic applications. Humanized Her2/neu specific antibody (Herceptin) has been successfully employed for treatment of some breast cancers. Herceptin binds HER2/neu and downregulates signal transduction from the growth factor receptor. Growth inhibition studies were performed with C35-specific 2C3 antibody. 21NT-D breast tumor and H16N2 "normal" breast cell lines were grown in vitro in the presence of various antibody concentrations. . An XTT assay was performed to evaluate cell expansion at 72 hours. Results shown in FIGS. 14A and 14B indicate that 2C3 inhibits growth of 21NT tumor cells by approximately 50% at concentrations as low as 1 ug/ml.

AC35 Class I epitope is HLA-A2 restricted:

[0547] Establishment of self-tolerance is a major obstacle to development of vaccines based on self proteins. Tolerance, however, must be defined in terms j of quantitative levels of expression. It is possible that even while high affinity antigen-specific T cells are tolerized, T cells with lower affinity receptors that do not have functional avidity for a low concentration of antigen escape tolerance induction. These same T cells could, however, subsequently become functionally significant if there is markedly increased avidity associated with overexpression of the target antigen. Even if they are few in number, such T cells could be expanded by the most fundamental of immunological manipulations, vaccination.

[0548] C35 is a self-protein expressed at low basal levels in normal human tissues. It was, therefore, necessary to determine if human T cells are tolerant to C35 at levels of expression characteristic of carcinomas. The only way to exclude tolerance is by demonstrating responsiveness, and the only way to demonstrate stimulation. Human T cells aad autologous dendritic cells were derived from PBL from a normal donor. The T cells were primed by alternate stimulation with autologous dendritic cells infected with retroviral or pox virus recombinants of the C35 cDNA. CTL recovered in vitro following several cycles of stimulation were analyzed for their ability to lyse C35+ target tumor cells (FIGS. 15A and 15B) or to secrete cytokines in response to antigen induced activation (FIGS. 16A and 16B). The targets either endogenously expressed C35 and/or HLA-A2.1, or were engineered to express these proteins via standard transfection with a C35-recombinant mammalian expression vector, or by infection with C35-recombinant vaccinia virus. Previous studies have demonstrated that protein expression by vaccinia virus is an efficient means oftargetingpeptides to theMHC-Iprocessingpathway (Moss, B., Science 252:1662-67 (1991).

[0549] Following several rounds of stimulation, both a bulk T cell line and a T cell clone were selected that differentially lyse C3S+ tumor cells relative to C35'° H16N2 normal breast epithelial cell line in a 51Cr release assay (FIGS. 15A and B). The HLA-A2 restricted C35-specific CTL clone 10G3 efficiently lysed the HLA-A2 transfected tumorigenic cell line, 21-NT.A2, which expresses C35 antigen at levels 15X greater than H16N2 and is stained with 2C3 monoclonal antibody. Specific lysis was also with the HLA-A2+ bladder tumor cell line ppTHA3 compared to the non-tumorigenic bladder cell line SV-HUC from which it was derived (FIG. 15B). The data demonstrate CTL sensitivity of tumors that express high levels of C35 with minimal lysis of C35l0 nontumorigenic immortalized cell lines. Importantly, the same CTL are not reactive with MEC, a primary culture of non-immortalized, non-transformed, HLA-A2+ breast epithelial cells that do not express C35 at significant levels. Further evidence to support C35+ tumor recognition by the T cells is shown in FIGS. 6A and 16B. The T cells secrete IFN-gamma and TNF-alpha in response to C35+, HLA-A2+ stimulator. Again, the non-tumorigenic, C35'° cell line H16N2.A2 did not induce cytokine secretion by C35-specific T cells. However, for£35 confers the ability \ ) to activate the T cells. Since the T cells do not secrete IFN-gamma or TNF-alpha in response to HI 6N2.A2 transduced with an irrelevant protein L3, this indicates that the response is specific to C35 protein expression (FIGS. 16A andB). {0550] Following several rounds of stimulation, both a bulk T cell line and a T cell clone were selected that differentially lyse C35+, HLA-A2+ tumor cells in a 5lCr release assay. The C35-specific CTL did not lyse the HLA-A2 transfected non-tumorigenic breast epithelial cell line, H16N2.A2 (FIGS. 15A and 15B), although this cell Une does express C35 at low levels based on the Northern blot data shown in FIG. 11 A. However, C35-specific CTL efficiently lysed the HLA-A2 transfected tumorigenic cell line, 21-NT.A2, which expresses C35 antigen at levels 15X greater than H16N2 and is stained with 2C3 monoclonal antibody. C35+ tumor-specific lysis was also shown with the bladder tumor cell line ppTllA3 compared to the non-tumorigenic bladder cell line SV-HUC from which it was derived. The data demonstrate CTL sensitivity of tumors that express high levels of C35 with minimal lysis of C35l0 nontumorigenic immortalized cell lines. Importantly, the same CTL are not reactive with MEC, a primary culture of non-immortalized, non-transformed, HLA-A2+ breast epithelial cells that do not express C35 at significant levels. Further evidence to support C35+ tumor recognition by the T cells is shown in FIGS. 16A and 16B. The T cells secrete IFN-gamma and TNF-alpha in response to C35+, HLA-A2+ stimulator. Again, the non-tumorigenic, C35l0 cell lineH16N2.A2 didnotinduce cytokine secretion by C35-specific T cells. However, infection of this line with vaccinia virus recombinant for C35 confers the ability to activate the T cells. Since the T cells do not secrete IFN-gamma or TNF-alpha in response to H16N2.A2 transduced with an irrelevant protein L3, this indicates that the response is specific to C35 protein expression. (0551] The C35-specific T cells were generated from a donor with HLA i haplotype A2, All, B8, B35. The bladder cell lines, SV-HUC and ppTllA3 derive from a donor with haplotype HLA-A2, B18, B44. However, since the tumor cell lines derived from the same HLA-A2 negative donor, these cell lines had to be transfected with HLA-A2.1 to provide a required MHC restriction element for recognition by HLA-A2 restricted 10G3 T cell clone (FIGS. 16Aand 16B). The T cells were strongly stimulated to secrete these lymphokines by the breast lines that expressed both C35 and HLA-A2 (compare 21-MT2 with 21-MT2.wA2). The data indicate that there is at least one HLA-A2.1 defined epitope of C35.

[0552] Deletion mutants of C35 coding region were constructed to identify cDNA segments that encode the peptide epitope recognized by the CTL. FIGS. v 15A and 15B demonstrate almost equivalent IFN-gamma and TNF-alpha secretion by T cells stimulated with the full length C35 or a truncated mutant encompassing only the first 50 amino acids.

Discussion

[0553] C35 is a novel tumor antigen that is overexpressed in breast and bladder carcinoma. The gene has properties that make it a promising candidate for tumor immunotherapy. It is expressed in a significant number of tumors derived from different individuals. Expression in vital normal tissues is relatively low, reducing the risk of autoimmune reactions and, equally important, making it unlikely that immune cells have been rendered tolerant to the gene product. C35 is characterized as a "tumor antigen" since C35 expressing dendritic cells induce autologous tumor specific human cytotoxic T lymphocytes in vitro.

[0554] C35 is a novel gene product of unknown function. However, our studies with monoclonal antibodies have provided some insight into the localization of the protein. Both serum and a monoclonal antibody derived from a C35-immunized mouse specifically stain unfixed cells that express C35. This suggests that the antibody recognizes a tumor surface membrane protein. Although the protein sequence does not conform with known transmembrane motifs based on insertioninto the membrane. Prenylation is apost-translational lipid modification that produces a substantially more hydrophobic protein with high affinity for the membrane (Fu, H.-W. and Casey, P. J., Recent Progress in Hormone Research 54:315-43 (1999)). Other proteins that contain prenylation sites include the Ras oncogene family. Ras GTPases act in signal tranduction cascades with MAPK to induce cell division and proliferation. Ras proteins are anchored to the plasma membrane via prenylation, but the proteins remain in the cytoplasmic face of the membrane. Therefore, it is possible that C35 also remains on the cytoplasmic side of the membrane, but there may be sufficient transport to the outer surface to be detected with a specific antibody.

[0555] C35-specific antibodies are valuable tools for studying the protein expression of C35, to corroborate Northern blot analysis, and for use in assays such as Western blots and immunohistochemistry. In addition, these antibodies may have therapeutic benefits, such as has been recently been demonstrated for Herceptin (Baselga, J. et al., J. Clin. Oncol. 14:737-44 (1996); Pegram, M.D. et al., J. Clin. Oncol. 16:2659-71 (1998)), an antibody to the tumor-associated antigen HER2-ne« (c-erbB-2) (Schechter, A.L. etal., Nature 3 72:513-16 (1984). Herceptin's anti-tumor effects include binding the epidermal growth factor receptor, which inhibits tumor cell growth, and eliciting antibody dependent cell-mediated cytotoxicity (Dillman, R.O., Cancer Biotherapy & Radiopharmaceuticals 14:5-10 (1999).

EXAMPLE 6 Induction of Cytotoxic T Cells Specific for Target Antigens of Tumors

[0556] Human tumor-specific T cells have been induced in vitro by stimulation of PBL with autologous tumors or autologous antigen presenting cells pulsed with tumor lysates (vanDerBruggen, P. etal., Science 254:1643-1647 (1991); Yasumura, S. et al., Cancer Res. 53:1461-68 (1993); Yasumura, S. et al, Int. ~ / etM^-Cancer Res, -57:1537-46 (1997); Jacob, L. et ah, Int. J. Cancer 71:325-332 (1997); Chaux, P. et al., J. Immunol. 163:2928-2936(1999)). PBL have been derived from either patients deliberately immunized with tumor, with tumor modified to enhance its immunogenicity, or with tumor extracts, orpatients whose only prior stimulation was in the natural course of disease. T cells with reactivity for infectious agents could be similarly derived by in vitro stimulation of T cells with autologous cells that have been either infected in vitro or were infected in vivo during the natural course of exposure to the infectious agent. CD4+ and CD8+ T cells or antibody selected under these or other conditions to be specific for either tumor cells or cells infected with either a virus, fungus or mycobacteria or T cells or antibodies specific for the target antigens of an autoimmune disease could be employed in the selection and screening methods of this invention to detect and isolate cDNA that encode these target antigens and that have been incorporated into a representative cDNA library.

[0557] In spite of demonstrated success in the induction of human T cell responses in vitro against a number of antigens of tumors and infected cells, it is not certain that these represent the full repertoire of responses that might be induced in vivo. Because safety considerations limit the possibilities of experimental immunization in people, there is a need for an alternative animal model to explore immune responses to human disease antigens. The major obstacle to developing such a model is that numerous molecules expressed in normal human cells are strongly immunogenic in other species. It is, therefore, 1 necessary to devise a means of inducing tolerance to normal human antigens in another species in order to reveal immune responses to any human disease-specific antigens. It is now recognized that activation of antigen-specific T lymphocytes requires two signals of which one involves presentation of a specific antigenic complex to the T cell antigen receptor and the second is an independent costimulator signal commonly mediated by interaction of the B7 family of molecules on the surface of the antigen presenting cell with the CD28 Lin the absence of a costimulator signal not only fails to induce T cell immunity but results in T cell unresponsiveness to subsequent stimulation (Lenschow, D J. et al., Ann. Rev. Immunol. 14:233-258 (1996)). Additional studies have revealed a key role for another pair of interactions between the CD40 molecule on the antigen presenting cell and CD40 ligand on the T cell. This interaction results in upregulation of the B7 costimulator molecules (Roy, M. etal., Eur. J. Immunol. 25:596-603 (1995)). In the presence of anti-CD40 ligand antibody either in vivo or in vitro, the interaction with CD40 is blocked, B7 costimulator is not up regulated, and stimulation with a specific antigenic complex results in T cell tolerance rather than T cell immunity (Bluestone, J.A. et al., Immunol. Rev. 165:5-12 (1998)). Various protocols to block either or both CD40/CD40 ligand interactions and B7/GD28 interactions have been shown to effectively induce transplantation tolerance (Larsen, C. etal., Nature 381:434-438 (1996); Kirk et al., Nature Medicine 5:686-693 (1999)). An example of the effect of anti-CD40 ligand antibody (anti-CD 154) in blocking the reactivity of murine T cells to specific transplantation antigens is shown in FIGS. 17A and 17B. DBA/2 (H-2d) mice were immunized with 107 C57B1/6 (H-2b) spleen cells intraperitoneally and, in addition, were injected with either saline or 0.5 mg monoclonal anti-CD40 ligand antibody (MR1, anti-CD154, Pharmingen 09021D) administered both at the time of immunization and two days later. On day 10 following immunization, spleen cells from these mice were removed and stimulated in vitro with either C57B1/6 or control allogeneic C3H■■(H-2k) spleen cells that had been irradiated (20 Gy). After 5 days in vitro stimulation, C57B1/6 and C3H specific cytolytic / ■ ■ . responses were assayed at various effector:target ratios by Cr release assay from specific labeled targets, in this case, either C3H or C57B1/6 dendritic cells pulsed with syngeneic spleen cell lysates. The results in FIGS. 17A and 17B show that significant cytotoxicity was induced against the control C3H alloantigens in both saline and anti-CD 154 treated mice whereas a cytotoxic response to C57B1/6 was induced in the saline treated mice but not the anti-CD154 treated mice. This stimulation at the time CD40/CD40 ligand interactions were blocked by anti-CD154. {0558] A tolerization protocol similar to the above employing either anti-CD 154 alone or a combination of anti-CD 154 and anti-B7 or anti-CD28 could be employed to induce tolerance to normal human xenoantigens in mice prior to immunization with a human tumor, hi one embodiment, the normal antigens would be expressed on immortalized normal cells derived from the same individual and tissue from which a tumor cell line is derived. In another embodiment, the normal and tumor antigens would derive from cell lysates of normal and tumor tissue of the same individual each lysate pulsed onto antigen presenting cells for presentation to syngeneic murine T cells both in vivo and in vitro. In a prefeired embodiment, the tumors would derive by in vitro mutagenesis or oncogene transformation from an immortalized, contact-inhibited, anchorage-dependent, non-tumorigenic cell line so that very well-matched non-tumorigenic cells would be available for tolerance induction.

[0559] An alternative to the tolerization protocols is depletion of T cells that are activated by normal antigenspriorto immunization with tumor. Activated T cells transiently express CD69 and CD25 with peak expression between 24 and 48 hours post-stimulation. T cells expressing these markers following activation with normal cells or normal cell lysates can be depleted with anti-CD69 and anti-CD25 antibody coupled directly or indirectly to a matrix such as magnetic beads. Subsequent immunization ofthe remaining T cells with tumor cells or tumor cell lysates either in vitro or in vivo following adoptive transfer will preferentially give rise to a tumor-specific response. \

[0560] In one embodiment, the mice to be tolerized to normal human cells or lysates and subsequently immunized with tumor cells or lysates are any of a variety of commercially available inbred and outbred strains. Because murine T cells are restricted to recognize peptide antigens in association with murine MHC molecules which are not expressed by human cells, effective tolerization or human cells with murine MHC molecules or re-presentation of human normal and tumor antigens by mouse antigen presenting cells. Dendritic cells are especially preferred as antigen presenting cells because of their ability to re-present antigenic peptides in both the class I and class II MHC pathways (Huang, et al, Science 264:961-965 (1994); Inaba, et al., J. Exp. Med. 176:1702 (1992); Inaba, et al, J. Exp. Med. 178:479-488 (1993)). In another embodiment, mice double transgenic for human HLA and human CD8 or CD4 are employed. The HLA transgene permits selection of a high affinity, HLA-restricted T cell repertoire in the mouse thymus. In addition, a human CDS or CD4 transgene is required because murine CD8 and CD4 do not interact efficiently with the cognate human class I or class II MHC molecules. The use of non-transgenic mice to generate human tumor-specific T cells would lead to identification of any human tumor antigens that can be processed in association with murine MHC molecules. Since multiple murine strains with diverse MHC molecules are available, this could encompass a wide range of antigens. However, it would have to be separately determined by stimulation of human T cells with autologous antigen presenting cells whether these tumor-specific antigens also express peptides that can be processed-and presented in association with human HLA. Such peptides may or may not overlap with those initially detected in association with murine MHC molecules but would deri ve from the same set of proteins. By employing HLA transgenic mice it is possible to more directly address the relevance of antigenic peptides to human MHC. There can, however, be no assurance that peptide processing will be identical in murine and human antigen presenting cells. It is essential, therefore, to confirm that HLA-restricted, human tumor antigen-specific T cells are indeed also Crossreactive on human tumor cells. Finally, no matter how the issue ofprocessing and presentation in association with human HLA is addressed, it must in all cases be determined whether human T cells are reactive to the identified antigens or whether they have beeri'rendered tolerant, perhaps due to expression of the same or a related antigen in some other non-homologous normal tissuerif^va# ^ eanbeobtained through in vitro stimulation of human T cell responses with the identified antigens or antigenic peptides presented by autologous antigen presenting cells. Ideally, it would be shown that patients with antigen positive tumors have an increased frequency of T cells reactive with the purported tumor-specific antigen. To demonstrate that the antigen-specific human T cells induced can be effective in eradicating tumors, the selected human T cells could be adoptively transferred into SCID mice bearing a human tumor xenograft as described by Renner, C. et al., Science 264:833-835 (1994). However, definitive evidence for clinical relevance would await the results of a human clinical trial.

Conditions for in vitro stimulation of primary human T cell responses are described in Example 2 and are applicable to both CD4+ and CD8+ responses. The strategies described for induction of human T cell or antibody responses specific for human tumors are equally applicable to induction of T cell or antibody responses to target antigens of human cells infected with either a virus, fungus or mycobacteria. Indeed, in this case the same uninfected cell population affords an immediately available normal control population for tolerance induction and to confirm infectious specificity.

The construction of transgenic mice is well known in the art and is described, for example, in Manipulating the Mouse Embroy: A laboratory Manual, Hogan, et al., Cold Spring Harbor Press, second edition (1994). Human CD8 transgenic mice maybe constructed by the method of LaFace, et al„ J. Exp. Med. 752:1315-25 (1995). Construction of new lines of transgenic mice expressing the human CD8alpha and CD8beta subunits maybe made by insertion ofthe corresponding human cDNA into a human CD2 minigene based vector for T cell-specific expression in transgenic mice (Zhumabekov, et al., J. Immunol. Methods 255:133-140 (1995)). HLA class I transgenic mice maybe constructed by the methods of Chamberlain, et al., Proc. Natl. Acad. Sci. USA 85'.7690-7694 (1988) orBernhard, etal, J. Exp. Med. 755:1157-1162 (1988) or Vitiello, etal, /. Exp. Med. 773:1007-1015 (1991) orBarra, etal, J. Immunol. 750:3681-3689

[0563] Construction of additional HLA class I transgenic mice may be achieved by construction of an H-2Kb cassette that includes 2 kb of upstream regulatory region together with the first two introns previously implicated in gene regulation (Kralova, et al, 1992, EMBO J. 11:4591-4600). Endogenous translational start sites are eliminated from this region and restriction sites for insertion of HLA cDNA are introduced into the third exon followed by a polyA addition site. By including an additional 3kb of genomic H-2Kb sequence at the 3' end of this construct, the class I gene can be targeted for homologous recombination at the H-2Kb locus in embryonic stem cells. This has the advantage that the transgene is likely to be expressed at a defined locus known to be compatible with murine class I expression and that these mice are likely to be deficient for possible competition by H-2Kb expression at the cell membrane. It is believed that this will give relatively reproducible expression of diverse human HLA class I cDNA introduced in the same construct.

EXAMPLE 7 Induction of GM-CSF Secretion by Line 4 T Cells Stimulated with the C3 5 Peptide Epitopes

[0564] T cell line 4 was generated by stimulating normal donor T cells for 12 days each with autologous dendritic cells (DC) and then autologous monocytes infected with C35 recombinant vaccinia, virus. "Weeklystimulation was continued with alio PBL and the 2 INT tumor transfected with HLA-A2/Kb (21NT-A2). The results of the experiment are depicted in FIG. 18. For this experiment, T cells were restimulated in vitro at 106 T cells per well with 5 x 104 irradiated (2500 rads)H16N2-A2/Kb pulsed with lug/ml of C3 5 peptides 9-17,77-85,104-112, or 105-113 and 105 irradiated alio PBL per well with IL2 (20U/ml) and IL-7 (lOng/ml) in AIM-V/5% human AB serum. After two (2) rounds of stimulation for 7 days, T cells were tested for induction of GM-CSF secretion following incubation with different stimulators pulsed or not pulsed with lug/ml of peptide or infected with vvC35 drvvwT at m01= 1. Tcells (5000) were incubated with 25000 of the various stimulator cells overnight in AIM-V/5% human AB serum ill triplicate.

[0565] As shown in FIG. 18, no GM-CSF stimulation was observed with normal breast epithelial cells transfected with HLA-A2/Kb (H16N2-A2). However, the same cells pulsed with the C35 peptides produced significant stimulation (A16N2-A2+peptide). Stimulation was seen for cells pulsed with each peptide, with peptide 77-85 showing the greatest stimulation. In addition, significant stimulation was seen with the 21NT tumor celis transfected with HLA-A2/Kb (21NT-A2) but not pulsed with C35 peptides, as well as normal breast epithelial cells transfected with HLA-A2/Kb and infeicted with C35 recombinant vaccinia virus (H16N2-A2 wC35). As expected, no stimulation was seen with normal breast epithelial cells transected with HLA-A2/Kb and infected with wild-type vaccinia virus.

[0566] The fact that minimal stimulation was seen HI 6N2-A2 cells that were hot pulsed with any ofthe C35 peptides yet substantial stimulation was seen with the same cells pulsed with peptides confirms that each of the C35 peptides tested associates with HLA2. Moreover, the fact that the 21NT-A2 tumor cells also showed stimulation even though they had not been pulsed with any C35 peptides confirms that the C35 peptides are produced (i.e., processed) by the tumor cells. Finally, the fact that stimulation was observed with the HI 6N2-A2 cells infected with C35 recombinant vaccinia virus confirms that the full-length C35 polypeptide introduced recombinantly is processed in the cells.

EXAMPLE 8 Generation of Peptide Specific CD8+ T Cells CD8+ T cell selection

[0567] PBMCs wereharvested using standard Ficoll-Hypaque separation of anti-coagulated hifiitaaMoidi ^Wii|0tod \p»^iitett^ithIffiSS (w/o Ca2+7Mg2*) 2:1, in 50 ml centrifuge tubes. 30 ml of blood was then layered over 12 ml ficoll. The blood was centrifuged at 18°C, 400 x g for 30 minutes, with the brake off. The interface layer containing PBMC was removed and washed 2x with HBSS.

[0568] CD8 positive cells were selected via magnetic activated cell sorting (MACS) manufactured by Miltenyi Biotec, Auburn, CA. Specifically, the PBMCs are pelleted and resuspended in 80 /A MACS buffer (degassed, ice-cold PBS pH 7.2, supplemented with 0.5% BS A and 2 mM EDTA) per 107 total cells. 20 fj\ of MACS CD8 microbeads was added per 107 cells, mixed well and incubated for 15 minutes at 6-12°C. The cells were then washed by adding 12 ml MACS buffer, centrifuged at 300 x g for 10 minutes at 4°C, the supernatant removed completely and the pellet resuspended in 1-2 ml MACS buffer. A positive selection VS+ MACS column was placed in the magnetic field of a separator. The column was prepared by washing with 3 ml MACS buffer. The cell suspension was applied to the column, allowing the cells to completely enter the column. The column was then rinsed with 3 x 3 ml MACS buffer.

[0569] The column was removed from the separator and placed in a collection tube. 5 ml of MACS buffer was then pipetted onto the column and the cells firmly flushed through with supplied plunger. The CD8+ cell type was verified via flow cytometry. The cells were either kept in culture in AIM-V media (Gibco, Carlsbad, CA) with 10% human AB serum (Gemini Bioproducts, Woodland, CA) or frozen in 10% DMSO & 90% human AB serum at -80°C for later use.

Generation & maturation of dendritic cells (DCs) DC selection from PBMCs

[0570] The PBMCs were plated out, either inclusive of all PBL or following CD8+ and/or CD4+ cell selection. CD4+ cells were selected in the same manner as the CDS^©gii^Q^US^i#lip^vBiofecMACS-CD4miGrobeads. The absence or presence of PBL does not make a difference in DC selection. PBMCs werethen plated at 5-7 x 106 cells/well in 6-well plates in RPMI serum free media for 2 hrs at 37°C. Non-adherent cells were removed and the adherent layer washed with 3x with HBSS. Adherent cells were incubated in StemSpan (StemCell Technologies, Vancouver, BC, Canada) with 1% human AB serum, 1000 U/ml GM-CSF and 1000 U/ml IL-4 at 37°C, 7% C02 for 7 days for generation of immature Dcs. Media and cytokines were replenished every other day.

DC maturation [05711 On day 7 immature DCs were collected by harvesting the non-adherent cells. The DCs were incubated in StemSpan with 1% human AB serum, 1000 U/ml GM-CSF, 1000 U/ml IL-4,10 ng/ml TNFa and 1 jug/ml CD40L for 24-48 hrs, 37°C, 7% C02, to mature.

CD8+ cell stimulations with peptide pulsed APCs [05721 A first stimulation was performed utilizing peptide pulsed autologous Dcs. The CD8+ cells used were either fresh or brought back into culture from -80° a minimum of 24 hr prior to the stimulation. Fresh matured DCs were plated at lxlO4 cells per well of 96-well U-bottom plate in AIM-V media. 10 jug/ml peptide and 3 ju g/ml (^-microglobulin were added to individual wells for a 4 hr pulse, 37°C, 7% C02. [05731 Wells were combined for pools of peptide pulsed DCs where indicated.

Cells were then transferred to 15 ml conical tubes, and the volume brought up to 12 ml with AIM-V media. The pellet was centrifuged and resuspended in AIM-V media and irradiated at 2500 rads. On Day 0,1x10s peptide pulsed DCs were added to 2xl06 CD8+ cells in 24-well plates at a ratio of 20 T-cells to 1 DC for stimulations. The cells were maintained in AIM-V with 5% human AB serum and 10 ng/ml IL-7. On Day 1,20 IU/ml IL-2 was added to each well.

The wells were then incubated at 37°C, 7% C02 for 12 days, refreshing media when necessary. 2nd & 3 rd stimulations

[0574] The protocol for the second and third stimulations was similar to the protocol for the 1st stimulation with the following exceptions. Frozen DCs were utilized by bringing back into culture and maturing. The DCs were pulsed with 1-10 A'g/ml peptide (experimentally dependent) for 2-4 hr. The DCs were irradiated at 2500 rads, omitting the washing step. Thus, any unbound peptide remained in media. The cells were maintained at a 20:1 ratio (CD8:DC) in 12 or 24-well plates, plating lxlO6 CD8+ cells/well. The T cells were assayed for target cell recognition via cytotoxicity and/or cytokine release assays 7-12 days post the 3ld stimulation. 4th stimulation and beyond

[0575] Various cell types can be used as APCs, i.e., DC, monocytes, EBV-B and tumor. Autologous monocytes are given as an example. PBMCs are irradiated at 2500 rads, then plated out at 4-6x106cells/well of 12-well plate in RPMI, and incubated for 2 hr at 37°C, 7% C02 Non-adherent cells are removed and the adherent monocytes washed 2x with HBSS.

[0576] The monocytes are then pulsed with peptides at 1-10 /^g/ml in AIM-V media for 2 hours, 37°C, 7% C02. Where CD8+ cells have previously been stimulated with peptide pulsed APCs in pools, combine peptides when pulsing monocytes into those same pools. Add 1-10 //g/ml of each peptide. CD8+ cells are added to the respective pulsed monocytes, maintaining the 20:1 ratio.

[0577] On Day 0 10 ng/ml IL-7 are added, and on Day 1 20 IU/ml IL-2 are added. The cells are then incubate at 37°C, 7% C02, for 7 days refreshing media when necessary. In general, T cells are assayed for target cell recognition via .cytotoxicity and/or cytokine release assays 5-7 days post each stimulation.

Clonal CD8+ cell populations

[0578] Cells were cloned out by limiting dilution. To the wells of 96-well U-bottom plates were added: 1-10 CD8+ cells, lxlO4 mixed irradiated allogeneic feeder cells (2500 rads), 1000 peptide pulsed autologous irradiated EBV-B cells (2500 rads) and 10 ng/ml IL-7 in AIM-V media with 5% human AB serum. 20 HJ/ml IL-2 was added on Day 1. Clones were refreshed weekly by changing 50% of the media, adding fresh cytokines and irradiated feeder and peptide pulsed B cells. Clones were selected for target cell recognition assays, cytotoxicity and/or cytokine release, and expansion, from plates showing <30% growth, indicating clonality of the limiting dilution.

Rapid expansion protocol

[0579] This protocol was utilized for clones showing lytic activity. (Protocol received from Dr. Steven Rosenberg (NCI) via personal communication.)

[0580] OnDay 0, allogeneic mixedPBMC were irradiated (2500 tads) and added to a 25 cm2 flask (4x 107 cells/flask) in 25 ml AIM-V with 10% human AB serum. OKT3 was added at 30 ng/m.1 followed by 1x10s viable cloned CD8+cells. On Day 2, IL-2 was added at 300 IU/ml. On Day 5,20 ml media changed/flask, 300 RJ/ml fresh IL-2 was added. Immune activity was tested for by cytotoxicity or cytokine release assay 8-11 days after REP.

Cytotoxicity 51Cr release assay

[0581] CD8+ cells were screened for activity against selected target cells. APCs were pulsed with peptide and cells transduced to express retrovirus or vaccinia virus, tumor, normal controls, etc. Targets were washed by removing cells from flanks to 15 ml conical tubes, adding 12 mis HBSS, resuspending the cells and centrifuging down. The supernatant was then poured off ~200,uls. To this was added 100 uCi 51Cr/ IxlO6 cells. Targets were then incubated at 37°C, 7% C02 for lhr, then washed 2x12 ml HBSS. y

[0582] Targets were resuspended in AIM-V with 5% human AB serumandadded to wells of 96-well U-bottom plates. Next, 1-20 ug/ml ofpeptides was pulsed onto targets at various time points dependent on the experiment; overnight, prior to the addition of 51Cr or following the 51Cr incubation. CD8+ effector cells were added in AIM-V with 5% human AB serum. E:T ratios ranging from 5:1 to 50:1 < Samples were in triplicate, 200 jul final volume. Controls included spontaneous release of 51Cr into the media, maximum release (incubation with 5% triton XI00) and un-pulsed targets. The plates were spun at 700 RPM/5 minutes and incubated 4-6 hrs 37°C, 7% C02. The supernatant was harvested and 51Crrelease measured via gamma counter.

Cytokine ELISA assays measuring GM-CSF or ylFN release

[0583] The Pharmingen (San Diego, CA) kits used may vary, need to follow manufacturer's instructions. In general, the protocol was as follows:

[0584] On Day 1, ELISA plates are coated with 100 jil diluted capture antibody per well in coating buffer (0. IM Carbonate, pH 9.5). The plates are then sealed and wrapped with foil and incubated overnight at 4°C. Targets are then incubated overnight with CD8+ cells, in 96 well U-bottom plates, in AIM-V media with 5% human AB serum. Samples in triplicate.

[0585] On Day 2, the wells of the ELISA plates were aspirated and washed 3x (Bio-Tekplate washer, Winooski, VT) with 300|il/well wash buffer (PBS, 0.05% Tween 20). The plates were then blocked with 200jil/well assay diluent, incubated at room temp for 1 hr, and the plates washed 3x with wash buffer.

[0586] 1 OOjxl standards or culture supernatant from each unknown sample were added to their respective wells and incubated at room temp for 2 hrs.

[0587] Plates were washed 5x with wash buffer, 100 p.l working detector added to each well, and the plates incubated at room temp for 1 hr. The plates were then washed 7x with wash buffer, 100 p.1 substrate solution added to each well, and the plates incubated for 15 - 30 min at room temp in dark. 50 |il 2N H2S04 was added to each well to stop the reaction. The plates were then read at 450 cm within 30 minutes with X correction 570 nm.

EXAMPLE 9 C35 Peptide Mediated T Cell Lysis

[0588] T cell activity on EBV cells pulsed with C35 peptide epitopes was analyzed. Specifically, T cells obtained from two separate human donors expressing different HLA specificities were incubated with EBV-B target cells pulsed with C35 peptide epitopes. The results are shown in Table 10.

TABLE10 T cell donor SB, HLA haplotype: A2, A3; B18, B44 % Lysis EBV-B cell Target T cell clone No peptide + p72-86 +p77-85 #46 4.6 78.5 97.1 % Lysis EBV-B cell Target T cell clone No peptide + pi 7-31 + p22-30 #72 0 0.5 72.8 #75 1.6 1.2 56.8 #104 0 6.4 100.3 peptide 17-31 VEPGSGVRIWEYAE peptide 22-30 GVRIWEYA peptide 72-86 QLVFSKLENGGFPYE peptide 77-85 KLENGGFPY T cell donor LE, HLA haplotype: A3, A66; B8, B41 % Lysis EBV-B cell Target T cell clone No peptide + p67-75 + p81-89 A .4 54.9 B 3.2 40.3 peptide 67-75 1EINGQLVF peptide 81-89 GGFPYEKDL T cell donor AH, HLA haplotype: A2, Al 1; B8, B35 See induction of GM-CSF secretion by Line 4 T cells stimulated with: peptides 9-17 (SVAPPPEEV); 77-85 (KLENGGFPY); 104-112 (KTTNSRPPC); 105-113 (ITNSRPPCV) As shown in TABLE 10, T cell clones from the donor expressing the A2, A3, B18, and B44 HLA haplotypes stimulated against the 15mer corresponding to amino acid residues 72-86 of C35 or the 9mer corresponding to amino acids 77-85 showed minimal lytic activity on EBV-B target cells that had not been pulsed with either peptide. However, a high level of lytic activity was observed with tiie EBV-B cells pulsed with either peptide (78.5 % and 97.1% for peptide 72-86 and peptide 77-85, respectively). Similarly, T cells from the same donor .raised against the 9 mer corresponding to amino acids 22-30 of C35 did not lyse target cells not pulsed with with the peptide, but were very active in lysing target cells pulsed with the peptide. Notably, however, target cells pulsed with the 15mer corresponding to amino acids 17-31 of C35 exhibited minimal lysis even though it contains the 9mer 22-30. T cell clones from another donor expressing the A3, A66, B8 and B41 HLA haplotypes stimulated against the 9mers corresponding to amino acids 67-75 and 81-89 of C35 exhibited moderate lytic activity (54.9% and 40.3%, respectively) on EBV-B target cells pulsed with these peptides.

The high level of lytic activity observed with EBV-B cells pulsed with either the 9mer p77-85 or the 15mer p72-86 demonstrates that in some instances larger peptides comprising a C35 peptide epitope are effective in stimulating a T cell response similar to that achieved with the actual epitope. However, the fact that minimal lysis was observed with pi7-31 even though it contained a C35 peptide epitope, p22-30, that triggered significant lytic activity, demonstrates that this effect is not seen in every instance.

EXAMPLE10: Monoclonal Antibodies Specific for C35 Immunization protocols:

[0591] In order to generate monoclonal antibodies specific for C35, BALB/cByJ mice were immunized using one of three methods.

[0592] 1. A syngeneic mouse fibrosarcoma cell line, BCA34, was transduced to express human C35 by infecting cells with C35 recombinant retrovirus. Stable C35 expressing cells were selected for resistance to G418. Two million cells were injected per mbuse, and spleens were removed 23 days later for fusion with NS1 mouse myeloma cells, employing methods well known to those practiced in the art.

[0593] 2. Linel, a poorly immunogenic mouse small cell lung carcinoma, was transduced to express C35 as described above for BCA34. Mice were immunized with20,000 cells, and spleens were removed 20 days later for fusion with NS1 mouse myeloma cells.

[0594] 3. Mice received an intraperitoneal injection of 10 million pfu of a vaccinia virus recombinant for human C35, W.hC35. Spleens were removed after 15 days for fusion with NS 1 mouse myeloma cells.

Screening hybridoma clones by ELISA.

[0595] ELISA assay were used to screen antibodies secreted by 500-1000 hybridoma clones from each fusion for reactivity and specificity for C35. ELISA plates were coated wjth G35 protein or Beta galactosidase as a negative control. Both proteins were generated and purified from E.coli in a similar fashion, including cleavage of selection tags. Supematants from hybridoma clones were then incubated on the coated plates, followed by incubation with anti-mouse antibodies labeled with horseradish peroxidase (HRP), and detection with OPD substrate. Clones that reacted strongly with C35 protein but did not react with P-galactosidase were selected for further characterization. Each selected hybridoma clone was subcloned several times to develop a stable antibody-producing cell line. Table 11 lists the clones with confirmed specificity for C35. In several cases, antibody specificity was confirmed by Western blot of a C35 protein gel orby immunohistochemical staining as described below. Immunoglobulin heavy and light chain genes were cloned and sequenced from three C35 specific hybridomas of which two were determined to be identical.

Table 11: Hybridoma clones with demonstrated specificity for C35 CLONE Immunization Isotype Reactivity Variable region genes 1B2 BCA34.hC35 IgM 1B3* BCA34.hC35 IgGl Western IE 11 BCA34.hC35 IgGl cloned (same as 1F2) 1F2 BCA34.hC35 IgGl Western, IHC cloned (same as 1E11) 3E9 BCA34.hC35 3E10* BCA34Jh.C35 IgGl Western KC5 Linel.hC35 IgM 11B10 W.hC35 IgM Western cloned * antibody 1B3 is identical in sequence to antibody 3E10

[0596] FIG. 19 shows a representative ELBA experiment. All clones were tested in triplicate on at least 3 separate occasions.

IH. Western Blot Immunodetection

[0597] Western Blot Immunodetection was performed with supemantants from selected hybridoma clones. Antibodies from 4 hybridomas (1B3, 1F2, 3E10, 1 IB 10) reacted specifically withhC35 protein in this assay. In these experiments, 100 ng of purified recombinant C35 protein or control p-galactosidase protein was loaded in each lane of an 18% SDS polyacrylamide gel. Gels were transferred to PVDF membrane, as is well known to those practiced in the art. Membranes were blocked with Trisbufferedsahne (TBS), including Tween-20 and 5% non-fat dry milk. Each blot was incubated with various dilutions of hybridoma supematants as the primary antibody, followed by incubation with a secondary antibody, goat anti-mouse IgG conjugated to HRP, and detected with the chemiluminescent substrate, ECL. Results for antibodies 1B3, 1F2, and 3E10 are shown in FIG. 20. Similar results were obtained with 11B10 (not shown).

IV. Immunohistochemistry.

ELISA and Western Blot data show that these monoclonal antibodies react with recombinant C35 protein. In addition, monoclonal antibody 1F2 was shown to have utility for immunohistochemical staining of primary breast tumor sections. FIG. 21 demonstrates that monoclonal antibody 1F2 can detect high levels of endogenous C35 expression in human breast tumors, with little or no staining of normal breast tissue. Antibody was affinity purified from 1F2 hybridoma supernatant. Paraffin-embedded slides were deparaffinized with \ xylene and rehydrated through graded alcohols. Target retrieval was achieved through steam and high pH treatment. Sections were blocked with normal serum, incubated with affinity purified 1F2 (5mg/ml), followed byVector ABC universal detection kit and development with DAB substrate. Slides were counterstained with hematoxylin, dehydrated with EtOH/xylene, and coverslipped.

FIG. 21 demonstrates strong staining of a section of invasive breast adenocarcinoma from patient 01A6, while normal breast tissue from the same patient is negative. Staining with the antibody could be competed with soluble C3 5 protein, but not with the irrelevant protein p-galactosidase (data not shown), this demonstrates that staining is specific for C35.

V. Cloning Variable Region Genes of Monoclonal Antibodies Once specificity of individual clones was confirmed, cell pellets of the hybridoma clones and the fusion partner NS 1 were snap frozen at -80°C for later cloning of variable region genes. RNA was extracted from the cell pellets and full-length cDNA was generated using Invitrogen's Generacer Kit. Briefly, the 5* end of the RNA is decapped, then ligated to Generacer 5' oligo. Reverse strand cDNA is generated using oligo-dT primers and reverse transcriptase. Double stranded cDNA was amplified by PCR using gene racer oligo as the 5' primer and a 3' primer designed from a conserved sequence in the IgGl constant region. PCR products were cloned and sequenced. Clones were identified that had unique sequences when compared to those of the fusion partner. The sequences were submitted to IgBLAST on theNCBI database to map the variable region framework and complementarity determining regions (CDR). To confirm that these V-genes are specific for C35, recombinant antibodies encoding these sequences have been generated and expressed in vitro and assayed by ELISA and Western (data not shown).

The sequences of two unique monoclonal antibody V-genes are shown below. Clones 1F2 and 1E11 have identical V-genes. Bold indicates CDR regions. Underline indicates framework regions. 1E11/1F2V-GENES: Kappa a/ggattttcaggtgcagattttcagcttcctgctaatcagtgcctcagtcagaatgtccagaggacaaattgttctc acccagtctccagcaatcatgtctgcatctccaggggagaaggtcaccatatcctgcagtgccagctcaagtgt aagttaeatgaactggtaccagcagaagccaggatcctcccccaaaccctggatttatcacacatccaacctg gcttctggagtccctgctcgcttcagtggcagtgggtctgggacctcttactctctcacaatcagcagcatggagg ctgaagatgctgccacttattactgccaacagtatcatagttacccacccacgttcggaggggggaccaagct ggaaataaaa IgGI ^gaaagtgttgagtctgttgtacctgttgacagccattcctggtatcctgtctgatgtacagcttcaggagtcagga cctggcctcgtgaaaccttcteagtctctgtctctcacctgctctgtcactggctactccatcaccagtggttatttct ggaactggatccggcagtttccagggaacaaactggaatggatgggctacataagctacgacggtagcaat aactccaacccatctctcaaaaatcgaatctccttcactcgtgacacatctaagaaccagtttttcctgaagtttaa ttctgtgactactgacgactcagctgcatattactgtacaagaggaactacggggtttgcttactggggccaagg gactctggtcactgtctctgca 3E10 V-GENES: Kappa vl^aggttccaggttcaggttctggggctccttctgctctggatatcaggtgcccactgtgatgtccagataaccca gtctccatcttttcttgctgcatctcctggagaaaccattactattaattgcagggcaagtaagtacattagcaaa catttagtctggtatcaggagaaacctggagaaactaaaaagcttcttatctactctggatccactttgcaatctg gacttccatcaaggttcagtggcagtggatctggtacagatttcactctcaccatcagtagcctggagcctgaaga ttttgcaatgtattactgtcaacagcataatgaatacccgctcacgttcggtgctgggaccaagctggagctgaa a IgGI atgatggtgttaagtcttctgtacctgttgacagcccttccgggtatcctgtcagaggtgcagcttcaggagtcagg acctagcctcgtgaaaccttctcagactctgtccctcacctgttctgtcactggcgactccatcaccagtggttact ggaactggatccggaaattcccaggaaataaacttgaatacgtggggtacataagctacagtggtggcactta ctacaatccatctctcaaaagtcgaatctccatcactcgagacacatccaagaaccactactacctgcagttga attctgtgactactgaggacacagccacatattactgtgcaagaggtgcttactacgggggggccttttttcctta cttcgatgtctggggcgctgggaccacggtcaccetctcctca EXAMPLE 11 C35 is an oncogene for normal breast epithelial cells C35 is a gene of unknown function that we have previously shown is overexpressed in a large fraction of human breast and bladder tumors. Antibody to C35 inhibits growth of C35 positive tumor cells in vitro. This suggests that the C35 gene product may play a role in signal transduction on the tumor cell membrane and raises the possibility that C35 is an oncogene. Growth of colonies in soft agar is an accepted measure of anchorage independence, a property that distinguishes cells that have undergone tumor transformation from normal cells. In order to assay the oncogenic activity of C35, a line of immortalized, non-tumorigenic breast epithelial cells (H16N2) was transected with pTag.hC35 recombinant for the full length C35 gene, with empty pTag vector alone (pCMV-tag mammalian expression vector, Stratagene Corporation, LaJolla, CA) or with ras, a known oncogene. Formation of colonies in soft agar, indicative of transformation, was assessed and compared to 21-MT1 breast tumor cells (see Table 12 below). The results show a factor of 10 increase in the number of soft agar colonies formed following transfection with C3 5. This is comparable to the frequency of colonies formed following transfection with ras or that result when the 21-MT1 tumor line is plated in soft agar.

Transformed colonies were picked from soft agar and it was attempted to propagate them in liquid medium in 24-well plates. The small number of apparent colonies recovered following transfection with the vector control could not be successfully propagated in liquid culture. In contrast, colonies recovered following transfection with C35 or with ras have been successfully established as cell lines. It appears that even the small number of control colonies recovered from soft agar represent abortive growth.

Table 12 C35 Transforms Human Breast Epithelial Cells Cell Line # of colonies Propagated? H16N2.pTag (vector control) 14 No H16N2.pTag-hC35 150 Yes H16N2.ras (positive control) 250 Yes 21-MT1 (metastatic tumor line, C354) 94 Yes

[0604] The fact that C35 appears to contribute to the transformed phenotype of tumor cells enhances the potential utility of a C35-based cancer vaccine or C35-specific antibodies as therapeutic agents for breast and bladder cancer. Immune evasion by down regulation of C35 gene expression in tumor cells or down regulation of C35 expression at the tumor surface membrane is less likely to be an obstacle to successful C35-based immunotherapy if the C35 gene product is required to maintain the tumor phenotype.

EXAMPLE 12 FLUORESCENCE POLARIZATION TO MONITOR MHC-PEPTIDE INTERACTIONS IN SOLUTION

[0605] Fluorescence is characterized by a process of absorption of incident radiation at one wavelength, followed by the emission of radiation at another wavelength. This behavior was first described by G. G. Stokes (1852) in the form of Stokes' Law of Fluorescence in which he stated that fluorescence (emission) always appears at a wavelength greater than the wavelength of the incident (excitation) radiation.

[0606] This behavior was successfully explained by A. Einstein (1905) using Planck's quantum hypothesis. A quantum of incident light with an energy of Eexcit is absorbed by the fluorescent molecule raising its energy to Eexcit. This is quickly followed by a downward transition of the molecule to one of fee vibration levels in. the ground state, Eemiss, with the emission of a quantum of light.

[0607]' By.using a fluorescent dye to label a small molecule, its binding to another molecule of equal or greater size can be monitored using fluorescence polarization (FP). FP operates on the principle that small molecules rotate faster than large molecules. If a molecule is labeled with a fluorophore, this rotation can be measured by exciting the fluorophore with plane polarized light and then measuring the emitted light with polarizers parallel and perpendicular to theplane I of excitation to determine if it is still oriented in the same plane as it was when excited. If a fluorophore is labeled on a small molecule it will rotate in the time between excitation and emission and the light emitted will be depolarized. If the labeled molecule binds to a large molecule (effectively increasing its overall size) the molecule will not rotate in the time between excitation and emission, and the light emitted will be polarized resulting in a polarization change between the free and bound forms. For convenience, units are usually 1000 rnP = P

[0608] The kinetics of association between HLA-A*0201 and a specific fluorescent-labeled peptide was determined in the presence of a test competitor peptide at 100 jjM. Binding increases over time until it plateaus when specific binding reaches equilibrium at Ymax. If the added test-competitor is able to Compete, equilibrium will be reached faster but with less binding. Ymax can be used to calculate % inhibition if the system is calibrated with an irrelevant competitor (0%) and a relevant competitor (100%). In this case, the irrelevant competitor was the HLA-B*2705 binding (non-HLA-A*0201 binding) peptide GRAFVTIGK while the relevant competitor was the known HLA-A*0201 binding peptide KLGEFYNQMM. To obtain Ymax, the curves are fitted to a mono-exponential association model using non-linear regression.

[0609] The following eight peptides (based on amino acid sequence of SEQ ID NO:2 were found to have High to Medium binding capacity to HLA-A*0201 as reflected by relative inhibition of binding of the relevant competitor.

Peptide % inhibition S9 to VI7 325 to A33 S21 to Y29 1105 to VI13 F65 to L73 G22 to A30 T38 to V46 G61 to 169 96.9 94.9 90.8 86.4 74.8 67 47.3 46.5

[0610] A similar analysis was conducted with C35 peptides that bind to soluble HLA-B*0702 employing a fluorescent labeled HLA-B*0702 binding standard and suitable relevant and irrelevant peptides to calibrate inhibition of binding by test peptides. Note that these inhibition values are sensitive to the choice and concentration of both MHC molecule and specific fluorescent peptides under the same assay conditions. It is not meaningful, however, to compare HLA-A*0201 and HLA-B*0702 inhibition values. As shown below, six C35-derived peptides nine amino acids in length were found to have high or medium relative binding affinity to HLA-B*0702.

Peptide % Inhibition K104to A112 69.4 (analog with Ala substituted for Cys at 112) N107toL115 68.2 (analogwith Ala substituted for Cys at 112) E4toP12 54.6 G63 to G71 51.4 1105 to VI13 45.2 (analog with Ala substituted for Cys at 112) T62 to N70 38.8 EXAMPLE 13 Construction of N-Terminal and/or C-Terminal Deletion Mutants (0611] The following general approach may be used to clone a N-terminal or C-terminal deletion C35 deletion mutant. Generally, two oligonucleotide primers of about 15-25 nucleotides are derived from the desired 5' and 3' positions of a polynucleotide of SEQ ID NO:l. The 51 and 3' positions of the primers are determined based on the desired C3 5 polynucleotide fragment. An initiation and stop codon are added to the 5' and 3' primers respectively, if necessary, to express the C3 5 polypeptide fragment encoded by the polynucleotide fragment. Preferred C35 polynucleotide fragments are those encoding the candidate MHC class I and MHC class II binding peptides disclosed above in the "Polynucleotide and Polypeptide Fragments" section of the Specification. (0612] Additional nucleotides containing restriction sites to facilitate cloning of the C35 polynucleotide fragment in a desired vector may also be added to the 5* and 3' primer sequences. The C35 polynucleotide fragment is amplified from genomic DNA or from the cDNA clone using the appropriate PCR oligonucleotide primers and conditions discussed herein or known in the art. The C35 polypeptide fragments encoded by the C35 polynucleotide fragments ofthe present invention may be expressed and purified in the same general manner as the fulllengthpolypeptid.es, although routine modifications maybe necessary due to the differences in chemical and physical properties between a particular fragment and full length polypeptide. (0613] As a means of exemplifying but not limiting the present indention, the polynucleotide encoding the C35 polypeptide fragment is amplified and cloned as follows: A 5' primer is generated comprising a restriction enzyme site followed by an initiation codon in frame with the polynucleotide sequence encoding the N-terminal portion of an MHC binding peptide epitope listed in any of Tables 1 through 6. A complementary 3' primer is generated comprising a restriction enzyme site followed by a stop codon in frame with the polynucleotide sequence encoding C-terminal portion of a C35 MHC binding peptide epitope listed in any of Tables 1 through 6.

[0614] The amplified polynucleotide fragment and the expression vector are digested with restriction enzymes which recognize the sites in the primers. The digested polynucleotides are then ligated together. The C35 polynucleotide fragment is inserted into the restricted expression vector, preferably in a maimer which places the C35 polypeptide fragment coding region downstream from the promoter. The ligation mixture is transformed into competent E. coli cells using standard procedures and as described in the Examples herein. Plasmid DNA is isolated from resistant colonies and the identity of the cloned DNA confirmed by restriction analysis, PCR and DNA sequencing.

EXAMPLE 14 Protein Fusions of C35

[0615] C35 polypeptides are preferably fused to other proteins. These fusion proteins can be used for a variety of applications. For example, fusion of C35 polypeptides to His-tag, HA-tag, protein A, IgG domains, and maltose binding protein facilitates purification. (See Example 5; see also EP A 394,827; Traunecfcer et al, Nature 331:84-86 (1988).) Similarly, fusion to IgG-1, IgG-3, and albumin increases the halflife time in vivo. Nuclear localization signals fused to C35 polypeptides can target the protein to a specific subcellular localization, while covalent heterodimer or homodimers can increase or decrease the activity of a fusion protein. Fusion proteins can also create chimeric molecules having more than one function. Finally, fusion proteins can increase solubility and/or stability of the fused protein compared to the non-fused protein. All of the types of fusion proteins described above can be made by modifying the following protocol, which outlines the fusion of a polypeptide to an IgG molecule,

[0616] Briefly, the human Fc portion ofthe IgG molecule can be PCR amplified, using primers that span the 5' and 3' ends of the sequencedescribed below. These 1 primers also should have convenient restriction enzyme sites that will facilitate cloning into an expression vector, preferably a mammalian expression vector. [06171 F°r example, if pC4 (Accession No. 209646) is used, the human Fc portion can be ligated into the BamHI cloning site. Note that the 3' BamHI site should be destroyed. Next, the vector containing the human Fc portion is re-restricted withBamHI, linearizing the vector, and C35 polynucleotide, isolated by the PCR protocol described in Example 1, is ligated into this BamHI site. Note that the C35 polynucleotide is cloned without a stop codon, otherwise a fusion protein will not be produced.

[0618] If the naturally occurring signal sequence is used to produce the secreted protein, pC4 does not need a second signal peptide. Alternatively, if the naturally occurring signal sequence is not used, the vector Gan be modified to include a heterologous signal sequence. (See, e.g., WO 96/34891.) Human IgG Fc region: GGGATCCGGAGCCCAAATCTTCTGACAAAACTCACACATGCCCACCGTGCCCA GCACCTGAATTCGAGGGTGCACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAA GGACACCCTCATGATCTCCCGGACTCCTGAGGTCACATGCGTGGTGGTGGACG TAAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAG GTGCATAATGCCAAGACAAAGCeGCGGGAGGAGCAGTACAACAGCACGTACCG TGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGT ACAAGTGCAAGGTCTCCAACAAA.GCCCTCCCAACCCCCATCGAGAAAACCATC TCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATC ' CCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAA.GGCT TCTATCCAAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAAC AACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTA CAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCAT GCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCC CTGTCTCCGGGTAAATGAGTGCGACGGCCGCGACTCTAGAGGAT (SEQ ID NO:[84])

[0619] A preferred fusion product is fusion of a C35 peptide to the amino terminus of an MHC molecule in such fashion that the peptide will naturally occupy the MHC peptide binding groove. Kang, X. et al., Cancer Res. 57:202-5 (1997) have reported that such fusion proteins can be employed in vaccine compositions that are especially effective for stimulation of specific T cells.

EXAMPLE 15 Method of Detecting Abnormal Levels of C35 in a Biological Sample

[0620] C35 polypeptides can be detected in a biological sample, and if an increased or decreased level of C35 is detected,-this polypeptide is a marker for a particular phenotype. Methods of detection are numerous, and thus, it is understood that one sldlled in the art can modify the following assay to fit their particular needs.

[0621] For example, antibody-sandwich ELISAs are used to detect C35 in a sample, preferably a biological sample. Wells of a microliter plate are coated with specific antibodies to C35, at a final concentration of 0.2 to 10 ug/ml. The antibodies are either monoclonal or polyclonal. The wells are blocked so that non-specific binding of C35 to the well is reduced.

[0622] The coated wells are then incubated for > 2 hours at RT with a sample containing C35. Preferably, serial dilutions of the sample should be used to validate results. The plates are then washed three times with saline to remove unbounded C35.

[0623] Next,' 50 ul of specific antibody-alkaline phosphatase conjugate that recognizes a C35 antigenic determinant which does not overlap with that recognized by the plate bound antibody, at a concentration of25-400 ng, is added and incubated for 2 hours at room temperature. The plates are again washed three times with deionized or distilled water to remove unbounded conjugate.

[0624] Add 75 ul of 4-methylumbelliferyl phosphate (MUP) or p-nitrophenyl phosphate (NPP) substrate solution to each well and incubate 1 hour at room temperature. Measure the reaction by a microtiter plate reader. Prepare a standard curve, using serial dilutions of a control sample, and plot C35 polypeptide concentration on the X-axis (log scale) and fluorescence or absorbance on the Y-axis (linear scale). Interpolate the concentration of the C35 in the sample using the standard curve.

EXAMPLE 16 Formulating a Polypeptide

[0625] TheC35 composition will be formulated and dosed in a fashion consistent with good medical practice, taking into account the clinical condition of the individual patient (especially the side effects of treatment with the C35 polypeptide alone), the site of delivery, the method of administration, the scheduling of administration, and other factors known to practitioners. The "effective amount" forpurposes hereinisthus determined by such considerations.

[0626] As a general proposition, the total pharmaceutically effective amount of C35 administered parenterally per dose will be in the range of about 1 ug/kg/day to 10 mg/kg/day of patient body weight, although, as noted above, this will be subject to therapeutic discretion. More preferably, this dose is at least 0.01 mg/kg/day, andmostpreferablyforhumansbetweenaboutO.Ol and 1 mg/kg/day. If given continuously, C35 is typically administered at a dose rate of about 1 ug/kg/hour to about 50 ug/kg/hour, either by 1-4 injections per day or by continuous subcutaneous infusions, for example, using a mini-pump. An intravenous bag solution may also be employed. The length of treatment needed to observe changes and the interval following treatment for responses to occur appears to vary depending on the desired effect.

[0627] Pharmaceutical compositions containing C35 are administered orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, gels, drops or transdermal patch), bucally, or as an oral or nasal spray. "Pharraaceutieally acceptableicanier'i refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. The term "parenteral" as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

[0628] C35 is also suitably administered by sustained-release systems. Suitable examples of sustained-release compositions include semi-permeable polymer matrices in the form of shaped articles, e.g., films, or mirocapsules. Sustained-release matrices include polylactides (U.S. Pat. No. 3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma-ethyl-L-glutamate (Sidman, U. et al., Biopolymers 22:547-556 (1983)), poly (2- hydroxyethyl methacrylate) , (R. Langeret al., J Biomed. Mater. Res. 15:167-277 (1981), and R. Langer, Chem. Tech. 12:98-105 (1982)), ethylene vinyl acetate (R. Langer et al.) or poly-D-(-)-3-hydroxybutyric acid (EP 133,988). Sustained-release compositions also include liposomally entrapped C35 polypeptides. Liposomes containing the C35 are prepared by methods known perse: DE 3,218,121; Epsteins al., Proc. Natl. Acad. Sci. USA 82:3688-3692 (1985); Hwang etal., Proc. Natl. Acad. Sci. USA 77:4030-4034 (1980); EP 52,322; EP 36,676; EP 88,046; EP 143,949; EP 142,641; Japanese Pat. AppL 83-118008; U.S. Pat. Nos. 4,485,045 and 4,544,545; and EP 102,324. Ordinarily, the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol. percent cholesterol, the selected proportion being adjusted for the optimal secreted polypeptide therapy.

[0629] For parenteral administration, in one embodiment, C35 is formulated generally by mixing it at the desired degree of purity, in a unit dosage injectable form (solution, suspension, or emulsion), with a pharmaceutically acceptable carrier, i.e., one that is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation. For example, the formulation preferably does not include oxidizing agents and other compounds that are known to be deleterious to polypeptide.

[0630] Generally, the formulations are preparedby contacting C35 uniformly and intimately with liquid carriers or finely divided solid carriers or both. Then, if necessary, the product is shaped into the desired formulation. Preferably the carrier is a parenteral carrier, more preferably a solution that is isotonic with the blood ofthe recipient. Examples of such carrier vehicles include water, saline, Ringer's solution, and dextrose solution. Non-aqueous vehicles such as fixed oils and ethyl oleate are also useful herein, as well as liposomes.

[0631] The carrier suitably contains minor amounts of additives such as substances that enhance isotonicity and chemical stability. Such materials are non-toxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, succinate, acetic acid, and other organic acids or (their salts; antioxidants such as ascorbic acid; low molecular weight (less than about ten residues) polypeptides, e.g., polyarginine or tripeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids, such as glycine, glutamic acid, aspartic acid, or arginine; monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, manose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; counterions such as sodium; and/or nonionic surfactants such as polysorbates, poloxamers, or PEG.

[0632] C35 is typically formulated in such vehicles at a concentration of about 0.1 mg/mlto 100 mg/ml, preferably 1-10 mg/ml, at a pH of about 3 to 8. It will be understood that the use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of polypeptide salts.

[0633] C3 5 used for therapeutic administration can be sterile. Sterility is readily accomplished by filtration through sterile filtration membranes (e.g., 0.2 micron membranes). Therapeutic polypeptide compositions generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.

[0634] C35 polypeptides ordinarily will be stored in unit or multi-dose containers, for example, sealed amjyoules or^^s,^ an^aqueous solution or as a lyophilized formulation for reconstitution. As an example of a lyophilized formulation, 10-ml vials are filled with 5 ml of sterile-filtered 1% (w/v) aqueous C35 polypeptide solution, and the resulting mixture is lyophilized. The infusion solution is prepared by reconstituting the lyophilized C35 polypeptide using bacteriostatic Water-for-Injection.

[0635] The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Associated with such containers) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. In addition, C35 may be employed in conjunction with other therapeutic compounds.

EXAMPLE 17 C35 Peptide Mediated Cell Lysis

[0636] T cell activity on various cell lines was analyzed Specifically, T cells obtained from one human donor stimulated with peptide pulsed DCs were incubated with different cell line targets. The results are shown in Tables 13 and 14.

[0637] CD8+ cells were stimulated using DCs and pulsed autologous DCs as described in Example 8. DCs were pulsed with a K104-V113 peptide fragment of C35 with TCEP (K104-V113), a reducing agent to protect the cysteine contained in the peptide. DCs were also pulsed with a K104-V113 peptide fragment containing an alanine or serine substitution at amino acid position 112 (K104-VI13-Ala and K104-V113-Ser). DCs were also pulsed with a K104-V 113 peptide fragment of C35 containing a cysteinylated cysteine at amino acid position 112 (K104-V 113-cys-cys).

[0638] The target cells used in the experiment were as follows: a normal breast endothelial cell line which is HLA-A2 positive and has low levels of C35 expression (HI 6. A2); a breast tumor cell line which is HLA-A2 negative and has high levels of C35 expression (2INT); a breast tumor cell line which is HLA-A2 positive and has high levels of C35 expression (21NT.A2); a cell line which is sensitive to non-specific killing by NK cells (K562); a head and neck cancer cell line which is HLA-A2 positive and does not express C35 (PC1-13); and the PC1-13 cell line pulsed with a 104-113 peptide fragment of C35 with a serine substitution at amino acid position 112 (PCI-13 K104-V113- Ser).

[0639] Cell lysis was measured in a cytotoxicity 5lCr release assay as described in Example 8. Raw chromium values, as measured from the supernatant from target cells used in the experiments, are shown in Table 13. The spontaneous values are from target cells incubated in medium with no CD8+ cells added The raflYtnm values are from target cells incubated in HC1 so that all cells are lysed. The percentage of cell lysed data is shown in Table 14.

TABLE 13 T cell donor SB, HLA haplotype: A2, A3; B18, B44 Raw Chromium Values In vitro Stimulus H16.A2 21NT 21NT.A2 K562 PCi-13 PCI-13 K104-V113-Ser DC 466 177 732 453 691 673 K104-V113-Ala 479 155 763 246 468 746 K104-V113-Ser 584 185 3228 323 581 2588 K104-V113-cys-cys 440 171 1329 287 486 1772 K104-V113 483 137 1429 311 804 1403 Spontaneous 425 173 440 267 543 538 Maximum 6628 2654 4853 2481 3962 4029 % Spontaneous 6.4 6.5 9.1 .8 13.7 13.4 TABLE 14 T cell donor SB, HLA haplotype: A2, A3; B18, B44 Percentage of Target Cells Lysed In vitro Stimulus H16.A2 21NT 21NT.A2 K562 PCI-13 Pcl-13 KI04-V113-Ser DC 0.7 0.2 6.6 8.4 4.3 3.9 K104-V113-Ala 0.9 -0.7 7.3 -0.9 -2.2 6.0 x K104-V113-Ser 2.6 0.5 63.2 2.5 1.1 58.7 K104-V113-cys-cys ' 0.2 -0.1 .1 0.9 -1.7 .3 K104-V113 0.9 -1.5 22.4 2.0 7.6 24.8 ] The cytotoxcity5 lCr release assay was repeated with the same CD8+ cells which received in vitro stimulus using C35 peptides described above and in Example 8. In addition to the cell lines described above, the 21NT.A2 breast tumor cell line pulsed with a K104-V113 C35 peptide fragment containing a serine substitution at amino acid position 112 (21NT.A2-Ser) was used. Various melanoma cell lines were also used as target cells. Melanoma cell lines 1700 (Mel 1700), 501 (Mel 501) and F002 (Mel F002) are HLA-A2 positive and express C35. Melanoma cell line 1359 (Mel 1359) is HLA-A2 negative and ^expresses C35. The effector to target cell ratio was 30:1 for this experiment. CD8+ cells used in the experiment have been maintained in IL-2 for 12 days after the fourth stimulation. Raw chromium values, as measured from the supernatant from target cells used in the experiments, are shown in Table 15. The percentage of lysed cells is shown in Table 16.

TABLE 15 T cell donor SB, HLA haplotype: A2, A3; B18, B44 Raw Chromium Values In vitro Stimulus H16.A2 21NT.A2 21NT.A2-Ser K562 DC 916 2383 2470 1403 K104-V113-Ala 829 1365 2423 815 K104-V113-Ser 1018 4957 4762 974 K104-V113-cys-cys 1024 2337 4474 1713 K104-V113 948 2753 3729 1156 Spontaneous 729 875 855 619 Maximum 5848 8521 7830 7356 In vitro Stimulus Mel 1700 Mel 1359 Mel 501 MeIF002 DC 1743 2443 2470 1403 K104-V113-AIa 1543 3050 2423 815 K104-V113-Ser 2951 2357 4762 974 K104-V113-cys-cys 1857 2299 4474 1713 K104-V113 1964 2758 3729 1156 Spontaneous 1387 2050 1637 1716 Maximum 7887 12157 8953 8003 TABLE 16 T cell donor SB, HLA haplotype: A2, A3; B18, B44 Percentage of Target Cells Lysed In vitro Stimulus H16.A2 21NT.A2 21NT.A2-Ser K562 • DC 3.7 19.7 231 11.6 K104-V113-Ala 2.0 6.4 22.5 2.9 K104-V113-Ser .6 53.4 56.0 .3 K104-V113- cys-cys .8 19.1 51.9 16.2 K104-V113 4.3 24.6 41.5 8.0 In vitro Stimulus Mel 1700 Mel 1359 Mel 501 Mel F002 DC .5 3.9 .8 11.5 K104-V113-Ala 2.4 9.9 1L1 7.6 K104-V113-Ser 24.1 3.0 45.3 .1 K104-V113-cys-cys 7.2 2.5 21.2 11.2 K104-V113 8.9 7.0 36.0 .7 (0641] • It will be clear that the invention may be practiced otherwise than as particularly described in the foregoing description and examples. Numerous modifications and variations of the present invention are possible in light of the above teachings and, therefore, within the scope ofthe appended claims, the invention may be practiced otherwise than as particularly described. (0642] The entire disclosure of each document cited (including patents, patent applications, journal articles, abstracts, laboratory manuals, books, or other disclosures) in the Background of the Invention, Detailed Description, Examples, and Sequence Listing is herefeyincdrporated hereto byireferende.

[0643] It will be clear that the invention may be practiced otherwise than as particularly described in the foregoing description and examples. Numerous modifications and variations of the present invention are possible in light of the above teachings and, therefore, within the scope of the appended claims, the invention may be practiced otherwise than as particularly described.

[0644] The entire disclosure of each document cited (including patents, patent applications, journal articles, abstracts, laboratory manuals, books, or other disclosures) in the Background of the Invention, Detailed Description, Examples, and Sequence Listing is hereby incorporated herein by reference.

NOW AMENDED

Claims (113)

WHAT WE CLAIM IS: 1. An isolated polynucleotide comprising a/ equence encoding at least one complementarity determining region (CDR) or a flmi/ional variant thereof of the murine 1F2 monoclonal antibody, wherein said poj^ /cleotide encodes a polypeptide that specifically binds to C35. 2. The polynucleotide according t claim 1, wherein said polynucleotide comprises a sequence encoding at least tvfo DRs of the murine 1F2 monoclonal antibody. 3. The polynucleotide acc -ding to claim 1, wherein said polynucleotide comprises a sequence encoding at lee /three CDRs of the murine 1F2 monoclonal antibody. 4. The polynucleotide According to claim 3, wherein said polynucleotide comprises: (a) posjWs 136 to 165 ofSEQ ID NO:148; ions 211 to 231 ofSEQ ID NO: 148; and (c) / positions 328 to 354 ofSEQ ID NO: 148. 5. The /polynucleotide according to claim 3, wherein said polynucleotide comprises: (a) positions 145 to 161 ofSEQ ID NO:149; (b) positions 205 to 252 of SEQ ID NO: 149; and (c) positions 348 to 370 of SEQ ID NO: 149. INTELLECTUAL PROPERTY OFFICE OF N.Z. - 1 AUG 2007 RECEIVED AS AMENDED -509- WHAT WE CLAIM IS:

1. An isolated polynucleotide comprising a sequence encoding at least one complementarity determining region (CDR) or a variant thereof of the murine 1F2 monoclonal antibody, wherein said polynucleotide encodes a polypeptide that specifically binds to C35.

2. The polynucleotide according to claim 1, wherein said polynucleotide comprises a sequence encoding at least two CDRs of the murine 1F2 monoclonal antibody.

3. The polynucleotide according to claim 1, wherein said polynucleotide comprises a sequence encoding at least three CDRs of the murine 1F2 monoclonal antibody.

4. The polynucleotide according to claim 3, wherein said polynucleotide comprises: (a) positions 136 to 165 ofSEQ ID NO:148; (b) positions 211 to 231 of SEQ ID NO: 148; and (c) positions 328 to 354 ofSEQ ID NO:148.

5. The polynucleotide according to claim 3, wherein said polynucleotide comprises: (a) positions 145 to 162 ofSEQ ID NO:149; (b) positions 205 to 252 of SEQ ID NO: 149; and (c) positions 349 to 369 of SEP ID NO: 149. INTELLECTUAL PROPERTY j OFFICE OF M 2 | -9 APR aws RECEIVED 6. An isolated polynucleotide comprising a sequence encoding at least one complementarity determining region (CDR) or a functional variant thereof of the murine 1B3 monoclonal antibody, wherein said polynucletrade encodes a polypeptjae that specifically binds to C35. 7. The polynucleotide according to clairrr 6, wherein said polynucleotide comprises a sequence encoding at least two CD^s of the murine 1B3 tponoclonal antibody. 8. The polynucleotide according ia claim 6, wherein said polynucleotide comprises a sequence encoding at least tlyce CDRs of the murine 1B3 monoclonal antibody. 9. The polynucleotide ac^Grding to claim 8, wherein said polynucleotide comprises: (a) positions /30 to 162- of SEQ ID Nb: 150; (b) positions 208 to 228 of SEQ JD NO: 150; and 325 (c) positions to ffo of SMQ ID NO: 150. 10. The polynucleotide according to claim 8, wherein said polynucleotide comprises: fa) positions 144 t</l58 of SEQ ID NO: 151; (b) positions 201 to 248 of SEQ ID NO: 151; and (c) position 346 to 387 ofSEQ ID NO:151. INTELLECTUAL PROPERTY OFFICE OP M.7 1 2 MAR 2008 received! NOW AMENDED -510- 6. An isolated polynucleotide comprising a sequence/encoding at least one complementarity determining region (CDR) or a variant merefof of the murine 1B3 monoclonal antibody, wherein said polynucleotide ejico^ies a polypeptide that specifically binds to C35. 7. The polynucleotide according to claim H wherein said polynucleotide comprises a sequence encoding at least two CD)ls pf the murine 1B3 monoclonal antibody. 8. The polynucleotide according Ao (claim 6, wherein said polynucleotide comprises a sequence encoding at least th/ee/CDRs of the murine 1B3 monoclonal antibody. 9. The polynucleotide ac^r^ng to claim 8, wherein said polynucleotide comprises; (a) positions 00162 ofSEQ ID N0;150; (b) positions 208 to 228 pf SEQ ID NO: 150; and (c) positio/s 325 to 351 ofSEQ ID N0:150. 10. The pojynycleotide according to claim 8, wherein said polynucleotide comprises: (a/ /positions 144 to 158 ofSEQ IDNO:151; (b/ positions 201 to 248 of SEQ ID NO: 151; and '(c) positions 346 to 387 ofSEQ ID N0.151. INTELLECTUAL PROPERTY OFRCE OF N.Z 11 MAR 2008 RECEIVED AS AMENDED -510-

6. An isolated polynucleotide comprising a sequence encoding at least one complementarity determining region (CDR) or a variant thereof of the murine 1B3 monoclonal antibody, wherein said polynucleotide encodes a polypeptide that specifically binds to C35.

7. The polynucleotide according to claim 6, wherein said polynucleotide comprises a sequence encoding at least two CDRs of the murine 1B3 monoclonal antibody.

8. The polynucleotide according to claim 6, wherein said polynucleotide comprises a sequence encoding at least three CDRs of the murine 1B3 monoclonal antibody.

9. The polynucleotide according to claim 8, wherein said polynucleotide comprises: (a) positions 130 to 162 ofSEQ ID NO: 150; (b) positions 208 to 228 of SEQ ID NO: 150; and (c) positions 325 to 351 ofSEQ ID NO: 150.

10. The polynucleotide according to claim 8, wherein said polynucleotide comprises: (a) positions 145 to 159 ofSEQ ID NO:151; (b) positions 202 to 249 of SEQ ID NO: 151; and (c) positions 346 to 387 of SEQ ID NO: 151. INTELLECTUAL PROPERTY OFFICE OF N.Z -9 APR 2009 RECEIVED -511 -

11. The polynucleotide according to any one of claims 1-4 or 6-9, wherein said polynucleotide encodes a VL region that specifically binds C35.

12. The polynucleotide according to claim 11, further comprising a polynucleotide sequence encoding a human immunoglobulin light chain constant region or functional fragment thereof.

13. The polynucleotide according to claim 12, wherein said light chain constant region or functional fragment thereof is kappa.

14. The polynucleotide according to any one of claims 1-3, 5, 6-8, or 10, wherein said polynucleotide encodes a VH region that specifically binds C35.

15. The polynucleotide according to claim 14, further comprising a polynucleotide sequence encoding a human immunoglobulin heavy chain constant region or functional fragment thereof.

16. The polynucleotide according to claim 15, wherein said heavy chain constant region or functional fragment thereof is IgG.

17. The polynucleotide according to any one of claim 1-10, wherein said polynucleotide encodes an antibody or antigen binding fragment thereof that specifically binds C35, wherein said antibody or antigen binding fragment is humanized.

18. An isolated polynucleotide comprising (a) SEQ ID No: 148; and INTELLECTUAL PROPERTY OFFICE OF N.Z. - 1 AUG 2007 RECEIVED -512- (b) SEQ ID NO: 149.

19. An isolated polynucleotide comprising (a) SEQ ID No: 150; and (b) SEQ ID NO:151.

20. An isolated polynucleotide comprising a sequence having at least 80% identity to SEQ ID No: 148.

21. The polynucleotide according to claim 20 comprising a sequence having at least 85% identity to SEQ ID No:148.

22. The polynucleotide according to claim 20 comprising a sequence having at least 90% identity to SEQ ID No: 148.

23. The polynucleotide according to claim 20 comprising a sequence having at least 95% identity to SEQ ID No:148.

24. The polynucleotide according to claim 20 comprising a sequence having at least 99% identity to SEQ ID No:148.

25. The polynucleotide according to claim 20 comprising the sequence of SEQ ID No: 148.

26. An isolated polynucleotide comprising a sequence having at least 80% identity to SEQ ID No: 149. "intellectual property office of n.z, 2 5 OCT 2386 -513-

27. The polynucleotide according to claim 27 comprising a sequence having at least 85% identity to SEQ ID No: 149.

28. The polynucleotide according to claim 27 comprising a sequence having at least 90% identity to SEQ ID No: 149.

29. The polynucleotide according to claim 27 comprising a sequence having at least 95% identity to SEQ ID No: 149.

30. The polynucleotide according to claim 27 comprising a sequence having at least 99% identity to SEQ ID No: 149.

31. The polynucleotide according to claim 27 comprising the sequence of SEQ ID No: 149.

32. An isolated polynucleotide comprising a sequence having at least 80% identity to SEQ ID No: 150.

33. The polynucleotide according to claim 32 comprising a sequence having at least 85% identity to SEQ ID No: 150.

34. The polynucleotide according to claim 32 comprising a sequence having at least 90% identity to SEQ ID No: 150.

35. The polynucleotide according to claim 32 comprising a sequence having at least 95% identity to SEQ ID No: 150. intellectual property office of n.z. 2 5 OCT 2006 RECEIVED -514-

36. The polynucleotide according to claim 32 comprising a sequence having at least 99% identity to SEQ ID No: 150.

37. The polynucleotide according to claim 32 comprising the sequence of SEQ ID No: 150.

38. An isolated polynucleotide comprising a sequence having at least 80% identity to SEQ ID No: 151.

39. The polynucleotide according to claim 38 comprising a sequence having at least 85% identity to SEQ ID No: 151.

40. The polynucleotide according to claim 38 comprising a sequence having at least 90% identity to SEQ ID No: 151.

41. The polynucleotide according to claim 38 comprising a sequence having at least 95% identity to SEQ ID No: 151.

42. The polynucleotide according to claim 38 comprising a sequence having at least 99% identity to SEQ ID No: 151.

43. The polynucleotide according to claim 38 comprising the sequence of SEQ ID No: 151.

44. The polynucleotide according to any one of claims 18-43, wherein said polynucleotide encodes an antibody or antigen binding fragment thereof that specifically binds C35. INTELLECTUAL PROPERTY OFFICE OF NZ -1 AUG 2007 RECEIVED -515-

45. An expression vector comprising the polynucleotide according to any of claims 1-44.

46. A host cell comprising the expression vector according to claim 45, with the proviso that said host cell is not present in a human.

47. A method of producing an isolated antibody or antigen binding fragment thereof that specifically binds C35 comprising culturing the host cell of claim 46, and recovering said antibody or antigen binding fragment thereof.

48. An antibody or antigen binding fragment thereof that specifically binds C35 produced by the method of claim 47.

49. An isolated polypeptide encoded by the polynucleotide according to any one of claims 1-44.

50. An isolated antibody or antigen binding fragment thereof comprising at least one complementarity determining region (CDR) or a functional variant thereof of the murine 1B3 monoclonal antibody, wherein said antibody or antigen binding fragment thereof specifically binds C35.

51. The antibody or antigen binding fragment thereof according to claim 50, wherein said antibody or antigen binding fragment thereof comprises at least two CDRs of the murine 1B3 monoclonal antibody.

52. The antibody or antigen binding fragment thereof according to claim 50, wherein said antibody or antigen binding fragment thereof comprises at least three CDRs of the murine 1B3 monoclonal antibody. INTELLECTUAL PROPERTY OFFICE 0FN.2 - 1 AUG 2007 -RECEIVED -516-

53. The antibody or antigen binding fragment thereof according to claim 50, wherein said antibody or antigen binding fragment thereof comprises at least four CDRs of the murine 1B3 monoclonal antibody.

54. The antibody or antigen binding fragment thereof according to claim 50, wherein said antibody or antigen binding fragment thereof comprises at least five CDRs of the murine 1B3 monoclonal antibody.

55. The antibody or antigen binding fragment thereof according to claim 50, wherein said antibody or antigen binding fragment thereof comprises at least six CDRs of the murine 1B3 monoclonal antibody.

56. The antibody or antigen binding fragment thereof according to claim 50, wherein said at least one CDR is the 1B3 heavy chain CDR3.

57. An isolated antibody or antigen binding fragment thereof comprising at least one complementarity determining region (CDR) or a variant thereof of the murine 1F2 monoclonal antibody, wherein said antibody or antigen binding fragment thereof specifically binds C35.

58. The antibody or antigen binding fragment thereof according to claim 57, wherein said antibody or antigen binding fragment thereof comprises at least two CDRs of the murine 1F2 monoclonal antibody.

59. The antibody or antigen binding fragment thereof according to claim 57, wherein said antibody or antigen binding fragment thereof comprises at least three CDRs of the murine 1F2 monoclonal antibody. intellectual property office of m.z. 2 5 OCT 2006 RECEIVED -517-

60. The antibody or antigen binding fragment thereof according to claim 57, wherein said antibody or antigen binding fragment thereof comprises at least four CDRs of the murine 1F2 monoclonal antibody.

61. The antibody or antigen binding fragment thereof according to claim 57, wherein said antibody or antigen binding fragment thereof comprises at least five CDRs of the murine 1F2 monoclonal antibody.

62. The antibody or antigen binding fragment thereof according to claim 57, wherein said antibody or antigen binding fragment thereof comprises at least six CDRs of the murine 1F2 monoclonal antibody.

63. The antibody or antigen binding fragment thereof according to any one of claims 50 to 62, wherein said antibody is a full antibody.

64. The antibody or antigen binding fragment thereof according to any one of claims 50 to 62, wherein said antigen binding fragment is selected from the group consisting of: an Fab fragment, an F(ab')2 fragment, an scFv fragment, and a dAb fragment.

65. The antibody or antigen binding fragment thereof of any of claims 50-64, wherein said antibody or antigen binding fragment is chimeric.

66. The antibody or antigen binding fragment thereof of claim 65, wherein said antibody or antigen binding fragment is humanized.

67. An isolated antibody or antigen binding fragment thereof that specifically binds C35, wherein said antibody or antigen binding fragment comprises the VH region of 1B3. INTELLECTUAL PROPERTY OFFICE OF N.Z. -I AUG 2007 RECEIVED -518-

68. An isolated antibody or antigen binding fragment thereof that specifically binds C35, wherein said antibody or antigen binding fragment comprises the VL region of 1B3.

69. An isolated antibody or antigen binding fragment thereof that specifically binds C35, wherein said antibody or antigen binding fragment comprises the VH region of 1F2.

70. An isolated antibody or antigen binding fragment thereof that specifically binds C35, wherein said antibody or antigen binding fragment comprises the VL region of 1F2.

71. An isolated antibody or antigen binding fragment thereof that specifically binds to C3 5, wherein said antibody or antigen binding fragment thereof competitively inhibits the 1B3 murine monoclonal antibody from specifically binding to C35.

72. An isolated antibody or antigen binding fragment thereof that specifically binds to C35, wherein said antibody or antigen binding fragment thereof competitively inhibits the 1F2 murine monoclonal antibody from specifically binding to C35.

73. An isolated antibody or antigen binding fragment thereof that specifically binds to an epitope of C35 located within positions 153 to K104 of SEQ ID NO:2.

74. An isolated polynucleotide encoding the antibody or antigen binding fragment thereof according to any one of claims 50-73.

75. A vector comprising the polynucleotide of claim 74. INTELLECTUAL PROPERTY OFFICE OF N.Z. - 1 AUG 2007 RECEIVED -519-

76. A host cell comprising the vector of claim 75 with the proviso that said host cell is not present in a human.

77. A composition comprising the antibody or antigen binding fragment thereof according to any one of claims 50-73.

78. The composition according to claim 77, wherein said composition further comprises a therapeutic agent.

79. The composition according to claim 78, wherein said therapeutic agent is selected from the group consisting of: an anti-tumor drug, a cytotoxin, and a radioactive agent.

80. The composition according to claim 79, wherein said therapeutic agent is a cytotoxin.

81. The composition according to claim 80, wherein said cytotoxin is selected from the group consisting of: taxol, ricin, doxorubicin, cytochalasin B, gramicidin D, ethidium bromide, etoposide, tenoposide, colchicin, dihydroxy anthracin dione, 1-dehydrotestosterone, and glucocorticoid.

82. The composition according to claim 81, wherein said cytotoxin is taxol.

83. The composition according to claim 78, wherein said therapeutic agent is conjugated to or complexed with said antibody or antigen binding fragment.

84. The composition according to any one of claims 77-83, wherein said composition further comprises a pharmaceutically acceptable carrier. INTELLECTUAL PROPERTY OFFICE OF N.Z. -1 AUG 2007 RECEIVED -520-

85. The antibody or antigen binding fragment according to any one of claims 50-73, or the composition according to any one of claims 77-84 for use in the treatment of a C35-associated cancer.

86. The antibody or antigen binding fragment or composition according to claim 85, wherein said cancer is selected from the group consisting of: breast cancer, ovarian cancer, bladder cancer, lung cancer, pancreatic cancer, and colon cancer.

87. The antibody or antigen binding fragment or composition according to claim 86, wherein said cancer is breast cancer.

88. Use of the antibody or antigen binding fragment according to any one of claims 50-73, or the composition according to any one of claims 77-87 for use in the manufacture of a medicament for the killing of cancer cells that express C35, or for treating C35-associated cancer.

89. The use according to claim 88, wherein said cancer is selected from the group consisting of: breast cancer, ovarian cancer, bladder cancer, lung cancer, pancreatic cancer, and colon cancer.

90. The use according to claim 89, wherein said cancer is breast cancer.

91. The use according to claim 88, wherein said medicament further comprises a therapeutic agent and said therapeutic agent is formulated for administration before, after or simultaneously with said antibody or antigen binding fragment or composition.

92. The use according to claim 91, wherein said therapeutic agent is selected from the group consisting of at least one of: an anti-tumor drug, a cytotoxin, and a radioactive agent.

93. The use according to claim 92, wherein said therapeutic agent is a cytotoxin. INTELLECTUAL PROPERTY OFFICE OF NZ - t AUG 2007 RECEIVED -521 -

94. The use according to claim 93, wherein said cytotoxin is selected from the group consisting of: taxol, ricin, doxorubicin, cytochalasin B, gramicidin D, ethidium bromide, etoposide, tenoposide, colchicin, dihydroxy anthracin dione, 1-dehydrotestosterone, and glucocorticoid.

95. The use according to claim 94, wherein said cytotoxin is taxol.

96. The use according to claim 95, wherein said therapeutic agent is conjugated to or complexed with said antibody or antigen binding fragment.

97. The use according to any one of claims 88-96, wherein said medicament is formulated for administration to cancer cells in vitro.

98. The use according to any one of claims 88-96, wherein said medicament is formulated for administration in vivo to a patient in need thereof.

99. The use according to claim 98, where said patient is a mammal in need of cancer treatment.

100. The use of claim 99, wherein the mammal is a human.

101. A method of detecting the presence of C35 in a sample, said method comprising: (a) contacting said sample with the antibody or antigen binding fragment thereof according to any one of claims 50-73 and (b) assaying for binding of said antibody or antigen binding fragment thereof to C35.

102. The method according to claim 101, wherein said assaying step is performed by an assay selected from the group consisting of: ELISA, radioimmunoassay, immunofluorescence, and immunocytochemistry. INTELLECTUAL PROPERTY OFFICE OF N.Z. -1 AUG 2007 Rprpi\/pn -522-

103. A diagnostic kit for detecting the presence of C35 in a sample, said kit comprising: (a) the antibody or antigen binding fragment thereof according to any one of claims 50-73; (b) a conjugate comprising a specific binding partner for the C35 antibody and a label capable of producing a detectable signal.

104. An isolated polynucleotide as claimed in any one of claims 1,6, 18, 19, 20, 26, 32, 38 and 74, substantially as herein described with reference to any example thereof.

105. An expression vector as claimed in claim 45, substantially as herein described with reference to any example thereof.

106. A host cell as claimed in claim 46 or 76, substantially as herein described with reference to any example thereof.

107 A method as claimed in claim 47 or 101, substantially as herein described with reference to any example thereof.

108. An antibody or antigen binding fragment as claimed in any one of claims 48, 50, 57, 67, 68, 69, 70, 71, 72 and 73, substantially as herein described with reference to any example thereof

109. An isolated polypeptide as claimed in claim 49, substantially as herein described with reference to any example thereof.

110. A vector as claimed in claim 75, substantially as herein described with reference to any example thereof.

111. A composition as claimed in claim 77, substantially as herein described with reference to any example thereof. INTELLECTUAL PROPERTY OFFICE OF N.Z. -1 AUG 2007 RECEIVED - 523 -

112. A use as claimed in claim 88, substantially as herein described with reference to any example thereof.

113. A diagnostic kit as claimed in claim 103, substantially as herein described with reference to any example thereof. intellectual property office of n.z. 2 5 OCT 2006 RECEIVED